TO EXTEND SURVIVAL

23% reduction in risk of death with XTANDI + GnRH therapy vs placebo + GnRH therapy in PREVAIL†‡

• Co-primary endpoint, OS: (HR = 0.77 [95% CI, 0.67-0.88])
• Median OS was 35.3 months (95% CI, 32.2-NR) with XTANDI vs 31.3 months (95% CI, 28.8-34.2) with placebo

Co-primary endpoint, rPFS*: (HR = 0.17 [95% CI, 0.14-0.21]; P < 0.0001)†

*Or after bilateral orchiectomy.

CI, confidence interval; HR, hazard ratio; mCRPC, metastatic castration-resistant prostate cancer; NR, not reached; OS, overall survival; rPFS, radiographic progression-free survival.

Indication
XTANDI (enzalutamide) capsules is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).

Important Safety Information
Contraindications
XTANDI is not indicated for women. XTANDI can cause fetal harm and potential loss of pregnancy.

Warnings and Precautions
Seizure occurred in 0.5% of patients receiving XTANDI in clinical studies. In placebo-controlled studies, 8 of 1671 (0.5%) patients treated with XTANDI and 1 of 1243 (0.1%) patients treated with placebo experienced a seizure. In patients who previously received docetaxel, 7 of 800 (0.9%) patients treated with XTANDI experienced a seizure and no patients treated with placebo experienced a seizure. In a placebo-controlled study in chemotherapy-naïve patients, 1 of 871 (0.1%) patients treated with XTANDI and 1 of 844 (0.1%) patients treated with placebo experienced a seizure. In bicalutamide-controlled studies conducted in chemotherapy-naïve patients, 3 of 380 (0.8%) patients treated with XTANDI and 1 of 387 (0.3%) patients treated with bicalutamide experienced a seizure. Permanently discontinue XTANDI in patients who develop a seizure during treatment.

Posterior Reversible Encephalopathy Syndrome (PRES) In post approval use, there have been reports of PRES in patients receiving XTANDI. PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably MRI. Discontinue XTANDI in patients who develop PRES.

Adverse Reactions
The most common adverse reactions (≥ 10%) that occurred more commonly (≥ 2% over placebo) in the XTANDI patients from the two placebo-controlled clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo. In the bicalutamide-controlled study of chemotherapy-naïve patients, the most common adverse reactions (≥ 10%) reported in XTANDI patients were asthenia/fatigue, back pain, musculoskeletal pain, hot flush, hypertension, nausea, constipation, upper respiratory tract infection, diarrhea, and weight loss.

In the study of patients taking XTANDI who previously received docetaxel, Grade 3 and higher adverse reactions were reported among 47% of XTANDI patients and 53% of placebo patients. Discontinuations due to adverse events were reported for 16% of XTANDI patients and 18% of placebo patients. In the placebo-controlled study of chemotherapy-naïve patients, Grade 3-4 adverse reactions were reported in 44% of XTANDI patients and 37% of placebo patients. Discontinuations due to adverse events were reported for 6% of both study groups. In the bicalutamide-controlled study of chemotherapy-naïve patients, Grade 3-4 adverse reactions were reported in 38.8% of XTANDI patients and 37.6% of bicalutamide patients. Discontinuations due to adverse events were reported for 7.6% of XTANDI patients and 6.3% of bicalutamide patients.

Lab Abnormalities: In the two placebo-controlled trials, Grade 1-4 neutropenia occurred in 15% of XTANDI patients (1% Grade 3-4) and 6% of placebo patients (0.5% Grade 3-4); Grade 1-4 thrombocytopenia occurred in 6% of XTANDI patients (0.3% Grade 3-4) and 5% of placebo patients (0.5% Grade 3-4); Grade 1-4 elevations in ALT occurred in 10% of XTANDI patients (0.2% Grade 3-4) and 16% of placebo patients (0.2% Grade 3-4).
CONVENIENT DOSING

Administer XTANDI as 160 mg (four 40 mg capsules) orally, once daily

Each capsule should be swallowed whole and should not be chewed, dissolved, or opened. If a patient experiences a ≥ Grade 3 toxicity or an intolerable side effect, withhold dosing for one week or until symptoms improve to ≤ Grade 2, then resume at the same or a reduced dose (120 mg or 80 mg), if warranted. For additional dosing information, see Drug Interactions and Full Prescribing Information.

Learn more about XTANDI at StartXtandi.com

Grade 1-4 elevations in bilirubin occurred in 3% of XTANDI patients (0.1% Grade 3-4) and 2% of placebo patients (no Grade 3-4).

Infections: In a study of patients taking XTANDI who previously received docetaxel, 1% of XTANDI patients compared to 0.3% of placebo patients died from infections or sepsis. In the placebo-controlled study of chemotherapy-naïve patients, 1 patient in each treatment group (0.1%) had an infection resulting in death.

Falls (including fall-related injuries) occurred in 9% of XTANDI patients and 4% of placebo patients in the two placebo-controlled trials. Falls were not associated with loss of consciousness or seizure. Fall-related injuries were more severe in XTANDI patients, and included non-pathologic fractures, joint injuries, and hematomas.

Hypertension occurred in 11% of XTANDI patients and 4% of placebo patients in the two placebo-controlled trials. No patients experienced hypertensive crisis. Medical history of hypertension was balanced between arms. Hypertension led to study discontinuation in < 1% of patients in each arm.

Drug Interactions

Effect of Other Drugs on XTANDI Avoid strong CYP2C8 inhibitors, as they can increase the plasma exposure to XTANDI. If co-administration is necessary, reduce the dose of XTANDI.

Avoid strong CYP3A4 inducers as they can decrease the plasma exposure to XTANDI. If co-administration is necessary, increase the dose of XTANDI.

Effect of XTANDI on Other Drugs Avoid CYP3A4, CYP2C9, and CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the plasma exposures of these drugs. If XTANDI is co-administered with warfarin (CYP2C9 substrate), conduct additional INR monitoring.

Please see adjacent pages for Brief Summary of Full Prescribing Information.

XTANDI® (enzalutamide) capsules for oral use
Initial Approval: 2012

BRIEF SUMMARY OF PRESCRIBING INFORMATION

The following is a brief summary. Please see the package insert for full prescribing information.

INDICATIONS AND USAGE

XTANDI is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).

CONTRAINDICATIONS

Pregnancy

XTANDI can cause fetal harm and potential loss of pregnancy.

WARNINGS AND PRECAUTIONS

Seizure

Seizure occurred in 0.5% of patients receiving XTANDI in clinical studies. In placebo-controlled studies, 8 of 1671 (0.5%) patients treated with XTANDI and 1 of 1245 (0.1%) patients treated with placebo experienced a seizure. In patients who previously received docetaxel, 7 of 800 (cause) patients treated with XTANDI experienced a seizure and no patients treated with placebo experienced a seizure. Seizure occurred from 31 to 603 days after initiation of XTANDI. In a placebo-controlled study in chemotherapy-naive patients, 1 of 971 (0.1%) treated with XTANDI and 1 of 844 (0.1%) patients treated with placebo experienced a seizure. In bicatulamide-controlled studies conducted in chemotherapy-naive patients, 1 of 380 (0.8%) patients treated with XTANDI and 1 of 387 (0.3%) patients treated with bicatulamide experienced a seizure. Patients experiencing seizure were permanently discontinued from therapy and all seizure events resolved. There is no clinical trial experience re-administering XTANDI to patients who experienced seizure.

Limited safety data are available in patients with predisposing factors for seizure because these patients were generally excluded from the trials. These exclusion criteria included a history of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accidents, and brain atrophy.

Study 1 included the use of concomitant medications that may lower the seizure threshold, whereas Study 2 permitted the use of these medications. Because the risks of seizure associated with XTANDI use, patients should be advised of the risk of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others. Permanently discontinue XTANDI in patients who develop a seizure during treatment.

Posterior Reversible Encephalopathy Syndrome (PRES)

There have been reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving XTANDI. PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinue XTANDI in patients who develop PRES.

ADVERSE REACTIONS

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Three randomized clinical trials enrolled patients with metastatic prostate cancer that has progressed on androgen deprivation therapy (GnRH therapy or bilateral orchiectomy), a disease setting that is also defined as metastatic CRPC. Two trials were placebo-controlled (Studies 1 and 2) and one trial was bicatulamide controlled (Study 3). In Studies 1 and 2, patients received XTANDI 160 mg or placebo orally once daily. In Study 3, patients received XTANDI 160 mg or bicatulamide 50 mg orally once daily. All patients continued androgen deprivation therapy. Patients were allowed, but not required, to take glucocorticoids.

The most common adverse reactions (≥ 10%) that occurred more commonly (≥ 2% over placebo) in the XTANDI-treated patients from the two randomized placebo-controlled clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.

Study 1: XTANDI versus Placebo in Metastatic CRPC Following Chemotherapy

Study 1 enrolled 1199 patients with metastatic CRPC who had previously received docetaxel. The median duration of treatment was 8.3 months with XTANDI and 3.0 months with placebo. During the trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids.

Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients. Discontinuations due to adverse events were reported for 16% of XTANDI-treated patients and 18% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients. Table 1 shows adverse reactions reported in Study 1 that occurred at a ≥ 2% higher frequency in the XTANDI arm compared to the placebo arm.

Table 1. Adverse Reactions in Study 1

<table>
<thead>
<tr>
<th></th>
<th>XTANDI N = 800</th>
<th>Placebo N = 399</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-4 (%)</td>
<td>Grade 3-4 (%)</td>
<td>Grade 1-4 (%)</td>
</tr>
<tr>
<td>General Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic Conditionsa</td>
<td>50.6</td>
<td>9.0</td>
</tr>
<tr>
<td>Peripheral Edema</td>
<td>15.4</td>
<td>1.0</td>
</tr>
<tr>
<td>Musculoskeletal And Connective Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back Pain</td>
<td>26.4</td>
<td>5.3</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>20.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Musculoskeletal Pain</td>
<td>15.0</td>
<td>1.3</td>
</tr>
<tr>
<td>Muscular Weakness</td>
<td>9.8</td>
<td>1.5</td>
</tr>
<tr>
<td>Musculoskeletal Stiffness</td>
<td>2.6</td>
<td>0.3</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>21.3</td>
<td>1.1</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hot Flush</td>
<td>20.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Hypertension</td>
<td>6.4</td>
<td>2.1</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>12.1</td>
<td>0.9</td>
</tr>
<tr>
<td>Dizzinessb</td>
<td>9.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Spinal Cord Compression And Cauda Equina Syndrome</td>
<td>7.4</td>
<td>6.6</td>
</tr>
<tr>
<td>Paresthesia</td>
<td>6.6</td>
<td>0.0</td>
</tr>
<tr>
<td>Mental Impairment Disordersd</td>
<td>4.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Hypoesthesia</td>
<td>4.0</td>
<td>0.3</td>
</tr>
<tr>
<td>Infections And infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper Respiratory Tract Infectione</td>
<td>10.9</td>
<td>0.0</td>
</tr>
<tr>
<td>Lower Respiratory Tract And Lung Infection</td>
<td>8.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>8.8</td>
<td>0.0</td>
</tr>
<tr>
<td>Anxiety</td>
<td>6.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Renal And Urinary Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematuria</td>
<td>6.9</td>
<td>1.6</td>
</tr>
<tr>
<td>Polkauria</td>
<td>6.9</td>
<td>0.2</td>
</tr>
<tr>
<td>Injury, Poisoning And Procedural Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fall</td>
<td>4.6</td>
<td>0.3</td>
</tr>
<tr>
<td>Non-pathologic Fractures</td>
<td>4.0</td>
<td>1.4</td>
</tr>
<tr>
<td>Skin And Subcutaneous Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>3.8</td>
<td>0.0</td>
</tr>
<tr>
<td>Dry Skin</td>
<td>3.5</td>
<td>0.0</td>
</tr>
<tr>
<td>Respiratory Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis</td>
<td>3.3</td>
<td>0.1</td>
</tr>
</tbody>
</table>

a. Includes asthenia and fatigue.

b. Includes dizziness and vertigo.

c. Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.

d. Includes paresthesia, lower respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.

Study 2: XTANDI versus Placebo in Chemotherapy-naive Metastatic CRPC

Study 2 enrolled 1717 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy. At whom 1715 received at least one dose of study drug. The median duration of treatment was 17.5 months with XTANDI and 4.6 months with placebo. Grade 3-4 adverse reactions were reported in 44% of XTANDI-treated patients and 37% of placebo-treated patients. Discontinuations due to adverse events were reported for 6% of XTANDI-treated patients and 6% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm. Table 2 includes adverse reactions reported in Study 2 that occurred at a ≥ 2% higher frequency in the XTANDI arm compared to the placebo arm.

<table>
<thead>
<tr>
<th>Studies</th>
<th>Adverse Reaction</th>
<th>Grade 1-4 (%)</th>
<th>Grade 3-4 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studies 1 and 2</td>
<td>XTANDI</td>
<td>7.9</td>
<td>1.5</td>
</tr>
<tr>
<td>Study 2</td>
<td>XTANDI</td>
<td>9.1</td>
<td>1.5</td>
</tr>
</tbody>
</table>

f. Includes pneumonia, lower respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.

g. Includes pneumonia, lower respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.

Investigations

Survival identified a lower time to progression in XTANDI vs placebo (HR 0.57, p < 0.001) and a lower risk of death in XTANDI vs placebo (HR 0.62, p < 0.001).

Study 3: XTANDI versus Bicalutamide in Chemotherapy-naive Metastatic CRPC

Study 3 enrolled 375 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy. At whom 1715 received at least one dose of study drug. The median duration of treatment was 11.6 months with XTANDI and
5.8 months with bicalutamide. Discontinuations with an adverse event as the primary reason were reported for 7.6% of XTANDI-treated patients and 6.3% of bicalutamide-treated patients. The most common adverse reactions leading to treatment discontinuation were back pain and pathological fracture, which occurred in 3.8% of XTANDI-treated patients for each event and in 2.1% and 1.8% of bicalutamide-treated patients, respectively. Table 3 shows overall and common adverse reactions (≥ 10%) in XTANDI-treated patients.

Table 3. Adverse Reactions in Study 3

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>XTANDI N = 183</th>
<th>Bicalutamide N = 189</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>94.0 (38.8)</td>
<td>94.2 (37.6)</td>
</tr>
<tr>
<td>General Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic Conditions$^a$</td>
<td>31.7 (16)</td>
<td>22.8 (11)</td>
</tr>
<tr>
<td>Musculoskeletal And Connective Tissue Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back Pain</td>
<td>19.1 (2.7)</td>
<td>18.0 (1.6)</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hot Flush</td>
<td>14.8 (0.0)</td>
<td>11.1 (0.0)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>14.2 (7.1)</td>
<td>7.4 (4.2)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>14.2 (0.0)</td>
<td>17.5 (0.0)</td>
</tr>
<tr>
<td>Constipation</td>
<td>12.6 (1.1)</td>
<td>13.2 (0.5)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>11.5 (0.0)</td>
<td>9.0 (1.1)</td>
</tr>
<tr>
<td>Infectious And Infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper Respiratory Tract Infections$^a$</td>
<td>12.0 (0.0)</td>
<td>6.3 (0.5)</td>
</tr>
<tr>
<td>Investigational</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight Loss</td>
<td>10.9 (0.5)</td>
<td>7.9 (0.5)</td>
</tr>
</tbody>
</table>

$^a$ CTCAE v 4.  
$^b$ Including asthenia and fatigue.  
$^c$ Including musculoskeletal pain and pain in extremity.  
$^d$ Including nasopharyngitis, upper respiratory tract infection, sinusitis, rhinopharyngitis, and laryngitis.

Laboratory Abnormalities

In the two randomized placebo-controlled clinical trials, Grade 1-4 neutropenia occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4). The incidence of Grade 1-4 thrombocytopenia was 6% of patients treated with XTANDI (0.3% Grade 3-4) and 5% of patients treated with placebo (0.5% Grade 3-4). Grade 1-4 elevations in ALT occurred in 10% of patients treated with XTANDI (0.2%, Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of patients treated with XTANDI (0.1% Grade 3-4) and 2% of patients treated with placebo (no Grade 3-4).

Infections

In Study 1, 1% of patients treated with XTANDI compared to 0.6% of patients treated with placebo died from infections or sepsis. In Study 2, 1 patient in each treatment group (0.1%) had an infection resulting in death.

Fails and Fall-related Injuries

In the two randomized placebo-controlled clinical trials, falls including fall-related injuries, occurred in 9% of patients treated with XTANDI compared to 4% of patients treated with placebo. Falls were not associated with loss of consciousness or seizure. Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hernomas.

Hypertension

In the two randomized placebo-controlled trials, hypertension was reported in 11% of patients receiving XTANDI and 4% of patients receiving placebo. No profound increase in blood pressure was reported. No relationship between the plasma concentration-time curve (AUC) of enzalutamide plus N-desmethyl enzalutamide by 2.2-fold. Co-administration of XTANDI with strong CYP2C8 inhibitors (e.g., phenytoin, warfarin, and N-desmethyl enzalutamide) should be avoided if possible. Co-administration of a strong CYP3A4 inducer with XTANDI cannot be avoided, increase the dose of XTANDI.

Disease Modifying Enzymes

In the two randomized placebo-controlled clinical trials, 75% were 75 and over, while 31% were 75 and over. No overall differences in enzalutamide clearance was observed in patients with pre-existing mild to moderate renal impairment (30 mL/min ≤ creatinine clearance [CrCl] ≤ 89 mL/min) compared to patients and volunteers with baseline normal renal function (CrCl ≥ 90 mL/min). No initial dosage adjustment is necessary for patients with mild to moderate renal impairment. Severe renal impairment (CrCl < 30 mL/min) and end-stage renal disease have not been assessed.

Patients with Hepatic Impairment

Dedicated hepatic impairment trials compared the composite systemic exposure of enzalutamide plus N-desmethyl enzalutamide in volunteers with baseline mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C, respectively) versus healthy controls with normal hepatic function. The composite AUC of enzalutamide plus N-desmethyl enzalutamide was similar in volunteers with mild, moderate, or severe baseline hepatic impairment compared to volunteers with normal hepatic function. No initial dosage adjustment is necessary for patients with baseline mild, moderate, or severe hepatic impairment.

OVERDOSE

In the event of an overdose, stop treatment with XTANDI and initiate general supportive measures taking into consideration the half-life of 5.8 days. In a dose escalation study, no seizures were reported at ≤ 240 mg daily, whereas 3 seizures were reported, each at 360 mg, 480 mg, and 600 mg daily. Patients may be at increased risk of seizure following an overdose.

NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies have not been conducted to evaluate the carcinogenic potential of enzalutamide.

Enzalutamide did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in either the in vitro mouse lymphoma thymidine kinase (Tk) gene mutation assay or the in vivo mouse micronucleus assay.

Based on nonclinical findings in repeat-dose toxicity studies, which were consistent with the pharmacological activity of enzalutamide, male fertility may be impaired by treatment with XTANDI. In a 26-week study in rats, atrophy of the prostate and seminal vesicles was observed at ≥ 30 mg/kg/day (equal to the human exposure based on AUC). Male fertility may be impaired by treatment with XTANDI.

Patients with Renal Impairment

A dedicated renal impairment trial for XTANDI has not been conducted. Based on the population pharmacokinetic analysis using data from clinical trials in patients with metastatic CRPC and healthy volunteers, no significant difference in enzalutamide clearance was observed in patients with pre-existing mild to moderate renal impairment (30 mL/min ≤ creatinine clearance [CrCl] ≤ 89 mL/min) compared to patients and volunteers with baseline normal renal function (CrCl ≥ 90 mL/min). No initial dosage adjustment is necessary for patients with mild to moderate renal impairment. Severe renal impairment (CrCl < 30 mL/min) and end-stage renal disease have not been assessed.
INDICATIONS AND USAGE
Myrbetriq® (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

IMPORTANT SAFETY INFORMATION
Myrbetriq is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet. Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥ 180 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg).

Urinary retention in patients with bladder outlet obstruction (BOO) and in patients taking antimuscarinic medications for the treatment of OAB has been reported in postmarketing experience in patients taking mirabegron. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in Myrbetriq patients; however, Myrbetriq should be administered with caution to patients with clinically significant BOO. Myrbetriq should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB.

Angioedema of the face, lips, tongue and/or larynx has been reported with Myrbetriq. In some cases angioedema occurred after the first dose. Cases of angioedema have been reported to occur hours after the first dose or after multiple doses. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue Myrbetriq and initiate appropriate therapy and/or measures necessary to ensure a patent airway.

Since Myrbetriq is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates such as metoprolol and desipramine is increased when co-administered with Myrbetriq. Therefore, appropriate monitoring and dose adjustment may be necessary, especially with narrow therapeutic index drugs metabolized by CYP2D6, such as thioridazine, flecainide, and propafenone.

In clinical trials, the most commonly reported adverse reactions (> 2% and > placebo) for Myrbetriq 25 mg and 50 mg versus placebo, respectively, were hypertension (11.3%, 7.5% vs 7.6%), nasopharyngitis (3.5%, 3.9% vs 2.5%), urinary tract infection (4.2%, 2.9% vs 1.8%), and headache (2.1%, 3.2% vs 3.0%).

In postmarketing experience, the following events have also occurred: constipation, diarrhea, and dizziness.

Please see Brief Summary of Prescribing Information for Myrbetriq® (mirabegron) on following pages.

Myrbetriq (mirabegron) extended-release tablets

INDICATIONS AND USAGE
Myrbetriq® is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

CONTRAINDICATIONS
Myrbetriq is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet.

WARNINGS AND PRECAUTIONS

Increases in Blood Pressure
Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in patients with severe uncontrolled hypertension (defined as systolic blood pressure greater than or equal to 180 mm Hg and/or diastolic blood pressure greater than or equal to 110 mm Hg).

In two, randomized, placebo-controlled, healthy volunteer studies, Myrbetriq was associated with dose-related increases in supine blood pressure. In these studies, at the maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic blood pressure was approximately 3.5/1.5 mm Hg greater than placebo.

In contrast, in OAB patients in clinical trials, the mean increase in systolic and diastolic blood pressure at the maximum recommended dose of 50 mg was approximately 0.5 - 1 mm Hg greater than placebo. Worsening of pre-existing hypertension was reported infrequently in Myrbetriq patients.

Urinary Retention in Patients with Bladder Outlet Obstruction and in Patients Taking Antimuscarinic Medications for OAB
Urinary retention in patients with bladder outlet obstruction (BOO) and in patients taking antimuscarinic medications for the treatment of OAB has been reported in postmarketing experience in patients taking mirabegron. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in Myrbetriq patients; however, Myrbetriq should be administered with caution to patients with clinically significant BOO.

Angioedema
Angioedema of the face, lips, tongue, and/or larynx has been reported with Myrbetriq. In some cases angioedema occurred after the first dose. Cases of angioedema have been reported to occur hours after the first dose or after multiple doses. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue Myrbetriq and initiate appropriate therapy and/or measures necessary to ensure a patent airway.

Patients Taking Drugs Metabolized by CYP2D6
Since mirabegron is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates such as metoprolol and desipramine is increased when co-administered with mirabegron. Therefore, appropriate monitoring and dose adjustment may be necessary, especially with narrow therapeutic index drugs metabolized by CYP2D6, such as thioridazine, flecaïnide, and propafenone.

ADVERSE REACTIONS

Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In three, 12-week, double-blind, placebo-controlled, safety and efficacy studies in patients with overactive bladder (Studies 1, 2, and 3), Myrbetriq was evaluated for safety in 2,736 patients. Study 1 also included an active control. For the combined Studies 1, 2, and 3, 432 patients received Myrbetriq 25 mg, 1375 received Myrbetriq 50 mg, and 929 received Myrbetriq 100 mg once daily. In these studies, the majority of the patients were Caucasian (94%), and female (72%) with a mean age of 59 years (range 18 to 95 years).

Myrbetriq was also evaluated for safety in 1,632 patients who received Myrbetriq 50 mg once daily (n=812 patients) or Myrbetriq 100 mg (n=820 patients) in a 1 year, randomized, fixed dose, double-blind, active controlled, safety study in patients with overactive bladder (Study 4). Of these patients, 731 received Myrbetriq in a previous 12-week study. In Study 4, 1,386 patients received Myrbetriq continuously for at least 6 months, 1,311 patients received Myrbetriq for at least 9 months, and 564 patients received Myrbetriq for at least 1 year.

The most frequent adverse events (0.2%) leading to discontinuation in Studies 1, 2 and 3 for the 25 mg or 50 mg dose were nausea, headache, hypertension, diarrhea, constipation, dizziness and tachycardia.

Atrial fibrillation (0.2%) and prostate cancer (0.1%) were reported as serious adverse events by more than 1 patient and at a rate greater than placebo.

Table 1 lists adverse reactions, derived from all adverse events, that were reported in Studies 1, 2 and 3 at an incidence greater than placebo and in 1% or more of patients treated with Myrbetriq 25 mg or 50 mg once daily for up to 12 weeks. The most commonly reported adverse reactions (greater than 2% of Myrbetriq patients and greater than placebo) were hypertension, nasopharyngitis, urinary tract infection and headache.

<table>
<thead>
<tr>
<th>Event</th>
<th>Placebo (%)</th>
<th>Myrbetriq 25 mg (%)</th>
<th>Myrbetriq 50 mg (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients</td>
<td>1380</td>
<td>432</td>
<td>1375</td>
</tr>
<tr>
<td>Hypertension*</td>
<td>7.6</td>
<td>11.3</td>
<td>7.5</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>2.5</td>
<td>3.5</td>
<td>3.9</td>
</tr>
<tr>
<td>Urinary Tract Infection</td>
<td>1.8</td>
<td>4.2</td>
<td>2.9</td>
</tr>
<tr>
<td>Headache</td>
<td>3.0</td>
<td>2.1</td>
<td>3.2</td>
</tr>
<tr>
<td>Constipation</td>
<td>1.4</td>
<td>1.6</td>
<td>1.6</td>
</tr>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td>1.7</td>
<td>2.1</td>
<td>1.5</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>1.1</td>
<td>1.6</td>
<td>1.3</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>1.3</td>
<td>1.2</td>
<td>1.5</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>0.6</td>
<td>1.6</td>
<td>1.2</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>0.7</td>
<td>1.4</td>
<td>0.6</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1.0</td>
<td>1.4</td>
<td>1.2</td>
</tr>
</tbody>
</table>

*Includes reports of blood pressure above the normal range, and BP increased from baseline, occurring predominantly in subjects with baseline hypertension.

Other adverse reactions reported by less than 1% of patients treated with Myrbetriq in Studies 1, 2, or 3 included:

Cardiac disorders: palpitations, blood pressure increased
Eye disorders: glaucoma
Gastrointestinal disorders: dyspepsia, gastritis, abdominal distension
Infections and Infestations: sinustis, rhinitis
Investigations: GGT increased, AST increased, ALT increased, LDH increased
Renal and urinary disorders: nephrolithiasis, bladder pain
Reproductive system and breast disorders: vulvovaginal pruritus, vaginal infection
Skin and subcutaneous tissue disorders: urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema

Table 2 lists the rates of the most commonly reported adverse reactions, derived from all adverse events in patients treated with Myrbetriq 50 mg for up to 52 weeks in Study 4. The most commonly reported adverse reactions (> 3% of Myrbetriq patients) were hypertension, urinary tract infection, headache, and nasopharyngitis.

Table 2: Percentages of Patients with Adverse Reactions, Derived from All Adverse Events, Reported by Greater Than 2% of Patients Treated with Myrbetriq 50 mg Once Daily in Study 4

<table>
<thead>
<tr>
<th>Event</th>
<th>Myrbetriq 50 mg (%)</th>
<th>Active Control (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients</td>
<td>812</td>
<td>812</td>
</tr>
<tr>
<td>Hypertension</td>
<td>9.2</td>
<td>9.6</td>
</tr>
<tr>
<td>Urinary Tract Infection</td>
<td>5.9</td>
<td>6.4</td>
</tr>
<tr>
<td>Headache</td>
<td>4.1</td>
<td>2.5</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>3.9</td>
<td>3.1</td>
</tr>
<tr>
<td>Back Pain</td>
<td>2.8</td>
<td>1.6</td>
</tr>
<tr>
<td>Constipation</td>
<td>2.8</td>
<td>2.7</td>
</tr>
<tr>
<td>Dry Mouth</td>
<td>2.8</td>
<td>8.6</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2.7</td>
<td>2.6</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>2.7</td>
<td>1.5</td>
</tr>
<tr>
<td>Influenza</td>
<td>2.6</td>
<td>3.4</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>2.1</td>
<td>2.0</td>
</tr>
<tr>
<td>Cystitis</td>
<td>2.1</td>
<td>2.3</td>
</tr>
</tbody>
</table>

In Study 4, in patients treated with Myrbetriq 50 mg once daily, adverse reactions leading to discontinuation reported by more than 2 patients and at a rate greater than active control included: constipation (0.9%), headache (0.6%), dizziness (0.5%), hypertension (0.5%), dry eyes (0.4%), nausea (0.4%), vision blurred (0.4%), and urinary tract infection (0.4%). Serious adverse events reported by at least 2 patients and exceeding active control included:

- Cystitis
- Arthralgia
- Influenza
- Urinary tract infection
- Hypertension
cerebrovascular accident (0.4%) and osteoarthritis (0.2%). Serum ALT/AST increased from baseline by greater than 10-fold in 2 patients (0.3%) taking Myrbetriq 50 mg, and these markers subsequently returned to baseline while both patients continued Myrbetriq.

In Study 4, serious adverse events of neoplasm were reported by 0.1%, 1.3%, and 0.5% of patients treated with Myrbetriq 50 mg, Myrbetriq 100 mg and active control once daily, respectively. Neoplasms reported by 2 patients treated with Myrbetriq 100 mg included breast cancer, lung neoplasm malignant and prostate cancer.

In a separate clinical study in Japan, a single case was reported as Stevens-Johnson syndrome with increased serum ALT, AST and bilirubin in a patient taking Myrbetriq 100 mg as well as an herbal medication (KyuGu Gold).

Postmarketing Experience
Because these spontaneously reported events are from the worldwide postmarketing experience, from a population of uncertain size, the frequency of events and the role of mirabegron in their causation cannot be reliably determined.

The following events have been reported in association with mirabegron use in worldwide postmarketing experience:
- Gastrointestinal disorders: nausea, constipation, diarrhea
- Nervous system disorders: dizziness, headache
- Skin and subcutaneous tissue: angioedema of the face, lips, tongue, and larynx, with or without respiratory symptoms; pruritus
- Urologic: urination retention

--- DRUG INTERACTIONS ---

Drug interaction studies were conducted to investigate the effect of co-administered drugs on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of co-administered drugs (e.g., ketoconazole, rifampin, solifenacin, tamsulosin, and oral contraceptives). No dose adjustment is recommended when these drugs are co-administered with mirabegron.

The following are drug interactions for which monitoring is recommended:

Drugs Metabolized by CYP2D6
Since mirabegron is a moderate CYP2D6 inhibitor, the systemic exposure of drugs metabolized by CYP2D6 enzyme such as metoprolol and desipramine is increased when co-administered with mirabegron. Therefore, appropriate monitoring and dose adjustment may be necessary when Myrbetriq is co-administered with these drugs, especially with narrow therapeutic index CYP2D6 substrates, such as thoridazine, flecainide, and propafenone.

Digoxin
When given in combination, mirabegron increased mean digoxin C_{max} from 1.01 to 1.3 ng/mL (29%) and AUC from 16.7 to 19.3 ng.h/mL (27%). Therefore, for patients who are initiating a combination of mirabegron and digoxin, the lowest dose for digoxin should initially be considered. Serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect.

Warfarin
The mean C_{max} of S- and R-warfarin was increased by approximately 4% and AUC by approximately 9% when administered as a single dose of 25 mg after multiple doses of 100 mg mirabegron. Following a single dose administration of 25 mg warfarin, mirabegron had no effect on the warfarin pharmacodynamic endpoints such as International Normalized Ratio (INR) and prothrombin time. However, the effect of mirabegron on multiple doses of warfarin and on warfarin pharmacodynamic end points such as INR and prothrombin time has not been fully investigated.

--- USE IN SPECIFIC POPULATIONS ---

Pregnancy
Pregnancy Category C
There are no adequate and well-controlled studies using Myrbetriq in pregnant women. Myrbetriq should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. Women who become pregnant during Myrbetriq treatment are encouraged to contact their physician.

Risk Summary
Based on animal data, mirabegron is predicted to have a low probability of increasing the risk of adverse developmental outcomes above background risk. Reversible adverse developmental findings consisting of delayed ossification and wavy ribs in rats and decreased fetal body weights in rabbits occurred at exposures greater than or equal to 22 and 14 times, respectively, the maximum recommended human dose (MRHD). At maternally toxic exposures decreased fetal weights were observed in rats and rabbits, and fetal death, dilated aorta, and cardiomegaly were reported in rabbits.

Nursing Mothers
It is not known whether Myrbetriq is excreted in human milk. Mirabegron was found in the milk of rats at concentrations twice the maternal plasma level. Mirabegron was found in the lungs, liver, and kidneys of nursing pups. No studies have been conducted to assess the impact of Myrbetriq on milk production in humans, its presence in human breast milk, or its effects on the breast-fed child. Because Myrbetriq is predicted to be excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use
The safety and effectiveness of Myrbetriq in pediatric patients have not been established.

Geriatric Use
No dose adjustment is necessary for the elderly. The pharmacokinetics of Myrbetriq is not significantly influenced by age. Of 5648 patients who received Myrbetriq in the phase 2 and 3 studies, 2029 (35.9%) were 65 years of age or older, and 557 (9.9%) were 75 years of age or older. No overall differences in safety or effectiveness were observed between patients younger than 65 years of age and those 65 years of age or older in these studies.

Renal Impairment
Myrbetriq has not been studied in patients with end stage renal disease (Cl_{cr} < 15 mL/min or eGFR < 15 mL/min/1.73 m² or patients requiring hemodialysis), and, therefore is not recommended for use in these patient populations.

In patients with severe renal impairment (Cl_{cr} 15 to 29 mL/min or eGFR 15 to 29 mL/min/1.73 m²), the daily dose of Myrbetriq should not exceed 25 mg. No dose adjustment is necessary in patients with mild or moderate renal impairment (Cl_{cr} 30 to 89 mL/min or eGFR 30 to 89 mL/min/1.73 m²).

Hepatic Impairment
Myrbetriq has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), and therefore is not recommended for use in this patient population.

In patients with moderate hepatic impairment (Child-Pugh Class B), the daily dose of Myrbetriq should not exceed 25 mg. No dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh Class A).

Gender
No dose adjustment is necessary based on gender. When corrected for differences in body weight, the Myrbetriq systemic exposure is 20% to 30% higher in females compared to males.

--- OVERDOSAGE ---

Mirabegron has been administered to healthy volunteers at single doses up to 400 mg. At this dose, adverse events reported included palpitations (1 of 6 subjects) and increased pulse rate exceeding 100 bpm (3 of 6 subjects). Multiple doses of mirabegron up to 300 mg daily for 10 days showed increases in pulse rate and systolic blood pressure when administered to healthy volunteers. Treatment for overdose should be symptomatic and supportive. In the event of overdose, pulse rate, blood pressure and ECG monitoring is recommended.

--- CLINICAL PHARMACOLOGY ---

Pharmacodynamics

Urodynamics
The effects of Myrbetriq on maximum urinary flow rate and detrusor pressure at maximum flow rate were assessed in a urodynamic study consisting of 200 male patients with lower urinary tract symptoms (LUTS) and BOD. Administration of Myrbetriq once daily for 2 weeks did not adversely affect the mean maximum flow rate or mean detrusor pressure at maximum flow rate in this study. Nonetheless, Myrbetriq should be administered with caution to patients with clinically significant BOD.

Cardiac Electrophysiology
The effect of multiple doses of Myrbetriq 50 mg, 100 mg and 200 mg once daily on QTc interval was evaluated in a randomized, placebo- and active- controlled (moxifloxacin 400 mg) four-treatment-arm parallel crossover study in 352 healthy subjects. In a study with demonstrated ability to detect small effects, the upper bound of the one-sided 95% confidence interval for the largest placebo adjusted, baseline-corrected QTc based on individual correction method (QTcI) was below 10 msec. For the 50 mg Myrbetriq dose group (the maximum approved dosage), the mean change from baseline on QTcI interval at 4-5 hours post-dose was 3.7 msec (upper bound of the 95% CI 5.1 msec).

For the Myrbetriq 100 mg and 200 mg doses groups (dosages greater than the maximum approved dose and resulting in substantial multiples of the anticipated maximum blood levels at 50 mg), the mean differences from placebo in QTcI interval at 4-5 hours post-dose were 6.1 msec (upper bound of the 95% CI 7.6 msec) and 8.1 msec (upper bound of the 95% CI 9.8 msec), respectively. At the Myrbetriq 200 mg dose, in females, the mean effect was 10.4 msec (upper bound of the 95% CI 13.4 msec).

In this thorough QT study, Myrbetriq increased heart rate on ECG in a dose dependent manner. Maximum mean increases from baseline in heart rate for the 50 mg, 100 mg, and 200 mg dose groups compared to placebo were 6.7 beats per minutes (bpm), 11 bpm, and 17 bpm, respectively. In the clinical efficacy and safety studies, the change from baseline in mean pulse rate for Myrbetriq 50 mg was approximately 1 bpm. In this thorough QT study, Myrbetriq also increased blood pressure in a dose dependent manner (see Effects on Blood Pressure).

Effects on Blood Pressure

In a study of 352 healthy subjects assessing the effect of the multiple daily doses of 50 mg, 100 mg, and 200 mg of Myrbetriq for 10 days on the QTc interval, the maximum mean increase in systolic blood pressure (SBP) was 4.0/1.6 mm Hg greater than placebo. The 24-hour average increases in SBP compared to placebo were 3.0, 5.5, and 9.7 mm Hg at Myrbetriq doses of 50 mg, 100 mg, and 200 mg, respectively. Increases in DBP were also dose-dependent, but were smaller than SBP.

In another study in 96 healthy subjects to assess the impact of age on pharmacokinetics of multiple daily doses of 50 mg, 100 mg, 200 mg, and 300 mg of Myrbetriq for 10 days, SBP also increased in a dose-dependent manner. The mean maximum increases in SBP were approximately 2.5, 4.5, 5.5 and 6.5 mm Hg for Myrbetriq exposures associated with doses of 50 mg, 100 mg, 200 mg and 300 mg, respectively.
In three, 12-week, double-blind, placebo-controlled, safety and efficacy studies (Studies 1, 2 and 3) in OAB patients receiving Myrbetriq 25 mg, 50 mg, or 100 mg once daily, mean increases in SBP/DBP compared to placebo of approximately 0.5 - 1 mm Hg were observed. Morning SBP increased by at least 15 mm Hg from baseline in 5.3%, 5.1%, and 6.7% of placebo, Myrbetriq 25 mg and Myrbetriq 50 mg patients, respectively. Morning DBP increased by at least 10 mm Hg in 4.6%, 4.1% and 6.6% of placebo, Myrbetriq 25 mg, and Myrbetriq 50 mg patients, respectively. Both SBP and DBP increases were reversible upon discontinuation of treatment.

---------------------------------------------------------------------NONCLINICAL TOXICOLOGY---------------------------------------------------------------------

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity

Long-term carcinogenicity studies were conducted in rats and mice dosed orally with mirabegron for two years. Male rats were dosed at 0, 12.5, 25, or 50 mg/kg/day and female rats and both sexes of mice were dosed at 0, 25, 50, or 100 mg/kg/day. Mirabegron showed no carcinogenic potential at systemic exposures (AUC) 38 to 45-fold higher in rats and 21 to 38-fold higher in mice than the human systemic exposure at the 50 mg dose.

Mutagenesis

Mirabegron was not mutagenic in the Ames bacterial reverse mutation assay, did not induce chromosomal aberrations in human peripheral blood lymphocytes at concentrations that were not cytotoxic, and was not clastogenic in the rat micronucleus assay.

Impairment of Fertility

Fertility studies in rats showed that mirabegron had no effect on either male or female fertility at non-lethal doses up to 100 mg/kg/day. Systemic exposures (AUC) at 100 mg/kg in female rats was estimated to be 22 times the MRHD in women and 93 times the MRHD in men.

---------------------------------------------------------------------PATIENT COUNSELING INFORMATION---------------------------------------------------------------------

Inform patients that Myrbetriq may increase blood pressure. Periodic blood pressure determinations are recommended, especially in patients with hypertension. Myrbetriq has also been associated with infrequent urinary tract infections, rapid heartbeat, rash, and pruritus. Inform patients that urinary retention has been reported when taking mirabegron in combination with antimuscarinic drugs used in the treatment of overactive bladder. Instruct patients to contact their physician if they experience these effects while taking Myrbetriq.

Patients should read the patient leaflet entitled “Patient Information” before starting therapy with Myrbetriq.

Rx Only

PRODUCT OF JAPAN OR IRELAND – See bottle label or blister package for origin

Marketed and Distributed by:
Astellas Pharma US, Inc.
Northbrook, Illinois 60062

Myrbetriq® is a registered trademark of Astellas Pharma Inc. All other trademarks or registered trademarks are the property of their respective owners.

© 2016 Astellas Pharma US, Inc.

Revised: August 2016
16A006-MIR-BRFS
057-1823-PM
Table of Contents

Board of Directors .................................................................................................................................................................... 3
Committees ............................................................................................................................................................................. 4
CME Information ................................................................................................................................................................ 7
Specialty Programs ............................................................................................................................................................... 9
Office of Education Courses ............................................................................................................................................... 11

Thursday
Society of Academic Urologists ........................................................................................................................................... 17
Castration-Resistant Prostate Cancer (CRPC) Live Forum for Urology Residents and Fellows .................. 18
Society for Fetal Urology ...................................................................................................................................................... 18

Friday
Plenary: Prime Time, Morning Session ..................................................................................................................... 21
Plenary: Prime Time, Afternoon Session ...................................................................................................................... 21
Poster, Podium and Video Sessions (MP1-5, PD1-4, V1) .............................................................................................. 22
Society for Pediatric Urology ........................................................................................................................................ 36
Engineering and Urology Section of the Endourological Society ............................................................................... 36
Indian American Urological Association .................................................................................................................... 37
World Chinese Urological Society ............................................................................................................................. 37
AUA/Confederación Americana de Urología ............................................................................................................. 39
Basic Sciences Symposium ........................................................................................................................................... 40
Urologic Oncology Research Symposium .................................................................................................................. 41
Sexual Medicine Society of North America .................................................................................................................. 41
Poster, Podium and Video Sessions (MP6-10, PD5-7, V2) ............................................................................................. 43
Society of Genitourinary Reconstructive Surgeons ................................................................................................. 55
American Society for Men’s Health ............................................................................................................................... 56
Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction .................................... 57
Poster and Podium Sessions (MP11-16, PD8-11) ........................................................................................................ 58
Poster, Podium and Video Sessions (MP17-22, PD12-15, V3) .................................................................................. 73

Saturday
Plenary: Next Frontier, Morning Session ...................................................................................................................... 89
Plenary: Next Frontier, Afternoon Session ....................................................................................................................... 89
Plenary: Prime Time, Afternoon Session .......................................................................................................................... 90
Poster, Podium and Video Sessions (MP23-28, PD16-20, V4) ..................................................................................... 91
Urology Update 2017: For Primary Care and Advanced Practice Providers ........................................................... 107
Society for Pediatric Urology ........................................................................................................................................ 108
Residents & Fellows Forum ........................................................................................................................................... 108
Society for Basic Urologic Research/Society of Urologic Oncology Joint Meeting ............................................. 109
American College of Osteopathic Surgeons ................................................................................................................ 109
Poster and Podium Sessions (MP29-34, PD21-24) ....................................................................................................... 110
Urologic Care for the Advanced Practice Provider ................................................................................................... 124
Society of Urologic Oncology ....................................................................................................................................... 125
Poster and Podium Sessions (MP35-39, PD25-28) ....................................................................................................... 126
Society for Basic Urologic Research ............................................................................................................................. 139
Polish Urological Association and Hungarian Urological Association Joint Session ........................................ 139
Poster, Podium and Video Sessions (MP40-44, PD29-33, V5) .................................................................................. 140

Sunday
Plenary: Prime Time, Morning Session .......................................................................................................................... 157
Plenary: Next Frontier, Morning Session ....................................................................................................................... 157
Plenary: Next Frontier, Afternoon Session ....................................................................................................................... 158
Plenary: Prime Time, Afternoon Session ................................................................. 159
Society of Women in Urology .................................................................................. 160
Poster, Podium and Video Sessions (MP45-49, PD34-37, V6) .................................. 160
Urologic Care for the Advanced Practice Provider .................................................. 175
Challenges for Urologic Research Symposium ....................................................... 175
Poster and Podium Sessions (MP50-55, PD38-40) .................................................. 176
15th International Prostate Forum ............................................................................ 190
AUA/American Association of Clinical Urologists Health Policy Forum ................. 191
Funding Opportunities and Grant Writing Guidance for Early-Career Investigators .... 191
Society for Infection and Inflammation in Urology .................................................. 191
Poster, Podium and Video Sessions (MP56-61, PD41-43, V7) ................................. 192
Korean World Urologic Congress ........................................................................... 207
Society of Urologic Robotic Surgery ........................................................................ 207
Society for the Study of Male Reproduction ........................................................... 208
Geriatric Urological Society .................................................................................... 209
Combined SPU Congenitalism Working Group Program ....................................... 210
British Association of Urological Surgeons/Urological Society of Australia and New Zealand .......................................................................................................................... 210
Japanese Urological Association ............................................................................ 210
Sociedad Argentina de Urología ............................................................................... 211
R. Frank Jones Urological Society .......................................................................... 211
Research Forum: Early-Career Investigators Showcase ......................................... 212
Association Française d’Urologie ............................................................................ 213
Poster, Podium and Video Sessions (MP62-67, PD44-48, V8) ................................. 213
Monday
Plenary: Prime Time, Morning Session ................................................................... 233
Plenary: Next Frontier, Morning Session ................................................................ 233
Plenary: Prime Time I - II, Afternoon Sessions ....................................................... 235
Poster and Podium Sessions (MP68-73, PD49-52) .................................................. 236
American Board of Urology Town Hall .................................................................. 252
Poster, Podium and Video Sessions (MP74-78, PD53-55, V9) ................................. 252
Young Urologists Forum ......................................................................................... 265
Poster and Podium Sessions (MP79-83, PD56-59) .................................................. 265
Asociación Española de Urología ............................................................................ 277
AUA/Brazilian Portuguese Urology Program .......................................................... 278
Urologic Society for Transplantation and Renal Surgery ....................................... 278
History of Urology Podium and Poster Sessions ................................................... 279
Research on Calculus Kinetics (ROCK) Society ..................................................... 280
Pan African Urological Surgeons Association/Caribbean Urological Surgeons Association .......................................................................................................................... 281
Philippine Urological Association ......................................................................... 282
Società Italiana di Urologia ..................................................................................... 282
Clinical Controversies in Men’s Health .................................................................. 282
Poster, Podium and Video Sessions (MP84-88, PD60-62, V10) ............................... 283
Tuesday
Plenary: Next Frontier, Morning Session ................................................................ 297
Plenary: Next Frontier, Afternoon Session .............................................................. 297
Poster, Podium and Video Sessions (MP89-94, PD63-67, V11) ............................... 298
Poster, Podium and Video Sessions (MP95-100, PD68-73, V12) ............................. 316
Exhibitor Listing ....................................................................................................... 335
Author Index ............................................................................................................ 337
2016-2017 Board of Directors

Officers of the Board of Directors

President.......................................................... Richard K. Babayan
President-Elect .......................................................... J. Brantley Thrasher
Immediate Past President............................................. William F. Gee
Secretary.................................................................. Manoj Monga
Treasurer............................................................. Steven M. Schlossberg

Section Representatives to the Board of Directors

Mid-Atlantic.......................................................... Roger E. Schultz
New England.......................................................... Kevin R. Loughlin
New York............................................................... Frederick A. Gulmi
North Central...................................................... Chandru P. Sundaram
Northeastern......................................................... John D. Denstedt
South Central...................................................... Randall B. Meacham
Southeastern............................................................. Thomas F. Stringer
Western.................................................................. Scott K. Swanson

AUA Headquarters
American Urological Association, Inc.
1000 Corporate Boulevard
Linthicum, Maryland 21090
Telephone: 410-689-3700
FAX: 410-689-3800
E-mail: aua@auanet.org
Website: www.auanet.org

Annual Business Meeting
Boston Convention & Exhibition Center
Room 205A
Tuesday, May 16, 2017 @ 12:00 pm
## 2016-2017 Committees

### Program Planning Committee

- Rosalyn M. Adam
- Michael Albo
- Joseph Alukal
- J. Christopher Austin
- John M. Barry
- Steven B. Brandes
- David A. Bushinsky
- Douglas A. Canning
- Gaetano Ciancio
- J. Quentin Clemens
- Hillary L. Copp
- Ross M. Dechter
- Ananias C. Dickno
- Scott Eggener
- Sean P. Elliott
- Christopher P. Evans
- Robert J. Evans
- John Gatti
- Inderbir S. Gill
- Leonard G. Gornella
- Chris M. Gonzalez
- Angelo E. Gousse
- Tomas L. Griebling
- Jeffrey M. Holzbeierlein
- Byron D. Joyner
- Anil K. Kapoor
- Louis R. Kavoussi
- Mohit Khera
- Edward D. Kim
- Badrinath R. Konety
- Hari Koul
- Kirk Lo
- Armando J. Lorenzo
- Surena F. Matin
- Stephen Y. Nakada
- Chris Nguan
- Victor W. Nitti
- Aria F. Olumi
- Priya Padmanabhan
- Lane S. Palmer
- Margaret S. Pearle
- Michel A. Pontari
- Christopher R. Porter
- James R. Porter
- Glenn M. Preminger
- Gail S. Prins
- Ganesh V. Raj
- Daniel I. Rosenberg
- Daniel B. Rukstalis
- Andrew D. Rule
- Edmund S. Sabanegh, Jr.
- Hossein Sadeghi-Nejad
- Evan M. Vapnek
- Run Wang
- John Wei
- J. Stuart Wolf, Jr.
- Hadley Wood

### Urologic Video Education Committee

- Chris Anderson
- Duane Baldwin
- Gregory Bales
- Joshua Broghammer
- Maude Carmel
- Brian S. Christine
- Daniel Dugi
- Jairam Eswara
- Dominic Frimberger
- Reza Ghavamian
- Mohan Gundeti
- Zach Hamilton
- Justin Han
- Jason Hedges
- Ashok Hemal
- Jim Hu
- Alton Ilkay
- Isaac Kim
- Richard Kim
- Bodo Knudsen
- Amy Krambeck
- John Lacy
- David Lee
- Eugene Lee
- Una Lee
- Raymond Leveillee
- Katie Murray
- Bobby Najari
- Gyan Pareek
- Justin Parker
- William Parker
- Sanjay Patel
- James Porter
- Jay Raman
- Lee Richstone
- Michelle Jo Semins
- Jay Simhan
- Ajay Singla
- Ariana Smith
- Alex Vanni
- Ramakrishna Venkatesh
- Stephen Williams
- Guan Wu
- Jennifer Yang
- Stanley Yap

### Program Abstract Review Committee

- Rosalyn M. Adam
- Peter C. Albertsen
- Zaki Almallah
- Seth Alpert
- Christopher L. Amling
- Karl-Erik Andersson
- Kenneth W. Angermeier
- Jodi Antonelli
- Monish Aron
- William J. Aronson
- Dean G. Assimos
- Anthony Atala
- Timothy D. Averch
- Michael Bailey
- Linda Baker
- K. C. Balaji
- D. Duane Baldwin
- Chris Bangma
- Daniel A. Barocas
- Julia S. Barthold
- Aaron P. Bayne
- Arie S. Belldegrun
- Carol J. Bennett
- Nelson Bennett
- Mitchell C. Benson
- Ryan K. Berglund
- Sam B. Bhayani
- Jay T. Bishoff
- Trinity Bivalacqua
- Jerry G. Blaivas
- Michael L. Blute
- Stephen A. Boorjian
- Robert Brannigan
- Peter N. Bretan
- Benjamin Breyer
- Gerald Brock
- Gregory A. Broderick
- Joshua Broghammer
- Benjamin Brucker
- Frank N. Burks
- Arthur L. Burnett
- Wade Bushman
- Ralph Buttyan
- Jeffrey A. Cadeddu
- Anne P. Cameron
- Steven C. Campbell
- Benjamin K. Canales
- Serge Carier
- Peter R. Carroll
- H. Ballentine Carter
- William J. Catalona
- Toby Chai
- Karim Chamie
- David Chan
- Michael Chancellor
- Sam S. Chang
- Brian Chapin
- Justin Chee
- Earl Y. Cheng
- Ben Chew
- George Chiang
- Joseph Chin
- George H. Chow
- Brian S. Christine
- Matthew Christman
- Bartley G. Clinto
- Peter E. Clark
- J. Quentin Clemens
Statement of Need

Urologists need a thorough knowledge of the most recent developments and techniques as well as established guidelines in urology to ensure the highest standards of patient care and safety.

Learning Objectives

At the conclusion of the 2017 Annual Meeting, participants should be able to:

● describe recent developments in the medical and surgical management of urology patients
● identify new technologies for the treatment of urologic problems
● analyze the potential challenges to urologic practice and specify possible solutions
● integrate the latest guidelines on the management of urological diseases into their practice

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this live activity for a maximum of 58.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credits™.

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

Resolution of Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

● Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director and/or Education Content Review Committee or its subgroup
● Limit content to evidence with no recommendations
● Introduction of a debate format with an unbiased moderator (point-counterpoint)
● Inclusion of moderated panel discussion
● Publication of a parallel or rebuttal article for an article that is felt to be biased
● Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
● Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA ATTENDEE INFORMATION & POLICIES

Disclaimer

The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images

Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.
Audio, Video and Photographic Equipment

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance

The American Urological Association (AUA), an organization accredited for continuing medical education (CME), complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.

Getting Your CME Credits or Certificate of Attendance

You can claim your CME/Certificate of Attendance several ways:

- Onsite: Hall A, CME Booth in Registration
  Saturday, 7:30 a.m. – 6 p.m.
  Sunday & Monday, 6:30 a.m. – 4 p.m.
  Tuesday, 6:30 a.m. – 5 p.m.
- Online
- Mobile App (iPhone, iPad, Android phones and tablets)

Note: All 2017 Annual Meeting CME credits/participation must be claimed by December 31, 2017. Credits/participation for the 2017 Annual Meeting cannot be claimed after this date. You must scan your badge upon entrance into courses and sessions (except for Plenary) offered for credit to have your credits automatically entered onto your transcript. All Plenary Session credits must be self-claimed with a valid badge login at the CME booth, online or via the Annual Meeting Mobile App. Credits will be awarded only to the person whose name is associated with the badge.

Questions? Email education@AUAnet.org.
<table>
<thead>
<tr>
<th>Specialty Programs</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>American College of Osteopathic Surgeons</td>
<td>109</td>
</tr>
<tr>
<td>American Society for Men’s Health</td>
<td>56</td>
</tr>
<tr>
<td>Asociación Española de Urología</td>
<td>277</td>
</tr>
<tr>
<td>Association Francaise d’Urologie</td>
<td>213</td>
</tr>
<tr>
<td>AUA/Brazilian Portuguese Urology Program</td>
<td>278</td>
</tr>
<tr>
<td>AUA/Confederación Americana de Urología</td>
<td>39</td>
</tr>
<tr>
<td>British Association of Urological Surgeons/Urological Society of Australia and New Zealand</td>
<td>210</td>
</tr>
<tr>
<td>Engineering and Urology Section of the Endourological Society</td>
<td>36</td>
</tr>
<tr>
<td>Geriatric Urological Society</td>
<td>209</td>
</tr>
<tr>
<td>Indian American Urological Association</td>
<td>37</td>
</tr>
<tr>
<td>Japanese Urological Association</td>
<td>210</td>
</tr>
<tr>
<td>Korean World Urologic Congress</td>
<td>207</td>
</tr>
<tr>
<td>Pan African Urological Surgeons Association/Caribbean Urological Association</td>
<td>281</td>
</tr>
<tr>
<td>Philippine Urological Association</td>
<td>282</td>
</tr>
<tr>
<td>Polish Urological Association and Hungarian Urological Association</td>
<td>139</td>
</tr>
<tr>
<td>R. Frank Jones Urological Society</td>
<td>211</td>
</tr>
<tr>
<td>Research on Calculus Kinetics (ROCK) Society</td>
<td>280</td>
</tr>
<tr>
<td>Sexual Medicine Society of North America</td>
<td>41</td>
</tr>
<tr>
<td>Sociedad Argentina de Urología</td>
<td>211</td>
</tr>
<tr>
<td>Società Italiana di Urologia</td>
<td>282</td>
</tr>
<tr>
<td>Society for Basic Urologic Research</td>
<td>109</td>
</tr>
<tr>
<td>Society for Basic Urologic Research/Society of Urologic Oncology</td>
<td>109</td>
</tr>
<tr>
<td>Society for Fetal Urology</td>
<td>18</td>
</tr>
<tr>
<td>Society for Infection and Inflammation in Urology</td>
<td>191</td>
</tr>
<tr>
<td>Society for Pediatric Urology</td>
<td>36</td>
</tr>
<tr>
<td>Society for the Study of Male Reproduction</td>
<td>208</td>
</tr>
<tr>
<td>Society of Academic Urologists</td>
<td>17</td>
</tr>
<tr>
<td>Society of Genitourinary Reconstructive Surgeons</td>
<td>55</td>
</tr>
<tr>
<td>Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction</td>
<td>57</td>
</tr>
<tr>
<td>Society of Urologic Oncology</td>
<td>125</td>
</tr>
<tr>
<td>Society of Urologic Robotic Surgery</td>
<td>207</td>
</tr>
<tr>
<td>Society of Women in Urology</td>
<td>160</td>
</tr>
<tr>
<td>Urologic Society for Transplantation and Renal Surgery</td>
<td>278</td>
</tr>
<tr>
<td>World Chinese Urological Society</td>
<td>37</td>
</tr>
</tbody>
</table>
### Thursday, May 11, 2017 7:00 am - 5:00 pm

#### 101 HO  
**HANDS-ON UROLOGIC ULTRASOUND**  
Pat Fulgham, Director  
Majid Eshghi, Christopher Porter, Stephen Savage,  
Eric Singer, Craig Smith, Philip Wise, Lewis Chan  
Rooms 106 and 107ABC

### Friday, May 12, 2017 7:30 am - 6:00 pm

#### 01 IC  
**NOCTURIA: ADVANCES IN DIAGNOSIS AND MANAGEMENT**  
Jeffrey Weiss, Director  
Room 253C

#### 02 IC  
**CHEMOTHERAPY AND IMMUNOTHERAPY OPTIONS FOR GENITOURINARY MALIGNancies**  
Costas Lallas, Director  
Anne Calvaresi, Edouard Trabulsi  
Room 258A

#### 03 IC  
**UROLOGICAL CARE FOR THE PATIENT WITH A PROGRESSIVE NEUROLOGICAL CONDITION**  
John Stoffel, Director  
Anne P. Cameron, Anne Suskind  
Room 258B

#### 04 IC  
**RISK-STRATIFICATION OF LOCALIZED RENAL MASSES**  
Mohamad Allaf, Director  
Steven Campbell, Phillip Pierorazio, Robert Uzzo  
Room 258C

#### 05 IC  
**SUCCESSFUL INTEGRATION OF ADVANCED PRACTICE NURSES AND PHYSICIAN ASSISTANTS INTO UROLOGY PRACTICES**  
Claus Roehrborn, Director  
Brad Hornberger  
Room 259AB

#### 06 IC  
**REAL MEN GET REAL PELVIC PAIN**  
Jeannette Potts, Director  
Rhonda Kotarinos, Dean Tripp  
Room 253C

#### 07 IC  
**PHOToselective VAPORIZATION Of THE PROSTATE (PVP) AND GREEN LASER ENucleATION Of THE PROSTATE (GREENLEP) USING THE 532NM LITHIUM TRIBORATE LASER**  
Henry Woo, Director  
Fernando Gómez-Sancha, Oliver Reich  
Room 257AB

#### 08 IC  
**BOTULINUM TOXIN: WHY USE IT, HOW TO DO IT, WHAT ARE THE RESULTS?**  
Michael Chancellor, Director  
Room 258B
17 IC  TESTICULAR CANCER: CURRENT CONCEPTS AND CONTROVERSIES  
Joel Sheinfeld, Director  
George Bosl, Brett Carver  
Room 253C  

18 IC  PROSTATE CANCER FOCAL THERAPY: IS IT THE RIGHT TIME FOR YOUR PRACTICE?  
John Davis, Director  
Peter Pinto, Ardeshr Rastinehad, Ashutosh Tewari  
Room 258A  

19 IC  AUA GUIDELINES UPDATE: MEDICAL AND SURGICAL MANAGEMENT OF RENAL AND URETERAL STONES  
Ojas Shah, Director  
Dean Assimos, David Goldfarb, James Lingeman, Brian Matlaga  
Room 253C  

20 IC  CODING AND REIMBURSEMENT UPDATE 2017  
Ronald Kaufman, Director  
Jonathan Rubenstein, Stephanie Stinchcomb  
Room 257AB  

21 IC  INFERTILITY UPDATE 2017: A COMPREHENSIVE APPROACH TO THE CLINICAL DIAGNOSIS AND TREATMENT OF THE INFERTILE MALE (TRADUCIDO EN ESPAÑOL)  
Larry Lipshultz, Director  
Robert Brannigan, Michael Eisenberg  
Room 258B  

22 IC  MANAGEMENT OF URETERAL STRicture DISEASE  
Louis Kavoussi, Director  
Sammy Elsamra, Thomas Jarrett, Richard Link  
Room 258A  

23 IC  ROBOTIC UPPER URINARY TRACT RECONSTRUCTION: A TOP TO BOTTOM APPROACH  
Michael Stifelman, Director  
Daniel Eun, Raju Thomas, Lee Zhao  
Room 258C  

24 IC  PESADILLAS EN ENDOUROLOGÍA (ESTE CURSO SE PRESENTA SÓLO EN ESPAÑOL)  
Daniel Olvera-Posada, Director  
Brian Eisner, Carlos Mendez-Probst  
Room 253C  

25 IC  WHAT A GENERAL UROLOGIST SHOULD KNOW ABOUT CARE OF TRANSGENDER PATIENTS  
Dmitriy Nikolavsky, Director  
Curtis Crane, Lee Zhao  
Room 257AB  

26 IC  CONTEMPORARY PHARMACOTHERAPY FOR OAB  
Eric Rovner, Director  
Christopher Chapple, Alan Wein  
Room 258A  

27 IC  DISORDERS OF THE PENIS: PEYRONIE’S DISEASE, CONGENITAL CURVATURE, AND ADULT ACQUIRED BURIED PENIS  
Laurence Levine, Director  
David Ralph  
Room 258B  

28 IC  NEW TECHNOLOGY IN THE MANAGEMENT OF STONE DISEASE: WHAT’S NEW, WHAT WORKS, AND WHAT TO BUY  
Bodo Knudsen, Director  
Ben Chew, Mitchell Humphreys  
Room 258C  

29 IC  MANAGEMENT OF INFERTILITY IN MEN WITH SPINAL CORD INJURY: A CURRICULUM FOR PRACTITIONERS  
Charles Lynne, Director  
Nancy Brackett, Emad Ibrahim  
Room 259AB  

30 IC  MR US FUSION GUIDED PROSTATE BIOPSY: INTEGRATING MP MRI AND BIOPSY INTO YOUR UROLOGIC PRACTICE FOR SCREENING, DIAGNOSIS AND TREATMENT PLANNING  
Peter Pinto, Co-Course Director  
Ardeshir Rastinehad, Co-Course Director  
Rooms 106 and 107ABC  

31 IC  PROSTATE MR IMAGING: WHAT A UROLOGIST SHOULD KNOW  
Rajan Gupta, Co-Director  
Ardeshir Rastinehad, Co-Director  
Eran Ben-Levi, Peter Choyke, Ismail Baris Turkbey  
Room 106
### 1:00 pm - 3:00 pm

**104 HO**  
**Title:** PROSTATE MR IMAGING: WHAT A UROLOGIST SHOULD KNOW (HANDS-ON SESSION)  
**Director:** Ardeshir Rastinehad  
**Room:** 107ABC

### 1:30 pm - 3:30 pm

**30 IC**  
**Title:** HOW GENERAL UROLOGISTS CAN EVALUATE AND TREAT MALE INFERTILITY  
**Directors:** Marc Goldstein, Peter Chan, Mark Sigman  
**Room:** 253C

**31 IC**  
**Title:** SURGEONS AS EDUCATORS: A PRIMER FOR ACADEMIC DEVELOPMENT AND TEACHING EXCELLENCE  
**Directors:** Tobias Kohler, Kurt McCammon, Bradley Schwartz  
**Room:** 257AB

**32 IC**  
**Title:** UROLOGY 911: HANDLING INTRAOPERATIVE CONSULTS  
**Directors:** Michael Schwartz, Brian Duty, Jessica Kreshover  
**Room:** 258A

**33 IC**  
**Title:** FOUNDATIONS OF FEMALE UROLOGY  
**Directors:** J. Christian Winters, Stephen Kraus, Nirit Rosenblum  
**Room:** 258B

**34 IC**  
**Title:** MANAGING MALE AND FEMALE IC/BPS: COMPREHENSIVE MULTIMODAL THERAPY FOR PATIENTS WITH UROLOGIC PELVIC PAIN  
**Directors:** Robert Evans, Jennifer Fariello, Robert Moldwin  
**Room:** 259AB

### 3:30 pm - 5:30 pm

**105 HO**  
**Title:** PROSTATE MR IMAGING: WHAT A UROLOGIST SHOULD KNOW (HANDS-ON SESSION)  
**Director:** Ardeshir Rastinehad  
**Room:** 107ABC

### 4:00 pm - 6:00 pm

**35 IC**  
**Title:** UROLOGICAL TRAUMA AND RECONSTRUCTION  
**Directors:** Michael Coburn, Noel Armenakas, Steven Hudak  
**Room:** 253C

**36 IC**  
**Title:** ENDOUROLOGIA AVANZADA - MANEJO DE CIRUGIA RENAL PERCUTEA Y CIRUGIA INTRARRENAL RETROGRADA COMPLEJA (ESTE CURSO SE PRESENTA SÓLO EN ESPAÑOL)  
**Directors:** Jorge Gutierrez-Aceves, Jose Amon Sesmero, Francisco Daels  
**Room:** 257AB

**37 IC**  
**Title:** SURGICAL MANAGEMENT OF STONES: HOW TO DO IT LIKE THE EXPERTS  
**Directors:** Stephen Nakada, Margaret Pearle  
**Room:** 258A

**38 IC**  
**Title:** VAGINAL SURGERY FOR THE UROLOGIST  
**Directors:** Victor Nitti, Benjamin Brucker  
**Room:** 258B

**39 IC**  
**Title:** COMPLICATIONS OF ROBOTIC UROLOGICAL SURGERY: PREVENTION, RECOGNITION AND MANAGEMENT  
**Directors:** Rene Sotelo, Monish Aron, Reza Ghavamian, Joseph Smith  
**Room:** 258C

**40 IC**  
**Title:** UROGENITAL TRACT INFECTIONS: EMERGING THREATS AND CLINICAL GUIDELINES  
**Directors:** Florian Wagenlehner, Kurt Naber, Daniel Shoskes  
**Room:** 259AB

### Sunday, May 14, 2017

#### 7:30 am - 6:00 pm

**41 IC**  
**Title:** MANAGEMENT OF COMPLEX URINARY COMPLICATIONS FOLLOWING TREATMENT FOR PROSTATE CANCER  
**Directors:** Jaspreet Sandhu, Kurt McCammon, O. Lenaine Westney  
**Room:** 253C

**42 IC**  
**Title:** PROSTATE CANCER DIAGNOSTICS: BIOMARKERS, MRI, AND BIOPSY TECHNIQUES  
**Directors:** Daniel Barocas, Scott Eggener, John Wei  
**Room:** 257AB

**43 IC**  
**Title:** PRACTICAL MEDICAL MANAGEMENT OF NEPHROLITHIASIS - A GUIDELINES AND CASE-BASED APPROACH  
**Directors:** Glenn Preminger, Roger Sur  
**Room:** 258A

**44 IC**  
**Title:** AUA GUIDELINES 2017: EVALUATION AND MANAGEMENT OF LOCALIZED RENAL MASS  
**Directors:** Steven Campbell, Mohamad Allaf, Brian Lane, Robert Uzzo  
**Room:** 258B

**45 IC**  
**Title:** TRANSURETHRAL RESECTION OF BLADDER CANCER - A DECEPTIVELY DIFFICULT COMMON OPERATION - HOW TO IMPROVE  
**Directors:** Mark Soloway, Arthur Sagalowsky, Alexandre Zlotta  
**Room:** 258C
### OFFICE OF EDUCATION COURSES

**ALL COURSES ARE APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

<table>
<thead>
<tr>
<th>Course Code</th>
<th>Title</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>46 IC</td>
<td>CREATING A SUCCESSFUL MEN'S HEALTH CENTER - AN EVIDENCE BASED APPROACH</td>
<td>8:00 am - 11:00 am</td>
<td>Room 259AB</td>
</tr>
<tr>
<td>47 IC</td>
<td>OPTIMIZING PROSTATE CANCER DIAGNOSTICS: TRANSPERINEAL, TRANSRECTAL AND MRI-ULTRASOUND FUSION TARGETED BIOPSIES</td>
<td>10:00 am - 12:00 pm</td>
<td>Room 253C</td>
</tr>
<tr>
<td>48 IC</td>
<td>URINARY DIVERSION AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY</td>
<td>2:00 pm - 3:30 pm</td>
<td>Room 257AB</td>
</tr>
<tr>
<td>49 IC</td>
<td>URODYNAMIC EVALUATION &amp; ADVANCES IN MANAGEMENT OF ADULT NEUROGENIC BLADDER: A CASE BASED APPROACH</td>
<td>4:00 pm - 5:00 pm</td>
<td>Room 258A</td>
</tr>
<tr>
<td>50 IC</td>
<td>MOLECULAR IMAGING IN UROLOGY: STATE OF THE ART AND FUTURE DIRECTIONS</td>
<td>6:00 pm - 7:00 pm</td>
<td>Room 258B</td>
</tr>
<tr>
<td>51 IC</td>
<td>CATASTROPHIES, COMPLICATIONS AND CORRECTIONS IN PERCUTANEOUS RENAL SURGERY</td>
<td>7:00 pm - 8:00 pm</td>
<td>Room 258C</td>
</tr>
<tr>
<td>52 IC</td>
<td>FLAPS IN PELVIC RECONSTRUCTIVE SURGERY</td>
<td>8:00 pm - 9:00 pm</td>
<td>Room 259AB</td>
</tr>
<tr>
<td>53 IC</td>
<td>NEW TECHNIQUES IN BPH SURGERY: ENDOSCOPIC ENUCLEATION</td>
<td>9:00 pm - 10:00 pm</td>
<td>Room 253C</td>
</tr>
<tr>
<td>54 IC</td>
<td>COMMON PROBLEMS IN PEDIATRIC UROLOGY: WHAT EVERY UROLOGIST SHOULD KNOW</td>
<td>10:00 am - 11:00 am</td>
<td>Room 257AB</td>
</tr>
<tr>
<td>55 IC</td>
<td>TESTOSTERONE THERAPY: CHALLENGES AND CONTROVERSIES FOR THE EXPERIENCED CLINICIST</td>
<td>11:00 am - 12:00 pm</td>
<td>Room 258A</td>
</tr>
<tr>
<td>56 IC</td>
<td>DIFFICULT CASES IN HIGH RISK BLADDER CANCER: AN EVIDENCE BASED APPROACH</td>
<td>2:00 pm - 3:00 pm</td>
<td>Room 259AB</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Course Code</th>
<th>Title</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>57 IC</td>
<td>MULTI-DISCIPLINARY, INTERACTIVE TUMOR BOARD: MRI-TRUS FUSION GUIDED PROSTATE BIOPSY</td>
<td>3:00 pm - 4:00 pm</td>
<td>Room 258C</td>
</tr>
<tr>
<td>58 IC</td>
<td>MAINTAINING AND RESTORING WOMEN'S SEXUAL FUNCTION</td>
<td>4:00 pm - 5:00 pm</td>
<td>Room 259AB</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Course Code</th>
<th>Title</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>59 IC</td>
<td>PRACTICAL URORADIOLOGY: THE OFFICE BASED INTERPRETATION OF UROLOGIC RADIOGRAPHIC STUDIES</td>
<td>5:00 pm - 6:00 pm</td>
<td>Room 253C</td>
</tr>
<tr>
<td>60 IC</td>
<td>PEROIOPERATIVE OPIOID-SPARING ANALGESIA STRATEGIES FOR ENHANCED RECOVERY AFTER UROLOGIC SURGER</td>
<td>6:00 pm - 7:00 pm</td>
<td>Room 257AB</td>
</tr>
<tr>
<td>61 IC</td>
<td>MANAGEMENT OF COMMON DILEMMAS IN PROSTATE CANCER DIAGNOSIS AND TREATMENT</td>
<td>7:00 pm - 8:00 pm</td>
<td>Room 257AB</td>
</tr>
<tr>
<td>62 IC</td>
<td>CREATIVE THINKING: UNDERSTANDING AND DEVELOPING YOUR INNOVATIVE ABILITIES</td>
<td>8:00 pm - 9:00 pm</td>
<td>Room 259AB</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 am - 9:30 am</td>
<td>HOW LASERS WORK - WHAT UROLOGISTS DON'T KNOW THAT THEY DON'T KNOW</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lori Lerner, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinton Collins</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 256C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 am - 9:30 am</td>
<td>PARADIGM CHANGES IN A 40 YEAR OLD OPERATION: INFATILABLE PENILE IMPLANT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(IPP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steven Wilson, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paul Pento, Robert Valenzuela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 259AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 am - 9:30 am</td>
<td>NUTRITION COUNSELING FOR THE PREVENTION OF UROLITHIASIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patrick Lowry, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sutchin Patel, Kristina Penniston</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 253C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 am - 9:30 am</td>
<td>EXTRAPERITONEAL LAPAROSCOPIC AND ROBOTIC UROLOGIC SURGERY</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jean Joseph, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hitlen Patel, Christian Pavlovich, James Porter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 257AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 am - 9:30 am</td>
<td>AUA GUIDELINES 2017: SURGICAL MANAGEMENT OF FEMALE STRESS URINARY</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>INCONTINENCE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kathleen Kobashi, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gary Lemack</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 258A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 am - 9:30 am</td>
<td>PROSTATE CANCER UPDATE 2017 (TRADUCIDO EN ESPAÑOL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>William Catalona, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Douglas Dahl, Stanley Liao, Stacy Loeb, Robert Nadler, Russell Szmulewitz</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 258B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 am - 9:30 am</td>
<td>ADVANCED ROBOTIC UROLOGIC ONCOLOGY: EXTREME UNFORGETTABLE CASES AND</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>THEIR MANAGEMENT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vipul Patel, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>David Albala, Sam Bhayani, Rafael Coelho, Alexandre Mottrie, Bernardo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maria Rocco</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 258C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 am - 9:30 am</td>
<td>THE ROLE OF SACRAL NEUROMODULATION IN UROLOGICAL PRACTICE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steven Siegel, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 259AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 am - 12:00 pm</td>
<td>ROBOT-ASSISTED RADICAL PROSTATECTOMY: BEYOND THE LEARNING CURVE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>John Davis, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fatih Atug, Declan Murphy, Koon Rha, Kevin Zorn</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 259AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 am - 12:00 pm</td>
<td>PRIMARY AND REOPERATIVE HYPOSPADIAS REPAIR: EVIDENCE-BASED DECISION</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MAKING</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Warren Snodgrass, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nicol Bush</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 257AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 am - 12:00 pm</td>
<td>ADVANCED URETEROSCOPY: OVERCOMING CHALLENGING PROBLEMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michael Grasso, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Demetrius Bagley, Scott Hubosky, Olivier Traxer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 258C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 pm - 3:30 pm</td>
<td>THE PRACTICAL MANAGEMENT OF OVERACTIVE BLADDER: INTEGRATING THE SUFU</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>OVERACTIVE BLADDER CLINICAL CARE PATHWAY INTO YOUR PRACTICE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Benjamin Brucker, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stephen Krause, Diane Newman</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 258A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 pm - 3:30 pm</td>
<td>AUA GUIDELINES 2017: MUSCLE INVASIVE BLADDER CANCER</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jeffrey Holzbeierlein, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jeff Michalski, Jonathan Rosenberg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 258B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 pm - 3:30 pm</td>
<td>NOVEL AGENTS AND CONCEPTS IN THE MANAGEMENT OF HORMONE NAÏVE AND</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CASTRATION RESISTANT PROSTATE CANCER</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Judd Moul, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lawrence Karah, Christopher Sweeney</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 253C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 pm - 3:30 pm</td>
<td>GLOBAL PERSPECTIVES IN URETHRAL RECONSTRUCTION</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hunter Wessells, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guido Barbari, Sanjay Kulkani</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 253C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 pm - 3:30 pm</td>
<td>GUIDELINES BASED EVALUATION AND TREATMENT OF MLUTS AND BPH</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steven Kaplan, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claus Roehrborn</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 257AB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 pm - 3:30 pm</td>
<td>EVALUATION AND MANAGEMENT OF URINARY TRACT BLEEDING: FROM ASYMPTOMATIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MICROHEMATURIA TO INTRACTABLE HEMORRHAGIC CYSTITIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stephen Boorjian, Jay Raman</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 258A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 pm - 3:30 pm</td>
<td>TESTOSTERONE: DIAGNOSIS AND MANAGEMENT OF THE HYPOGONADAL MALE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wayne Hellstrom, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mohit Khera, Martin Miner</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 258B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 pm - 3:30 pm</td>
<td>HOW TO PREPARE AND GIVE MORE EFFECTIVE MEDICAL PRESENTATIONS: IMPROVING</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>YOUR SLIDES AND TIPS ON BETTER PUBLIC SPEAKING</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stephen Leslie, Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 259AB</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# OFFICE OF EDUCATION COURSES

**ALL COURSES ARE APPROVED FOR **AMA PRA CATEGORY 1 CREDIT™**

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Title</th>
<th>Instructor(s)</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 pm - 6:00 pm</td>
<td><strong>82 IC</strong> VASECTOMY: A VERY PRACTICAL CASE-BASED COURSE ON PREOPERATIVE, INTRAOPERATIVE AND POSTOPERATIVE MANAGEMENT</td>
<td>Ira Sharlip, Director, Stanton Honig, Joel Marmar, Jay Sandlow</td>
<td>85 IC</td>
</tr>
<tr>
<td></td>
<td><strong>83 IC</strong> EVALUATION AND MANAGEMENT OF PEDIATRIC BLADDER AND BOWEL DYSFUNCTION</td>
<td>Lane Palmer, Director, Paul Austin, Christopher Cooper</td>
<td>86 IC</td>
</tr>
<tr>
<td></td>
<td><strong>84 IC</strong> REOPERATIVE PELVIC FLOOR MEDICINE: FOR THE UROLOGIST AND GYNECOLOGIST</td>
<td>Roger Dmochowski, Director, Howard Goldman, Alexander Gomelsky, Mickey Karram</td>
<td>87 IC</td>
</tr>
<tr>
<td>Tuesday, May 16, 2017</td>
<td><strong>85 IC</strong> MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER: PRACTICAL SOLUTIONS FOR COMMON PROBLEMS</td>
<td>Cheryl Lee, Director, Ashish Kamat, Kamal Pohar, J. Alfred Wiljes</td>
<td>88 IC</td>
</tr>
<tr>
<td></td>
<td><strong>86 IC</strong> AUA GUIDELINE UPDATE: CASTRATION-RESISTANT PROSTATE CANCER</td>
<td>Michael Cookson, Director, Adam Kibel, William Lowrance</td>
<td>89 IC</td>
</tr>
<tr>
<td></td>
<td><strong>87 IC</strong> GERIATRIC UROLOGY: BASIC PRINCIPLES FOR UROLOGIC PRACTICE</td>
<td>Tomas Griebling, Director, Camille Vaughan</td>
<td>90 IC</td>
</tr>
<tr>
<td>7:30 am - 9:30 am</td>
<td><strong>88 IC</strong> FILM STUDY TO IMPROVE SURGICAL OUTCOMES – WATCHING AND UNDERSTANDING LAPAROSCOPIC/ROBOTIC SURGERY STEP-BY-STEP</td>
<td>Wesley White, Director, James Bienvenu, Georges Pascal Haber, David Thiel</td>
<td>91 IC</td>
</tr>
<tr>
<td></td>
<td><strong>89 IC</strong> MANAGEMENT OF PROSTATE CANCER: A CASE BASED APPROACH WITH EMPHASIS ON INTEGRATING NEW MOLECULAR DIAGNOSTICS INTO CLINICAL PRACTICE</td>
<td>Eric Klein, Director, Andrew Stephenson</td>
<td>92 IC</td>
</tr>
<tr>
<td></td>
<td><strong>90 IC</strong> ADVANCED PERCUTANEOUS NEPHROLITHOTOMY</td>
<td>Evangelos Liatsikos, Director, John Denstedt, Mantu Gupta, Thomas Knoll</td>
<td>93 IC</td>
</tr>
<tr>
<td></td>
<td><strong>91 IC</strong> UROLITHIASIS: METABOLIC EVALUATION AND MEDICAL TREATMENT</td>
<td>Michael Lipkin, Director, Jodi Antonelli, Sara Best, Brian Eisner</td>
<td>94 IC</td>
</tr>
<tr>
<td></td>
<td><strong>92 IC</strong> CONTEMPORARY EVALUATION AND MANAGEMENT OF BILATERAL, MULTIFOCAL, OR HEREDITARY RENAL CELL CARCINOMA: A CASE BASED APPROACH</td>
<td>Gennady Bratslavsky, Director, Adam Metwalli, Eric Singer</td>
<td>95 IC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Title</th>
<th>Instructor(s)</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 am - 12:00 pm</td>
<td><strong>93 IC</strong> SUPINE VS. PRONE PERCUTANEOUS NEPHROLITHOTOMY: PATIENT SELECTION, POSITIONING AND DIRECT VISION PERCUTANEOUS RENAL ACCESS. SAFER, FASTER, EASIER.</td>
<td>James Borin, Director, Brian Eisner, Guido Giusti</td>
<td>94 IC</td>
</tr>
<tr>
<td></td>
<td><strong>94 IC</strong> ACTIVE SURVEILLANCE FOR PROSTATE CANCER</td>
<td>Laurence Klotz, Director, Mark Emberton, Ian Thompson</td>
<td>95 IC</td>
</tr>
<tr>
<td></td>
<td><strong>95 IC</strong> LYMPH NODE DISSECTION FOR UROLOGICAL CANCERS: INDICATIONS, TEMPLATES, TECHNIQUES AND ONCOLOGICAL AS WELL AS FUNCTIONAL OUTCOMES</td>
<td>Agostino Mattei, Director, R. Jeffrey Karnes, Jochen Walz</td>
<td>96 IC</td>
</tr>
</tbody>
</table>
8:00  WELCOME AND INTRODUCTION
     Program Chairs: Benjamin Breyer, Badrinath Konety

8:05  RESIDENT EDUCATION IN A MANAGED CARE SETTING
     BENEFITS/CHALLENGES OF A PRIVATE PRACTICE ROTATION
     Kathleen Kobashi

8:20  UNIQUE ADVANTAGES OF A NON-UNIVERSITY BASED RESIDENCY PROGRAM
     Gary W. Chien

8:40  SIMULATION IN RESIDENT EDUCATION
     NEW ADVANCES IN SIMULATION BASED EDUCATION
     Robert Sweet

9:00  JUDGING THE IMPACT OF SIMULATION ON RESIDENT PERFORMANCE
     Kristin Chrouser

9:15  INTERNATIONAL EDUCATION OPPORTUNITIES FOR RESIDENTS
     GLOBAL VOLUNTEERISM
     Catherine DeVries

9:30  BENEFITS OF INTERNATIONAL EXPOSURE IN RESIDENCY TRAINING
     Kurt McCammon

9:40  SOCIETY OF WOMEN IN UROLOGY UPDATE
     Kathleen Kieran

9:50  BREAK

10:10 PREDICTORS OF A SUCCESSFUL UROLOGY RESIDENT USING MED-STUDENT APPLICANT MATERIALS
     R. Houston Thompson

10:20 HOT OFF OF THE PRESS: NEW REGULATIONS
     Chad Ritenour

10:50 GLOBAL HEALTHCARE AND RESIDENT EDUCATION
     INTERNATIONAL BOARD CERTIFICATION PATHWAY- OPPORTUNITY FOR ENHANCING GLOBAL HEALTHCARE?
     John Denstedt

11:10 AUA APPROACH TO GLOBAL RESIDENT EDUCATION
     Inderbir Gill

11:30 ABU UPDATE
     Gerald Jordan

11:45 AUA OFFICE OF EDUCATION UPDATE
     Victor Nitti

12:00 LUNCH - ANNUAL BUSINESS MEETING

1:00 GRANT RECIPIENT REPORTS

SERIOUS GAMES: COMPETITION VS. INCENTIVES TO ENGAGE RESIDENT IN QUALITY-IMPROVEMENT EDUCATION
     Charles Scales

ASSESSING SURGICAL SKILLS AMONG UROLOGY RESIDENT APPLICANTS: CAN CROWD SOURCING IDENTIFY THE NEXT GENERATION OF SURGEONS?
     Ralph Clayman

MULTI-INSTITUTIONAL TRIAL OF A COMPUTER-BASED ASSESSMENT OF SURGICAL SKILL (C-BASS)
     Joel Koenig

WORKFORCE UPDATE - PANEL DISCUSSION
     Moderator: Eila Skinner

WOMEN IN THE WORKFORCE
     Panelists: E. Ann Gormley, Sima Porten, Angela Smith

DIVIDENDS FROM ENHANCING DIVERSITY AMONG RESIDENTS AND FACULTY
     Panelists: Arthur Burnett, Tracy Downs, Cheryl Lee, Christopher Warlick

IMPACT OF HEALTHCARE REFORM AND RE-REFORM
     Patrick McKenna

THE COMPLETE DEAN: 350 YEARS OF LEADERSHIP LESSONS
     Ralph Clayman

LEADERSHIP IN UROLOGY: IS IT FOR YOU?
     Stephen Nakada

THE CHANGING FACE OF ACADEMIC HEALTH SYSTEMS
     Louis Kavoussi

BURNOUT IN UROLOGY
     Raj Pruthi

APP - TRAINING AND DEVELOPMENT

PREVALENCE OF APP INCORPORATION INTO THE UROLOGIC WORKFORCE
     Bradley Erickson

ESTABLISHING A SPECIALIZED UROLOGY TRAINING PROGRAM FOR APPS
     Bradley Leibovich

AUA OFFICE OF RESEARCH UPDATE
     Aria Olumi

WRAP-UP/ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Co-Course Directors</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>PRESENTATIONS AND DISCUSSION</td>
<td>Michael Cookson,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Jarrard</td>
</tr>
<tr>
<td>5:00</td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>

**Thursday, May 11, 2017 6:00 pm - 8:00 pm**

**SOCIETY FOR FETAL UROLOGY (SFU)**

Room 208 @ Boston Convention & Exhibition Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00</td>
<td>SFU CASE PRESENTATIONS</td>
</tr>
<tr>
<td>8:00</td>
<td>ADJOURN</td>
</tr>
</tbody>
</table>
Friday, May 12, 2017

Plenary: Prime Time, Friday Morning Session

8:00 am - 11:30 am

Ballroom West @ Boston Convention & Exhibition Center

8:00 SURGICAL TECHNIQUES: RADICAL PROSTATECTOMY
Moderator: Prokar Dasgupta
Radical Perineal Prostatectomy: Michael Harris
Laparoscopic Prostatectomy: Karim Touijer
Single-Port Robotic Perineal Prostatectomy: Jihad Kaouk

9:00 TUMOR BOARD: PROSTATE CANCER
Moderator: Andrew Stephenson
Panelists: Anthony D'Amico, Adam Kibel, Stacy Loeb, Matthew Smith

9:30 TUMOR BOARD: TESTIS CANCER
Moderator: Joel S. Sheinfeld
Panelists: Clair Beard, Michael Jewett, Phillip Pierorazio, Philip Saylor

9:55 TUMOR BOARD: BLADDER CANCER
Moderator: Mark Soloway
Panelists: Jason Elstsathou, Ashish Kamat, Richard Lee, Chad Ritch

10:20 TUMOR BOARD: KIDNEY CANCER
Moderator: W. Marston Linehan
Panelists: Michael Blute, Toni Choueiri, Jonathan Coleman, M. Dror Michaelson

10:50 AUA GUIDELINES 2017: MUSCLE INVASIVE BLADDER CANCER
Jeffrey Holzbeierlein

11:00 AUA GUIDELINES 2017: RENAL CELL CANCER
Steven Campbell

11:10 AUA GUIDELINES 2017: LOCALIZED PROSTATE CANCER-LOW RISK
Jeffrey Cadeddu

11:15 AUA GUIDELINES 2017: LOCALIZED PROSTATE CANCER-INTERMEDIATE RISK
Martin Sanda

11:25 AUA GUIDELINES 2017: LOCALIZED PROSTATE CANCER-HIGH RISK
Mary Taplin

11:30 SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 12, 2017

Plenary: Prime Time, Friday Afternoon Session

1:00 pm - 4:00 pm

COURT IS IN SESSION: CLINICAL LESSONS THROUGH A LEGAL LENS

Ballroom West @ Boston Convention & Exhibition Center

1:00 COURT IS IN SESSION: JUDGE’S OPENING REMARKS AND INTRODUCTIONS
Judge: Vijaya Vemulakonda
Attorneys: Glenn Dopf, John Cassidy

1:10 CASE 1: COLOSTOMY AFTER ROBOTIC PROSTATECTOMY
Moderator: Christopher Evans
Expert Witness (Plaintiff): Gerald Andriole
Expert Witness (Defense): Christopher Kane
Defendant: Alejandro Rodriguez

2:05 CASE 2: MYOCARDIAL INFARCTION ON ANDROGEN REPLACEMENT THERAPY
Moderator: Culley Carson
Expert Witness (Plaintiff): John Mulhall
Expert Witness (Defense): Mohit Khera
Defendant: Mark Lindgren

3:00 CASE 3: SEPSIS AFTER MINI-PCNL
Moderator: Stephen Nakada
Expert Witness (Plaintiff): Qjas Shah
Expert Witness (Defense): Glenn Preminger
Defendant: Zeph Okeke

4:00 SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP01-01</td>
<td>STENT EARLY ENCRUSTATION (SEE) STUDY: FACTORS ASSOCIATED WITH ACUTE CALCIFICATIONS William T. Berg*, Yefim Sheynkin, David Schulsinger, Stony Brook, NY</td>
</tr>
<tr>
<td>MP01-02</td>
<td>A NOMOGRAM FOR PREDICTING URETERAL STONE PASSAGE Vishnu Ganesan*, Michael Kattan, Cleveland, OH, Christopher Loftus, Seattle, WA, Bryan Hinck, Daniel Greene, Yaw Nyame, Sri Sivalingam, Manoj Monga, Cleveland, OH</td>
</tr>
<tr>
<td>MP01-03</td>
<td>PATIENT CENTERED FACTORS INFLUENCING URETERAL STONE PASSAGE Andrew Portis*, Jennifer Portis, Suzanne Neises, St Paul, MN</td>
</tr>
<tr>
<td>MP01-04</td>
<td>INNOVATION IN URETERAL STONE CARE DELIVERY AFTER EMERGENCY DEPARTMENT (ED) VISIT: MATCHED CONTROLLED STUDY. Abdulrahman Alruwaily*, Sapan Ambani, Steven Kronick, Gary Faerber, John Hollingsworth, William Roberts, J. Stuart Wolf, Jr., ANN ARBOR, MI</td>
</tr>
<tr>
<td>MP01-05</td>
<td>CAN A STONE OBSTRUCTING THE URETER CEASE TO CAUSE PAIN? Natalia Hernandez, Yan Song, Sarah Mozaifarpoor*, Brian Eisner, Boston, MA</td>
</tr>
<tr>
<td>MP01-07</td>
<td>THE ADDED UTILITY OF DIGITAL TOMOSYNTHESIS TO STANDARD ABDOMINAL RADIOGRAPHY FOR IDENTIFICATION OF URINARY CALCULI Daniel Wollin*, Rajan Gupta, Brian Young, Eugene Cone, Adam Kaplan, Daniele Marin, Bhavik Patel, Michael Ferrandino, Glenn Preminger, Michael Lipkin, Durham, NC</td>
</tr>
<tr>
<td>MP01-08</td>
<td>USE OF DEDICATED STONE ANALYSIS SOFTWARE TO ASSESS URINARY STONE SIZE: TOWARDS SEMI-AUTOMATED METRICS TO ENHANCE PREDICTION OF SPONTANEOUS STONE PASSAGE Scott Heiner*, John Lieske, Roy Marcus, John Knoedler, Shane Dirks, Joel Fletcher, Cynthia McCollough, Rochester, MN</td>
</tr>
<tr>
<td>MP01-09</td>
<td>IMPLEMENTING ULTRASOUND AND KIDNEY, URETER, BLADDER FILM AS FIRST-LINE IMAGING REQUIREMENTS FOR PATIENTS WITH KNOWN URINARY CALCULOUS DISEASE IN AN OUTPATIENT SETTING Robert Medairos, M. Ryan Farrell*, Chicago, IL, Jacob Hess, Deborah Lamm, Christopher Buckle, Deerfield, IL, Christopher Coogan, Chicago, IL</td>
</tr>
<tr>
<td>MP01-11</td>
<td>CT-BASED DIAGNOSIS OF VISCERAL OBESITY IS ASSOCIATED WITH LOW URINARY PH, URIC ACID NPHROLITHIASIS, AND LARGER STONE VOLUMES Nishant D. Patel*, Ryan Ward, Juan Calle, Erick Remer, Manoj Monga, Cleveland, OH</td>
</tr>
<tr>
<td>MP01-12</td>
<td>THE ASSOCIATION OF HEMOGLOBIN A1C AND URINARY OXALATE IN STONE FORMERS Kyle Wood*, Birmingham, AL, Marc Colaco, Winston-Salem, NC, John Knight, Ross Holmes, Dean Assimos, Birmingham, AL</td>
</tr>
<tr>
<td>MP01-13</td>
<td>IS THERE A SHIFT FROM INFECTIOUS STONES IN STAGHORN CALCULI? Tyler Haden*, Paige Kuhlmann, Jacqueline Ross, Stephen Kalkhoff, Carrie Johans, Alex Jones, Stephen Weinstein, Mark Wakefield, Daniel Hoyt, James Cummings, Naveen Pokala, Columbia, MO</td>
</tr>
<tr>
<td>MP01-14</td>
<td>DO METABOLIC FACTORS INFLUENCE THE FORMATION AND RECURRENT OF BLADDER CALCULI? Julie Thai*, Tim Tran, Egor Parkhomenko, Mantu Gupta, New York, NY</td>
</tr>
</tbody>
</table>
MP01-16 **METABOLIC SYNDROME INCREASES THE RISK FOR CALCIUM OXALATE STONE FORMATION: RESULTS FROM A NATIONWIDE SURVEY ON UROLITHIASIS IN JAPAN**

Akinori Iba*, Yasuo Kohjimoto, Takashi Iguchi, Shimpei Yamashita, Satoshi Nishizawa, Kazuro Kikkawa, Isao Harah, Wakayama, Japan

MP01-17 **AGE, SEX, AND CLIMATE DIFFERENCES IN THE TEMPERATURE-DEPENDENCE OF KIDNEY STONE PRESENTATION**


MP01-18 **PRECIPITATION (AND NOT TEMPERATURE) IS ASSOCIATED WITH URINARY STONE DISEASE IN CALIFORNIA**

Kai Dallas*, Stanford, CA, Simon Conti, John Leppert, Palo Alto, CA, Christopher Elliott, Santa Clara, CA, Mario Sofer, Tel Aviv, Israel, Alan Thong, Palo Alto, CA

MP01-19 **RECENT EPIDEMIOLOGICAL AND METABOLIC TRENDS IN STONE DISEASE: RISING HYPOCITRATURIA AND HYPOXALURIA**

Ramy F. Youssef, Jeremy W. Martin*, Orange, CA, Khashayar Sakhaee, John Poindexter, Dallas, TX, Simone L. Vemez, Rahul Dutta, Orange, CA, Charles D. Scales, Glenn M. Preminger, Michael E. Lipkin, Durham, NC

MP01-20 **SHOCKWAVE LITHOTRIPSY IMPAIRS URINE PH: RESULTS OF THE PROSPECTIVE SWISS KIDNEY STONE COHORT REGISTER**

Veronika Skuginna, Bern, Switzerland, Nilufar Mohebbi, Zurich, Switzerland, Daniel Fuster, Bern, Switzerland, Min-Jeong Kim, Basel, Switzerland, Carsten A. Wagner, Zurich, Switzerland, Gregoire Wuerzner, Geneva, Switzerland, Nasser Dhayat, Zurich, Switzerland, Olivier Bonny, Lausanne, Switzerland, Beat Roth*, Bern, Switzerland

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
MP02-07 EN-BLOC GREEN LIGHT 532NM ENUCLEATION OF PROSTATE (GLEEP): FIRST U.S. EXPERIENCE
Kai Li*, Alan Yaghoubian, Mahdi Zangi, Bo Wu, Shahin Tabatabaei, Boston, MA

MP02-08 HOLEP IN PATIENTS WITH LOW RISK PROSTATE CANCER IS SAFE AND EFFECTIVE
Kristian Stensland*, Burlington, MA, Daniel Peizman, Christopher Robertson, Boston, MA, Jared Schober, Alireza Mooinzadeh, David Canes, Jessica Mandeville, Burlington, MA

MP02-09 EVALUATION OF SURGICAL OUTCOMES WITH PHOTOSELECTIVE GREENLIGHT XPS LASER VAPORIZATION OF THE PROSTATE IN HIGH MEDICAL RISK MEN WITH BENIGN PROSTATIC ENLARGEMENT: A MULTICENTER STUDY
Emad Rajih*, Owings Mills, MD, Abdullah Alenizi, Malek Meskawi, Come Tholomier, Pierre-Alain Hueber, Mounaif Azizi, Montreal, Canada, Ricardo R. Gonzalez, Houston, TX, Gregg Eure, Virginia beach, MD, Lewis Krileman, Roswell, GA, Mahmood Hai, Westland, MD, Kevin Zorn, Montreal, Canada

MP02-10 LOW-POWER VERSUS HIGH-POWER EN-BLOC NO-TOUCH HOLEP: COMPARING FEASIBILITY, SAFETY AND EFFICACY
Cesare Marco Scoffone*, Manuela Ingrosso, Nicola Russo, Cecilia Cracco, Torino, Italy

MP02-11 POSTOPERATIVE DYSURIA AFTER HIGH AND LOW-POWER EN-BLOC NO-TOUCH HOLEP
Cecilia Cracco*, Manuela Ingrosso, Nicola Russo, Cesare Marco Scoffone, Torino, Italy

MP02-12 INTRAVESICAL PROSTATIC PROTRUSION IS NOT THE SAME IN ITS SHAPE: EVALUATION BY PREOPERATIVE CYSTOSCOPY AND OUTCOME IN HOLEP
Hiromitsu Negoro*, Ktsuhiro Ito, Atsuro Sawada, Shusuke Akamatsu, Ryoichi Saito, Takashi Kobayashi, Naoki Terada, Toshinari Yamasaki, Takahiro Inoue, Tomomi Kamba, Osamu Ogawa, Kyoto, Japan

MP02-13 PROSTATE ENucleATION TECHNIQUE: SHORT TERM RESULTS OF PROSPECTIVE RANDOMIZED TRIAL OF COMPARING HOLMIUM LASER AND BIPOLAR ENERGY FOR OBSTRUCTIVE BPH.
Ajay Bhandarkar*, Vadodara, India

MP02-14 FIRST POST-VOID RESIDUAL URINE VOLUME FOLLOWING HOLMIUM LASER ENucleATION OF THE PROSTATE: PREDICTOR OF DE NOVO URINARY INCONTINENCE
Jun Seok Kim*, Dong Hoon Yoo, Dong Hoon Lim, Gwangju, Korea, Republic of, Myung Ki Kim, Jeonju, Korea, Republic of, Hee Jong Jeong, Iksan, Korea, Republic of, Eun Mi Yang, Seong Woon Park, Joon Hwa Noh, Gwangju, Korea, Republic of

MP02-15 PSA-CHANGES AND MICTURITION IMPROVEMENT 5-YEARS AFTER THULIUM VAPONEUCLEATION OF THE PROSTATE FOR SYMPTOMATIC BENIGN PROSTATIC OBSTRUCTION
Christopher Netsch*, Benedikt Becker, Ann Kathrin Orywal, Hamburg, Germany, Thomas Herrmann, Hannover, Germany, Andreas Gross, Hamburg, Germany

MP02-16 EFFECTS OF 5a-REDUCTASE INHIBITION ON BENIGN PROSTATIC HYPERPLASIA TREATED BY PHOTOSELECTIVE VAPORIZATION PROSTATECTOMY WITH THE 180 WATT GREENLIGHT XPS LASER SYSTEM: RESULTS FROM THE GOLIATH POPULATION
Aldo Brasstetti*, Flavia Proietti, riccardo Lombardo, Cosimo De Nunzio, Andrea Tubaro, Rome, Italy

MP02-17 EJACULATORY DYSFUNCTION AFTER TREATMENT FOR LOWER URINARY TRACT SYMPTOMS. WHAT DO PATIENTS REALLY THINK?
Steeve Doizi*, Bertrand Lukacs, PARIS, France

MP02-18 TRENDS IN MINIMALLY INVASIVE SIMPLE PROSTATECTOMY FOR BENIGN PROSTATIC ENLARGEMENT IN THE UNITED STATES
Jeffrey Leow*, Boston, MA, Gregory Mills, Portland, ME, Steven Chang, Nicolas Van Landerberg, Philipp Gild, Quoc-Dien Trinh, Boston, MA, Jesse Sammon, Portland, ME

MP02-19 MINIMALLY INVASIVE PROSTATIC URETHRAL LIFT (PUL) EFFICACIOUS IN A LARGE PERCENTAGE OF TURP CANDIDATES: A MULTI-CENTER GERMAN STUDY AFTER TWO YEARS
Karl-Dietrich Sievert*, Salzburg, Austria, Martin Schonthaler, Freiburg, Germany, Richard Berges, Cologne, Germany, Florian Miller, Tubingen, Germany, Bjorn Volkmer, Kassel, Germany, Annika Herlemann, Munich, Germany, Ulrich Wetterauer, Freiburg, Germany, Bastian Amend, Tubingen, Germany, Christian Graztke, Munich, Germany

MP02-20 DEFINITIVE MANAGEMENT OF CARCINOGENIC SURGICAL SMOKE DURING TRANSURETHRAL RESECTION OF THE PROSTATE USING A CLOSED IRRIGATION SYSTEM
Yohei Okada*, Hideki Takeshita, Yutaka Uchijima, Satoru Kawakami, Kawagoe, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**Moderated Poster Session 3**

**PROSTATE CANCER: DETECTION & SCREENING I**

Room 160 @ Boston Convention & Exhibition Center

Moderators: Kevin Loughlin, Seiji Naito and Ahmad Shabsigh

---

**ABSTRACT**

**NUMBER** | **TITLE**
--- | ---

**MP03-01** | MAGNETIC RESONANCE IMAGING-GUIDED PROSTATE BIOPSIES FAIL TO OUTPERFORM STANDARD TRANSRECTAL ULTRASOUND-GUIDED BIOPSY IN DETECTING HIGH-RISK PROSTATE CANCER: A BAYESIAN NETWORK META-ANALYSIS OF 24 RANDOMISED CONTROLLED TRIALS

Shi Qiu*, Lu Yang, Qiang Wei, chengdu, China, People’s Republic of

**MP03-02** | COMBINED CLINICAL PARAMETERS AND MULTIPARAMETRIC MRI FOR ADVANCED RISK MODELING OF PROSTATE CANCER-PATIENT-TAILORED RISK STRATIFICATION CAN REDUCE UNNECESSARY BIOPSIES

Jan Philipp Radtke*, Bonekamp David, Claudia Kesch, Martin Freitag, Bertram Hitthaler, Matthias Claudius Roethke, Heidelberg, Germany, Celine Alt, Düsseldorf, Germany, Kathrin Wieczorek, Heidelberg, Germany, Wilfried Roth, Mainz, Germany, Stefan Duensing, Dogu Teber, Heinz-Peter Schlemmer, Markus Hohenfellner, Boris Hadaschik, Heidelberg, Germany

**MP03-03** | CHANGES IN PROSTATE CANCER DETECTION RATE OF FUSION VS SYSTEMATIC BIOPSY OVER TIME: A SINGLE CENTER EXPERIENCE

Brian Calio*, Abhinav Sidana, Dordaneh Sugano, Amit Jain, Mahir Maruf, Maria Merino, Baris Turkbey, Peter Choyke, Bradford Wood, Peter Pinto, Bethesda, MD

**MP03-04** | DOES THE INCLUSION OF NON-INDEX LESIONS AT BIOPSY IMPROVE OUR ABILITY TO PREDICT ADVERSE PATHOLOGIC OUTCOMES AT RADICAL PROSTATECTOMY? IMPLICATIONS FOR TARGETED PLUS SYSTEMATIC BIOPSY SCHEMES

Giorgio Gandaglia*, Marco Bandini, Paolo Dell’Oglio, Nicola Fossati, Francesco Pellegrino, Giuseppe Fallara, Emanuele Zaffuto, Carlo Andrea Bravi, Luigi Nocera, Milan, Italy, Rocco Damiano, Catanzaro, Italy, Massimo Freschi, Milan, Italy, Rodolfo Montironi, Ancona, Italy, Francesco Montorsi, Alberto Briganti, Milan, Italy

**MP03-05** | NOT ALL MPMRI TARGETED BIOPSIES ARE EQUAL: THE IMPACT OF THE TYPE OF APPROACH AND OPERATOR EXPERTISE ON THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER

Paolo Dell’Oglio*, Ammando Stabile, Giorgio Gandaglia, Nicola Fossati, Vincenzo Scattoni, Giorgio Brembilla, Tommaso Maga, Elia Kinzieva, Andrea Losa, Franco Gaboardi, Gianpietro Cardone, Antonio Esposito, Francesco De Cobelli, Alessandro Del Maschio, Francesco Montorsi, Alberto Briganti, Milan, Italy

**MP03-06** | DIAGNOSTIC PERFORMANCE OF MULTIPARAMETRIC MRI IN PROSTATE CANCER: PER CORE ANALYSIS OF THREE PROSPECTIVE ULTRASOUND/MRI FUSION BIOPSY DATASETS

Mariacristina Ferrero*, Rome, Italy, Alessandro Giacobbe, Turin, Italy, Rocco Papalia, Rome, Italy, Devis Collura, Turin, Italy, Emanuela Altobelli, Riccardo Mastroianni, Gabriele Tuderti, Francesco Minisola, Leonardo Misuraca, Salvatore Guaglionone, Giovanni Muto, Michele Gallicci, Giuseppe Simone, Rome, Italy

**MP03-07** | COMBINED CLINICAL PARAMETERS AND MULTIPARAMETRIC MRI FOR PREDICTION OF SIDE-SPECIFIC EXTRAPROSTATIC DISEASE - A RISK-MODEL FOR PATIENT-TAILORED RISK STRATIFICATION BEFORE RADICAL PROSTATECTOMY

Jan Philipp Radtke*, Boris Hadaschik, Claudia Kesch, Bonekamp David, Martin Freitag, Heidelberg, Germany, Celine Alt, Düsseldorf, Germany, Bertram Hitthaler, Matthias Claudius Roethke, Kathrin Wieczorek, Heidelberg, Germany, Wilfried Roth, Mainz, Germany, Stefan Duensing, Heinz-Peter Schlemmer, Markus Hohenfellner, Dogu Teber, Heidelberg, Germany

**MP03-08** | IMPACT OF DYNAMIC CONTRAST-ENHANCED SEQUENCES IN PROSTATE CANCER DETECTION: BIPARAMETRIC VERSUS MULTIPARAMETRIC MRI INTERPRETED BY 5 RADIOLOGY RESIDENTS.

Paolo Gontero*, Giorgio Calleris, Giancarlo Marra, Marco Oderda, Jacopo Giglio, Francesca Miaschi, Francesco Gentile, Patricio Cimpoesu, Luca Molinaro, Laura Bergamasco, Riccardo Faletti, Paolo Fonio, Bruno Frea, Turin, Italy

*Presenting author
MP03-09 MRI-BASED NOMOGRAM PREDICTING THE PROBABILITY OF DIAGNOSING A CLINICALLY SIGNIFICANT PROSTATE CANCER WITH MRI-US FUSION BIOSPY

Giuseppe Simone*, Rocco Papalia, Rome, Italy, Emanuela Altobelli, Alessandro Giacobbe, Turin, Italy, Luigi Benecchi, Cremona, Italy, Gabriele Tuderti, Leonardo Misuraca, Salvatore Guaglianone, Rome, Italy, Devis Collura, Turin, Italy, Giovanni Muto, Michele Gallucci, Mariaconsiglia Ferriero, Rome, Italy

MP03-10 CONTEMPORARY ASSESSMENT OF THE PREDICTIVE VALUE OF MULTIPARAMETRIC MRI FOR INDEX LESION LOCALIZATION IN PROSTATE CANCER

Samuel Lagabrielle*, Edouard Descat, Yann Lebras, Camille Dupin, Rémi Kaboré, Nicolas Grenier, Jean-Marie Ferrière, Henri Bensadoun, Jean-Christophe Bernhard, Grégoire Robert, Bordeaux, France

MP03-11 INSTITUTIONAL LEARNING CURVE ASSOCIATED WITH IMPLEMENTATION OF A MRI/US FUSION BIOSPY PROGRAM USING PI-RADS VERSION 2: FACTORS THAT INFLUENCE SUCCESS

Matthew Truong*, Eric Weinberg, Gary Hollenberg, Marianne Borch, Ji Hae Park, Jacob Gantz, Changyong Feng, Thomas Frye, Ahmed Ghazi, Guan Wu, Jean Joseph, Hani Rashid, Edward Messing, Rochester, NY

MP03-12 ACCURACY OF MULTIPARAMETRIC MR IMAGING WITH PI-RADS V2 ASSESSMENT IN DETECTING INFILTRATIONS OF THE NEUROVASCULAR BUNDLES PRIOR TO PROSTATECTOMY

Markus Sauer*, Julius Weinrich, Georg Salomon, Pierre Tennenstedt, Gerhard Adam, Dirk Beyersdorff, Hamburg, Germany

MP03-13 MULTIPARAMETRIC MRI CANNOT PREDICT CLINICALLY SIGNIFICANT PROSTATE CANCER OUTSIDE THE INDEX LESION: IMPLICATIONS FOR EXTENDED BIOPSY TEMPLATES

Armando Stabile*, Paolo Dell’Oglio, Giorgio Gandaglia, Giulia Cristel, Ella Kinzikheeva, Tommaso Maga, Andrea Losa, Antonio Espoalto, Gianpietro Cardone, Vincenzo Scattoni, Francesco De Cobelli, Alessandro Del Maschio, Nazareno Suardi, Franco Gaboardi, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP03-14 HIGH ACCURACY OF TUMOR-FOCI LOCATION IN THE PROSTATE BY MP MRI-BASED STEREOTACTIC TRANSPERINEAL FUSION BIOSPY COULD ALLOW PRECISE FOCAL THERAPY

Julia Bohr*, Anne Vogel, Michaela Vanberg, Michael Musch, Susanne Krage, Darko Kroepfl, Essen, Germany

MP03-15 THE ANALYSIS OF PROSTATE BIOSPY IN NEGATIVE MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING PATIENTS

Ming Liu*, Zhipeng Zhang, Jianye Wang, Beijing, China, People’s Republic of

MP03-16 UTILITY OF MULTI-PARAMETRIC MRI/ULTRASOUND FUSION: COGNITIVE NOT INFERIOR TO TARGETED SOFTWARE-BASED PROSTATE BIOPSIES

Avinash Chennamsetty*, Steve Kardos, William Chu, Justin Emtage, Nora Ruel, Paul Gellhaus, Clayton Lau, Bertram Yuh, Ali Zhumkhawala, Kevin Chan, Jonathan Yamzon, Duarte, CA

MP03-17 MRI-BASED NOMOGRAM TO PREDICT THE PROBABILITY OF PROSTATE CANCER DIAGNOSIS WITH MRI-US FUSION BIOSPY

Giuseppe Simone*, Mariaconsiglia Ferriero, Rome, Italy, Emanuela Altobelli, Alessandro Giacobbe, Turin, Italy, Luigi Benecchi, Cremona, Italy, Gabriele Tuderti, Leonardo Misuraca, Salvatore Guaglianone, Rome, Italy, Devis Collura, Turin, Italy, Giovanni Muto, Michele Gallucci, Rocco Papalia, Rome, Italy

MP03-18 ABSENCE OF LEARNING CURVE IMPACT MAY LET MRI-TRUS FUSION GUIDED BIOPSY UP FOR EARLY DIAGNOSIS OF PROSTATE CANCER

Giuliana Lista*, Giovanni Lughhezanni, Massimo Lazzeri, Rozzano (MI), Italy, Vittorio Bini, Perugia, Italy, Rodolfo Hurle, Nicolò Buffi, Pasquale Cardone, Luisa Pasini, Silvia Zandegiacomo DeZorzi, Roberto Peschechera, Rozzano (MI), Italy, Giorgio Bozzini, Castellanza (VA), Italy, Davide Maffei, Giorgio Guazzoni, Rozzano (MI), Italy

MP03-19 DIFFERENCE BETWEEN THE PZ AND THE TZ IN DIAGNOSTIC ACCURACY OF MAGNETIC RESONANCE IMAGING (MRI) 5-POINT LIKERT SCORING SYSTEM EVALUATED BY THE RESULT OF MRI/ULTRASONOGRAPHY FUSION TARGETED BIOSPY OF THE PROSTATE

Toshitaka Shin*, Los Angeles, CA, Thomas Smyth, Owings Mills, MD, Osamu Ukimura, Nariman Ahmad, Andre Luis Abreu, Daniel Freitas, Carlos Fay, Masakatsu Oishi, Los Angeles, CA, Hiromitsu Mimata, Oita, Japan, Inderbir Gill, Los Angeles, CA

MP03-20 DIAGNOSTIC PERFORMANCE OF APPARENT DIFFUSION COEFFICIENT BETWEEN THE PERIPHERAL ZONE AND TRANSITIONAL ZONE IN LOCALIZED PROSTATE CANCER

Jung Keun Lee*, In Jae Lee, Tae Jin Kim, Hakmin Lee, Jong Jin Oh, Sangchul Lee, Seong Jin Jeong, Seok-Soo Byun, Sang Eun Lee, Sung Kyu Hong, Seongnam, Korea, Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP04-02</td>
<td>Long Term Incidence of Venous Thromboembolic Event’s Following Cystectomy: A Population-Based Analysis</td>
<td>Christopher Wallis*, Diana Magee, Raj Satkunasivam, Robert Nam, Toronto, Canada</td>
</tr>
<tr>
<td>MP04-03</td>
<td>Non-Muscle Invasive Bladder Cancer Is Associated with Decreased Physical Health-Related Quality of Life</td>
<td>Wayne Brisbane*, Sarah Holt, Brian Winters, John Gore, Atreya Dash, Michael Porter, Jonathan Wright, George Schade, Seattle, WA</td>
</tr>
<tr>
<td>MP04-04</td>
<td>Characterizing the Costs of Complications After Cystectomy: Can We Target the Primary Drivers?</td>
<td>Matthew Mossanen*, Ross E. Krasnow, Matthew D. Ingham, Mark A. Preston, Quoc D. Trinh, Adam S. Kibel, Boston, MA, Steven I. Chung, Stanford, CA, Steven L. Chang, Boston, MA</td>
</tr>
<tr>
<td>MP04-05</td>
<td>Declining Use of Continent Diversions for Bladder Cancer</td>
<td>Nicholas Farber*, Izak Faena, Viktor Dombrovskiy, Alexandra Tabakin, Brian Shinder, Rutveej Patel, Sammy Elsamra, Thomas Jang, Eric Singer, Robert Weiss, New Brunswick, NJ</td>
</tr>
<tr>
<td>MP04-06</td>
<td>Personalized Decision Support Tool to Prevent Hospital Readmission for Patients Treated With Radical Cystectomy</td>
<td>Sarah Finley, Shivani Joshi*, Tudor Borza, Xiang Liu, Ted A. Skolarius, Ann Arbor, MI, Bruce L. Jacobs, Pittsburgh, PA, Benjamin Y. Li, Ann Arbor, MI, Heather Jim, Scott M. Gilbert, Tampa, FL, Zhilong Xie, Ann Arbor, MI, Jonathan E. Helm, Bloomington, IN, Mariel S. Lavieri, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP04-07</td>
<td>Prognostic Impact of Immunohistochemical Classification of Bladder Cancer According to Luminal (Uroplakin III) and Basal (Cytokeratin 5/6) Markers</td>
<td>Tetsutaro Hayashi*, Kazuhiro Santani, Shinji Kakumoto, Hiroshima, Japan, Htoo Zami Oo, Vancouver, Canada, Naoya Sakamoto, Hiroshima, Japan, Kazuaki Mutaguchi, Nakatsu, Japan, Kohei Kobatake, Keisuke Goto, Shogo Inoue, Jun Teishima, Hiroshima, Japan, Peter Black, Vancouver, Canada, Akio Matabara, Hiroshima, Japan</td>
</tr>
<tr>
<td>MP04-08</td>
<td>Why Investigate Asymptomatic Microhematuria? Implications of Applying UK National Guidance</td>
<td>Adam Cox*, Matthew Jefferies, Mohamad Kamarizan, Maureen Hunter, Jim Wilson, Daniel Painter, Adam Carter, Newport, United Kingdom</td>
</tr>
<tr>
<td>MP04-09</td>
<td>A Longitudinal Study of Health Disparity in Metastatic Bladder Cancer Using the California Cancer Registry</td>
<td>Kevin Pan, Davis, CA, Amy Klapheke, Rosemary Cress, Stanley Yap*, Sacramento, CA</td>
</tr>
<tr>
<td>MP04-10</td>
<td>A Prospective Cohort Study of 112 Elderly Patients with Bladder Cancer: Predictive Factors of Early Death After a Comprehensive Geriatric Assessment</td>
<td>Cyrielle Rambaud, Marine Sanchez, Sébastien Gonfrier, Matthieu Durand*, Delphine Borchiellini, Nice, France, Hervé Quintens, Saint-Laurent-Du-Var, France, Romain Prader, Rabia Boulahssass, Olivier Guerin, Nice, France</td>
</tr>
<tr>
<td>MP04-11</td>
<td>Obesity May Be a Risk Factor for Ureterointestinal Anastomotic Strictures After Radical Cystectomy with Urinary Diversion</td>
<td>Belinda Li*, Robert H. Blackwell, Bethany K. Burge, Elizabeth L. Koehne, Marcus L. Quek, Maywood, IL</td>
</tr>
<tr>
<td>MP04-12</td>
<td>Outcomes of Nested Variant of Urothelial Carcinoma Following Radical Cystectomy</td>
<td>Joel Hillelsohn*, Brooklyn, NY, Amy Tin, Dev Mally, Daniel Sjoberg, Guido Dalbagni, New York, NY</td>
</tr>
</tbody>
</table>
MP04-13 CANCER SURVEILLANCE AFTER RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA: A NOVEL RISK-ADAPTED STRATEGY
Ross Mason*, William Parker, Stephen A. Boorjian, Rochester, MN, Suzanne Merrill, Hershey, PA, Prabin Thapa, Igor Frank, Rochester, MN

MP04-14 SURVIVAL DIFFERENCES AMONG BLADDER CANCER PATIENTS ACCORDING TO GENDER: CRITICAL EVALUATION OF RADICAL CYSTECTOMY USE AND DELAY TO TREATMENT
Justin E. Fang*, Galveston, TX, Jinhai Huo, Houston, TX, Preston Kerr, Tamer Dafashy, Cameron Ghaffary, Leslie Ynalvez, Jacques G. Baillargeon, Galveston, TX, Edwin Morales, San Antonio, TX, Simon Kim, Cleveland, OH, Padraic O’Malley, Halifax, Canada, Yong-Fang Kuo, Eduardo Ornhuela, Douglas S. Tyler, Galveston, TX, Stephen J. Freedland, Los Angeles, CA, Ashish M. Kamat, Houston, TX, Stephen B. Williams, Galveston, TX

MP04-15 THE PREVALENCE AND IMPACT OF PREOPERATIVE FRAILTY: A PROSPECTIVE STUDY OF PATIENTS UNDERGOING CYSTECTOMY
Conrad Tobert*, Nathan Brooks, Lewis Thomas, Chermaine Hung, Sarah Bell, Kenneth Nepple, Iowa City, IA

MP04-16 PERIOPERATIVE AND LONG TERM OUTCOMES AFTER RADICAL CYSTECTOMY IN HEMODIALYSIS PATIENTS
Scott Johnson*, Zachary Smith, Joseph Rodriguez III, Gary Steinberg, Chicago, IL

MP04-17 BLOOD-BASED BIOMARKERS AS PREDICTORS OF ONCOLOGIC OUTCOMES FOR NON-MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA
Daher Chade*, Andre Machado, Ricardo Waksman, Guilherme Garcia, Paulo Esteves, Sanarely Adonias, Flavio Areas, Luis Botelho, Mauricio Cordeiro, Claudio Murta, Leopoldo Ribeiro-Filho, Alvaro Sarkis, Sao Paulo, Brazil, Shahrokhi Shariat, Vienna, Austria, Diogo Bastos, Carlos Dzik, Miguel Srougi, William Nahas, Sao Paulo, Brazil

MP04-18 SMOKING INTENSITY AS A PREDICTOR OF SURVIVAL IN BLADDER CANCER PATIENTS: RESULTS FROM A POPULATION-BASED FLORIDA CANCER REGISTRY (1981-2009)
Luís Felipe Sávio*, Tulay Koru-Sengul, Diana M Lopategui, Feng Miao, Nachiketh Soodana Prakash, Bruno Nahar, Vivek Venkatraman, Sanjaya Swain, Sanoj Punn, Dipen J Parekh, Chad Ritch, Mark L. Gonzalgo, Miami, FL

MP04-19 PROGNOSTIC IMPACT OF SERUM CYFRA 21-1 AMONG CLASSIC TUMOR MARKERS IN PATIENTS WITH NON-METASTATIC BUT POTENTIALLY LETAL BLADDER CANCER
Akihiro Yano*, Kojiro Tachibana, Shunsuke Hiranuma, Hironori Sugiyama, Makoto Kagawa, Hideki Takeshita, Yohei Okada, Makoto Morozumi, Satoru Kawakami, Kawagoe, Japan

MP04-20 THE ASSOCIATION BETWEEN MORTALITY AND DISTANCE TO TREATMENT FACILITY IN PATIENTS WITH INVASIVE BLADDER CANCER
Stephen Ryan*, Portland, ME, Patrick Karabon, Detroit, MI, Gregory Mills, Moritz Hansen, Matthew Hayn, Portland, ME, Mani Menon, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Firas Abdollah, Detroit, MI, Jesse Sammon, Portland, ME

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP05-03 CONTINENCE AFTER POST-PROSTATECTOMY INTENSITY MODULATED RADIATION THERAPY
Itay Sagy*, Nimrod Barashi, Shay Golan, Scott eggener, Stanley Liauw, Arieh Shalhav, Chicago, IL

MP05-04 EFFECTIVENESS OF COMBINATION THERAPY OF EXTERNAL-BEAM RADIATION AND HIGH DOSE-RATE BRACHYTHERAPY FOR HIGH-RISK PROSTATE CARCINOMA
Kenjiro Suzuki*, Suguru Shirotake, Koshiro Nishimoto, Soichi Makino, Hideyuki Kondo, Takashi Okabe, Yota Yasumizu, Kiichiro Kodaira, Shingo Kato, Masafumi Oyama, Saitama, Japan

MP05-05 LONG-TERM OUTCOMES OF MEN WITH STAGE PT3B PROSTATE CANCER DIAGNOSED BY SEMINAL VESICLE BIOPSY AND TREATED BY BRACHYTHERAPY AND EXTERNAL BEAM IRRADIATION
Nelson Stone*, Richard Stock, New York, NY

MP05-06 LONG-TERM SURVIVAL IN MEN WITH GLEASON SCORE 9-10 TREATED WITH PROSTATE BRACHYTHERAPY AND EXTERNAL BEAM IRRADIATION
Nelson Stone*, Richard Stock, New York, NY

MP05-07 PROLONGED HORMONAL THERAPY AND EXTERNAL BEAM RADIATION INDEPENDENTLY INCREASE THE RISK OF PERSISTENT HYPOGONADISM IN MEN TREATED WITH PROSTATE BRACHYTHERAPY

MP05-08 THE IMPACT OF BASELINE SERUM TESTOSTERONE ON THE RISK OF BIOCHEMICAL FAILURE AFTER DEFINITIVE RADIATION THERAPY FOR PROSTATE CANCER: MORE FAVOURABLE ONCOLOGICAL OUTCOMES IN HYPOGONADAL INVIDIDUALS
Emanuele Zaffuto*, Milan, Italy, Pierre I. Karakiewicz, Helen Davis Bondarenko, Montreal, Canada, Sami-Ramzi Leyh-Bannurah, Hamburg, Germany, Guilla Delouya, Carole Lambert, Jean-Paul Bahary, Marie Claude Beauchemin, Maroie Barkati, Cynthia Ménard, Montreal, Canada, Markus Graefen, Hamburg, Germany, Alberto Briganti, Milan, Italy, Fred Saad, Daniel Taussky, Montreal, Canada

MP05-09 RISK OF HOSPITALIZATION FOLLOWING OUTPATIENT PROSTATE BRACHYTHERAPY

MP05-10 LONG-TERM URINARY SYMPTOMS FOLLOWING PROSTATE BRACHYTHERAPY

MP05-11 PROSTATE BRACHYTHERAPY AND TURP: PRE-IMPLANT SYMPTOM SEVERITY HAS GREATER INFLUENCE THAN TIMING OF TURP ON LONG-TERM URINARY QUALITY OF LIFE

MP05-12 RACE, COMORBIDITIES AND LONG-TERM ERECTILE FUNCTION AFTER PROSTATE BRACHYTHERAPY: WHAT ROLE DOES EACH HAVE ON POTENCY PRESERVATION

MP05-13 THE COST OF TREATMENT FOR LOCALIZED PROSTATE CANCER
Alaina Garbens*, Christopher Wallis, Refik Saskan, Robert Nam, Toronto, Canada

MP05-14 MORBIDITIES OF RADIOFREQUENCY TRACKING BEACONS VS CONE BEAM CT (CBCT) IMAGE-GUIDED RADIOTHERAPY ON PROSTATE CANCER
Virginia Li*, Nashville, TN, Carl Peterson, Youngstown, Ohio, OH

MP05-15 HETEROGENEOUS OUTCOMES IN GLEASON SCORE 7 PROSTATE CANCER PATIENTS ARE ASSOCIATED WITH DIFFERENTIAL BIOLOGICAL EFFECTIVE DOSE AND HORMONE UTILIZATION

MP05-16 WHAT IS THE IMPACT OF DIABETES MELLITUS ON RADIATION INDUCED PROCTITIS AFTER RADICAL RADIOTHERAPY FOR ADENOCARCINOMA PROSTATE?
Catherine Paterson*, Dundee, United Kingdom, Abduelmenem Alashkham, Edinburgh, United Kingdom, Stephen Hubbard, Ghulam Nabi, Dundee, United Kingdom

MP05-17 SHIFT TO SEED STRANDING IN PROSTATE BRACHYTHERAPY – ARE THERE CONSEQUENCES?
Elizabeth Malm-Buatsi, Patricia Heller*, Elizabeth Koehne, Bradley Moore, Columbia, MO, Julie M Riley, Albuquerque, NM, Steven Westgate, Mark R Wakefield, Columbia, MO

*Presenting author
MP05-18 PROSTATE FIDUCIAL MARKER PLACEMENT IN PATIENTS WHILE ON ANTICOAGULATION: FEASIBILITY PRIOR TO PROSTATE SBRT
Jonathan Haas*, Aaron Katz, Joshua Harris, Todd Carpenter, Susan Carbone, Mineola, NY, Thomas Kole, Ridgewood, NJ, Steven Pristupa, Matthew Witten, Seth Blacksburg, Mineola, NY

MP05-19 OUTCOMES OF TREATMENT FOR LOCALIZED PROSTATE CANCER IN A SINGLE INSTITUTION; COMPARISON OF RADICAL PROSTATECTOMY VS RADIATION THERAPY PROPENSITY SCORE MATCHING ANALYSIS
Narihiko Hayashi*, Yumiko Yokomizo, Kimito Osaka, Hisashi Hasumi, Kazuhiko Makiyama, Keichi Kondo, Noboru Nakaigawa, Masahiro Yao, Eiko Ito, Madoka Sugiuara, Shoko Takano, Yuki Mukai, Takeo Kasuya, Masataka Taguri, Yokohama, Japan

MP05-20 ADJUVANT RADIATION REFERRAL PATTERNS IN MEN WITH HIGH-RISK PROSTATE CANCER
Stephen Ryan*, Gregory Mills, Matthew Cheney, Matthew Hayn, Portland, ME

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 12, 2017
Podium Session 1
7:00 am - 9:00 am
INFECTIONS/INFLAMMATION/CYSTIC DISEASE OF THE GENITOURINARY TRACT: INTERSTITIAL CYSTITIS I
Room 159 @ Boston Convention & Exhibition Center
Moderators: Robert Moldwin, Kurt Naber and C. Lowell Parsons

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 PD01-01</td>
<td></td>
<td>RESULTS FROM A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE EFFICACY AND SAFETY OF INTRA-TRIGONAL INJECTION OF ONABOTULINUM TOXIN A IN PATIENTS WITH BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS. Rui Pinto*, Daniel Costa, Afonso Morgado, Pedro Pereira, Joao Silva, Francisco Cruz, Porto, Portugal</td>
</tr>
<tr>
<td>7:10 PD01-02</td>
<td></td>
<td>GENE THERAPY WITH REPLIICATION-DEFICIENT HERPES SIMPLEX VIRUS (HSV) VECTORS ENCODING PORELESS TRPV1 (PL) OR PROTEIN PHOSPHATASE 1α (PP1α) IN A RAT MODEL OF HYDROGEN PEROXIDE-INDUCED CYSTITIS Shun Takai*, Pittsburgh, PA, Tatsuyoshi Majima, Nagoya, Japan, Takahiro Shimizu, Kochi, Japan, Naoki Wada, Asahikawa, Japan, Nobukata Shimizu, Takahisa Suzuki, Eiichiro Takaoka, Pittsburgh, PA, Momokazu Gotoh, Nagoya, Japan, William Goins, Joseph Glorioso, Naoki Yoshimura, Pittsburgh, PA</td>
</tr>
<tr>
<td>7:30 PD01-04</td>
<td></td>
<td>STRESS INDUCED VISCERAL PAIN IS MEDIATED BY ALPHA 1A ADRENOCEPTORS Rita Matos, Paula Serrão, Porto, Portugal, Larissa Rodriguez, Los Angeles, CA, Lori Bird, Pittsburgh, PA, Francisco Cruz*, Ana Charrua, Porto, Portugal</td>
</tr>
<tr>
<td>7:40 PD01-05</td>
<td></td>
<td>SIGNIFICANT LINKAGE EVIDENCE FOR INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME ON CHROMOSOME 3 Kristina Allon-Brady*, Kerry Rowe, Melissa Cessna, Peggy Norton, Salt Lake City, UT</td>
</tr>
<tr>
<td>7:50 PD01-06</td>
<td></td>
<td>LOW ANESTHETIC BLADDER CAPACITY IS ASSOCIATED WITH A UNIQUE MUCOSAL GENE EXPRESSION PROFILE IN IC/BPS PATIENTS Stephen Walker*, Gopal Badlani, Catherine Mathews, Joao Zambon, Robert Evans, Winston Salem, NC</td>
</tr>
<tr>
<td>8:00 PD01-07</td>
<td></td>
<td>EXPRESSION OF THE PROGRAMMED DEATH LIGAND 1 IN INTERSTITIAL CYSTITIS IS CORRELATED WITH THE BLADDER PAIN DEGREE AND HYDRODISTENSION OUTCOME Yuke Chen*, Wei Yu, Yang Yang, Shiliang Wu, Jie Jin, Beijing, China, People’s Republic of China</td>
</tr>
<tr>
<td>8:10 PD01-08</td>
<td></td>
<td>NOVEL CONTRAST MIXTURE IMPROVES BLADDER WALL CONTRAST FOR VISUALIZING INTERSTITIAL CYSTITIS Pradeep Tyagi*, Joseph Janicki, T. Kevin Hitchens, Lesley Foley, Mahendra Kashyap, Naoki Yoshimura, Jonathan Kaufman, Pittsburgh, PA</td>
</tr>
</tbody>
</table>
### Podium Session 2

**URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: PELVIC PROLAPSE I**

Room 162 @ Boston Convention & Exhibition Center

**Moderators:** Humberto Chiangi, Alexander Gomelsky and J. Christian Winters

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD02-01</td>
<td>TYPES OF PELVIC FLOOR DEFECTS IN WOMEN WITH PELVIC ORGAN PROLAPSE</td>
<td>George Kasyan*, Nataliya Tupikina, Dmitry Pushkar, Moscow, Russian Federation</td>
</tr>
<tr>
<td>7:10</td>
<td>PD02-02</td>
<td>THE STUDY OF OVERACTIVE BLADDER ASSOCIATED WITH PELVIC ORGAN PROLAPSE.</td>
<td>masao kataoka*, Kanako Matsuoka, Junya Hata, Hidenori Akaiaha, Souichirou Ogawa, Nobuhiro Kushida, Ken Aikawa, Yosiyuki Kojima, Fukushima, Japan</td>
</tr>
<tr>
<td>7:20</td>
<td>PD02-03</td>
<td>FRAILTY AND THE ROLE OF OBLITERATIVE VERSUS RECONSTRUCTIVE SURGERY FOR PELVIC ORGAN PROLAPSE; A NATIONAL STUDY</td>
<td>Anne M Suskind*, Chengshi Jin, Louise C Walter, Emily Finlayson, San Francisco, CA</td>
</tr>
<tr>
<td>7:30</td>
<td>PD02-04</td>
<td>PRACTICE PATTERNS IN THE DIAGNOSIS AND TREATMENT OF FECAL INCONTINENCE WITH SACRAL NEUROMODULATION: CAN UROLOGISTS IMPACT THIS GAP IN CARE?</td>
<td>Dana Moskowitz*, Sarah Adelstein, Alvaro Lucioni, Kathleen Kobashi, Uni Lee, Seattle, WA</td>
</tr>
<tr>
<td>7:40</td>
<td>PD02-05</td>
<td>DEFINING THE PREVALENCE OF ASYMPTOMATIC MICROSCOPIC HEMATURIA AMONG WOMEN WITH PELVIC ORGAN PROLAPSE: IMPLICATIONS FOR RECOMMENDING SUBSEQUENT DIAGNOSTIC EVALUATION</td>
<td>Brian Linder*, Stephen Boorjian, Emanuel Trabuco, John Geibhart, John Occhino, Rochester, MN</td>
</tr>
<tr>
<td>7:50</td>
<td>PD02-06</td>
<td>DYNAMIC PELVIC MRI IN THE EVALUATION OF PELVIC ORGAN PROLAPSE AND CORRELATION WITH PHYSICAL EXAM FINDINGS</td>
<td>Frank C. Lin*, Hina A. Tiwari, Bobby T. Kalb, Joel T. Funk, Christian O. Twiss, Tucson, AZ</td>
</tr>
<tr>
<td>8:00</td>
<td>PD02-07</td>
<td>THE USE OF GOOGLE TRENDS® TO DETECT PUBLIC AWARENESS OF THE FDA COMMUNICATIONS ON THE USE OF MORCELLATION OF UTERINE SPECIMENS</td>
<td>Lauren N. Wood*, Juzar Jammangerwalla, D. Joseph Thum, Andrew R. Medendorp, Shlomo Raz, Ja-Hong Kim, Los Angeles, CA</td>
</tr>
<tr>
<td>8:10</td>
<td>PD02-08</td>
<td>PREVENTATIVE CONCOMITANT SLING FOR DE-NOVO STRESS URINARY INCONTINENCE AFTER ROBOTIC SACRAL COLPOPEXY DOES NOT IMPROVE LONG TERM CONTINENCE OR SATISFACTION</td>
<td>Charles Powell*, Bridget Eckrich, Jeffrey Rothenberg, Thomas Gardner, Indianapolis, IN</td>
</tr>
</tbody>
</table>

*Presenting author
8:20 PD02-09 ADJUSTABLE MIDURETHRAL TAPE FOR SURGICAL TREATMENT OF STRESS URINARY INCONTINENCE: SHORT-TERM OUTCOMES.

Dmitry Shkarupa*, Alexey Pisarev, Nikita Kubin, Anastasia Zaytseva, Olga Staroseltseva, Saint-Petersburg, Russian Federation

8:30 PD02-10 TRANSVAGINAL MESH DOES NOT CAUSE CARCINOGENESIS

Bilal Chughtai*, Art Sedrakyan, Jialin Mao, Dominique Thomas, New York, NY, Karyn Elber, Jennifer Anger, Beverly Hills, CA, J. Quentin Clemens, Ann Arbor, MI

8:40 PD02-11 ADDITIONAL TREATMENTS, SATISFACTION, AND QUALITY OF LIFE IN WOMEN AFTER TRANSVAGINAL AND ABDOMINAL PELVIC ORGAN PROLAPSE REPAIR

Laura Nguyen, Natalie Gaines*, Larry Sirls, Kim Killinger, Royal Oak, MI, Morgan Gruner, Michelle Jankowski, Rochester, MI, Kenneth Peters, Royal Oak, MI

8:50 PD02-12 THE EFFECT OF RESIDENT INVOLVEMENT IN PELVIC PROLAPSE SURGERY: A RETROSPECTIVE STUDY FROM A NATIONWIDE INPATIENT SAMPLE

Maxx Caveney, Catherine Matthews, Majid Mirzazadeh*, Winston-Salem, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 12, 2017

Podium Session 3

PROSTATE CANCER: EPIDEMIOLOGY & NATURAL HISTORY I

Room 161 @ Boston Convention & Exhibition Center

Moderators: Mitchell Benson, William Lowrance and Bernardo Rocco

7:00 PD03-01 METASTASES AND DEATH AFTER 15 YEAR OF FOLLOW-UP IN MEN WITH SCREEN-DETECTED LOW-RISK PROSTATE CANCER TREATED WITH PROTOCOL BASED ACTIVE SURVEILLANCE, RADICAL PROSTATECTOMY OR RADIOTHERAPY

Jan Verbeek, Chris Bangma, Frank-Jan Drost, Monique Roobol*, Rotterdam, Netherlands

7:10 PD03-02 FREQUENCY OF DNA REPAIR GENE MUTATIONS IN LOCALIZED AND METASTATIC PROSTATE CANCER

Allison Glass*, Primo Lara, Sacramento, CA, Ryan Hartmaier, Boston, MA, Ralph deVere White, John McPherson, Marc Dall’Era, Sacramento, CA

7:20 PD03-03 DOES PROSTATE CANCER REPRESENT THE MAIN CAUSE OF DEATH IN ALL NODE POSITIVE PROSTATE CANCER PATIENTS? THE IMPACT OF COMPETING CAUSES OF MORTALITY ACCORDING TO TUMOR CHARACTERISTICS AND RECURRENCE STATUS

Paolo Dell'Oglio*, Emanuele Zaffuto, Armando Stabile, Giorgio Gandaglia, Milan, Italy, Michele Collocchia, Rochester, NY, Nicola Fossati, Umberto Capitanio, Federico Dehó, Renzo Colombo, Roberto Bertini, Francesco Montorsi, Milan, Italy, R. Jeffrey Karnes, Rochester, NY, Alberto Briganti, Milan, Italy

7:30 PD03-04 LONG-TERM RATES OF PROSTATE CANCER DIAGNOSIS AND ALL-CAUSE MORTALITY IN A POPULATION-BASED COHORT OF MEN WITH AN INITIALLY NEGATIVE PROSTATE BIOPSY

Rashid Sayyid*, Shabbir Aliibhai, Rinku Suradhar, Maria Eberg, Kinwah Fung, David Urbach, Neil Fleshner, Toronto, Canada

7:40 PD03-05 EXTERNAL VALIDATION OF THE AGE-ADJUSTED PROSTATE SPECIFIC COMORBIDITY INDEX (PCCI), A CLAIMS-BASED TOOL FOR PREDICTION OF LIFE EXPECTANCY IN MEN WITH PROSTATE CANCER

Timothy Daskivich*, Los Angeles, CA, I-Chun Thomas, Stanford, CA, Ted Skolarus, Ann Arbor, MI, John Leppert, Stanford, CA

7:50 PD03-06 CONTEMPORARY TRENDS IN INCIDENCE OF METASTATIC PROSTATE CANCER AMONG US MEN: RESULTS FROM NATIONWIDE ANALYSES

Deepansh Dalela*, Detroit, MI, Maxine Sun, Boston, MA, Patrick Karabon, Detroit, MI, Thomas Seisen, Boston, MA, Srim Eleswarapu, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Mani Menon, Firas Abdollah, Detroit, MI
8:00 PD03-07 THE IMPACT OF SOCIOECONOMIC STATUS, RACE, AND INSURANCE TYPE ON THE RISK OF NEWLY DIAGNOSED METASTATIC PROSTATE CANCER IN THE UNITED STATES
Adam Weiner*, Richard Matulewicz, Chicago, IL, Jeffrey Tosoian, Baltimore, MD, Joseph Feinglass, Edward Schaeffer, Chicago, IL

8:10 PD03-08 IMPACT OF AGE, COMORBIDITY, AND PSA DOUBLING TIME ON LONG-TERM COMPETING RISKS FOR MORTALITY AMONG MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Colette Whitney, Lauren Howard, Durham, NC, Stephen Freedland, Los Angeles, CA, Christopher Amling, Portland, OR, William Aronson, San Francisco, CA, Christopher Kane, San Diego, CA, Martha Terris, Augusta, GA, Timothy Daskivich*, Los Angeles, CA

8:20 PD03-09 RISING INCIDENCE OF METASTATIC PROSTATE CANCER IN CALIFORNIA, 1988-2014
Marc Dall’Era*, Ralph Devere White, Danielle Rodriguez, Rosemary Cress, Sacramento, CA

8:30 PD03-10 VALIDATION OF THE 2015 PROSTATE CANCER PROGNOSTIC GRADE GROUPS FOR PREDICTING LONG-TERM ONCOLOGIC OUTCOMES IN A SHARED EQUAL ACCESS HEALTH SYSTEM.

8:40 PD03-11 COMORBIDITY AND PROSTATE-CANCER SPECIFIC MORTALITY
Prabhakar Rajan*, London, United Kingdom, Prasanna Sooriakumaran, Oxford, United Kingdom, Tommy Nyberg, Olof Akre, Stefan Carlsson, Lars Egevad, Gunnar Steineck, Peter Wiklund, Stockholm, Sweden

8:50 PD03-12 PROSTATE CANCER INCIDENCE STRATIFIED BY RACE AND GLEASON SCORE: A SEER DATABASE ANALYSIS OF THE USPSTF GUIDELINE ERA
Daniel Au*, Johar Syed, Sameer Siddiqui, Saint Louis, MO

Friday, May 12, 2017

Podium Session 4

KIDNEY CANCER: ADVANCED (INCLUDING DRUG THERAPY) I
Room 205 BC @ Boston Convention & Exhibition Center
Moderators: Christopher Wood

ABSTRACT
TIME NUMBER TITLE
7:00 PD04-01 DETERMINANTS OF ALL-CAUSE MORTALITY IN PATIENTS WITH METASTATIC PAPILLARY RENAL CELL CANCER
Abhinav Sidana*, Amit Jain, Meet Kadakia, Akhil Muthigil, Louis Krane, Martha Ninos, Julia Friend, Johanna Shih, Ramaprasad Srinivasan, Bethesda, MD

ABSTRACT
TIME NUMBER TITLE
7:10 PD04-02 ADJUVANT SUNITINIB IN PATIENTS WITH HIGH RISK RENAL CELL CARCINOMA: SUBGROUP ANALYSES FROM S-TRAC TRIAL
Allan Pantuck*, Los Angeles, CA, Jean-Jacques Patard, Le Kremlin Bièvre, France, Anup Patel, London, United Kingdom, Alain Ravaud, Bordeaux, France, Robert J Motzer, New York, NY, Hardev S Pandha, Surrey, United Kingdom, Daniel J George, Durham, NC, Yen-Hwa Chang, Taipei, Taiwan, Bernard Escudier, Villejuif, France, Frede Donskov, Aarhus, Denmark, Ahmed Magheli, Berlin, Germany, Giacomo Carteni, Naples, Italy, Brigitte Laguerre, Rennes, France, Piotr Tomczak, Poznan, Poland, Jan Breza, Bratislava, Slovakia(Slovak Republic), Paola Gerletti, Mariapaz Lechuga, Milan, Italy, Xun Lin, La Jolla, CA, Michelle Casey, Collegeville, PA, Michael Staehtler, Munich, Germany

*Presenting author
7:20 PD04-03 SURVIVAL FOLLOWING NEOADJUVANT TARGETED THERAPY AND CYTOREDUCTIVE NEPHRECTOMY IN MRCC PATIENTS WITH TUMOR THROMBUS: A CONTEMPORARY MULTI-INSTITUTIONAL SERIES
Shivashankar Damodaran*, Madison, WI, Philippe E. Spiess, Tampa, FL, Jose A. Karam, Vitaly Margulis, Dallas, TX, Viraj A. Master, Atlanta, GA, Jay D. Raman, Hershey, PA, Wade J. Sexton, Tampa, FL, Datta Patil, Atlanta, GA, Leonardo D. Borregales, Dallas, TX, Haley Robyak, Hershey, PA, Sarena F. Matin, Christopher G. Wood, Dallas, TX, E. Jason Abel, Madison, WI

7:30 PD04-04 THE EFFECT OF ANATOMICAL LOCATION OF RETROPERITONEAL LYMPH NODE METASTASES ON CANCER SPECIFIC SURVIVAL IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA
Alessandro Nini*, Alessandro Larcher, Milan, Italy, Carlo Terrone, Alessandro Volpe, Novara, Italy, Fabio Muttin, Francesco Ripa, Milan, Italy, Federica Regia, Novara, Italy, Roberta Lucianiò, Alberto Briganti, Roberto Bertini, Francesco Montorsi, Umberto Capitanio, Milan, Italy

7:40 PD04-05 RADICAL NEPHRECTOMY AND CAVATRIAL THROMBECTOMY ON NORMOTHERMIC CARDIOPULMONARY BY-PASS AND BEATING HEART: OUR EXPERIENCE
Elena Strada*, Antonio Galfano, Silvia Secco, Giovanni Petralia, Dario Di Trapani, Claudio Francesco Russo, Aldo Massimo Bocciardi, Milan, Italy

7:50 PD04-06 ROBOT ASSISTED RADICAL NEPHRECTOMY AND INFERIOR VENA CAVA THROMBECTOMY: SURGICAL TECHNIQUE, PERIOPERATIVE AND ONCOLOGIC OUTCOMES
Giuseppe Simone, Rome, Italy, David Hatcher, Los Angeles, CA, Mariaconsiglia Ferriero, Francesco Minisola*, Leonardo Misuraca, Gabriele Tuderti, Salvatore Guaglionone, Rome, Italy, Andre Luis De Castro Abreu, Monish Aron, Mihir Desai, Inderbir Singh Gill, Los Angeles, CA, Michele Gallucci, Rome, Italy

8:00 PD04-07 HIGHER PD-L1 MRNA LEVEL IN CLEAR CELL RENAL CELL CARCINOMAS IS ASSOCIATED WITH A FAVORABLE OUTCOME
Xianghui Ning*, Yanqing Gong, Shining He, Teng Li, Jiangyi Wang, Shuanghe Peng, Jinchao Chen, Jiayuan Liu, Nienie Qi, Yinglu Guo, Kan Gong, Beijing, China, People’s Republic of

8:10 PD04-08 METASTASECTOMY IS ASSOCIATED WITH IMPROVED SURVIVAL IN THE TARGETED THERAPY ERA FOR METASTATIC RENAL CELL CARCINOMA
Zeyad Schwen*, Gregory Joice, Hiten Patel, Michael Gorin, Mohamad Alaf, Phillip Pierorazio, Baltimore, MD

8:20 PD04-09 SHOULD PATIENTS WITH METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA UNDERGO CYTOREDUCTIVE NEPHRECTOMY?
Sarp Keskin*, Hiten Patel, Leonardo Borregales, Houston, TX, Patrick Kennedy, New Haven, CT, Surena Matin, Jose Karam, Christopher Wood, Houston, TX

8:30 PD04-10 EXTERNAL VALIDATION OF THE MAYO CLINIC STAGE, SIZE, GRADE, AND NECROSIS SCORE IN PATIENTS WITH RENAL CELL CARCINOMA AND VENOUS TUMOR THROMBUS
Adam Lorentz*, Atlanta, GA, Caroline Tai, San Francisco, CA, Umberto Capitanio, Milano, Italy, Joaquin Carballido, Madrid, Spain, Gaetano Cliancio, Miami, FL, Siarnak Daneeshmand, Los Angeles, CA, Christopher Evans; Sacramento, CA, Paolo Gontero, Turin, Italy, Axel Haferkamp, Frankfurt, Germany, Markus Hohenfellner, Heidelberg, Germany, William Huang, New York, NY, Estefania Linares Espinós, Juan Martinez-Salamanca, Madrid, Spain, James McKiernan, New York, NY, Francesco Montorsi, Milano, Italy, Sascha Pahernik, Heidelberg, Germany, Juan Palou, Barcelona, Spain, Raj Pruthi, Chapel Hill, NC, Paul Russo, Douglas Scherr, New York, NY, Martin Spahn, Würzburg, Germany, Carlo Terrone, Novara, Italy, Derya Tiiki, Sacramento, CA, Cesar Vera-Donoso, Valencia, Spain, Daniel Vergho, Würzburg, Germany, Eric Wallen, Chapel Hill, NC, Richard Zigeuner, Graz, Austria, John Libertino, Burlington, MA, Viraj Master, Atlanta, GA

8:40 PD04-11 DELAY OF THE INITIATION OF SYSTEMIC THERAPY AFTER CYTOREDUCTIVE NEPHRECTOMY IS NOT ASSOCIATED WITH WORSE OVERALL SURVIVAL
Zeyad Schwen*, Hiten Patel, Michael Gorin, Gregory Joice, Mohamad Alaf, Phillip Pierorazio, Baltimore, MD

8:50 PD04-12 CLINICAL CORRELATION OF PATIENT-DERIVED XENOGRAFT MODEL USING THE EX-OVO AVIAN EMBRYO TO PREDICT TARGETED THERAPY TUMOR RESISTANCE IN RENAL CELL CARCINOMA
Melissa Huynh*, Matthew Lowerison, Victor McPherson, Hon Leong, Nicholas Power, London, Canada

APPREVED FOR AMA PRA CATEGORY 1 CREDIT™
### Video Session 1

#### RECONSTRUCTION LOWER TRACT (I)

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 254 @ Boston Convention & Exhibition Center

**Moderators:** John Lacy, Daniel Moon and Jay Simhan

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V1-01</td>
<td>RADIAL FOREARM FREE FLAP SUBSTITUTION URETHROPLASTY FOR THE TREATMENT OF A LONG URETHRAL DEFECT</td>
<td>V1-08</td>
<td>SURGICAL CORRECTION OF URORECTAL FISTULA (URF) FOLLOWING RADICAL PROSTATECTOMY FOR THE TREATMENT OF PROSTATE CANCER.</td>
</tr>
<tr>
<td>V1-02</td>
<td>ROBOT ASSISTED LAPAROSCOPIC PLACEMENT OF BLADDER NECK ARTIFICIAL URINARY SPINCIETER.</td>
<td>V1-09</td>
<td>REPAIR OF ADULT BURIED PENIS WITH REMOVAL OF SUPRAPUBIC FAT PAD AND SPLIT THICKNESS SKIN GRAFT: EMPHASIS ON PATIENT BODY HABITUS</td>
</tr>
<tr>
<td></td>
<td>John Schomburg*, Mya Levy, Sean Elliott, Minneapolis, MN</td>
<td></td>
<td>Jeremy B. Myers*, Salt Lake City, UT, Bradley A. Erickson, Iowa City, IA, Sorena Keihani, Salt Lake City, UT</td>
</tr>
<tr>
<td>V1-03</td>
<td>MEMBRANOUS URETHROPLASTY USING DORSAL ONLAY BUCCAL MUCOSAL GRAFT FOR STRICTURES ASSOCIATED WITH TURP OR RADIATION THERAPY</td>
<td>V1-10</td>
<td>IS CONTINENCE POSSIBLE IN PATIENTS WITH DOUBLE BLOCK AT BLADDER NECK - PROSTATE AND MEMBRANOBULBAR URETHRA AFTER PELVIC FRACTURE URETHRAL INJURY?</td>
</tr>
<tr>
<td></td>
<td>Stephen Blakely, Daniela Kaerfel, Michael Daugherity, Dmitry Nikolavsky*, Syracuse, NY</td>
<td></td>
<td>Pankaj Joshi*, Devang Desai, Sandesh Surana, Hazem Orabi, Craig Hunter, Sanjay Kulkami, Pune, India</td>
</tr>
<tr>
<td>V1-04</td>
<td>RECONSTRUCTION OF BULBO-MEMBRANOUS URETHRAL STENOSIS AFTER SURGERY FOR BENIGN PROSTATIC HYPERPLASIA WITH PRESERVATION OF CONTINENCE</td>
<td>V1-11</td>
<td>STAGED URETHROPLASTY FOR PENILE URETHRAL STRICTURES AFTER HYPOSPADIAS REPAIR AND LICHEN SCLEROSUS</td>
</tr>
<tr>
<td></td>
<td>Cristina Baeza, Reynaldo Gomez*, Rodrigo Campos, Laura Velarde, Santiago, Chile</td>
<td></td>
<td>Andrew Gomella, Logan Hubbard, Hong Truong, Philadelphia, PA, Bradley Figler*, Chapel Hill, NC</td>
</tr>
<tr>
<td>V1-05</td>
<td>REDO BULBO-PROSTATIC ANASTOMOTIC (BPA) URETHROPLASTY FOR RECURRENT PELVIC FRACTURE-RELATED URETHRAL STRICTURES</td>
<td>V1-12</td>
<td>SURGICAL MANAGEMENT OF ADULT ACQUIRED BURIED PENIS (AABP)</td>
</tr>
<tr>
<td></td>
<td>Enrique Fes Ascanio*, Ibiza, Islas Baleares, Spain, Simon Bugeja, San Luka, Pieta, Malta, Stella Ivaz, London, United Kingdom, Felix Campos Juanatey, Santander, Cantabria, España, Spain, Anastasia Frost, Daniela Andrich, Anthony Mundy, London, United Kingdom</td>
<td></td>
<td>Thomas Fuller*, Katherine Theisen, Paul Rusilko, Pittsburgh, PA</td>
</tr>
<tr>
<td>V1-06</td>
<td>THE URETHRAL PULL-THROUGH: RECONSTRUCTING THE DEVASTATED POSTERIOR URETHRA AND BLADDER NECK AFTER RADIATION</td>
<td></td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Lot-Doyle*, Mukul Patil, Stuart Boyd, Los Angeles, CA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>V1-07</td>
<td>CLAMPO-TRACTOR. A NOVEL SELF RETAINING CLAMP RETRACTOR FOR PENILE URETHRAL RECONSTRUCTION: IMPROVING SURGEON ERGONOMICS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pankaj Joshi*, Sanjay Kulkami, Pune, India</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
### SOCIETY FOR PEDIATRIC UROLOGY (SPU)

**Pacific Ballroom @ Renaissance**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30</td>
<td>REGISTRATION/BREAKFAST</td>
<td></td>
</tr>
</tbody>
</table>
| 7:30   | WELCOME AND INTRODUCTIONS                                            | President: Doug Canning
Program Chair: J. Christopher Austin                                               |
| 7:35   | SESSION 1: PRIZE ABSTRACT SESSION: BASIC SCIENCE                      | Moderators: Linda Baker, John Park                                            |
| 8:35   | HYPOSPADIAS PANEL-PROXIMAL HYPOSPADIAS REPAIR                         | Moderator: Mark Zaontz
Panelists: Saul Greenfield, Tony Khoury, Paul Zelkovic, Paul Merguerian           |
| 9:35   | SESSION 2: DSD HYPOSPADIAS                                            | Moderators: Eric Kurzock, Grace Hyun                                           |
| 10:25  | BREAK                                                                 |                                                                                |
| 10:50  | SESSION 3: DSD/HYPOSPADIAS MODERATOR POSTERS                         | Moderators: Candace Granberg, Jordan Gitlin                                     |
| 11:15  | SPU LECTURE: PARTIAL NEPHRECTOMY FOR WILMS TUMOR: PAST, PRESENT, AND  | Michael Ritchey                                                               |
|        | FUTURE                                                                |                                                                                |
| 12:00  | SFU BUSINESS MEETING                                                 |                                                                                |
| 12:15  | LUNCH                                                                 |                                                                                |
| 1:30   | SFU PROGRAM                                                           |                                                                                |
| 1:30   | SFU PANEL: UTD CLASSIFICATION: PROS, CONS, AND WHAT'S AHEAD           | Moderators: Dennis Liu
Panelists: Luis Braga, Jeanne (Mei) Chow, Tony Herndon                           |
| 2:20   | SESSION 4: HYDRONEPHROSIS                                             |                                                                                |
| 3:27   | BREAK                                                                 |                                                                                |
| 4:00   | SFU LECTURE: DIAGNOSIS, MANAGEMENT AND LONG-TERM OUTCOMES OF PATIENTS | Francisco Dénes                                                                 |
|        | WITH PRUNE BELLY SYNDROME                                            |                                                                                |
| 4:30   | SESSION 5: PUV AND FETAL UROLOGY                                      | Moderators: Edward Gong, Armando Lorenzo                                      |
| 5:30   | ADJOURN                                                              |                                                                                |

### ENGINEERING AND UROLOGY SECTION OF THE ENDOUROLOGICAL SOCIETY (EUS)

**Ballroom AB @ Westin Harbor**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15</td>
<td>REGISTRATION</td>
<td></td>
</tr>
<tr>
<td>7:40</td>
<td>WELCOME</td>
<td>Chairs: Alberto Breda, Martijn De Bruin</td>
</tr>
</tbody>
</table>
| 7:45   | THE IMPACT AND LIMITATIONS OF VOLUMETRIC DIAGNOSTIC ENDOMICROSCOPY   | Brett Bouma
Provoker: Jeffrey Cadeddu                                                        |
| 8:10   | SURGICAL TRAINING: VIRTUAL OR SYNTHETIC?                             | Domenico Veneziano
Provoker: Robert Sweet                                                            |
| 8:35   | INNOVATIVE MEDICAL TECHNOLOGIES TO IMPROVE PATIENT CONSULTATION       | Salim Hawatmeh
Provoker: Louis Kavoussi                                                           |
| 9:00   | MAGNETIC PUNCTURE FOR PCNL                                          | Estevao Lima
Provoker: Margaret Pearle                                                          |
| 9:25   | ULTRASOUND TECHNOLOGY IN KIDNEY STONES                               | Jonathan Harper
Provoker: Stephen Nakada                                                            |
| 9:50   | IMAGE GUIDED SURGERY: IS THERE A FUTURE IN UROLOGY?                  | Jasper Nijkamp
Provoker: Pilar Laguna                                                               |
| 10:15  | REGENERATIVE MEDICINE: WHERE DO WE STAND?                            | Anthony Atala
Provoker: John Leppert                                                               |
| 10:40  | BREAK                                                                |                                                                                |
| 10:55  | CONFOCAL MICROSCOPY: APPLICATIONS IN UROLOGY                         | Joseph Liao
Provoker: Olivier Traxer                                                            |
| 11:20  | NEW ROBOTS ARE COMING!                                               | Alexandre Mottrie
Provoker: Jens Rassweiller                                                           |
| 11:45  | KEYNOTE LECTURE: HYPERSPECTRAL IMAGING IN MEDICINE                   | Mario Parente                                                                   |
| 12:10  | 3D PRINTING IN UROLOGICAL SURGICAL PLANNING: RCC                     | Aurus Durado
Provoker: Evangelos Liatsikos                                                        |
### INDIAN AMERICAN UROLOGICAL ASSOCIATION (IAUA)

**Welcome and Introductions**
- Program Co-Chairs: Ajay Singla, Ojas Shah

**Male Health**
- Moderators: Harcharan Gill, Joseph Alukal

**Male Infertility Treatment Update**
- Puneet Sindhwani

**Hypogonadism Treatment – Current Role and Controversies**
- Mohit Khera

**Female Pelvic Medicine and Reconstruction**
- Moderators: Ajay Singla, Sorvin Shah
  - Debate: Vaginal Vault Prolapse Repair
    - Abdominal Approach
      - Kathleen Kobashi
    - Vaginal Approach
      - Sandip Vasavada

**Endourology and Stone Disease**
- Moderators: Ojas Shah, Gyan Pareek

**Consumer Reports in Endourology – What’s New?**
- Brian Eisner

**Metabolic Evaluation in Stone Disease – Is It Really Worth It?**
- David Goldfarb

**Upper Urinary Tract Reconstruction**
- Moderators: Ashok Hemal, Ravindra Sabinis Prem Nath Dogra

**Break, Posters and Exhibits**

**Urologic Oncology**
- Moderators: Alok Shrivastava, Ramakrishna Venkatesh

**Removing the Blindfold: Using Prostate MRI to Illuminate the Path to Prostate Cancer Detection and Focal Ablation**
- Samir Taneja

**New Technologies in Minimally Invasive BPH Treatment**
- Claus Roehrborn

**Management of High Grade Muscle Invasive Bladder Cancer in 2017**
- Ashish Kamat

**Industry Sponsored Lunch Program & Exhibits - TBD**

### WORLD CHINESE UROLOGICAL SOCIETY (WCUS)

**Welcome**
- Tom F. Lue

**Scientific Program**
- Richard Lo

**Session 1: Lo Ping-Wan Memorial Lecture**
- Moderators: Edmund Chiong, Richard Lo

**Multimodality Management of UTUC: Chemotherapy, Lymphadenectomy, Robotics**
- Surena F. Matlin

**Discussion**

**Session 2: Oncology**
- Moderators: George K Chow, Chao-hsiang Chang
8:30 CHARACTERISTIC FUNDAMENTAL AND CLINICAL RESEARCH OF RENAL CELL CARCINOMA IN THE INSTITUTE OF UROLOGY, PEKING UNIVERSITY (IUPU)
Liqaun Zhou

8:38 PRECISION MEDICINE IN PROSTATE CANCER MANAGEMENT
Liyan Zhuang

8:46 MR PET SCAN WITH 68GA PSMA IN PROSTATE CANCER
Richard Lo, Lo CS, Chan JK, Cheung WS, Lo GG

8:54 MAXIMIZING CONTINENCE AFTER RADICAL PROSTATECTOMY
Vincent Tse

9:02 UPDATE ON PROSTATE FUSION BIOPSY- THE HONG KONG EXPERIENCE
James Tsu

9:20 ONCOLOGICAL CHARACTERISTICS AND OUTCOME OF UPPER TRACT UROTHELIAL CARCINOMA (UTUC)-A POPULATION-BASED STUDY FROM A HIGH-VOLUME CENTER OF CHINA
Xuesong Li, Liqun Zhou

9:28 DISCUSSION

9:33 SESSION 3: ENDUROLOGY
Moderators: Guan Wu, Qian Zhang

9:33 ROBOTIC MICROSURGERY IN 2017
Tung Shu

9:41 ULTRASOUND-NAVIGATED TRANSURETHRAL VAPOR ENULCEATION OF THE PROSTATE
Liping Xie

9:49 ROBOTIC ASSISTED PARTIAL NEPHRECTOMY: SEVEN-YEAR EXPERIENCE FROM TAIPEI VETERANS GENERAL HOSPITAL
Hsiao-Jen Chung

9:57 THE PERIOPERATIVE APPLICATION OF THREE-DIMENSIONAL RECONSTRUCTION, SIMULATION AND PRINTING IN LAPAROSCOPIC UROLOGY
Dongwen Wang

10:05 CLINICAL APPLICATION OF NEW TIP-FLEXIBLE SEMI-RIGID URETERORENOSCOPE
Xiaofeng Gao

10:13 APPLICATION OF FLEXIBLE URETEROSCOPE IN THE DIAGNOSIS AND TREATMENT OF UPPER URINARY TRACT DISEASES
Shaogang Wang

10:21 DISCUSSION

10:26 BREAK

10:35 SESSION 4: BOSTON SCIENTIFIC LECTURES
Moderators: Teng-Lung Lin, Anthony CF Ng

10:35 ARTIFICIAL URINARY SPHINCRTER FOR MALE URINARY INCONTINENCE – PATIENT SELECTION AND SURGICAL STEPS
Tom F. Lue

10:45 LEARNING TO DO IPP AND AUS SURGERY: MY AMERICAN EXPERIENCE BASED ON B.S. SUPPORTING PROGRAM
Tie Zhou

10:55 PENILE PROSTHESIS IMPLANTATION SURGERY: SURGICAL TECHNIQUE A-Z
Run Wang

11:05 DISCUSSION

11:10 SESSION 5: AJA LECTURE AND WCUS AWARDS
Moderators: Tom F. Lue, Run Wang

11:20 ASIAN MEN’S HEALTH REPORT 2
Hui Meng Tan

11:25 WCUS AWARDS

11:25 SESSION 6: BASIC SCIENCE IN ONCOLOGY
Moderators: Benyi Li, Alan Gao

11:33 GENETIC CHANGES IN BLADDER CANCER
Xue-Ru Wu

11:41 SEX DISPARITY IN BLADDER CANCER
Sean Li

11:49 QUANTITATIVE AND MULTICOMPONENT ANALYSIS OF PREVALENT URINARY CALCULI OR CRYSTAL USING MICRO-RAMAN SPECTROSCOPY
Yi-Chun Chiu

11:57 LNCRNA BLACAT2 IN BLADDER CANCER PROGRESSION
Tianyu Lin

12:07 DISCUSSION

12:20 LIGHT LUNCH

12:25 SESSION 7: ANDROLOGY
Moderators: Phillips Li, Hui Jiang

12:33 ANALYSIS OF AN ONLINE CHINESE MALE SEXUAL HABITS: SURVEY OF 2016
Nicholas (Hsueh-Fu) Lu

12:42 WHAT IS THE BEST TOOL TO DIAGNOSE ERECTILE DYSFUNCTION? AN UPDATE
Ong Teng Aik

12:57 THE EFFECT OF LOW INTENSITY PULSED ULTRASOUND (LIUS) ON ERECTILE DYSFUNCTION
Zhongcheng Xin

13:05 SEXUAL HABITS OF CHINESE PEOPLE - A LARGE DATA STUDY
Haosheng Lin

13:13 IMPROVING OUTCOMES OF NOCTURNAL ERECTIONS MONITORING, COMPARISON OF SUMMARY STATISTICS OF CONSECUTIVE NPTR TESTING
Yan Zhan

13:21 DISCUSSION
1:35  Session 8: Interstitial Cystitis and Others
Moderators: Lee Zhao, Eugen Wang, Kang Hong

1:35  Interstitial Cystitis/Chronic Prostatitis (Chronic Pelvic Pain)
Henry Lai

1:43  Holistic Approach by Bio-Psychosocial Model to Patients with Interstitial Cystitis / Bladder Pain Syndrome
Ming-Huei Lee

1:51  Maximizing Learning from Online CME: Experiences of Taiwan Urological Association
Chung-You Tsai

1:59  Laparoscopic Partial Nephrectomy with a Remote Activated Bullgod Clamp in a Pig Model
Chen Wei

2:07  Plasma Button Transurethral Vapor Enucleation or Vapor Resection Technique for Benign Prostatic Hyperplasia
Qiang Fu

2:15  The Probability of Cancer in Patients of Repeat Prostate Biopsy Can Be Predicted by Multi-Parametric Magnetic Resonance Imaging and Prostate-Specific Antigen Velocity
Gang Song

2:23  Discussion

2:40  Closing Remarks

3:00  Adjourn

---

Friday, May 12, 2017  8:00 am - 4:30 pm

AUA/CONFEDERACION AMERICANA DE UROLOGIA (CAU)
Ballroom East @ Boston Convention & Exhibition Center

---

8:00  Morning Session
Moderator: Shlomo Raz

8:30  Update on Bladder Cancer
Fernando Pablo Secin

9:00  Update on Prostate Cancer
William Catalona

9:30  Treatment of Overactive Bladder
Victor Nitti

10:00  Break

10:30  Treatment of Vesico-Ureteric Reflux
Alan Retick

11:00  Treatment of Testicular Cancer
Joel Sheinfeld

11:30  Treatment of Impotence
Drogo Montague

12:00  AUA/CAU Remarks
AUA Secretary: Manoj Monga
Society Secretary General: Jorge Gutierrez-Aceves

12:05  Tissue Engineering
Anthony Atala

12:30  Break

1:30  Afternoon Session: New Technology in Urologic Surgery
Moderator: Jorge Gutierrez-Aceves

1:30  Flexible Ureteroscopy: Update on Endoscopic Technology and Disposables
Brian Matlaga

1:50  Laser Lithotripsy: Fragmentation, Dusting, Short Pulse and Long Pulse, Physical Concepts and Clinical Outcomes
Olivier Traxer

2:10  Progressive Endoscopic Technology and Instruments: What Else Do We Need to Improve Stone Treatment Outcomes?
Ralph Clayman

2:30  Ablative New Technologies and Techniques for BPH
Panelists: Gopal Badlani, Peter Gilling, Claus Roehrborn, Jaspreet Sandhu

3:10  Focal Therapy for Prostate Cancer: Is It Ready for Prime Time?
Rafael Sanchez Salas

3:30  Laparoscopic Surgery: Update on 3D, 4K and New Technology for Endoscopes, Instruments and Tools
Alejandro Rodriguez

3:50  Robotic Surgery: Future Platform and Technology
Mihir Desai

4:05  Update on Imaging, Biopsy and Ablative Therapy for Small Renal Masses
Jaime Landman

4:10  Adjourn

Approved for AMA PRA Category 1 Credit™

*Presenting author
**2017 BASIC SCIENCES SYMPOSIUM: FUNCTION AND DYSFUNCTION OF STEM CELLS, REGENERATION AND REPAIR IN UROLOGY**

**Room 204 @ Boston Convention & Exhibition Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
</tr>
</thead>
</table>
| 8:00  | WELCOME                                                                 | Program Chair: Rosalyn Adam  
Program Chair: Rosalyn Adam  
Director, AUA Office of Research: Carolyn Best |
| 8:05  | SESSION I: DEVELOPMENTAL PRINCIPLES IN REGENERATION-INTRODUCTION       | Chair: Darius Bagli     |
| 8:10  | KEYNOTE I: DEVELOPMENTAL PRINCIPLES AND KIDNEY ENGINEERING             | Andrew McMahon         |
| 8:50  | UROTHELIAL PROGENITORS IMPORTANT IN DEVELOPMENT, REGENERATION AND CANCER | Cathy Lee Mendelsohn   |
| 9:15  | PROGENITOR CELLS AND THE ORIGIN OF PROSTATE CANCER                      | Michael Shen           |
| 9:40  | GLOMERULAR DAMAGE IN CHRONIC KIDNEY DISEASE: EFFECT OF AMNIOTIC FLUID STEM CELLS AND THEIR EXTRACELLULAR VESICLE | Laura Perin            |
| 10:05 | NEUROGENESIS IN THE LOWER URINARY TRACT - TEMPORAL PROCESSES AND SIGNALING PATHWAYS | E. Michelle Southard-Smith |
| 10:30 | Q & A                                                                    |                        |
| 10:40 | SESSION II: REGENERATION & REPAIR: LEARNING FROM OUTSIDE UROLOGY-INTRODUCTION | Chair: Trinity Bivalacqua |
| 10:45 | GENERATION OF AN ARTIFICIAL INTESTINE FOR THE TREATMENT OF SHORT BOWEL SYNDROME IN INFANTS | David Hackam           |
| 11:10 | BIOPRINTED MICROENGINEERED HYDROGELS FOR TISSUE FABRICATION             | Ali Khademhosseini     |
| 11:35 | ENGINEERING STEM CELL IDENTITY FOR REGENERATIVE MEDICINE               | Samantha Morris        |
| 12:00 | Q & A                                                                    |                        |
| 12:10 | LUNCH                                                                   |                        |
| 1:00  | SESSION III: HOST RECIPIENT-BIOMATERIAL-MICROENVIRONMENT INTERACTIONS - INTRODUCTION | Chair: X. Sean Li     |
| 1:05  | KEYNOTE II: FUNCTIONAL TISSUE RECONSTRUCTION BY AN ACELLULAR REGENERATIVE MEDICINE APPROACH | Stephen Badylak       |
| 1:45  | BIOMATERIALS FOR CARDIOVASCULAR TISSUE ENGINEERING                      | Joyce Wong             |
| 2:10  | UROTHELIAL PROGENITORS IN MODELS OF BLADDER RECONSTRUCTION              | Joshua Mauney          |
| 2:35  | BIOENGINEERING AND ENGRAFTMENT OF HUMAN VASCULAR NETWORKS               | Juan Melero-Martin     |
| 3:00  | REGENERATION OF ERECTILE FUNCTION POST PROSTATECTOMY                     | Carol Podlasek         |
| 3:25  | Q & A                                                                    |                        |
| 3:35  | SESSION IV: CLINICAL TRIALS AND BIOETHICS OF REGENERATION - INTRODUCTION | Chair: Carlos Estrada, Jr. |
| 3:40  | THE FIRST TISSUE ENGINEERED NEO-URINARY CONDUIT CLINICAL TRIAL FOR COMPLETE ORGAN REPLACEMENT: SUCCESSES, PITFALLS, CHALLENGES | Trinity Bivalacqua     |
| 4:05  | REGENERATING AND REPLACING ORGANS: RESEARCH ETHICS AND POLICY ISSUES    | Nancy King             |
| 4:30  | FROM BENCH TO BEDSIDE: THE CLINICAL DRUG & DEVICE DEVELOPMENT PATHWAYS  | Christopher Cutie      |
| 4:55  | Q & A                                                                    |                        |
| 5:00  | FINAL THOUGHTS, ACKNOWLEDGEMENTS & ADJOURN                               | Rosalyn Adam           |

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
### UROLOGIC ONCOLOGY RESEARCH SYMPOSIUM: INNOVATIVE THERAPEUTICS FOR PERSONALIZED MEDICINE: FROM CELL AND PROTEIN ENGINEERING TO NOVEL NANOMEDICINES

**Room 206 @ Boston Convention & Exhibition Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>WELCOME</td>
</tr>
<tr>
<td>8:05</td>
<td>SYMPOSIUM INTRODUCTION</td>
</tr>
<tr>
<td>8:15</td>
<td>SESSION I: NANOTHERAPEUTICS AND DRUG DELIVERY - INTRODUCTION</td>
</tr>
<tr>
<td>8:20</td>
<td>KEYNOTE: SPHERICAL NUCLEIC ACIDS AND THEIR ROLE IN DIGITAL DRUG DESIGN</td>
</tr>
<tr>
<td>9:00</td>
<td>EXPANSILE NANOPARTICLES IN CANCER DRUG DELIVERY</td>
</tr>
<tr>
<td>9:25</td>
<td>DOXIL®, THE FIRST FDA APPROVED NANO-DRUG: LESSONS LEARNED</td>
</tr>
<tr>
<td>9:50</td>
<td>CELL MEMBRANE-CLOAKED NANOPARTICLES FOR TARGETED DRUG DELIVERY</td>
</tr>
<tr>
<td>10:15</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>10:25</td>
<td>SESSION II: NOVEL BIOLOGICS AND PROTEIN THERAPEUTICS - INTRODUCTION</td>
</tr>
<tr>
<td>10:30</td>
<td>EMERGING ROLE OF PSMA TARGETED IMAGING AND THERAPY OF PROSTATE CANCER</td>
</tr>
<tr>
<td>10:55</td>
<td>FROM MOLECULAR FARMING TO MOLECULAR MEDICINE</td>
</tr>
<tr>
<td>11:20</td>
<td>BIOPODAL LIGANDS: A NOVEL CLASS OF HIGH-AFFINITY PEPTIDES FOR BIOMEDICAL APPLICATIONS</td>
</tr>
<tr>
<td>11:45</td>
<td>IMPROVING THE EFFICACY AND SAFETY OF BIOLIGIC DRUGS WITH TOLERGENIC NANOPARTICLES</td>
</tr>
<tr>
<td>12:10</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>12:20</td>
<td>LUNCH</td>
</tr>
<tr>
<td>1:00</td>
<td>SESSION III: IMAGING DIAGNOSTICS AND MOLECULAR - INTRODUCTION</td>
</tr>
<tr>
<td>1:45</td>
<td>KEYNOTE: IMAGING DRUG DELIVERY</td>
</tr>
<tr>
<td>2:10</td>
<td>MOLECULAR CHARACTERIZATION OF CIRCULATING TUMOR CELLS</td>
</tr>
<tr>
<td>2:55</td>
<td>ACTIVITY-BASED NANOSENSORS AS SYNTHETIC BIOMARKERS OF CANCER</td>
</tr>
<tr>
<td>3:15</td>
<td>CAR THERAPY: THE CD19 AND BEYOND</td>
</tr>
<tr>
<td>3:40</td>
<td>NANOPARTICULATE DELIVERY OF THERAPEUTIC RNA AND GENOME EDITING COMPLEXES</td>
</tr>
<tr>
<td>4:05</td>
<td>ENGINEERING IMMUNITY AGAINST INFECTIOUS DISEASE AND CANCER</td>
</tr>
<tr>
<td>4:30</td>
<td>HARNESSING RNAI-BASED NANOMEDICINES FOR THERAPEUTIC GENE SILENCING IN HEMATOLOGICAL MALIGNANCIES</td>
</tr>
<tr>
<td>4:55</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>5:10</td>
<td>FINAL THOUGHTS &amp; ACKNOWLEDGEMENTS</td>
</tr>
<tr>
<td>5:05</td>
<td>ADJOUR</td>
</tr>
</tbody>
</table>

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

### SEXUAL MEDICINE SOCIETY OF NORTH AMERICA (SMSNA)

**Room 210AB @ Boston Convention & Exhibition Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>PRESIDENTIAL WELCOME</td>
</tr>
<tr>
<td>8:05</td>
<td>CME ACTIVITY ANNOUNCEMENTS</td>
</tr>
<tr>
<td>8:10</td>
<td>SESSION 1 – FEMALE SEXUAL DYSFUNCTION</td>
</tr>
<tr>
<td>8:15</td>
<td>UPDATING THE FSD NOMENCLATURE</td>
</tr>
</tbody>
</table>

*Presenting author*
8:25 | UROGYNECOLOGIC SURGERY AND IT’S SEXUAL FUNCTION CONSEQUENCES
Irwin Goldstein

8:40 | BRAIN ACTIVITY AND FEMALE SEXUAL DYSFUNCTION
James Pfaus

8:55 | Q & A

9:00 | SESSION 2 – GRAND MASTER LECTURES
Moderators: Lawrence Hakim, Hossein Sadeghi-Nejad

9:15 | CLINICAL TRIALS, REGISTRIES, OUTCOMES AND QUALITY OF LIFE ASSESSMENT: IMPACT ON SEXUAL MEDICINE
Raymond Rosen

9:30 | DIAGNOSTIC AND THERAPEUTIC MILESTONES IN SEXUAL MEDICINE
Irwin Goldstein

9:45 | EVOLUTION OF PENILE PROSTHESIS SURGERY IN THE LAST 40 YEARS
Steven Wilson

9:55 | Q & A

10:00 | BREAK

10:15 | SESSION 3 – POINT COUNTERPOINT
Moderators: Serge Carrier, Tobias Kohler

10:25 | DEBATE 1: PROSTATE BIOPSY PROTOCOL IN ACTIVE SURVEILLANCE FOR PROSTATE CANCER causes ED: PRO
Trinity Bivalacqua

10:55 | DEBATE 2: CIRCUMCISION WILL SIGNIFICANTLY REDUCE PENILE SENSITIVITY: CON
Ira Sharlip

11:05 | Q & A

11:15 | SESSION 4 – SMSNA FELLOWSHIPS AND NOVEL CONCEPTS
Moderators: Trinity Bivalacqua, Mohit Khera

11:30 | SMSNA-PFIZER FELLOW - TRANSDERMAL DELIVERY OF CURCUMIN, A NATURAL ANTI-INFLAMMATORY COMPOUND, THROUGH THE USE OF A NOVEL NANOPARTICLE DELIVERY SYSTEM
Andrew Draganski

11:45 | SMSNA-AUA UROLOGY CARE FOUNDATION FELLOW - LEYDIG STEM CELL AUTOGRRAFT FOR TREATMENT OF HYPOGONADISM IN KLINEFELTER SYNDROME AND STEM CELL THERAPY IN THE MANAGEMENT OF ERECTILE DYSFUNCTION
Ranjith Ramasamy

11:50 | THE IRA SHARLIP LECTURE
Moderator: Run Wang

12:00 | LUNCH SYMPOSIUM

1:00 | SESSION 5 – MEDICAL AND HORMONAL
Moderators: William Conners, Nelson Bennett, Jr.

1:15 | DEFINING HYPOGONADISM THAT DOES NOT FIT THE CLASSICAL PRIMARY OR SECUNDARY HYPOGONADISM DEFINITIONS – TIME FOR A RESET?
Mohit Khera

1:30 | MANAGEMENT OF DELAYED EJACULATION
Stanton Honig

1:45 | Q & A

1:50 | SESSION 6 – CANCER AND SEXUAL FUNCTION
Moderators: Ronald Lewis, Luiz Torres

2:00 | SEXUAL FUNCTION IN MALE CANCER SURVIVORS
Gregory Broderick

2:15 | SEXUAL DYSFUNCTION IN WOMEN WITH CANCER: NAVIGATING INTIMACY AND INTERCOURSE BETWEEN WOMEN AND THEIR PARTNERS
Don Dizon

2:20 | Q & A

2:30 | EVIDENCE SUPPORTING TESTOSTERONE THERAPY IN PROSTATE CANCER
Abraham Morgentaler

2:40 | EVIDENCE AGAINST TESTOSTERONE THERAPY IN PROSTATE CANCER
Landon Trost

2:50 | Q & A

3:05 | SESSION 7 – PSYCHOLOGICAL FACTORS IN SEXUAL DYSFUNCTION
Moderators: Annamaria Giraldi, Michael Perelman

3:20 | PSYCHOLOGICAL TREATMENT FOR HSDD IN MEN AND WOMEN
Marita McCabe

3:35 | THE PSYCHOLOGICAL AND RELATIONSHIP IMPACT OF MALE SEXUAL DYSFUNCTION
Christian Nelson

3:50 | Q & A

4:05 | SESSION 8 – SURGICAL THERAPIES
Panelists: William Brant, Rafael Carrion, Brian Christine, Gerard Henry

4:20 | PENILE FRACTURE: CURRENT CONCEPTS FOR DIAGNOSIS AND REPAIR
Allen Morey

4:30 | Q & A

4:45 | BREAK

5:00 | LUNCH SYMPOSIUM

5:15 | SESSION 9 – CONCLUSIONS AND FUTURE DIRECTIONS
Moderators: Trinity Bivalacqua, Mohit Khera

5:30 | CONCLUSIONS AND FUTURE DIRECTIONS
Gregory Broderick

5:45 | Q & A

5:55 | BREAK

6:00 | LUNCH SYMPOSIUM

6:15 | SOCIAL EVENT

6:30 | THE IRA SHARLIP LECTURE
Moderator: Run Wang

6:45 | LUNCH SYMPOSIUM
Friday, May 12, 2017 9:30 am - 11:30 am

Moderated Poster Session 6

TRANSPLANTATION & VASCULAR SURGERY: RENAL TRANSPLANTATION & VASCULAR SURGERY I

Room 153 @ Boston Convention & Exhibition Center

Moderators: Peter Bretan, Dicken Ko and Ho Yee Tiong

---

**ABSTRACT NUMBER** | **TITLE**
--- | ---
**MP06-01** | EVALUATION OF THE RELATIONSHIP BETWEEN THE DONOR AND RECIPIENT DURING KIDNEY TRANSPLANT

Christopher Dru*, D. Joseph Thum, Devin Patel, Justin Houman, Gerhard Fuchs, Los Angeles, CA

**MP06-02** | SERUM SIALYL HYBRID TYPED N-GLYCAN LEVELS PREDICTS EARLY ABMR IN LIVING DONOR KIDNEY TRANSPLANT PATIENTS

Daisuke Noro*, Tohru Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Kazuhiro Mori, Yasuhiro Hashimoto, Takuya Koie, Hiroaki, Japan, Masakazu Tanaka, Shinichiro Nishimura, Sapporo, Japan, Hideo Sasaki, Kawasaki, Japan, Hideki Ishida, Kazunari Tanabe, Tokyo, Japan, Shigeru Satoh, Akita, Japan, Chikara Ohyama, Hiroaki, Japan

**MP06-03** | ROBOT ASSISTED TRANSPLANT ALOGRAFT NEPHRECTOMY SERIES: A NOVEL APPROACH FOR A CHALLENGING OPERATION

Rafael Nunez*, Nicholas Jakob, Sean McAdams, Kelli Gross, Haidar Abdul-Muhsin, Nitin Katariya, Erik Castle, Phoenix, AZ

**MP06-04** | SAFETY AND EFFICACY OF SOFOSBUVIR-BASED DIRECT-ACTING ANTIVIRAL AGENTS IN KIDNEY TRANSPLANT RECIPIENTS WITH HEPATITIS C VIRUS INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS

Ping Tan*, Lu Yang, Liangren Liu, Qiang Wei, Chengdu, China, People’s Republic of China

**MP06-05** | LEARNING CURVE OF A NEW SURGICAL PROCEDURE: EXPERIENCE FROM A NEW CENTER ADOPTING ROBOTIC KIDNEY TRANSPLANT.

Sohrab Arora*, New Delhi, India, Volkan Tugcu, Istanbul, Turkey, Akshay Sood, Mahendra Bhandari, Detroit, MI, Rajesh Ahlawat, New Delhi, India, Mani Menon, Detroit, MI

**MP06-06** | PRE-TRANSPLANT ANTIBODY REMOVAL CAN BE AVOIDED IN ABO INCOMPATIBLE KIDNEY TRANSPLANTATION.

Masayuki Tasaki*, Yuki Nakagawa, Kazuhide Saito, Naofumi Imai, Yumi Ito, Vladimir Blim, Kota Takahashi, Yoshihiko Tomita, Niigata, Japan

**MP06-07** | CD4*IFN-γ*IL-10* CELLS FACILITATE A PROLONGATION OF GRAFT SURVIVAL IN OLD RECIPIENT MICE TREATED WITH RAPAMYCIN

Koichiro Minami*, Timm Heinbokel, Markus Quante, Hirofumi Uehara, Abdala Elkhal, Boston, MA, Haruhito Azuma, Osaka, Japan, Stefan G. Tullius, Boston, MA

**MP06-08** | MIRABEGRON IMPROVES SYMPTOMS ASSOCIATED WITH SMALL BLADDER CAPACITY FOLLOWING KIDNEY TRANSPLANTATION

Charbel Chalouhy*, Jessica Moore, Benjamin Philosophe, Baltimore, MD

---

*Presenting author
MP06-09 LOCAL SILDENAFIL ACCELERATE RENAL REGENERATION AFTER ISCHEMIA/REPERFUSION INJURY IN CANINE MODEL.

MP06-10 THE ACTIVATION OF INFLAMMATION AMPLIFIER IN KIDNEY TRANSPLANT GRAFT AND URINARY BIOMARKER FOR CHRONIC REJECTION
Haruka Higuchi*, Daiki Iwami, Kiyohiko Hotta, Nobuo Shinohara, Masaaki Murakami, Sapporo, Japan

MP06-11 INCIDENTAL NEPHROLITHIASIS IN LIVE RELATED KIDNEY DONORS: EPIDEMIOLOGY, LONG TERM OUTCOME OF DONOR AND RECIPIENT.
Sanjoy Sureka*, Aneeshr Srivastava, Uday Singh, Rakesh Kapoor, M S Ansari, Sandeep Kumar, Lucknow, India

MP06-12 USEFULNESS OF MULTI-DETECTOR COMPUTED TOMOGRAPHY SCANNING FOR REPLACEMENT OF DIETHYLENETRIAMINE PENTACETIC ACID (DTPA)
Hyung Ho Lee*, Sook Young Kim, Young Eun Yoon, Sung Ku Kang, Jae Yong Jeong, Kwang Hyun Kim, Seoul, Korea, Republic of, Kyung Hwa Choi, Seongnam, Korea, Republic of, Joong Shik Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Woong Kyu Han, Seoul, Korea, Republic of

MP06-13 BENEFICIAL EFFECT OF HYDROGEN SULFIDE ON RENAL ISCHEMIA-REPERFUSION INJURY IN CLAWN MINIATURE SWINE
Yuichi Ariyoshi*, Mitsuhito Sekijima, Takahiro Murokawa, Hisashi Sahara, Kagoshima, Japan, Motoo Araki, Yasutomo Nasu, Okayama, Japan, Kazuhiko Yamada, Kagoshima, Japan

MP06-14 IMPACT OF VISCERAL AND SUBCUTANEOUS ADIPOSE TISSUE ON POST DONATION RENAL FUNCTION IN LIVING KIDNEY DONORS
Hyung Ho Lee*, Sook Young Kim, Young Eun Yoon, Sung Ku Kang, Jae Yong Jeong, Kwang Hyun Kim, Seoul, Korea, Republic of, Kyung Hwa Choi, Seongnam, Korea, Republic of, Joong Shik Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Woong Kyu Han, Seoul, Korea, Republic of

MP06-15 EFFECT OF CORM-3 IN ISCHEMIA REPERFUSION INJURY AND CISPLATIN-INDUCED TOXICITY: DIFFERENCES IN NORMAL KIDNEY CELL AND RENAL CANCER CELL

MP06-16 OUR EXPERIENCE IN THE MANAGEMENT OF PROSTATE CANCER IN RENAL TRANSPLANT RECIPIENTS
Alonso Narvaez Barros*, Luis Riera Canals, Jaime Fernandez-Concha Schwabl, Jose Suarez Novo, Manel Castells Esteve, Francesc Vigués Julià, Barcelona, Spain

MP06-17 UROTHELIAL CARCINOMA AFTER KIDNEY TRANSPLANT: A HETEROGENEOUS ENTITY IN TERMS OF DIAGNOSIS, TREATMENTS AND ONCOLOGICAL OUTCOMES
Vital Hevia*, Javier Lorca, Victoria Gomez, Sara Alvarez, Victor Diez, Francisco Javier Burgos, Madrid, Spain

MP06-18 CT VOLUMETRY OF THE KIDNEY IS A COST EFFECTIVE ALTERNATIVE TO MAG3 SCAN IN PREDICTING RENAL FUNCTION AFTER DONOR NEPHRECTOMY
Yosuke Mitsui*, Takuya Sadahira, Motoo Araki, Shingo Nishimura, Koichiro Wada, Yasuyuki Kobayashi, Toyoiko Watanabe, Yasutomo Nasu, Okayama, Japan

MP06-19 LONG-TERM OUTCOME OF ADULT RENAL TRANSPLANTATION IN PATIENT WITH CONGENITAL LOWER URINARY TRACT MALFORMATIONS: A MULTICENTER STUDY.
Stéphane MARCHEL*, Nicolas Kalfa, Francois IBORRA, Montpellier, France, Lionel BADET, Lyon, France, Georges Karam, Julien Branchereau, Lucas Broudeur, Nantes, France, Rodolphe Thuret, Montpellier, France

MP06-20 RANDOMIZED EXPERIMENTAL STUDY COMPARING NON-OXYGENATED VS OXYGENATED HYPOTHERMIC MACHINE PERFUSION IN A TYPE III NON-HEART-BEATING DONOR PIG MODEL OF AUTOTRANSPANTATION.
Vital Hevia*, Victoria Gomez, Maria Laura Garcia-Bermejo, Sara Alvarez, Francisco Donis, Victor Diez, Ana Saiz, Adolfo Martinez, Francisco Javier Burgos, Madrid, Spain

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP07-01</td>
<td>GENETIC OUTCOMES OF CONCEPTION IN MEN WITH ELEVATED SPERM ANEUPLOIDY</td>
</tr>
<tr>
<td>MP07-02</td>
<td>POLYA TAG LIBRARY PREPARATION FOR NEW GENERATION SEQUENCING (NGS) IN HUMAN TESTIS FAILS TO DETECT NON-CODING AND TRANSLATED RNAs IMPORTANT IN TESTICULAR FUNCTION AS COMPARED TO RIBOSOMAL RNA DEPLETION METHOD.</td>
</tr>
<tr>
<td></td>
<td>Ryan Flannigan*, New York, NY, Anna Mielnik, Alex Bolyakov, Phil V. Bach, New York, NY, Peter Schlegel, New York, NY, Darius Paduch, New York, NY</td>
</tr>
<tr>
<td>MP07-03</td>
<td>IMPROVED SPERM DNA INTEGRITY IN THE SECOND SEMEN SAMPLE FROM MEN PROVIDING DOUBLE EJACULATES</td>
</tr>
<tr>
<td></td>
<td>Tristan Juvet*, Susan Lau, Kirk Lo, Ethan Grober, Keith Jarvi, Toronto, Canada</td>
</tr>
<tr>
<td>MP07-04</td>
<td>ABNORMAL HYPERMETHYLATION OF VDAC2 PROMOTER IS ASSOCIATED WITH MALE IDIOPATHIC ASTHENOSPERMIA</td>
</tr>
<tr>
<td></td>
<td>Zengjun Wang*, Biaojian Liu, Shifeng Su, Aiming Xu, Jianzhong Zhang, Nanjing, China, People’s Republic of</td>
</tr>
<tr>
<td>MP07-05</td>
<td>ANALYSIS OF 23,000 IUI CYCLES: CORRELATING SPERM STRICT KRUGER MORPHOLOGY WITH CYCLE PREGNANCY OUTCOMES</td>
</tr>
<tr>
<td></td>
<td>Jared Winoker*, Joseph Lee, Michael Whitehouse, Alan Copperman, Natan Bar-Chama, New York, NY</td>
</tr>
<tr>
<td>MP07-06</td>
<td>STUDY ON SINGLE NUCLEOTIDE POLYMORPHISMS WITHIN THE NOVEL TESTIS-SPECIFIC HASP5 GENE ENCODING A SERINE/THREONINE PROTEIN KINASE IN HUMAN MALE INFERTILITY</td>
</tr>
<tr>
<td></td>
<td>Yasushi Miyagawa*, Tetsuji Soda, Norichika Ueda, Shinichiro Fukuhara, Hiroshi Kuchi, Suita, Japan, Akira Tsujimura, Urayasu, Japan, Hirotsugu Tanaka, Sasebo, Japan, Norio Nonomura, Suita, Japan</td>
</tr>
<tr>
<td>MP07-07</td>
<td>RADICAL ORCHIDECTOMY AND FERTILITY PRESERVATION: A NEED TO CHANGE PRACTICE</td>
</tr>
<tr>
<td></td>
<td>Jemma Moody*, Catherine Horsfield, London, United Kingdom, Malene Pedersen, Vejle, Denmark, Kamran Ahmed, Pippa Sangster, Majed Shabbir, London, United Kingdom</td>
</tr>
<tr>
<td>MP07-08</td>
<td>CHARACTERIZATION OF LACTOFERRIN RECEPTOR ON HUMAN SPERMATOZOA</td>
</tr>
<tr>
<td></td>
<td>Zengjun Wang*, Pengqi Wang, Biaojian Liu, Xiaobin Niu, Shifeng Su, Wei Zhang, Nanjing, China, People’s Republic of</td>
</tr>
<tr>
<td>MP07-09</td>
<td>EXPLORING RNA EXPRESSION PROFILES OF KLINEFELTER’S SYNDROME IN THE SETTING OF NON-OBSTRUCTIVE AZOOSPERMIA</td>
</tr>
<tr>
<td></td>
<td>Ryan Flannigan*, New York, NY, Alex Bolyakov, Anna Mielnik, Phil V. Bach, Darius Paduch, New York, NY</td>
</tr>
<tr>
<td>MP07-10</td>
<td>USEFULNESS OF A PORTABLE COMPUTER-ASSISTED SPERM ANALYZER SYSTEM USING SMARTPHONE</td>
</tr>
<tr>
<td></td>
<td>Kazumitsu Yasasaki*, Tsukuba, Japan, Noriko Watanabe, Tatsuji Ihana, Sumio Ishijima, Toshihiro Fujiwara, Osaka Tsutsui, Tokyo, Japan, Teruaki Iwamoto, Nasushiobara, Japan</td>
</tr>
<tr>
<td>MP07-11</td>
<td>ROLES OF HISTONE H3.5 IN HUMAN SPERMATOGENESIS AND SPERMATOGENIC DISORDERS</td>
</tr>
<tr>
<td></td>
<td>Koji Shirasishi*, Aya Shindo, Ube, Japan, Akihito Harada, Yasuyuki Ohkawa, Fukushima, Japan, Hitoshi Kurumizaka, Hiroshi Kimura, Tokyo, Japan, Hideyasu Matsuyama, Ube, Japan</td>
</tr>
<tr>
<td>MP07-12</td>
<td>DAMAGE TO SEMINIFEROUS TUBULES IN PATIENTS WITH SERTOLI CELL ONLY SYNDROME PROGRESSES WITH AGING</td>
</tr>
<tr>
<td></td>
<td>Shiochiro Iwatsuki*, Yukihiro Umemoto, Tomoki Takeda, Satoshi Nozaki, Hideki Takada, Hiroki Kubota, Yasunori Itoh, Shoichi Sasaki, Takahiro Yasui, Nagoya, Japan</td>
</tr>
<tr>
<td>MP07-13</td>
<td>THERAPEUTIC EFFECT OF RIPK1 INHIBITOR IN TESTICULAR ISCHEMIA-REPERFUSION</td>
</tr>
<tr>
<td></td>
<td>Shin Ohira*, Ryooi Hara, Kurashiki City, Japan, Shigenobu Tone, Hatoyama-cho, Japan, Seiitsu Ken, Shinjiro Shimizu, Tomohiro Fujii, Yoshiyuki Miyaji, Atsushi Nagai, Kurashiki City, Japan</td>
</tr>
<tr>
<td>MP07-14</td>
<td>CO-INCUBATION OF HUMAN SPERMATOZOA WITH ANTI-VDAC ANTIBODY REDUCED SPERM MOTILITY</td>
</tr>
<tr>
<td></td>
<td>Biaojian Liu*, Shifeng Su, Min Tang, Zengjun Wang, Nanjing, China, People’s Republic of</td>
</tr>
</tbody>
</table>

*Presenting author
MP07-15 ALTERATIONS IN OXIDATIVE STRESS PARAMETERS IN THE TESTIS AND EPIDIDYMIS IN A NICOTINE-EXPOSED RAT MODEL. CAN NICOTINE-ABSTINENCE OVERCOME THE OXIDATIVE DAMAGE?
Panagiota Tsounapi*, Masashi Honda, Yonago, Japan, Fotios Dimitriadis, Ioannina, Greece, Yusuke Kimura, Yonago, Japan, Shogo Shimizu, Nankoku, Japan, Bunya Kawamoto, Katsuya Hikita, Yonago, Japan, Motoaki Saito, Nankoku, Japan, Nikolaos Sofikitis, Ioannina, Greece, Atsushi Takenaka, Yonago, Japan

MP07-16 UTILIZATION RATES OF CRYOPRESERVED SPERM BASED ON THE INDICATION FOR STORAGE
Graham Machen*, Erin Bird, Monica Brown, Dale Ingalsbe, Milaide East, Michelle Reyes, Thomas Kuehl, Temple, TX

MP07-17 ROLE OF OXIDATION REDUCTION POTENTIAL IN VARICOCELE ASSOCIATED MALE INFERTILITY
Mohamed Arafa*, Haitham ElBardisi, Ahmad Majzoub, Sami AlSaid, Abdel Rahman Jaber, Kareim Khalfalla, Doha, Qatar, Siew May Wang, Ashok Agarwal, Cleveland, OH

MP07-18 IMPACTS OF SMOKING ON THE GLYCOCALYX OF HUMAN SPERMATOZOA
Rick Paschold*, Susanne Bour, Armin Becker, Christian Stief, Matthias Trottmann, München, Germany

MP07-19 INVOLVEMENT OF OXIDATION REDUCTION POTENTIAL IN THE PATHOPHYSIOLOGY OF MALE INFERTILITY IN PATIENTS WITH VARICOCELE
Ashok Agarwal*, Siew May Wang, Nicholas Tadros, Edmund Sabanegh, Cleveland, OH

MP07-20 THE IMPACT OF TESTICULAR CANCER ON MALE FERTILITY; ABNORMALITIES DETECTED AND AEITIOPATHOGENESIS
Khaled Almekaty*, Chris Poullis, Elizabeth Williamson, London, United Kingdom, Mohamed Zahran, Mansoura, Egypt, Gideon Blecher, Tet Yap, Suks Minhas, London, United Kingdom

MP08-01 ACTIVE SURVEILLANCE FOR CYSTIC RENAL MASSES WITH ≥5 YEARS OF FOLLOW-UP
Andrew McIntosh*, Pranav Parikh, Anthony Tokarski, Eric Ross, David Chen, Richard Greenberg, Alexander Kutikov, Marc Smaldone, Rosalia Viterbo, Robert Uzzo, Philadelphia, PA

MP08-02 NEPHROMETRY SCORES ARE USELESS FOR EXPERIENCED UROLOGISTS IN CLINICAL PRACTICE.
Henrique Nonemacher*, Giuliano Guglielmetti, George Lins de Albuquerque, Rafael Coelho, Mauricio Cordeiro, Arnaldo Fazoli, Paulo Afonso Carvalho, Tiago Magalhaes Freire, kayann Kaled R el Hayek, Vitor Pagotto, George Lins de Albuquerque, Mauricio Cordeiro, Bruno Aragao Rocha, Diego Parga Rodrigues, Alexandre Filgلمan Kanas, Publico Cesar Cavalcan tI Viana, William Nahas, Sao Paulo, Brazil

MP08-03 PREDICTION OF HISTOLOGICAL SUBTYPES OF SMALL RENAL MASSES: STRIVING FOR A STANDARDIZED MRI DIAGNOSTIC ALGORITHM
Fernando U. Kay*, Noah E. Canvasser, Yin Xi, Daniella F. Pinho, Daniel Costa, Alberto Diaz de Leon, Gaurav Khatri, John R. Leyendecker, Takeshi Yokoo, Aaron Lay, Nicholas Kavoussi, Ersin Koseoglu, Jeffrey A. Cadeddu, Ivan Pedrosa, Dallas, TX

MP08-04 DIAGNOSTIC EVALUATION OF MICROSCOPIC HEMATURIA IN YOUNG ADULTS: TIME TO RETHINK THE AMERICAN UROLOGICAL ASSOCIATION GUIDELINE
Erfan Amini*, Farhad Pishgar, Mohsen Ayati, Bila Foratikashani, Iman Ghazi, Elnaz Ayati, Mohammad Reza Nowroozi, Majid Ali Asgari, Ramin Pourghorban, Faeze Salahshour, Hassan Jamshidian, Tehran, Islamic Republic of Iran
MP08-05 CALCULATION OF BLADDER VOLUMES USING 2D AND 3D ULTRASOUND COMPARED TO URODYNAMIC MEASUREMENTS IN WOMEN WITH OVERACTIVE BLADDER
Anna Nagle*, Rachel Bernardo, Jary Varghese, Adam Klausner, John Speich, Richmond, VA

MP08-06 COMBINATION OF RGB AND NARROW BAND IMAGING FOR DISCRIMINATION OF NON-MUSCLE INVASIVE BLADDER CANCER
Kwang Suk Lee*, Kyo Chul Koo, Do Kyung Kim, Jongsoo Lee, Jong Won Kim, Jae Yong Jeong, Sung Ku Kang, Byung Ha Chung, Seoul, Korea, Republic of

MP08-07 SINGLE PULSE-PER-SECOND SETTING SIGNIFICANTLY REDUCES FLUOROSCOPY TIME DURING URETEROSCOPY
Todd Yecies*, Anisleidy Fombona, Michelle Semins, Pittsburgh, PA

MP08-08 READING REPORTS VS REVIEWING IMAGES . . . . . . HOW IMPORTANT IS IT FOR ENDUROLOGISTS TO LOOK AT FILMS PRIOR TO DECISION-MAKING?
Haresh Thummar*, Ponkhraj S, Shivang D, N Thummar, Vadodara, India

MP08-09 POPULATION-LEVEL CANCER DETECTION AND PATTERNS OF CARE FOLLOWING MRI-GUIDED PROSTATE BIOPSY
Wen Liu*, Dattatraya Patil, David Howard, Renee Moore, Heqiong Wang, Martin Sandra, Christopher Filson, Atlanta, GA

MP08-10 PROSPECTIVE EVALUATION OF CANCER DETECTION RATES OF THE PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2
Sherif Mehralivand*, Sandra Bednarova, Bethesda, MD, Joanna Shih, Rockville, MD, Francesca Merten, Sonia Gaur, Maria Merino, Bradford Wood, Peter Pinto, Peter Choyke, Baris Turkbey, Bethesda, MD

MP08-11 RADIOLOGIST EXPERIENCE LEVEL DOES NOT PREDICT THE ACCURACY OF PROSTATE MRI INTERPRETATION FOR CLINICALLY SIGNIFICANT PROSTATE CANCER: ARE CONSENSUS READS THE ANSWER?
Eric Kim*, Joel Vetter, Anup Shetty, Kathryn Fowler, Aaron Mintz, Cary Siegel, Gerald Andriole, Robert Grubb III, St. Louis, MO

MP08-12 MULTI-INSTITUTIONAL EVALUATION OF MRI AND FUSION BIOPSY IN CONFIRMATORY BIOPSY FOR ACTIVE SURVEILLANCE

MP08-13 MR RADIOIMAGES IN THE RISK STRATIFICATION OF PROSTATE CANCER
Frank Chen, Bino Varghese, Darryl Hwang, Steve Cen, Mihir Desai, Suzanne Palmer, Monish Aron, Manju Aron, Inderbir Gill, Gangning Liang, Andre Abreu, Sameer Chopra, Osamu Ukimura, Vinay Duddalwar*, Los Angeles, CA

MP08-14 DEVELOPMENT AND VALIDATION OF A NOMOGRAM FOR PREDICTING PI-RADS 4-5 LESIONS ON MULTIPARAMETRIC PROSTATE MRI
Matthew Truong*, Thomas Frye, Dang Lam, Ji Hae Park, Bokai Wang, Changyong Feng, Gary Hollenberg, Eric Weinberg, Edward Messing, Rochester, NY

MP08-15 MULTI INSTITUTIONAL STUDY ON MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION BIOPSY, ARE WE GETTING BETTER?
Wei Phin Tan*, Thomas Hwang, Mukund Gande, Daniel Dalton, Paul Yonover, Kalyan Latchamsetty, Christopher Coogan, Chicago, IL

MP08-16 USE OF DUPLICATE AXIAL IMAGING IN NEWLY DIAGNOSED PROSTATE CANCER – TRENDS ACROSS THE PENNSYLVANIA UROLOGIC REGIONAL COLLABORATIVE (PURC)
Serge Ginzburg*, Adam Reese, Edouard Trabulsi, Tianyu Li, Claudette Fonshell, Bret Marlowe, Thomas Guzzo, Thomas Lanchoney, Marc Smaldone, Robert Uzzo, Philadelphia, PA

MP08-17 IS MAGNETIC RESONANCE IMAGING SENSITIVE ENOUGH FOR PARTIAL GLAND HIGH INTENSITY FOCUSED ULTRASOUND TREATMENT? COMPARING PROSTATE CANCER LESIONS BETWEEN MAGNETIC RESONANCE IMAGING AND PROSTATECTOMY SPECIMENS
Clinton Bahler*, Clint Cary, Ronald Boris, Temel Tirkes, Timothy Masterson, Thomas Gardner, Michael Koch, Indianapolis, IN

MP08-18 DIAGNOSTIC ACCURACY OF THE SHEAR WAVE ELASTOGRAPHY FOR THE IDENTIFICATION OF PROSTATE CANCER: A DIAGNOSTIC META-ANALYSIS
Xiang Tu*, Lu Yang, Qiang Wei, Chengdu, China, People’s Republic of
**MP08-19** PROSTATE MRI: THE TRUTH LIES IN THE EYE OF THE BEHOLDER  
Joseph C. Riney*, Nabeel E. Sarwani, Shehzad Siddique, Jay D. Raman, Hershey, PA

**MP08-20** RAPID PHENOTYPING OF GENITOURINARY ANOMALIES IN MICE USING MICRO-CT  
Gene Huang*, Marisol O'Neill, Meade Haller, Carolina Jorgez, D.J. Lamb, Houston, TX

---

**Friday, May 12, 2017**  
**9:30 am - 11:30 am**

**Moderated Poster Session 9**

**BENIGN PROSTATIC HYPERPLASIA: MEDICAL & NON-SURGICAL THERAPY**  
Room 252 @ Boston Convention & Exhibition Center  
**Moderators:** Bradley Erickson, Christian Gratzke and Seth Strope

---

**ABSTRACT NUMBER** | **TITLE**
--- | ---
**MP09-01** | SILDENAFIL FOR TREATMENT OF LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA  
Ahmed M. Ragheb*, Mahmoud M. Arefa, Ayman S. Moussa, Amr M. Massoud, Giza, Egypt

**MP09-02** | EFFECTS OF TADALAFIL ON STORAGE AND VOIDING FUNCTION IN PATIENTS WITH MALE LOWER URINARY TRACT SYMPTOMS INCLUDING BENIGN PROSTATIC ENLARGEMENT, BASED ON A URODYNAMIC STUDY  
Yoshihisa Matsukawa*, Shohei Ishida, Kazuna Matsu, Yudai Miyata, Hideo Narita, Momokazu Gotoh, Nagoya, Japan

**MP09-03** | COMBINATION THERAPY OF TADALAFIL AND TAMSULOSIN FOR MEN WITH MODERATE TO SEVERE BENIGN PROSTATIC HYPERPLASIA  
Hyun Jun Park*, Tae Nam Kim, Jong Kil Nam, Busan, Korea, Republic of, Du Geon Moon, Seoul, Korea, Republic of, Nam Cheol Park, Busan, Korea, Republic of

**MP09-04** | COMPARISON BETWEEN TADALAFIL 5 MG VS. SERENOA REPENS/SELENIUM/LYCOPENE FOR THE TREATMENT OF BENIGN PROSTATIC LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA. A PHASE IV, RANDOMIZED, MULTICENTER, NON-INFRINGEMENT CLINICAL STUDY.  
SPRIT  
Giuseppe Morgia, Giulio Reale, Catania, Italy, Giuseppe Vespasiani, Roma, Italy, Marina Di Mauro, Catania, Italy, Rosaria M. Parea, Roma, Italy, Salvatore Voce, Ravenna, Italy, Massimo Madonia, Sassari, Italy, Paolo Fedelini, Napoli, Italy, Pasquale Veneziano, Reggio Calabria, Italy, Marco Carini, Florence, Italy, Giuseppe Salvia, Acireale, Italy, Francesco Santaniello, Ancona, Italy, Andrea Ginepri, Roma, Italy, Marco Bitelli, Cuneo, Italy, Carlo Terrone, Novara, Italy, Marcello Gentile, Avellino, Italy, Antonella Giannantoni, Perugia, Italy, Franco Blefari, Prato, Italy, Valerio Beatrici, Pesaro, Italy, Patrizio Polledoro, Cuneo, Italy, Pasquale La Rosa, Catania, Italy, Salvatore Amon, Lugo of Romagna, Italy, Giorgio Santelli, Lucca, Italy, Giorgio Ivan Russo*, Catania, Italy

**MP09-05** | DOES CONCOMITANT TESTOSTERONE REPLACEMENT IMPROVE THE RESPONSE OF TADALAFIL 5 MG ONCE DAILY IN MEN WITH LOWER URINARY TRACT SYMPTOMS?  
Hyun Jun Park*, Tae Nam Kim, Jong Kil Nam, Nam Cheol Park, Busan, Korea, Republic of, Du Geon Moon, Seoul, Korea, Republic of

**MP09-06** | ADMINISTRATION OF DAILY 5MG TADALAFIL IMPROVES NOT ONLY LOWER URINARY TRACT SYMPTOMS BUT ALSO VESSEL ENDOTHELIAL FUNCTION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA  
Toshiyasu Amano*, Takahiro Kishikage, Tetsuya Imao, Nagano, Japan
MP09-07 EVALUATION OF EFFICACY OF PDE5 INHIBITER BY PENILE BLOOD PRESSURE FOR BENIGN PROSTATIC HYPERPLASIA PATIENTS WITH LOWER URINARY TRACT SYMPTOMS
Juntaro Koyama*, Shirakawa-shi, Fukushima, Japan, Yoshide Kawasaki, Tomonori Sato, Sendai-shi, Miyagi, Japan, Taro Fukushi, Atsushi Kyan, Shirakawa-shi, Fukushima, Japan, Yasuhiro Kaizo, Sendai-shi, Miyagi, Japan

MP09-08 SLEEPING PROBLEMS ARE ASSOCIATED WITH INCREASED RISK OF BPH PROGRESSION: RESULTS FROM REDUCE
Brandee Branche*, Lauren Howard, Durham, NC, Daniel Moreira, Chicago, IL, Ramiro Castro-Santamaria, King of Prussia, PA, Gerald Andriole, St. Louis, MO, Martin Hopp, Stephen Freedland, Los Angeles, CA

MP09-09 DESMOPRESSIN FOR MALE NOCTURIA: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
Julia Han*, Gainesville, FL, Jae Hung Jung, Wonju, Korea, Republic of, Caitlin Bakker, Minneapolis, MN, Mark Ebell, Athens, GA, Philipp Dahm, Minneapolis, MN

MP09-10 TAMSULOSIN PRESCRIBING PATTERNS BASED ON A UNITED STATES HEALTH PLAN CLAIMS DATABASE
Bruce Kava*, Miami, FL, Anna E. Verbeek, Jan M. Wruck, Ridgefield, CT, Marc Gittelman, Aventura, FL

MP09-11 MEASURING AND PREDICTING THE PATIENT-REPORTED GOAL ACHIEVEMENT AFTER TREATING MALE BENIGN PROSTATIC HYPERPLASIA WITH TAMSULOSIN MONOTHERAPY
Bum Soo Kim*, Jae Wook Chung, Phil Hyun Song, Jun Nyung Lee, Yun-Sok Ha, Tae Gyun Kwon, Seock Hwan Choi, Hyun Tae Kim, Tae-Hwan Kim, Sung Kwang Chung, Daegu, Korea, Republic of, Ki Ho Kim, Gyeongju, Korea, Republic of, Byung Hoon Kim, Ji Yong Ha, Daegu, Korea, Republic of, Deok Hyun Cho, Gun Nam Kim, Gumi, Korea, Republic of, Yoon Hyung Lee, Jae Soo Kim, Hyun-Jin Jung, Hong Seok Shin, Daegu, Korea, Republic of, Jong Hyun Yoon, Jae Ho Kim, Gumi, Korea, Republic of, Eun Sang Yoo, Daegu, Korea, Republic of

MP09-12 DECISION-MAKING IN MEN CONSIDERING USE OF NON-PRESCRIPTION TAMSULOSIN FOR LOWER URINARY TRACT SYMPTOMS
Joshua Cohn*, Roger Dmochowski, Casey Kowell, Nashville, TN, Claus Roehrborn, Dallas, TX, Douglas Bierer, Cincinnati, OH, Anna Verbeek, Jan Wruck, Ridgefield, CT

MP09-13 CLINICAL EFFICACY AND SAFETY OF FULL DOSE ANTIMUSCARINIC AGENT TREATMENT ON UNSATISFACTORY IMPROVEMENT OF SYMPTOMS AFTER LOW DOSE ANTIMUSCARINIC TREATMENT IN MALE PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE MULTICENTER STUDY
Myungsun Shim*, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Jin Seon Cho, Anyang-si, Gyeonggi-do, Korea, Republic of

MP09-14 COMPARISON OF THE EFFICACY OF COMBINATION THERAPY WITH AN ANTICHOLINERGIC AGENT AND AN α1-BLOCKER VERSUS A β3-ADRENOCEPTOR AGONIST AND AN α1-BLOCKER FOR PATIENTS WITH BENIGN PROSTATIC ENLARGEMENT COMPlicated BY OVERACTIVE BLADDER: A RA
Yoshihisa Matsukawa*, Takashi Fujita, Masashi Kato, Yasuhiro Funahashi, Tokunori Yamamoto, Momokazu Gotoh, Nagoya, Japan

MP09-15 THE CONTINUOUS USE OF ANTIMUSCARINICS AFTER TURP IN BPH PATIENTS WITH STORAGE SYMPTOMS REQUIRING ANTIMUSCARINICS BEFORE SURGERY – A NATIONWIDE POPULATION-BASED STUDY
Eric Yi-Hsiu Huang*, Hsiao-Jen Chung, Chih-Chieh Lin, Ruo-Shin Peng, Yen-Hwa Chang, Alex T.L. Lin, Kuang-Kuo Chen, Taipei, Taiwan

MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
Herney Garcia-Perdomo*, Cali, Colombia, Hugo Lopez, Bogota, Colombia, Philipp Dahm, Minneapolis, MN

MP09-17 5-ALPHA REDUCTASE INHIBITORS FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA DOES NOT INCREASE THE RISK OF ERECTILE DYSFUNCTION

MP09-18 CHANGE OF URINARY STEROID METABOLITES IN BPH PATIENTS TREATED WITH DUTASTERIDE
Yota Yasumizu*, Eiji Kikuchi, Takahiro Maeda, Masanori Hasegawa, Akira Miyajima, Mototsugu Oya, Tokyo, Japan

MP09-19 THE EFFECT OF STATINS ON THE RISK OF RECEIVING TRANSURETHRAL RESECTION OF PROSTATE IN OUTPATIENTS OF GENITOURINARY CLINIC - A STUDY BY APPLYING NATION-WIDE POPULATION BASED DATABASE
Chih-Chieh Lin*, Hsiao-Jen Chung, Yi-Hsiu Huang, Alex Tong-Long Lin, Taipei, Taiwan

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP10-01</td>
<td>AN UNEQUAL NATION: THE RISKS OF INCIDENCE AND DEATH FROM BLADDER CANCER ACROSS ALL U.S. COUNTIES</td>
</tr>
<tr>
<td></td>
<td>Michael Goltzman*, Jonathan Bloom, John Phillips, Valhalla, NY</td>
</tr>
<tr>
<td>MP10-02</td>
<td>TEMPORAL TRENDS IN PERIOPERATIVE MORBIDITY FOR RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td></td>
<td>Zachary Smith*, Scott Johnson, Vignesh Packiam, Joseph Rodriguez III, Norm Smith, Gary Steinberg, Chicago, IL</td>
</tr>
<tr>
<td>MP10-03</td>
<td>PREOPERATIVE RISK FACTORS PREDICTING POSTOPERATIVE COMPLICATIONS IN RADICAL CYSTECTOMY FOR BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Vassili Glazyrine*, Stefan Graw, Sida Niu, Derek Jensen, Devin Koestler, Eugene Lee, Kansas City, KS</td>
</tr>
<tr>
<td>MP10-04</td>
<td>EFFECT OF RADICAL CYSTECTOMY AND URINARY DIVERSION FOR BLADDER CANCER TREATMENT ON RENAL FUNCTION OVER TIME</td>
</tr>
<tr>
<td></td>
<td>Shahab Bozorgmehr*, Gainesville, FL, Scott Gilbert, Tampa, FL, Xiaomin Lu, Robert L. Cook, Rebecca Beyth, Muna Canales, Gainesville, FL</td>
</tr>
<tr>
<td>MP10-05</td>
<td>IS DE NOVO UPPER TRACT UROTHELIAL CARCINOMA A DISTINCT ENTITY FROM BLADDER CARCINOMA?</td>
</tr>
<tr>
<td></td>
<td>Hanan Goldberg*, Thenappan Chandrasekar, Zachary Klaassen, Robert Hamilton, Girish Kulkarni, Neil Fleshner, Toronto, Canada</td>
</tr>
<tr>
<td>MP10-06</td>
<td>ISOLATED RED PATCHES SEEN DURING ENDOSCOPIC SURVEILLANCE OF BLADDER CANCER – HOW OFTEN SHOULD WE BIOPSY?</td>
</tr>
<tr>
<td></td>
<td>Nkwam Nkwam*, Shaun Trecarten, Stefan Momcilovic, Alvaro Bazo, Guminder Mann, Benedict Sherwood, Richard Parkinson, Nottingham, United Kingdom</td>
</tr>
<tr>
<td>MP10-07</td>
<td>INCREASED RISK OF BLADDER CANCER IN CHRONIC KIDNEY DISEASE PATIENTS WITH RENAL TRANSPLANTATION</td>
</tr>
<tr>
<td></td>
<td>Min-Chie Tung*, Kuan-Chun Hsueh, Taichung, Taiwan, Kuan-Hua Huang, Tainan, Taiwan, Chiao-Ling Chen, Yuan-Hung Wang, Chia-Chang Wu, New Taipei City, Taiwan</td>
</tr>
<tr>
<td>MP10-08</td>
<td>A PANEL OF MICRO-RNA SIGNATURE AS A TOOL FOR PREDICTING SURVIVAL OF PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER</td>
</tr>
<tr>
<td></td>
<td>Teruo Inamoto*, Kiyoshi Takahara, Naokazu Ibuiki, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Yuki Yoshikawa, Koichiro Minami, Hajime Hirano, Hayahito Nomri, Haruhito Azuma, Takatsuki, Japan</td>
</tr>
<tr>
<td>MP10-09</td>
<td>SUPPRESSED RECURRENT BLADDER CANCER AFTER ANDROGEN DEPRIVATION THERAPY OR 5α-REDUCTASE INHIBITOR</td>
</tr>
<tr>
<td></td>
<td>Masaki Shioda*, Keijiro Kyoshima, Akira Yokomizo, Ario Takeuchi, Eiji Kashiwagi, Ryosuke Takahashi, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto, Fukuoka, Japan</td>
</tr>
<tr>
<td>MP10-10</td>
<td>CAN UROLOGISTS ACCURATELY STAGE AND GRADE UROTHELIAL CARCINOMA BY ASSESSING ENDOSCOPIC PHOTOGRAPHS OF TUMORS?</td>
</tr>
<tr>
<td></td>
<td>Snir Dekalo*, Alexander Greenstein, Gal Karen Paz, Avi Beri, Juzza Chen, Jacob Ben Chaim, Mario Sofer, Nicola Mabjeesh, Haim Matzkin, Tel Aviv, Israel</td>
</tr>
<tr>
<td>MP10-11</td>
<td>ASSOCIATION OF PERIOPERATIVE VENOUS THROMBOEMBOLISM WITH LONG-TERM ONCOLOGIC OUTCOMES FOLLOWING RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td></td>
<td>Harras Zaid*, Matthew Tollefsen, Igor Frank, William Parker, R. Houston Thompson, Robert Tarrell, Prabin Thapa, John Cheville, Stephen Boorjian, Rochester, MN</td>
</tr>
<tr>
<td>MP10-12</td>
<td>EPIDEMIOLOGICAL TRENDS AND SOCIOECONOMIC DISPARITIES IN BLADDER CANCER SURVIVAL: ANALYSIS OF CALIFORNIA CANCER REGISTRY</td>
</tr>
<tr>
<td></td>
<td>Jeremy W. Martin*, Nobel Nguyen, Jenny Chang, Rahul Dutta, Simone L. Vernez, Argyrios Zioga, Hoda Anton-Culver, Ramy F. Youssef, Irvine, CA</td>
</tr>
<tr>
<td>MP10-13</td>
<td>IMPACT OF HISTOLOGIC SUBTYPE ON BLADDER CANCER OUTCOME</td>
</tr>
</tbody>
</table>
**MP10-14** STAGE AND SURVIVAL FOR PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER IN THE UNITED STATES (2004-2013): THE EFFECT OF SOCIODEMOGRAPHICS
Adam Weiner*, Joshua Meeks, Chicago, IL

**MP10-15** PATTERNS OF RECURRENCE IN DIFFERENT HISTOLOGICAL SUBTYPES OF BLADDER CANCER FOLLOWING RADICAL CYSTECTOMY
Rahul Dutta*, Newark, NJ, Jeremy Martin, Simone L Vernez, Ahmed Abdelhalim, Orange, CA, Ahmed Shoekir, Hassan Abol-Enein, Ahmed Mosbah, Mohamed Ghoneim, Mansoura, Egypt, Ramy Youssef, Orange, CA

**MP10-16** UTILIZATION OF NEOADJUVANT CHEMOTHERAPY IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA IN A CONTEMPORARY TERTIARY CARE COHORT
Tanner Miest*, R. Jeffery Karnes, Stephen Boorjian, Robert Tarrell, R. Houston Thompson, Matthew Tollefson, Bradley Leibovich, Igor Frank, Rochester, MN

**MP10-17** HEALTH RELATED QUALITY OF LIFE AFTER RADICAL CYSTECTOMY AND URINARY DIVERSION. OPEN VERSUS ROBOTIC ASSISTED TECHNIQUES.

**MP10-18** CREATION OF A QUALITY-IMPROVEMENT DATABASE FOR TRANURETHRAL RESECTION OF BLADDER TUMORS
Jason Cohen*, Alex Glaser, Leslie Okorji, Daniel Oberlin*, Joshua Meeks, Chicago, IL

**MP10-19** SYSTEMIC THERAPY AND OVERALL SURVIVAL TRENDS IN PATIENTS WITH NON-UROTHELIAL HISTOLOGIC VARIANTS OF MUSCLE INVASIVE BLADDER CANCER UNDERGOING RADICAL CYSTECTOMY
Shreyas Joshi*, Elizabeth Handorf, Andres Correa, Benjamin Ristau, Michael Haifler, Robert Uzzo, Richard Greenberg, David Chen, Rosalia Viterbo, Alexander Kutikov, Daniel Geynisman, Marc Smaldone, Philadelphia, PA

**MP10-20** PROSPECTIVE EVALUATION OF A CLINICAL TOOL FOR SEGREGATION OF HEMATURIA PATIENTS AT RISK FOR HIGH-GRADE UROTHELIAL CARCINOMA
Jay D. Raman*, Hershey, PA, Laimonis Kavaliers, Paul O’Sullivan, David Darling, Parry Guillford, Jimmie Suttie, Dunedin, New Zealand

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 12, 2017
Podium Session 5
9:30 am - 11:30 am

**INFECTIONS/INFLAMMATION/CYSTIC DISEASE OF THE GENITOURINARY TRACT: PROSTATE & GENITALIA I**
Room 159 @ Boston Convention & Exhibition Center

**Moderators:** Robert Evans and Giuseppe Morgia

**ABSTRACT**
**TIME** | **NUMBER** | **TITLE**
--- | --- | ---
9:30 | PD05-01 | THE EVOLVING CLINICAL PICTURE OF CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME (CP/CPPS): A LOOK AT 1310 PATIENTS OVER 16 YEARS.
R. Christopher Doiron*, Victoria Tolls, J. Curtis Nickel, Kingston, Canada

9:40 | PD05-02 | FEASIBILITY TESTING OF A MALE CHRONIC GENITAL PAIN CLINIC TO IDENTIFY MEN WITH CHRONIC UNEXPLAINED ORCHIALGIA
Susanne Quallich*, Janis Miller, Cynthia Artzianian-Ergoren, Anne Pelletier Cameron, Ann Arbor, MI

**ABSTRACT**
**TIME** | **NUMBER** | **TITLE**
--- | --- | ---
9:50 | PD05-03 | UTILITY OF TRIGGER POINT INJECTION AS AN ADJUNCT TO PHYSICAL THERAPY IN MEN WITH CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME
Anup Shah, Daniel Shoskes*, Cleveland, OH

10:00 | PD05-04 | EARLY EXPERIENCE WITH MICROSURGICAL SPERMATIC CORD DENERVATION IN A CANADIAN CENTRE
Darby Cassiday*, Prince George, Canada

10:10 | PD05-05 | MICRODENERVATION OF THE SPERMATIC CORD FOR POST VASECTOMY PAIN SYNDROME- A SINGLE SURGEON’S EXPERIENCE
Wei Phin Tan*, Peter Tsambarlis, John Richgels, Laurence Levine, Chicago, IL

*Presenting author
10:20 PD05-06 PHYSICAL THERAPY FOR ORCHALGIA
Matthew Nielsen*, Norfolk, VA, Charles Gresham, Norfolk, VA, Erin Glace, Virginia Beach, VA, Courtney Anderson, Hadiza Galadima, Jessica Delong, Jeremy Tonkin, Ramon Virasoro, Kurt McCammon, Norfolk, VA

10:30 PD05-07 ROLE OF PDE -5 INHIBITOR IN THE TREATMENT OF CHRONIC PELVIC PAIN SYNDROME: A RANDOMIZED CONTROL TRIAL
Prabjot Singh*, Abhishek Shukla, Prem Nath Dogra, New Delhi, India

10:40 PD05-08 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION FOR TREATMENT OF REFRACTORY CHRONIC PELVIC PAIN SYNDROME IN MEN: A PROSPECTIVE STUDY.
Yassine EL Abiad*, Meknes, Morocco

10:50 PD05-09 POLLEN EXTRACT IN ASSOCIATION WITH VITAMINS (DEPROX 500 ®) VERSUS SERENOA REPENS IN CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME; A SINGLE CENTER EXPERIENCE.
Nicola Macchione*, Michele Catalani, Milano, Italy

11:00 PD05-10 ANTIBIOTIC PROPHYLAXIS PRIOR TO URINARY CATHETER REMOVAL AFTER RADICAL PROSTATECTOMY DOES NOT PREVENT URINARY TRACT INFECTIONS: A RANDOMIZED CONTROLLED CLINICAL TRIAL
Claudia Berrondo*, Changyong Feng, Rochester, NY, Janet Kukreja, Houston, TX, Edward Messing, Jean Joseph, Rochester, NY

11:20 PD05-11 CONTEMPORARY PERCEPTIONS OF HUMAN PAPILLOMAVIRUS AND PENILE CANCER – PERSPECTIVES FROM A NATIONAL SURVEY

Friday, May 12, 2017
9:30 am - 11:30 am
Podium Session 6
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, QUALITY OF LIFE AND SHARED DECISION MAKING I
Room 161 @ Boston Convention & Exhibition Center
Moderators: David Penson and Christopher Saigal

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD06-01</td>
<td>CLOVIZ: CLINICAL OUTCOMES VISUALIZATION OF IMDC CRITERIA IN METASTATIC RENAL CELL CARCINOMA FOR PATIENT-CENTERED DECISION MAKING</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40</td>
<td>PD06-02</td>
<td>DECISIONAL QUALITY AND THE IMPACT OF SHARED DECISION MAKING AMONG PATIENTS WITH UROLOGIC STONE DISEASE</td>
</tr>
<tr>
<td></td>
<td>Matthew Pollard*, Joseph Shirk, Casey Pagan, Sylvia Lambrechts, Lorna Kwan, Nazih Khater, Christopher Saigal, Los Angeles, CA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:50</td>
<td>PD06-03</td>
<td>PERSONALIZED DECISION SUPPORT FOR LOCALIZED PROSTATE CANCER: RESULTS OF A MULTI-SITE RANDOMIZED TRIAL</td>
</tr>
<tr>
<td></td>
<td>Donna Berry*, Fangxin Hong, Traci Blonquist, Barbara Halpenny, Boston, MA, Martin Sandra, Viraj Master, Christopher Filson, Peter Rossi, Atlanta, GA, Peter Chang, Boston, MA, Gary Chien, Los Angeles, CA, Randy Jones, Tracey Krupski, Charlottesville, VA, Mitchell Sokoloff, Worcester, MA, Leslie Wilson, San Francisco, CA, Seth Wolpin, Seattle, WA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>PD06-04</td>
<td>FEASIBILITY AND INITIAL REPORT OF INCORPORATING A SHARED DECISION MAKING METRIC AT POINT OF SERVICE IN MEN WITH LOCALIZED PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Patrick Murray*, Paul Han, Gregory Mills, Stephen Prato, Caitlin Guthrie, Leo Waterston, Jesse Sammon, Mortiz Hansen, Portland, ME</td>
<td></td>
</tr>
<tr>
<td>TIME</td>
<td>NUMBER</td>
<td>TITLE</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>10:10</td>
<td>PD06-05</td>
<td>A RANDOMISED CONTROLLED TRIAL EVALUATING THE UTILITY OF A PATIENT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DECISION AID TO IMPROVE A PROSTATE CANCER CLINICAL TRIAL RELATED</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DECISION-MAKING AND RECRUITMENT</td>
</tr>
<tr>
<td>10:20</td>
<td>PD06-06</td>
<td>THE BURDEN OF CYSTOSCOPIC BLADDER CANCER SURVEILLANCE – ANXIETY,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DISCOMFORT, AND PATIENT PREFERENCES FOR DECISION MAKING</td>
</tr>
<tr>
<td>10:30</td>
<td>PD06-07</td>
<td>THE TRANSITION FROM A STATEWIDE PROSTATE CANCER TREATMENT PROGRAM TO</td>
</tr>
<tr>
<td></td>
<td></td>
<td>COMPREHENSIVE INSURANCE UNDER THE AFFORDABLE CARE ACT IN LOW-INCOME</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MEN</td>
</tr>
<tr>
<td>10:40</td>
<td>PD06-08</td>
<td>DISPARITY IN MINORITY REPRESENTATION WITHIN MEDICARE ACCOUNTABLE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CARE ORGANIZATIONS</td>
</tr>
<tr>
<td>10:50</td>
<td>PD06-09</td>
<td>HEALTHCARE DISPARITIES: DO MEDICAID PATIENTS HAVE LONGER WAIT TIMES</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FOR OUTPATIENT UROLOGICAL EVALUATION?</td>
</tr>
</tbody>
</table>

**Podium Session 7**

**PROSTATE CANCER: DETECTION & SCREENING II**

**Room 162 @ Boston Convention & Exhibition Center**

**Moderators:** Stephen Boorjian

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD07-01</td>
<td></td>
<td>THE 4KSCORE TEST ACCURATELY PREDICTS AGGRESSIVE PROSTATE CANCER IN</td>
<td>Bruno Nahar*, Miami, FL, Daniel Sjoberg, New York City, NY, Stephen Zappala, Andover, MA, Vivek</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MEN OF ALL AGES AND RACE.</td>
<td>Venkatramani, Dipen Parekh, Sanj Punnun, Miami, FL</td>
</tr>
<tr>
<td>9:40</td>
<td>PD07-02</td>
<td></td>
<td>PCA3 IN PROSTATE CANCER RISK ASSESSMENT: HOW DOES IT HELP IN REAL</td>
<td>Marine Lesourd*, Jean Baptiste Beauval, Benjamin Pradere, Daniel Portalez, Xavier Gamé,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LIFE? RESULT OF A 5-YEAR PROSPECTIVE STUDY</td>
<td>Eric Huynge, Michel Soulé, Pascal Rischmann, Bernard Malavaud, Mathieu Roumigué, TOULOUSE,</td>
</tr>
</tbody>
</table>

*Presenting author*
9:50 PD07-03 MICHIGAN PROSTATE SCORE (MIPS): AN ANALYSIS OF A NOVEL URINARY BIOMARKER PANEL FOR THE PREDICTION OF PROSTATE CANCER AND ITS IMPACT ON BIOPSY RATES
Amir H. Lebastchi*, Christopher M. Russell, Alexander M. Helfand, Takahiro Osawa, Javed Siddiqui, Rabia Siddiqui, Arul M. Chinnaiyan, Priya Kunju, Rohit Mehra, Debbie Snyder, Scott A. Tomlins, Jont T. Wei, Todd M. Morgan, Ann Arbor, MI

10:00 PD07-04 CLINICAL PERFORMANCE OF AN EPIGENETIC ASSAY TO IDENTIFY OCCULT HIGH-GRADE PROSTATE CANCER IN AFRICAN AMERICAN MEN

10:10 PD07-05 UTILITY OF DIGITAL RECTAL EXAMINATION (DRE) IN DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: AGE AND PROSTATE-SPECIFIC ANTIGEN (PSA)-BASED ANALYSIS

10:20 PD07-06 REGIONAL VARIATION IN THE SCREENING, BIOPSY, AND DIAGNOSIS OF PROSTATE CANCER IN A MEDICARE POPULATION
Rachel A. Moses*, Andrea M. Austin, Donald Carmichael, Elias S. Hyams, Lebanon, NH

10:30 PD07-07 PERSONAL PSA SCREENING AND TREATMENT CHOICES FOR LOCALIZED PROSTATE CANCER AMONG EXPERT PHYSICIANS
Christopher Wallis*, Douglas Cheung, Laurence Klotz, Toronto, Canada, Venu Chalasani, Sydney, Australia, Ricardo Leao, Juan Garisto, Gerard Morton, Robert Nam, Ian Tannock, Raj Satkunasivam, Toronto, Canada

10:40 PD07-08 A NOVEL NOMOGRAM TO PREDICT POSTOPERATIVE BIOCHEMICAL RECURRENCE IN PATIENTS WITH LOCALIZED HIGH-RISK PROSTATE CANCER
Ridwan Alam*, Jeffrey J. Tosoian, Baltimore, MD, Yaw A. Nyame, Lamont Wilkins, Cleveland, OH, Kasra Yousefi, Vancouver, Canada, Meera R. Chappidi, Baltimore, MD, Chandana A. Reddy, Cleveland, OH, Elizabeth B. Humphreys, Baltimore, MD, Debashis Sundi, Brian F. Chapin, Houston, TX, Andrew J. Stephenson, Eric A. Klein, Cleveland, OH, Ashley E. Ross, Baltimore, MD

10:50 PD07-09 PROSTATE SPECIFIC ANTIGEN TESTING AFTER RADICAL PROSTATECTOMY: CAN WE STOP AT 20 YEARS?
Wesley Ludwig*, Zhaoyong Feng, Bruce Trock, Elizabeth Humphreys, Patrick Walsh, Baltimore, MD

11:00 PD07-10 MALIGNANCIES IN MALE BRCA MUTATION CARRIERS – RESULTS FROM A PROSPECTIVELY SCREENED COHORT OF PATIENTS ENROLLED TO A DEDICATED MALE BRCA CLINIC
Roy Mano*, Ofer Benjaminov, Inbal Kedar, Yaara Bar, Sivan Sela, Rachel Ozalvo, Jack Daniel, David Margel, Petah Tikva, Israel

11:10 PD07-11 PROSTATE CANCER SCREENING IN HIGH RISK FAMILIES. A EIGHT-YEAR PROSPECTIVE PROGRAM IN YOUNG FIRST DEGREE RELATIVES AGED 40-49.
Pierre Callerot*, Marie-Pierre Moineau, Brest, France, Isabelle Cussenot, Francoise Baschet, Paris, France, Joel L’her, Laurent Doucet, Brest, France, Luc Cormier, Dijon, France, Philippe Mangin, Olivier Cussenot, Paris, France, Georges Fournier, Antoine Valeri, Brest, France

11:20 PD07-12 MOLECULAR PROFILING OF MULTI-FOCAL PROSTATE CANCER AND CONCOMITANT LYMPH NODE METASTASIS: IMPLICATIONS FOR TISSUE-BASED PROGNOSTIC BIOMARKERS
Simpa Salami*, Daniel Hovelson, Ann Arbor, MI, Romain Mathieu, Vienna, Austria, Jeremy Kaplan, Ann Arbor, MI, Martin Susani, Vienna, Austria, Christopher Russell, Ann Arbor, MI, Nathalie Rioux-Leclercq, Rennes, France, Shahrokh Shariat, Vienna, Austria, Scott Tomlins, Ganesh Palapattu, Ann Arbor, MI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**Video Session 2**

**FEMALE PELVIC MEDICINE**

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 254 @ Boston Convention & Exhibition Center

**Moderators:** Maude Carmel, Oscar Martinez and Ajay Singla

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V2-01</td>
<td>REPAIR OF A COMPLEX VAGINAL J-POUCH FISTULA UTILIZING A GRACILIS MUSCLE INTERPOSITION FLAP</td>
<td>V2-07</td>
<td>FEMALE URETHROPLASTY WITH BUCCAL MUCOSAL GRAFT FOR STRicture DISEASE</td>
</tr>
<tr>
<td>V2-02</td>
<td>TOTAL AUTOLOGOUS FASCIA LATA ANTERIOR REPAIR AND APICAL SUSPENSION: A NEW TECHNIQUE</td>
<td>V2-08</td>
<td>A NEW LIMITED OPEN TECHNIQUE FOR COMPLETE REMOVAL OF RETROPUbic SYNTHETIC MIDURETHRAL SLING MESH</td>
</tr>
<tr>
<td></td>
<td>Christian Twiss*, Miguel Craig, Frank Lin, Joel Funk, Tucson, AZ</td>
<td></td>
<td>Elodi Dietlubanza*, Jessica Lloyd, Cleveland, OH, Howard Goldman, Cleveland, OH</td>
</tr>
<tr>
<td>V2-03</td>
<td>ROBOT-ASSISTED REPAIR OF SUPRATRIGONAL VESICOVAGINAL FISTULAE USING A PERITONEAL FLAP INLAY</td>
<td>V2-09</td>
<td>LAPAROSCOPIC CERVICOSACRopeXY AND VAGINOSACRopeXY TECHNIQUES AS TREATMENT OF PELVIC ORGAN PROLAPSE AND URINARY INCONTINENCE</td>
</tr>
<tr>
<td></td>
<td>Christoph Schregel*, Beatrice Breu, Kevin Horton, Hubert John, Winterthur, Switzerland</td>
<td></td>
<td>Sebastian Ludwig*, Cologne, Germany, Sokol Rexhepi, Eichstaett, Germany, Wolfram Jäger, Cologne, Germany</td>
</tr>
<tr>
<td>V2-04</td>
<td>A NOVEL ROBOTIC-ASSISTED LAPAROSCOPIC REPAIR OF POSTERIOR COMPARTMENT PROLAPSE: TREATING WOMEN WITH DEFCATION DYSFUNCTION</td>
<td>V2-10</td>
<td>SURGICAL TECHNIQUE: TOTAL COLPOCLEISIS</td>
</tr>
<tr>
<td></td>
<td>Ron Golan*, Brian Dinerman, Adrien Bernstein, Kiersten Craig, Patrick Culligan, New York, NY</td>
<td></td>
<td>Rena Malik*, Carlos Finsterbusch, Catherine Harris, Maude Carmel, Dallas, TX</td>
</tr>
<tr>
<td>V2-05</td>
<td>THE NOVEL TECHNIQUE OF POST-Hysterectomy VAGINAL VAULT PROLAPSE REPAIR: APICAL SLING AND NEOCErVIX FORMATION</td>
<td>V2-11</td>
<td>HIGH UTEROSACRAL HYSTEROPEXY FOR THE MANAGEMENT OF PELVIC ORGAN PROLAPSE</td>
</tr>
<tr>
<td></td>
<td>Dmitry Shkarupa*, Alexey Pisarev, Ekaterina Shapovalova, Anastasia Zaytseva, Nikita Kubin, Saint-Petersburg, Russian Federation</td>
<td></td>
<td>Naveen Kachroo*, Solafa Elshatanoufy, Humphrey Aliemo, Detroit, MI</td>
</tr>
<tr>
<td>V2-06</td>
<td>FEMALE DORSAL ONLAY BUCCAL MUCOSA GRAFT URETHROPLASTY</td>
<td>V2-12</td>
<td>VESICOVAGINAL FISTULA REPAIR IN ORTHOTOPIC NEOBLADDER WITH PEDICLED ISLAND SKIN FLAP</td>
</tr>
</tbody>
</table>

---

**SOCIETY OF GENITOURINARY RECONSTRUCTIVE SURGEONS (GURS/SUPS)**

Room 157 @ Boston Convention & Exhibition Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>OPENING REMARKS</td>
<td>Steven Brandes</td>
</tr>
<tr>
<td>10:05</td>
<td>PENILE TRANSPLANTATION: THE FUTURE OF RECONSTRUCTION?</td>
<td>Jai Eswara</td>
</tr>
<tr>
<td>10:05</td>
<td>1ST PENILE TRANSPLANT IN NORTH AMERICA</td>
<td>Dicken Ko</td>
</tr>
<tr>
<td>10:15</td>
<td>CTA TRANSPLANT BASICS AND CHALLENGES</td>
<td>Curtis Cetrulo</td>
</tr>
<tr>
<td>10:25</td>
<td>LESSONS LEARNED FROM FACE TRANSPLANTS</td>
<td>Bodhan Pomehac</td>
</tr>
<tr>
<td>10:35</td>
<td>PENILE TRANSPLANT AND THE WOUNDED WARRIOR</td>
<td>Arthur Burnett</td>
</tr>
</tbody>
</table>

*Presenting author
10:45 Q&A

10:55 ADVANCED ROBOTIC URINARY TRACT RECONSTRUCTION
  Moderator: Jill Buckley
  ROBOTIC BASICS AND PORT PLACEMENT STRATEGIES
  Luke Wiegand

11:05 ADVANCED URETERAL RECONSTRUCTION
  Daniel Eun

11:15 URETERO-ENTERIC STRICTURE RECONSTRUCTION
  Lee Zhao

11:25 SURGICAL MISADVENTURES AND COMPLICATIONS OF ROBOTIC RECONSTRUCTION
  Patricio Gargollo

11:35 Q&A

11:45 BRANTLEY SCOTT LECTURE
  Moderator: Benjamin Breyer
  MY JOURNEY IN TREATING POST PROSTATECTOMY INCONTINENCE
  Tim Boone

12:00 INDUSTRY SPONSORED SYMPOSIUM (NON-CME)

12:05 Q&A

12:15 LUNCH - INDUSTRY SPONSORED TALK

1:15 COMPLEX BLADDER AND PROSTATIC URINARY FISTULAS
  Moderator: Ramon Virasoro
  RADIATION URINARY FISTULA REPLAIR USING GRACILIS AND GLUTEAL MUSCLE
  Alex Vanni

1:30 POST PROSTATECTOMY FISTULAS: TRANS-SPHINCTERIC APPROACHES
  Angelo Gousse

1:45 ABANDON THE OUTLET - ROLE FOR SUPRAVESICAL DIVERSION
  Andrew Peterson

2:00 Q&A

2:10 CHARLES DEVINE LECTURE
  Moderator: Reynaldo Gomez

---

Friday, May 12, 2017 11:45 pm - 5:35 pm

AMERICAN SOCIETY FOR MEN’S HEALTH (ASMH)
Marina Ballroom @ Westin Waterfront

11:45 OPENING REMARKS
  HOLEP
  Mitchell Humphreys

12:00 INDUSTRY SPONSORED SYMPOSIUM (NON-CME)
  1:45 THE IMPACT OF ALTERNATIVE TECHNOLOGIES IN BPH
  Steven Kaplan

1:00-2:00 BPH TECHNOLOGIES FORUM

1:00 PROSTATE URETHRAL LIFT
  Steven Gange
  Q&A

1:15 WATER VAPOR THERAPY
  Kevin McVary
  CAN WE SAVE PSA? A LEGISLATIVE VIEW
  Thomas Rechtschaffen

---

56
2:15  PSA CONTROVERSY: PRIMARY CARE PERSPECTIVE
PRIMARY CARE GUIDELINES FOR PSA
Joel Heidelbaugh

2:25  REAL LIFE PCP PRACTICES, THE CANADIAN EXPERIENCE
David Greenberg

2:35  “SMARTER” PSA SCREENING
Matt Rosenberg

2:45  Q & A

2:50  BREAK WITH EXHIBITORS

3:05  HOT TOPICS IN MEN’S HEALTH
MEN’S HEALTH STATUS IN 2017
Jason Jameson

3:15  OPIOID ADDICTION IN MEN
Hossein Sadeghi-Nejad

3:35  CURRENT ASPECTS OF TESTOSTERONE REPLACEMENT
Shalender Bhasin

3:55  HPV GENITAL INFECTIONS AND CANCER
Jasmine Han

4:25  Q&A

4:30  THE POTENTIAL OF “OVER THE COUNTER” BPH TREATMENT
Claus Roehrborn

4:50  MOLECULAR MARKERS IN PROSTATE CANCER
Leonard Gomella

5:10  MRI OF THE PROSTATE
Samir Taneja

5:30  Q&A

5:35  ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 12, 2017 12:30 pm - 4:30 pm
SOCIETY OF URODYNAMICS, FEMALE PELVIC MEDICINE AND UROGENTIAL RECONSTRUCTION (SUFU)
Room 205 @ Boston Convention & Exhibition Center

12:30  WELCOME AND INTRODUCTION
12:35  WHAT YOU NEED TO KNOW ABOUT TREATING INTERSTITIAL CYSTITIS
Christopher Payne

12:55  UPDATE: SUFU RECOMMENDATIONS ON THE USE OF ANTIBIOTICS WITH UDS
Michael Kennelly

1:05  PANEL: INITIAL TREATMENT FOR SUI IN THE INDEX PATIENT
Panelists: Jerry Blaivas, Arthur Mourtzinos, Diane Newman, O. Lenaine Westney

1:35  POINT-COUNTERPOINT: REFRACTORY URGE INCONTINENCE - WHICH COMES FIRST
David Ginsberg, Stephen Kraus, Suzette Sutherland

2:00  POINT-COUNTERPOINT: RETENTION AFTER MIDURETHRAL SLING
Benjamin Brucker, Matthew Rutman

2:25  BREAK

2:40  POINT-COUNTERPOINT: CYSTOCELE - INITIAL TREATMENT - PESSARY OR SURGERY
Gamal Ghoniem, Leslie Rickey

3:05  URODYNAMICS IS EASY
Craig Comiter

3:20  UROLOGIC PROBLEMS IN THE PREGNANT WOMAN
Kevin Loughlin

3:40  MANAGEMENT OF RECURRENT UTI
Tomas Griebling

4:10  MANAGEMENT OF THE EXPOSED SLING
Howard Goldman

4:30  ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Friday, May 12, 2017 1:00 pm - 3:00 pm

Moderated Poster Session 11

INFECTIONS/INFLAMMATION/CYSTIC DISEASE OF THE GENITOURINARY TRACT: PROSTATE AND GENITALIA II
Room 151 @ Boston Convention & Exhibition Center
Moderators: Travis Jerde and Michel Pontari

ABSTRACT
NUMBER TITLE
MP11-01 ROLE OF CHRONIC INFLAMMATION IN PROSTATE CANCER: A STUDY ON NEEDLE BIOPSY SPECIMENS
Shardul Soni*, Michael Glover, Qinghu Ren, Gregory MacLennan, Pingfu Fu, Sanjay Gupta, Cleveland, OH

MP11-02 URETHRAL LICHEN SCLEROSUS UNDER THE MICROSCOPE
Brennan Tesdahl*, Maria Voznesensky, Iowa City, IA, Nejd Alsikafi, Maywood, IL, Benjamin Breyer, San Francisco, CA, Joshua Broghammer, Kansas City, KS, Jill Buckley, San Diego, CA, Sean Elliott, Minneapolis, MN, Christopher McClung, Columbus, OH, Jeremy Myers, Salt Lake City, UT, Thomas Smith III, Houston, TX, Alex Vanni, Burlington, MA, Bryan Voelzke, Seattle, WA, Lee Zhao, New York City, NY, William Brant, Salt Lake City, UT, Bradley Erickson, Iowa City, IA

MP11-03 HPV PREVALENCE IN MALES IN THE UNITED STATES FROM PENILE SWABS: RESULTS FROM NHANES
Michael Daugherty*, Timothy Byler, Syracuse, NY

MP11-04 MENINGOCOCCAL URETHRITIS. A PITFALL IN THE CONVENTIONAL DIAGNOSTIC PROCESS BASED ON THE NUCLEIC ACID AMPLIFICATION TEST IN MEN WITH SUSPECTED GONOCOCCAL URETHRITIS
Munekado Kojima*, Yasufumi Yada, Kazuhiro Yoshida, Yosimasa Hayase, Nagoya, Japan

MP11-05 THERAPEUTIC EFFECT OF INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR IN EPIDIDYMISIS
Shin Ohira*, Ryoei Hara, Kurashiki City, Japan, Shigenobu Tone, Hatayama-cho, Japan, Seietsu Kin, Shinjiro Shimizu, Tomohiro Fujii, Yoshiyuki Miyaji, Atsushi Nagai, Kurashiki City, Japan

MP11-06 EXPRESSION OF INFLAMMATORY MEDIATORS IN SENSORY GANGLIA INNERVATING LOWER URINARY TRACT AND DYSFUNCTIONAL VOIDING
Pradeep Tyagi*, Mahendra Kashyap, Zhou Wang, Naoki Yoshimura, Pittsburgh, PA

MP11-07 CLINICALLY ISOLATED GRAM-POSITIVE PROSTATE BACTERIA INDUCE CHRONIC PELVIC PAIN.
Stephen Murphy, Jonathan Anker, Anthony Schaeffer, Praveen Thumbikat*, Chicago, IL

MP11-08 REASSESSMENT OF NON-TRADITIONAL UROPATHOGENS IN CHRONIC PELVIC PAIN SYNDROME (CP/PAPS)
Daniel Mazur, Jonathan Anker, Stephen Murphy, Anthony Schaeffer, Praveen Thumbikat*, Chicago, IL

MP11-09 NEXT-GENERATION SEQUENCING OF CHRONIC PROSTATITIS: PRELIMINARY RESULTS OF COMPREHENSIVE SPECIES LEVEL DESCRIPTION IN 212 MEN WITH PELVIC PAIN
Eugene Park*, Richmond, VA

MP11-10 CLINICAL PHARMACOKINETICS OF BETA-LACTAM ANTIBIOTICS IN PROSTATE TISSUE, AND DOSING CONSIDERATIONS FOR PROSTATITIS BASED ON SITE-SPECIFIC PHARMACODYNAMICS
Kogenta Nakamura*, Nagakute, Japan, Kazuro Ikawa, Hiroshima, Japan, Ikuo Kobayashi, Genya Nishikawa, Keishi Kajikawa, Yoshiharu Kato, Masahito Watanabe, Nagakute, Japan, Motoi Tobiume, Owariasahi, Japan, Kenji Mitsu, Masahiro Narushima, Tokoname, Japan, Kent Kanao, Nagakute, Japan, Norifumi Morikawa, Hiroshima, Japan, Makoto Sumitomo, Nagakute, Japan

MP11-11 INCREASED INFECTIVE COMPLICATIONS FROM TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY FOLLOWING TRANSITION TO SINGLE DOSE ORAL CIPROFLOXACIN PROPHYLAXIS
Sophie Riddell*, Matthew Farag, John Daffy, Lih-Ming Wong, Melbourne, Australia

MP11-12 ANTIMICROBIAL PROPHYLAXIS FOR TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY: A PROSPECTIVE COHORT TRIAL
Teresa Zembower, Kelly Maxwell*, Chicago, IL, Robert Nadler, Chicago, IL, John Cashy, Marc Scheetz, Chao Qi, Anthony J. Schaeffer, Chicago, IL

MP11-13 RISK FACTOR ASSESSMENT FOR FLUOROQUINOLONE RESISTANT E. COLI (FRE) IN BOWEL FLORA IS NOT SUFFICIENTLY DISCRIMINATORY: THE CASE FOR A PRE-BIOPSY RECTAL SWAB IN ALL PATIENTS.
Michael Holmes*, Ray Littler, Megan Lyons, Lisa Smit, Glen Devich, Adam Davies, John Iveyland, Chris Mansell, Hamilton, New Zealand
MP11-14 COST EFFECTIVENESS OF TARGETED ANTIMICROBIAL THERAPY IN TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY
Alaya Yassein*, Jean-Eric Tarride, Timothy Davies, Hamilton, Canada

MP11-15 PREDICTORS OF FLUOROQUINOLONE RESISTANCE IN THE RECTAL VAULT OF MEN UNDERGOING PROSTATE BIOPSY
Nathaniel Wilson, Dimitri Papagiannopoulos*, Nicholas O'Block, Michael Abern, Lester Raff, Christopher Coogan, Kalyan Latchamsetty, Chicago, IL

MP11-16 INDICATIONS, UTILIZATION, AND COMPLICATIONS FOLLOWING PROSTATE BIOPSY: A NEW YORK STATE ANALYSIS
Joshua Halpern*, Art Sedrakyan, Brian Dinerman, Wei-chun Hsu, Jialin Mao, Jim Hu, New York, NY

MP11-17 TRANSRECTAL PROSTATE BIOPSY AFTER PROPHYLACTIC PREPARATION OF THE RECTUM WITH Povidone-Iodine – A PROSPECTIVE RANDOMIZED TRIAL
José Cadilhe*, Viana do Castelo, Portugal

MP11-18 EFFECTIVENESS OF SINGLE DOSE OF AMIKACIN COMPARED WITH LEVOFLOXACIN FOR PROPHYLACTIC USE IN TRANSRECTAL PROSTATE BIOPSY.
Marcela Pelayo-Nieto*, Edgar Linden-Castro, Iván A. Ramírez-Galindo, Daniel Espinosa-Perez Grovas, Roberto C. Rodríguez-Alvarado, Felipe Guzmán-Hernández, Jesús A. Morales-Covarrubias, Mexico City, Mexico, Edy D. Rubio-Arellano, Guadalajara, Mexico, Roberto Cortez-Betancourt, Mexico City, Mexico

MP11-19 TARGETED ANTIBIOTIC PROPHYLAXIS BY β-LACTAMS BASED ON RECTAL SWAB CULTURE IS NOT SUFFICIENT TO PREVENT INFECTIVE COMPLICATIONS AFTER TRANSRECTAL PROSTATE BIOPSY
Yoshitsugu Nasu*, Tadashi Murata, Morito Sugimoto, Atsushi Takamoto, Okayama, Japan

MP11-20 THE DIFFICULTY INTERPRETING ENDOTOXAEMIA POST TRANSRECTAL PROSTATE BIOPSY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 12, 2017
1:00 pm - 3:00 pm

Moderated Poster Session 12
STONE DISEASE: BASIC RESEARCH AND PATHOPHYSIOLOGY I
Room 153 @ Boston Convention & Exhibition Center
Moderators: Benjamin Canales and Ross Holmes

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP12-01</td>
<td>INCREASED URINARY EXCRETION OF GLYCOLATE AND OXALATE IN OBESE AND DIABETIC MICE MODELS</td>
</tr>
<tr>
<td>Kyle Wood*, John Knight, Dean Assimos, Ross Holmes, Birmingham, AL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP12-02</td>
<td>AUTOPHAGY MAINTAINS CELLULAR HOMEOSTASIS AND INHIBITS RENAL CRYSTAL FORMATION</td>
</tr>
<tr>
<td>Rei Unno*, Naoko Unno, Yuya Ota, Teruaki Sugino, Kazumi Taguchi, Shuzo Hamamoto, Ryogetsu Ando, Atsushi Okada, Keiichi Tozawa, Kenjiro Kohri, Takahiro Yasui, Nagoya, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP12-03</td>
<td>METFORMIN REDUCE THE RENAL STONE FORMATION IN HIGH OXALIC ACID RATS BY INHIBITING THE ACTIVATION OF NLRP3 PATHWAY</td>
</tr>
<tr>
<td>Hongyang Jiang, Tao Wang, Zhuo Liu, Jihong Liu*, Shaogang Wang, Zhangqun Ye, Wuhan, China, People’s Republic of China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP12-04</td>
<td>TWO-STAGE MODEL TO STUDY IDIOPATHIC CALCIUM OXALATE STONE FORMATION</td>
</tr>
<tr>
<td>Allison O’Kell*, Archana Lovett, Benjamin Canales, Laurie Gower, Saeed Khan, Gainesville, FL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP12-05</td>
<td>COMPARATIVE ANALYSIS OF HIGH-THROUGHPUT SEQUENCING PLATFORMS FOR AN OXALATE METABOLIZING MICROBIOME: IMPLICATIONS FOR THE STUDY OF THE UROLOGIC MICROBIOME</td>
</tr>
<tr>
<td>Anna Zampini*, Aaron W. Miller, Manoj Monga, Cleveland, OH, Denise Dearing, Salt Lake City, UT</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP12-06</td>
<td>OXALATE AND COM-CRYSTALS ACTIVATE TOLL-LIKE RECEPTOR 4 (TLR4)-MEDIATED NF-κB SIGNALING PATHWAY AND PROINFLAMMATORY RESPONSE IN HUMAN RENAL EPITHELIAL CELLS</td>
</tr>
<tr>
<td>Sweaty Koul*, Quin Dong, Fentian Wang, Hari Koul, Shreveport, LA</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP12-07 URINE KIDNEY INJURY MARKERS DO NOT INCREASE FOLLOWING GASTRIC BYPASS: A MULTI-CENTER CROSS-SECTIONAL STUDY.
Bryan Hinck*, Cleveland, OH, Ricardo Miyaoka, Campinas, Brazil, James Lingeman, Indianapolis, IN, Dean Assimos, Birmingham, AL, Brian Matlaga, Baltimore, MD, Rocky Pramanik, John Asplin, Chicago, IL, Benjamin Cohen, Manoj Monga, Cleveland, OH

MP12-08 GEOGRAPHICAL AND PREVALENCE TRENDS IN UROLITHIASIS IN ENGLAND: A TEN-YEAR REVIEW
Holly Ni Raghallaigh*, Camberley, United Kingdom, Dene Ellis, Andrew Symes, Brighton, United Kingdom

MP12-09 MATRIX PROTEIN DIFFERENCES BETWEEN URIC ACID AND CALCIUM OXALATE STONES
Jeffrey Wesson*, Ann Kolbach-Mandel, Carley Davis, Neil Mandel, Brian Hoffmann, Milwaukee, WI

MP12-10 SNP RS17383719 IN THE PBX1 GENE IS ASSOCIATED WITH CYSTINURIA
Sabrina Reis*, Ronaldo Guimarães, Nayara Viana, Katia Leite, Giovanni Marchini, Fabio Torricelli, William Nahas, Miguel Srougi, Eduardo Mazzucchi, Sao Paulo, Brazil

MP12-11 HOW PREVALENT IS CYSTINE STONE? A PERSPECTIVE FROM GENETICS
Chen-Han Wilfred Wu*, Fernando J. Kim, Trevor Wild, Anne Tsai, Naomi Meeks, Rodrigo Donalisio Da Silva, Wilson R. Molina, Aurora, CO

MP12-12 α-LIPOIC ACID SUPPRESSES CYSTINE STONE FORMATION IN A GENETIC MOUSE MODEL OF CYSTINURIA

MP12-13 A RAT MODEL TO STUDY THE ROLE OF GUT BACTERIA IN REGULATION OF URINARY CALCIUM

MP12-14 THE UPPER URINARY TRACT MICROBIOME IS MODULATED BY STONE TYPE AND PATIENT AGE IN URINARY STONE DISEASE: A PILOT STUDY
Manint Usawachintachit*, Douglas Fadrosh, Susan Lynch, Thomas Chi, San Francisco, CA

MP12-15 COMPARATIVE METAGENOMICS OF THE GUT MICROBIOME REVEALS BROAD SCALE CHANGES AFTER EXPOSURE TO HIGH LEVELS OF OXALATE
Aaron Miller*, Anna Zampini, Manoj Monga, Cleveland, OH

MP12-16 N7T GENE SUPPRESSES OXIDATIVE STRESS AND KIDNEY CRYSTAL DEPOSITION.
Masayuki Usami*, Yuya Ota, Teruaki Sugino, Rei Unno, Kazumi Taguchi, Shuzo Hamamoto, Ryoosuke Ando, Atsushi Okada, Hideki Honma, Keiichi Tozawa, Kenjiro Kohri, Takahiro Yasui, Nagoya, Japan

MP12-17 PROTEOMIC ANALYSIS OF KIDNEY STONES FROM MALE AND FEMALE BRUSHITE (M-BR AND F-BR) AND MALE CALCIUM OXALATE (M-CAOX) PATIENTS
Frank Witzmann, James Lingeman, Andrew Evan, Indianapolis, IN, Fredric Coe, Elaine Worcester, Chicago, IL, James Williams*, Indianapolis, IN

MP12-18 CALCIUM OXALATE AND HYDROXYAPATITE HAVE OPPOSITE EFFECTS ON HUMAN MACROPHAGE DIFFERENTIATION
Paul Domínguez-Gutiérrez*, Sergei Kusmartsev, Benjamin Canales, Saeed Khan, Gainesville, FL

MP12-19 CALCIUM OXALATE CRYSTALS INDUCE MITOCHONDRIAL DYSFUNCTION AND HEME OXYGENASE–1 EXPRESSION IN A HUMAN MONOCYTE DERIVED CELL LINE
Vidhush K Yarlagadda*, Dean G Assimos, Ross P Holmes, Tanecia R Mitchell, Birmingham, AL

MP12-20 OPTIMIZING RNA EXTRACTION OF RENAL PAPILLA BIOPSY TISSUE IN KIDNEY STONE FORMERS: A NEW METHODOLOGY FOR GENOMIC STUDY
Kazumi Taguchi*, Manint Usawachintachit, David T Tzou, Benjamin A Sherer, Sunita Ho, San Francisco, CA, Shuzo Hamamoto, Takahiro Yasui, Nagoya, Japan, Marshall L Stoller, Thomas Chi, San Francisco, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT NUMBER TITLE
MP13-01 COMPARISON OF A MEXICAN VISUAL ANALOG SCALE (GEA SCALE) Vs IPSS (INTERNATIONAL PROSTATE SYMPTOM SCORE) IN THE EVALUATION OF LOWER URINARY TRACT SYMPTOMS IN A LOW SOCIO-CULTURAL LEVEL POPULATION.
Diego Preciado Estrella*, Mexico City, Mexico, Steven Kaplan, New York, NY, Edgar Mayorga Gómez, Mauro Carrillo, Orozco, Carlos Martinez Arroyo, Carlos Pacheco Gahlber, Mexico City, Mexico

MP13-02 IS POSTOPERATIVE URINARY RETENTION AN INDEPENDENT PREDICTOR OF LONG-TERM FUTURE BLADDER OUTLET PROCEDURE IN MEN?
Robert H Blackwell*, Maywood, IL, Srikanth Vedachalam, Downers Grove, IL, Arpees S Shah, Anil N Kohari, Paul C Kuo, Gopal N Gupta, Thomas MT Turk, Maywood, IL

MP13-03 ASSOCIATION BETWEEN MALE LOWER URINARY TRACT SYMPTOMS AND THE IMBALANCE OF AUTONOMIC ACTIVITY
Seol Ho Choo*, Se Joong Kim, Jong Bo Choi, Sun Il Kim, Hyun Soo Ahn, Taewoo Kim, Suwon-si, Korea, Republic of

MP13-04 RISK FACTORS OF WEAK DETRUSOR FUNCTION IN BENIGN PROSTATE HYPERPLASIA PATIENTS: DETERMINING A PROGNOSTIC FACTOR FROM URODYNAMIC FINDINGS.
Tetsuichi Saito*, Takashi Nagai, Tomonori Minagawa, Teruyuki Ogawa, Osamu Ishizuka, Matsumoto, Japan

MP13-05 CLINICAL -NOT CYSTOMETRIC- PREDICTION OF BLADDER OUTFLOW OBSTRUCTION IN ELDERLY MALE PATIENTS.
Peter Rosier*, Utrecht, Netherlands

MP13-06 PHARMACOLOGICAL TREATMENT OF LOWER URINARY TRACT SYMPTOMS AFTER A TRANSURETHRAL RESECTION OF THE PROSTATE IS PREDICTIVE OF A NEW SURGICAL TREATMENT: 10 YEARS FOLLOW-UP
Cosimo De Nunzio*, Alessandro Borghesi, Fabrizio Presicce, Riccardo Lombardo, Fabiana Cancrini, Luca Sarchi, Andrea Tubaro, Rome, Italy

MP13-07 FINASTERIDE MONOTHERAPY BEFORE TURP: SIGNIFICANT IMPROVEMENT IN EARLY POSTOPERATIVE QUALITY OF LIFE
Ahmed Ali*, Emad Ramadan, Mamdouh El-Hawy, tarek fathelbab, Ayman Hussein, Minia, Egypt, Luay Alshara, Boston, MA, Ahmed Fawzy, Ehab Tawfiek, Minia, Egypt

MP13-08 SURGEON BEHAVIOR AND SURGICAL MODALITY DRIVE VARIATION IN THE SURGICAL MANAGEMENT OF BPH
Jamal Nabhani*, Vishnu Kamal Golla, Alan Kaplan, Christopher Saigal, Los Angeles, CA

MP13-09 ASSESSMENT OF THE LEARNING CURVES FOR PROSTATE PHOTOCYCLE VAPORIZATION USING GREENLIGHTTM 180-WATT-XPS LASER THERAPY: A MULTICENTER STUDY
Claire Bastard*, Paris, France, Vincent Misrai, Toulouse, France - Metropolitan, Morgan Roupret, Paris, France, Kevin Zorn, Pierre Alain Hueber, Montreal, Canada, Benoit Peyronnet, Paris, France

MP13-10 SURGICAL MANAGEMENT OF BENIGN PROSTATIC OBSTRUCTION: 20-YEAR POPULATION-LEVEL TRENDS
Christopher Wallius*, Lesley Carr, Sender Herschorn, Refik Saksin, Sidney Radomski, Armando Lorenzo, Robert Nam, Toronto, Canada

MP13-11 FACTORS THAT INFLUENCE ON LOWER URINARY TRACT SYMPTOM (LUTS) RELATED QUALITY OF LIFE (QOL)
Woo Suk Choi*, Hyoung Keun Park, Sung Hyun Paik, Hyeong Gon Kim, Hwancheol Son, Seoul, Korea, Republic of

MP13-12 SHIFT WORKERS WITH SHIFT WORK SLEEP DISORDER HAVE INCREASED LOWER URINARY TRACT SYMPTOMS
John Sigalos*, Javier Santiago, Edgar Kirby, Mark Hockenberry, Taylor Kohn, Stephen Pickett, Alexander Pastuszak, Larry Lipshultz, Houston, TX

MP13-13 DOES TREATING NOCTURIA LEAD TO BETTER SLEEP? RESULTS FROM REDUCE
Stephen Freedland*, Los Angeles, CA, Lauren Howard, Shalini Jha, Durham, NC, Daniel Moreira, Chicago, IL, Gina-Maria Pomann, Durham, NC, Gerald Androile, King of Prussia, PA, Ramiro Castro-Santamarina, St. Louis, MO, Martin Hopp, Los Angeles, CA, Claus Roehrborn, Dallas, TX

MP13-14 STUDYING THE EFFECT OF DIABETES MELLITUS TYPE 2 ON PROSTATE RELATED PARAMETERS: A PROSPECTIVE SINGLE INSTITUTIONAL STUDY.
MP13-15 THE RELATIONSHIP BETWEEN SLEEP DISORDERS AND LOWER URINARY TRACT SYMPTOMS: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES)

Richard Fantus*, Chicago, IL, Brian Helfand, Chi-Hsiung Wang, Evanston, IL

MP13-16 FACTORS THAT PREDISPOSE TO LOWER URINARY TRACT SYMPTOMS IN DIABETIC MEN: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES)

Richard Fantus*, Chicago, IL, Brian Helfand, Chi-Hsiung Wang, Evanston, IL, Brad Erickson, Iowa City, IA

MP13-17 CATHETER MANAGEMENT AFTER TRANSURETHRAL RESECTION AND ABLATION PROCEDURES FOR BENIGN PROSTATIC HYPERPLASIA: APPROPRIATENESS CRITERIA OBTAINED USING THE RAND/UCLA APPROPRIATENESS METHOD

Ted Skolarus*, Casey Dauw, Karen Fowler, Jason Mann, Steven Bernstein, Jennifer Meddings, Ann Arbor, MI

MP13-18 IMPACTS OF APOLIPOPROTEIN A-1 AND ALPHA-FETOPROTEIN ON THE DEVELOPMENT OF BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS: RESULTS FROM A HIGH-VOLUME HEALTH CHECK-UP DATABASE

Kwang Suk Lee*, Kyo Chul Koo, Do Kyung Kim, Jongsoo Lee, Jong Won Kim, Jae Yong Jeong, Sung Ku Kang, Byung Ha Chung, Seoul, Korea, Republic of

MP13-19 MEDIATORS OF PROSTATIC INFLAMMATION: SIMULTANEOUS MULTIPLEX ANALYSIS OF URINE AND SERUM SPECIMENS

Pradeep Tyagi*, Mahendra Kashyap, Jeffrey Gingrich, Zhou Wang, Naoki Yoshimura, Pittsburgh, PA

MP14-01 THE UNCOUPLING OF DIAGNOSIS AND IMMEDIATE TREATMENT IN VERY LOW AND LOW RISK PROSTATE CANCER: A NATIONAL PERSPECTIVE

Richard Matulewicz*, John Oliver DeLancey, Anuj Desai, Adam Weiner, Edward Schaeffer, Chicago, IL

MP14-02 THE NATURAL HISTORY OF MEN ON ACTIVE SURVEILLANCE WITH LOW-RISK PROSTATE CANCER AT A SAFETY-NET, COUNTY HOSPITAL

E. Charles Osterberg, Austin, TX, Nynikka Palmer, Catherine Harris, Gregory Murphy, Sarah Blaschko, Carissa Chu*, Matthew Cooperberg, Peter Carroll, Benjamin Breyer, San Francisco, CA

MP14-03 HIGHER CHOLESTEROL IS LINKED WITH INCREASED RISK OF HIGH-GRADE PROSTATE CANCER: RESULTS FROM THE REDUCE STUDY

Juzar Jamnagerwalla*, Los Angeles, CA, Lauren E. Howard, Durham, NC, Adriana C. Vidal, Los Angeles, CA, Daniel M. Moreira, Rochester, MN, Ramiro Castro-Santamaría, King of Prussia, PA, Gerald L. Andriole, St. Louis, MO, Stephen J. Freedland, Los Angeles, CA

MP14-04 CARDIOVASCULAR DISEASE CHARACTERISTICS OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS: FINDINGS FROM THE PILOT PHASE OF RADICAL PC: A PROSPECTIVE STUDY OF CARDIOVASCULAR DISEASE IN MEN WITH PROSTATE CANCER

Jehonathan Pinthus*, Hamilton, Canada, Laurence Klotz, Toronto, Canada, Himu Lukka, Philip J Devereaux, Kayla Pohl, Hamilton, Canada, Idan Roifman, Toronto, Canada, Vincent Fradet, Quebec City, Canada, Robert Siemens, Kingston, Canada, Tamara Wallington, Brampton, Canada, Shayegan Bobby, Edward Matsumoto, Tom Corbett, Wilhelmina Duijvenvoorden, Mahshid Dehghan, Hamilton, Canada, Marina Mourtzakis, Waterloo, Canada, Darryl P. Leong, Hamilton, Canada

MP14-05 THE ASSOCIATION OF AGE WITH PERIOPERATIVE MORBIDITY AND MORTALITY AMONG PATIENTS UNDERGOING RADICAL PROSTATECTOMY

Jorge Pereira*, Gyan Pareek, Dragan Golijanin, Joseph Renzulli, Boris Gershman, Providence, RI
MP14-06 RISKS OF CYTOCHROME P450 1B1 POLYMORPHISMS AND LIFESTYLE CHOICES ON PROSTATE CANCER
Taku Kato*, Yutaka Hashimoto, Shigekatsu Maekawa, Marisa Shinya, Mitsuo Imai-Sumida, Priyanka Kulkami, Soichiro Yamamura, Shahana Majid, Sharanjot Saini, Varahram Sharryari, Guoren Deng, Rajvir Dahiya, Yuichiro Tanaka, San Francisco, CA

MP14-07 EFFECT OF HYPOGONADISM ON PROSTATE IMAGING AND CANCER DETECTION
Dordaneh Sugano*, Abhinav Sidana, Brian Calio, Sonia Gaur, Mahir Maruf, Amit L. Jain, Maria Merino, Peter Choyke, Baris Turkbey, Bradford J. Wood, Peter A. Pinto, Bethesda, MD

MP14-08 A MULTISCALE SURVEY OF INFLAMMATORY DISEASES AND PROSTATE ONCOPHENOTYPES.
Kamlesh K Yadav*, Khader Shameer, Shalini S Yadav, Cordelia Elias, Li Li, James O’Connor, Benjamin Glicksberg, Kipp Jhanson, Marcus Badgeley, Benjamin Readhead, Brian Kidd, Andrew Kasarskis, Joel Dudley, Ashutosh Tewari, New York, NY

MP14-09 GEOGRAPHIC DISPARITIES IN PREVALENCE OF BASELINE PROSTATE INFLAMMATION AND PROSTATE CANCER RISK
Emma Allott*, Chapel Hill, NC, Sarah Markt, Boston, MA, Lauren Howard, Durham, NC, Adriana Vidal, Los Angeles, CA, Daniel Moreira, Chicago, IL, Ramiro Castro-Santamaria, King of Prussia, PA, Gerald Andriole, St Louis, MO, Lorelei Mucci, Boston, MA, Stephen Freedland, Los Angeles, CA

MP14-10 IS IT NECESSARY TO PREVENT TESTOSTERONE FLARE? A SYSTEMATIC REVIEW AND REASSESSMENT IN THE ERA OF THE SATURATION MODEL
Yonah Krakowsky*, Abraham Morgenthaler, Chestnut Hill, MA

MP14-11 QUANTIFYING ANXIETY AND DEPRESSION AFTER A RECENT PROSTATE CANCER DIAGNOSIS: SHOULD ROUTINE MENTAL HEALTH COUNSELING FOLLOW THE BAD NEWS?
Ricardo Sanchez*, Cristian Bernaschina, Carla Méndez-Busó, Ricardo Sánchez-Ortiz, Guaynabo, PR

MP14-12 PATIENT-REPORTED URINARY BOTHER – WHAT IS REALLY BOtherING PROSTATE CANCER PATIENTS?
Lin Yang*, Wien, Austria, Adam Kibel, Boston, MA, Graham Colditz, Ratna Pakpahan, Kellie Imml, Sonya Izadi, Robert Grubb, St Louis, MO, Kathleen Wolin, Chicago, IL, Stobhan Sutcliffe, St Louis, MO

MP14-13 CHANGES IN HEALTH-RELATED QUALITY OF LIFE AMONG OLDER ADULTS WITH PROSTATE CANCER: A CASE-CONTROL STUDY
Angela Smith*, Byron Jaeger, Laura Pinheiro, Lloyd Edwards, Bryce Reeve, Chapel Hill, NC

MP14-14 ANALYSIS OF INPATIENT PALLIATIVE CARE CONSULTATION FOR PATIENTS WITH METASTATIC PROSTATE CANCER
Neil Mistry*, Sameer Siddiqui, St. Louis, MO

MP14-15 INCREASE IN THE INCIDENCE OF ADVANCED PROSTATE CANCER IN THE UNITED STATES
Jonathan Shoaq*, Art Sedrakyan, Joshua Halpern, Wei-Chun Hsu, Jim Hu, New York, NY

MP14-16 ANTERIOR PROSTATE LESIONS AND CANCER DETECTED BY MRI IN AFRICAN AMERICAN MEN
Bryan Bissarz*, Michelle Van Kuiken, Joseph Yaccoub, Ari Goldberg, Steven Shea, Neelam Balasuabramanian, Marcus Quek, Gopal Gupta, Maywood, IL

MP14-17 INCREASED RISK OF BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY AMONG AFRICAN AMERICAN MEN WITH HIGH RISK PROSTATE CANCER
Yaw Nyame*, Cleveland, OH, Jeffrey Tosoian, Baltimore, MD, Lamont Wilkins, Cleveland, OH, Ridwan Alam, Baltimore, MD, Kasra Yousefi, Vancouver, Canada, Meera Chappidi, Baltimore, MD, Chandana Reddy, Cleveland, OH, Elizabeth Humphreys, Baltimore, MD, Debashis Sundi, Brian Chapin, Houston, TX, Andrew J. Stephenson, Eric Klein, Cleveland, OH, Ashley Ross, Baltimore, MD

MP14-18 ALKALINE PHOSPHATASE VELOCITY PREDICTS METASTASIS AMONG PROSTATE CANCER PATIENTS WHO EXPERIENCE BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
Carolyn Salter*, Bethesda, MD, Jennifer Culler, Rockville, MD, Inger Rosner, Bethesda, MD, Hui-Ching (Claire) Kuo, Rockville, MD, Adam Metwali, Bethesda, MD

MP14-19 PREDICTING METASTASIS IN MEN WITH LOCALIZED HIGH RISK PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
Lamont Wilkins*, Cleveland, OH, Alam Ridwan, Jeffrey J. Tosoian, Baltimore, MD, Yaw A. Nyame, Cleveland, OH, Kasra Yousefi, Vancouver, Canada, Meera R Chappidi, Baltimore, MD, Chandana A Reddy, Cleveland, OH, Elizabeth B Humphreys, Baltimore, MD, Debashis Sundi, Brian F. Chapin, Houston, TX, Andrew J. Stephenson, Eric A. Klein, Cleveland, OH, Ashley E. Ross, Baltimore, MD

*Presenting author
### ABSTRACTS

#### MP14-20 PREDICTORS OF EARLY DISEASE SPECIFIC MORTALITY AMONG PATIENTS WITH PROSTATE ADENOCARCINOMA BONE METASTASIS AT DIAGNOSIS


**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

Friday, May 12, 2017 1:00 pm - 3:00 pm

**Moderated Poster Session 15**

**BLADDER CANCER: NON-INVASIVE I**

**Room 252 @ Boston Convention & Exhibition Center**

**Moderators:** Fiona Burkhard, Ashish Kamat and Mark Soloway

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP15-01</td>
<td>CAN THE USE OF NARROW-BAND IMAGING (NBI) REDUCE PERSISTENT BLADDER CANCER RATE DURING WHITE-LIGHT CLASSIC TRANS-URETHRAL RESECTION OF TUMOR (WLCTURBT)? A PRELIMINARY SINGLE-CENTER EXPERIENCE IN A LARGE CASE SERIES. Cristina Falavolti*, Barbara Cristina Gentile, Gabriella Mirabile, Paola Tariciotti, Luca Albanesi, Giorgio Rizzo, Maurizio Buscarini, Rome, Italy</td>
</tr>
<tr>
<td>MP15-02</td>
<td>BLUE LIGHT CYSTOSCOPY FOR DIAGNOSIS OF UROTHELIAL BLADDER CANCER: RESULTS FROM A PROSPECTIVE MULTICENTER REGISTRY Soroush T Bazargani*, Hooman Djaladat, Anne Schuckman, Los Angeles, CA, Badrinath Kondely, Minneapolis, MN, Trinity J Bivalacqua, Baltimore, MD, Jeff Holzbeierlein, Lawrence, KS, Brian Willard, Lexington, SC, Jennifer Taylor, Houston, TX, Joseph Liao, Palo Alto, CA, Kamal Pohar, Columbus, OH, James Tierney, South Charleston, WV, siamak Daneshmand, Los Angeles, CA</td>
</tr>
<tr>
<td>MP15-03</td>
<td>WHO COULD BE ELIMINATED FOR RANDOM BIOPSIES AFTER BCG THERAPY IN PATIENTS WITH BLADDER CARCINOMA IN SITU? Kimiharu Takamatsu*, Eiji Kikuchi, Koichiro Oghara, Nozomi Hayakawa, Kazuhiro Matsumoto, Ryuichi Mizuno, Akira Miyajima, Masafumi Oyama, Mototsugu Oya, Tokyo, Japan</td>
</tr>
<tr>
<td>MP15-04</td>
<td>NEW PREDICTIVE SCORING MODEL FOR RECURRENCE INCORPORATING BLADDER NECK INVOLVEMENT IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER Yuma Waseda*, Masaharu Inoue, Masaya Ito, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Yasuhsia Fujii, Tokyo, Japan</td>
</tr>
<tr>
<td>MP15-05</td>
<td>GUIDELINE-ADHERENCE TO ADEQUATE TREATMENT FOR T1 NON-MUSCLE-INVASIVE BLADDER CANCER: EVIDENCE FROM A GERMAN MULTICENTER OBSERVATION Malte W. Vetterlein*, Julia Roschinski, Philipp Gild, Hamburg, Germany, Ousman Doh, Wedel, Germany, Wolfgang Höppner, Itzehoe, Germany, Hendrik Isbarn, Wedel, Germany, Walter Wagner, Guido Sauter, Armin Soave, Margit Fisch, Michael Rink, Hamburg, Germany</td>
</tr>
<tr>
<td>MP15-06</td>
<td>ASSESSMENT OF QUALITY OF CARE IN NON-MUSCLE INVASIVE BLADDER CANCER: UPTAKE OF RE-RESECTION FOR HIGH GRADE OR T1 BLADDER TUMORS IN CALIFORNIA Stanley Yap, Ann Brunson, Yvonne Chan*, Rosemary Cress, Theresa Keegan, Ralph deVere White, Ted Wun, Sacramento, CA</td>
</tr>
<tr>
<td>MP15-07</td>
<td>VARIATIONS IN MANAGEMENT OF NON-MUSCLE INVASIVE MICROPAPILLARY UROTHELIAL CARCINOMA OF THE BLADDER Kyle Scarberry, Yu Zheng*, Shree Agrawal, John Francis, Kelly Scarberry, Albert Kim, Itunu Arojo, Simon Kim, Cleveland, OH</td>
</tr>
<tr>
<td>MP15-08</td>
<td>HIGH GRADE NON-INVASIVE RECURRENCE FOLLOWING INDUCTION BCG FOR PT1/CIS UROTHELIAL CARCINOMA OF BLADDER, IS IT AN INDICATION FOR CYSTECTOMY? Manmeet Saluja*, Daljit Kaur, Auckland, New Zealand, Jonathan Masters, Andrew Williams, Michael Rice, Kamran Zargar-Shoshtari, Auckland, New Zealand</td>
</tr>
<tr>
<td>MP15-09</td>
<td>USING GRADE OF TUMOR RECURRENCE AFTER BCG THERAPY TO GUIDE FURTHER THERAPY Roger Li*, Michael J. Metcalfe, J.E. Ferguson 3rd, Siddhartha Gorantla, Neema Navai, Jay B. Shah, H. Barton Grossman, Colin P. Dinney, Ashish M. Kamat, Houston, TX</td>
</tr>
</tbody>
</table>
**MP15-10** IMMUNOLOGIC RESPONSE TO A THERAPEUTIC CANCER VACCINE (PANVAC): INITIAL RESULTS FROM A RANDOMIZED PHASE 2 CLINICAL TRIAL

Thomas Sanford*, Renee Donahue, Bethesda, MD, Caroline Jochems, Maryland, MD, Rebecca Dolan, Sonia Bellfield, Bethesda, MD, Megan Anderson, Bethesda, MD, Eric Singer, Robert Weiss, Sammy Elsamra, Thomas Jang, New Brunswick, NJ, Sam Brancato, Iowa City, IA, Daniel Su, Irvine, CA, Yvonne Wall, James Gulley, Jeffrey Schlam, Piyush Agarwal, Bethesda, MD

**MP15-11** BLADDER PRESERVATION IN ELDERLY PATIENTS HAVING NON-MUSCLE INVASIVE HIGH GRADE RECURRENT TA, T1 UROTHELIAL CARCINOMA WITH GEMCITABINE, PACLITAXEL, DOXORUBICIN AND RADIOTHERAPY: SURVIVAL AND QUALITY OF LIFE.

Mohamed Wishahi*, Hossam Elganzoury, Cairo, Egypt

**MP15-12** PHASE IB TRIAL OF ALT-803, AN IL-15 SUPERAGONIST, PLUS BACILLUS CALMETTE GUERIN (BCG) FOR THE TREATMENT OF BCG-NAÏVE PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC).

Charles J. Rosser*, Honolulu, HI, Jeffrey Nix, Birmingham, AL, Lydia Ferguson, Hing C. Wong, Miramar, FL

**MP15-13** A PHASE I TRIAL FOR THE USE OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) IN THE TREATMENT OF BCG-REFRACTORY NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER

Guarionex DeCastro*, Wilson Sul, Jamie Pak, Cory Abate-Shen, Shing Lee, Christopher Anderson, Dara Holder, James McKiernan, New York, NY

**MP15-14** NEUTROPHIL LYMPHOCYTE RATIO PREDICTS PROGRESSION OF NON MUSCLE INVASIVE BLADDER CANCER – PROSPECTIVE STUDY ONE YEAR FOLLOW UP

Itamar Getzler, Zaher Bahouth, Ofer Nativ, Jacob Rubinstein, Sarel Halachmi*, Haifa, Israel

**MP15-15** URINE SAMPLE DERIVED CK20- AND IGF2-EXPRESSION AS BIOMARKER FOR THE DETECTION OF BLADDER CANCER

Karsten Salomo*, Doreen Huebner, Manja U. Boehme, Alexander Herr, Ulrike Heberling, Dresden, Germany, Oliver W. Hakenberg, Daniela Jahn, Rostock, Germany, Marc-Oliver Grimm, Astrid Enkelmann, Daniel Steinbach, Jena, Germany, Susanne Fuessel, Manfred P. Wirth, Dresden, Germany

**MP15-16** THE ASSOCIATION OF AGE WITH PERIOPERATIVE AND CLINICOPATHOLOGIC OUTCOMES FOLLOWING RADICAL CYSTECTOMY FOR NON-MUSCLE INVASIVE BLADDER CANCER


**MP15-17** BEYOND SUPPLEMENTATION: THE ROLE OF VITAMIN D IN NON-MUSCLE INVASIVE BLADDER CANCER

Ziling Wang*, Yew Koon Lim, Ratha Mahendran, Esuvaranathan Kesavan, Edmund Chiong, Singapore, Singapore

**MP15-18** SAFETY AND TOLERABILITY ANALYSIS OF HYPERTHERMIC INTRAVESICAL MITOMYCIN TO MITOMYCIN ALONE IN HIVEC I AND HIVEC II: AN ANALYSIS OF 307 PATIENTS

Wei Shen Tan*, London, United Kingdom, Juan Palou, Barcelona, Spain, John Kelly, London, United Kingdom, HIVEC I and HIVEC II Clinical Trials Group, London/ Barcelona, United Kingdom

**MP15-19** IMPROVED RECURRENCE FREE SURVIVAL IN NMIBC PATIENTS TAKING METFORMIN DEMONSTRATES DOSE DEPENDENCE

Timothy Rushmer*, Shiva Damodaran, E. Jason Abel, Shi Fangfang, Kyle Richards, David Jarrard, Tracy Downs, Madison, WI

**MP15-20** MCM-2 CELL BASED ASSAY IS A SENSITIVE AND SPECIFIC TEST FOR RISK STRATIFICATION OF BLADDER CANCER PATIENTS.

Kasra Saeb-Parasy*, Cambridge, United Kingdom, Peter Caeo, St Andrews, United Kingdom, Durgesh Rana, Nadira Narine, Manchester, United Kingdom, Bensita Mary Viju Jose Thottakam, Sushant Dhanvijay, Andrew Ball, Alexander Wilson, Aberdeen, United Kingdom, David Harrison, St Andrews, United Kingdom

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
<table>
<thead>
<tr>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP16-01</td>
<td>CLINICAL IMPLICATIONS OF SUNITINIB AND N-DESETHYL-SUNITINIB PLASMA CONCENTRATIONS FOR TREATMENT OUTCOME IN METASTATIC RENAL CELL CARCINOMA PATIENTS</td>
</tr>
<tr>
<td>Kazuyuki Numakura*, Nobuhiro Fujiyama, Makoto Takahashi, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Shintaro Narita, Mingguo Huang, Shigeru Satoh, Takenori Nioka, Masatomo Miura, Tomonori Habuchi, Akita, Japan</td>
<td></td>
</tr>
</tbody>
</table>

| MP16-02 | INFLUENCE OF GENETIC POLYMORPHISMS ON THE PHARMACOKINETICS OF SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA |
| Kazuyuki Numakura*, Nobuhiro Fujiyama, Makoto Takahashi, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Shintaro Narita, Mingguo Huang, Shigeru Satoh, Takenori Nioka, Masatomo Miura, Tomonori Habuchi, Akita, Japan |

| MP16-03 | UTILITY OF INFLAMMATORY MARKERS IN PROGNOSIS FOR PATIENTS WITH RENAL CELL CARCINOMA AND VENA CAVA TUMOR THROMBUS |
| Adam Lorentz*, Atlanta, GA, Manik Gupta, Detroit, MI, Matthew Broggi, Augusta, GA, Andrew Leung, Dattatraya Patil, Viraj Master, Atlanta, GA |

| MP16-04 | MEAN HOUNSFIELD UNITS ON UNENHANCED CT PREDICTS RESPONSE TO EVEROLIMUS IN TUBEROUS SCLEROSIS COMPLEX ASSOCIATED ANGIOMYOLIPOMAS |
| Yi Cai*, Hanzhong Li, Yushi Zhang, BEIJING, China, People’s Republic of |

| MP16-05 | EARLY TUMOR SHRINKAGE UNDER SECOND-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA AS A PREDICTOR OF OVERALL SURVIVAL: A RETROSPECTIVE MULTIINSTITUTIONAL STUDY IN JAPAN |
| Keita Tamura, Hideaki Miyake*, Seiichiro Ozono, Hamamatsu, Japan |

| MP16-06 | EARLY RESPONSE AT FOUR WEEKS OF C-REACTIVE PROTEIN PREDICTS SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS |
| Yosuke Yasuda*, Kazutaka Saito, Naoko Kawamura, Sho Uehara, Takeshi Yuasa, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Shinya Yamamoto, Shunji Takahashi, Tokyo, Japan, Tetsuo Okuno, Ibaraki, Japan, Junji Yonese, Kazunori Kihara, Yasuhisa Fuji, Tokyo, Japan |

| MP16-07 | USEFULNESS OF INFLAMMATORY MARKER DYNAMICS ONE MONTH AFTER THE FIRST-LINE TARGETED THERAPY INITIATION FOR PFS PREDICTION IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA |
| Keiichi Ito*, Ayako Masunaga, Saitama, Japan, Nobuyuki Tanaka, Ryuichi Mizuno, Tokyo, Japan, Suguru Shirotake, Yota Yasumizu, Hidaka, Japan, Yojiro Ito, Yasumasa Miyazaki, Tokyo, Japan, Masayuki Hagiwara, Ichikawa, Japan, Kent Kanao, Nagakute, Japan, Shuji Mikami, Tokyo, Japan, Tetsuo Monma, Wako, Japan, Ken Nakagawa, Ichikawa, Japan, Tsuyoshi Masuda, Saitama, Japan, Masafumi Oyama, Hidaka, Japan, Tomohiko Asano, Saitama, Japan, Mototsugu Oya, Tokyo, Japan |

| MP16-08 | CONTRIBUTION OF GENETIC POLYMORPHISMS RELATED TO AXITINIB PHARMACOKINETICS TO THE CLINICAL SAFETY AND EFFICACY IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA |
| Ryoma Igarashi*, Akita, Japan, Norihiko Tsuchiya, Yamagata, Japan, Takamitsu Inoue, Nobuhiro Fujiyama, Kazuyuki Numakura, Hiroshi Tsuruta, Hideaki Kagaya, Atsushi Maeno, Mitsuru Saito, Shintaro Narita, Takenori Nioka, Masatomo Miura, Shigeru Sato, Tomonori Habuchi, Akita, Japan |

| MP16-09 | REEXAMINING THE ROLE OF EXTENDED LYMPHADENECTOMY FOR THE MANAGEMENT OF RENAL MALIGNANCY IN THE TARGETED THERAPY ERA |
| Dean Laganosky*, Christopher Filson, Dattatraya Patil, Viraj Master, Atlanta, GA |
MP16-10 THE IMPACT OF KINETICS OF BIOMARKERS ON THE PREDICTION OF OVERALL SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH A TYROSINE KINASE INHIBITOR.

Jun Teishima*, Shinya Ohara, Kousuke Sadahide, Shinzuke Fuji, Hiroyuki Kitanoe, Shunsuke Shinmei, Keisuke Hieda, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Akio Matsubara, Hiroshima, Japan

MP16-11 JAPANESE PHASE I/II STUDY OF MULTipePTIDE-BASED CANCER VACCINE IMA901 AFTER SINGLE-DOSE CYCLOphosphamide IN JAPANESE PATIENTS WITH ADVANCED RENAL CELL CANCER

Fumi Hongo*, Natsuki Takaha, Takashi Ueda, Kimihiro Yano, Kyoto, Japan, Satoshi Tamada, Osaka, Japan, Schoor Oliver, Singh-Jasuja Harpreet, Tuebingen, Germany, Tatsuya Nakatani, Osaka, Japan, Tsuneharu Miki, Osamu Ukimura, Kyoto, Japan

MP16-12 SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH YTTRIUM-90 (Y-90) RESIN MICROSPHERES IN PATIENTS WITH PRIMARY RENAL CELL CARCINOMA (RCC): IMPACT ON RENAL FUNCTION AND QUALITY OF LIFE IN THE RESIRT STUDY

Peter Aslan*, Hurstville, Australia, William Clark, Korgarah, Australia, Manish Patel, Westmead, Australia, Justin Vass, Ryde, Australia, David N. Cade, Suresh Janeendra de Silva, Sydney, Australia, Paul L. de Souza, Liverpool, Australia

MP16-13 CLINICAL BENEFIT OF PRESURGICALAXITINIB THERAPY IN RENAL CELL CARCINOMA PATIENTS WITH THROMBUS EXTENDING TO INFERIOR VENA CAVA

Yoshimi Tanaka*, Yasuhiro Hashimoto, Shingo Hatakeyama, Shogo Hosogoe, Toshikazu Tanaka, Masaaki Oikawa, Kazuhisa Hagiwara, Takuma Narita, Daisuke Noro, Yuki Tobisawa, Hayato Yamamoto, Tohru Yoneyama, Takahiro Yoneyama, Takuya Kole, Chikara Ohyama, Hirosaki, Japan

MP16-14 CLINICAL IMPLICATION OF METASTASECTOMY IN METACHRONOUS METASTATIC RENAL CELL CARCINOMA IN THE ERA OF TARGETED THERAPY

Jong Won Kim*, Jongsoo Lee, Jae Yong Jeong, Sung Ku Kang, Jang Hee Han, Seung Hwan Lee, Won Sik Ham, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Young Eun Yoon, Woong Kyu Han, Seoul, Korea, Republic of

MP16-15 NATURAL HISTORY OF SURGICALLY TREATED LOCAL RECURRENT AFTER NEPHRECTOMY

Paolo Capogrosso*, Milan, Italy, Eric Barret, Igor Nunes-Silva, Rafael Sanchez-Salas, Francois Rozel, Paris, France, Alessandro Larcher, Ettore Di Trapani, Alberto Briganti, Andrea Salonia, Francesco Montorsi, Roberto Bertini, Umberto Capitano, Milan, Italy, Xavier Cathelinneau, Paris, France

MP16-16 IS THERE ANY DIFFERENCE IN PROGNOSIS BETWEEN SYNCHRONOUS AND METACHRONOUS BRAIN METASTASIS FROM METASTATIC RENAL CELL CARCINOMA?

Se Young Choi, Jeman Ryu, Jae Hyeon Han*, Wonchul Lee, Han Kyu Chae, Sangjun Yoo, Daisan You, In Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyeok Hong, Hanjong Ahn, Choung-Soo Kim, Seoul, Korea, Republic of

MP16-17 OUTCOMES IN OVER 4,000 PATIENTS WITH RENAL CELL CARCINOMA FROM THE LATIN AMERICAN RENAL CANCER GROUP (LARGO): A FOCUS ON METASTATIC DISEASE

Diego Abreu*, Montevideo, Uruguay, Guillermo Gueglio, Patricio Garcia, Buenos Aires, Argentina, Walter da Costa, Daniel Beltrame, San Pablo, Brazil, Alvaro Zuñiga, Santiago, Chile, Liu Meza, Lima, Peru, Ruben Bengió, Cordoba, Argentina, Carlos Scorticati, Buenos Aires, Argentina, Ricardo Castilloyos, Francisco Rodríguez, Ciudad de Mexico, Mexico, Ana Maria Autran, Carmen Gonzalez, Miguel Sanchez, Madrid, Spain, Jose Gudju, Ciudad de Mexico, Mexico, Alejandro Nolazco, Pablo Marinez, Carlos Ameri, Buenos Aires, Argentina, Hamilton Zampolli, San Pablo, Brazil, Raul Langenhin, Diego Muguruz, Paysandu, Uruguay, Marcos Tobias Machado, Antonio Lima Pompeo, San Pablo, Brazil, Pablo Mingote, Nicolas Ginéstard, Neuquén, Argentina, Matías López, Luján, Argentina, Boris Camacho, La Paz, Bolivia, Juan Yandian, Jorge Clavijo, Roberto Puente, Montevideo, Uruguay, Sergio de Miceu, Buenos Aires, Argentina, Lucas Nogueira, Carlos Corradi, Belo Horizonte, Brazil, Marcelo Torrico, Cochabamba, Bolivia, Martin Varela, Omar Clark, Montevideo, Uruguay, Luis Montes de Oca, Sebastian Saviñano, Buenos Aires, Argentina, Ricardo Decia, Montevideo, Uruguay, Fernando Secin, Agustín Rovegno, Buenos Aires, Argentina, Gustavo Guimarães, Sidney Glima, San Pablo, Brazil, Joan Palau, Barcelona, Spain, Gustavo Carvalhal, Porto Alegre, Brazil, Philippe Spiess, Tampa, FL, Stenio Zequi, San Pablo, Brazil, Marston Linehan, Bethesda, MD
TREATMENT OF KIDNEY TUMORS WITH RADIOFREQUENCY ABLATION (RFA) COMBINED WITH SYSTEMIC PD-1 INHIBITION RESULTS IN BOTH PRIMARY TUMOR CONTROL AND PREVENTION OF LUNG METASTASIS IN A PRECLINICAL ANIMAL MODEL

Xiaofeng Chang*, Nanjing, China, People’s Republic of

NEOADJUVANT AND ADJUVANT CHEMOTHERAPY FOLLOWING NEPHROURETERECTOMY: CHANGES IN UTILIZATION AND OUTCOMES

Adrien Bernstein*, Ron Golan, Brian Dinerman, Michael Cosiano, Khushabu Kasabwala, Jim C. Hu, NEW YORK, NY

LITMUS TEST OR DESTINATION SYSTEMIC THERAPY? REFERRAL FOR CYTOREDUCTIVE NEPHRECTOMY AFTER INITIAL SYSTEMIC THERAPY IN METASTATIC KIDNEY CANCER

Liam C. Macleod*, Atreya Dash, George R. Schade, Anobel Y. Odisho, Scott S. Tykodi, John L. Gore, Seattle, WA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
2:30 PD08-10 DOES DETECTION OF DDX4 MRNA IN CELL FREE SEMINAL PLASMA REPRESENTS A RELIABLE NON-INVASIVE GERM CELL MARKER IN PATIENTS WITH NON-OBSTRUCTIVE AZOOSPERMIA?
Wafaa Abdallah, Doaa Hashad, Rania Abdelmakssoud, Mohamed Mohieeldin Hashad*, Alexandria, Egypt

2:40 PD08-11 LEYDIG STEM CELL AUTOGRAFT IN MICE: A NOVEL APPROACH TO INCREASE SERUM TESTOSTERONE WHILE PRESERVING FERTILITY
Himanshu Arora*, Marilia Sanches Santos Rizzo Zutti, Bruno Nahar, Joshua M. Hare, Ranjith Ramasamy, Miami, Fl

2:50 PD08-12 IN VITRO EXPANSION AND MANIPULATION OF HUMAN SPERMATOGONIAL STEM CELLS
Hye-Won Song, Tung-Chin Hsieh, Miles Wilkinson*, San Diego, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
2:20 PD09-09 NATIONWIDE DISPARITIES IN TESTICULAR CANCER CARE DELIVERY: RACIAL, ETHNIC AND ECONOMIC MARKERS OF PATIENT VULNERABILITY
Liam Macleod*, Shannon Cannon, Seattle, WA, Oliver Ko, Chicago, IL, Jonathan Wright, George Schade, Daniel Lin, John Gore, Atreyo Dash, Seattle, WA

2:30 PD09-10 TEMPORAL TRENDS IN MANAGEMENT AND OUTCOMES OF TESTICULAR CANCER: A POPULATION-BASED STUDY
Michael Leveridge*, D Robert Siemens, Kelly Brennan, Jason Izard, Safiya Karim, Christopher Booth, Kingston, Canada

2:40 PD09-11 MANAGEMENT OF THE POST-PUBERTAL UNDESCENDED TESTIS: AN UPDATED RISK ANALYSIS
Ankur Shah*, Blake Wynia, Paul Feustel, Jennifer Knuth, Charles Welliver, Albany, NY

2:50 PD09-12 THE IMPACT OF SURGEON AND HOSPITAL EXPERIENCE ON THE PERIOPERATIVE OUTCOMES OF PATIENTS RECEIVING ROBOTIC PARTIAL NEPHRECTOMY
Yash Khandwala*, San Diego, CA, In Gab Jeong, Palo Alto, CA, Ye Wang, Boston, MA, Deok Hyun Han, Seoul, Korea, Republic of, Jae Heon Kim, Seol, Korea, Republic of, Shufeng Li, Palo Alto, CA, Steven L. Chang, Boston, MA, Benjamin I. Chung, Stanford, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
1:50 PD10-06 INTRA-OPERATIVE OPTICAL IMAGING UTILIZING ANTI-PSMA (PROSTATE SPECIFIC MEMBRANE ANTIGEN) FLUORESCENT ANTIBODY DURING ROBOT ASSISTED RADICAL PROSTATECTOMY (RARP)
Avinash Chennamsetty*, William Chu, Justin Emtage, Paul Gellhaus, Jonathan Yamzon, Clayton Lau, Bertram Yuh, Tommy Tong, David Colcher, Timothy Wilson, Ali Zhumkhawala, Duarte, CA

2:00 PD10-07 RELIABILITY OF PROSTATE HISTOSCANNING IN THE LOCALIZATION AND VOLUME ESTIMATION OF CARCINOMA PROSTATE
Abhishek Singh*, Ankush Jairath, Jaimin Shah, Arvind Ganpule, Ravindra Sabnis, Mahesh Desai, Nadiad, India

2:10 PD10-08 LIGHT-REFLECTANCE SPECTROSCOPY TO DETECT POSITIVE SURGICAL MARGINS AT RADICAL PROSTATECTOMY: EXPLORATION OF NEW ALGORITHMS TO REFINE DETECTION RATE
Igor Sorokin*, Noah Canvasser, Dallas, TX, Xinlong Wang, Henry Chan, Hanli Liu, Arlington, TX, Payal Kapur, Claus Roehrborn, Jeffrey Cadeddu, Dallas, TX

2:20 PD10-09 EFFECT OF DEHYDRATED HUMAN AMNION/CHORION MEMBRANE ALLOGRAFT ON URINARY CONTINENCE FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY
Khaled Refaai, Hao Nguyen*, Ameli Niloufar, Wang Huiqing, Matthew Cooperberg, Peter Carroll, San Francisco, CA

2:30 PD10-10 RACIAL DISPARITIES IN DELIVERING DEFINITIVE THERAPY FOR INTERMEDIATE-HIGH RISK LOCALIZED PROSTATE CANCER: THE IMPACT OF FACILITY FEATURES AND SOCIOECONOMIC CHARACTERISTICS
David F. Friedlander*, Nicolas von Landenberg, Philipp Gild, Quoc-Dien Trinh, Boston, MA, Patrick Karabon, Detroit, MI, Maxine Sun, Paul L. Nguyen, Adam S. Kibel, Tony K. Choueiri, Joel S. Weissman, Boston, MA, Mani Menon, Firas Abdollah, Detroit, MI

2:40 PD10-11 ANALYSIS OF THE PREDICTIVE UTILITY OF PROGNOSTIC GRADE GROUPS (PGG) FOR PREDICTING PERIOPERATIVE ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY IN THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) DATABASE.

2:50 PD10-12 PROGNOSTIC SIGNIFICANCE OF THE PROPORTION OF DUCTAL COMPONENT IN DUCTAL ADENOCARCINOMA OF THE PROSTATE
Won Sik Jang*, Myung Soo Kim, Jae Won Park, Jong Soo Lee, Jong Won Kim, Jae Yong Jeong, Sung Ku Kang, Seoul, Korea, Republic of, Young Sig Kim, Goyang, Korea, Republic of, In Rae Cho, Gimhae, Korea, Republic of, Young Deuk Choi, Seoul, Korea, Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD11-01</td>
<td>COMPARISON BETWEEN THE DIAGNOSTIC ACCURACIES OF 18F-FRONTODEOXYGLUCOSE (FDG) POSITRON EMISSION TOMOGRAPHY (PET)/COMPUTED TOMOGRAPHY (CT) AND MORPHOLOGICAL IMAGING IN RECURRENT UROTHELIAL CARCINOMAS: A RETROSPECTIVE, MULTI-CENTER STUDY</td>
<td>Fabio Zattoni*, Padua and Udine, Italy, Vincenzo Ficarra, Udine, Italy, Alberto Briganti, Milan, Italy, Michele Colicchia, Rochester, MN, Stefano Fanti, Bologna, Italy, R. Jeffrey Karnes, Rochester, MN, Elena Incerti, Milan, Italy, Val Lowe, Rochester, MN, Marco Moschini, Milan, Italy, Stefano Panareo, Ferrara, Italy, Maria Picchio, Milan, Italy, Ilaria Rambaldi, Ferrara, Italy, Riccardo Schiavina, Bologna, Italy, Filiberto Zattoni, Laura Evangelista, Padua, Italy</td>
</tr>
<tr>
<td>1:20</td>
<td>PD11-03</td>
<td>IMPACT OF MAGNETIC RESONANCE SPECTROSCOPIC IMAGING ON DIFFERENTIAL DIAGNOSIS OF RENAL TUMORS.</td>
<td>Masahiro Sumura*, Haruki Ajiki, Chiaki Koike, Keita Inoue, Keisuke Nakashita, Hiroaki Yasumoto, Tsuyoshi Yoshizako, Hajime Kitagaki, Hiroaki Shira, Izumo, Shimane, Japan</td>
</tr>
<tr>
<td>1:30</td>
<td>PD11-04</td>
<td>CONVENTIONAL VERSUS COMPUTER ASSISTED STEREOSCOPIC ULTRASOUND NEEDLE GUIDANCE FOR RENAL ACCESS: A RANDOMIZED BENCH-TOP CROSSOVER TRIAL</td>
<td>Alexander Thomas, Jerry Thomas, Mohamed Keheila*, Braden Mattison, Benjamin West, David Ruckel, Samuel Abouribeh, Reed Krause, Vi Dinh, D. Daniel Baldwin, D. Duane Baldwin, Loma Linda, CA</td>
</tr>
<tr>
<td>1:40</td>
<td>PD11-05</td>
<td>CONTRAST-ENHANCED ULTRASOUND AS A REPLACEMENT FOR FLUOROSCOPIC NEPHROSTOMOGRAM FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY</td>
<td>Thomas Chi*, Maniint Usawachintachat, David Tzou, Helena Chang, Benjamin Sherer, Marshall Stoller, Stefanie Weinstein, John Mongan, San Francisco, CA</td>
</tr>
<tr>
<td>2:00</td>
<td>PD11-06</td>
<td>CYSTIC RENAL MASSES: IS THE BOSNIAK CLASSIFICATION SYSTEM AN ADEQUATE PREDICTOR OF SURVIVAL?</td>
<td>Thenappan Chandrasekar*, Ardalan E. Ahmad, Kamel Fadaak, Michael A.S. Jewett, Antonio Finelli, Toronto, Canada</td>
</tr>
<tr>
<td>2:20</td>
<td>PD11-08</td>
<td>COMPUTER-AIDED DIAGNOSIS OF PROSTATE CANCER USING A DEEP NEURAL NETWORKS ALGORITHM IN PRE-BIOPSY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING</td>
<td>Junichiro Ishioka*, Yoh Matsuoka, Masaya Itoh, Masaharu Inoue, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Kazutaka Saito, Kazunori Kihara, Yasuhsita Fujii, Hiroshi Tanaka, Tomo Kimura, Tokyo, Japan</td>
</tr>
<tr>
<td>2:30</td>
<td>PD11-10</td>
<td>IMPACT OF GLEASON PATTERN 4 CRIBRIFORM ARCHITECTURE ON PROSTATE CANCER DETECTION USING MULTIPARAMETRIC MRI</td>
<td>Matthew Truong*, Hiroshi Miyamoto, Eric Weinberg, Gary Hollenberg, Edward Messing, Thomas Frye, Rochester, NY</td>
</tr>
<tr>
<td>2:40</td>
<td>PD11-11</td>
<td>DO PATIENTS WHO UNDERGO MULTIPARAMETRIC MRI FOR PROSTATE CANCER NEED ANY OTHER IMAGING? RESULTS FROM A STATEWIDE COLLABORATIVE</td>
<td>Justin Drobish*, Grand Rapids, MI, Ji Qi, Tae Kim, James Montie, Ann Arbor, MI, Sabrina Noyes, Grand Rapids, MI, Dinesh Telang, Roseville, MI, Brian Lane, Grand Rapids, MI, Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI</td>
</tr>
</tbody>
</table>
2:50  PD11-12 FEASIBILITY OF AUTOMATING THE MEASUREMENT OF KIDNEY STONE DIAMETER, VOLUME, AND DENSITY ON CT
Justin Ziemba*, George Fung, Rishab Gurnani, Elliot Fishman, Brian Matlaga, Satomi Kawamoto, Baltimore, MD

ABSTRACT
NUMBER  TITLE
MP17-01 INFAMMASOME ACTIVATION LEADS TO IL-18 EXPRESSION IN PROSTATIC INFLAMMATION ASSOCIATED WITH BPH
Pradeep Tyagi*, Mahendra Kashyap, Jeffrey Gingrich, Zhou Wang, Naoki Yoshimura, Pittsburgh, PA

MP17-02 TNFa ANTAGONISTS REDUCE INCIDENCE OF BPH IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY CONDITIONS
Brittany Lapan, Omar Franco, Jaclyn Pruitt, Jacqueline Petkewicz, Brian Helfand, Charles Brendler, Chi-Hsiung Wang, Simon Hayward*, Evanston, IL

MP17-03 INFAMMATION-INDUCED PROSTATIC ENLARGEMENT AND PROLIFERATION OF PROSTATE EPITHELIAL CELLS IS REDUCED BY GROWTH HORMONE-RELEASING HORMONE (GHRH) ANTAGONISTS THROUGH THE INHIBITION OF EPITHELIAL-TO-MESENCHYMAL TRANSITION
Petra Popovics*, Andrew Schally, Luis Salgueiro, Krisztina Kovacs, Ferenc Rick, Miami, FL

MP17-04 COMPLEMENT ACTIVATION MECHANISM ACTIVATED BY AUTOANTIGEN RECOGNITION DURING GROWTH OF BENIGN PROSTATIC HYPERPLASIA
Junya Hata*, Kanako Matsuoka, Yuichi Sato, Hidenori Akaibata, Masao Kataoka, Soichiro Ogawa, Nobuhiro Haga, Kei Ishibashi, Ken Aikawa, Yoshiyuki Kojima, Fukushima City, Japan

MP17-05 TOXOPLASMA GONDII INFECTS THE PROSTATE AND INDUCES MICROGLANDULAR HYPERPLASIA IN A MOUSE MODEL OF PROSTATIC HYPERPLASIA
Darrelle Colinot*, Tamila Garbuz, Indianapolis, IN, Maarten Bosland, Chicago, IL, William Sullivan, Gustavo Arribaldaga, Travis Jerde, Indianapolis, IN

MP17-06 THYROID HORMONES AND BENIGN PROSTATIC HYPERPLASIA
Jun Ho Lee*, Young Bin Kim, Gyeong Eun Min, Dong-Gi Lee, Seoul, Korea, Republic of

MP17-07 ANDROGENIC TO ESTROGENIC SWITCH IN PROSTATE GLAND AS A RESULT OF EPIGENETIC SILENCING OF STEROID 5α-REDUCTASE 2
Zongwei Wang*, Libing Hu, Rongbin Ge, Keyan Salari, Seth Bechis, Shulin Wu, Cyrus Rassoulian, Jonathan Pham, Shahn Tabetas, Boston, MA, Chin-Lee Wu, Belmont, MA, Douglas Strand, Dallas, TX, Aria Ouml, Boston, MA

MP17-08 THE IDENTIFICATION OF ESTROGEN RECEPTOR GENE NETWORKS IN BENIGN PROSTATIC HYPERPLASIA
Teresa Liu*, Jalissa Wynder, Taryn James, Madison, WI, Jill Macoska, Boston, MA, William Ricke, Madison, WI

MP17-09 CXCL12-CXCR4 AXIS ACTIVATION PROMOTES COP II VESICLE-MEDIATED SECRETION OF COLLAGEN BY PROSTATE MYOFIBROBLASTS
Susan Patalano-Salsman, Jose A. Rodriguez-Nieves, Diego Almanza, Amy Avery, Andrew Judell-Haffpenney, Todd Riley, Jill Macoska*, Boston, MA

MP17-10 E-CADHERIN DOWNREGULATION IS ASSOCIATED WITH INCREASED LUMINAL EPITHELIAL PERMEABILITY IN BENIGN PROSTATE HYPERPLASIA
Feng Li*, Laura E Pascal, Pittsburgh, PA, Anil Parwani, Columbus, OH, Rajiv Dhir, Joel B Nelson, Pittsburgh, PA, Peng Guo, Dalin He, Xi’an, China, People’s Republic of, Zhou Wang, Pittsburgh, PA

MP17-11 CONTRIBUTIONS OF PROSTATE VOLUME AND FIBROSIS TO BLADDER OUTLET OBSTRUCTION
Matthew D Grimes*, Will Lyon, Sijian Wang, Lori M Gettle, Wade A Bushman, Madison, WI

MP17-12 TH2 CYTOKINES PROMOTE MYOFIBROBLAST PHENOCOVNSION AND PROSTATIC FIBROSIS
Mehraz Gharaeae-Kermani*, Jill Macoska, Boston, MA

*Presenting author

Friday, May 12, 2017 3:30 pm - 5:30 pm
Moderated Poster Session 17
BENIGN PROSTATIC HYPERPLASIA: BASIC RESEARCH & PATHOPHYSIOLOGY
Room 151 @ Boston Convention & Exhibition Center
Moderators: Peter Chin, Robert Getzenberg and Simon Hayward
MP17-13 MAGNETIC RESONANCE IMAGING STUDIES OF AN EXPERIMENTAL MOUSE MODEL OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
Erin McAuley*, Devkumar Mustafi, Chicago, IL, Brian Simons, Baltimore, MD, Rebecca Valek, Marta Zamora, Erica Markiewicz, Sophia Lampesis, Greg Karczmarz, Aytekin Oto, Donald Vander Griek, Chicago, IL

MP17-14 DEPLETION OF PERIPHERAL SEROTONIN SYNTHESIS INDUCES BENIGN PROSTATIC GROWTH IN MICE: MORE EVIDENCE FOR THE NEW “NEUROENDOCRINE THEORY” IN BPH ETIOLOGY
Paulo Mota*, Emanuel Carvalho-Dias, Alice Miranda, Olga Martinho, Natalia Alenina, Michael Bader, Berlin, Germany, Ricardo Autorino, Estevão Lima, Jorge Correia-Pinto, Braga, Portugal

MP17-15 LONG-TERM LEPTIN TREATMENT RESULTS IN A REDUCTION IN PROSTATIC EPITHELIAL HYPERPLASIA IN THE OBOB MOUSE MODEL
Takeshi Sasaki*, Omar Franco, LaTayia Aaron, Rodrigo Javier, Yana Filipovich, Susan Crawford, Simon Hayward, Evanston, IL

MP17-16 METFORMIN INHIBITS BENIGN PROSTATIC EPITHELIAL CELLS THROUGH SUPPRESSION OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR
Zongwei Wang*, Xingyuan Xiao, Rongbin Ge, Jijun Li, Cameron Johnson, Cyrus Rassoulian, Aria Olumi, Boston, MA

MP17-17 EFFECT OF AGENT ORANGE EXPOSURE ON THE DEVELOPMENT OF BENIGN PROSTATIC ENLARGEMENT
Daniel Sackman*, Wesley Stoller, Laura Peters, Jackileen Shannon, Mark Garzotto, Portland, OR

MP17-18 PERI-PROSTATIC FAT (PPF) SECRETOME IN BPH PROGRESSION
Omar Franco*, Rodrigo Javier, Evanston, IL, Mathew Brady, Chicago, IL, Susan Crawford, Simon Hayward, Evanston, IL

MP17-19 THE EXPRESSION AND FUNCTIONAL ACTIVITIES OF SMOOTH MUSCLE MYOSIN AND NON-MUSCLE MYOSIN ISOFORMS IN RAT PROSTATE
Ping Chen, Jing Yin, Yuming Guo, Xinghuan Wang, Wuhan, China, People’s Republic of, Michael E DiSanto, Camden, NJ, Xinhua Zhang*, Wuhan, China, People’s Republic of

MP17-20 PHOSPHODIESTERASE TYPE 5 (PDE5) IN THE HUMAN PROSTATE: RELATION TO KEY ENZYMES OF THE NITRIC OXIDE/CYCLIC GMP SIGNALING
Stefan Ueckert*, Hannover, Germany, Andreas Bannowsky, Rendsburg, Germany, Markus Kuczyk, Hannover, Germany, Petter Hedlund, Linköping, Sweden

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 12, 2017
3:30 pm - 5:30 pm
Moderated Poster Session 18

IMAGING/RADIOLOGY: URORADIOLOGY III
Room 153 @ Boston Convention & Exhibition Center
Moderators: Vincenzo Ficarra, Pat Fulgham and Christopher Porter

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP18-01</td>
<td>IDENTIFICATION OF PROSTATE SPECIFIC ANTIGEN AND PROSTATE SPECIFIC ANTIGEN DENSITY THRESHOLDS AT WHICH FUSION-GUIDED BIOPSY OUTPERFORMS SYSTEMATIC BIOPSY</td>
</tr>
<tr>
<td>Sherif Mehralivand*, Sandra Bednarova, Francesca Mertan, Sonia Gaur, Maria Merino, Bradford Wood, Peter Pinto, Peter Choyke, Baris Turkbey, Bethesda, MD</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP18-02</td>
<td>EVALUATION OF MRI/ULTRASOUND-FUSION BIOPSY IN PATIENTS WITH LOW-RISK PROSTATE CANCER UNDER ACTIVE SURVEILLANCE</td>
</tr>
<tr>
<td>Angelika Borkowetz*, Ivan Platzek, Marieta Toma, Toma, Theresa Renner, Martin Baunacke, Michael Froehner, Stefan Zastrau, Manfred Wirth, Dresden, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP18-03</td>
<td>TRANSPERINEAL MR/US FUSION-GUIDED PROSTATE BIOPSY MAINTAINS A HIGH DEGREE OF CANCER DETECTION REGARDLESS OF TARGETED LESION VOLUME</td>
</tr>
<tr>
<td>Harry Anastos*, Jared S. Winoker, Pratik A. Shukla, Kyle A. Blum, Cynthia J. Knauer, Ashutosh K. Tewari, Sara C. Lewis, Bachir Taouli, Aradesh R. Rastinehad, New York, NY</td>
<td></td>
</tr>
</tbody>
</table>

74
MP18-04 ROLE OF PI-RADS VERSION 2 FOR PREDICTION OF UPGRADING AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PROSTATE BIOPSY GLEASON SCORE 6
Song Wan*, Chan Kyo Kim, Young Hyo Choi, Hyun Woo Chung, Chung Un Lee, Jun Phil Na, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, Hyun Moo Lee, Seoul, Korea, Republic of

MP18-05 PROSTATIC ARTERIAL VARIANTS: LESSONS LEARNED FROM INTERVENTIONAL RADIOLOGY
Jessica Jackson*, Charlottesville, VA, George Rueb, Charlottesville, VA, Andre Uflacker, Ziv Haskal, Noah Schenkman, Charlottesville, VA

MP18-06 LIMITATIONS OF ABDOMINAL IMAGING FOR DETECTION OF LYMPH NODE METASTASES PRIOR TO PROSTATECTOMY
Henry Peabody*, Grand Rapids, MI, Ji Qi, Tae Kim, James Montie, Ann Arbor, MI, Christopher Brede, Grand Rapids, MI, Jeffrey Montgomery, Ann Arbor, MI, Brian Lane, Grand Rapids, MI, Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP18-07 THE ACCURACY AND VALIDATION OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING (MPMRI) USING PI-RADS V2 IN DISEASE UPGRADING ON RE-BIOPSY AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER ON ACTIVE SURVEILLANCE (AS) – A BRAZILIAN PERSPECTIVE.
Públio Viana*, Natally Horvat, Rodrigo Pessoa, Thiana Rodrigues, Giuliano Guglielmetti, Rafael Coelho, Rubens Park, São Paulo, Brazil, Herbert Alberto Vargas, New York, NY, William Nahas, São Paulo, Brazil

MP18-08 COMPARISON OF FLUCICLOVINE (18F) PET-CT AND MRI IN DETECTION OF RECURRENT PROSTATE CANCER
Oladunni Akin-Akintayo*, Funmilayo Tade, Pardeep Mittal, Courtney Moreno, Peter Nieh, Peter Rossi, Halkar Raghuvreer, Baowei Fei, Mark Goodman, David Schuster, Atlanta, GA

MP18-09 INFLUENCE OF GA-PSMA PET/CT ON CLINICAL DECISION MAKING IN THE TREATMENT OF PATIENTS WITH PROSTATE CANCER.
Carlos Ferreira*, Liliana Violante, Rui Freitas, Isaac Braga, Victor Silva, Sanches Magalhães, Francisco Lobo, António Morais, Hugo Duarte, Jorge Oliveira, Porto, Portugal

MP18-10 COMPARISON OF PLANAR SCINTIGRAPHY AND SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY / COMPUTED TOMOGRAPHY (SPECT/CT) IN PREOPERATIVE IMAGING OF SENTINEL LYMPH NODES IN PENILE CANCER PATIENTS.
Carsten Maik Naumann*, Moritz Franz Hamann, Christian Colberg, Klaus-Peter Jünemann, Daniar Osmonov, Ulf Lützen, Kiel, Germany

MP18-11 EXPLORING THE CLINICAL UPTAKE AND USE OF PSMA PET MRI HYBRID IMAGING IN PROSTATE CANCER PATIENTS AT AN ACADEMIC CENTER IN AUSTRALIA

MP18-12 DIFFUSION WEIGHTED IMAGING: DIFFERENTIATION OF CLEAR CELL FROM PAPILLARY RENAL CELL CARCINOMA
Sayyedeh Mojdeh Mimromen, Moozhan Nikpanah, Rabindra Gautam, Adam Metwalli, Amir Pourmortezoa, William Linehan, Ashkan Malayeri*, Bethesda, MD

MP18-13 TEXTURE ANALYSIS OF ENHANCING, NON-LIPID CONTAINING SOLID RENAL MASSES: DIFFERENTIATION OF MALIGNANT FROM BENIGN RENAL TUMORS.
Bino Varghese, Vinay Duddalwar*, Frank Chen, Darryl Hwang, Steven Cen, Bhushan Desai, Gangning Liang, Mihir Desai, Sameer Chopra, Manju Aron, Monish Aron, Inderbir Gill, Los Angeles, CA

MP18-14 MULTIPLE RADIOFREQUENCY ABLATION ZONES ON KIDNEY FUNCTION
Julie At*, Shawna Boyle, Venkatesh Krishnasamy, Adam Metwalli, W. Marston Linehan, Bradford Wood, Bethesda, MD

MP18-15 NEW CLASSIFICATION OF HYDRONEPHROSIS ON FDG-PET/CT PREDICTS POSTOPERATIVE RENAL FUNCTION AND PATHOLOGICAL OUTCOMES IN PATIENTS WITH UPPER URINARY TRACT UROTHELIAL CARCINOMA
Seiji Asai*, Ousuke Arai, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yutaka Yanagihara, Yuki Miyauchi, Masao Miyagawa, Tadahiko Kikugawa, Takashi Saika, Toon, Japan

MP18-16 THE IMPORTANCE OF UROLOGIST ESTIMATION OF STONE BURDEN: RESULTS FROM THE REGISTRY FOR STONES OF THE KIDNEY AND URETER (RESKU™)
David T. Tzou*, Dylan Isaacson, Manint Usawachintachit, Kazumi Taguchi, Benjamin A. Sherer, Marshall L. Stoller, Thomas Chi, San Francisco, CA

*Presenting author
MP18-17 AUTOMATED COMPREHENSIVE STONE PROFILE IS JUST ONE CLICK AWAY
  John Roger Bell*, Perry J Pickhardt, Stephen Y Nakada, Madison, WI

MP18-18 THREE-DIMENSIONAL VS. TWO-DIMENSIONAL SHEAR-WAVE ELASTOGRAPHY OF THE TESTES – PRELIMINARY STUDY ON A HEALTHY COLLECTIVE
  Julian Marcon*, Matthias Trottmann, Johannes Ruebenthaler, Melvin D’Anastasi, Christian G. Stief, Maximilian F. Reiser, Dirk Andre Clevert, Munich, Germany

MP18-19 ASSESSING THE RELATIONSHIP BETWEEN CNS DISEASE BURDEN, URINARY SYMPTOMS AND URODYNAMIC FINDINGS IN PATIENTS WITH MULTIPLE SCLEROSIS UTILIZING MRI SEGMENTATION POST-PROCESSING
  Jessica Eastman*, Catherine Harris, Alana Christie, Ryan Hutchinson, Ben Wagner, Joseph A. Maldjian, Marco Pinho, Gary E. Lemack, Dallas, TX

MP18-20 ASSESSMENT OF TO RESPONSE RATE FOLLOWING NEOADJUVANT CHEMOTHERAPY FOR BLADDER CANCER UTILIZING A COMPUTERIZED VOLUME ANALYSIS SYSTEM

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 12, 2017 3:30 pm - 5:30 pm

Moderated Poster Session 19

STONE DISEASE: BASIC RESEARCH & PATHOPHYSIOLOGY II
Room 156 @ Boston Convention & Exhibition Center
Moderators: Dean Assimos, Saeed Khan and Palle Osther

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP19-01</td>
<td>HIGH-RESOLUTION GUT MICROBIOME PROFILING REVEALS SPECIES-LEVEL AND GENE CONTENT DIFFERENCES BETWEEN KIDNEY STONE FORMERS AND CONTROLS</td>
</tr>
</tbody>
</table>
  James White*, Baltimore, MD, Kelvin Davies, Joshua Stern, New York City, NY |
| MP19-02 | SALIVARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND CORTISOL MEASUREMENT IN ACUTE RENAL COLIC |
  Ashraf Tamimi*, Eyal Kord, Yishai Rapaport, Ramziya Abu hamad, Shai Efrati, Amnon Zisman, Yoram Siegel, zrifin, Israel |
| MP19-03 | CT-BASED DIAGNOSIS OF LOW VERTEBRAL BONE MINERAL DENSITY IS ASSOCIATED WITH 24-HOUR URINE ABNORMALITIES AND LARGER KIDNEY STONE VOLUMES |
  Nishant D. Patel*, Ryan Ward, Juan Calle, Erick Remer, Manoj Monga, Cleveland, OH |
| MP19-04 | THE RELATIONSHIP BETWEEN VASCULAR CALCIFICATION AND KIDNEY STONE FORMERS IN A HOSPITAL-BASED CASE CONTROL STUDY |
  Aneesh K Piramal*, Ilir Agaliu, Joseph DiVito, Joshua M Stern, Bronx, NYC, NY |
| MP19-05 | COMPUTERIZED SIMULATION OF FLUID DYNAMICS WITHIN THE RENAL COLLECTING SYSTEM AND THEIR ASSOCIATION WITH NEPHROLITHIASIS |
  Scott Wiener*, Farmington, CT, Alexandros Mathioudakis, Storrs, CT, Phillip Smith, Marco Molina, Farmington, CT, Xinyu Zhao, Storrs, CT, Erica Lambert, Hartford, CT |
| MP19-06 | CALCIUM OXALATE DIHYDRATE AS A MARKER OF HYPERCALCIURIA IN STONE PATIENTS: A META-ANALYSIS AND EXPLORATION OF THE DIFFICULTIES IN PROPER STONE ANALYSIS |
  Maria Pless*, Odense, Denmark, Palle Osther, Vejle, Denmark, James Lingeman, James Williams, Indianapolis, IN |
| MP19-07 | AUTOFLUORESCENCE OF RANDALL’S PLAQUE PRECURSORS |
  Ling Chen*, San Francisco, CA, Ryan Hsi, Nashville, TN, Benjamin Sherer, Marshall Stoller, Sunita Ho, San Francisco, CA |
| MP19-08 | VALIDATION OF A RENAL PAPILLARY GRADING SYSTEM FOR PATIENTS WITH NEPHROLITHIASIS |
  Michael S. Borofsky*, Minneapolis, MN, Hazem M. Elmansy, Nadya E. York, Indianapolis, IN, Casey A. Dauw, Ann Arbor, MI, James C. Williams, Jr., Indianapolis, IN, Elaine M. Worcester, Chicago, IL, Daniel L. Gillen, Irvine, CA, James E. Lingeman, Indianapolis, IN |
MP19-09 DAILY HYDROGEN SULFIDE THERAPY DURING PROLONGED URETERIC OBSTRUCTION ENABLES EARLY RENAL RECOVERY FOLLOWING DECOMPRESSION


MP19-10 IDENTIFICATION OF NEW URINARY RISK MARKERS FOR URINARY STONE PATIENTS USING LOGISTIC MODEL AND MULTINOMIAL-LOGIT MODEL

Atsushi Okada*, Teruaki Sugino, Rei Unno, Kazumi Taguchi, Shuzo Hamamoto, Ryosuke Ando, Keiichi Tozawa, Takahiro Yasui, Nagoya, Japan

MP19-11 SYSTEMIC BIOMINERALIZATION IN KIDNEY STONE FORMERS

Benjamin Sherer*, Sunita Ho, Marshall Stoller, San Francisco, CA

MP19-12 PAPILLARY DUCTAL PLUGGING AS A MECHANISM FOR EARLY STONE RETENTION IN BRUSHITE STONE DISEASE

James Williams*, Indianapolis, IN, Michael Borofsky, Minneapolis, MN, Andrew Evan, Indianapolis, IN, Fredric Coe, Elaine Worcester, Chicago, IL, James Lingeman, Indianapolis, IN

MP19-13 SIMULTANEOUS ULTRASONIC PROPULSION WITH BURST-WAVE LITHOTRIPSY TO IMPROVE STONE BREAKAGE IN AN ARTIFICIAL KIDNEY MODEL

Justin Ahn*, Theresa Zwaschka, Bryan Cunitz, Michael Bailey, Barbbrina Dunmire, Mathew Sorensen, Jonathan Harper, Adam Maxwell, Seattle, WA

MP19-14 MECHANISTIC EVIDENCE THAT PAPILLARY PITS OCCUR SECONDARY TO DISLODGE METAL OF RANDALL'S PLAQUE ATTACHED STONES

Michael S. Borofsky*, Minneapolis, MN, James C. Williams, Jr., Indianapolis, IN, Elaine M. Worcester, Chicago, IL, Casey A. Dauw, Ann Arbor, MI, Nadya E. York, Andrew P. Evan, James E. Lingeman, Indianapolis, IN

MP19-15 THE RELATIONSHIP BETWEEN HYPERURICEMIA AND URIC-ACID STONE FORMATION FOR RENAL FUNCTION DETERIORATION: A POPULATION-BASED ANALYSIS

Toshikazu Tanaka*, Shingo Hatakeyama, Yuriko Terayama, Fumitada Saitoh, Hisao Saitoh, Yasuhiko Hashimoto, Takuya Koi, Chikara Ohyama, Hiroaki, Japan

MP19-16 RENAL PAPILLARY PLUGGING IN CALCIUM STONE FORMERS MAY ARISE VIA RANDOM AND INDEPENDENT CRYSTALLIZATION EVENTS

Melanie Adamsky*, Andrew Cohen, Glenn Gerber, Elaine Worcester, Frederic Coe, Chicago, IL

MP19-17 RENAL PAPILLARY MAPPING AND QUANTIFICATION OF RANDALL'S PLAQUE IN PEDIATRIC CALCIUM OXALATE STONE FORMERS

Annie Darves-Bornoz*, John Thomas, Tracy Marien, Gabriel Fiscus, Douglass Clayton, Nicole Miller, Nashville, TN

MP19-18 VARIABILITY IN RENAL PAPILLARY PITTING SCORES EXCEEDS THAT OF RANDALL'S PLAQUE: EVIDENCE FOR THE PATHOGENESIS OF CALCIUM STONE FORMATION

Melanie Adamsky*, Andrew Cohen, Glenn Gerber, Elaine Worcester, Frederic Coe, Chicago, IL

MP19-19 PATIENTS WITH CALCIUM STONES AND RANDALL'S PLAQUE EXCRETE DISTINCT POPULATIONS OF MICRO RNA-CONTAINING URINARY EXTRACELLULAR VESICLES


MP19-20 A PILOT STUDY COMPARING VIRTUAL AND REAL CONSULTATION OUT PATIENT FOR STONE PATIENTS FUTURE OF ENDOUROLOGY STONE CLINIC

Haresh Thummar*, Vadodara, India, Shivang D, New York, India, N Thummar, Nelson Z, Vadodara, India

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP20-01</td>
<td>VALIDATION OF THE AMERICAN JOINT COMMITTEE ON CANCER (AJCC) 8TH EDITION PROSTATE CANCER STAGING SYSTEM</td>
</tr>
</tbody>
</table>

Bimal Bhindi*, R. Jeffrey Karnes, Laureano Rangel, Ross Mason, Matthey Gettman, Igor Frank, Matthew Tollefson, R. Houston Thompson, Stephen Boorjian, Rochester, MN

| MP20-02 | NOVEL RISK STRATIFICATION GROUPING USING STANDARD CLINICAL AND BIOPSY INFORMATION FOR PATIENTS UNDERGOING RADICAL PROSTATECTOMY: RESULTS FROM SEARCH |

Zachary Zumsteg, Los Angeles, CA, Ziman Chen, Lauren Howard, Christopher Amling, Durham, NC, William Aronson, Los Angeles, CA, Matthew Cooperberg, San Francisco, CA, Christopher Kane, San Diego, CA, Martha Tents, Augusta, GA, Daniel Spratt, Ann Arbor, MI, Howard Sandler, Stephen Freedland*, Los Angeles, CA

| MP20-03 | POPULATION-BASED VALIDATION OF THE 2014 ISUP GLEASON GRADING GROUPING IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY, BRACHYTHERAPY, EXTERNAL BEAM RADIATION OR NO LOCAL TREATMENT |

Helen Davis Bondarenko*, Montreal, Canada, Raisa Sinaida Pompe, Hamburg, Germany, Emanuele Zaffuto, Milan, Italy, Zhe Tian, Montreal, Canada, Jonas Schiffmann, Braunschweig, Germany, Sami-Ramzi Leyh-Bunnurah, Hamburg, Germany, Kevin Zorn, Marc Zanaty, Montreal, Canada, Shahrokh F. Shariat, Vienna, Austria, Markus Graefen, Derya Tilki, Hamburg, Germany, Pierre I. Karakiewicz, Montreal, Canada

| MP20-04 | DECIPHER PROSTATE CANCER CLASSIFIER DOES NOT CORRELATE WITH CLINICOPATHOLOGIC PROSTATE CANCER CLASSIFIERS IN AFRICAN AMERICAN MEN |

Jordan Alger*, Rohit Patil, Anna Chichura, Filipe La Fuente Carvalho, Jonathan Hwang, Lambros Stamatakis, Washington, DC

| MP20-05 | A DIAGNOSTIC BIOPSY-BASED GENOMIC PROSTATE SCORE AS AN INDEPENDENT PREDICTOR OF PROSTATE CANCER DEATH AND METASTASIS IN MEN WITH LOCALIZED PROSTATE CANCER |

Stephen Van Den Eeden*, Oakland, CA, Nan Zhang, Redwood City, CA, Jun Shan, Charles Quesenberry, Jeong Han, Oakland, CA, Athanasios Tsiatis, Ruixiao Lu, Jeffrey Lawrence, Phillip Febbo, Redwood City, CA, Joseph Presti, Oakland, CA

| MP20-06 | EXTENT OF BASELINE PROSTATE ATROPHY IS ASSOCIATED WITH LOWER INCIDENCE OF LOW- AND HIGH-GRADE PROSTATE CANCER ON REPEAT BIOPSY |

Daniel MO Freitas*, Los Angeles, CA, Gerald Andriole, Saint Louis, WA, Ramiro Castro-Santamaria, Pennsylvania, PA, Stephen J. Freedland, Los Angeles, CA, Daniel M. Moreira, Chicago, IL

| MP20-07 | ASSOCIATION OF ATROPHY IN BASELINE PROSTATE BIOPSY AND LOWER PROSTATE CANCER GRADE IN RADICAL PROSTATECTOMY SPECIMENS |

Daniel MO Freitas*, Los Angeles, CA, Gerald Andriole, Saint Louis, WA, Ramiro Castro-Santamaria, Pennsylvania, PA, Stephen J. Freedland, Los Angeles, CA, Daniel M. Moreira, Chicago, IL

| MP20-08 | PROSTATE CANCER LOCI WITH NEGATIVE MULTIPARAMETRIC MRI FOR PROSTATE CANCER: CORRELATION WITH PROSTECTOMY SPECIMENS |

Katsushiro Ito, Takashi Kobayashi*, Akihiro Furuta, Yuki Teramoto, Naoki Terada, Shusuke Akamatsu, Toshinari Yamasaki, Takahiro Inoue, Osamu Ogawa, Kyoto, Japan

| MP20-09 | EVALUATING MRI FUSION BIOPSY VS SYSTEMATIC ULTRASOUND GUIDED BIOPSY IN PREDICTING HIGH GRADE CANCER AT TIME OF RADICAL PROSTATECTOMY |

Hao Nguyen*, Katsuto Shinohara, Janet Cowan, Antonio Westphalen, Matthew Cooperberg, Jeff Simko, Peter Carroll, San Francisco, CA

| MP20-10 | THE ACCURACY OF MAGNETIC RESONANCE IMAGING (MPMRI) GUIDED TRANSPERINEAL FUSION PROSTATE BIOPSIES (TPFB) TO EVALUATE LESIONS ON PROSTATE MPMRI USING PROSTECTOMY SPECIMENS AS A VALIDATION TOOL. |

Alberto Macchi, Thomas Lloyd, Cambridge, United Kingdom, Hansen Nienke, Aachen, Germany, Lisa Whittington, Vincent Gnanapragasam, Brendan Koo, Saeb-Parsy Kasra*, Nadeem Shaia, Anne Warren, Ola Bratt, Nimish Shah, Tristan Barrett, Christof Kastner, Cambridge, United Kingdom

| MP20-11 | ACCURACY OF MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING FOR DETECTION OF PROSTATE CANCER EXTRACAPSULAR EXTENSION AND RELATION TO ITS HISTOLOGIC EXTENT |

Melanie Adamsky*, Scott Johnson, Vignesh Packiam, Alexander Gallant, Taljana Antic, Arieh Shaibah, Aytekin Oto, Chicago, IL
MP20-12 PREDICTIVE VALUE OF TUMOR CONTACT LENGTH ON MAGNETIC RESONANCE IMAGING FOR EXTRACAPSULAR EXTENSION OF PROSTATE CANCER
Kazumi Kamoi*, Koji Okihara, Fumiya Hongo, Yasuyuki Naitoh, Atsuko Iwata, Motohiro Kanazawa, So Ushijima, Osamu Ukimura, Kyoto, Japan

MP20-13 VALIDATION OF A MODIFIED GLEASON GRADING SYSTEM IN A CANADIAN COHORT
Marc Zanaty*, Mansour Alnazari, Mila Mansour, Pierre Karakiewicz, Emanuele Zaffuto, Raisa Pompe, Roger Valdivieso, Assaad Elhakim, Kevin Zorn, Montreal, Canada

MP20-14 ANATOMICAL EVALUATION OF SENTINEL LYMPH NODES FOR PROSTATE CANCER USING INDOCYANINE GREEN DURING LAPAROSCOPIC RADICAL PROSTATECTOMY
Jun Miki*, Takafumi Yanagisawa, Minoru Nakazono, Taisuke Yamazaki, Sotaro Kayano, Taro Igarashi, Seiro Tanaka, Chiba, Japan, Takahiro Kimura, Hiroyuki Takahashi, Takashi Yorozu, Tokyo, Japan, Koichi Kishimoto, Chiba, Japan, Shin Egawa, Tokyo, Japan

MP20-15 THE ACCURACY OF 68GALLIUM-PSMA PET/CT IN PRIMARY LYMPH NODE STAGING FOR HIGH RISK PROSTATE CANCER
Can Obek*, Tunkut Doganca, Emre Demirci, Meltem Ocak, Ali Riza Kural, Asif Yildirim, Ugur Yucetas, Cetin Demirdag, Sarper M. Erdogan, Levent Kabasakal, Istanbul, Turkey

MP20-16 A MORE EXTENDED LYMPH NODE DISSECTION TEMPLATE AT RADICAL PROSTATECTOMY DETECTS METASTASES IN THE COMMON ILIAC REGIONS AND IN THE FOSSA OF MARCILLE
Lydia Maderthaner*, Marc-Alain Furrer, Daniel P. Nguyen, Bern, Switzerland

MP20-17 THE IMPACT OF NODE POSITIVE DISEASE FOLLOWING RADICAL PROSTATECTOMY ON SURVIVAL: A CONTEMPORARY POPULATION-BASED COHORT
Ron Golan*, Adrien Bernstein, Wei-Chun Hsu, Brian Dinerman, Michael Cosiano, Jonathan E. Shoag, Art Sedrakyan, Jim C. Hu, New York, NY

MP20-18 OUTCOMES OF VERY-HIGH-RISK PROSTATE CANCER: VALIDATION STUDY FROM 3 INSTITUTIONS OVER 10 YEARS
Debasish Sundi*, Houston, TX, Jeffrey Toscan, Baltimore, MD, Yaw Nyame, Cleveland, OH, Mary Achim, Houston, TX, Ridwan Alam, Baltimore, MD, Chandana Reddy, Lamont Wilkins, Cleveland, OH, Amol Narang, Baltimore, MD, Andrew Stephenson, Cleveland, OH, John Davis, Houston, TX, Edward Schaeffer, Chicago, IL, Ashley Ross, Baltimore, MD, Eric Klein, Cleveland, OH, Brian Chapin, Houston, TX

MP20-19 WHAT ARE THE BEST CUT-POINTS FOR PSA DOUBLING TIME IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER?
Lauren Howard*, Durham, NC, Daniel Moreira, Chicago, IL, Amanda De Hoedt, Durham, NC, William Aronson, Los Angeles, CA, Christopher Kane, San Diego, CA, Christopher Amling, Durham, NC, Matthew Cooperberg, San Francisco, CA, Martha Terris, Augusta, GA, Stephen Freedland, Los Angeles, CA

MP20-20 IDENTIFICATION OF DISSEMINATED TUMOR CELLS IN THE BONE MARROW WITH DISEASE-SPECIFIC MARKERS AT RADICAL PROSTATECTOMY
Emma van der Toom*, Stephanie Glavari, Michael Gorin, James Verdone, Kenneth Pienta, Heath chalkin, Baltimore, MD

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

**Presenting author**
MP21-03 DEFINITIVE TREATMENT OF BLADDER CANCER IN OCTOGENARIANS: BALANCING INCREASED PERIOPERATIVE MORTALITY WITH SUPERIOR OVERALL SURVIVAL
William R Boysen*, Vignesh Packiam, Joseph Rodriguez, Melanie Adamsky, Norm Smith, Gary D Steinberg, Chicago, IL

MP21-04 THE EFFICACY OF TRIMODAL CHEMORADIOThERAPY AS A BLADDER-PRESERVING STRATEGY FOR MUSCLE INVASIVE BLADDER CANCER
Kazuhiro Nagao*, Takahiko Hara, Jun Nishijima, Junichi Mori, Kosuke Shimizu, Nakanori Fujii, Keita Kobayashi, Yoshihisa Kawai, Ryo Inoue, Yoshiaki Yamamoto, Hiroaki Matsumoto, Hideyasu Matsuyama, Ube, Japan

MP21-05 MULTIMODAL BLADDER PRESERVATION TECHNIQUE FOR MUSCLE INVASIVE BLADDER CANCER: RESULTS FROM A PROSPECTIVE TRIAL
Teruo Inamoto*, Kiyoshi Takahara, Naokazu Ibuki, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Yuki Yoshikawa, Koichiro Minami, Hajime Hirano, Hayahito Nomi, Haruhiro Azuma, Kiyohito Yamamoto, Taiju Shinbo, Kazuhiro Yamamoto, Yoshifumi Narumi, Takatsuki, Japan

MP21-06 RADICAL CYSTECTOMY AFTER PRIOR PARTIAL CYSTECTOMY FOR UROTHELIAL CARCINOMA: PERIOPERATIVE AND ONCOLOGIC OUTCOMES
Ross Mason*, Igor Frank, Bimal Bhindi, Matthew K. Tollesfon, R. Houston Thompson, R. Jeffrey Karnes, Robert Tarrell, Stephen A. Boorjian, Rochester, MN

MP21-07 SELECTION EFFECTS MAY EXPLAIN SMOKING-RELATED OUTCOME DIFFERENCES AFTER RADICAL CYSTECTOMY
Michael Froehner*, Rainer Koch, Matthias Hübler, Ulrike Heberling, Vladimir Novotny, Stefan Zastrow, Manfred P. Wirth, Dresden, Germany

MP21-08 THE USE OF ANTIBIOTIC PROPHYLAXIS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER
Maximilian Haider, Roman Mayr, Hans-Martin Frilsche, Regensburg, Germany, Christian Ladurner, Armin Pycha, Evi Comploj, Bolzano, Italy, Francis Lemire, Louis Lacombe, Yves Fradet, Michele Lodde*, Quebec, Canada

MP21-09 PROLONGED LENGTH OF STAY NOT ASSOCIATED WITH DECREASED HOSPITAL READMISSIONS FOLLOWING UNCOMPLICATED HOSPITALIZATION AFTER RADICAL CYSTECTOMY
Kirven Gilbert, Adam Lorentz*, Dattatraya Patil, Mehrdad Alemozzafar, Christopher Filson, Atlanta, GA

MP21-10 CLINICAL FEATURE IN DIALYSIS PATIENT WITH UROTHELIAL CARCINOMA AFTER COMPLETE URINARY TRACT EXENTERATION
Ze-Hong Lu*, Chien-Hui Ou, Wen-Hong Yang, Tainan, Taiwan

MP21-11 INCREASED UTILIZATION OF ADVANCED IMAGING TECHNOLOGY AND ITS ECONOMIC IMPACT FOR PATIENTS DIAGNOSED WITH BLADDER CANCER IN THE UNITED STATES
Christopher Kosarek*, Galveston, TX, Jinhai Huo, Houston, TX, Jacques Baillargeon, Yong-Fang Kuo, Justin Fang, Cameron Ghaffary, Preston Kerr, Galveston, TX, Stephen Kim, Cleveland, OH, Eduardo Orihuela, Douglas Tyler, Galveston, TX, Sharan Giordano, Houston, TX, Stephen Freedland, Los Angeles, CA, Ashish Kamat, Houston, TX, Stephen Williams, Galveston, TX

MP21-12 HEALTH RELATED QUALITY OF LIFE FOLLOWING RADICAL CYSTECTOMY: COMPARATIVE ANALYSIS FROM THE MEDICAL HEALTH OUTCOMES STUDY
Brian Winters*, George Schade, Sarah Holt, Atreya Dash, John Gore, Jonathan Wright, Seattle, WA

MP21-13 DOES QUALITY OF CARE IMPACT OUTCOMES IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY?

MP21-14 MANAGEMENT OF URETERO-ENTERIC STRICTURES AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY
Youssef Ahmed*, Ahmed Hussein, Paul May, Basim Ahmad, Taimoor Ali, Prasanna Kumar, Khurshid Guru, Buffalo, NY

MP21-15 FISTULOUS COMPLICATIONS FOLLOWING RADICAL CYSTECTOMY FOR BLADDER CANCER: ANALYSIS OF A LARGE MODERN COHORT
Zachary Smith*, Riley McGinnis, Chicago, IL, Vibraj Maniar, Indianapolis, IN, Gary Steinberg, Norm Smith, Chicago, IL

MP21-16 THE ASSOCIATION BETWEEN BLOOD TYPE AND RISK OF VENOUS THROMBOEMBOLISM FOLLOWING RADICAL CYSTECTOMY
Kayvan Kazerooni*, Sorosh T. Bazargani, Gus Miranda, Jie Cai, Siamak Daneshmand, Hooman Djaladat, Los Angeles, CA

MP21-17 COMPARISON OF DIFFERENT LYMPH NODE STAGING SCHEMES FOR PREDICTING SURVIVAL IN PATIENTS FOLLOWING RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER
Leilei Xia*, Jose Pulido, Jeremy Bonzo, Benjamin Taylor, Thomas Guzzo, Philadelphia, PA
MP21-18 POST-THERAPEUTIC RECOVERY OF SKELETAL MUSCLE MASS PREDICTS FAVORABLE PROGNOSIS IN ADVANCED UROTHELIAL CARCINOMA PATIENTS RECEIVING 1ST-LINE PLATINUM-BASED CHEMOTHERAPY
Hiroshi Fukushima*, Yasukazu Nakanishi, Madoka Kataoka, Ken-ichi Tobisu, Fumitaka Koga, Tokyo, Japan

MP21-19 RELATIONSHIP BETWEEN POSTOPERATIVE WEIGHT LOSS FOLLOWING RADICAL CYSTECTOMY AND ONCOLOGICAL OUTCOMES
Shingo Hatakeyama*, Naoki Fujita, Osamu Soma, Tepppei Matsumoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama, Hirosaki, Japan

MP21-20 THE IMPACT OF PLASMACYTOID VARIANT HISTOLOGY ON SURVIVAL OF PATIENTS WITH UROTHELIAL CARCINOMA OF BLADDER AFTER RADICAL CYSTECTOMY
Qiang Li*, Melissa Assel, Eugene Pietzak, Daniel Sjoberg, Harry Herr, Machele Donat, Eugene Cha, Bernard Bochner, Guido Dalbagni, New York, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Friday, May 12, 2017 3:30 pm - 5:30 pm
Moderated Poster Session 22
KIDNEY CANCER: EPIDEMIOLOGY & EVALUATION/STAGING I
Room 253 AB @ Boston Convention & Exhibition Center
Moderators: Robert Flanigan, Pilar Laguna and John Pattaras

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP22-01</td>
<td>PERIOPERATIVE MORBIDITY, ONCOLOGICAL OUTCOMES AND PREDICTORS OF PT3A UPSTAGING FOR PATIENTS UNDERGOING PARTIAL NEPHRECTOMY FOR CT1 TUMORS</td>
</tr>
<tr>
<td>MP22-02</td>
<td>SYNERGISTIC PROGNOSTIC IMPACT OF ELEVATED DE RITIS RATIO AND RENAL SCORE FOR PREDICTION OF SURVIVAL OUTCOMES IN RENAL CELL CARCINOMA AFTER SURGICAL TREATMENT</td>
</tr>
<tr>
<td>MP22-03</td>
<td>OFFICE-BASED ULTRASOUND GUIDED PERCUTANEOUS RENAL MASS BIOPSY</td>
</tr>
<tr>
<td>MP22-04</td>
<td>RACIAL DISPARITIES IN THE TREATMENT AND SURVIVAL OF METASTATIC RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>MP22-05</td>
<td>ROLE OF BIOPSY IN MANAGEMENT OF LARGE, LOCALLY ADVANCED, AND METASTATIC RENAL MASSES</td>
</tr>
<tr>
<td>MP22-06</td>
<td>THE IMPACT OF QUALITY VARIATION ON PATIENTS UNDERGOING SURGERY FOR RENAL CELL CARCINOMA: A NATIONAL CANCER DATABASE STUDY</td>
</tr>
<tr>
<td>MP22-07</td>
<td>CORRELATION OF CAD PEAK LESION ENHANCEMENT WITH QUANTITATIVE TUMOR ANGIGENESIS TO NON-INVASIVELY ASSESS FURHMAN GRADES I-IV IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA</td>
</tr>
</tbody>
</table>

*Presenting author
MP22-08 ESTIMATED GLOMERULAR FILTRATION RATE: DO WE MEASURE THE REAL RENAL FUNCTION OR ARE WE STILL GROPING IN THE DARK?
Francesco Trevisani*, Umberto Capitanio, Alessandro Larcher, Luigi Gianolfi, Alessandra Cinque, Arianna Bettiga, Riccardo Vago, Lina Bua, Cristina Carenzi, Fabio Benigni, Fabio Muttin, Roberto Bertini, Andrea Salonia, Alberto Briganti, Milan, Italy, Natalia Negrin, Ana Gonzales Rinne, Armando Torres, Sergio Louis Lima, Esteban Porrini, La Laguna, Tenerife, Spain, Francesco Montorsi, Milan, Italy

MP22-09 DIAGNOSTIC NEEDLE BIOPSIES IN RENAL MASSES: PATIENT AND PHYSICIAN PERSPECTIVES
Shay Goian*, Chicago, IL, Paz Lotan, Shlomi Tapiero, Jack Daniel, Andrei Nadu, Ofer Yosses, Petach Tikva, Israel

MP22-10 COMPARATIVE ANALYSIS OF PREOPERATIVE INFLAMMATORY MARKERS FOR ONCOLOGIC AND RENAL FUNCTIONAL OUTCOMES AFTER SURGICAL TREATMENT OF RENAL CELL CARCINOMA
Charles Field, Zachary Hamilton*, Aaron Bloch, Katherine Fero, Daniel Han, Richmond Owusu, James Proudfoot, Ithaar Derweesh, San Diego, CA

MP22-11 PERFORMANCE OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING TO IDENTIFY CLEAR CELL RENAL CELL CARCINOMA IN CT1A RENAL MASSES
Noah Canvasser*, Fernando Kay, Xin Xi, Daniella Pinho, Daniel Costa, Alberto Diaz de Leon, Gaurav Khatri, John Leyendecker, Takeshi Yokoo, Aaron Lay, Nicholas Kavoussi, Ersin Koseoglu, Jeffrey Cadeddu, Ivan Pedrosa, Dallas, TX

MP22-12 POSTOPERATIVE OUTCOME OF CYSTIC RENAL CELL CARCINOMA DEFINED ON PREOPERATIVE IMAGING: A RETROSPECTIVE STUDY
Taesoo Choi, Jun Phil Na, CHUNG UN LEE, Hyunwoo Chung*, Seoul, Korea, Republic of, SEUNGHEE YUM, Gunpo, Korea, Republic of, Hyun Hwan Sung, Hwang Gyun Jeon, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Chan Kyo Kim, Byung Chang Jeong, Seoul, Korea, Republic of

MP22-13 CLINICAL AND PATHOLOGIC CHARACTERISTICS OF EARLY ONSET RENAL CELL CARCINOMA
Win Shun Lai*, Tyler Clemmensen, Ava Saidian, Soroush Rais-Bahrami, Jennifer Gordetsky, Birmingham, AL

MP22-14 PREOPERATIVE HAEMATOLOGICAL PARAMETERS AS PREDICTORS OF LONG-TERM SURVIVAL IN RENAL CELL CARCINOMA
Giovanni La Croce*, Fabio Muttin, Alessandro Larcher, Paolo Dell’Oglio, Alessandro Nini, Francesco Ripa, Ettore Di Trapani, Cristina Carenzi, Federico Dehò, Milan, Italy, Vincenzo Mirone, Naples, Italy, Patrizio Rigatti, Francesco Montorsi, Roberto Bertini, Umberto Capitanio, Milan, Italy

MP22-15 RENAL MASS SIZE AND SYNCHRONOUS METASTATIC DISEASE IN RENAL CELL CARCINOMA: AN ANALYSIS OF THE NATIONAL CANCER DATABASE
Mary E. Westerman*, Vidit Sharma, Bimal Bhindi, Stephen A. Boorjian, R. Houston Thompson, Bradley C. Leibovich, Matthew K. Tollefsen, Rochester, MN

MP22-16 CYTOREDUCTIVE PARTIAL NEPHRECTOMY FOR SMALL PRIMARY TUMORS IMPROVES OVERALL SURVIVAL IN METASTATIC KIDNEY CANCER
Andrew Lenis*, Amir Salmasi, Izak Falena, Nicholas Donin, Alexandra Drakaki, Arie Beldegrun, Allan Pantuck, Karim Chamie, Los Angeles, CA

MP22-17 THE METASTATIC POTENTIAL OF RENAL TUMORS: INFLUENCE OF HISTOLOGIC SUBTYPES ON DEFINITION OF SMALL RENAL MASSES, RISK STRATIFICATION, AND FUTURE ACTIVE SURVEILLANCE PROTOCOLS
Michael Daugherty*, Dillon Sedaghatpour, Oleg Shapiro, Sriivasa Vourganti, Syracuse, NY, Alexander Kutikov, Philadelphia, PA, Grennady Bratalskvy, Syracuse, NY

MP22-18 CONTEMPORARY INCIDENCE AND EPIDEMIOLOGIC TRENDS OF BRAIN METASTASES AT RENAL CELL CARCINOMA DIAGNOSIS
Nicolas von Landenberg*, Philipp Gild, Maxine Sun, Guillermo DeVelasco, Priscilla K Brastianos, Boston, MA, Mari Menon, Detroit, MI, Joachim Noldus, Herne, Germany, Paul L. Nguyen, Quoc-Dien Trinh, Toni K. Choueiri, Boston, MA

MP22-19 ALLOGENEIC BLOOD TRANSFUSION IS ASSOCIATED WITH INCREASED MORTALITY AND INFECTIOUS COMPLICATIONS AFTER NEPHROURETERECTOMY
Michael Lam*, Nicholas Chakiriyan, Ann Martinez-Acevedo, Christopher Amling, Jen-Jane Liu, Portland, OR

MP22-20 ABNORMAL LAB VALUES IN PATIENTS UNDERGOING SURGERY FOR LOCALIZED RENAL CELL CARCINOMA: PREVALENCE AND EFFECT ON POSTOPERATIVE COMPLICATIONS
Michael J Lipsky*, Christopher B Anderson, New York, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD12-01</td>
<td>A NOVEL FAMILY OF NATURAL PRODUCTS THAT TARGETS UROPATHOGENIC ESCHERICHIA COLI IRON ACQUISITION</td>
<td>Laura Mike*, Ashootosh Tripathi, David Sherman, Harry Mobjley, Ann Arbor, MI</td>
</tr>
<tr>
<td>3:40</td>
<td>PD12-02</td>
<td>ANTIMICROBIAL GENE EXPRESSION AND UTI SUSCEPTIBILITY IS DEPENDENT ON IL-6/STAT3 SIGNALING</td>
<td>Christina Ching*, Sudipti Gupta, Birong Li, Brian Becknell, Columbus, OH</td>
</tr>
<tr>
<td>3:50</td>
<td>PD12-03</td>
<td>NORMAL PERINEAL MICROBIOME IN PREPUBERTAL FEMALES WITH DYSBIOSIS IF RECURRENT URINARY TRACT INFECTIONS</td>
<td>Christina Ching*, Elizabeth Lucas, Shareef Dabdoub, Purnima Kumar, Sheryl Justice, Columbus, OH</td>
</tr>
<tr>
<td>4:00</td>
<td>PD12-04</td>
<td>LEUKOTRIENE B4 SIGNALING ACTIVATES INNATE UROTHELIAL DEFENSES AND PROTECTS THE BLADDER AND KIDNEYS AGAINST UROPATHOGENIC E. COLI (UPEC)</td>
<td>Yan Liu, Ellen Shapiro, Herbert Lepor, Xue-Ru Wu*, New York, NY</td>
</tr>
<tr>
<td>4:10</td>
<td>PD12-05</td>
<td>BIG POTASSIUM CHANNEL (BK) ACTIVITY IN FEMALE MOUSE BLADDER UMBRELLA CELLS IS ENHANCED BY BACTERIAL LIPOPOLYSACCHARIDE: AN ACUTE HOST RESPONSE IN URINARY TRACT INFECTION (UTI) PATHOGENESIS</td>
<td>Ming Lu*, New Haven, CT, Jian-ni Li, Taichung, Taiwan, Yan Li, Shanghai, China, People’s Republic of, Shian Yu, Toby Chai, New Haven, CT</td>
</tr>
<tr>
<td>4:20</td>
<td>PD12-06</td>
<td>INFLAMMASOME ACTIVATION EARLY IN THE DEVELOPMENT OF DIABETIC BLADDER DYSFUNCTION</td>
<td>Brian Inouye*, Francis M Hughes, Robin Lütolf, Clay Rouse, Wen-Chi Foo, J Todd Purves, Durham, NC</td>
</tr>
<tr>
<td>4:30</td>
<td>PD12-07</td>
<td>HISTONE DEACETYLASE INHIBITOR SUBEROYLANILIDE HYDROXAMIC ACID AMELIORATES HEMORRHAGIC CYSTITIS VIA DNA DAMAGE REPAIR GENE PATHWAYS</td>
<td>Subhash Haldar, Christopher Dru*, Rajeev Mishra, Manisha Tripathi, Frank Duong, Bryan Angara, Neil Bhwomick, Los Angeles, CA</td>
</tr>
<tr>
<td>4:40</td>
<td>PD12-08</td>
<td>THE ROLE OF IL-10 IN UNILATERAL URETERAL OBSTRUCTION: REGULATION OF ANGIOGENESIS AND FIBROSIS</td>
<td>Bethany Desroches*, Xinyi Wang, Pu Duann, Meredith Rae, Swathi Balaji, Sundeeeps Keswani, Houston, TX</td>
</tr>
<tr>
<td>4:50</td>
<td>PD12-09</td>
<td>CONNECTIVE TISSUE GROWTH FACTOR INDUCTION PROMOTES EPITHELIAL MALADAPTIVE REPAIR IN RENAL FIBROSIS</td>
<td>Alex Arnouk*, Albany, NY, Roel Goldschmeding, Utrecht, Netherlands, Paul Higgins, Rohan Samarakoon, Albany, NJ</td>
</tr>
<tr>
<td>5:00</td>
<td>PD12-10</td>
<td>KIDNEY INJURY MOLECULE-1 AS A POTENTIAL URINARY BIOMARKER OF HYDRONEPHROSIS MAY NOT BE AFFECTED BY INFLAMMATORY CAUSES IN THE URINARY TRACT</td>
<td>Daniel Olvera-Posada*, Monterrey, Mexico, Stephen Pautler, Alp Sener, John Denstedt, Hassan Razvi, London, Canada</td>
</tr>
<tr>
<td>5:10</td>
<td>PD12-11</td>
<td>DECREASED VASCULAR ENDOTHELIAL GROWTH FACTOR IN RADIATION CYSTITIS</td>
<td>Bernadette Zwaans*, Sarah Bartolone, Royal Oak, MI, Heinz Nicholai, Santiago de Chile, Chile, Michael Chancellor, Laura Lamb, Royal Oak, MI</td>
</tr>
<tr>
<td>5:30</td>
<td>PD12-12</td>
<td>EVALUATION OF SURFACE MICROPATTERN (SHARKLET) ON FOLEYS SILICON CATHETER IN REDUCING URINARY TRACT INFECTIONS</td>
<td>Vinodh Kumar Adithyaa Arthanareeswaran*, András Magyar, Lila Soos, Bela Koves, Abinaya Ravichandran Chandra, Budapest, Hungary, Nora Justh, Imre Miklos Szilagy, Budapest, Hungary, Tenke Peter, Budapest, Hungary</td>
</tr>
</tbody>
</table>
FRIDAY, MAY 12, 2017 3:30 pm - 5:30 pm
Podium Session 13
INFERTILITY: EPIDEMIOLOGY & EVALUATION I
Room 161 @ Boston Convention & Exhibition Center
Moderators: Raymond Costabile, Ates Kadioglu and Larry Lipshultz

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD13-01</td>
<td>PREGNANCY OUTCOMES IN MEN EVALUATED FOR SPERM ANEUPLOIDY – A GRADED-MODEL OF RISK</td>
<td>Taylor P. Kohn*, Alexander W. Pastuszak, Matthew F. Cherches, Stephen M. Pickett, Dolores J. Lamb, Larry I. Lipshultz, Houston, TX</td>
</tr>
<tr>
<td>3:40</td>
<td>PD13-02</td>
<td>IMPACT OF ABSTINENCE TIME ON SEMEN PARAMETERS IN A LARGE POPULATION BASED COHORT OF SUBFERTILE MEN</td>
<td>James R. Craig*, Sorena Keihani, Chong Zhang, Angela P. Presson, Jeremy B. Myers, William O. Brant, Kenneth I. Aston, Benjamin R. Emery, Timothy G. Jenkins, Douglas T. Carrell, James M. Hotaling, Salt Lake City, UT</td>
</tr>
<tr>
<td>4:10</td>
<td>PD13-05</td>
<td>TESTICULAR CANCER AMONG INFERTILE MEN: A COST BASED RATIONALE FOR PROMOTING TESTICULAR SELF EXAMINATIONS</td>
<td>Aditya Balasubramanian*, Naveen Yadav, Edgar W. Kirby, Alexander W. Pastuszak, Larry I. Lipshultz, Houston, TX</td>
</tr>
<tr>
<td>4:20</td>
<td>PD13-06</td>
<td>SEX-SPECIFIC THYROID CANCER AND MELANOMA RISK IN RELATIVES OF MEN WITH POOR SEMEN QUALITY</td>
<td>Piyush Pathak*, Heidi Hanson, Ross Anderson, William Lowrance, Ken Smith, Kenneth Aston, Douglas Carrell, James Hotaling, Salt Lake City, UT</td>
</tr>
<tr>
<td>4:30</td>
<td>PD13-07</td>
<td>MEN WITH INSULIN RESISTANCE ARE AT INCREASED RISK OF AZOOSPERMIA: RESULTS FROM A CROSS-SECTIONAL STUDY</td>
<td>Walter Cazzaniga*, Eugenio Ventimiglia, Paolo Capogrosso, Filippo Pedezzoli, Nicola Frego, Luca Boeri, Massimo Alfano, Federico Dehò, Franco Gaboardi, Milan, Italy, Vincenzo Mirone, Naples, Italy, Lorenzo Piemonti, Francesco Montorsi, Andrea Salonia, Milan, Italy</td>
</tr>
<tr>
<td>4:40</td>
<td>PD13-08</td>
<td>SHIFT WORK IS ASSOCIATED WITH ALTERED SEMEN PARAMETERS IN INFERTILE MEN</td>
<td>Taylor P. Kohn*, Alexander W. Pastuszak, Stephen M. Pickett, Jaden R. Kohn, Larry I. Lipshultz, Houston, TX</td>
</tr>
<tr>
<td>4:50</td>
<td>PD13-09</td>
<td>MEDICATION PATTERNS AND FERTILITY RATES IN A COHORT OF ANABOLIC STEROID USERS</td>
<td>Mary E. Westerman*, Cameron M. Charchenko, Manaf Alom, Francisco Maldonado, Tanner Miest, Landon Trost, Rochester, MN</td>
</tr>
<tr>
<td>5:00</td>
<td>PD13-10</td>
<td>BARRIERS IN ACCESS TO MALE ONCOCERTILITY CARE AMONG MEN RECEIVING TARGETED CANCER THERAPY</td>
<td>Joris Ramstein*, Puneet Kamal, Katy Tsai, James Smith, San Francisco, CA</td>
</tr>
<tr>
<td>5:10</td>
<td>PD13-11</td>
<td>COST—EFFECTIVENESS OF FERTILITY PRESERVATION IN TESTIS CANCER PATIENTS</td>
<td>Kirven Gilbert*, Atlanta, GA, Ajay Nangia, Kansas City, KS, Akarisha Mehta, Atlanta, GA</td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>AUTHOR(S)</th>
<th>LOCATION(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD14-01</td>
<td>VARIATION IN 90-DAY EPISODE PAYMENTS FOR UROLOGICAL CANCER SURGERY: IMPLICATIONS FOR BUNDLED PAYMENT PROGRAMS</td>
<td>Jonathan Li*, Zaojun Ye, Hye Sung Min, Deborah Kaye, Lindsey Herrel, James Dupree, David Miller, Chad Ellimoottil, Ann Arbor, MI</td>
<td>Ann Arbor, MI</td>
</tr>
<tr>
<td>3:40</td>
<td>PD14-02</td>
<td>CENTERS FOR MEDICARE AND MEDICAID SERVICES’ (CMS) HOSPITAL COMPARE STAR RANKINGS AND SHORT-TERM OUTCOMES AFTER MAJOR UROLOGICAL CANCER SURGERY</td>
<td>Deborah R. Kaye*, Chad Ellimoottil, James M. Dupree, Zaojun Ye, Lindsey A. Herrel, Hye Sung Min, Edward C. Norton, David C. Miller, Ann Arbor, MI</td>
<td>Ann Arbor, MI</td>
</tr>
<tr>
<td>3:50</td>
<td>PD14-03</td>
<td>POST-ACUTE CARE AS A DRIVER OF EPISODE COST VARIATION FOR AMBULATORY STONE SURGERY</td>
<td>John M. Hollingsworth*, Hechuan Hou, Jim Dupree, Ann Arbor, MI, Brian Seifman, West Bloomfield, MI, Adam Kadlec, Holland, MI, Anita Tekchandani, Midland, MI, David Leavitt, Detroit, MI, Khurshid Ghani, Ann Arbor, MI</td>
<td>Ann Arbor, MI</td>
</tr>
<tr>
<td>4:00</td>
<td>PD14-04</td>
<td>ROUTINE HOME HEALTH AFTER PROSTATECTOMY DOES NOT REDUCE ED VISITS OR CATHETER COMPLICATIONS</td>
<td>Deborah R. Kaye*, John Syrjamaki, Chad Ellimoottil, M Hugh Solomon, Ann Arbor, MI, Thomas J. Maatman, Grand Rapids, MI, Susan Linsell, Khurshid R. Ghani, David C. Miller, James E. Montle, James M. Dupree, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI</td>
<td>Ann Arbor, MI</td>
</tr>
<tr>
<td>4:10</td>
<td>PD14-05</td>
<td>ECONOMIC IMPLICATIONS OF UROLOGIST PRESCRIPTION PRACTICES AMONG MEDICARE PART D BENEFICIARIES</td>
<td>Peter Kirk*, Tudor Borza, James Dupree, John Wei, Chad Ellimoottil, Megan Caram, Brent Hollenbeck, Ted Skolarus, Ann Arbor, MI</td>
<td>Ann Arbor, MI</td>
</tr>
<tr>
<td>TIME</td>
<td>NUMBER</td>
<td>TITLE</td>
<td>ABSTRACT</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td>PD15-01</td>
<td>RETZIUS SPACE RECONSTRUCTION FOLLOWING TRANSPERITONEAL LAPAROSCOPIC</td>
<td>RETZIUS SPACE RECONSTRUCTION FOLLOWING TRANSPERITONEAL LAPAROSCOPIC ROBOT-ASSISTED RADICAL PROSTATECTOMY: DOES IT HAVE ANY ADDED VALUE?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ROBOT-ASSISTED RADICAL PROSTATECTOMY: DOES IT HAVE ANY ADDED VALUE?</td>
<td>Yasmin Abu-Ghanem, Zohar Dotan, Jacob Ramon, Dorit Zilberman*, Ramat Gan, Israel</td>
<td></td>
</tr>
<tr>
<td>3:40</td>
<td>PD15-02</td>
<td>HYPOTHERMIC NERVE-SPARING RADICAL PROSTATECTOMY FACILITATES EARLIER</td>
<td>HYPOTHERMIC NERVE-SPARING RADICAL PROSTATECTOMY FACILITATES EARLIER RECOVERY OF POTENCY AT ONE YEAR</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>RECOVERY OF POTENCY AT ONE YEAR</td>
<td>Young-Hwii Ko*, Yeoungnam, Korea, Republic of, Douglas Skarecky, Linda Huynh, Thomas Ahlering, Orange, CA</td>
<td></td>
</tr>
<tr>
<td>3:50</td>
<td>PD15-03</td>
<td>DOES INTRAPERITONEAL EVALUATION OF RETROGRADE LEAK POINT PRESSURE</td>
<td>DOES INTRAPERITONEAL EVALUATION OF RETROGRADE LEAK POINT PRESSURE (RLPP) DURING ROBOTIC ASSISTED RADICAL PROSTATECTOMY (RALP) FOR PROPER AUTOLOGOUS SLING TENSIONING IMPROVES EARLY URINARY CONTINENCE (EUC) RECOVERY COMPARED TO AUTOLOGOUS SLING ALONE?</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(RLPP) DURING ROBOTIC ASSISTED RADICAL PROSTATECTOMY (RALP) FOR</td>
<td>Andrea Cestari*, Carolina Lolli, Mattia Sangalli, Matteo Zanoni, Massimo Ghezzi, Patrizio Rigatti, Milan, Italy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PROPER AUTOLOGOUS SLING TENSIONING IMPROVES EARLY URINARY CONTINENCE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(EUC) RECOVERY COMPARED TO AUTOLOGOUS SLING ALONE?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00</td>
<td>PD15-04</td>
<td>A RANDOMIZED CONTROLLED TRIAL EXAMINING THE IMPACT OF THE RETZIUS-</td>
<td>A RANDOMIZED CONTROLLED TRIAL EXAMINING THE IMPACT OF THE RETZIUS- SPARING APPROACH ON EARLY URINARY CONTINENCE RECOVERY AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SPARING APPROACH ON EARLY URINARY CONTINENCE RECOVERY AFTER ROBOT-</td>
<td>Deepansh Dalela*, Wooju Jeong, Madhu Ashni-Prasad, Akshay Sood, Firas Abdollah, Patrick Karabon, Mireya Diaz, Sriram Eleswarapu, Detroit, MI, Jesse Sammon, Portland, ME, Brad Baize, Andrea Simone, Mani Menon, Detroit, MI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ASSISTED RADICAL PROSTATECTOMY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:10</td>
<td>PD15-05</td>
<td>REAL-WORLD OUTCOMES OF OPEN VERSUS ROBOT-ASSISTED RADICAL PROSTATE-</td>
<td>REAL-WORLD OUTCOMES OF OPEN VERSUS ROBOT-ASSISTED RADICAL PROSTATECTOMY</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CTOMCY</td>
<td>Anrika Herlemann*, Janet E. Cowan, Peter R. Carroll, Matthew R. Cooperberg, San Francisco, CA</td>
<td></td>
</tr>
<tr>
<td>4:20</td>
<td>PD15-06</td>
<td>IMPACT OF TUMOR LOCATION ON BIOCHEMICAL RECURRENCE OF PT3 PROSTATE</td>
<td>IMPACT OF TUMOR LOCATION ON BIOCHEMICAL RECURRENCE OF PT3 PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL ANALYSIS</td>
<td></td>
</tr>
<tr>
<td>4:30</td>
<td>PD15-07</td>
<td>ERECTILE-FUNCTION AND ONCOLOGIC OUTCOMES AFTER OPEN RETROPUBIC AND</td>
<td>ERECTILE-FUNCTION AND ONCOLOGIC OUTCOMES AFTER OPEN RETROPUBIC AND ROBOT-ASSISTED RADICAL PROSTATECTOMY: RESULTS FROM A LARGE, PROSPECTIVE SWEDISH TRIAL</td>
<td></td>
</tr>
<tr>
<td>4:40</td>
<td>PD15-08</td>
<td>ASSOCIATION BETWEEN EARLY URINARY CONTINENCE AND ERECTILE FUNCTION</td>
<td>ASSOCIATION BETWEEN EARLY URINARY CONTINENCE AND ERECTILE FUNCTION RECOVERY AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: DEVELOPMENT OF A NOVEL POSTOPERATIVE RISK SCORE TO OPTIMIZE PATIENT COUNSELING AND FOLLOW-UP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>RECOVERY AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: DEVELOPMENT OF</td>
<td>Giorgio Gandaglia*, Nazareno Suardi, Andrea Gallina, Paolo Dell’Oglio, Nicola Fossati, Vito Cucciara, Marco Moschini, Marco Bandini, Emanuele Zaffuto, Andrea Salonia, Franco Gaboardi, Milan, Italy, Rocco Damiano, Catanzaro, Italy, Vincenzo Mironie, Naples, Italy, Italy, Francesco Montors, Alberto Briganti, Milan, Italy</td>
<td></td>
</tr>
<tr>
<td>4:50</td>
<td>PD15-09</td>
<td>IDENTIFYING THE OPTIMAL CANDIDATE FOR SALVAGE LYMPH NODE DISSECTION</td>
<td>IDENTIFYING THE OPTIMAL CANDIDATE FOR SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENT OF PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL ANALYSIS</td>
<td></td>
</tr>
</tbody>
</table>

86
5:00 PD15-10 SURGICAL EXPERTISE IS THE MAJOR DETERMINANT OF DECREASED COMPLICATION RATES IN CONTEMPORARY PATIENTS TREATED WITH ROBOT-ASSISTED RADICAL PROSTATECTOMY

5:10 PD15-11 MORE EXTENSIVE LYMPH NODE DISSECTION AT RADICAL PROSTATECTOMY IS ASSOCIATED WITH IMPROVED OUTCOMES AFTER SALVAGE RADIOTHERAPY FOR RISING PSA AFTER SURGERY: A LONG-TERM, MULTI-INSTITUTIONAL ANALYSIS
Nicola Fossati*, Milan, Italy, R. Jeffrey Karnes, Stephen Boorjian, Michele Colicchia, Rochester, NY, Alberto Bossi, Villejuif, France, Cesare Cozzarini, Claudio Fiorino, Barbara Norris Chiorda, Giorgio Gandaglia, Milan, Italy, Thomas Wiegel, Ulm, Germany, Shahrkh F. Shariat, Gregor Goldner, Vienna, Austria, Steven Joniau, Karin Haustermans, Aleksandar Meurer, Piet Ost, Ghent, Belgium, Hein Van Poppel, Leuven, Belgium, Francesco Montorsi, Alberto Briganti, Milan, Italy

5:20 PD15-12 THE IMPACT OF NERVE SPARING RADICAL PROSTATECTOMY ON ONCOLOGICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH HIGH RISK PROSTATE CANCER: A RETROSPECTIVE LONG-TERM SINGLE CENTER STUDY.
Marc Alain Furrer*, Tobias Gross, Daniel P. Nguyen, Silvan Boxler, Vera Genitsch, Fiona C. Burkhard, George N. Thalmann, Bern, Switzerland

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ROBOTIC ASSISTED LAPAROSCOPIC TUMOR ENUCLEATION WITH ARTERY HYPOTHERMIC PERFUSION COMBINED WITH NEOADJUVANT TARGET THERAPY FOR A MULTIFOCAL SOLITARY KIDNEY CANCER
Xiaozhi Zhao*, Hongqian Guo, Nanjing, China, People’s Republic of

CONVENTIONAL LAPAROSCOPIC RADICAL NEPHRECTOMY WITH INFERIOR VENA CAVA THROMBECTOMY
Giuliano Guglielmetti, Henrique Nonemacher*, George Lins de Albuquerque, Rafael Coelho, Mauricio Cordeiro, William Nahas, Sao Paulo, Brazil

SALVAGE ROBOTIC PARTIAL NEPHRECTOMY AFTER CRYOABLACTION
Joan C. Delto*, Alan M. Nieder, Akshay Bhandari, Miami Beach, FL

PARTIAL NEPHRECTOMY OF AN ENDOPHYTIC MASS IN A HORSESHOE KIDNEY
Gregory Mitchell*, Russell Libby, Jonathan Silberstein, Raju Thomas, New Orleans, LA

NEPHRON-SPARING LAPAROSCOPIC PARTIAL NEPHRECTOMY AFTER SUPERSELECTIVE EMBOLIZATION OF A RENAL TUMOR IN A HYBRID OPERATING ROOM: A NEW APPROACH OF ZERO ISCHAEMIA
Paul Panayotopoulos*, Antoine Bouvier, Pierre Bigot, Angers, France

ROBOTIC-ASSISTED LAPAROSCOPIC NEPHRECTOMY OF AN AUTO-TRANSPLANTED KIDNEY FOR RECURRENT RENAL CELL CARCINOMA
Belinda Li*, Parth Patel, Alex Gorbonos, Maywood, IL

ROBOTIC PARTIAL NEPHRECTOMY INVOLVING INTRACORPOREAL COLD ISCHEMIA FOR POST CRYOABLATION FAILURE
Zachary Hamilton*, Omer Raheem, Ithaar Derweesh, San Diego, CA

ROBOT ASSISTED PARTIAL NEPHRECTOMIES – 12 TUMORS, 1 KIDNEY
Karen Stern*, Scottsdale, AZ, Catherine Chen, Cave Creek, AZ, Gwen Grimbsy, Thai Ho, Erik Castle, Phoenix, AZ

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
### Plenary: Next Frontier, Saturday Morning Session

**Ballroom East @ Boston Convention & Exhibition Center**

**Saturday, May 13, 2017**  
**7:45 am - 11:30 am**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation/Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45</td>
<td>JOURNAL OF UROLOGY 2016: YEAR IN REVIEW</td>
</tr>
<tr>
<td></td>
<td>Joseph Smith</td>
</tr>
<tr>
<td>7:50</td>
<td>TOP PAPERS:</td>
</tr>
<tr>
<td>8:00</td>
<td>FEMALE UROLOGY AND STONES</td>
</tr>
<tr>
<td></td>
<td>Toby Chai</td>
</tr>
<tr>
<td>8:10</td>
<td>BPH AND ERECTILE DYSFUNCTION</td>
</tr>
<tr>
<td></td>
<td>Kevin McVary</td>
</tr>
<tr>
<td>8:20</td>
<td>PROSTATE AND TESTIS CANCER</td>
</tr>
<tr>
<td></td>
<td>Laurence Klotz</td>
</tr>
<tr>
<td>8:30</td>
<td>BLADDER AND RENAL CANCER</td>
</tr>
<tr>
<td></td>
<td>Badrinath Konety</td>
</tr>
<tr>
<td>8:40</td>
<td>INVESTIGATIVE UROLOGY</td>
</tr>
<tr>
<td></td>
<td>Karl-Erik Andersson</td>
</tr>
<tr>
<td>8:50</td>
<td>JOURNAL OF UROLOGY LECTURE: SURGICAL ADAPTATION AND ADOPTION OF SKILLS: STAYING RELEVANT IN THE MODERN AGE</td>
</tr>
<tr>
<td></td>
<td>Robert Sweet</td>
</tr>
<tr>
<td>9:00</td>
<td>PRESENTATION OF HONORARY MEMBERS AND SECRETARY COMMENDATIONS FOR GLOBAL LEADERSHIP</td>
</tr>
<tr>
<td>9:15</td>
<td>JOHN K. LATTIMER LECTURE: NET BENEFIT AND CLINICAL DECISION MAKING IN UROLOGY</td>
</tr>
<tr>
<td></td>
<td>Andrew Vickers</td>
</tr>
<tr>
<td>9:35</td>
<td>PRESIDENTIAL ADDRESS</td>
</tr>
<tr>
<td></td>
<td>AUA President: Richard Babayan</td>
</tr>
<tr>
<td>9:55</td>
<td>RAMON GUITERAS LECTURE: WHY THE Y CHROMOSOME?</td>
</tr>
<tr>
<td></td>
<td>David Page</td>
</tr>
<tr>
<td></td>
<td>Sarah Tubett</td>
</tr>
<tr>
<td>10:45</td>
<td>STATE-OF-THE-ART LECTURE: ADVANCES IN ANGIogenesInH InHibitors, ConHrolled Drug DeHivery Systems and Tissue Engineering</td>
</tr>
<tr>
<td></td>
<td>Robert Langer</td>
</tr>
<tr>
<td>11:05</td>
<td>JOURNAL CLUB—EDITOR’S PICK</td>
</tr>
<tr>
<td></td>
<td>Joseph Smith, Prokar Dasgupta, Christian Gratzke, Eric Klein</td>
</tr>
<tr>
<td>11:30</td>
<td>SESSION CONCLUDES</td>
</tr>
<tr>
<td></td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
</tr>
</tbody>
</table>

---

### Plenary: Next Frontier, Saturday Afternoon Session

**Ballroom East @ Boston Convention & Exhibition Center**

**Saturday, May 13, 2017**  
**1:00 pm - 4:00 pm**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation/Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>RISING STARS SPOTLIGHT: UROLOGICAL HEALTH SERVICES RESEARCH: PRACTICE PATTERNS, POLICY, AND PERFORMANCE IMPROVEMENT</td>
</tr>
<tr>
<td></td>
<td>Introduction: Carolyn Best</td>
</tr>
<tr>
<td></td>
<td>Presenter: David Miller</td>
</tr>
<tr>
<td>1:20</td>
<td>UROLOGY CARE FOUNDATION: OUR FOUNDATION. TOGETHER WE CARE</td>
</tr>
<tr>
<td></td>
<td>John Lynch</td>
</tr>
<tr>
<td>1:30</td>
<td>DATA GRANT SHOWCASE</td>
</tr>
<tr>
<td></td>
<td>Benjamin Breyer</td>
</tr>
<tr>
<td>1:40</td>
<td>STATE-OF-THE-ART LECTURE: HOW REGISTRIES ARE CHANGING UROLOGY IN THE UK</td>
</tr>
<tr>
<td></td>
<td>Mark Speakman</td>
</tr>
<tr>
<td>1:55</td>
<td>CRITICAL DISCUSSION: FRILTY AND SURGICAL PLANNING</td>
</tr>
<tr>
<td></td>
<td>Moderator: John Barry</td>
</tr>
<tr>
<td></td>
<td>Panelists: Charles Scales, Anne Suskind</td>
</tr>
</tbody>
</table>

*Presenting author*
2:15 PANEL DISCUSSION: PALLIATIVE AND END-OF-LIFE CARE IN UROLOGY
Moderator: Tomas Griebling
Panelists: Jonathan Bergman, Sharon Levine

2:35 PANEL DISCUSSION: UROLOGIST BURNOUT AROUND THE WORLD: HOW REAL IS THIS PROBLEM?
Moderator: Raj Pruthi
Panelists: John A. Thornhill, Chris Weight, Evanguelos Xylinas

2:55 PANEL DISCUSSION: HOW CAN YOU WORK SMARTER, NOT HARDER?
Moderator: Deepak Kapoor
Panelists: J. Quentin Clemens, Gary Kirsh, Mike McGuire

3:20 CHRONIC URINARY RETENTION WHITE PAPER
John Stoffel

3:30 PATIENT SAFETY INITIATIVES
Timothy Averch

3:40 CHOOSING WISELY
Chris Tessier

3:50 AMERICAN BOARD OF UROLOGY PRESENTATION
H. Ballentine Carter

4:00 SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 13, 2017 1:00 pm - 4:15 pm
Plenary: Prime Time, Saturday Afternoon Session
Ballroom West @ Boston Convention & Exhibition Center

1:00 CROSSFIRE: CONTROVERSIES IN UROLOGY: URETEROSCOPY: HAS THE DUST SETTLED?
Moderator: Gerhard Fuchs
Debater-Basketer: Jodi Antonelli, Sara Best
Debater-Duster: Khurshid Ghani, Olivier Traxer

1:30 SECOND OPINION CASES: ASYMPTOMATIC RENAL CALCULI
Moderator: Roger Low
Panelists: Christian Seitz, Michelle Semins

2:00 SURGICAL TECHNIQUES: PERCUTANEOUS NEPHROLITHOTOMY (PCNL)
Moderator: Peter Alken
Lithotripsy with Shock and Awe: D. Duane Baldwin
Ureteroscope-guided Percutaneous Renal Access in the Supine Position: James Borin
A Pragmatic Approach to PCNL: Brian Matlaga
Minimally Invasive Percutaneous Nephrolithotomy: Julio Davalos, Udo Nagele

3:15 POINT-COUNTERPOINT DEBATE: CA-VIT D IN POST-MENOPAUSAL WOMEN: STONES AND BONES
Moderator: Margaret Pearle
Debater-Pro: David Goldfarb
Debater-Con: Eric Taylor

3:35 POINT-COUNTERPOINT DEBATE: UPPER POLE CALYCEAL DIVERTICULUM
Moderator: Marshall Stoller
Debater-PCNL: Guido Giusti
Debater-URS: Kelly Healy

3:55 SETBACKS AND OPERATIVE SOLUTIONS (SOS): PCNL
Moderator: Bodo Knudsen
Panelists: Benjamin Canales, Mantu Gupta, Amy Krambeck

4:15 SESSION CONCLUDES
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Moderated Poster Session 23
INFECTIONS/INFLAMMATION/CYSTIC DISEASE OF THE GENITOURINARY TRACT: KIDNEY & BLADDER II
Room 151 @ Boston Convention & Exhibition Center
Moderators: Mauro Cervigni, Daniel Shoskes and Michael Whalen

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP23-01</td>
<td>HUMAN URINE-DERIVED STEM CELLS LESSEN INFLAMMATION AND FIBROSIS WITHIN KIDNEY TISSUE IN A RODENT MODEL OF AGING-RELATED RENAL INSUFFICIENCY</td>
</tr>
<tr>
<td>Ting Long*, Yaodong Jiang, Hua Shi, Liren Zhong, Deying Zhang, Wei Li, Yong Zhang, Dong Chen, Yan Jiao, Debra Diz, Yuanyuan Zhang, Winston-Salem, NC</td>
<td></td>
</tr>
<tr>
<td>MP23-02</td>
<td>A STEP TOWARDS CLINICAL APPLICATION OF ACELLULAR MATRIX: A CLUE FROM MACROPHAGE POLARIZATION</td>
</tr>
<tr>
<td>Astgik Petrosyan*, Stefano Da Sacco, Nikita Tripuraneni, Los Angeles, CA, Ursula Kreuser, Nijmegen, Netherlands, Maria Lavarreda-Pearce, Los Angeles, CA, Riccardo Tamburini, Winston Salem, NC, Roger E. De Filippo, Orlando Giuseppe, Los Angeles, CA, Paolo Cravedi, New York, NY, Laura Perin, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>MP23-03</td>
<td>URINE BASED RAPID MOLECULAR DIAGNOSIS OF ZIKA VIRUS</td>
</tr>
<tr>
<td>Laura Lamb*, Sarah Bartolone, Royal Oak, MI, Michael Conway, Maya Tree, Olivia Lossia, Gary Dunbar, Julien Rossignol, Mt. Pleasant, MI, Christopher Smith, Houston, TX, Michael Chancellor, Royal Oak, MI</td>
<td></td>
</tr>
<tr>
<td>MP23-04</td>
<td>COLORIMETRIC, PH-RESPONSIVE MEMBRANES ALLOW FOR IMMEDIATE, REAL-TIME AND REVERSIBLE URINE MONITORING IN A MULTIPART SYSTEM FOR DETECTION OF CHANGES SECONDARY TO UREASE-PRODUCING BACTERIA</td>
</tr>
<tr>
<td>Cory French, Madeline Fuchs, Hammad Huda, Neal Patel*, Brandey Andersen, Kirk Ziegler, Victoria Bird, Gainesville, FL</td>
<td></td>
</tr>
<tr>
<td>MP23-05</td>
<td>USING FEMTOUCH™ IN THE TREATMENT OF WOMEN WITH RECURRENT URINARY TRACT INFECTIONS: FIRST EXPERIENCE IN THE UNITED KINGDOM</td>
</tr>
<tr>
<td>Bob Yang*, Steve Foley, Reading, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>MP23-06</td>
<td>A RANDOMIZED, CONTROLLED TRIAL OF ACTIVE VS. PASSIVE VOIDING TRIALS</td>
</tr>
<tr>
<td>James Mills*, Nathan Shaw, Helen Hougen, Hannah Agard, Robert Case, Timothy McMurry, Noah Schenkmam, Tracey Knupski, Charlottesville, VA</td>
<td></td>
</tr>
<tr>
<td>MP23-07</td>
<td>INTERNATIONAL COMPARISON OF CAUSATIVE BACTERIA AND ANTIMICROBIAL SUSCEPTIBILITIES OF URINARY TRACT INFECTIONS BETWEEN DEVELOPED AND DEVELOPING COUNTRIES</td>
</tr>
<tr>
<td>Katsumi Shigemura*, Koichi Kitagawa, Kobe, Japan, Kuntaman Kuntaman, Surabaya, Indonesia, Toshiro Shirakawa, Masato Fujisawa, Kobe, Japan</td>
<td></td>
</tr>
<tr>
<td>MP23-08</td>
<td>RISK FACTORS FOR RECURRENT URINARY TRACT INFECTION IN URINARY STONE PATIENTS WITH ACUTE OBSTRUCTIVE PYELONEPHRITIS WITHIN 1 YEAR</td>
</tr>
<tr>
<td>Sin Woo Lee*, Sol Yoon, Jinju, Korea, Republic of, Deok Ha Seo, Chunwoo Lee, Changwon, Korea, Republic of, Seong Uk Jeh, See Min Choi, Jinju, Korea, Republic of, Sung Chul Kam, Changwon, Korea, Republic of, Jeong Seok Hwa, Jinju, Korea, Republic of, Ky Hyun Chung, Changwon, Korea, Republic of, Jae Seog Hyun, Jinju, Korea, Republic of</td>
<td></td>
</tr>
<tr>
<td>MP23-09</td>
<td>PRACTICE PATTERNS ACROSS SPECIALTIES IN THE TREATMENT OF WOMEN WITH RECURRENT UTIS IN AN ACADEMIC HEALTHCARE SYSTEM</td>
</tr>
<tr>
<td>Matthew Sterling*, Eliza Lamin, Alexander Skokan, Alan Wein, Ariana Smith, Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>MP23-10</td>
<td>LAPAROSCOPIC VERSUS OPEN NEPHRECTOMY FOR XANTHOGRANULOMATOUS PYELONEPHRITIS: A CONTEMPORARY SERIES</td>
</tr>
<tr>
<td>Justin Benabdallah*, Joel Vetter, Ramakrishna Venkatesh, R. Sherburne Figenahau, St. Louis, MO</td>
<td></td>
</tr>
<tr>
<td>MP23-11</td>
<td>SURGICAL SITE INFECTION AFTER RADICAL CYSTECTOMY – INCIDENCE AND RISK FACTORS</td>
</tr>
<tr>
<td>Hanan Goldberg*, Toronto, Canada, Chen Shenhar, Roy Mano, Jack Daniel, Daniel Kedar, David Margel, Ofer Yosseopowitch, Petach Tiqva, Israel</td>
<td></td>
</tr>
<tr>
<td>MP23-12</td>
<td>ENDOMETRIOSIS – URINARY TRACT INVOLVEMENT AND PREDICTIVE FACTORS FOR MAJOR SURGERY</td>
</tr>
<tr>
<td>Maria José Freire*, Paulo Jorge Dinis, Rita Medeiros, Luis Sousa, Fernanda Águas, Armando Figueiredo, Coimbra, Portugal</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP23-13 TRANSFUSION-DEPENDENT GROSS HEMATURIA REQUIRING SURGICAL MANAGEMENT: ARE OUTCOMES WORSE AMONG PATIENTS WITH PREVIOUS PELVIC RADIATION?
Matthew D. Grimes*, Brady L. Miller, Tyler Wittmann, Sarah E. McCharran, David F. Jarrard, Wade A. Bushman, Daniel H. Williams, Tracy M. Downs, Kyle A. Richards, Sara L. Best, E. Jason Abel, Madison, WI

MP23-14 EN-BLOC STAPLING OF THE RENAL HILUM DURING LAPAROSCOPIC NEPHRECTOMY FOR BENIGN INFLAMMATORY AND INFECTIOUS RENAL PATHOLOGY: A MULTI-INSTITUTIONAL ANALYSIS OF SAFETY AND EFFICACY
Alyssa Greiman*, Charleston, SC, Alexander Chow, Melanie Adamsky, Christopher Coogan, Scott Eggener, Arieh Shalhav, Kalyan Latchamsetty, Chicago, IL, Sandip Prasad, Charleston, SC

MP23-15 EARLY DISCHARGE FOLLOWING DECOMPRESSION FOR SEPSIS AND AN OBSTRUCTING STONE? A MULTI-INSTITUTIONAL STUDY TO IDENTIFY PREDICTORS OF ANTIBIOTIC SENSITIVITY
Timothy Tran*, New York, NY, Madeline Cancian, Providence, RI, Egor Parkhomenko, New York, NY, Gyan Pareek, Providence, RI, Manu Gupta, New York, NY

MP23-16 TARGETED ANTIBIOTIC PROPHYLAXIS CAN PREVENT FEBRILE URINARY TRACT INFECTION AFTER REMOVAL OF URETERAL STENTS IN RADICAL CYSTECTOMY PATIENTS WITH INTESTINAL URINARY DIVERSION.
Yoshitsugu Nasu*, Tadashi Murata, Morito Sugimoto, Atsushi Takamoto, Okayama, Japan, Noriaki Ono, Kochi, Japan

MP23-17 THE CHARACTERISTICS AND PROGRESSION OF BACTERIAL BIOFILMS ON URINARY CATHETERS
Anh Nguyen*, Glenn Werneburg, Jason Kim, Annie Rohan, David Thanassi, Stony Brook, NY

MP23-18 SYNERGISTIC PHOTODYNAMIC THERAPY FOR CATHETER-ASSOCIATED URINARY TRACT INFECTION IN RATS
Anton Wintner*, Yingying Huang, Jeffrey Gelfand, Francis McGovern, Michael Hamblin, Boston, MA

MP23-19 FIBRINOGEN DEPOSITS ON URINARY CATHETERS IN A TIME-DEPENDENT MATTER AND CO-LOCALIZES WITH E. FAECALIS URINE CULTURES

MP23-20 NLRP3/IL-1/H9252 MEDIATES DENERVATION DURING BLADDER OUTLET OBSTRUCTION IN RATS
Robin Lüttolf*, Zurich, Switzerland, Huixia Jin, Francis Monty Hughes, J Todd Purves, Durham, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 13, 2017 7:00 am - 9:00 am

Moderated Poster Session 24
TRAUMA/RECONSTRUCTION/DIVERSION: URETER (INCLUDING PYELOPLASTY) AND BLADDER RECONSTRUCTION (INCLUDING FISTULA), AUGMENTATION, SUBSTITUTION, DIVERSION 1
Room 153 @ Boston Convention & Exhibition Center
Moderators: Kristin Chrousler, Miro Djordjevic and R. Caleb Kovell
MP24-05 UPPER URINARY TRACT DECOMPRESSION USING ILEAL URETER REPLACEMENT IN COMPARISON TO ENDOURETERAL THERMOEXPANDABLE STENT [MEMOKATH 051]
Ilgar Akbarov*, Mustafa Al-Mahmid, David Pfister, Axel Heidenreich, Cologne, Germany

MP24-06 MULTICENTRE STUDY REGARDING THE OUTCOMES OF PYELOPLASTY AND THE ROLE OF FOLLOW UP IMAGING.
Marcelino Yazbek Hanna*, Preston, United Kingdom, Muhammad Elmussareh, Wakefield, United Kingdom, Conor Devlin, Hull, United Kingdom, Peter Smith, Manchester, United Kingdom, Ata Jaffer, Catriona Shenton, Wakefield, United Kingdom, Naeem Desai, Preston, United Kingdom, Muhammad Elmussareh, Wakefield, United Kingdom, Conor Devlin, Manchester, United Kingdom, Anthony Browning, Wakefield, United Kingdom, Andrew Myatt, Hull, United Kingdom, Bachar Zelhif, Preston, United Kingdom

MP24-07 LAPAROSCOPIC DISMEMBERED PYELOPLASTY IN A HORSESHOE KIDNEY
Boris Komyakov, Bakhman Guliev*, Alexander Shipilov, Saint Petersburg, Russian Federation

MP24-08 SECONDARY LAPAROSCOPIC PYELOPLASTY AFTER FAILED OPEN REPAIR OF URETEROPELVIC JUNCTION OBSTRUCTION: CASE- MATCHED MULTI-INSTITUTIONAL STUDY

MP24-09 SINGLE INSTITUTIONAL EXPERIENCE WITH LIGHTED URETERAL STENTS FOR MINIMALLY INVASIVE COLORECTAL SURGERY
Justina Tam*, Wai Lee, Daniel Grajower, Andrew Chen, Stony Brook, NY, Patrick Pfizenmayer, Camden, NJ, Wanye Waltzer, Jason Kim, Stony Brook, NY

MP24-10 UPPER VERSUS LOWER URETERAL RECONSTRUCTION: WHAT ARE THE DIFFERENCES?
Rodrigo R Pessoa*, Lisa M. Parrillo, Paul D. Maroni, Ty T. Higuchi, Brian J. Flynn, Denver, CO

MP24-11 MITROFANOFF APPENDICO-VESICOSTOMY AS A SOLUTION OF DELAYING END STAGE RENAL FAILURE IN CHILDREN: INDICATIONS AND RESULTS
Mohamed Nabil Mhiri*, Mohamed Amine Mseffid, Mohamed Fourati, Anis Masmoudi, Mehdi Bouassida, Mourad Hadj Slimen, Nouri Rebai, Sfax, Tunisia

MP24-12 A MODIFIED ILEO CONDUIT TECNIQUE TO AVOID URETHEROENTERIC STRICTURE.
Mauro Maru*, Alesandra Ambu, Stefano Guercio, Francesco Mangione, Maria Teresa Carchedi, Susanna Grande, Maurizio Bellina, Rivoli (Torino), Italy

MP24-13 MANAGING PREGNANCY IN PATIENTS FOLLOWING COMPLEX UROLOGICAL RECONSTRUCTION
Simon Rajendran, Neha Sihra*, Patrick O’Brien, Dan Wood, London, United Kingdom

MP24-14 NO STOMA, ONE, OR TWO? SETTING EXPECTATIONS FOR PATIENTS WITH RECTOURTHERAL FISTULA
Amanda Chi*, Shree Agrawal, Cleveland, OH, John M Lacy, Knoxville, TN, Hadley M Wood, Kenneth W Angermeier, Cleveland, OH

MP24-15 MANAGEMENT OF PUBIC OSTEOMYELITIS FOLLOWING PELVIC DEBRIDE SENT AND URINARY DIVERSION
Daniel Shapiro*, David Goodspeed, Wade Bushman, Madison, WI

MP24-16 UROSYMPHYSEAL FISTULATION - WHAT’S IN A NAME?
Simon Bugeja*, Stella Ivaz, Stacey Frost, Mariya Dragova, Daniela E Andrich, Anthony R Mundy, London, United Kingdom

MP24-17 NATURAL HISTORY, PREVALENCE, PREDICTORS & OUTCOMES OF PARASTOMAL HERNA AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY
Youssef Ahmed*, Ahmed Hussein, Paul May, Basim Ahmad, Taimoor Ali, Khurshid Guru, Buffalo, NY

MP24-18 DETRUSOR BIOENGINEERING USING COMPRESSED COLLAGEN, ADIPOSE-DERIVED STEM CELLS AND SMOOTH MUSCLE CELLS
Jakub Smolar*, Schlieren, Switzerland, Maya Horst, Daniel Eberli, Zurich, Switzerland

MP24-19 TRANSVESICAL VENTRAL BUCCAL MUCOSA GRAFT INLAY CYSTOPLASTY FOR RECONSTRUCTION OF REFRACTORY BLADDER NECK CONTRACTURES AFTER BENIGN PROSTATIC HYPERPLASIA SURGERY: SURGICAL TECHNIQUE AND PRELIMINARY RESULTS
Rodrigo Donalisio da Silva*, Jeffrey M. Marks, Fernando J. Kim, Brian J. Flynn, Denver, CO

MP24-20 EARLY AMBULATION DECREASES HOSPITAL LENGTH OF STAY IN RENAL TRAUMA: A RANDOMIZED, PROSPECTIVE STUDY
Ilija Aleksic*, Igor Sorokin, Himanshu Aggarwal, Adam Walker, Paul Feustel, Ronald Kaufman, Albany, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT

MP25-01 CURVATURE CORRECTION TECHNIQUES FOR RESIDUAL CURVATURE AFTER PENILE PROSTHESIS PLACEMENT: FROM PERSONAL OPINION TO OBJECTIVE DATA
Gerard Henry*, Shreveport, LA, Ed Karpman, Mountain View, CA, Anthony Bella, Ottawa, Canada, Nelson Bennett, Burlington, MA, Brian Christine, Birmingham, AL, LeRoy Jones, San Antonio, TX, Bryan Kansas, Austin, TX, Mohit Khera, Houston, TX, Tobias Kohler, Springfield, IL, Eugene Rhee, San Diego, CA, Will Brant, Salt Lake City, UT

MP25-02 EXPLORING THE PREDICTORS OF LOW SATISFACTION AFTER PENILE PROSTHESIS IMPLANTATION

MP25-03 NEW DATA REGARDING PENILE LENGTH PRESERVATION AFTER IPP IMPLANTATION
Jared J Wallen*, Tampa, FL, HI Ayoub, OL Westrey, Houston, TX, MS Gross, Hanover, NH, PE Pento, Coral Gables, FL

MP25-04 COST-EFFECTIVENESS OF IPP VERSUS INJECTION TREATMENT IN PATIENTS WHO FAIL ORAL MEDICATION
Nancy Wang*, Remy Lamberts, Stanford, CA, Catherine Harris, San Jose, CA

MP25-05 A SURVEY ON KOREAN UROLOGIST’S PRACTICE PATTERN IN SURGICAL MANAGEMENT OF PREMATURE EJACULATION
Sun Tae Ahn*, Hyeong Guk Jeong, Ji Yun Chae, Jong Wook Kim, Je jong Kim, Du Geon Moon, Seoul, Korea, Republic of

MP25-06 PRESERVATION OF EJACULATION FUNCTION WITH NERVE SPARING IN PATIENTS UNDERGOING RETROPERITONEAL LYMPH NODE DISSECTION.
Sudhir Isharwal*, Sij Hemal, Shree Agrawal, Eric Klein, Andrew Stephenson, Cleveland, OH

MP25-07 OUTCOMES OF INFLATABLE PENILE PROSTHESIS IN PATIENTS EXPOSED TO PELVIC RADIATION
Jeffrey Loh-Doyle*, Zein Nakhoda, Wesley Yip, Nima Nassiri, Stuart Boyd, Los Angeles, CA

ABSTRACT

MP25-08 OUTCOMES OF INFLATABLE PENILE PROSTHESIS AFTER RADICAL CYSTOPROSTATECTOMY AND URINARY DIVERSION
Jeffrey Loh-Doyle, Los Angeles, CA, Mukul Patil, Washington, PA, Hari Sawkar*, Stuart Boyd, Los Angeles, CA

MP25-09 USE OF 3D PRINTING TO PROTOTYPE A CUSTOM SHAPE MEMORY ALLOY PENILE PROSTHESIS
Brian Le*, Madison, WI, Kevin McVary, Alberto Colombo, Springfield, IL

MP25-10 CHARACTERISTICS AND INFECTION RISK IN PATIENTS UNDERGOING MULTIPLE INFLATABLE PENILE PROSTHESSES
Brian Montgomery*, Matthew Ziegelmann, Landon Trost, Rochester, MN

MP25-11 THE RISE OF OUTPATIENT PENILE PROSTHESIS SURGERY: A CROSS-SECTIONAL ANALYSIS OF NATIONAL TRENDS
Richmond Owusu*, San Diego, CA, Karen Seybold, Dongfeng Qi, Guanghui Liu, Minneapolis, MN, Tung-Chin Hsieh, San Diego, CA

MP25-12 DIABETES IS A RISK FACTOR FOR IPP INFECTION: ANALYSIS OF A LARGE STATEWIDE DATABASE

MP25-13 PROSPECTIVE ANALYSIS OF ACCESSORY PUDENDAL ARTERY TRANSSECTION ON POTENCY DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY (RARP)
Stephan Williams, Galveston, TX, Kathym Osann, Orange, CO, Bianca Morales, Boston, MA, Linda Huynh, Douglas Skarecky, Thomas Ahlerring*, Orange, CA

MP25-14 SURGERY FOR INFECTED PENILE PROSTHESES IN NEW YORK STATE: PRACTICE PATTERNS, OUTCOMES AND IMPACT OF SURGEON FACTORS
MP25-15 FACTORS ASSOCIATED WITH INFLATABLE PENILE PROSTHESIS (IPP) EXPLANTATION: EVALUATING THE ROLE FOR POSTOPERATIVE ORAL ANTIBIOTICS ADMINISTRATION
William R. Boysen*, Melanie A. Adamsky, Andrew J. Cohen, Joseph Rodriguez, Sandra Ham, Chicago, IL, Roger Dmochowski, Nashville, TN, Sarah F. Faris, Gregory T. Bales, Chicago, IL, Joshua A. Cohn, Nashville, TN

MP25-16 PENILE REVASCULARIZATION SURGERY IN PATIENTS WITH DIABETIC ERECTILE DYSFUNCTION: LONG TERM RESULTS
Onder Kaygil*, Emrah Okulu, Ankara, Turkey, Fatih Akdemir, Samsun, Turkey

MP25-17 ASSOCIATION OF RADIATION DOSES WITH DEVELOPMENT OF ERECTILE DYSFUNCTION IN PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED WITH PERMANENT PROSTATE BRACHYTHERAPY
Keisuke Shigeta*, Eiji Kikuchi, Masashi Mastushima, Tokyo, Japan, Toshiyuki Ando, Kanagawa, Japan, Takeo Kosaka, Ryuichi Mizuno, Akira Miyajima, Tomoaki Tanaka, Toshi Ohashi, Mototsugu Oya, Tokyo, Japan

MP25-18 OUTCOMES OF MEN UNDERGOING GLANULOPEXY FOR MANAGING SST DEFORMITY WITH PENILE PROSTHESES
Matthew Ziegelmann*, Landon Trost, Rochester, MN

MP25-19 SURVEY ON THE CONTEMPORARY MANAGEMENT OF INTRAOPERATIVE URETHRAL INJURIES DURING PENILE PROSTHESIS IMPLANTATION
Stephanie J. Sexton*, Michael A. Granieri, Aaron C. Lentz, Durham, NC

MP25-20 EVALUATING THE EFFICACY AND SAFETY OF MAGNETIC INDUCTION ACTIVATION OF SHAPE MEMORY PENILE PROSTHESIS THROUGH ANIMAL TISSUE
Alberto Colombo, Kevin McVary, Springfield, IL, Brian Le*, Madison, WI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP26-05 RELAXING EFFECT OF PHOSPHODIESTERASE INHIBITORS AND β3-ADRENOCEPTOR AGONIST IN AN EXPERIMENTAL MODEL OF DETRUSOR OVERACTIVITY
Bruno Lima Linhares*, Lúcio F. Gonzaga-Silva, Rommel P. Regadas, Lucas B. Marinho, João B. G. Carqueira, Manoel O. Moraes Filho, Cláudia F. Santos, Nilberto R. F. Nascimento, Ricardo Reges, Fortaleza, Brazil

MP26-06 NON-HUMAN PRIMATE (NHP) MODEL OF URINARY INCONTINENCE AND ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY
João Zambon*, Manish Patel, Ashok Hemal, Gopal Badlani, Ashley Dean, Shannon Lankford, Koudy Williams, Winston-Salem, NC

MP26-07 INTRAVESICAL ONABOTULINUMTOXIN-A INJECTIONS DECREASE BOTH NERVE GROWTH FACTOR AND BRAIN DERIVED NEUROTROPHIC FACTOR LEVELS IN BLADDER TISSUE AND URINE IN PATIENTS WITH IDIOPATHIC AND NEUROGENIC DETRUSOR OVERACTIVITY
Jai Seth*, Javed Burki, Juliana Ochulor, Rizwan Hamid, London, United Kingdom

MP26-08 TADALAFIL SHOWS THE INHIBITORY ROLE IN UROTHELIAL SIGNAL TRANSDUCTION VIA TRP CHANNELS
Xiao Dong, Shenyang, China, People's Republic of, Hiroshi Nakagomi*, Tatsuya Miyamoto, Tatsuya Ihara, Satoru Kira, Norifumi Sawada, Takahiko Mitsui, Masayuki Takeda, Chuo City, Japan

MP26-09 INVOLVEMENT OF TOLL-LIKE RECEPTOR 4 IN NONBACTERIAL BLADDER INFLAMMATION AND FREQUENT URINATION VIA INFLAMMASOME PATHWAYS IN SPONTANEOUSLY HYPERTENSIVE RATS
Shinsuke Mizoguchi*, Kanichi Mori, Naoyuki Yamanaka, Fuminori Sato, Yufu, Japan, Naoki Yoshimura, Pittsburgh, PA, Hiromitsu Mimata, Yufu, Japan

MP26-10 NEUROGENIC DETRUSOR UNDERACTIVITY: SHOULD WE TARGET THE BLADDER?
Karel Dewulf*, Emmanuel Weyne, Yves Deruyver, Rita Van Bree, Godelieve Verbist, Dirk De Ridder, Maarten Albersen, Wouter Everaerts, Leuven, Belgium

MP26-11 THERAPEUTIC OUTCOMES OF INSULINLIKE GROWTH FACTOR-1 RELEASED FROM ALGINATE-GELEIN MICROBEADS ON STRESS URINARY INCONTINENCE IN RATS WITH SIMULATED CHILDBIRTH INJURY
Hao Yan*, Beijing, China, People’s Republic of, Liren Zhong, Yaodong Jiang, Jian Yang, Winston-Salem, NC, Dan Li Lin, Cleveland, OH, Xiaoyi Yuan, Wuhan, China, People’s Republic of, Mei Kuang, Anna Rietzsch, Cleveland, OH, Emmanuel Opara, Winston-Salem, NC, Margot Damaser, Cleveland, OH, Yuanyuan Zhang, Winston-Salem, NC

MP26-12 MOTOR UNIT NUMBER ESTIMATION OF THE PUBORECTALIS MUSCLE
Nicholas Dias, Yun Peng, Houston, TX, Jingbao He, Ningbo, China, People’s Republic of, Charles Popeney, Sugar Land, TX, Yingchun Zhang*, Houston, TX

MP26-13 PHYSIOLOGIC FACTORS THAT DETERMINE VOLUNTARY DETRUSOR CONTRACTION DURATION IN MALES
Henry Tran*, Arindam RoyChoudhury, Carrie Miyynarczyk, Marissa Theofanides, Gina Badalato, Matthew Rutman, Doreen Chung, New York, NY

MP26-14 A CADAVER MODEL DESCRIBING A NOVEL RETROGRADE APPROACH FOR PERCUTANEOUS PLACEMENT OF AN IMPLANTABLE TIBIAL NERVE STIMULATION LEAD
Larry Sirls*, Kenneth Peters, Royal Oak, MI

MP26-15 INTERPRET UROFLOWMETRY SCIENTIFICALLY: GRADE AND PATTERN
Stephan Shei-Dei Yang*, Shang-Jen Chang, New Taipei City, Taiwan

MP26-16 SUCCINATE IN VOIDING DYSFUNCTION ASSOCIATED WITH METABOLIC SYNDROME
Monica Velasquez Flores*, Abubakr Mossa, Philippe Cammisotto, Lysanne Campeau, Montreal, Canada

MP26-17 URINARY LEVEL OF MONOCYTE CHEMOTACTIC PROTEIN-1 (MCP-1) PREDICTS THE SEVERITY OF SYMPTOM IN PATIENT WITH OVERACTIVE BLADDER (OAB): PILOT PROSPECTIVE STUDY.
Bilal Farhan*, Ahmed Ahmed, Kheira Bettir, Ko Young Hwi, Frank Zaldivair, Gamal Ghoniem, Irvine, CA

MP26-18 TIME-DEPENDENT BLADDER AND URETHRAL DYSFUNCTIONS IN AGING RATS
Takuma Oshiro*, Naha, Okinawa, Japan, Minoru Miyazato, Asuka Ashikari, Seiich Saito, Nishihara, Okinawa, Japan
MP26-19 DOWNREGULATION OF MONOAMINE OXIDASE A MAY CONTRIBUTE TO DEVELOPMENT OF DETRUSOR HYPERCONTRACTILITY IN URINARY BLADDER WITH PARTIAL BLADDER OUTLET OBSTRUCTION IN RATS
Mai Michishita, Izunokuni, Japan, Tsuyoshi Hattori*, Tokyo, Japan, Kazuo Yano, Ken-ichi Tomita, Ken-ichi Kasahara, Izunokuni, Japan

MP26-20 EFFECTS OF DECREASED ESTROGEN ON LOWER URINARY TRACT FUNCTION AND ASSESSMENT OF PURINERGIC SYSTEM CHANGES IN THE GUINEA PIG BLADDER
Nobuhiro Kushida*, Junya Yoshida, Hidenori Akaithana, Kei Ishibashi, Yoshiyuki Kojima, Fukushima, Japan

ABSTRACT
NUMBER  TITLE
MP27-01 CHARACTERISTICS OF PATIENTS WITH PERSISTENT LOWER URINARY TRACT SYMPTOMS AFTER HOLEP IN BPH
Kang Sup Kim*, Yong Sun Choi, Hong Jin Suh, Hyun Woo Kim, Joon Chul Kim, Donh Hwan Lee, Seoul, Korea, Republic of

MP27-02 EFFICACY AND SAFETY OF HOLMIUM LASER ENUCLEATION OF PROSTATE (HOLEP) IN PATIENTS WITH UNDERLYING NEUROLOGIC DISEASE
Myong Kim*, Myung-So Soo Choo, Tai Young Ahn, Seoul, Korea, Republic of

MP27-03 PREDICTION OF URGE URINARY INCONTINENCE (UUI) AFTER HOLMIUM LASER ENUCLEATION OF PROSTATE (HOLEP): REVISITING THE URODYNAMIC DETRUSOR OVERACTIVITY (DO)
Myong Kim*, Tai Young Ahn, Myung-So Choo, Seoul, Korea, Republic of

MP27-04 GIVING UNDERACTIVE BLADDERS A SECOND CHANCE: HOLMIUM LASER ENUCLEATION OF THE PROSTATE FOR MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH DETRUSOR UNDERACTIVITY.
Garrett Smith*, Dongliang Wang, Jessica E. Paoneesa, Syracuse, NY

MP27-05 PROSPECTIVE STUDY COMPARING SAFETY AND EFFICACY OF HOLEP FOR RECURRENT BPH AFTER INITIAL TURP
Hemendra Shah*, Rashmi Shah, Mumbai, India

MP27-06 DOES A PARTIAL PROSTATE RESECTION IMPROVE VOIDING SYMPTOMS WHILE SHORTENING THE LEARNING CURVE FOR HOLEP?
Saum Ghodoussipour*, Adith Shah, Eli Thompson, Anirban Mitra, Matthew Dunn, Los Angeles, CA

MP27-07 CAN WE PREDICT THE LEARNING CURVE FOR HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) BY USING SIMULTANEOUS PARAMETER OF ENUCLEATION-MORCELLATION?
Sung Tae Cho*, Don Kyoung Choi, Ohseong Kwon, Young Goo Lee, Ki Kyung Kim, Seoul, Korea, Republic of, Kyungtae Ko, Seoul, Korea, Republic of

MP27-08 ASSESSMENT OF THE LEARNING CURVES FOR INTRAVESICAL ADENOMA MORCELLATION USING PIRANHA© DEVICE DURING ENDOSCOPIC ENUCLEATION
Benjamin Pradere*, Tours, France, Benoit Peyronnet, Rennes, France, Benoit Bordier, Julien Guillotreau, Toulouse, France, Kevin Zorn, Montreal, Canada, Vincent Misraï, Toulouse, France

MP27-09 PREDICTORS OF POSTOPERATIVE BACTERIURIA AFTER HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP)
Amr Elmekresh*, Victor Villarreal II, Jordyn Farewell, Karen Doersch, Marawan El Tayeb, Temple, TX
MP27-10 ROLE OF DEBULKING PROCEDURES IN MEN WITH PROSTATES LESS THAN 40 GRAMS.
Ramy Goueli*, Lesa Deonarine, Dominique Thomas, Kristina Navrazhina, New York, NY, Kelsey Lawson, Malek Meskawi, Marc Zanaty, Montreal, Canada, Vincent Misrai, Toulouse, France, Roger Valdivieso, Pierre-Alain Hueber, Kevin Zorn, Montreal, Canada, Alexis Te, Bilal Chughtai, New York, NY

MP27-11 COMPLICATIONS AND FUNCTIONAL OUTCOMES OF HIGH-RISK PATIENT WITH CARDIOVASCULAR DISEASE NECESSITATING ACO TREATED WITH THE 532NM-LASER PHOTO-VAPORIZATION GREENLIGHT XPS 180W
Roger Valdivieso*, Pierre-Alain Hueber, Malek Meskawi, Kelsey Lawson, Mounsif Azizi, Montreal, Canada, Benjamin Pradere, Toulouse, France, Kevin Zorn, Montreal, Canada, Vincent Misrai, Toulouse, France

MP27-12 GREENLIGHT LASER (XPS) 180W PHOTOSELECTIVE VAPORIZATION (PV) VS. PLASMA KINETIC VAPORIZATION OF THE PROSTATE (PKVP) FOR TREATMENT OF SMALL TO MODERATE SIZED BENIGN PROSTATIC HYPERPLASIA. A RANDOMIZED CONTROLLED TRIAL

MP27-13 RANDOMIZED STUDY OF GREENLIGHT XPS LASER VS BIPOLAR VAPORIZATION ELECTRODE (BIVAP) SALINE VAPORIZATION OF THE PROSTATE IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
Jonathan Fainberg*, Joshua Halpern, New York, NY, Edward Zoltan, Ivan Colon, Brent Yanke, Ivan Grunberger, Brooklyn, NY

MP27-14 COMBINED BIPOLAR VAPORIZATION AND RESECTION VERSUS VAPORIZATION ALONE IN TREATMENT OF BPH: A RANDOMIZED PROSPECTIVE TRIAL
Osama Abdelwahab*, Tarek Soliman, Hammoda Sheriff, Benha, Egypt, Mohamed Habous, Jeddah, Saudi Arabia

MP27-15 READMISSION FOLLOWING TRANSURETHRAL PROSTATECTOMY FOR TREATMENT OF BENIGN PROSTATE HYPERPLASIA IN THE POST TURP ERA; DOES THE TECHNIQUE DIFFER?

MP27-16 SURGEON-SPECIFIC VARIATION FOR OUTCOMES AFTER BENIGN PROSTATIC HYPERPLASIA SURGERY
John Weaver*, Saint Louis, MO, Eric Kim, Joel Vetter, Niraj Badhiwala, Seth Strope, Saint Louis, MO

MP27-17 3 YEAR RESULTS OF A PROSPECTIVE MULTI-CENTER STUDY ON LOCAL ANESTHESIA FOR THE PROSTATIC URETHRAL LIFT (PUL)
Steven Gange*, Salt Lake City, UT, Neal Shore, Myrtle Beach, SC, Sheldon Freedman, Las Vegas, NV, William Moseley, San Diego, CA, Sean Heron, St. Petersburg, United Arab Emirates, Ronald Tutrone, Baltimore, MD, Thomas Brown, Daytona Beach, FL, Jack Barkin, Toronto, Canada

MP27-18 CROSSOVER STUDY ON THE PROSTATIC URETHRAL LIFT (PUL): 4 YEAR RESULTS
Henry Woo*, Sydney, Australia, Jack Barkin, Toronto, Canada, Damien Bolton, Heidelberg, Australia, Prem Rashid, Port Macquarie, Australia, Anthony Cantwell, Daytona Beach, FL, William Bogache, Myrtle Beach, SC, Stephen Richardson, Salt Lake City, UT, Ronald Tutrone, Baltimore, MD, James Fagelson, Englewood, CO, Peter Chin, Figtree, Australia

MP27-19 POOLED DATA FROM COMMERCIAL CASES USING THE UROLIFT ® DEVICE
Paul Cozzi*, Miranda, Australia, Lance Walsh, Rancho Mirage, CA, Douglass Grier, Edmonds, WA, Andrew Hirsh, Somers Point, NJ, Gregg Eure, Virginia Beach, VA

MP27-20 CONVECTIVE RADIOFREQUENCY WATER VAPOR ENERGY PROSTATE ABLATION (REZUM ®) EFFECTIVELY TREATS URINARY RETENTION

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP28-01 A 17-GENE PANEL FOR PREDICTION OF ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY: PROSPECTIVE VALIDATION
Scott Eggener*, Chicago, IL, Tim Richardson, Wichita, KS, Steven Rosenberg, Des Moines, IA, Evan Goldfischer, Poughkeepsie, NY, Ruixiao Lu, Redwood City, CA, Allan Shindel, John Bennett, Redwood City, CA, Lawrence Karsh, Denver, CO, Howard Korman, Roaylor Oak, MI, Phillip Febo, Bela Denes, Redwood City, CA

MP28-02 PHYSIOLOGICAL EVIDENCE OF DNA DAMAGE BY CARCINOGENS KNOWN TO BE PRESENT IN CHARRED AND PROCESSED MEATS (PHIP DNA ADDUCTS), IN A SMALL COHORT OF PROSTATE CANCER PATIENTS.
Christopher Weight*, Shun Xiao, Jingshu Guo, Byeong Hwa Yun, Badrinath Konety, Peter Villalta, Resha Tejpaul, Minneapolis, MN, Suprita Krishna, Minneapolis, MN, Paari Murugan, Minneapolis, MN, Robert Turesky, Minneapolis, MN

MP28-03 ALTERATION OF METASTATIC BEHAVIOR BY SHRNA MEDIATED KNOCKDOWN (KD) OF CHD1 IN HUMAN PROSTATE XENOGRAFT TUMORS AND CLINICAL OUTCOME OF PATIENTS WITH CHD1 DELETION
Su Jung Oh*, Derya Tilki, Christiane Matuszcak, Pierre Tennstedt, Hamburg, Germany, Simon Baumgart, Steven A. Johnsen, Göttingen, Germany, Hüseyin Sirma, Ronald Simon, Tobias Lange, Hamburg, Germany

MP28-04 SENSITIVITY OF [-2]PROPSA (P2PSA) MEASUREMENTS FOR PREDICTION OF BIOCHEMICAL RECURRENCE (BCR) IN MEN AFTER RADICAL PROSTATECTOMY: A 3-YEARS PROSPECTIVE COHORT STUDY
Massimo Lazzeri*, Giovanni Lugezzani, Nicolò Maria Buffi, Giuliana Lista, Paolo Casale, Rodolfo Hurle, Alberto Salti, Silvia Zandegiacomo, Luisa Pasini, Alessio Benetti, Roberto Peschechera, Pasquale Cardone, Rozzano, Italy, Ferruccio Ceriotti, Marina Pontillo, Milano, Italy, Vittorio Bini, Perugia, Italy, Giorgio Guazzoni, Rozzano, Italy

MP28-05 A COMBINATION OF NEW PROTEIN BIOMARKERS REDUCES UNNEEDED PROSTATE BIOPSIES AND IMPROVES THE DETECTION OF PROSTATE CANCER: FINDINGS OF A RECENT STUDY
Pierre Tennstedt*, Thomas Steuber, Hamburg, Germany, Annalisa Macagno, Bruno Golding, Ralph Schiess, Schlieren, Switzerland, Silke Gilleissen, St. Gallen, Switzerland

MP28-06 A NOVEL SERUM BASED MULTIPLEXED 21 AUTOANTIBODY ASSAY TO PREDICT HIGH-GRADE PROSTATE CANCER AT INITIAL BIOPSY
Stephen Freedland*, Los Angeles, CA, Shrat Singh, Kalamazoo, MI, Kristopher Kapphahn, Palo Alto, CA, Lauren Howard, Durham, NC, Jeanne Ohmberger, Kalamazoo, MI, Jason Hafron, Troy, MI

MP28-07 AN AUTOMATED-MICROCAPILLARY ELECTROPHORESIS-BASED IMMUNOASSAY SYSTEM MAY IMPROVE DIAGNOSTIC ACCURACY OF PROSTATE CANCER AND BE A GOOD INDICATOR OF GLEASON SCORE
Tomokazu Ishikawa*, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakayama, Hiroasaki, Japan, Tatsuuo Kurosawa, Kenji Nakamura, Amagasaki, Japan, Takuya Koie, Yasuhiro Hashimoto, Chikara Ohyama, Hiroasaki, Japan

MP28-08 REFUSAL OF PROSTATE-SPECIFIC ANTIGEN TESTING IN THE UNITED STATES
Philipp Gild*, Nicolas von Landenberg, Nawar Hanna, Ye Wang, Steven L Chang, Boston, MA, Mani Menon, Detroit, MI, Felix K.H. Chum, Margit Fisch, Hamburg, Germany, Quoc-Dien Trinh, Boston, MA

MP28-09 HIGH SERUM DEHYDROEPIANDROSTERONE EXAMINED BY ULTRASENSITIVE LIQUID-CHROMATOGRAPHY TANDEM MASS SPECTROMETRY AS A PREDICTOR OF BENIGN PROSTATE OR GLEASON SCORE ≤7 CANCER IN MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS BELOW 10 NG/ml
Yasuhide Miyoshi, Hiroto Uemura, Yokohama, Japan, Kazuhiro Suzuki, Yasuhiro Shibata, Maebashi, Japan, Seijiro Homma, Kawasaki, Japan, Masaaki Harada, Yoshinobu Kubota, Yutaro Hayashi*, Yokohama, Japan

*Presenting author
MP28-10 PANEL OF 6 MICRORNAS FOR MINIMALLY INVASIVE DIAGNOSIS OF PROSTATE CANCER
Boris Alekseev*, Evgeniy Knyazev, Maksim Shkurnikov, Dmitriy Mikhailenko, Alexandr Zolikov, Kirill Nuyashko, Alexandr Tonevitskiy, Andrey Kaprin, Moscow, Russian Federation

MP28-11 IMPACT OF THE 17-GENE PANEL ON ACTIVE SURVEILLANCE PERSISTENCE IN CONTEMPORARY UROLOGIC PRACTICES: AN INTERIM ANALYSIS IN AN OBSERVATIONAL COHORT
Gregg Eure*, Virginia Beach, VA, Raymond Germany, Shreveport, LA, Robert Given, Virginia Beach, VA, Richard Glowacki, West Des Moines, IA, Tim Richardson, Wichita, KS, Evan Goldfischer, Poughkeepsie, NY, Ruixiao Lu, Alan Shindel, John Bennett, Phil Febbo, Bela Denes, Redwood City, CA

MP28-12 IMPACT OF LYMPHOVASCULAR INVASION ON LYMPH NODE METASTASIS FOR T3 PATIENTS UNDERGOING RADICAL PROSTATECTOMY IN CONSIDERATION OF RESECTION MARGIN STATUS
Yong Jin Kang*, Won Sik Jang, Myung Soo Kim, Won Sik Jung, Cheol Yong Yoon, Seoul, Korea, Republic of, In Rae Cho, Gimhae, Korea, Republic of, Young Deuk Choi, Seoul, Korea, Republic of

MP28-13 PROGNOSTIC UTILITY OF BIOPSY-DERIVED CELL CYCLE PROGRESSION SCORE IN PATIENTS WITH NCCN LOW-RISK PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY: IMPLICATIONS FOR TREATMENT GUIDANCE
Jeffrey Tosoian, Meera Chappidi*, Baltimore, MD, Jay Bishoff, Murray, UT, Stephen Freedland, Durham, NC, Julia Reid, Michael Brawer, Steven Stone, Salt Lake City, UT, Thorsten Schlomm, Hamburg, Germany, Ashley Ross, Baltimore, MD

MP28-14 DECREASED EXPRESSION OF MALE SPECIFIC HISTONE DEMETHYLASE “KDM5D” IS PROGNOSTIC FOR DEVELOPMENT OF CASTRATION-RESISTANT PROSTATE CANCER
Kazumasa Komura*, Takatsuki, Japan, Seong Ho Jeong, HERSHEY, PA, Haruhito Azuma, Takatsuki, Japan, Gwo-Shu Lee, Christopher Sweeney, Boston, MA, Philip Kantoff, New York, NY

MP28-15 MODIFIED GLASGOW PROGNOSTIC SCORE AS AN INDEPENDENT PREDICTOR OF SURVIVAL IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Junpei lizuka*, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi, Keisuke Hata, Taichi Kanzawa, Daigo Okada, Kazuhiro Yoshida, Kazunari Tanabe, Tokyo, Japan

MP28-16 PROSTATIC TISSUE ANDROGEN LEVELS AS PROGNOSTIC FACTOR FOR MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Yasuhide Miyoshi*, Takashi Kawahara, Mari Ohtaka, Sohgo Tsutsumi, Koichi Uemura, Masato Yasui, Shuko Yoneyama, Yumiko Yokomizo, Narihiko Hayashi, Hiroji Uemura, Yokohama, Japan

MP28-17 IMMUNOHISTOCHEMICAL STAINING OF ERG AND SOX9 AS POTENTIAL BIOMARKERS OF DOCETAXEL RESPONSE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Song Wan*, Ghee Young Kwon, Jeong Hoon Kim, Young Eun Lim, Young Hye Choi, Hyun Woo Chung, Chung Un Lee, Jun Phil Na, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, Hyun Moo Lee, Seoul, Korea, Republic of

MP28-18 IMPLEMENTATION OF PROSTATE BIOSPY TISSUE PRINT TECHNOLOGIES FOR MOLECULAR BIOMARKER STUDIES
Sandra Gaston*, Boston, MA, Peter Kolettis, James Bryant, Soroush Rais-Bahrami, Jeffrey Nix, Mark DeGuenther, Birmingham, AL, Michael Kearney, Boston, MA, George Adams, William Grizzle, Birmingham, AL, Gary Kearney, Boston, MA

MP28-19 EVALUATING THE PROGNOSTIC UTILITY OF THE CCP SCORE FOR PREDICTING PROSTATE CANCER AGGRESSIVENESS IN AFRICAN AMERICAN MEN
Stephen Bardot*, Harahan, LA, Julia Reid, Salt Lake City, UT, Maria Latsis, Margaret Variano, Shams Halat, Daniel Canter, Harahan, LA, Zaina Sangale, Michael Brawer, Steven Stone, Salt Lake City, UT

MP28-20 EXPRESSION OF HMGB1 IN PROSTATE CANCER: CLINICAL AND BIOLOGICAL CORRELATIONS
Yong Hyun Park*, Ae Ryang Jung, Jin Bong Choi, U-Syn Ha, Sung-Hoo Hong, Sae Woong Kim, Ji Youl Lee, Seoul, Korea, Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
## Podium Session 16

**STONE DISEASE: SURGICAL THERAPY I**

**Room 162 @ Boston Convention & Exhibition Center**

**Moderators:** Jodi Antonelli, Brian Eisner and Ali Kural

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD16-01</td>
<td>ENDOSCOPIC DESCRIPTION OF RENAL PAPILLARY ABNORMALITIES IN STONE DISEASE BY FLEXIBLE URETEROSCOPY - A PROPOSED CLASSIFICATION OF SEVERITY AND TYPE.</td>
<td>Christophe Almeras*, Toulouse, France - Metropolitan, Michel Daudon, Paris, France, Guillaume Ploussard, Jean Romain Gautier, Toulouse, France, Olivier Traxter, Paul Meria, Paris, France</td>
</tr>
<tr>
<td>7:10</td>
<td>PD16-02</td>
<td>MODIFIED ERGONOMIC LITHOTRIPSY (MEL): A PROSPECTIVE SINGLE CENTRE STUDY DEMONSTRATING A NOVEL METHOD FOR RETROGRADE INTRARENAL SURGERY (RIRS) TO ACHIEVE HIGH STONE FREE RATES WITHOUT SURGEON FATIGUE</td>
<td>Vineet Gauhar*, Sarvajit Biligere, Girider Swaminathan, Ruo Xuan Goh, Chin Tiong Heng, Singapore, Singapore</td>
</tr>
<tr>
<td>7:20</td>
<td>PD16-03</td>
<td>A DECISION ANALYSIS MODEL OF OBSERVATION VS. IMMEDIATE RE-INTERVENTION FOR ASYMPTOMATIC RESIDUAL FRAGMENTS &gt; 4MM FOLLOWING URETEROSCOPIC LITHOTRIPSY: A STUDY FROM THE EDGE CONSORTIUM</td>
<td>Michal Ursiny*, Alan Yaghoubian, Boston, MA, Mitchell Humphreys, Scottsdale, AZ, Hillary Brotherhood, Benjamin Chew, Vancouver, Canada, Manoj Monga, Cleveland, OH, Amy Krambeck, Amy Krambeck, Indianapolis, IN, Cameron Charchenko, Scottsdale, AZ, An Qi Wang, Roger Sur, San Diego, CA, Nicole Miller, Tracy Marien, Nashville, TN, Yui-Hui Chang, Scottsdale, AZ, Bodo Knudsen, Courtney Yong, Columbus, OH, Brian Matlaga, Baltimore, MD, Vernon Pais, Lebanon, NH, Ojas Shah, New York, NY, Brian Eisner, Boston, MA</td>
</tr>
<tr>
<td>7:30</td>
<td>PD16-04</td>
<td>INFECTION PREVENTION BUNDLE FOR UPPER TRACT ENDOSCOPY FOR UROLITHIASIS</td>
<td>Dennis Joseph Thum*, Santa Monica, CA, Ali Afsar, California, CA, Justin Houman, Devin Patel, Alex Hannemann, Los Angeles, CA, Gerhard Fuchs, California, CA</td>
</tr>
<tr>
<td>7:40</td>
<td>PD16-05</td>
<td>FACTORS ASSOCIATED WITH POST-OPERATIVE INFECTION AFTER PERCUTANEOUS NEPHROLITHOTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
<td>Win Shun Lai*, Dean Assimos, Birmingham, AL</td>
</tr>
<tr>
<td>7:50</td>
<td>PD16-06</td>
<td>INCREASING THE SIZE OF URETERAL ACCESS SHEATH DURING RETROGRADE INTRARENAL SURGERY IMPROVES SURGICAL EFFICIENCY WITHOUT INCREASING COMPLICATIONS</td>
<td>Chad Tracy, George Ghareeb*, Charles Paul, Nathan Brooks, Iowa City, IA</td>
</tr>
<tr>
<td>8:00</td>
<td>PD16-07</td>
<td>DETERMINING OPTIMAL STENT DURATION FOLLOWING URETEROSCOPY: 3 VS 7 DAYS</td>
<td>Charles Paul, Nathan Brooks*, George Ghareeb, Chad Tracy, Iowa City, IA</td>
</tr>
<tr>
<td>8:10</td>
<td>PD16-08</td>
<td>IMPACT OF PRIOR URETERAL STENT ON FUTURE TREATMENT DECISIONS: EDGE MULTI-INSTITUTIONAL SURVEY.</td>
<td>Annah Vollstedt*, Rajiv Raghavan, Lebanon, NH, Manoj Monga, Anna Zampini, Cleveland, OH, Ojas Shah, Rafael Yanes, Stephanie Thompson, New York, NY, Vernon Pais Jr, Lebanon, NH</td>
</tr>
<tr>
<td>8:20</td>
<td>PD16-09</td>
<td>EXTERNALIZED URETERAL CATHETER VERSUS DOUBLE J STENTING IN TUBELESS PERCUTANEOUS NEPHROLITHOTOMY: A PROSPECTIVE, RANDOMIZED STUDY.</td>
<td>Gyanprakash Singh, Datteswar Hota*, Sabyasachi Panda, Samir Swain, Pramod Kumar Mohanty, CUTTACK, India</td>
</tr>
<tr>
<td>8:30</td>
<td>PD16-10</td>
<td>IS PCNL A SAFE AND EFFECTIVE OPTION FOR OCTOGENARIAN PATIENT?. ANALYSIS OF OVER 4000 CASES FROM A NATIONAL DATABASE.</td>
<td>Stuart Irving, Norwich, United Kingdom, Oliver Wiseman*, Cambridge, United Kingdom, William Finch, Norwich, United Kingdom, James Armitage, Cambridge, United Kingdom, Sarah Fowler, John Withington, Jonathan Glass, London, United Kingdom, Neil Burgess, Norwich, United Kingdom</td>
</tr>
<tr>
<td>8:40</td>
<td>PD16-11</td>
<td>PERCUTANEOUS MANAGEMENT OF CALYCEAL DIVERTICULA: ASSOCIATED FACTORS AND OUTCOMES</td>
<td>Egor Parkhomenko*, Timothy Tran, Kyle Blum, Julie Thai, Mantu Gupta, NY, NY</td>
</tr>
</tbody>
</table>

*Presenting author
8:50 PD16-12 A COMPARISON AMONG PCNL, MINIPERC AND ULTRAMINIPERC FOR LOWER CALYCEAL STONES BETWEEN 1 AND 2 CM: A MULTICENTER EXPERIENCE
Serena Maruccia*, Stefano Casellato, Monza, Italy, Gianluigi Taverna, Castellanza, Italy, Javier Romero Otero, Madrid, Spain, Francesco Sanguedolce, London, United Kingdom, orietta dal piaz, graz, Austria, emanuele montanari, MILANO, Italy, paolo verze, vincenzo mirone, Napoli, Italy, Giorgio Bozzini, Castellanza, Italy

8:50 PD16-12 A COMPARISON AMONG PCNL, MINIPERC AND ULTRAMINIPERC FOR LOWER CALYCEAL STONES BETWEEN 1 AND 2 CM: A MULTICENTER EXPERIENCE
Serena Maruccia*, Stefano Casellato, Monza, Italy, Gianluigi Taverna, Castellanza, Italy, Javier Romero Otero, Madrid, Spain, Francesco Sanguedolce, London, United Kingdom, orietta dal piaz, graz, Austria, emanuele montanari, MILANO, Italy, paolo verze, vincenzo mirone, Napoli, Italy, Giorgio Bozzini, Castellanza, Italy

Saturday, May 13, 2017
Podium Session 17
URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: PELVIC PROLAPSE II
Room 161 @ Boston Convention & Exhibition Center
Moderators: Kathleen Kobashi and Lenaine Westney

7:00 PD17-01 A SUBANALYSIS OF A RANDOMIZED CONTROLLED TRIAL: ABDOMINAL VS LAPAROSCOPIC SACROCOLPOPEXY
Ester Illiano*, Luigi Mearini, Alessandro Zucchi, Manuel Di Biase, Elisabetta Costantini, Perugia, Italy

7:00 PD17-01 A SUBANALYSIS OF A RANDOMIZED CONTROLLED TRIAL: ABDOMINAL VS LAPAROSCOPIC SACROCOLPOPEXY
Ester Illiano*, Luigi Mearini, Alessandro Zucchi, Manuel Di Biase, Elisabetta Costantini, Perugia, Italy

7:10 PD17-02 THE IMPACT OF CONCURRENT PROCEDURES ON PERIOPERATIVE OUTCOMES AMONG WOMEN UNDERGOING ABDOMINAL SACROCOLPOPEXY: MIDURETHRAL SLING PLACEMENT IS ASSOCIATED WITH INCREASED RISK OF COMPLICATION
William R. Boysen*, Andrew Cohen, Melanie Adamsky, Joseph Rodriguez, Sarah Faris, Gregory Bales, Chicago, IL

7:10 PD17-02 THE IMPACT OF CONCURRENT PROCEDURES ON PERIOPERATIVE OUTCOMES AMONG WOMEN UNDERGOING ABDOMINAL SACROCOLPOPEXY: MIDURETHRAL SLING PLACEMENT IS ASSOCIATED WITH INCREASED RISK OF COMPLICATION
William R. Boysen*, Andrew Cohen, Melanie Adamsky, Joseph Rodriguez, Sarah Faris, Gregory Bales, Chicago, IL

7:20 PD17-03 MATCHED PAIR ANALYSIS COMPARING HEAVY WEIGHT VERSUS LIGHTER WEIGHT WIDE PORE POLYPOLYPROPYLENE MESH FOR ROBOTIC SACROCOLPOPEXY
Robert Carey*, Ali Harris, Maximilian Carey, Karim Ghazli, Sarasota, FL

7:20 PD17-03 MATCHED PAIR ANALYSIS COMPARING HEAVY WEIGHT VERSUS LIGHTER WEIGHT WIDE PORE POLYPOLYPROPYLENE MESH FOR ROBOTIC SACROCOLPOPEXY
Robert Carey*, Ali Harris, Maximilian Carey, Karim Ghazli, Sarasota, FL

7:30 PD17-04 POLYVINYLIDENFLUORID (PVDF) VERSUS POLYPROPYLENE (PP) MESH FOR SACROCOLPOPEXY
Manuel Di Biase*, Illiano Ester, Elena Sarti, Alessandro Zucchi, Perugia, Italy, Raffaele Balsamo, Catanzaro, Italy, Antonio Pastore, Latina, Italy, Elisabetta Costantini, Perugia, Italy

7:30 PD17-04 POLYVINYLIDENFLUORID (PVDF) VERSUS POLYPROPYLENE (PP) MESH FOR SACROCOLPOPEXY
Manuel Di Biase*, Illiano Ester, Elena Sarti, Alessandro Zucchi, Perugia, Italy, Raffaele Balsamo, Catanzaro, Italy, Antonio Pastore, Latina, Italy, Elisabetta Costantini, Perugia, Italy

7:40 PD17-05 LAPAROSCOPIC VERSUS ROBOTIC ASSISTED SACROCOLPOPEXY: A RANDOMIZED, CONTROLLED TRIAL
Ester Illiano*, Manuel Di Biase, Perugia, Italy, Pasquale Di Tono, Gaetano De Rienzo, Bari, Italy, Alessandro Zucchi, Luigi Mearini, Daniele Maglia, Elisabetta Costantini, Perugia, Italy

7:40 PD17-05 LAPAROSCOPIC VERSUS ROBOTIC ASSISTED SACROCOLPOPEXY: A RANDOMIZED, CONTROLLED TRIAL
Ester Illiano*, Manuel Di Biase, Perugia, Italy, Pasquale Di Tono, Gaetano De Rienzo, Bari, Italy, Alessandro Zucchi, Luigi Mearini, Daniele Maglia, Elisabetta Costantini, Perugia, Italy

7:50 PD17-06 DIRECT TO CONSUMER ADVERTISING FOR ROBOTIC ASSISTED SACROCOLPOPEXY: ARE PATIENTS GETTING THE RIGHT INFORMATION?
Brent Medoff*, Scranton, PA, Juzar Jammagerwalla, Los Angeles, CA, Dominique Dana Marie Thomas, Bilal Chughtai, New York City, NY, Jennifer T. Anger, Los Angeles, CA

7:50 PD17-06 DIRECT TO CONSUMER ADVERTISING FOR ROBOTIC ASSISTED SACROCOLPOPEXY: ARE PATIENTS GETTING THE RIGHT INFORMATION?
Brent Medoff*, Scranton, PA, Juzar Jammagerwalla, Los Angeles, CA, Dominique Dana Marie Thomas, Bilal Chughtai, New York City, NY, Jennifer T. Anger, Los Angeles, CA

8:00 PD17-07 AUTOLOGOUS FASCIA SACROCOLPOPEXY AFTER COMPLETE REMOVAL OF SACROCOLPOPEXY MESH
Andrew Medendorp*, Zaid Chaudhry, Janine Oliver, Lauren Wood, Ja-Hong Kim, Zachery Baxter, Shlomo Raz, Los Angeles, CA

8:00 PD17-07 AUTOLOGOUS FASCIA SACROCOLPOPEXY AFTER COMPLETE REMOVAL OF SACROCOLPOPEXY MESH
Andrew Medendorp*, Zaid Chaudhry, Janine Oliver, Lauren Wood, Ja-Hong Kim, Zachery Baxter, Shlomo Raz, Los Angeles, CA

8:10 PD17-08 IS VAGINAL MESH A STIMULUS OF AUTOIMMUNE DISEASE?
Bilal Chughtai*, Art Sedrakyan, Jialin Mao, New York, NY, Karyn S. Eilber, Los Angeles, CA, Jennifer T. Anger, Los Angeles, CA, J. Quentin Clemens, Ann Arbor, MI

8:10 PD17-08 IS VAGINAL MESH A STIMULUS OF AUTOIMMUNE DISEASE?
Bilal Chughtai*, Art Sedrakyan, Jialin Mao, New York, NY, Karyn S. Eilber, Los Angeles, CA, Jennifer T. Anger, Los Angeles, CA, J. Quentin Clemens, Ann Arbor, MI

8:20 PD17-09 FIVE-YEAR EXPERIENCE WITH PELVIC FLOOR MESH EXPLANT SURGERY: PATIENT CHARACTERISTICS AND PATIENT REPORTED OUTCOMES
Elliot Blau*, Sarah Adelstein, Alvaro Lucioni, Kathleen Kobashi, Una Lee, Seattle, WA

8:20 PD17-09 FIVE-YEAR EXPERIENCE WITH PELVIC FLOOR MESH EXPLANT SURGERY: PATIENT CHARACTERISTICS AND PATIENT REPORTED OUTCOMES
Elliot Blau*, Sarah Adelstein, Alvaro Lucioni, Kathleen Kobashi, Una Lee, Seattle, WA

8:30 PD17-10 VAGINAL MESH REMOVAL OUTCOMES: EIGHT YEARS OF EXPERIENCE AT AN ACADEMIC HOSPITAL
Olivia O. Cardenas-Trowers*, Pouran Malekzadeh, David E. Nix, Kenneth D. Hatch, Tucson, AZ

8:30 PD17-10 VAGINAL MESH REMOVAL OUTCOMES: EIGHT YEARS OF EXPERIENCE AT AN ACADEMIC HOSPITAL
Olivia O. Cardenas-Trowers*, Pouran Malekzadeh, David E. Nix, Kenneth D. Hatch, Tucson, AZ

8:40 PD17-11 LONG-TERM FOLLOW-UP OF ANTERIOR VAGINAL REPAIR: A COMPARISON AMONG COLPORRAPHY, COLPORRAPHY WITH REINFORCEMENT BY XENOGR AFT, AND MESH
Matteo Balzarro*, Emanuele Rubilotta, Antonio Benito Porcaro, Nicolò Trabacchin, Sarti Alessandra, Maria Angela Cerruto, Salvatore Siracusano, Walter Artibani, Verona, Italy

8:40 PD17-11 LONG-TERM FOLLOW-UP OF ANTERIOR VAGINAL REPAIR: A COMPARISON AMONG COLPORRAPHY, COLPORRAPHY WITH REINFORCEMENT BY XENOGR AFT, AND MESH
Matteo Balzarro*, Emanuele Rubilotta, Antonio Benito Porcaro, Nicolò Trabacchin, Sarti Alessandra, Maria Angela Cerruto, Salvatore Siracusano, Walter Artibani, Verona, Italy
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Time</th>
<th>Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:50</td>
<td>PD17-12</td>
<td>TWENTY-YEAR EXPERIENCE WITH THE ANTERIOR VAGINAL WALL SUSPENSION PROCEDURE: A NATIVE TISSUE VAGINAL REPAIR FOR STRESS URINARY INCONTINENCE WITH EARLY STAGE ANTERIOR COMPARTMENT PROLAPSE Alexander Rozanski*, Philippe Zimmer, Alana Christie, Feras Alhalabi, Dallas, TX</td>
<td>7:50</td>
<td>PD18-06</td>
<td>5 YEARS FOLLOW-UP OF A PROSPECTIVE RANDOMISED CONTROLLED TRIAL COMPARING LAPAROSCOPIC VERSUS ROBOT-ASSISTED RADICAL PROSTATECTOMY: ONCOLOGICAL AND FUNCTIONAL OUTCOMES Francesco Porpiglia, Cristian Fiori*, Riccardo Bertolo, Matteo Manfredi, Fabrizio Mele, Diletta Garrou, Daniele Amparore, Giovanni Cattaneo, Enrico Checcucci, Stefano De Luca, Orbassano, Italy, Roberto Passera, Turin, Italy, Roberto Mario Scarpa, Orbassano, Italy</td>
</tr>
</tbody>
</table>

Saturday, May 13, 2017
Podium Session 18

PROSTATE CANCER: LOCALIZED: SURGICAL THERAPY III
Room 159 @ Boston Convention & Exhibition Center
Moderators: Ketan Badani, Octavio Castillo and Michael Gong

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7:00 PD18-01</strong></td>
<td><strong>7:50 PD18-06</strong></td>
</tr>
<tr>
<td>RANDOMIZED STUDY EVALUATING SHORT-TERM FUNCTIONAL OUTCOMES OF ROBOT-ASSISTED RADICAL PROSTATECTOMY IN LOW-RISK PROSTATE CANCER PATIENTS Alexander Govorov*, Dmitry Pushkar, Konstantin Kolontarev, Pavel Rasner, Vladimir Dyakov, Moscow, Russian Federation</td>
<td>5 YEARS FOLLOW-UP OF A PROSPECTIVE RANDOMISED CONTROLLED TRIAL COMPARING LAPAROSCOPIC VERSUS ROBOT-ASSISTED RADICAL PROSTATECTOMY: ONCOLOGICAL AND FUNCTIONAL OUTCOMES Francesco Porpiglia, Cristian Fiori*, Riccardo Bertolo, Matteo Manfredi, Fabrizio Mele, Diletta Garrou, Daniele Amparore, Giovanni Cattaneo, Enrico Checcucci, Stefano De Luca, Orbassano, Italy, Roberto Passera, Turin, Italy, Roberto Mario Scarpa, Orbassano, Italy</td>
</tr>
</tbody>
</table>

**7:10 PD18-02** | **8:00 PD18-07** |
| MEASURING TO IMPROVE: PATIENT REPORTED OUTCOMES DURING THE FIRST YEAR AFTER PROSTATECTOMY IN A STATEWIDE COLLABORATIVE Gregory Auffenberg*, Rodney Dunn, Tae Kim, Ann Arbor, MI, James Peabody, Mani Menon, Detroit, MI, David Miller, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI | THE IMPACT OF TRAVEL DISTANCE TO THE TREATMENT FACILITY ON OVERALL MORTALITY IN PROSTATE CANCER PATIENTS: EVIDENCE FROM THE NATIONAL CANCER DATA BASE Malte W. Vetterlein*, Björn Lüppenberg, Patrick Karabon, Deepansh Dalela, Tarun Jindal, Akshay Sood, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Mani Menon, Firas Abdollah, Detroit, MI |

**7:20 PD18-03** | **8:10 PD18-08** |

**7:30 PD18-04** | **8:30 PD18-09** |
<p>| PROSTATE CANCER-RELATED ANXIETY IN LONG-TERM SURVIVORS AFTER RADICAL PROSTATECTOMY Kathleen Herkommer*, Valentin H. Meissner, Andreas Dinkel, Birgitt Marten-Mittag, Jürgen E. Gschwend, Munich, Germany | |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD19-01</td>
<td>ACTIVE SURVEILLANCE FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC): RESULT FROM BLADDER CANCER ITALIAN ACTIVE SURVEILLANCE (BIAS) PROJECT.</td>
</tr>
<tr>
<td>7:10</td>
<td>PD19-02</td>
<td>IS THERE A ROLE FOR UPPER URINARY TRACT IMAGING SURVEILLANCE IN THE FOLLOW-UP OF NON-MUSCLE INVASIVE BLADDER CANCER?</td>
</tr>
<tr>
<td>7:20</td>
<td>PD19-03</td>
<td>THE VALUE OF IMMEDIATE POST-OPERATIVE INTRAVESICAL EPIRUBICIN INSTILLATION IN INTERMEDIATE AND HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC): A RANDOMIZED CONTROLLED TRIAL</td>
</tr>
<tr>
<td>7:30</td>
<td>PD19-04</td>
<td>IMMEDIATE INTRAVESICAL CHEMOTHERAPY FOR LOW GRADE BLADDER TUMORS IN CALIFORNIA: AN UNDERUTILIZED PRACTICE AND ITS IMPACT ON RECURRENCE</td>
</tr>
<tr>
<td>8:00</td>
<td>PD19-07</td>
<td>ONE-YEAR FOLLOW-UP RESULTS AFTER SEQUENTIAL INTRAVESICAL BACILLUS CALMETTE-GUÉRIN AND DEVICE-ASSISTED CHEMO-HYPERTHERMIA (MITOMYCIN C DELIVERED BY THE COMBAT BRS SYSTEM) FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS . A BACILLUS CALMETTE-GUÉRI</td>
</tr>
<tr>
<td>7:40</td>
<td>PD19-05</td>
<td>THE BENEFIT OF CONTINUOUS SALINE BLADDER IRRIGATION AFTER TRANURETHRAL RESECTION IN HIGH GRADE NON-MUSCULAR INVASIVE BLADDER CANCER - A SINGLE CENTER RANDOMIZED PROSPECTIVE STUDY</td>
</tr>
<tr>
<td>7:50</td>
<td>PD19-06</td>
<td>HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) TREATED WITH SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION MITOMYCIN-C (EMDA-MMC): 2% DISEASE-SPECIFIC MORTALITY AT 4 YEARS' FOLLOW-UP</td>
</tr>
<tr>
<td>8:00</td>
<td>PD19-07</td>
<td>ONE-YEAR FOLLOW-UP RESULTS AFTER SEQUENTIAL INTRAVESICAL BACILLUS CALMETTE-GUÉRIN AND DEVICE-ASSISTED CHEMO-HYPERTHERMIA (MITOMYCIN C DELIVERED BY THE COMBAT BRS SYSTEM) FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS . A BACILLUS CALMETTE-GUÉRI</td>
</tr>
</tbody>
</table>
8:10 PD19-08 RADIOFREQUENCY-INDUCED THERMOCHEMOTHERAPY EFFECT (RITE) PLUS MITOMYCIN VERSUS A SECOND COURSE OF BACILLUS CALMETTE-GUÉRIN (BCG) OR INSTITUTIONAL STANDARD IN PATIENTS WITH RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWING INDUCTION OR MAINTENANCE
Weï Shen Tan*, London, United Kingdom, Laura Buckley, Adam Devall, Laurence Loubiere, Ann Pope, Birmingham, United Kingdom, Mark Feneley, London, United Kingdom, Jo Cresswell, Middlesbrough, United Kingdom, Rami Issa, London, United Kingdom, Hugh Mostafid, Basingstoke, United Kingdom, Sanjeev Madaan, Dartford, United Kingdom, Rupesh Bhatt, Birmingham, United Kingdom, John McGrath, Exeter, United Kingdom, Vijay Sangar, Manchester, United Kingdom, Leyshon Griffiths, Leicester, United Kingdom, Toby Page, Newcastle, United Kingdom, Dominic Hodgson, Portsmouth, United Kingdom, Shibis Datta, London, United Kingdom, Lucinda Billingham, Birmingham, United Kingdom, John Kelly, London, United Kingdom

8:20 PD19-09 PERFORMANCE OF A NOVEL URINE-BASED BIOMARKER FOR THE MONITORING OF BLADDER CANCER RECURRENCE
Ofer Nativ*, Sarel Halachmi, Kohava Biton, Marina Zlotnik, Haifa, Israel, Chen Yoffe, Noa Davis, Yael Glickman, Tel Aviv, Israel, Jacob Bejar, Haifa, Israel

8:30 PD19-10 THE CHEMOABLATIVE EFFECT OF VESIGEL INSTALLATION IN PATIENTS WITH NMIBC – RESPONSE RATE AND 1-YEAR DURABILITY
Andrew Lenis*, Karim Chamie, Los Angeles, CA, Boris Friedman, Haifa, Israel, Andrea Tubaro, Rome, Italy, Ami Sidi, Holon, Israel, Daniel Kedar, Petah Tikva, Israel, Lorenzo Colombo, Milan, Italy, Dov Engelstein, Nahariya, Israel, Joan Palau, Barcelona, Spain, Gregory Wirth, Genève, Switzerland, Ilan Leibovitch, Kfar Saba, Israel, Eddy Fridman, Ramat Gan, Israel, Ifat Klein, Michal Jeshurun, Ra’anana, Israel, Fred Witjes, Nijmegen, Netherlands

8:40 PD19-11 WHAT FALSE-NEGATIVE RATES ARE BLADDER CANCER PATIENTS AND URO-Oncologists WILLING TO ACCEPT IN ORDER TO AVOID SURVEILLANCE CYSTOSCOPY?
Rashid Sayyid*, Toronto, Canada, Abdallah Sayyid, Beirut, Lebanon, Ricardo Leao, Ardalanejaz Ahmad, Hanan Goldberg, Robert Hamilton, Girish Kulkarni, Antonio Finelli, Alexandre Ziotta, Neil Fleshner, Toronto, Canada

8:50 PD19-12 THE REVOLIX(TM) 2/H9262 M CONTINUOUS WAVE LASER EN BLOC ENUCLEATION FOR NONMUSCLE-INVASIVE BLADDER CANCER
Hai Bi*, Beijing, China, People’s Republic of

ABSTRACT

Saturday, May 13, 2017
Podium Session 20
7:00 am - 9:00 am

KIDNEY CANCER: LOCALIZED: SURGICAL THERAPY I
Room 251 @ Boston Convention & Exhibition Center
Moderators: Adam Feldman, Woong Kyu Han and Karim Touijer

ABSTRACT

TIME NUMBER TITLE
7:00 PD20-01 OUTCOMES OF RADICAL NEPHRECTOMY WITH LEVEL IV TUMOR THROMBUS USING CARDIOPULMONARY BYPASS

7:10 PD20-02 LAPAROSCOPIC INFERIOR VENA CAVA THROMBUS SURGERY BY PURE RETROPERITONEAL APPROACH
Shudong Zhang*, Lulin Ma, Lei Liu, Yu Tian, Beijing, China, People’s Republic of

7:20 PD20-03 ROBOTIC INFERIOR VENA CAVA THROMBECTOMY IN 64 PATIENTS: PREDICTORS OF INTRA-OPERATIVE EFFICIENCY
David Hatcher*, Los Angeles, CA, Xin Ma, Beijing, China, People’s Republic of, Giuseppe Simone, Salvatore Guaglianone, Mariaconsiglia Ferriero, Rome, Italy, Baojun Wang, Beijing, China, People’s Republic of, Michele Gallucci, Rome, Italy, Xu Zhang, Beijing, China, People’s Republic of, Inderbir Gill, Los Angeles, CA

7:30 PD20-04 PERIOPERATIVE OUTCOMES OF ROBOTIC AND OPEN PARTIAL NEPHRECTOMY FOR MODERATELY AND HIGHLY COMPLEX T1B RENAL TUMORS

*Presenting author
7:40 PD20-05 COMPARISON BETWEEN PARTIAL NEPHRECTOMY AND RADICAL NEPHRECTOMY FOR T2N0M0 TUMORS, A STUDY BASED ON THE NATIONAL CANCER DATABASE
Cheuk Fan Shum*, Clinton D Bahler, Chandru P Sundaram, Indianapolis, IN

7:50 PD20-06 THE ONCOLOGIC OUTCOMES OF PARTIAL NEPHRECTOMY FOR PT3 RENAL CELL CARCINOMA
Ricardo Alvim*, Shawn Mendonca, Toshikazu Takeda, Souhil Lebdai, Amy Tin, Melissa Assel, Paul Russo, Jonathan Coleman, New York, NY

8:00 PD20-07 ONCOLOGIC AND SURVIVAL OUTCOMES FOR PATHOLOGIC T3A UPSTAGING IN CLINICALLY LOCALIZED RENAL MASSES: DOES PARTIAL NEPHRECTOMY INCREASE ONCOLOGICAL RISK?
Zachary Hamilton*, San Diego, CA, Deepak Pruthi, San Antonio, TX, Alessandro Larcher, Milan, Italy, Aaron Bloch, Charles Field, Katherine Fero, Sean Berquist, Abd–erahma Hassan, Daniel Han, San Diego, CA, Michael Liss, San Antonio, TX, Thomas McGregor, Kingston, Canada, Umberto Capitanio, Francesco Montorsi, Milan, Italy, Ithaa Derweesh, San Diego, CA

8:10 PD20-08 ONCOLOGIC OUTCOMES OF PATIENTS WITH POSITIVE SURGICAL MARGINS AFTER PARTIAL NEPHRECTOMY: A 25-YEAR SINGLE INSTITUTION EXPERIENCE
Firas Petros*, Kai-Jie Yu, Michael Metcalfe, Sarp Keskin, Courtney Chang, Cindy Gu, Surena Matin, Jose Karam, Christopher Wood, Houston, TX

8:20 PD20-09 SURGICAL APPROACH DOES NOT IMPACT POSITIVE MARGIN RATE IN PARTIAL NEPHRECTOMY FOR LARGE RENAL MASSES
Abimbola Ayangbesan*, David Golombies, New York, NY, Padraic O’Malley, Halifax, Canada, Patrick Lewicki, LaMont Barlow, Xian Wu, Paul Christos, Douglas Scherr, New York, NY

8:30 PD20-10 DOES TUMOR COMPLEXITY HAVE AN IMPACT ON MIC AND TRIFECTA OUTCOME IN ROBOT-ASSISTED PARTIAL NEPHRECTOMY? A MULTI-CENTER STUDY OF OVER 500 CASES
Nina Harke*, Rostock, Germany, Christian Wagner, Gronau, Germany, Alexander Roosen, Bochum, Germany, Frank Schiefelbein, Wuerzburg, Germany, Burkhard Ubrig, Bochum, Germany, Georg Schoen, Wuerzburg, Germany, Jorn H. Witt, Gronau, Germany

8:40 PD20-11 ACUTE KIDNEY INJURY AFTER PARTIAL NEPHRECTOMY: IMPACT ON LONG-TERM STABILITY OF RENAL FUNCTION
Joseph Zabel*, Wen Dong, Diego Aguilar Palacios, Joseph Abraham, Sudhir Isharwal, Erick Remer, Steven C. Campbell, Cleveland, OH

8:50 PD20-12 RISK OF URINE LEAK IN HIGH-RISK PATIENTS AFTER MINIMALLY INVASIVE PARTIAL NEPHRECTOMY WITHOUT COLLECTING SYSTEM CLOSURE
Amul Bhalodi*, Adam Berneking, Stephen Strup, Jason Bylund, Lexington, KY

ABSTRACT NUMBER TITLE
V4-01 PATIENT SPECIFIC REHEARSAL USING 3D PRINTING FOR COMPLEX PARTIAL NEPHRECTOMY CASES

V4-02 GOLD NANO-PARTICLE DIRECTED FOCAL LASER ABLATION FOR PROSTATE TUMORS USING US AND MR FUSION TECHNOLOGY
Jared S Winoker*, Pratik A Shukla, Michael A Carrick, Harry Anastos, Cynthia J Knauer, Ashutosh K Tewari, Bachir M Taouli, Sara C Lewis, New York, NY, Jon A Schwartz, Houston, TX, Joshua M Stern, Bronx, NY, Steven E. Canfield, Houston, TX, Ardeshir Rastinehad, New York, NY
V4-03 CT/MRI-US FUSION GUIDED RENAL MASS BIOPSY: INITIAL EXPERIENCE
Andre Abreu*, Sameer Chopra, Carlee Beckler, Masakatsu Oishi, Nariman Ahmadi, Toshitaka Shin, Andre Berger, Mihir Desai, Monish Aron, Inderbir Gill, Osamu Ukimura, Los Angeles, CA

V4-04 NOVEL USE OF FLUORESCENCE LYMPHANGIOGRAPHY DURING ROBOTIC GROIN DISSECTION FOR PENILE CANCER
Alexander P. Kenigsberg*, Marc A. Bjurlin, Alon Y. Mass, Lee C. Zhao, William C. Huang, New York, NY

V4-05 IMPACT OF THE 20 G ALL-SEEING NEEDLE AND 4.8 FR MICRO PCNL WITH THE HIGH DEFINITION IMAGE GUIDE (HDIG) SYSTEM
Koichiro Wada*, Hiromi Kumon, Ryuta Tanimoto, Yosuke Mitsui, Takuya Sadahira, Atsushi Takamoto, Katsumi Sasaki, Motoo Araki, Toyohiko Watanabe, Yasutomo Nasu, Okayama, Japan

V4-06 THE DEVELOPMENT OF A WEB-BASED VIDEO PLATFORM FOR TEACHING THE ROBOTIC SIMPLE PROSTATECTOMY
Nicholas Kavoussi*, Igor Sorokin, Jeffrey Gahan, Dallas, TX

V4-07 CONTRAST-ENHANCED ULTRASOUND (CEUS): EVALUATION OF HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) ABLATION OF THE PROSTATE

V4-08 PRELIMINARY RESULTS OF ADVANCED IMAGE-GUIDED RENAL BIOPSY AND THERMAL ABLATION UTILIZING CONE-BEAM COMPUTERIZED TOMOGRAPHY: A SURGEONS PROCEDURE
Emily Kelly*, Boca Raton, FL, Raymond Leveillee, Boynton Beach, FL

V4-09 MRI GUIDED SALVAGE CRYOABLATION OF RECURRENT PROSTATE CANCER
David Y. Yang*, David A Woodrum, Lance A. Mynderse, Rochester, MN

V4-10 “URODYNAMIC 4D-CT” EVALUATION IS A HIGHLY EFFECTIVE TECHNIQUE FOR THE ASSESSMENT OF URINARY CONDITIONS.
Shintaro Mori*, Kanagawa, Japan, Masanori Inoue, Masahiro Jinzaki, Tokyo, Japan, Ryoichi Shiroki, Aichi, Japan

V4-11 MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION IN PATIENTS WITH LOCALIZED PROSTATE CANCER: PRIMARY OUTCOMES OF A PROSPECTIVE PHASE I STUDY

V4-12 SIMULATION MODEL FOR ULTRASOUND AND FLUOROSCOPY GUIDED PERCUTANEOUS RENAL ACCESS: STEP BY STEP TUTORIAL
Manuel Carballo-Quinta*, Sabela López-García, Máximo Castro-Iglesias, Grethel Rivas-Dangel, Sheila Domínguez-Almúster, Moisés Elías Rodriguez-Socarrás, Miguel Pérez-Schoch, Jorge Sánchez-Ramos, María Elena López-Diez, Antonio Ojea-Calvo, Vigo, Spain

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 13, 2017 7:30 am - 12:15 pm

UROLOGY UPDATE 2017: FOR PRIMARY CARE AND ADVANCED PRACTICE PROVIDERS
Room 210C @ Boston Convention & Exhibition Center

7:30 INTRODUCTION
Howard Winfeld

7:35 PRE-TEST
Howard Winfield

7:50 SESSION I: ONCOLOGY
PROSTATE CANCER – WHY ALL THE CONTROVERSY?
Howard Winfield

8:30 BLADDER CANCER – THE DANGEROUS LURKING MALIGNANCY
Michael O’Donnell

9:00 RENAL CANCER – THE INTERNIST’S DISEASE IN THE ERA OF CT SCANNING
David Wang

9:25 PANEL DISCUSSION: WHEN TO REFER?

9:40 SESSION I POST-TEST

9:45 BREAK

*Presenting author
| 10:00 | SESSION II: VOIDING DYSFUNCTION         | 11:20 | BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS – FEMALES       |
|       | STRESS URINARY INCONTINENCE – EVALUATION AND MANAGEMENT STRATEGIES |       | Sandip Vasavada                                                |
| 10:20 | OVERACTIVE BLADDER – MAKING AND SETTING EXPECTATIONS FOR TREATMENT SELECTION | 11:50 | PANEL DISCUSSION: WHEN TO REFER?                             |
|       | Matthew Thom                                                                 | 12:05 | SESSION II POST-TEST/WRAP-UP                                 |
| 11:00 | NOCTURIA – IMPORTANT CONSIDERATIONS AND MANAGEMENT STRATEGIES        | 12:15 | ADJOURN                                                      |
|       | Sandip Vasavada                                                            |       |                                                              |

Saturday, May 13, 2017

SOCIETY FOR PEDIATRIC UROLOGY (SPU)
Pacific Ballroom @ Renaissance

| 6:30  | REGISTRATION/BREAKFAST                                   | 1:30  | COMBINED SPU/CONGENITALISM WORKING GROUP PROGRAM            |
| 7:30  | SESSION 6: TUMOR, TRAUMA, AND TRANSPLANT                 |       | USE OF BOWEL IN GENITOURINARY RECONSTRUCTION IN THE NEUROGENIC PATIENT |
|       | Moderators: Kathleen Kieran, Nicholas Cost              |       | Moderator: TBD                                              |
| 8:18  | PUOWG PANEL: PELVIC RHABDOMYOSARCOMA                    | 2:20  | DEBATE: TREATMENT OF CONSTIPATION/BOWEL MANAGEMENT           |
|       | Moderator: Fernando Ferrer                              |       | Moderator: TBD                                              |
|       | Panelists: Katherine Janeway, Torrun Yock, Jonathan Routh|       | Panelists: Melinda Dickey, Terry Burchmiller, Lillianna Bordelianou |
| 9:18  | SESSION 7: DYSFUNCTIONAL VOIDING AND ENURESIS            | 2:45  | SESSION 9: NEUROPATHIC BLADDER AND RECONSTRUCTION-TRANSITIONAL CARE |
|       | Moderators: Israel Franco, Israel Nosnik                |       | Moderators: Stacy Tanaka, Konrad Szymanski                  |
| 10:10 | BREAK                                                    | 3:15  | BREAK                                                        |
| 10:35 | SESSION 8: NEUROPATHIC BLADDER AND RECONSTRUCTION - EXSTROPHY | 3:45  | SESSION 10: HYPOSPADIAS/PENILE                               |
|       | Moderators: John Kryger, Heather DiCarlo                |       | Moderators: Bartley Cilento, Emilie Johnson                 |
|       | Jack McAninch                                            |       | Moderators: Chad Wallis, Alison Keenan                      |
| 11:50 | PRESENTATION OF SPU RESEARCH GRANTS/INTRODUCTION OF FELLOWS | 5:30  | ADJOURN                                                      |
| 12:00 | SPU PRESIDENTIAL ADDRESS / SPU BUSINESS MEETING        |       |                                                              |
| 12:30 | LUNCH                                                    |       |                                                              |

Saturday, May 13, 2017

Forums

2017 AUA RESIDENTS & FELLOWS FORUM
Room 206 @ Boston Convention & Exhibition Center

| 7:45  | WELCOME AND INTRODUCTORY REMARKS                      | 8:50  | DEBT MANAGEMENT & INVESTMENTS                               |
|       | Committee Chair: Hans Arora                           |       | Marshall Gifford                                            |
| 7:50  | SPONSORED TALK: “THE GREAT LEAP: TRANSITIONING FROM TRAINING TO PRACTICE” | 9:25  | Q & A                                                       |
|       | Moderator: Karen Stern                               |       | BREAK                                                       |
| 8:10  | MEDICOLEGAL PRACTICE AND ADDITIONAL TOPIC TBD        | 9:45  | ABU UPDATE AND ISSUES FACING NEWLY PRACTICING UROLOGISTS   |
|       | Richard Anthony Santucci                            |       | Gerald Jordan                                               |
10:05 CONTRACT NEGOTIATION
   Roger Bonds
10:20 Q & A
10:30 YU UPDATE
   John Lam
10:40 TEACHING AWARD PRESENTATION

Saturday, May 13, 2017 8:00 am - 11:55 am
SOCIETY FOR BASIC UROLOGIC RESEARCH (SBUR) / SOCIETY OF UROLOGIC ONCOLOGY (SUO) JOINT MEETING
Grand Ballroom @ Westin Waterfront

8:00 WELCOME & INTRODUCTION
8:05 BIG DATA IN PROSTATE CANCER
   Moderators: Christopher Evans, Ganesh Raj
   IDENTIFYING CANCER VULNERABILITIES THROUGH PERSONALIZED NETWORK IDENTIFICATION
   Joshua Stuart
8:25 DNA REPAIR PATHWAYS IN METASTATIC THERAPY RESISTANT CANCER
   Peter Nelson
8:45 TRANSLATING BIG DATA IN PROSTATE CANCER TO THE CLINIC
   Scott Tomlins
9:05 PANEL DISCUSSION AND QUESTIONS
9:20 INTRODUCTION: OPPORTUNITIES AND CHALLENGES ASSOCIATED WITH BIG DATA
   Moderators: Christopher Barbieri, Hannelore Heemers
9:25 LEVERAGING THE POWER OF ULTRA-DEEP SEQUENCING
   Colin Collins

9:45 STUDYING NICHE POPULATIONS: NEUROENDOCRINE PROSTATE CANCERS
   Himisha Beltran
10:05 CREATING AN INSTITUTION-WIDE SYSTEMS BIOLOGY INITIATIVE
   David Solit
10:25 GENOME DRIVERS OF RESPONSE TO EXISTING AND EMERGING THERAPIES IN BLADDER CANCER
   Eliezer Van Allen
10:45 PANEL DISCUSSION AND QUESTIONS
11:00 DONALD S. COFFEY LECTURE: INTRODUCTION
   Ganesh Raj
11:05 DONALD S. COFFEY LECTURE: BROAD BIG DATA AND BEYOND
   Levi Garraway
11:45 QUESTIONS
11:55 ADJOURN

Saturday, May 13, 2017 8:00 am - 5:00 pm
AMERICAN COLLEGE OF OSTEOPATHIC SURGEONS (ACOS)
Room 208 @ Boston Convention & Exhibition Center

8:00 INTRODUCTION
   Program Chairs: Craig Hunter, Nathan Hale
   CAstrate Resistant Prostate Cancer
   Gordon Brown
8:45 UROLOGIC ONCOLOGY
   Benjamin Davies
9:30 APPROACH TO ACQUIRED BURIED PENIS REPAIR
   Paul Rusilko
10:15 PROSTHESIS COMPLICATIONS
   Kenneth Angemeier
11:00 BREAK
11:15 BLADDER CANCER AND FEMALE FUNCTIONAL OUTCOMES
   Megan Merrill
12:15 INTERVENTIONAL UROLOGY AND MRI PROSTATE
   Art Rastinehad

12:45 TUBELESS PERCUTANEOUS NEPHROLITHOTOMY
   Joel Abbott
1:30 PELVIC FLOOR DYSFUNCTION
   Aisha Taylor
2:10 INCORPORATING HIFU FOR PROSTATE CANCER INTO YOUR PRACTICE
   Mark Leo
2:50 REFRACTORY OAB: BOTOX OR SACRAL NEUROMODULATION
   Karin Syed
3:30 MODERN MANAGEMENT OF VARICOCELE
   Michael Butcher
4:10 APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
   4:15 ADJOURN
   4:55 APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
MP29-01 ANALYSES OF URINE MARKERS IN PATIENTS WITH INTERSTITIAL CYSTITIS BEFORE AND AFTER FULGURATION OR HYDRODISTENTION

Akira Furuta*, Tokyo, Japan, Tokunori Yamamoto, Nagoya, Japan, Yusuke Koike, Yasuyuki Suzuki, Tokyo, Japan, Momokazu Gotoh, Nagoya, Japan, Shin Egawa, Tokyo, Japan, Naoki Yoshimura, Pittsburgh, PA

MP29-02 NEUROMETER MEASUREMENT OF CURRENT PERCEPTION (CPT) AND PAIN TOLERANCE THRESHOLDS (PTT) IN PATIENTS WITH PAINFUL BLADDER SYNDROME BEFORE AND AFTER TREATMENT WITH CYCLOSPORINE

Marisa Clifton*, Lewisburg, PA, Courtenay Moore, Daniel Shoskes, Cleveland, OH

MP29-03 CHILDHOOD STRESSFUL EVENTS INDUCE CHRONIC BLADDER PAIN IN ADULTHOOD THROUGH A TRPV1 DEPENDENT MECHANISM.

Rita Matos, Francisco Cruz*, Ana Charrua, Porto, Portugal

MP29-04 COMPARISON OF FIVE DIFFERENT ANIMAL MODELS TO ESTABLISH THE BEST INTERSTITIAL CYSTITIS RAT MODEL SIMILAR TO HUMAN DISEASE

Bum Soo Kim*, Jae Wook Chung, Phil Hyun Song, So Young Chun, Yeon Yong Kim, Hyo Jung Lee, Jun Nyung Lee, Yun-Sok Ha, Eun Sang Yoo, Tae Gyun Kwon, Seock Hwan Choi, Hyun Tae Kim, Tae-Hwan Kim, Sung Kwang Chung, Daegu, Korea, Republic of

MP29-05 PAIN RELIEF AFTER TRIAMCINOLONE INFLTRATION IN PATIENTS WITH BLADDER PAIN SYNDROME WITH HUNNER’S ULCERS

Laura Mateu Arrom*, Laura Izquierdo, Agustín Franco, Barcelona, Spain, Nathan Lawrence, Melbourne, Australia, Lluis Peri, Mentxell Costa, Antonio Alcaraz, Barcelona, Spain

MP29-06 THERAPEUTIC EXPLOITATION OF THE SCHISTOSOMA HAEMATOBIUM HOMOLOG OF INTERLEUKIN-4-INDUCING PRINCIPLE OF SCHISTOSOMA MANSONI EGGS FOR CHEMOTHERAPY-INDUCED HEMORRHAGIC CYSTITIS AND BLADDER HYPERSONSITIVITY


MP29-07 DEVELOPMENT OF THE ULCERATIVE INTERSTITIAL CYSTITIS RISK SCORE (ICUS): A URINE-BASED MULTIPLE PROTEIN ASSAY TO PREDICT ULCERATIVE INTERSTITIAL CYSTITIS

Laura Lamb*, Royal Oak, MI, Joseph Janicki, Pittsburgh, PA, Sarah Bartolone, Royal Oak, MI, Interstitial Cystitis Association, McLean, VA, Bernadette Zwans, Kenneth Peters, Michael Chancellor, Royal Oak, MI

MP29-08 SMALL FIBER POLYNEUROPATHY – A BIG CLUE TO ETIOLOGY AND MANAGEMENT OF CHRONIC PELVIC PAIN (CPP)

Annie Chen*, Charles E. Argoff, Elise De, Albany, NY

MP29-09 ROLE OF SPINAL MICROGLIA IN COLON-TO-BLADDER NEURAL CROSSTALK IN A RAT MODEL OF COLITIS

Tsuyoshi Majima*, Yasuhide Funahashi, Nagoya, Japan, Naoki Kawamori, Sendai, Japan, Yoshisasa Matsukawa, Tokunori Yamamoto, Nagoya, Japan, Naoki Yoshimura, Pittsburgh, PA, Momokazu Gotoh, Nagoya, Japan

MP29-10 ALTERATIONS IN THE URINARY FUNGAL MYCOBIOME IN PATIENTS WITH BLADDER PAIN AND URINARY URGENCY

A. Lenore Ackerman*, Jennifer Anger, Jae Tang, Karyn Elber, Jayoung Kim, Michael Freeman, David Underhill, Los Angeles, CA, MAPP Research Network, Washington, DC

MP29-11 OVERACTIVE BLADDER AND CO-OCurring INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME: THE ROLE OF CENTRAL SENSITIZATION IN CLINICAL PRESENTATION.

Lindsey McKernan*, Joshua Cohn, Stephen Bruehl, Roger Dmochowski, W. Stuart Reynolds, Nashville, TN

MP29-12 USE OF A BODY PAIN MAP TO CHARACTERIZE UROLOGIC CHRONIC PELVIC PAIN SYNDROME – A MAPP RESEARCH NETWORK STUDY

MP29-13 HISTAMINE INTOLERANCE AND MICROBIOTA CHANGES IN PATIENTS WITH PAINFUL BLADDER SYNDROME / INTERSTITIAL CYSTITIS
Elke Hessdorfer*, Berlin, Germany

MP29-14 BLADDER CAPACITY IS A BIOMARKER FOR A BLADDER-CENTRIC VERSUS SYSTEMIC MANIFESTATION IN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS)
Joao Zambon*, Steve J Walker, Gopal Badiani, Catherine Matthews, Heather Bowman, Robert Evans, Winston-Salem, NC

MP29-15 BIOPSYCHOSOCIAL PREDICTORS OF SUICIDALITY IN PATIENTS WITH INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
Dean Tripp*, J Curtis Nickel, Joel Dueck, Abigale Muere, Haley Yurgan, Madelaine Gierc, Kingston, Canada

MP29-16 IMPROVING THE UTILITY OF CLINICAL PHENOTYPING IN INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME: FROM UPON TO INPUT
Alice Crane*, Jessica Lloyd, Daniel Shoskes, Cleveland, OH

MP29-17 MAST CELL SUBTYPES: IMPLICATIONS FOR THE PATHOGENESIS OF INTERSTITIAL CYSTITIS
Brian Birch*, Shabana Malik, Bashir Lwaleed, Southampton, United Kingdom

MP29-18 BOTULINUM TOXIN A BLADDER INJECTION IN THE TREATMENT OF BLADDER PAIN SYNDROME/IC: TRYING TO STANDARDIZE THE TECHNIQUE
Cristina Gutierrez*, Carlos Errando, Nicolas Nervo, Pedro Araño, Humberto Villavicencio, Barcelona, Spain

MP29-19 CHARACTERIZATION OF UROLOGIC AND NON-URLOGIC FEATURES OF INTERSTITIAL CYSTITIS PATIENTS WITH HUNNER LESIONS
H. Henry Lai*, Frederick Moh, Joel Vetter, St Louis, MO

MP29-20 TREATMENT EFFECTIVENESS IN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME: DO PATIENT PERCEPTIONS ALIGN WITH EFFICACY BASED GUIDELINES?

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 13, 2017
9:30 am - 11:30 am

Moderated Poster Session 30

TRANSPLANTATION & VASCULAR SURGERY: RENAL TRANSPLANTATION & VASCULAR SURGERY II
Room 153 @ Boston Convention & Exhibition Center
Moderators: David A. Goldfarb and Alp Sener

MP30-01 PENIS TRANSPLANTATION: FIRST U.S. EXPERIENCE
Dicken Ko*, Kai Li, Harry Salinas, Ilse Schol, Branko Bojovic, Kyle Eberlin, Jonathan Winograd, Jeffrey Lee, Garry Choy, Raymond Liu, Ivy Rosales, Michael Grant, Francis McGovern, Adam Feldman, Cigdem (Cori) Tanrikut, Robert Colvin, Curtis Cetrulo, Jr., Boston, MA

MP30-02 SURVIVAL OF KIDNEY TRANSPLANTS FROM UNCONTROLLED DCD DONORS UNDER NORMOTHERMIC PRESERVATION: ARE THEY AS GOOD AS DBD KIDNEYS?
Félix Guerrero Ramos*, Teresa Cavero Escrivan, Angel Tejido Sánchez, Alfredo Rodríguez Antolinez, Manuel Pampolona Casamayor, José Medina Polo, Federico de la Rosa Kehrmann, José Manuel Duarte Ojeda, Felipe Villacampa Aubé, Amado Andrés Belmonte, Juan Passas Martinez, Madrid, Spain

MP30-03 ROBOTIC KIDNEY TRANSPLANTATION: EUROPEAN ONE-YEAR DATA
Alberto Breda*, Angelo Territo, Lluis Guasa, Barcelona, Spain, Volkan Tugcu, Istanbul, Turkey, Karel Decaestecker, Ghent, Belgium, Michael Stoeckle, Homburg/Saar, Germany, Paolo Formara, Halle, Germany, Jonathan Olasburgh, London, United Kingdom, Giampaolo Siena, Florence, Italy, Nicolas Doumerc, Toulouse, France

MP30-04 INDUCTION OF DELAYED RENAL ALLOGRAFT TOLERANCE WITH CLINICAL AVAILABLE REAGENTS IN NON-HUMAN PRIMATES
Kiyohiko Hotta*, Tetsu Oura, Abbas Dehnadi, Gilles Benichou, A. Benedict Cosimi, Tatsuo Kawai, Boston, MA

*Presenting author
MP30-05 OPTIMIZING WAITING DURATION FOR RENAL TRANSPLANTS IN THE SETTING OF RENAL MALIGNANCY: IS TWO YEARS TOO LONG TO WAIT?
Kevin Nguyen*, Jamil Syed, Brian Shuch, New Haven, CT, Srinivas Vourganti, Chicago, IL

MP30-06 SOCIAL ECONOMIC STATUS AND DEMOGRAPHIC DATA OF NON-DIRECTED LIVING KIDNEY DONORS
Avi Baskin*, Loma Kwan, Amy Waterman, Sarah Connor, Los Angeles, CA, Marc Melcher, Palo Alto, CA, Jeffrey Veale, Los Angeles, CA

MP30-07 BLADDER AUGMENTATION IN KIDNEY TRANSPLANT PATIENTS: COMPARISON BETWEEN TYPES OF LOWER URINARY RECONSTRUCTION.
Kleiton Yamac¸ake*, Affonso Piovesan, Renato Falcı, Gustavo Messi, Ioannis Antonopoulos, Elias David-Neto, Hideki Kanashiro, Rafael Locali, Gustavo Ebaid, William Nahas, Sao Paulo, Brazil

MP30-08 DOES MARIJUANA INTAKE AFFECT OUTCOMES IN LIVING RENAL DONORS AND THEIR RECIPIENTS?
David Ruckle, Mohamed Keheila*, Benjamin West, Braden Mattison, Jerry Thomas, Samuel Abourbih, Michael De Vera, Arputharaj Kore, Pedro Baron, D. Duane Baldwin, Loma Linda, CA

MP30-09 TREATMENT MODALITY FOR SMALL RENAL MASSES MAY AFFECT TIME TO ELIGIBILITY FOR RENAL TRANSPLANT CANDIDATES
Alp Tun˚ Bekszac*, David Paulucci, John Sfakianos, Susan Lerner, Jorge Pereira, Ketan Badani, New York, NY

MP30-10 GLOBAL KIDNEY EXCHANGE: STRIVING FOR TRIFECTA OUTCOMES IN MANAGEMENT OF KIDNEY FAILURE
Obi Ekwenna*, Toledo, OH, Ty Dunn, Minneapolis, MN, Susan Rees, Perrysburg, OH, Jeffrey Rogers, Winston Salem, NC, Christian Kuhr, Seattle, WA, Alvin Roth, Palo Alto, CA, Laurie Reece, Perrysburg, OH, Kimberly Krawiec, Raleigh-Durham, NC, Samay Jain, David Fumo, Toledo, OH, Christian Marsh, La Jolla, CA, Alejandro Cicero, Mexico City, Mexico, Jonathan Kopke, Perrysburg, OH, Miguel Tan, Atlanta, GA, Puneet Sindhwani, Toledo, OH, Siegfredo Paloyo, Manilla, Philippines, Michael Rees, Toledo, OH

MP30-11 CHOSING THE LARGER KIDNEY ON CT VOLUMETRY – A STUDY ON THE EARLY POST-DONATION KIDNEY FUNCTION OF LIVING DONORS
Lynnette Tan*, Singapore, Singapore

MP30-12 PREEMPTIVE KIDNEY TRANSPLANTATION RECIPIENTS ARE NOT AS MENTALLY SATISFIED AS NON-PREEMPTIVE PATIENTS
Yuichi Aiyoshi*, Kagoshima, Japan, Motoo Araki, Yosuke Mitsui, Koichiro Wada, Okayama, Japan, Toyohiko Watanabe, Okayama, Japan, Yasutomo Nasu, Okayama, Japan

MP30-13 MTH SCORE – A NOVEL SCORING SYSTEM TO RISK STRATIFY RENAL TRANSPLANT CASES AND TO IMPROVE OUTCOMES POST RENAL TRANSPLANT
Aditya Yelikar*, Sachin Joseph, Kochi, India

MP30-14 SURVIVAL OUTCOMES FROM DCD RENAL TRANSPLANT ARE COMPARABLE TO DBD TRANSPLANTS FROM KIDNEYS PROCURED FROM DONORS OVER 50 YEARS OF AGE: UNOS/OPTN ANALYSIS

MP30-15 VISCERAL OBESITY IN LIVING KIDNEY ASIAN DONORS SIGNIFICANTLY IMPACTS ON RENAL FUNCTION AFTER DONOR NEPHRECTOMY
Xiang Wen Gregory Pek, Dublin, Ireland, Lee Ying Clara Ngo, Boon Wee Teo, Anantharaman Vathsala, Yen Seow Benjamin Goh, Hsiang Rong Clement Yong, Lata Nee Mani Raman, Ho Yee Tiong*, Singapore, Singapore

MP30-16 LONGER FUNCTIONAL WARM ISCHEMIC TIMES DO NOT IMPACT DONATION AFTER CARDIAC DEATH RENAL ALLOGRAFT OUTCOMES

MP30-17 COMPARED INCIDENCE OF POSTOPERATIVE COMPLICATIONS IN A SERIES OF 150 UNCONTROLLED DCD VERSUS 150 DBD KIDNEY TRANSPLANTS
Félix Guerrero Ramos*, Teresa Cavero Escribano, Alfredo Rodrı´guez Antolı´n, Manuel Pampolona Casamayor, José Medina Polo, Angel Tejido Sánchez, Federico de la Rosa Kehrmann, José Manuel Duarte Ojeda, Felipe Villacampa Aubá, Amado Andrés Belmonte, Juan Passas Martinez, Madrid, Spain

MP30-18 RACIAL DISPARITIES IN RENAL TRANSPLANTATION
Benjamin Abelson*, Colette Harris, Cleveland, OH, Jamie Mitchell, Ann Arbor, MI, Songhua Lin, Charles Modlin, Cleveland, OH

MP30-19 1 YEAR FOLLOW-UP: PERCUTANEOUS RENAL HILAR BLOCKADE TO PREDICT SUCCESS OF AUTO KIDNEY TRANSPLANTATION FOR LOIN PAIN HEMATURIA SYNDROME
Jeffrey Campsen, Mitchell Bassett*, Ryan O’hara, Alec Rosales, Robin Kim, Rulon Hardman, Blake Hamilton, Salt Lake City, UT
MP30-20 SUPRARENAL VENA CAVA RESECTION WITHOUT RECONSTRUCTION
Cory Hugen*, Jeffrey Loh-Doyle, Anne Schuckman, Hooman Djaladat, Stamak Daneshmand, Los Angeles, CA

ABSTRACT
MP30-01 LONG-TERM SAFETY AND EFFICACY OF SER120 1.5 MCG IN PATIENTS WITH NOCTURIA: RESULTS FROM A 2-YEAR OPEN-LABEL EXTENSION STUDY
Scott MacDiarmid*, Greensboro, NC, JP Nicandro, Irvine, CA, Maria Cheng, Milford, PA, Steven Abrams, Irvine, CA, Seymour Fein, Milford, PA, Alan Wein, Philadelphia, PA

MP30-02 MICRONOMA-132 INDUCES BLADDER HYPERSTROPHY AND BLADDER OVERACTIVITY VIA DOWNREGULATION OF ACETYCHOLINESTERASE
Mahendra Kashyap*, Christopher Chermansky, Naoki Yoshimura, Pradeep Tyagi, Pittsburgh, PA

MP30-03 THE RELATIONSHIP BETWEEN THE URINARY MICROBIOME AND CENTRAL SENSITIZATION IN WOMEN WITH OVERACTIVE BLADDER

MP30-04 THE POWER OF CROWDSOURCING: NOVEL METHOD FOR DISCOVERY OF URINE BIOMARKERS
Michael Chancellor*, Sarah Bartolone, Royal Oak, MI, Interstitial Cystitis Association, McLean, VA, Joseph Janicki, Pittsburgh, PA, Bernadette Zwaans, Abdrew Verneecke, Kenneth Peters, Laura Lamb, Royal Oak, MI

MP30-05 IMPACT OF BRAIN-TYPE NARIURETIC PEPTIDE, A REPRESENTATIVE BIOMARKER FOR CARDIAC LOAD, ON NOCTURIA IN MEN.
Keita Izumi*, Masaya Ito, Masaharu Inoue, Toshiki Kijima, Kazuoka Ito, Kazunori Kihara, Yasuhisa Fuji, Tokyo, Japan

MP30-06 UTILITY OF BLADDER DIARIES CONTAINING FREQUENCY VOLUME CHARTS

MP30-07 URINARY STEM CELL FACTOR MAY BECOME THE DIAGNOSABLE BIOMARKER OF OVERACTIVE BLADDER IN WOMEN
Takashi Hamakawa*, Yasue Kubota, Yuya Ota, Naoko Unno, Rika Banno, Masa Takada, Shoichi Sasaki, Kenjiro Kohri, Takahiro Yasui, Nagoya, Japan

MP30-08 IS OSTEOPOROSIS AN INDEPENDENT RISK FACTOR FOR URINARY INCONTINENCE? RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
Sarah Mozafarpour*, Boston, MA, Jessica Lloyd, Cleveland, OH, Farsad Afshinina, Ann Arbor, MI, Libing Hu, Boston, MA, Howard Goldman, Cleveland, OH

MP30-09 ASSOCIATION BETWEEN POSTOPERATIVE URETHRAL AND VESICAL ANATOMICAL FEATURES ON MRI AND LOWER TRACT URINARY SYMPTOMS AFTER RADICAL PROSTATECTOMY.
Nobuhiro Haga*, Tomohiko Yanagida, Ken Aikawa, Yoshiyuki Kojima, Fukushima, Japan

MP30-10 HEALTH LITERACY, COGNITION AND URINARY INCONTINENCE AMONG GERIATRIC INPATIENTS DISCHARGED TO SKILLED NURSING FACILITIES
Joshua Cohn*, Avantika Shah, Sandra Simmons, Kathryn Goggins, Sunil Kripalani, Roger Dmochowski, John Schnelle, W. Stuart Reynolds, Nashville, TN

MP30-11 NOVEL ORAL THERAPY FOR INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME
Amandeep Mahal, Amy Dobberfrau*, Craig Comiter, Palo Alto, CA

MP30-12 PREVALENCE AND PREDICTIVE FACTORS OF DE NOVO DETRUSOR UNDERACTIVITY AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY
Junya Hata*, Kanako Matsuoka, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Nobuhiro Haga, Kei Ishibashi, Ken Aikawa, Yoshiyuki Kojima, Fukushima City, Japan

*Motting author
### MP31-13

**DOES 3-VOLT MOTOR PROVOCATION DURING SACRAL NEUROMODULATION IMPROVE CLINICAL OUTCOME FOR OBS AND URINARY RETENTION?**

Serge Marinkovic*, Joseph Ford, Detroit, MI

### MP31-14

**IMBALANCE BETWEEN MATRIX METALLOPROTEINASE-1 (MMP-1) AND TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) CONTRIBUTES TO INCREASED FIBROSIS OF BLADDER IN LONG-TERM DIABETIC RATS**

Rania Elrashidy, Zagazig, Egypt, Zhenqun Xu, Shenyang, China, People’s Republic of, Firouz Daneshgari, Guiming Liu*, Cleveland, OH

### MP31-15

**A NEW APPROACH TO MEASURING DETRUSOR CONTRACTION PATTERN CHANGE AFTER RADICAL PROSTECTOMY**

Takeya Kitta*, Yukiko Kanno, Mifuka Ouchi, Kimihiko Moriya, Satoru Maruyama, Takashige Abe, Nobuo Shinhara, Sarboro, Japan

### MP31-16

**CONCOMITANT OVERACTIVE BLADDER MEDICATION USAGE AFTER SACRAL NEUROMODULATION IMPLANT**

Karen Noblett*, Riverside, CA, Jeffrey Mangel, Cleveland, OH, Craig Comiter, Stanford, CA, Samuel Zylistra, Whittinsville, MA, Erin T. Bird, Temple, TX, Tomas L. Griebling, Kansas City, KS, Daniel Culkin, Oklahoma City, OK, Suzette E. Sutherland, Seattle, WA, Kellie Berg, Fangyu Kan, Minneapolis, MN, Steven Siegel, Woodbury, MN

### MP31-17

**SEX SPECIFIC RESPONSE OF GABAB RECEPTOR INHIBITION DURING TIBIAL AND PUDENDAL NEUROMODULATION OF BLADDER OVERACTIVITY IN CATS**

Thomas Fuller*, Pittsburgh, PA, Xuewen Jiang, Jinan, China, People’s Republic of, Utsav Bansal, Vladimir Lamm, Bing Shen, Jicheng Wang, James Roppolo, William DeGroat, Changfeng Tai, Pittsburgh, PA

### MP31-18

**SPINAL CORD STIMULATION ATTENUATES VISCERAL PAIN-RELATED VISEROMOTOR REFLEXES IN RODENTS WITH CYCLOPHOSPHAMIDE-INDUCED CYSTITIS**

Jih-Chao Yeh*, David A. Ginsberg, Larissa V. Rodriguez, Huiyi Harriet Chang, Los Angeles, CA

### MP31-19

**SYMPTOMATIC OVERLAP IN OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME**

A. Lenore Ackerman*, Los Angeles, CA, H. Henry Lai, St. Louis, MO, Karyn Eilber, Jennifer Anger, Los Angeles, CA

### MP31-20

**CORRELATION BETWEEN SYMPTOM SEVERITY AND BOTHER IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS**


---

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
MP32-05 MEDICARE ACO ENROLLMENT AND THE PREVALENCE OF PROSTATE CANCER SCREENING
Matthew Resnick*, Robert Gambrel, Amy Graves, Mark Tyson, Daniel Lee, Melinda Buntin, David Penson, Nashville, TN

MP32-06 VARIATIONS IN ACCRUAL AND RACE/ETHNICITY REPORTING IN UROLOGY AND NON-uroLOGY RELATED CANCER TRIALS.
Koushik Paul*, Chap Le, Badrinath Konety, Minneapolis, MN

MP32-07 ASSOCIATION BETWEEN HOSPITAL ACCOUNTABLE CARE ORGANIZATION STATUS AND READMISSION FOLLOWING CYSTECTOMY AND OTHER MAJOR SURGERY
Tudor Borza*, Mary K. Oerline, Ted A. Skolarsar, Ann Arbor, MI, Bruce L. Jacobs, Pittsburgh, PA, Amy N. Luckbaugh, Matthew Lee, Rita Jen, John M. Hollingsworth, Vahakn B. Shahinian, Brent K. Hollenbeck, Ann Arbor, MI

MP32-08 ACCOUNTABLE CARE ORGANIZATIONS AND THE USE OF PROSTATE CANCER SCREENING
Christian P. Meyer*, Anna Krasnova, Boston, MA, Jesse D. Sammon, Detroit, MI, Philipp Gild, Nicolas von Landenberg, Stuart R. Lipsitz, Joel S. Weissman, Boston, MA, Felix K.H. Chun, Margit Fisch, Hamburg, Germany, Maxine Sun, Quoc-Dien Trinh, Boston, MA

MP32-09 PATIENTS RECEIVING VALUE-BASED CARE FOR BPH SURGERY DO NOT EXPERIENCE WORSE CLINICAL OUTCOMES
Alan L Kaplan*, Vishnukamal Golla, Catherine M. Crespi, Jamal Nabhani, Mark S. Litwin, Christopher Saigal, Los Angeles, CA

MP32-10 VARIATIONS IN THE PATIENT EXPERIENCE AT AN ACADEMIC UROLOGY DEPARTMENT: HOW SURVEY RESULTS DRIVE LIKELIHOOD TO RECOMMEND METRICS
Richard Matulewicz*, Kalen Rimar, Kent Perry, Edward Schaeffer, Chicago, IL

MP32-11 THE IMPACT OF THE CHOOSING WISELY CAMPAIGN ON LOW VALUE UROLOGY PRACTICES
Blayne Welk*, Jennifer Winick-Ng, Andrew McClure, London, Canada, Girish Kulkarni, Michael Ordon, Toronto, Canada

MP32-12 HARNESSING FULL TEXT PATHOLOGY DATA FROM THE ELECTRONIC HEALTH RECORD TO ADVANCE BLADDER CANCER CARE – DEVELOPMENT OF A NATURAL LANGUAGE PROCESSING SYSTEM TO GENERATE LONGITUDINAL PATHOLOGY DATA
Florian Schroек*, White River Junction, VT, Olga Patterson, Patrick Alba, Scott DuVall, Salt Lake City, UT, Brenda Sirovich, Douglas Robertson, White River Junction, VT, John Seigne, Lebanon, NH, Philip Goodney, White River Junction, VT

MP32-13 COMPLIANCE WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) GUIDELINES: AN UPDATED POPULATION-BASED ASSESSMENT OF CARE DELIVERY
Conrad Tobert*, Bradley Erickson, Bradley McDowell, Thomas Graca, Mary Charlton, Sarah Bell, Kenneth Neppe, Iowa City, IA

MP32-14 A COST-EFFECTIVENESS ANALYSIS OF ARTIFICIAL URINARY SPHINCTER VERSUS ADVANCE MALE SLING IN POST PROSTATECTOMY STRESS URINARY INCONTINENCE: A CANADIAN PERSPECTIVE
Samer Shamout*, Sara Nazha, Alice Dragomir, Noemie Prevost, Lysanne Campeau, Montreal, Canada

MP32-15 CARE PATHWAY VARIATION AND SURGICAL COST MEASUREMENT FOR PERCUTANEOUS NEPHROLITHOTOMY WITH TIME-DRIVEN ACTIVITY-BASED COSTING
Ian Metzler*, Dylan Issac, Manint Usawachintachit, Matthew Hudnall, Kazumi Taguchi, David Tzou, Tom Chi, San Francisco, CA

MP32-16 COST IMPACT ANALYSIS OF ENHANCED RECOVERY AFTER SURGERY PROTOCOL IMPLEMENTATION IN A RADICAL CYSTECTOMY COHORT OF PATIENTS
Juan Chipollini*, Dominic Tang, Karim Hussein, Sephalie Patel, Rosemarie Garcia Getting, Michael Poch, Tampa, FL

MP32-17 THE IMPACT OF SOCIAL MEDIA PRESENCE ON ONLINE CONSUMER RATINGS AND SURGICAL VOLUME AMONG CALIFORNIA UROLOGISTS
Justin Houman*, James Weinberger, Los Angeles, CA, Ashley Caron, Davis, CA, Joe Thum, Devin Patel, Timothy J. Daskivich, Los Angeles, CA

MP32-18 ERRONEOUS INTERPRETATION OF ONLINE SURGICAL SCORECARD MAY HARM PATIENTS BY INCREASING WILLINGNESS TO PAY OUT-OF-POCKET EXPENSES FOR A VANISHINGLY LOW CHANCE OF LOWERING THE POSTOPERATIVE COMPLICATION RISK
Christopher J Weight*, Brett J Watson, Lucas Labine, Jacob A Albersheim-Carter, Matthew T Rasmussen, Daniel L Plack, Badrinath R Konety, Minneapolis, MN

MP32-19 COST ANALYSIS FOR INITIAL EVALUATION OF HEMATURIA: IMPACT OF TELE-UROLOGY CLINICS
Vitaly Zhuludev*, Dean Laganosky, Ilan Safrir, Maggie Dear, Jennifer Lindelow, Brooks Goodgame, James Baumgardner, Dominick Vior, Ralph Gary, Donald Finnerty, Filson Christopher, Muta Issa, Decatur, GA

*Presenting author
ABSTRACT
NUMBER TITLE
MP33-01 SIMILAR HIGH-GRADE PROSTATE CANCER DETECTION BY SEXTANT BIOPSY, 12-CORE TRUS BIOPSY AND MRI-TARGETED BIOPSY IN THE 5TH SCREENING ROUND OF THE ERSPC ROTTERDAM
Arnoud Alberts*, Ivo Schoots, Frank-Jan Drost, Leonard Bokhorst, Geert van Leenders, Roy Dwarkasing, Rotterdam, Netherlands, Jelle Barentsz, Nijmegen, Netherlands, Fritz Schröder, Chris Bangma, Monique Roobol, Rotterdam, Netherlands

MP33-02 DISADVANTAGED SOCIOECONOMIC STATUS IS STRONGLY ASSOCIATED WITH METASTATIC PROSTATE CANCER
Jared P. Schober*, Kristian D. Stensland, Alireza Moinzadeh, Karim Hamawy, David Canes, Burlington, MA

MP33-03 USPSTF Fallout: Is Disease Burden at Diagnosis of Metastatic Disease Rising?
Jared P. Schober*, Kristian D. Stensland, Karim Hamawy, Alireza Moinzadeh, David Canes, Burlington, MA

MP33-04 A Eight-Year Screening Program in High Risk Families. Number of Affected Relatives and Early Onset Are Associated With a High Risk Detection.
Pierre Callerot*, Marie-Pierre Moreau, Brest, France, Isabelle Cussenot, Françoise Baschet, Paris, France, Joel L’her, Laurent Doucet, Brest, France, Luc Cormier, Dijon, France, Philippe Marginx, Olivier Cussenot, Paris, France, Georges Fournier, Antoine Valeri, Brest, France

MP33-05 Radical Prostatectomy Outcomes from a Validated Urine Exosome Gene Expression Assay Which Predicts High-Grade (GS7) Prostate Cancer Suggests Utility for Men Enrolled in Active Surveillance
Michael Donovan*, NYC, NY, Philipp Torkler, Mikkel Noerholm, Martinsried, Germany, Johan Skog, Cambridge, MA, James McKieman, New York City, NY

MP33-06 Combined Urine and Plasma Biomarkers Are Highly Accurate for Predicting High Grade Prostate Cancer
Maher Albitar*, Wanyong Ma, Aliso Viejo, CA, Lars Lund, Odense, Denmark, Babak Shahbaba, Edward Uchio, Irvine, CA, Soren Feddersen, Odense, Denmark, Donald Moylan, Kirk Wojto, Royal Oak, MI, Neal Shore, Myrtle Beach, SC

MP33-07 Characterizing Local Recurrence After Radical Prostatectomy Using MR-Targeted Biopsy
Shawn Mendonca*, John Graham, Daniel Sjoberg, Melissa Assel, Jonathan Coleman, Behfar Ehdai, New York, NY

MP33-08 Baseline PSA in Older Males Predicts Prostate Cancer Mortality and Metastatic Disease
Adrien Bernstein*, Ron Golan, Brian Dinerman, Aaron Bernie, Jim C. Hu, New York, NY

MP33-09 Clinical Utility of Pseudouridine as a Diagnostic Marker to Detect Prostate Cancer
Jennifer Stockert*, Shalini S Yadav, Ashutosh Tewari, Kamlesh K Yadav, New York, NY

MP33-10 Evaluation of the Clinical Utility of an Epigenetic Assay to Reduce Unnecessary Repeat Prostate Biopsies
Leander Van Neste, Maastricht, Netherlands, Jack Groskopf, Irvine, CA, Wim Van Crienc*, Ghent, Belgium

MP33-11 Genetic Risk Score Can Distinguish Risk of Prostate Cancer Among Family Members With Similar Degrees of Relationship
Brian Helfand*, Evanston, IL, Hailao Chen, Rong Na, Shanghai, China, People’s Republic of, Carly Conran, Evanston, IL, William Catalona, Chicago, IL, Jianfeng Xu, Evanston, IL
MP33-12 DEVELOPMENT OF A PROSTATE CANCER GENE EXPRESSION PANEL TO ADDRESS RACIAL DIFFERENCES OF MOLECULAR ALTERATIONS IN PROSTATE CANCER

MP33-13 THE DIAGNOSTIC VALUE OF DIGITAL RECTAL EXAMINATION FOR PROSTATE CANCER: AN ANALYSIS OF OVER 20,000 BIOPSIES
Lorenzo DiGiorgio*, Nitin Patel, Vladislav Bargman, Robert Weiss, Newark, NJ

MP33-14 THE ROLE OF CHRONIC PROSTATIC INFLAMMATION IN PROSTATE CARCINOGENESIS: A RETROSPECTIVE FOLLOW-UP STUDY
Liwei Jia, Shawn Silver*, Gregory MacLennan, Cleveland, OH

MP33-15 GENDER DISPARITY: OVERLOOKING HEREDITARY PROSTATE CANCER AND IMPLICATIONS FOR UROLOGY PRACTICE
Lauren Bowling*, Carin Espenschied, Michelle Jackson, Bryan Mak, Holly Laduca, Aliso Viejo, CA

MP33-16 PATIENT SELECTION FOR MULTIPARAMETRIC PROSTATE MRI: IDENTIFYING CLINICAL PREDICTORS FOR ACTIONABLE PIRADS LESIONS ON IMAGING

MP33-17 POTENTIAL ROLE OF A NOVEL URINARY BIOMARKER-BASED RISK SCORE TO SELECT PATIENTS FOR MULTIPARAMETRIC MRI FOR PROSTATE CANCER DETECTION.
Rianne J Hendriks, Nijmegen, Netherlands, Leander Van Neste, Maastricht, Netherlands, Mulders Marloes, Jack A Schalken*, Inge M Van Oort, Nijmegen, Netherlands

MP33-18 OVER HALF OF CONTEMPORARY CLINICAL GLEASON 8 ON PROSTATE BIOPSY ARE DOWNGRADED AT RADICAL PROSTATECTOMY
Tracy Han*, Ilhan Gokhan, Ghalib Jibara, Robert Qi, Judd Moul, Durham, NC

MP33-19 AN EXOME-WIDE ASSOCIATION STUDY REPLICATED FOR PROSTATE CANCER IN KOREAN POPULATION
Jong Jin Oh*, Tae Jin Kim, In Jae Lee, Byund Do Song, Dong Hwan Lee, Yeon Soo Jung, Hak Min Lee, Sung Kyu Hong, Sangchul Lee, Jin-Nyoung Ho, Seongnam, Korea, Republic of, Sungroh Yoon, Soo Ji Lee, Jooohon Sung, Seoul, Korea, Republic of, Seok-Soo Byun, Seongnam, Korea, Republic of

MP33-20 THE SMARTTARGET BIOPSY TRIAL: A PROSPECTIVE PAIRED BLINDED TRIAL WITH RANDOMISATION TO COMPARE VISUAL-ESTIMATION AND IMAGE-FUSION TARGETED PROSTATE BIOPSIES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT NUMBER TITLE
MP34-01 MOLECULAR SUBTYPES OF MUSCLE INVASIVE BLADDER CANCER ARE RELATED TO BENEFIT FROM NEOADJUVANT CHEMOTHERAPY: DEVELOPMENT OF A SINGLE SAMPLE PATIENT ASSAY
Roland Seiler*, Hussam Al Deen Ashab, Nicholas Erho, Vancouver, Canada, Bas W.G. van Rhijn, Amsterdam, Netherlands, Brian Winters, Seattle, WA, James Douglas, Hampshire, United Kingdom, Kim Van Kessel, Rotterdam, Netherlands, Elisabeth E. Fransen van de Putte, Amsterdam, Netherlands, Matthew Sommerlad, Hampshire, United Kingdom, Qei Wang, Voleak Cheoung, Ewan A. Gibb, Beatrix Palmer-Aronsten, Lucia L. Lam, Christine Buerki, Elai Davicioni, Vancouver, Canada, Gottfrid Sjödahl, Malmo, Sweden, Jordan Kardos, Katherine A. Hoadley, Chapel Hill, NC, Seth P. Lerner, David J. McConkey, Woonyoung Choi, Houston, TX, William Y. Kim, Chapel Hill, NC, Bernhard Kiss, George N. Thalmann, Bern, Switzerland, Tilman Todenhöfer, Vancouver, Canada, Simon J. Crabb, Hampshire, United Kingdom, Scott North, Edmonton, Canada, Ellen C. Zwarthoff, Joost L. Boormans, Rotterdam, Netherlands, Jonathan Wright, Seattle, WA, Marc Dall’Era, Sacramento, CA, Michiel S. van der Heijden, Amsterdam, Netherlands, Peter C. Black, Vancouver, Canada

MP34-02 PRACTICE PATTERNS AND SURVIVAL FOR PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA OF THE BLADDER: DOES REAL WORLD PRACTICE PARALLEL CLINICAL TRIAL OUTCOMES?
William Parker*, Lance Pagliaro, Brian Costello, Igor Frank, Elizabeth Habermann, Matthew Tolleson, R. Houston Thompson, R. Jeffrey Karnes, Harras Zaid, Rochester, MN, Jeffrey Holzbeierlein, Kansas City, KS, Stephen Boorjian, Rochester, MN

MP34-03 ONCOLOGIC OUTCOMES FOR PATIENTS WITH RESIDUAL CANCER AT CYSTECTOMY FOLLOWING PREOPERATIVE CHEMOTHERAPY: A PATHOLOGIC STAGE-MATCHED COMPARATIVE ANALYSIS
Bimal Bhindi*, Igor Frank, William Parker, Ross Mason, Robert Terrell, Prabin Thapa, John Cheville, Brian Costello, Lance Pagliaro, R. Jeffrey Karnes, R. Houston Thompson, Matthew Tolleson, Stephen Boorjian, Rochester, MN

MP34-04 POST-CHEMOTHERAPY PD-L1 EXPRESSION CORRELATES WITH CLINICAL OUTCOMES IN JAPANESE BLADDER CANCER PATIENTS TREATED WITH TOTAL CYSTECTOMY.
Yasuhiro Hashimoto*, Hiromi Murasawa, Hiromichi Iwamura, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Takuya Koie, Chikara Ohyama, Hirosaki, Japan, Ikuya Iwabuchi, Masaru Ogasawara, Toshiaki Kawkuguchi, Aomori, Japan

MP34-05 THE PROGNOSTIC SIGNIFICANCE OF TNM STAGING IN BLADDER CANCER AFTER NEOADJUVANT CHEMOTHERAPY CAN BE ENHANCED WITH TUMOR REGRESSION GRADING
Roland Seiler*, Htoo Zarni Oo, Tilman Todenhöfer, Ladan Fazli, Mads Daugaard, Peter Black, Vancouver, Canada

MP34-06 DEVELOPMENT AND EXTERNAL VALIDATION OF A NOVEL 12-GENE SIGNATURE ON MUSCLE-INVASIVE BLADDER CANCER FOR PREDICTION OF OVERALL SURVIVAL: LINKAGE TO DATA FROM THE CANCER GENOME ATLAS
Huyang Xie*, Fangning Wan, Beihe Wang, Yiping Zhu, Yijun Shen, Dingwei Ye, Shanghai, China, People’s Republic of China

MP34-07 MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION OF GENOMIC ABERRATIONS OF CIRCULATING, CELL-FREE DNA IN BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY: A PROSPECTIVE STUDY
Armin Soave*, Felix Chun, Michael Rink, Lars Weisbach, Valentin Maurer, Philipp Gild, Bettina Steinbach, Margit Fisch, Klaus Pantel, Heidi Schwarzenbach, Hamburg, Germany

MP34-08 HIPEC WITH CYTOREDUCTIVE SURGERY CAN CURE PATIENTS WITH LIMITED PERITONEAL CARCINOMATOSIS FROM ADENOCARCINOMA OF THE URACHUS
Mark Behrendt, Amsterdam, Netherlands, Akash Mehta, Hampshire, United Kingdom, Elisabeth Fransen van de Putte, Michiel Van der Heijden, Simon Horenblas, Luc Moonen, Amsterdam, Netherlands, Vic Verwaal, Aarhus, Denmark, Wim Meinhardt, Bas Van Rhijn*, Amsterdam, Netherlands

MP34-09 IS A DELAY IN THE TIMING OF RADICAL CYSTECTOMY REALLY DETRIMENTAL? A RETROSPECTIVE STUDY ON A SINGLE CENTRE COHORT
Alessandro Antonelli, Stefania Zamboni, Maria Cristina Marconi, Carlotta Palumbo*, Sandra Belotti, Luca Cristinelli, Vincenzo De Luca, Claudio Simeone, Brescia, Italy
MP34-10 DEVELOPMENT AND VALIDATION OF CYSTECTOMY ASSESSMENT AND SURGICAL EVALUATION (CASE) SCORING FOR MALE RADICAL CYSTECTOMY

MP34-11 NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY
Malte W. Vetterlein*, Stephanie Mullane, Thomas Seisen, Richard Lander, Björn Löppenberg, Toni K. Choueiri, Joaquim Bellmunt, Mani Menon, Detroit, MI, Adam S. Kibel, Quoc-Dien Trinh, Mark A. Preston, Boston, MA

MP34-12 OVEREXPRESSION OF AUTOPHAGY-RELATED GENE ATG7 PROMOTES BLADDER CANCER INVASION VIA AUTOPHAGIC REMOVAL OF PRE-MRNA PROCESSING PROTEIN AUFI AND INCREASED STABILITY OF RHOGDIβ mRNA IN VITRO AND IN VIVO
Junlan Zhu*, Yang Li, Chuanshu Huang, Xue-Ru Wu, New York, NY

MP34-13 NEOADJUVANT SORAFENIB, GEMCITABINE, AND CISPLATIN (SGC) FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIUBC): FINAL RESULTS AND TRANSLATIONAL FINDINGS OF AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY.
Andrea Necchi*, Salvatore Lo Vullo, Daniele Raggi, Patrizia Giannatempo, Nicola Nicolai, Davide Biasoni, Mario Catanzaro, Tullo Torelli, Silvia Stagni, Giuseppina Calareso, Elena Togliardi, Maurizio Colecchia, Adele Busico, Federica Perrone, Luigi Mariani, Roberto Salvioni, Milan, Italy

MP34-14 THE EFFECT OF ADJUVANT CHEMOTHERAPY FOR PATIENTS WITH ADVERSE PATHOLOGY AFTER NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
William Parker*, Elizabeth Habermann, Courtney Day, Harras Zaid, Igor Frank, R. Houston Thompson, Matthew Tollefson, Stephen Boorjian, Lance Pagliaro, R. Jeffrey Kames, Rochester, MN

MP34-15 A EUROPEAN MULTI-CENTRE REPORT ON CURRENT NEOADJUVANT CHEMOTHERAPY ADMINISTRATION RATES IN ROBOT-ASSISTED RADICAL CYSTECTOMY PATIENTS AND THE IMPACT ON PATHOLOGICAL STAGING
Justin Collins*, Abolfazl Hosseini, Christopher Adding, Stockholm, Sweden, Anthony Koupparis, Edward Rowe, Bristol, United Kingdom, Matthew Perry, Rami Issa, London, United Kingdom, Tommy Nyberg, Stockholm, Sweden, Martin Schumacher, Aarau, Switzerland, Carl Wijburg, Arnhem, Netherlands, A. Erdem Canda, Ankara, Turkey, Mevlana Balbay, Istanbul, Turkey, Karel Decaestecker, Ghent, Belgium, Christian Schwentner, Arnulf Stenzl, Tuebingen, Germany, Sebastian Edeling, Sasa Pokupik, Hanover, Germany, Ferderiek D’Hondt, Alexandre Mottrie, Aalst, Belgium, Peter Wiklund, Stockholm, Sweden

MP34-16 COULD ADJUVANT CHEMOTHERAPY HAVE THERAPEUTIC BENEFIT AFTER NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH EQUAL TO OR GREATER THAN PT3 MUSCLE INVASIVE BLADDER CANCER?
Minami Omura*, Eiji Kikuchi, Koichiro Ogihara, Kyoei Hakozaki, Keishiro Fukumoto, Tokyo, Japan, Go Kaneko, Yasumasa Miyazaki, Kanagawa, Japan, Nobuyuki Tanaka, Suguru Shirotake, Kunimitsu Kanai, Saitama, Japan, Kazuhiro Matsumoto, Hirohiko Nagata, Akira Miyajima, Mototsugu Oya, Tokyo, Japan

MP34-17 PROGNOSTIC SIGNIFICANCE OF SERUM ♦-GLUTAMYLTRANSFERASE IN ADVANCED UROTHELIAL CARCINOMA PATIENTS
Hiroshi Fukushima*, Yasukazu Nakanishi, Madoka Kataoka, Ken-ichi Tobisu, Fumitaka Koga, Tokyo, Japan

MP34-18 EARLY DETECTION OF ASYMPTOMATIC VISCERAL RECURRENCE BY ROUTINE CT SCAN AFTER RADICAL CYSTECTOMY CONTRIBUTES BETTER PROGNOSIS IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
Ayumu kusaka*, Shingo Hatakeyama, Hayato Yamamoto, Atsushi Imai, Takahiro Yoneyama, Yasuhisa Hashimoto, Takuya Koie, Chikara Ohyama, Hiroaki Nakata, Tokyo, Japan

MP34-19 EFFECT OF HISTOLOGICAL VARIANTS ON THE OUTCOMES OF RADICAL CYSTECTOMY FOR NON-METASTATIC MUSCLE-INVASIVE URINARY BLADDER CANCER

*Presenting author
MP34-20 CAN RADICAL CYSTECTOMY BE PERFORMED SAFELY IN THE METASTATIC SETTING? LOCATION OF METASTATIC BLADDER CANCER AS A DETERMINANT OF IN-HOSPITAL MORTALITY
Emanuele Zaffuto*, Marco Moschini, Milan, Italy, Sami-Ramzi Leyh-Bannurah, Hamburg, Germany, Stephanie Gazdovich, Montreal, Canada, Paolo Dell’Oglio, Milan, Italy, Raisa S. Pompe, Hamburg, Germany, Shahrokh F. Shariat, Vienna, Austria, Francesco Montorsi, Alberto Briganti, Milan, Italy, Fred Saad, Pierre I. Karakiewicz, Montreal, Canada

ABSTRACT

PD21-01
DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE AFTER SURGERY: URETEROSCOPIC VERSUS SHOCK WAVE LITHOTRIPSY
Shuzo Hamamoto*, Teruaki Sugino, Rei Unno, Kazumi Taguchi, Ryosuke Ando, Nagoya, Japan, Shinsuke Okada, Chiba, Japan, Takaaki Inoue, Osaka, Japan, Atsushi Okada, Keiichi Tozawa, Takahiro Yasui, Nagoya, Japan

PD21-02
MINIMIZING THE COST OF TREATING ASYMPTOMATIC URETEROLITHIASIS
Remy Lamberts*, Simon conti, John Leppert, Christopher Elliott, Stanford, CA

PD21-03
PERCUTANEOUS ACCESS OBTAINED BY UROLOGIST IS ASSOCIATED WITH DECREASED COMPLICATIONS, SHORTER LENGTH OF STAY, AND LOWER HOSPITAL COSTS IN PCNL
Ruslan Korets*, Jacqueline M Speed, Ye Wang, Steven L Chang, Boston, MA

PD21-04
COMPARISON OF ULTRASOUND-GUIDED, CONVENTIONAL FLUOROSCOPIC, AND A NOVEL LASER DIRECT ALIGNMENT RADIATION REDUCTION TECHNIQUE FOR PERCUTANEOUS NEPHROLITHOTOMY
Samuel Abourbih*, Mohamed Keheila, Patrick Yang, Muhammad Alsyouf, Jason Smith, Braden Mattison, Nazih Khater, Jim Shen, Salim Cherian, D. Duane Baldwin, Loma Linda, CA

PD21-05
A NEW NAVIGATION SYSTEM OF RENAL PUNCTURE FOR ENDOSCOPIC COMBINED INTRARENAL SURGERY: REAL-TIME VIRTUAL SONOGRAPHY-GUIDED RENAL ACCESS
Shuzo Hamamoto*, Teruaki Sugino, Rei Unno, Kazumi Taguchi, Ryosuke Ando, Nagoya, Japan, Shinsuke Okada, Chiba, Japan, Takaaki Inoue, Osaka, Japan, Atsushi Okada, Keiichi Tozawa, Takahiro Yasui, Nagoya, Japan

PD21-06
“DOES SIZE OF SHEATH MATTER?” FOR MINIMALLY INVASIVE PERCUTANEOUS NEPHROLITHOTOMY: OUR PROSPECTIVE AND RANDOMIZED TRIAL FOR SMALL SIZE (10-20 MM) RENAL CALCULI
Ajay Bhandarkar*, Vadodara, India

PD21-07
PROSPECTIVE RANDOMIZED STUDY OF FLEXIBLE URETEROSCOPIC HOLMIUM LASER LITHOTRIPSY USING HIGH-FREQUENCY STONE DUSTING VERSUS A LOW-FREQUENCY STONE BREAKING PROTOCOL FOR THE TREATMENT OF RENAL STONES LARGER THAN 2 CM
Abhishek Singh*, Abhinav Jain, Arvind Ganpule, Ravindra Sabnis, Mahesh Desai, Nadiad, India

PD21-08
IS ENDOSCOPIC EVALUATION AT THE END OF RETROGRADE INTRA-RENAL SURGERY A RELIABLE PREDICTOR OF POST-OPERATIVE SIGNIFICANT RESIDUAL FRAGMENTS?
Andrea Bosio*, Eugenio Alessandria, Ettore Dalmasso, Dario Peretti, Federico Vitiello, Alessandro Biscotti, Paolo Destefanis, Paolo Gorrono, Turin, Italy
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50</td>
<td>PD21-09</td>
<td>TRUE STONE FREE RATES OF FLEXIBLE URETEROSCOPY FOR RENAL CALCULI UTILIZING STRICT CT CRITERIA</td>
<td>Nadya E. York*, Hazem M. Elmansy, Marcelino E. Rivera, Amy E. Krambeck, James E. Lingeman, Indianapolis, IN</td>
</tr>
<tr>
<td>11:00</td>
<td>PD21-10</td>
<td>ACTIVE STONE REMOVAL CAN PREVENT UROLITHIASIS-RELATED DEATHS IN PATIENTS WITH POOR PERFORMANCE STATUS.</td>
<td>Shimpei Yamashita*, Yasuo Kohjimoto, Takashi Iguchi, Akinori Iba, Isao Hara, Wakayama, Japan</td>
</tr>
<tr>
<td>11:10</td>
<td>PD21-11</td>
<td>PCNL IN GERIATRIC PATIENTS: AN EVALUATION OF OUTCOMES, COMPLICATIONS AND DISCHARGE NEEDS</td>
<td>Brandon Otto, Russell Terry*, John Shields, Forat Lutti, Mohit Gupta, Vincent Bird, Gainesville, FL</td>
</tr>
<tr>
<td>11:20</td>
<td>PD21-12</td>
<td>ECIRS (ENDOSCOPIC COMBINED INTRARENAL SURGERY) IN THE GALKADAKAO-MODIFIED SUPINE VALDIVIA POSITION</td>
<td>Cesare Marco Scoffone*, Cecilia Cracco, Torino, Italy</td>
</tr>
</tbody>
</table>

**Podium Session 22**

**SEXUAL FUNCTION/DYSFUNCTION: SURGICAL THERAPY II**

**Room 161 @ Boston Convention & Exhibition Center**

**Moderators:** Arthur Burnett, Ian Eardley and Ricardo Munarriz

**ABSTRACT**

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD22-01</td>
<td>GLANS NECROSIS FOLLOWING PENILE IMPLANT: WHAT CAN BE LEARNED?</td>
<td>Steven Wilson*, Cesar Mora-Estaves, La Quinta, CA, Paulo Egydio, Sao Paulo, Brazil, David Ralph, London, United Kingdom</td>
</tr>
<tr>
<td>9:40</td>
<td>PD22-02</td>
<td>LONG ACTING PREOPERATIVE LOCAL ANESTHETIC BLOCK TO LIMIT OPIOID ADMINISTRATION AFTER INFLATABLE PENILE PROSTHESIS INSERTION</td>
<td>John Griffith*, Robert Valenzuela, New York, NY</td>
</tr>
<tr>
<td>9:50</td>
<td>PD22-03</td>
<td>OXIDIZED REGENERATED CELLULOSE (FIBRILLAR™) REDUCES RISK OF POSTOPERATIVE HEMATOMA FOLLOWING INFLATABLE PENILE PROSTHESIS</td>
<td>Alexander Rozanski*, Alexander Liu, Nabeel Shakir, Boyd Viers, Travis Pagliara, Billy Cordon, Maia VanDyke, Jeremy Scott, Allen Morey, Dallas, TX</td>
</tr>
<tr>
<td>10:10</td>
<td>PD22-04</td>
<td>&quot;DISTAL CORPORAL ANCHORING STITCH&quot; A TECHNIQUE TO ADDRESS DISTAL CORPORAL CROSVERS AND IMPENDING LATERAL EXTURSIONS OF A PENILE PROSTHESIS</td>
<td>Gian Maria Busetto*, Gabriele Antonini, Francesco Del Giudice, Ettore De Berardinis, Roma, Italy, Paul E. Perito, Coral Gables, FL</td>
</tr>
<tr>
<td>10:20</td>
<td>PD22-05</td>
<td>HIGH SUBMUSCULAR PLACEMENT OF UROLOGIC PROSTHETIC BALLOONS AND RESERVOIRS: REVIEW OF 500 CASE EXPERIENCE AND REFINED TECHNIQUE FOR OPTIMAL OUTCOMES</td>
<td>Travis Pagliara*, Boyd Viers, Jeremy Scott, Allen Morey, Dallas, TX</td>
</tr>
<tr>
<td>10:30</td>
<td>PD22-06</td>
<td>REAR TIP EXTENDERS DURING INFLATABLE PENILE PROSTHESIS PLACEMENT: IMPACT ON NEED FOR REVISION</td>
<td>Kenneth DeLay*, Andrew Gabrielson, New Orleans, LA, Faysal Yafi, Orange, CA, Wayne Hestrom, New Orleans, LA</td>
</tr>
<tr>
<td>10:40</td>
<td>PD22-07</td>
<td>SUBTUNICAL VERSUS CONVENTIONAL PENILE PROSTHESIS IMPLANTATION A PROSPECTIVE RANDOMIZED STUDY</td>
<td>Osama Abdelwahab*, Tarek Soliman, Hammouda Sherif, Benha, Egypt, Mohamed Habous, Jeddah, Saudi Arabia, John Mulhall, NY, NY</td>
</tr>
<tr>
<td>10:50</td>
<td>PD22-08</td>
<td>TIMES ARE A CHANGING: DEFINING THE SPECTRUM OF BACTERIA CAUSING INFLATABLE PENILE PROSTHESIS INFECTIONS IN THE ERA OF INFECTION-RETARDANT COATED DEVICES.</td>
<td>Bruce Kava*, Miami, FL, Steven Wilson, LaQuinta, CA</td>
</tr>
<tr>
<td>11:00</td>
<td>PD22-09</td>
<td>NEW DATA REGARDING HIV STATUS AS A PREDICTOR OF POSTOPERATIVE IPP INFECTION</td>
<td>Martin Gross*, Keene, NH, Jared Wallen, Tampa, FL, SriGita Madiraju, Kevin Tayon, Boca Raton, FL, Nathan Davoudzadeh, Harris Nagler, New York City, NY, Paul Perito, Miami, FL, Ricardo Munarriz, Boston, MA, Doron Stember, New York City, NY</td>
</tr>
<tr>
<td>11:10</td>
<td>PD22-10</td>
<td>PENILE PROSTHESIS IN SOLID ORGAN TRANSPLANT RECIPIENTS – A MATCHED COHORT STUDY</td>
<td>Andrew Sun*, Paurush Babbar, Nitin Yerram, Hans Arora, Drogo Montague, Bradley Gill, Cleveland, OH</td>
</tr>
</tbody>
</table>

*Presenting author
A CUT-OFF HBA1C VALUE OF 8.5% PREDICTS INCREASED RISK OF PENILE IMPLANT INFECTION
Mohamad Habous*, Jedda, Saudi Arabia, Raanan Tal, New York, NY, Osama Abdelwahab, Benha, Egypt, Osama Laban, Tabouk, Saudi Arabia, Saad Mahmoud, Jedda, Saudi Arabia, Alaa Tsaolab, Zagazig, Egypt, Saleh Binsaleh, Riyadh, Saudi Arabia, John Mulhall, New York, NY

A RETROSPECTIVE ANALYSIS OF THE INFLUENCE OF HIGH DOSE GENTAMICIN ON IPP INFECTION RATES
Martin Gross*, Keene, NH, Jared Wallen, Tampa, FL, SriGita Madiraju, Kevin Tayon, Boca Raton, FL, Ricardo Munariz, Boston, MA, Paul Perito, Miami, FL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 13, 2017 9:30 am - 11:30 am
Podium Session 23
BENIGN PROSTATIC HYPERPLASIA: SURGICAL THERAPY & NEW TECHNOLOGY III
Room 162 @ Boston Convention & Exhibition Center
Moderators: Andreas Gross, Steven Kaplan and Kevin Zorn

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40</td>
<td>PD23-02</td>
<td>TRANSURETHRAL ENucleATION WITH BIPOLAR FOR BENIGN PROSTATIC HYPERPLASIA: 2-YEAR OUTCOME AND LEARNING CURVE BASED ON A SINGLE SURGEON’S EXPERIENCE WITH 584 CONSECUTIVE PATIENTS Yosuke Hirasawa*, Tokyo, Japan, Yuji Kato, Kiichiro Fujita, Saitama, Japan</td>
</tr>
<tr>
<td>9:50</td>
<td>PD23-03</td>
<td>PROSPECTIVE RANDOMIZED STUDY COMPARING MONOPOLAR WITH BIPOLAR TRANSURETHRAL RESECTION OF PROSTATE ON A LARGE COHORT OF PATIENTS WITH BENIGN PROSTATIC OBSTRUCTION: LONG TERM OUTCOMES Giovanni Palleschi*, Antonio Luigi Pastore, Yazan Al Salhi, Andrea Fuschis, Gennaro Velotti, Antonino Leto, Antonio Carbone, Latina, Italy</td>
</tr>
<tr>
<td>10:00</td>
<td>PD23-04</td>
<td>THULIUM LASER ENucleATION (THULEP) VERSUS TRANSURETHRAL RESECTION OF THE PROSTATE IN SALINE (TURIS): A RANDOMIZED PROSPECTIVE TRIAL TO COMPARE COSTS PER PROCEDURE Giorgio Bozzini*, Castellanza, Italy, Stefano Casellato, Serena Maruccia, Monza, Italy, giovanni saredi, varese, Italy, paolo parma, mantova, Italy, Gianluigi Taverna, Castellanza, Italy</td>
</tr>
<tr>
<td>10:10</td>
<td>PD23-05</td>
<td>INFERIOR TISSUE ABLATION AFTER 120W GREENLIGHT LASER VAPORIZATION DOES NOT TRANSLATE INTO INFERIOR CLINICAL OUTCOME COMPARED CONVENTIONAL TURP: 3-YEAR RESULTS OF A PROSPECTIVE 3D ULTRASOUND VOLUMETRY STUDY Benedikt Kranzbu¨hler*, Oliver Gross, Christian D. Fankhauser, Marian S. Wettstein, Nico C. Grossmann, Etienne X. Keller, Daniel Eberl, Tullio Sulser, Cédric Poyet, Thomas Herrmanns, Zurich, Switzerland</td>
</tr>
<tr>
<td>10:20</td>
<td>PD23-06</td>
<td>THULIUM VAPOENUCLEATION OF THE PROSTATE VERSUS HOLMIUM LASER ENUCLEATION OF THE PROSTATE: 6-MONTH SAFETY AND EFFICACY RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL Christopher Netsch*, Benedikt Becker, Christian Tiburtius, Christina Moritz, Arcangelo Vennervi Becci, Hamburg, Germany, Thomas Herrmann, Hannover, Germany, Andreas Gross, Hamburg, Germany</td>
</tr>
<tr>
<td>10:30</td>
<td>PD23-07</td>
<td>EFFECT OF HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) ON THE SEXUAL FUNCTION Petr Glybochko, Yuriy Alyaev, Leonid Rapoport, Mikhail Enikeev, Dmitry Enikeev*, Nikolay Sorokin, Roman Sukhanov, Alim Dymov, Otabek Khamraev, Denis Davydov, Mark Taratkin, Moscow, Russian Federation</td>
</tr>
<tr>
<td>10:40</td>
<td>PD23-08</td>
<td>TRUE COST OF MORCELLATION: COMPARISON OF THE LUMENS® VERSACUT™ AND WOLF PIRANHA MORCELLATORS Marcelino Rivera*, James Lingeman, Nadya York, Hazem Elmansy, Amy Krambeck, Indianapolis, IN</td>
</tr>
</tbody>
</table>

122
### Podium Session 24

PROSTATE CANCER: ADVANCED (INCLUDING DRUG THERAPY) I

**Room 205 BC @ Boston Convention & Exhibition Center**

**Moderator:** E. David Crawford

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD24-01</td>
<td>COMPARATIVE ASSESSMENT OF EFFICACIES BETWEEN TWO ALTERNATIVE THERAPEUTIC SEQUENCES WITH NOVEL ANDROGEN RECEPTOR-AXIS-TARGETED AGENTS IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER</td>
<td>Yuto Matsushita*, Hideaki Miyake, Seiichiro Ozono, Hamamatsu, Japan</td>
<td></td>
</tr>
<tr>
<td>9:40</td>
<td>PD24-02</td>
<td>68GA-PSMA PET/CT IMPROVES BIOCHEMICAL RESPONSE AFTER SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENTNESS IN PROSTATE CANCER PATIENTS</td>
<td>Annika Herlemann*, Alexander Kretschmer, Alexander Buchner, Alexander Karl, Stefan Tritschler, Lina El-Malazi, Vera Wenter, Harun Ilhan, Peter Bartenstein, Christian Georg Stief, Christian Gratzke, Munich, Germany</td>
<td></td>
</tr>
</tbody>
</table>

**9:50** PD24-03

ONCOLOGICAL OUTCOMES OF PATIENTS TREATED WITH SALVAGE LYMPHNODE DISSECTION (SLND) FOR POSITRON-EMISSION TOMOGRAPHY (PET) POSITIVE PROSTATE CANCER (PCA) RELAPSE

Andreas Hiester*, Duesseldorf, Germany, Alessandro Nini, Milan, Italy, Günter Niegisch, Peter Albers, Volker Mueller-Mattheis, Robert Rabenalt, Duesseldorf, Germany

**10:00** PD24-04

THE IMPORTANCE OF IMAGING STUDIES TO MONITOR TREATMENT WITH NOVEL AR-TARGETED AGENTS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)

Isabel Heidegger*, David Pfister, Daniel Porres, Pia Paffenholz, Axel Heidenreich, Köln, Germany

**10:10** PD24-05

IMPACT OF ABRIRATONERE ACETATE IN THE POST-DOCETAXEL SETTING ON THE SURVIVAL OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A POPULATION-BASED STUDY IN QUEBEC

Alice Dragomir*, Joice Rocha, Marie Vanhuysse, Fabio Cury, Jason Hu, Noémie Prévost, Armen Aprikian, Montreal, Canada

---

*Presenting author
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45</td>
<td>STI SCREENING AND MANAGEMENT</td>
<td>Michelle Lajiness</td>
<td>5:00</td>
<td>ADJOURN</td>
<td></td>
</tr>
<tr>
<td>4:20</td>
<td>MANAGEMENT OF MALE CHRONIC PELVIC PAIN/SCROTAL PAIN/TESTICULAR PAIN</td>
<td>Susanne Quallich</td>
<td></td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td>Q&amp;A ON INFECTIONS</td>
<td>Michelle Lajiness, Susanne Quallich</td>
<td>5:00</td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>

Saturday, May 13, 2017  
12:30 pm - 5:00 pm

SOCIETY OF UROLOGIC ONCOLOGY (SUO)  
Grand B @ Westin Waterfront

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45</td>
<td>INTRODUCTION TO THE WHITMORE LECTURE</td>
<td>Colin Dinney</td>
<td>3:26</td>
<td>HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER</td>
<td>Charles Drake, Wassim Kassouf</td>
</tr>
<tr>
<td>12:55</td>
<td>WHITMORE LECTURE</td>
<td></td>
<td>3:38</td>
<td>NON-MUSCLE INVASIVE BLADDER CANCER GUIDELINES</td>
<td>Stephen Boorjian, Maria Ribal</td>
</tr>
<tr>
<td>1:25</td>
<td>BEST PROSTATE CANCER PAPERS FROM PAST YEARS</td>
<td>Mark A. Preston</td>
<td>4:10</td>
<td>KIDNEY CANCER: ACCURATE DIAGNOSIS AND TARGETED TREATMENT</td>
<td>Moderator: Antonio Finelli</td>
</tr>
<tr>
<td>1:40</td>
<td>GENETIC TESTING IN INHERITED PROSTATE CANCER RISK: CONSENSUS STATEMENT</td>
<td>Veda Giri</td>
<td>4:20</td>
<td>ROLE OF BIOPSY IN THE MANAGEMENT OF SMALL RENAL MASSES</td>
<td>Tracey Krupski</td>
</tr>
<tr>
<td>1:55</td>
<td>REFLEX TESTING WITH SERUM, URINE, AND TISSUE BIOMARKERS - WHICH, WHEN AND HOW VALUABLE?</td>
<td>Stacy Loeb</td>
<td>4:30</td>
<td>CYSTIC RENAL MASSES: RADIOGRAPHIC ASSESSMENT AND MANAGEMENT</td>
<td>Vincenzo Ficarra</td>
</tr>
<tr>
<td>2:10</td>
<td>MULTIPARAMETRIC MRI - WHEN, WHO, AND HOW TO INTERPRET?</td>
<td>Moderator: Peter Carroll Caroline Moore, Peter Pinto</td>
<td>4:40</td>
<td>THE ROLE OF NEOADJUVANT AND ADJUVANT SYSTEMIC THERAPY IN RCC</td>
<td>Mohamad Allaf</td>
</tr>
<tr>
<td>2:30</td>
<td>HOW I SCREEN - PANEL</td>
<td>H. Ballentine Carter, Kazuto Ito, Nicolas Mottet, J. Kellogg Parsons</td>
<td>4:50</td>
<td>THE REEMERGENCE OF IMMUNOTHERAPY IN RCC AND NOVEL CLINICAL TRIALS</td>
<td>Lauren Harshman</td>
</tr>
<tr>
<td>2:40</td>
<td>BREAK</td>
<td></td>
<td>5:00</td>
<td>ADJOURN</td>
<td></td>
</tr>
<tr>
<td>2:50</td>
<td>BEST KIDNEY CANCER PAPERS FROM THE PAST YEAR</td>
<td>Alexander Kutikov</td>
<td></td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>BEYOND CYTOLOGY: WHAT IS THE URINARY MARKER WE SHOULD USE NOW AND WHAT WILL BE THE BEST IN THE FUTURE?</td>
<td>Kristen Scarpato</td>
<td></td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author*
<table>
<thead>
<tr>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP35-01</td>
<td>ATTITUDES TOWARDS FERTILITY AND REPRODUCTIVE HEALTH AMONG TRANSGENDER ADOLESCENTS</td>
</tr>
<tr>
<td>Diane Chen, Ilina Rosoklija, Courtney Finlayson, Kathryn Macapagal, Brian Mustanski, Emilie Johnson*, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>MP35-02</td>
<td>VARIABLE ADOPTION OF WORLD HEALTH ORGANIZATION 2010 SEMEN ANALYSIS REFERENCE RANGES: THE DIFFERENCE BETWEEN “NORMAL” AND “ABNORMAL” MAY DEPEND ON WHERE YOU GO</td>
</tr>
<tr>
<td>Anuj S. Desai*, Kevin Lewis, Daniel J. Mazur, Barbara E. Kahn, Mary Kate Keeter, Emmanuel Ogele, Chicago, IL, Alexander J. Tatem, Indianapolis, IN, Marah Hehemann, Maywood, IL, Nelson E. Bennett, Robert E. Brannigan, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>MP35-03</td>
<td>SEX HORMONE BINDING GLOBULIN INDEPENDENTLY PREDICTS OLIGOSPERMIA IN MALE FERTILITY PATIENTS</td>
</tr>
<tr>
<td>MP35-04</td>
<td>EFFECT OF MEDICAL COMORBIDITIES AND THEIR TREATMENT ON SPERMATOGENESIS IN MALE INFERTILITY PATIENTS</td>
</tr>
<tr>
<td>Koji Shiraishi*, Shintaro Oka, Hideyasu Matsuyama, Ube, Japan</td>
<td></td>
</tr>
<tr>
<td>MP35-05</td>
<td>HIGH BLOOD PRESSURE IS MORE FREQUENT IN INFERTILE THAN IN AGE-COMPARABLE FERTILE MEN - FINDINGS OF A CASE-CONTROL AND CROSS-SECTIONAL REAL-LIFE STUDY</td>
</tr>
<tr>
<td>Walter Cazzaniga*, Luca Boeri, Eugenio Ventrimiglia, Paolo Capogrosso, Filippo Peferzoli, Roberta Scano, Rayan Matloob, Federico Dehò, Milan, Italy, Emanuele Montanari, Milano, Italy, Franco Gaboardi, Francesco Montorsi, Andrea Salonia, Milan, Italy</td>
<td></td>
</tr>
<tr>
<td>MP35-06</td>
<td>STATIN USE IS NOT DETRIMENTAL TO SEMEN PARAMETERS IN SUBFERTILE MEN</td>
</tr>
<tr>
<td>James M. Hotaling, Sorena Keihani*, James R. Craig, Chong Zhang, Angela P. Presson, Jeremy B. Myers, William O. Brant, Kenneth I. Aston, Benjamin R. Emery, Douglas T. Carrell, Salt Lake City, UT</td>
<td></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP35-07</td>
<td>PROTON-PUMP INHIBITOR USE AND SEMEN QUALITY IN SUBFERTILE MEN: IS THERE A HARMFUL EFFECT?</td>
</tr>
<tr>
<td>Sorena Keihani*, James R. Craig, Chong Zhang, Angela P. Presson, Jeremy B. Myers, William O. Brant, Kenneth I. Aston, Benjamin R. Emery, Douglas T. Carrell, James M. Hotaling, Salt Lake City, UT</td>
<td></td>
</tr>
<tr>
<td>MP35-08</td>
<td>IMPACT OF SEMINAL QUALITY ON THE ANEUPLOIDY EMBRYONIC RATE</td>
</tr>
<tr>
<td>Caudivo Teloken*, David Kvitko, Ricardo Azambuja, Porto Alegre, Brazil, Virginia Reig, Porto Alegre, Brazil, Alice Tagliani-Ribeiro, Alvaro Petracco, Porto Alegre, Brazil, Lilian Okada, Mariangela Badalotti, Porto Alegre, Brazil</td>
<td></td>
</tr>
<tr>
<td>MP35-09</td>
<td>SPERM ANEUPLOIDY IS ASSOCIATED WITH WORSE GENERAL HEALTH IN INFERTILE MEN</td>
</tr>
<tr>
<td>Taylor P. Kohn*, Alexander W. Pastuszak, Katherine M. Rodriguez, Zachary J. Solomon, Matthew F. Cherches, Dolores J. Lamb, Larry I. Lipshultz, Houston, TX</td>
<td></td>
</tr>
<tr>
<td>MP35-10</td>
<td>RELATIONSHIP BETWEEN SEMINAL PARAMETERS AND SPERMAL DNA FRAGMENTATION</td>
</tr>
<tr>
<td>Jose Olmedo*, Rosa Molina, Andrea Tissera, Enzo Malizia, Trisante Dellavedova, Cordoba, Argentina</td>
<td></td>
</tr>
<tr>
<td>MP35-11</td>
<td>HEAVY CIGARETTE SMOKING IS THE MOST DETRIMENTAL FACTOR FOR SPERM DNA FRAGMENTATION – RESULTS OF A CROSS-SECTIONAL STUDY IN PRIMARY INFERTILE MEN</td>
</tr>
<tr>
<td>Luca Boeri*, Filippo Peferzoli, Eugenio Ventrimiglia, Paolo Capogrosso, Walter Cazzaniga, Davide Oreggia, Nicola Fregò, Rayan Matloob, Franco Gaboardi, Milan, Italy, Emanuele Montanari, Milano, Italy, Francesco Montorsi, Andrea Salonia, Milan, Italy</td>
<td></td>
</tr>
<tr>
<td>MP35-12</td>
<td>SURGICAL TREATMENT OF MALE FACTOR INFERTILITY: DOES INSURANCE COVERAGE MATTER?</td>
</tr>
<tr>
<td>Barbara E Kahn*, Daniel J Mazur, Mary Kate Keeter, Chicago, IL, Marah Hehemann, Maywood, IL, Alexander J Tatem, Indianapolis, IN, Anuj S Desai, Kevin Lewis, Daniel Oberlin, Sarah Flury, Nelson E Bennett, Robert E Brannigan, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>ABSTRACT NUMBER</td>
<td>TITLE</td>
</tr>
<tr>
<td>----------------</td>
<td>-------</td>
</tr>
<tr>
<td><strong>MP35-13</strong></td>
<td>VASECTOMY AND THE GENDER GAP: SHIFTING DEMOGRAPHICS OF THE UROLOGIC WORKFORCE</td>
</tr>
<tr>
<td><strong>Alexander J Tatem</strong>*, Indianapolis, IN, Barbara E Kahn, Marah Hehemann, Daniel J Mazur, Anuj S Desai, Daniel Oberlin, Mary Kate Keeter, Kevin Lewis, Sarah Flury, Nelson E Bennett, Robert E Brannigan, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td><strong>MP35-14</strong></td>
<td>DOES THE STUMP SIZE IN VASOVASOSTOMY CAN BE A PREDICTIVE FACTOR TO IMPROVE THE OUTCOMES OF SEMEN ANALYSIS ASSOCIATED WITH VASAL PATENCY?</td>
</tr>
<tr>
<td><strong>Phil Hyun Song</strong>, Jae Young Choi, Young Hwii Ko, Ki Hak Moon***, Hee Chang Jung, Daegu, Korea, Republic of</td>
<td></td>
</tr>
<tr>
<td><strong>MP35-15</strong></td>
<td>TRENDS IN DIAGNOSIS AND MANAGEMENT OF VARICOCELES AMONG U.S. MEN</td>
</tr>
<tr>
<td><strong>Akanksha Mehta</strong>*, Dattatraya Patil, Atlanta, GA</td>
<td></td>
</tr>
<tr>
<td><strong>MP35-16</strong></td>
<td>ISOLATED RIGHT VARICOCELE AND INCIDENCE OF ASSOCIATED CANCER</td>
</tr>
<tr>
<td><strong>Daniel Greene</strong>*, Bradley Gill, Yaw Nyame, Molly Elmer-Dewitt, Samuel Haywood, Edmund Sabanegh, Cleveland, OH</td>
<td></td>
</tr>
<tr>
<td><strong>MP35-17</strong></td>
<td>SPERM ULTRASTRUCTURAL DEFECTS IN MEN WITH SEVERE ASTHENOSPERMIA IS NOT A POOR PROGNOSTICATOR FOR VARICOCELECTOMY OUTCOMES</td>
</tr>
<tr>
<td><strong>Sarah Ferrara</strong>*, Keith Jarvi, Toronto, Canada, Jared Bieniek, Hartford, CT</td>
<td></td>
</tr>
<tr>
<td><strong>MP35-18</strong></td>
<td>ULTIMATE TIME TO IMPROVEMENT IN SEMEN QUALITY AFTER SUBINGUINAL VARICOCELECTOMY</td>
</tr>
<tr>
<td><strong>Ahmed M. Ragheb</strong>, Ayman S. Moussa, Taha A. Ahmed, Amr M. Massoud, Giza, Egypt</td>
<td></td>
</tr>
<tr>
<td><strong>MP35-19</strong></td>
<td>PRIMARY, SECONDARY, AND COMPENSATED HYPOGONADISM: A NOVEL RISK STRATIFICATION FOR INFERTILE MEN</td>
</tr>
<tr>
<td><strong>Eugenio Ventimiglia</strong>, Paolo Capogrosso, Milan, Italy, Luca Boeri, Milano, Italy, Walter Cazzaniga, Filippo Federzoli, Nicola Fregeo, Davide Oreggia, Federico Dehò, Franco Gaboardi, Milan, Italy, Vincenzo Mironcini, Naples, Italy, Francesco Montorsi, Andrea Salonia, Milan, Italy</td>
<td></td>
</tr>
</tbody>
</table>

**Saturday, May 13, 2017**

**Moderated Poster Session 36**

**TRAUMA/RECONSTRUCTION/DIVERSION: URETHRAL RECONSTRUCTION (INCLUDING STRICTURE, DIVERTICULUM) I**

**Room 156 @ Boston Convention & Exhibition Center**

**Moderators: Sean Elliott, Margit Fisch and Ramon Virasoro**

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP36-01</strong></td>
<td>COLLAGEN CELL CARRIER FOR URETHRAL RECONSTRUCTIVE SURGERY: FIRST RESULTS OF A LONG-TERM MINIPIG MODEL</td>
</tr>
<tr>
<td><strong>Stefan Auferklamm</strong>*, Alexandra Kelp, Sabine Maurer, Tübingen, Germany, Silke Busch, Weinheim, Germany, Martin Vaegler, Berlin, Germany, Arnulf Stenzl, Karl-Dietrich Sievert, Bastian Amend, Tübingen, Germany</td>
<td></td>
</tr>
<tr>
<td><strong>MP36-02</strong></td>
<td>CELL-SEEDED ACELLULAR DERMAL MATRIX GRAFT FOR RECONSTRUCTION OF LONG URETHRAL DEFECTS IN A CANINE MODEL</td>
</tr>
<tr>
<td><strong>Li Cheng</strong>, <strong>Jian Lin</strong>*, Zicheng Wang, Beijing, China, People’s Republic of</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP36-03</strong></td>
<td>LOW TESTOSTERONE LEVELS PREDISPOSE TO URETHRAL ATROPHY DUE TO DECREASED URETHRAL VASCULARITY VIA AN ANDROGEN RECEPTOR-MEDIATED PROCESS</td>
</tr>
<tr>
<td><strong>Matthias D Hofer</strong>*, Chicago, IL, Payal Kapur, Billy H Cordon, Farrah Hamoun, David Russell, Jeremy M Scott, Claus G Roehrborn, Allen F Morey, Dallas, TX</td>
<td></td>
</tr>
<tr>
<td><strong>MP36-04</strong></td>
<td>LOW TESTOSTERONE IS COMMON IN PATIENTS WITH ANTERIOR URETHRAL STRICTURE: RISK-FACTOR OR COINCIDENCE?</td>
</tr>
<tr>
<td><strong>Jeffrey Spencer</strong>*, Michael Daughtery, Stephen Blakely, Dmitriy Nikolavsky, Timothy Byler, Syracuse, NY</td>
<td></td>
</tr>
</tbody>
</table>
MP36-05 FACILITATING FASTER WOUND REMODELING AND MATURATION IN A RAT MODEL OF SUBSTITUTION URETHROPLASTY UTILIZING ANTI-INFLAMMATORY NANOFIBERS
Joceline Fuchs*, Matthew Bury, Natalie Fuller, Nida Ahmad, Arun Sharma, Chicago, IL

MP36-06 INFLAMMATION IN URETHRAL STRICTURE SPECIMENS IS UNDERAPPRECIATED, UNDERANALYZED AND IN NEED OF A STANDARDIZED PATHOLOGIC PROTOCOL
Brennan Tesdahl*, Laila Dahmoush, James Mason, Karl Kreder, Bradley Erickson, Iowa City, IA

MP36-07 COMPARISON OF ULTRASONOGRAPHY IMAGING AND PATHOLOGICAL FINDINGS IN BULBAR URETHRAL STRICTURES: A PRELIMINARY REPORT.
Guido Barbagli, Arezzo, Italy, Rosario Caltabiano, Catania, Italy, Sofia Balò, Arezzo, Italy, Salvatore Sansalone*, Roma, Italy, Carla Loreto, Catania, Italy, Massimo Lazzeri, Milano, Italy

MP36-08 UNDERESTIMATION OF URETHRAL STRICTURE LENGTH IN MEN WITH HIGH-GRADE ANTERIOR URETHRAL STRICTURE
Travis Moncrief*, Ronak Gor, Stephanie Jarosek, Lei Zhang, Minneapolis, MN, Neid Alsikafi, Chicago, IL, Alex Vanni, Boston, MA, Benjamin Breyer, San Francisco, CA, Bradley Erickson, Iowa City, IA, Joshua Broghammer, Kansas City, KS, Christopher McClung, Columbus, OH, Jill Buckley, San Diego, CA, Jeremy Myers, Salt Lake City, UT, Zhao Lee, New York City, NY, Bryan Voelzke, Seattle, WA, Sean Elliott, Minneapolis, MN

MP36-09 BUCCAL MUCOSA GRAFT (BMG) FOR FEMALE URETHRAL RECONSTRUCTION IS NOT ASSOCIATED WITH POSTOPERATIVE VOIDING DYSFUNCTION
Angelo Gousse*, Miramar, FL, Lee J. Milas, Hari Tunuguntla, New Brunswick, NJ

MP36-10 URETHROVAGINAL FISTULA REPAIR: LONG-TERM OUTCOMES
Sender Herschorn*, Toronto, Canada

MP36-11 QUALITY OF LIFE AMONG MEN AFTER RECTOURUHERAL FISTULA REPAIR
Lindsay Hampson*, San Francisco, CA, Wade Muncey, Mika Sinanan, Bryan Voelzke, Seattle, WA

MP36-12 PERMANENT PERINEAL URETHROSTOMY FOR COMPLEX ANTERIOR URETHRAL STRICTURES – A CRITICAL APPRAISAL OF LONG TERM OUTCOMES, QUALITY OF LIFE AND SEXUAL HEALTH.
Sanjoy Sureka*, Priyank Yadav, Rahul Soni, Aneesh Srivastava, Uday Singh, Rakesh Kapoor, Lucknow, India

MP36-13 CHANGES IN NOCTURNAL BLADDER DIARY PARAMETERS IN MEN AFTER URETHROPLASTY FOR ANTERIOR URETHRAL STRICTURES
Rajveer Purohit*, Jyoti D. Chouhan, frank copelli, Dennis Robins, Andrew Tam, Jeffrey P Weiss, Brooklyn, NY

MP36-14 EVALUATION OF GENERIC VERSUS CONDITION-SPECIFIC QUALITY OF LIFE INDICATORS FOR SUCCESSFUL URETHRAL STRICTURE SURGERY
Paul H Chung*, Seattle, WA, Alex J Vanni, Burlington, MA, Benjamin N Breyer, San Francisco, CA, Bradley A Erickson, Iowa City, IA, Jeremy B Myers, Salt Lake City, UT, Bryan B Voelzke, Seattle, WA

MP36-15 LIVE SURGERY IN UROLOGY - EVALUATION OF THE EDUCATIONAL BENEFIT OF THE INTERNATIONAL MEETING ON RECONSTRUCTIVE UROLOGY (IMORU)
Victor Schuettfort*, Jesssica Langetepe, Roland Dahlem, Christoph-Philip Reiss, Clemens Rosenbaum, Tim Ludwig, Felix Chun, Margit Fisch, Luis Kluth, Hamburg, Germany

MP36-16 SALVAGE INTERNAL URETHROTOMY FOR MANAGEMENT OF URETHRAL STRICTURE FOLLOWING URETHROPLASTY
Joshua Halpem*, New York, NY, Billy Cordon, Miami Beach, FL, Noel Arnnenakas, Steven Brandes, New York, NY

MP36-17 THE T-PLASTY AS A MODIFIED Y-V-PLASTY FOR THE TREATMENT OF HIGHLY RECURRENT BLADDER NECK STENOSIS: HIGH SUCCESS AND PATIENT’S SATISFACTION RATES
Clemens Rosenbaum*, Philipp Reiss, Oliver Engel, Luis Kluth, Margit Fisch, Roland Dahlem, Hamburg, Germany

MP36-18 PATTERNS AND TIMING OF ARTIFICIAL URINARY SPHINCTER FAILURE
Andrew Cohen*, Chicago, IL, Kristine Kuchta, Sangtae Park, Jaclyn Corrine Milose, Evanston, IL

MP36-19 DE NOVO PENILE DEVIATION AFTER URETHROPLASTY WITH ORAL MUCOSA: A RELEVANT PROBLEM?
Abhishek Pandey*, Cristina Raita, Joern Beier, Hansjörg Keller, Hof, Germany

MP36-20 OUTCOMES OF STAGED URETHROPLASTY IN THE MANAGEMENT OF URETHRAL STRICTURES RELATED TO HYPOSPADIAS
Shree Agrawal*, Amanda Chi, Kenneth Angermeyer, Hadley Wood, Cleveland, OH

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>MP37-01</th>
<th>PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN PHEOCHROMOCYTOMA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yasuhiro Hashimoto*, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Takuya Koie, Chikara Ohyama, Hirosaki, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-02</th>
<th>NUTLIN-3A AS A NOVEL ANTICANCER AGENT FOR ADRENOCORTICAL CARCINOMA WITH CTNNB1 MUTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chenchen Feng*, Shanwen Chen, Shanghai, China, People’s Republic of</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-03</th>
<th>LEVEL OF PRENATAL ADRENAL STEROIDS HORMONES AFFECTS BODY WEIGHT AT BIRTH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Takahiko Mitsu*, Chu-o-city, Japan, Atsuko Araki, Sachiko Itfo, Chihiro Miyashita, Kimihiko Moriya, Takeya Kitta, Kazutoshi Cho, Keita Morioka, Nobuo Shinohara, Sapporo, Japan, Masayuki Takeda, Chu-o-city, Japan, Reiko Kishi, Sapporo, Japan, Katsuya Nonomura, Kushiro, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-04</th>
<th>THE LIMITED VALUE OF REPEATED HORMONAL EXAMINATION IN NONFUNCTIONING ADRENAL INCIDENTALOMAS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Masayuki Tasaki*, Takashi Kasahara, Itsuhiro Takizawa, Vladimir Bilim, Kazuhide Saito, Tsutomu Nishiyama, Yoshihiko Tomita, Niigata, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-05</th>
<th>PREOPERATIVE PLASMA ALDOSTERONE-TO-RENIN RATIO IS A PREDICTOR OF DECREMENT IN GLOMERULAR FILTRATION RATE AFTER ADRENALECTOMY FOR PRIMARY ALDOSTERONISM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Keiko Fujino*, Toshiaki Tanaka, Toshihiro Maeda, Naoya Masumori, Sapporo, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-06</th>
<th>SUPER-SELECTIVE ADRENAL VENOUS SAMPLING IS USEFUL FOR EVALUATING CORTISOL-PRODUCING ADENOMA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Koshiro Nishimoto*, Hidaka, Japan, Kohzoh Makita, Tokyo, Japan, Kanako Kitamoto-Kiriyama, Yokohama, Japan, Tsugio Seki, Colton, CA, Masanori Yasuda, Masafumi Oyama, Hidaka, Japan, Mototsugu Oya, Tokyo, Japan, Masao Omura, Tetsuo Nishikawa, Yokohama, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-07</th>
<th>THE ADRENAL SCORE: A COMPREHENSIVE SCORING SYSTEM FOR STANDARDIZED EVALUATION OF ADRENAL MASS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Xiaochen Zhou, Bin Fu, Weipeng Liu, Cheng Zhang, Gongxian Wang*, Nanchang, China, People’s Republic of</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-08</th>
<th>A NEW INSIGHT FOR THE TREATMENT OF PRIMARY MACRONODULAR ADRENAL HYPERPLASIA: ADRENAL SPARING SURGERY EARLY OUTCOMES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fabio Tanno*, Victor Srougi, Vania Brondani, Madson Almeida, Berenice Mendonca, Miguel Srougi, Jose Chambo, Maria Fragoso, Sao Paulo, Brazil</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-09</th>
<th>CLINICAL OUTCOME OF LAPAROSCOPIC ADRENALECTOMY IN SUB CLINICAL CUSHING SYNDROME; IS SURGICAL REMOVAL BETTER OR NOT?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Miki Fuse*, Shinichi Sakamoto, Kodai Sato, Takaaki Tamura, Akinori Takei, Satoshi Yamamoto, Yusuke Imamura, Koji Kawamura, Takashi Imamoto, Akira Komiya, Tomohiko Ichikawa, Chiba, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-10</th>
<th>INCIDENCE AND RISK FACTORS FOR ADRENAL INSUFFICIENCY FOLLOWING UNILATERAL ADRENALECTOMY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jeffrey B. Walker*, Brian D. Saunders, Kathleen Lehman, Jay D. Raman, Hershey, PA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-11</th>
<th>LAPAROSCOPIC VS. OPEN ADRENALECTOMY: UROLOGIC OUTCOMES FROM A NATIONAL PROSPECTIVE DATABASE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pamela W. Lu, Valary Raup*, Malte Vetterlein, Bjorn Loeppenberg, Christian Meyer, Quoc-Dien Trinh, Jairam Esware, Boston, MA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MP37-12</th>
<th>ROBOTIC EXCISION OF LARGE ADRENAL TUMORS VIA RETROPERITONEAL APPROACH: EXPERIENCE FROM 21 CASES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Xiaochen Zhou, Bin Fu, Weipeng Liu, Cheng Zhang, Gongxian Wang*, Nanchang, China, People’s Republic of</td>
</tr>
</tbody>
</table>
MP37-13 OUTCOMES OF ADRENALECTOMY FOR ADRENAL METASTASIS OF RENAL CELL CARCINOMA IN THE ERA OF ADRENAL-SPARING RADICAL NEPHRECTOMY: A MULTICENTER STUDY
benoit peyronnet*, rennes, France, nadja schoentgen, brest, France, andrea manunta, rennes, France, jean-baptiste beauval, toulouse, France, francck bruyere, tours, France, francois-xavier nouhaud, toulouse, France, georges fournier, renou, France, alexandre gryn, toulouse, France, tristan grevez, tours, France, benjamin prade, rennes, France, samy oumakhlouf, rouen, France, mathieu thoulouzan, toulouse, France, adham ramnal, orteans, France, anna goujon, rennes, France, michel soulié, toulouse, France, fabien saint, amiens, France, vincent joulin, brest, France, eric huyghe, toulouse, France, karim bensalah, rennes, France

MP37-14 ONCOLOGICAL OUTCOMES OF RADICAL NEPHROURETERECTOMY WITH AND WITHOUT SYNCHRONOUS IPSILATERAL ADRENALECTOMY
benoit peyronnet*, quentin alimi, gregory verhoest, lauranne tondut, vivien graffeille, anne goujon, roomain mathieu, andrea manunta, solene-florences kaimmer-jaquet, nathalie roux-leclercq, karim bensalah, rennes, France

MP37-15 CONTRALATERAL ADRENAL THICKNESS PREDICTS THE DURATION OF PROLONGED POST-SURGICAL STEROID REPLACEMENT FOR SUBCLINICAL CUSHING SYNDROME
Yusuke Imamura*, Masahiro Sugiura, Satoshi Yamamoto, Tomokazu Sazuka, Miki Fuse, Kazuyoshi, Nakamura, Shinichi Sakamoto, Koji Kawamura, Takashi Imamoto, Akira Komiya, Tomohiko Ichikawa, Chiba, Japan

MP37-16 PROGNOSIS OF PATIENTS WITH MALIGNANT ADRENALECTOMY: A CONDITIONAL PROBABILITY ANALYSIS
Wenjun Xiao*, Yao Zhu, Dingwei Ye, Shanghai, China, People's Republic of

MP37-17 EVALUATION OF THE ACCURACY OF THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM (NSQIP) RISK CALCULATOR FOR PREDICTING COMPLICATIONS FOLLOWING ADRENALECTOMY
Jeffrey B. Walker*, Brian D. Saunders, Kathleen Lehman, Jay D. Raman, Hershey, PA

MP37-18 LONGITUDINAL EVALUATION OF HEALTH RELATED QUALITY OF LIFE FOLLOWING LAPAROSCOPIC ADRENALECTOMY: IMPACT OF ADRENALECTOMY ON CORTISOL PRODUCING ADENOMA.
Shogo Inoue*, Tetsutaro Hayashi, Keisuke Hieda, Shunsuke Shinmei, Jun Teishima, Akio Matusbara, Hiroshima, Japan

MP37-19 SHORT-TERM IMPACT ON HEALTH-RELATED QUALITY OF LIFE OF LAPAROSCOPIC ADRENALECTOMY FOR PRIMARY ALDOSTERONISM IN JAPANESE PATIENTS
Yosshihide Kawasaki*, Yasuhiro Kaiho, Hideaki Izumi, Naoki Kawamorita, Shinichi Yamashita, Hisanobu Adachi, Koji Mitsuzuka, Akihiro Ito, Shigeto Ishidoya, Yoichi Arii, Sendai, Japan

MP37-20 NEW SEVERITY CLASSIFICATION SCALE FOR PHEOCHROMOCYTOMAS
Joel Hillelsohn*, Michael Zhang, Michael Stern, John Phillips, Valhalla, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP38-03 PREDICTIVE VALUE OF MULTIPARAMETRIC MRI (MP-MRI) FOR THE DETECTION OF PROSTATE CANCER USING 12-CORE TRUS-GUIDED PROSTATE BIOPSY – A UNITED KINGDOM MULTICENTER STUDY
Iqbal Miakhil*, Peterborough, United Kingdom, Peter Macneal, Eastbourne, United Kingdom, Ianish Sadien, Peterborough, United Kingdom, Tian Tian Yeong, Eastbourne, United Kingdom, Tim Larner, Brighton, United Kingdom, Sashi Kommu, Eastbourne, United Kingdom, Chris Lockett, Peterborough, United Kingdom, Steve Gamett, Peter Rimington, Eastbourne, United Kingdom

MP38-04 IS AN UPGRADED PIRADS 4 EQUIVALENT TO A TRUE PIRADS 4? A VALIDATION OF PIRADS VERSION 2 IN A PROSPECTIVE COHORT OF MEN UNDERGOING MRI-US FUSION BIOPSY OF THE PROSTATE
Nachiketh Soodana Prakash*, Pratik Kanabur, Leonardo Kayat Bittencourt, Vivek Venkatramani, Bruno Nahar, Sanjaya Swain, Chad Ritch, Mark Gonzalbo, Dipen Parekh, Sanoj Punnfen, Miami, FL

MP38-05 DEFINING A COHORT OF MEN WHO MAY NOT REQUIRE REPEAT PROSTATE BIOPSY BASED ON PCA3 AND MRI: THE DOUBLE NEGATIVE EFFECT.
Nathan Perlis*, Thamir Al-Kasab, Ardalan Ahmad, Estee Goldberg, Kamel Fadaak, Rashid Sayyid, Antonio Finelli, Girish Kulkarni, Alexandre Zlotta, Rob Hamilton, Neil Fleschner, Toronto, Canada

MP38-06 ZERO HOSPITAL ADMISSIONS FOR INFECTION AFTER 1359 TRANSPERINEAL PROSTATE BIOPSIES
Lana Pepdjonovic, Sean Huang, Anthony Dat, Sarah Mann, Mark Frydenberg, Daniel Moon, Ross Snow, Uri Hanegbi, Adam Landau, Jeremy Grummet*, Melbourne, Australia

MP38-07 SHOULD WE AIM FOR THE CENTRE OF AN MRI PROSTATE LESION? CORRELATION BETWEEN MPMRI AND 3-DIMENSIONAL 5MM TRANSPERINEAL PROSTATE BIOPSY MAPPING FROM THE PROMIS TRIAL.

MP38-08 EVIDENCE OF GRADE PROGRESSION FROM LONG-TERM FOLLOW-UP OF COHORTS NOT SUBJECT TO PROSTATE-SPECIFIC ANTIGEN SCREENING

MP38-09 PROSTATE-SPECIFIC ANTIGEN (PSA) LEVELS IN MEN AGED 60 TO 70 AND DEVELOPMENT OF LETHAL PROSTATE CANCER OVER 30 YEARS: IMPLICATIONS FOR RISK-STRATIFIED SCREENING
Mark Preston*, Mary Kathryn Downer, Boston, MA, Travis Gerke, Tampa, FL, Sigrid Carlsson, New York, NY, Howard Sesso, Adam Kibel, Quoc-Dien Trinh, Boston, MA, Hans Lilja, Andrew Vickers, New York, NY, Kathryn Wilson, Lorelei Mucci, Boston, MA

MP38-10 COMPLICATIONS FOLLOWING EXTENDED TRANSPERINEAL TEMPLATE MAPPING MRI/TRUS FUSION BIOPSY OF THE PROSTATE – INITIAL EXPERIENCE FROM 421 PROCEDURES
Oliver Gross*, Basil Kaufmann, Ashkan Mortezavi, Olivia Maerzendorfer, Marian Wettstein, Tullio Sulser, Daniel Eberli, Zürich, Switzerland

MP38-11 PROSTATE CANCER VOLUME ON 3-TESLA MULTIPARAMETRIC DIFFERENT SEQUENCES: CORRELATED AND VERIFIED ON WHOLE MOUNT HISTOPATHOLOGY SECTIONED WITH 3D-PRINTED CUSTOM-DESIGNED MOLDS
Pooja Khoshoonoo*, Sepideh Shakeri, Alan Priester, Nazanin Avsadi, Ashkan Shademian, Leila Mostafavi, Ely Felker, Los Angeles, CA, Daniel Margolis, New York, NY, Anthony Sisk, Robert Reiter, Steven Raman, Los Angeles, CA

MP38-12 PROPENSITY SCORE ANALYSIS OF PATHOLOGICAL OUTCOME AT RADICAL PROSTATECTOMY FOR MAGNETIC RESONANCE IMAGING-TRANSRECTAL ULTRASOUND FUSION PROSTATE BIOPSY VERSUS UNTARGETED EXTENDED TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY
Hans Arora*, Ahmed Elshafei, Yaw Nyame, Daniel Sun, Helen Liang, Niltin Yerram, Daniel Greene, Dominic Grimberg, Karishma Gupta, Shree Agrawal, Sudhir Isharwal, Paurush Babbar, Andrew Sun, Khaled Fareed, Michael Gong, Ryan Berglund, Eric Klein, Andrew Stephenson, Andrei Purysko, J. Stephen Jones, Cleveland, OH

MP38-13 OUTCOMES OF MRI-US FUSION-TARGETED BIOPSY IN MEN WITH NO PREVIOUS BIOPSY: OPPORTUNITY TO REDUCE BIOPSY UTILIZATION AND SECONDARY OVER-DETECTION
Xiaosong Meng*, Andrew Rosenkrantz, Fang-Ming Deng, Richard Huang, James Wysock, Marc Bjurlin, William C. Huang, Herbert Lepor, Samir S. Tanerja, New York, NY
MP38-14 USING MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING TO PREDICT THE CORRECT LOCATION OF PROSTATE CANCER BEFORE BIOPSY – AN AUSTRALIAN MULTICENTRE STUDY
Dominic Gavin*, Matthew Krelle, Tom Sutherland, Daphne Loh, Melbourne, Australia, Jonathan Kam, Yuigi Yuminaga, Raymond Kim, Kushlan Aluwihare, Sean Khoury, Finlay Macneil, Rupert Ouyang, Stephen Ruthven, Mark Louie-Johnsun, Gosford, Australia, Lih-Ming Wong, Melbourne, Australia

MP38-15 DETECTION AND CHARACTERIZATION OF DISSEMINATED TUMOR CELLS FROM THE BONE MARROW IN LOCALIZED PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY
Stephanie Glavaris*, Emma van der Toom, Michael Gorin, James Verdone, Changxue Lu, Jun Luo, Kenneth Plinta, Heather Chaffin, Baltimore, MD

MP38-16 COMBINING 68GA-PSMA-PET AND MULTIPARAMETRIC MRI: ENHANCING THE ABILITY TO DETECT INTRAPROSTATIC TUMOUR LESIONS AND PATIENTS ELIGIBLE FOR FOCAL TREATMENT?
Sami-Ramzi Leyh-Bannurah*, Antonia Steves, Dirk Beyersdorff, Clemens Rosenbaum, Kudtman Susanne, Janos Mester, Georg Salomon, Markus Graefen, Lars Budilus, Hamburg, Germany

MP38-17 CLINICOPATHOLOGIC CHARACTERISTICS OF PATIENTS WITH VERY LOW-RISK (PI-RADS 1 OR 2) LESIONS BY MULTIPARAMETRIC PROSTATE MAGNETIC RESONANCE IMAGING
Aaron Udager, Joel Friedman*, Nicole Curci, John Wei, Chandy Ellimoottil, Rohit Mehra, Scott Tomlins, Jeffrey Montgomery, Matthew Davenport, Angela Wu, Lakshmi Kunju, Ann Arbor, MI

MP38-18 CLINICOPATHOLOGIC CHARACTERISTICS OF PATIENTS UNDERGOING PROSTATE CORE BIOPSY WITH HIGH-RISK (PI-RADS 5) LESIONS BY MULTIPARAMETRIC PROSTATE MAGNETIC RESONANCE IMAGING.
Joel Friedman*, Aaron Udager, Nicole Curci, Chandy Ellimoottil, Rohit Mehra, Scott Tomlins, Jeffrey Montgomery, John Wei, Matthew Davenport, Angela Wu, Lakshmi Kunju, Ann Arbor, MI

MP38-19 MULTIPARAMETRIC MRI/ULTRASOUND FUSION BIOPSY IMPROVES BUT DOES NOT REPLACE STANDARD TEMPLATE BIOPSY FOR THE DETECTION OF PROSTATE CANCER

MP38-20 METABOLIC DIFFERENCE IDENTIFIED BY PROTON MR-SPECTROSCOPY IS ASSOCIATED WITH INTRA-TUMOR HETEROGENEITY IN PROSTATE CANCER
Hiroaki Shina*, Yusuke Nakanishi, Naoko Arichi, Masahiro Sumura, Hirofumi Kishi, Keiichi Onoda, Hiroaki Yasumoto, Izumo, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP39-03 IMPACT OF SOMATIC MUTATIONS ON PATTERNS OF METASTASIS IN CLEAR CELL RENAL CELL CARCINOMA
Maria Becerra*, Francisco Sanchez-Vega, Ed Reznik, Brandon Manley, Mahyar Kashan, Mazayr Ghanaat, New York, NY, Jozefina Casuscelli, Munich, Germany, Almedina Redzematovic, Shawn Mendonca, Maria Arcila, Jonathan Coleman, Paul Russo, James Hsieh, A. Ari Hakimi, New York, NY

MP39-04 MOLECULAR AND CLINICAL CHARACTERIZATION OF RENAL CELL CARCINOMA WITH UNCLASSIFIED HISTOLOGY: NF2 LOSS PREDICTS WORST OUTCOMES
Mazayr Ghanaat*, Mahyar Kashan, Maria Becerra, Brandon Manley, New York, NY, Jozefina Casuscelli, Munich, Germany, Shawn Mendonca, Almedina Redzematovic, Maria Arcila, Paul Russo, Jonathan Coleman, James Hsieh, Yingbei Chen, A. Ari Hakimi, New York, NY

MP39-05 TRANSPOSON MUTAGENESIS DRIVES RENAL CYST FORMATION IN VIVO WHEN COMBINED WITH C-MET HYPERACTIVATION: IMPLICATIONS FOR ACQUIRED RENAL CYSTIC DISEASE
Jason Scovell*, Juan Hernandez, Adam Hollander, Richard Link, Houston, TX

MP39-06 WHOLE GENOME TRANSCRIPTIONAL ANALYSIS OF CLEAR CELL RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS REVEALS INTRATUMORAL HETEROGENEITY AND GENES ASSOCIATED WITH POOR OUTCOME
Dharam Kaushik*, Wasim Chowdhury, Ping Wu, Teresa Johnson-Pais, Yidong Chen, Michael A. Liss, Ronald Rodriguez, San Antonio, TX

MP39-07 INTEGRATED ANALYSIS OF MICRONRNA AND mRNA EXPRESSION PROFILES IN TUBEROUS SCLEROSIS COMPLEX ANGIOMYOLIPOMA
Yi Cai*, Hanzhong Li, Yushi Zhang, Beijing, China, People’s Republic of

MP39-08 THE MICRONRNA EXPRESSION SIGNATURE OF PATIENTS WITH RENAL CELL CARCINOMA: TUMOR-SUPPRESSIVE MIR-149-5P TARGETING FOXM1
Atsushi Okato*, Takayuki Arai, Akira Kurozumi, Mayuko Kato, Yusuke Goto, Chiba-shi, Japan, Satoko Kojima, Yukio Naya, Ichihara-shi, Japan, Tomohiko Ichikawa, Naohiko Seki, Chiba-shi, Japan

MP39-09 IMPACT OF MICRONRNA EXPRESSION SIGNATURE OF PATIENTS WITH TKI FAILURE: REGULATION OF MIR-10A-5P PATHWAYS IN RENAL CELL CARCINOMA
Takayuki Arai*, Atsushi Okato, Akira Kurozumi, Mayuko Kato, Yusuke Goto, Chiba, Japan, Satoko Kojima, Yukio Naya, Ichihara, Japan, Tomohiko Ichikawa, Naohiko Seki, Chiba, Japan

MP39-10 INTRA-TUMOR HETEROGENEITY IN RENAL CELL CARCINOMA: IMPLICATIONS FOR PROTEOMIC ANALYSIS OF RENAL MASS BIOPSIES
Rustin Massoud*, Christian Hoener, Thomas Metzner, Jennifer O’Rourke, Rachael Curtis, Laurel Steil, Chiara Sabatti, James Brooks, Alice Fan, John Leppert, Stanford, CA

MP39-11 THE NEWLY FOUND BIOMARKERS OF RENAL CELL CARCINOMA BY PROTEINOMICS
Yimeng Song*, Lijun Zhong, Lulin Ma, Beijing, China, People’s Republic of

MP39-12 HIGHER SERUM C-REACTIVE PROTEIN LEVEL REPRESENTS THE IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA
Takayuki Nakayama*, Kazutaka Saito, Yuma Waseda, Hajime Tanaka, Masaharu Inoue, Masaya Ito, Naoko Kawamura, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazunori Kihara, Yasuhisa Fujii, Tokyo, Japan

MP39-13 IDENTIFICATION OF ISYNA1 AS A POTENTIAL PROGNOSTIC BIOMARKER FOR RENAL CANCER
Tomoyuki Koguchi*, Kanako Matsuoka, Junya Hata, Yuichi Sato, Hidenori Akahata, Masao Kataoka, Soichiro Ogawa, Nobuhiro Haga, Nobuhiro Kushida, Kei Ishibashi, Ken Ikawa, Yoshiyuki Kojima, Fukushima, Japan

MP39-14 IRON ACCUMULATION DURING RENAL CELL CARCINOGENESIS AND REVERSAL WITH TUMOR PROGRESSION
Christopher Greene*, Ramkishen Narayanan, Cornelia Willis, Nihita Sharma, Gary Smith, Kenneth Gross, Bo Xu, Eric Kauffman, Buffalo, NY

MP39-15 SDCT2 AS A FUNCTIONAL BIOMARKER OF RENAL CELL CARCINOMA
Andre Jordan, Augusta, GA, Martin Hennig*, Axel Merseburger, Marie Hupe, Mario Kramer, Luebeck, Germany, Mark Soloway, Aventura, FL, Vinata Lokeshwar, Augusta, GA

MP39-16 SERUM TISSUE FACTOR AS A BIOMARKER FOR RENAL CLEAR CELL CARCINOMA
Daniel Silva*, Bartira Pinheiro da Costa, Jorge Antonio Porto Noronha, Gustavo Carvalhal, Porto Alegre, Brazil

MP39-17 MITOCHONDRIAL DNA COPY NUMBER VARIATION AS A POTENTIAL PREDICTOR OF RENAL CELL CARCINOMA.
Eman Elsayed, Mohamed Mohieeldin Hashad*, Eman Elghory, Alexandria, Egypt

*Presenting author
MP39-18 MITOCHONDRIA FUNCTION CHANGE AND ACTIVATION OF AMPK-PGC1α PATHWAY THROUGH INDUCTION OF CLEAR CYTOPLASM IN RENAL CELL CARCINOMA
Hyung Ho Lee*, Sook Young Kim, Young Eun Yoon, Sung Ku Kang, Jae Yong Jeong, Kwang Hyun Kim, Seoul, Korea, Republic of, Kyung Hwa Choi, Seongnam, Korea, Republic of, Joong Shik Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Woong Kyu Han, Seoul, Korea, Republic of

MP39-19 SUNITINIB DRIVES CELL-TO-CELL MITOCHONDRIAL TRAFFICKING IN KIDNEY CANCER
Jason Scovell*, Juan Hernandez, Richard Link, Houston, TX

MP39-20 ADVANCES IN THE DIAGNOSIS OF HEREDITARY KIDNEY CANCER: INITIAL RESULTS OF A MULTIGENE PANEL TEST
Kevin Nguyen*, Jamil Syed, New Haven, CT, Carin Espenschied, Holly Laduca, Aliso Viejo, CA, Ansh Bhagat, New Haven, CT, Timothy O’Rourke, North Haven, CT, Brian Shuch, New Haven, CT

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 13, 2017
Podium Session 25
SEXUAL FUNCTION/DYSFUNCTION: SURGICAL THERAPY III
Room 159 @ Boston Convention & Exhibition Center
Moderators: Edgardo Becher, Brian Christine and Laurence Levine

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD25-01</td>
<td>ENGINEERING BUCKLING FORCE STUDY FOR SUPPORTING THAT CYLINDER CONSTRUCTION AND REAR TIP EXTENDER ARE ASSOCIATED WITH REDUCED AXIAL RIGIDITY – THE IMPLICATIONS ON CLINICAL PRACTICE</td>
</tr>
<tr>
<td>1:10</td>
<td>PD25-02</td>
<td>TAKING RESPONSIBILITY FOR FEMALE PREPUCIAL DISORDERS: UROLOGIC MANAGEMENT OF PHIMOSIS-BASED CLITORODYNIA</td>
</tr>
<tr>
<td>1:20</td>
<td>PD25-03</td>
<td>FEAR OF POSTOPERATIVE INFECTION FOLLOWING PLACEMENT OF INFLATABLE PENILE PROSTHESIS AT AN ACADEMIC TRAINING CENTER IS UNWRITTEN: DATA FROM A SINGLE SURGEON SERIES</td>
</tr>
<tr>
<td>1:30</td>
<td>PD25-04</td>
<td>MOLECULAR ANALYSIS USING PCR TO AMPLIFY EXTRACTED 16S RIBOSOMAL DNA APPEARS TO IDENTIFY BIOFILM AND ANTIMICROBIAL SENSITIVITIES/RESISTANCES ON PENILE PROSTHESIS IN-VIVO</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:40</td>
<td>PD25-05</td>
<td>‘ANDRIANNE MINI-JUPETTE’ GRAFT AT THE TIME OF INFLATABLE PENILE PROSTHESIS PLACEMENT FOR THE MANAGEMENT OF POST-PROSTECTOMY CLIMACTURIA AND MINIMAL URINARY INCONTINENCE</td>
</tr>
<tr>
<td>1:50</td>
<td>PD25-06</td>
<td>PRE-VAGINOPLASTY BILATERAL ORCHIOTOMY FOR TRANSGENDER WOMEN: AN EFFICIENT SURGICAL TECHNIQUE THAT PRESERVES COLLATERAL TISSUES AND SENSATION</td>
</tr>
<tr>
<td>2:00</td>
<td>PD25-07</td>
<td>DURASPHERE AS NEW AGENT FOR THE TREATMENT OF HYPERMOBILE GLANS</td>
</tr>
<tr>
<td>2:10</td>
<td>PD25-08</td>
<td>HIGH FLOW PRIAPISM IS ASSOCIATED WITH HIGH RISK OF ERECTILE DYSFUNCTION AND CORPORAL FIBROSIS</td>
</tr>
<tr>
<td>2:20</td>
<td>PD25-09</td>
<td>EMERGING MECHANICAL FAILURES AND COMPLICATIONS OF ECTOPICALLY PLACED CONCEAL RESERVOIRS</td>
</tr>
</tbody>
</table>

134
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD26-01</td>
<td>THE ASSOCIATION OF PTSD AND CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME IN YOUNG MALE VETERANS</td>
<td>1:40</td>
<td>PD26-05</td>
<td>THE IMPACT OF ATHEROSCLEROSIS-INDUCED PELVIC ISCHEMIA ON LUTS IN ELDERLY MEN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marah Hohemann*, Michelle Van Kuiken, Maywood, IL, Bella Etingen, Frances M. Weaver, Hines, IL, Jeffrey Branch, Maywood, IL</td>
<td></td>
<td></td>
<td>Daniel Costa, Alice Porto, Ana Coelho, João Neves, Luis Vale, Carlos Silva, Tiago Antunes-Lopes*, Francisco Cruz, Porto, Portugal</td>
</tr>
<tr>
<td>1:10</td>
<td>PD26-02</td>
<td>THE EFFECT OF SACRAL NEUROMODULATION ON COMPLETE CONTINENCE AT 5 YEARS FOR SUBJECTS WITH URINARY INCONTINENCE</td>
<td>1:50</td>
<td>PD26-06</td>
<td>EFFICACY AND SAFETY OF MIRABEGRON ADD-ON THERAPY TO SOLifenacin IN OLDER PATIENT POPULATIONS WITH OVERACTIVE BLADDER</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Steven Siegel*, Woodbury, MN, Jeffrey Mangel, Cleveland, OH, Craig Comiter, Stanford, CA, Samuel Zystra, Whittsville, MA, Erin T. Bird, Temple, TX, Tomas L. Griebing, Kansas City, KS, Daniel Culkin, Oklahoma City, OK, Suzette E. Sutherland, Seattle, WA, Kellie Berg, Fangyu Kan, Minneapolis, MN, Karen Noblett, Riverside, CA</td>
<td></td>
<td></td>
<td>William Gibson*, Edmonton, Canada, Scott MacDiarmid, Greensboro, NC, Moses Huang, Emad Siddiqui, Chertsey, United Kingdom, Matthias Stölzel, Leiden, Netherlands, Nurul Choudhury, Chertsey, United Kingdom, Marcus Drake, Bristol, United Kingdom</td>
</tr>
<tr>
<td>1:20</td>
<td>PD26-03</td>
<td>SER120 NASAL SPRAY IS EFFECTIVE IN PATIENTS WITH NOCTURIA IRRESPECTIVE OF ETIOLOGY: A POOLED ANALYSIS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIALS</td>
<td>2:00</td>
<td>PD26-07</td>
<td>URETHRAL DIVERTICULA IN WOMEN ARE ASSOCIATED WITH INCREASED URETHRA-SPHINCTER COMPLEX VOLUMES</td>
</tr>
<tr>
<td>1:30</td>
<td>PD26-04</td>
<td>MEDIUM TERM OUTCOMES OF VENTRAL-ONLAY BUCCAL MUCOSA GRAFT SUBSTITUTION URETHROPLASTY FOR URETHRAL STRICTURE IN FEMALES</td>
<td>2:10</td>
<td>PD26-08</td>
<td>A LONG TERM COMPARISON OF ADHERENCE OF DRUG THERAPY IN 1,917 PATIENTS WITH OVERACTIVE BLADDER</td>
</tr>
<tr>
<td>2:20</td>
<td>PD26-09</td>
<td>STAGED APPROACH TO SLING REMOVAL IN WOMEN PRESENTING WITH PAIN ONLY</td>
<td>2:30</td>
<td>PD25-10</td>
<td>SURGICAL MANAGEMENT OF PRIAPISM: COMPLICATIONS DATA FROM THE NSQIP DATABASE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carlos Finsterbusch*, Feras Alhalabi, Philippe Zimmern, Dallas, TX</td>
<td></td>
<td></td>
<td>David Qi*, Erik Lehman, Susan MacDonald, Hershey, PA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jonathan Beilan*, Tampa, FL, Enrique Barrera, Ge Leihui, Houston, TX, Paul Perito, Coral Gables, FL, Steven Wilson, Indio, CA, Rafael Carrion, Tampa, FL, Tariq Hakky, Atlanta, GA</td>
<td></td>
<td></td>
<td>Paholo Barboglio Romo*, Harshitha P. Chikkatur, Sahana Beldona, Yooni Yi, Tim M. Bruns, Bahaa S. Maleeb, Ann Arbor, MI</td>
</tr>
<tr>
<td>2:50</td>
<td>PD25-12</td>
<td>EVALUATION OF INFLATABLE PENILE PROSTHESSES: HOW THEY PERFORM IN THE LAB?</td>
<td></td>
<td></td>
<td>Paholo Barboglio Romo*, Harshitha P. Chikkatur, Sahana Beldona, Yooni Yi, Tim M. Bruns, Bahaa S. Maleeb, Ann Arbor, MI</td>
</tr>
</tbody>
</table>
2:30 PD26-10 ONABOTULINUMTOXINA PROVIDES EARLY AND CONSISTENT IMPROVEMENTS IN OVERACTIVE BLADDER SYMPTOMS AND QUALITY OF LIFE OUTCOMES IN PATIENTS WITH OVERACTIVE BLADDER

2:40 PD26-11 SYMPTOMS AND NONINVASIVE PARAMETERS THAT PREDICT DETERUSOR UNDERACTIVITY IN MEN WITH LOWER URINARY TRACT SYMPTOMS: AN ANALYSIS USING A LARGE GROUP OF PATIENTS UNDERGOING PRESSURE FLOW STUDY
Ryo Namitome*, Mineo Takei, Ryosuke Takahashi, Tomoko Maki, Ken Lee, Shunichi Kajioka, Akito Yamaguchi, Masatoshi Eto, Fukuoka, Japan

2:50 PD26-12 DOES STRESS INCONTINENCE DECREASE THE RATE OF CATHETERIZE AFTER INTRADETRUSOR ONABOTULINUMTOXINA IN THE MIXED INCONTINENCE PATIENT?

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
1:50 PD27-06 THULIUM LASER VAPORIZATION OF THE PROSTATE AND BIPOLAR TRANSURETHRAL RESECTION OF THE PROSTATE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA – SINGLE CENTER PROSPECTIVE RANDOMIZED STUDY
Prarthan Joshi*, Puvvada Sandeep, Prasad Mylarappa, Ramesh Desigowda, Arvind Nayak, Kuldeep Aggarwal, Bangalore, India

2:00 PD27-07 PREOPERATIVE TRANSRECTAL ULTRASONOGRAPHIC FINDINGS CAN PREDICT THE IMPROVEMENT OF THE PEAK URINARY FLOW RATE AFTER SURGICAL TREATMENT OF BENIGN PROSTATIC ENLARGEMENT IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS
Juhyun Park*, Chu Hong Park, Inyoung Sun, Sung Yong Cho, Min Chul Cho, Hyeon Jeong, Hwancheol Son, Seoul, Korea, Republic of

2:10 PD27-08 ENDOSCOPIC ENUCLEATION OF THE PROSTATE IN THE LEARNING CURVE VERSUS OPEN SIMPLE PROSTATECTOMY: MORBIDITY AND EARLY FUNCTIONAL OUTCOMES
Benjamin PRADERE*, Tours, France, Benoit PEYRONNET, Rennes, France, Jérome Gas, Benoit Bordier, Pascal Rischmann, Julien Guillotreau, Mathieu Thoumouzan, Michel Soulé, Toulouse, France, Kevin Zorn, Montreal, Canada, Xavier Gamé, Vincent Misrai, Toulouse, France

Romain Huet*, Sébastien Vincendeau, Rennes, France, Philippe Sebe, Alexandre Colau, Bertrand Guillonneau, Paris, France, Benoit Peyronnet, Gregory Verhoest, Karim Bensalah, Romain Mathieu, Rennes, France

2:30 PD27-10 ROBOTIC SIMPLE PROSTATECTOMY: THE USC EXPERIENCE
Carlos Fay*, Daniel Melecchi Freitas, Andre Abreu, Sameer Chopra, Nariman Ahmad, Toshtaka Shin, Michael Qiu, Giovanni Cacciarni, Oishi Masakatsu, Mihir Desai, Inderbir Gill, Andre Berger, Monish Aron, Los Angeles, CA

2:40 PD27-11 COMPARATIVE EFFECTIVENESS OF TRANSCURETHRAL RESECTION TECHNIQUES FOR BENIGN PROSTATIC HYPERPLASIA – ANALYSIS OF AN ALL PAYER INPATIENT DISCHARGE DATABASE

2:50 PD27-12 MULTICENTER INTERNATIONAL EXPERIENCE OF 180W LBO LASER PHOTO-VAPORIZATION IN MEN WITH VERY LARGE PROSTATES (PROSTATE VOLUME200CC)
Roger Valdivieso*, Pierre-Alain Hueber, Malek Meskawi, Montreal, Canada, Vincent Misrai, Toulouse, France, Kevin Zorn, Montreal, Canada

*Presenting author
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD28-01</td>
<td>ASSOCIATION BETWEEN GERMLINE GENETIC VARIATION AND PROGRESSION IN MEN WITH LOW-RISK PROSTATE CANCER ON ACTIVE SURVEILLANCE</td>
<td>Viranda Jayalath*, Antonio Finelli, Maria Komisareniko, Narhari Timilshina, Qihuang Zhang, Wei Xu, Neil Fleshner, Robert Hamilton, Toronto, Canada</td>
</tr>
<tr>
<td>1:10</td>
<td>PD28-02</td>
<td>THE IMPACT OF CLINICAL CCP TESTING IN MEN WITH LOCALIZED PROSTATE CANCER FOR EXPANDING THE POPULATION OF MEN ELIGIBLE FOR ACTIVE SURVEILLANCE</td>
<td>Behfar Ehtdaie*, New York, NY, Steve Stone, Ryan Bernhiseil, Salt Lake City, UT, James Eastham, New York, NY, Thomas Keane, Charleston, SC, John Davis, Houston, TX, E David Crawford, Denver, CO, Michael Brawer, Salt Lake City, UT, Daniel Lin, Seattle, WA, Peter Scardino, New York, NY</td>
</tr>
<tr>
<td>1:20</td>
<td>PD28-03</td>
<td>CORRELATION BETWEEN A GENOMICS TEST AND ADVERSE PATHOLOGY AFTER RADICAL PROSTATECTOMY AMONG ACTIVE SURVEILLANCE CANDIDATES</td>
<td>Patrick Hurley*, Novi, MI, Greg Auffenberg, Ji Qi, Chris Maurino, Ann Arbor, MI, Samantha Farida, Ivi Latifi, Lansing, MI, Donald Moylan, Royal Oak, MI, Bincy Johnson, Royal Oak, MI, David Miller, Ann Arbor, MI, Kirk Wojno, Royal Oak, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI</td>
</tr>
<tr>
<td>1:40</td>
<td>PD28-05</td>
<td>WORLDWIDE VARIATION IN DETERMINANTS FOR INCLUSION AND FOLLOW-UP IN ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER: RESULTS OF THE MOVEMBER FOUNDATION'S GLOBAL ACTION PLAN PROSTATE CANCER ACTIVE SURVEILLANCE (GAP3) INITIATIVE</td>
<td>Sophie Bruinsma*, Rotterdam, Netherlands, Lijing Zhang, Toronto, Canada, Chris Bangma, Monique Roobol, Ewout Steyerberg, Daan Nieboer, Rotterdam, Netherlands, Mieke Van Hemelrijck, London, United Kingdom</td>
</tr>
<tr>
<td>1:50</td>
<td>PD28-06</td>
<td>VARIATION IN THE USE OF ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER</td>
<td>Björn Lüppenberg*, David F. Friedlander, Andrew Tam, Boston, MA, Jeffrey J. Leow, Singapore, Singapore, Anna Krasnova, Paul Nguyen, Adam S. Kibel, Stuart R. Lipsitz, Boston, MA, Mani Menon, Detroit, MI, Maxine Sun, Tony K. Choueiri, Quoc-Dien Trinh, Boston, MA</td>
</tr>
<tr>
<td>2:00</td>
<td>PD28-07</td>
<td>TRACKING OF PRIOR POSITIVE SITES BY MRI/UUS FUSION IMPROVES DETECTION OF GLEASON SCORE UPGRADING</td>
<td>Edward Chang*, Tonye Jones, Los Angeles, CA, Daniel Margolis, New York, NY, Jiaoti Huang, Durham, NC, Shyam Natarajan, Devi Sharma, Merdie Delfin, Frederick Dorey, Leonard Marks, Los Angeles, CA</td>
</tr>
<tr>
<td>2:10</td>
<td>PD28-08</td>
<td>CONCORDANCE BETWEEN PHYSICIAN-DOCUMENTED VERSUS PATIENT-REPORTED COMORBIDITIES IN PROSTATE CANCER: VALIDATION OF A NOVEL INFORMATICS TOOL</td>
<td>Katherine Fleshner*, London Ontario, Canada, Amy Til, Nicole Benfante, Sigrid Carlson, Andrew Vickers, New York, NY</td>
</tr>
<tr>
<td>2:20</td>
<td>PD28-09</td>
<td>DOES MRI-FUSION PROSTATE BIOPSY IMPROVE RISK RECLASSIFICATION FOR PATIENTS WITH PROSTATE CANCER ON ACTIVE SURVEILLANCE COMPARED TO TRANSRECTAL ULTRASOUND-GUIDED SATURATION BIOPSY</td>
<td>Ahmed El Shafei, Yaw Nyame*, Hans Arora, Mohamed Eltemamy, Onder Kara, Ercan Malkoc, Khaled Fareed, J Stephen Jones, Cleveland, OH</td>
</tr>
</tbody>
</table>
### PD28-10 MULTIPARAMETRIC-MRI PRIOR TO REPEAT BIOPSY FOR ACTIVE SURVEILLANCE CAN IDENTIFY MEN WITH HIGH-RISK PROSTATE CANCER

Nicolai Hübner, Christopher Evans, Stanley Yap, Michael Corwin, John McGahan, Thomas Loehfelm, Marc Dall’Era*, Sacramento, CA

### PD28-11 PROSPECTIVE STUDY OF BIOPSY DECIPHER SCORES IN POTENTIAL CANDIDATES FOR ACTIVE SURVEILLANCE


### PD28-12 EFFECTS OF INITIAL GLEASON GRADE ON OUTCOMES DURING ACTIVE SURVEILLANCE FOR PROSTATE CANCER

Selma Masic*, Samuel Washington, Janet Cowan, Hao Nguyen, Katsuto Shinohara, Matthew Cooperberg, Peter Carroll, San Francisco, CA

### SATURDAY, MAY 13, 2017 1:00 pm - 3:50 pm

**SOCIETY FOR BASIC UROLOGIC RESEARCH (SBUR)**
Douglass @ Westin Waterfront

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>INTRODUCTION TO PROSTATE CELL OF ORIGIN</td>
<td>Douglas Strand</td>
</tr>
<tr>
<td>1:05</td>
<td>EAST COAST PERSPECTIVE</td>
<td>Michael Shen</td>
</tr>
<tr>
<td>1:25</td>
<td>TEXAS PERSPECTIVE</td>
<td>Li Xin</td>
</tr>
<tr>
<td>1:45</td>
<td>WEST COAST PERSPECTIVE</td>
<td>Andrew Goldstein</td>
</tr>
<tr>
<td>2:05</td>
<td>ROUNDTABLE DISCUSSION</td>
<td>Moderator: Douglas Strand</td>
</tr>
<tr>
<td>2:25</td>
<td>INTRODUCTION TO BLADDER CELL OF ORIGIN</td>
<td>David DeGraff</td>
</tr>
<tr>
<td>2:30</td>
<td>THE NORTHERN PERSPECTIVE</td>
<td>Cathy Mendelsohn</td>
</tr>
<tr>
<td>2:50</td>
<td>THE CENTRAL PERSPECTIVE</td>
<td>David McConkey</td>
</tr>
<tr>
<td>3:10</td>
<td>THE SOUTHERN PERSPECTIVE</td>
<td>Keith Chan</td>
</tr>
<tr>
<td>3:30</td>
<td>ROUNDTABLE DISCUSSION</td>
<td>Moderator: David DeGraff</td>
</tr>
<tr>
<td>3:50</td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>

### SATURDAY, MAY 13, 2017 3:00 pm - 5:30 pm

**POLISH UROLOGICAL ASSOCIATION (PTU) AND HUNGARIAN UROLOGICAL ASSOCIATION (HUA) JOINT SESSION**
Room 209 @ Boston Convention & Exhibition Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 3:00  | WELCOME AND INTRODUCTIONS                                               | PTU President: Piotr Chlosta, Peter Tenke  
HUA President: Istvan Buzogany                                                                 |
| 3:10  | MRI FUSION PROSTATE BIOPSY CURRENT STATUS                                | Anna K. Czech                                                                                      |
| 3:25  | TISSUE ENGINEERING IN LAPAROSCOPIC AND ROBOTIC UROLOGY                 | Tomasz Drewa                                                                                       |
| 3:40  | HIGH RISK PROSTATE CANCER ADJUVANT TREATMENT IN PATIENTS WITH POSITIVE LYMPH NODES | Sebastian Piotrowicz                                                                              |
| 3:55  | LYMPHADENECTOMY IN BLADDER CANCER PATIENTS                               | Lukasz Nyk                                                                                        |
| 4:10  | CURRENT DEVELOPMENTS OF BCG IMPROVES LOCAL RESPONSE IN BLADDER CANCER PATIENTS | Anna Kolodziej                                                                            |
| 4:25  | CHANGES OF TISSUE AND SERUM LEVELS OF SYNDENAC-1 DURING PCA-PROGRESSION | Peter Nyirady                                                                                      |
| 4:45  | SALVAGE AND ADJUVANT RADIOTHERAPY AFTER RADICAL PROSTATECTOMY           | Zsolt Molnar, Zolton Bajory                                                                        |
### Abstracts

**MP40-01** **USE OF MODIFIED FASCIAL PUBOVAGINAL SLING FOR THE TREATMENT OF STRESS URINARY INCONTINENCE: UP TO 20 YEARS FOLLOW UP.**


**MP40-02** **COMPARISON OF OUTCOMES BETWEEN SIMPLE AND COMPLEX PATIENTS UNDERGOING AUTOLOGOUS PUBOVAGINAL SLING PLACEMENT.**

Michael Maccini*, Tamara Lhungay, Tyler Doumaney, Lisa Parrillo, Brian Flynn, Aurora, CO

**MP40-03** **WHAT IS THE IMPACT OF COITAL INCONTINENCE ON WOMEN SEXUALITY AND SEXUAL FUNCTION?**

Mariana Felippe, Marcia Eli Girotti, Maira dos Santos, Monique Rodrigues, Tatiana Rodarte, Fernanda Almeida*, Sao Paulo, Brazil

**MP40-04** **THE RELATIONSHIP OF FEMALE URETHRAL LENGTH WITH STRESS URINARY INCONTINENCE.**

Myung Ki Kim*, Jae Hyung You, Yu Seob Shin, Jeonju, Korea, Republic of

**MP40-05** **USING DATA FROM THE CALIFORNIA OFFICE OF STATEWIDE HEALTH PLANNING AND DEVELOPMENT (OSHPD) TO DETERMINE THE 30-DAY COMPLICATION RATE FROM URETHRAL SLING PLACEMENT.**

Kai Dallas*, Stanford, CA, Christopher Elliott, Santa Clara, CA

**MP40-06** **PREDICTORS OF A FAILED VOIDING TRIAL AFTER SLING AND CONCOMITANT PELVIC SURGERY.**

J. Margaret Lovin*, Clifton F. Frilot II, Alexander Gomelsky, Shreveport, LA

**MP40-07** **WET AND HAPPY VS. DRY AND UNHAPPY AFTER SLING SURGERY: AN ANALYSIS OF DIVERGENT POSTOPERATIVE OUTCOMES.**

Umar R. Karaman*, Clifton F. Frilot II, Alexander Gomelsky, Shreveport, LA

**MP40-08** **CCL7, A STEM CELL HOMING FACTOR, HAS LOW RESPONSIVE表达 DURING SLING PROCEDURE ASSOCIATED WITH POSTPARTUM URINARY INCONTINENCE.**

Qi-Xiang Song, Shanghai, China, People's Republic of, Hai-Yan Li, Ling Qing, Xiangxiang Ye, Wenzhou, China, People's Republic of, Limin Liao, Beijing, China, People's Republic of, Hai-Hong Jiang*, Wenzhou, China, People's Republic of

**MP40-09** **ESTABLISHMENT OF A NEW LARGE ANIMAL MODEL FOR STRESS URINARY INCONTINENCE USING GERMAN LANDRACE PIGS.**

Anika Albrecht, Alexandra Kelp, Bastian Amend, Tuebingen, Germany, Mario Kluender, Stuttgart, Germany, Arnulf Stenzl, Wilhelm K. Aicher*, Tuebingen, Germany

**MP40-10** **CAN URETHRAL BULKING AGENTS SALVAGE FAILED SLINGS?**

Elizabeth Dray*, Anne Cameron, Marybeth Hall, J. Quentin Clemens, John Stoffel, Ann Arbor, MI

**MP40-11** **IS INITIAL RETENTION AFTER MACROPLASTIQUE® INJECTION A PREDICTOR OF SUCCESS?**

Himanshu Aggarwal*, Montgomery, AL, Feras Alhalabi, Philippe Zimmern, Dallas, TX

**MP40-12** **ROBOT-ASSISTED ARTIFICIAL URINARY SPHINCTER IMPLANTATION IN FEMALE PATIENTS: A MULTICENTER STUDY.**

**MP40-13** THE IMPACT OF PERCEIVED STRESS AND HEALTH ON INSOMNIA IN WOMEN WITH OVERACTIVE BLADDER SYMPTOMS
K’dee Elsen, Christina Moldovan, Jim Shen, Mohamed Keheila, Salim Cheriyani, Matthew Pierce*, Andrea Stack, Loma Linda, CA

**MP40-14** COGNITIVE EFFECTS OF TRANSDERMAL OXYBUTYNIN IN ELDERLY PATIENTS WITH OVERACTIVE BLADDER SYNDROME
Carlos Muller-Arteaga*, Ourense, Spain, Jose Emilio Batista Miranda, Barcelona, Spain, Carmen Zubiaur, Alina Rabade Ferreiro, Bilbao, Spain, Rafael El Khoury Moreno, Sevilla, Spain, Gonzalo Morales Solchaga, Alzira, Spain, Javier Casas Nebra, Lugo, Spain, Manuel Leva Vallejo, Cordoba, Spain, Oscar Gonzalez Garcia, Osuna, Spain, Salvador Arlandis-Guzman, Valencia, Spain, Carlos Errando-Smet, Barcelona, Spain

**MP40-15** USE OF THIRD LINE THERAPY FOR OVERACTIVE BLADDER IN A PRACTICE WITH MULTIPLE SUBSPECIALTY PROVIDERS: ARE WE DOING ENOUGH?
Dena Moskowitz*, Sarah Adelstein, Alvaro Lucioni, Una Lee, Kathleen Kobashi, Seattle, WA

**MP40-16** OUTCOMES OF TREATMENT OF STRESS URINARY INCONTINENCE ASSOCIATED WITH FEMALE URETHRAL DIVertICula: A SELECTIVE APPROACH

**MP40-17** PROSPECTIVE RANDOMIZED COMPARISON OF REPAIRING SIMPLE VESICOVAGINAL FISTULA WITH OR WITHOUT INTERPOSITION FLAP: A TERTIARY CARE HOSPITAL STUDY FROM NOTHERN INDIA
Vishwajeet Singh*, Rahul Janak Sinha, Ankur Bansal, Seema Mehrotra, Kawaljit Singh, Lucknow, India

**MP40-18** HIATAL SMOOTH MUSCLES: A NOVEL ANATOMICAL LANDMARK FOR FEMALE NERVE-SPARING RADICAL CYSTECTOMY
 Nobuyuki Hinata*, Kobe, Japan, Ahmed Aly Hussein, Buffalo, NY, Tomaoki Terakawa, Yukari Bando, Kobe, Japan, Gen Murakami, Iwamizawa, Japan, Khurshid Guru, Buffalio, NY, Masato Fujisawa, Kobe, Japan

**MP40-19** MIRABEGRON IN WOMEN WITH OAB: A REAL SETTING STUDY
Ester Illiano*, Perugia, Italy, Raffaele Balsamo, Catanzaro, Italy, Martina Milanesi, Vincenzo Li Marzi, Florence, Italy, Enrico Finazzi Agro, Franca Natale, Rome, Italy, Stefania Maddonni, Elisabetta Costantini, Perugia, Italy

**MP40-20** DO SURGEONS WISH TO KNOW ABOUT THEIR LONG-TERM COMPLICATIONS?
Jennifer Wimberly*, Shawn Okpara, Philippe Zimmern, Dallas, TX

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

**Saturday, May 13, 2017**

**3:30 pm - 5:30 pm**

**Moderated Poster Session 41**

**STEM CELL RESEARCH**

**Room 156 @ Boston Convention & Exhibition Center**

**Moderators:** Anthony Atala

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP41-01</strong></td>
<td>EXTRACELLULAR VESICLES REGULATE GLOMERULAR VEGF HOMEOSTASIS IN CHRONIC KIDNEY DISEASE</td>
</tr>
<tr>
<td>Sargis Sedrakyan*, Valentina Villani, Los Angeles, CA, Stefano Porta, Turin, Italy, Stefano Da Sacco, Nikita Tripuraneni, Andrea Achena, Maria Lavarrada-Pearce, Hasmik Soloyan, Roger De Filippo, Los Angeles, CA, Benedetta Bussoliati, Turin, Italy, Laura Perin, Los Angeles, CA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP41-02</strong></td>
<td>PROPHYLAXIS AGAINST RENAL ISCHEMIA REPERFUSION INJURY IN CANINE MODEL: STEM CELL APPROACH.</td>
</tr>
<tr>
<td>Yasser Osman*, Sahar M. Hamed, Nashwa Barakat, Sherry Khater, Mahmoud Gabr, Ahmed Mosbah, Mohamed Gaballah, Atallah Shaaban, Mansoura, Egypt</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP41-03</strong></td>
<td>FIVE-YEAR CLINICAL EFFECTS OF DONOR BONE MARROW CELLS INFUSIONS IN KIDNEY ALLOGRAFT RECIPIENTS</td>
</tr>
<tr>
<td>Ghasem Solgi, Hamedan, Islamic Republic of Iran, Vijayakrishna Gadi, Gholamreza Pourmand*, Abdolrasoul Mehrsai, Moslem Ranbar, Mousa Mohammadnia, Behrouz Nikbin, Ali Akbar Amirzargar, Tehran, Islamic Republic of Iran</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP41-04</strong></td>
<td>THE EFFICACY OF CHA1 MESENCHYMAL STEM CELL IN A CHRONIC INTERSTITIAL CYSTITIS RAT MODEL</td>
</tr>
<tr>
<td>Kyung Hwa Choi*, Young Eun Lee, Seung Ryool Lee, Young Kwan Hong, Dong Soo Park, Jae Yup Hong, Seongnam, Korea, Republic of</td>
<td></td>
</tr>
</tbody>
</table>
MP41-05 BIOFABRICATED BONE MARROW-DERIVED CELL PATCHES RESTORE STRUCTURE AND FUNCTION OF RADIATION-INJURED URINARY BLADDERS IN RAT
Tetsuya Imamura*, Teruyuki Ogawa, Tomonori Minagawa, Takashi Nagai, Gautam Sudha, Tetsuichi Saito, Matsumoto, Japan, Mitsuru Shimamura, Nanami Hatakeyama, Tokyo, Japan, Masaki Nakazawa, Osamu Ishizuka, Matsumoto, Japan

MP41-06 MULTIPOTENT ADULT PROGENITOR CELL TREATMENT PROMOTES BLADDER FUNCTION RECOVERY AND DECREASES MORBIDITY AND DURATION OF URINARY TRACT INFECTION IN SPINAL CORD INJURED RATS
James Jones*, Portland, OR, Marc DePaul, Cleveland, OH, MaiHua Zhu, Portland, OR, Bradley Lang, Cleveland, OH, Sarah Busch, Cleveland, OR, Cynthia Gregory, Michael Rutten, Lisa Buckley, Kenton Gregory, Hua Xie, Portland, OR

MP41-07 PRECLINICAL STUDY AND LONG-TERM IN VIVO CONFOCAL IMAGING OF HUMAN EMBRYONIC STEM CELL DERIVED MULTIPOTENT STEM CELLS TARGETED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
Aram Kim*, Hwan Yeul Yu, Jisun Lim, Ju Young Han, Chae-Min Ryu, Jun Ki Kim, Hyung-Min Chung, Dong-Myung Shin, Myung-Soo Choo, Seoul, Korea, Republic of

MP41-08 CCR1 AND CCL7 ENHANCES MESENCHYMAL STEM CELLS ENGRAFTMENT AFTER SIMULATED BIRTH INJURY
Hai-Hong Jiang*, Wenzhou, China, People’s Republic of, Jian-Li Feng, Chongqing, China, People’s Republic of, Qi-Xiang Song, Shanghai, China, People’s Republic of, Qi Ling, Wenzhou, China, People’s Republic of, Guiming Liu, Cleveland, OH

MP41-09 ADIPOSE-DERIVED STROMAL VASCULAR FACTOR (SVF) INJECTION IN SHORT RECURRENT BULBAR STRicture POST DVIU – AN INITIAL EXPERIENCE
Pankaj Joshi*, Fabio Castiglione, Devang Desai, Sandesh Surana, Hazem Orabi, Sanjay Kulkarni, Pune, India

MP41-10 MODELLING PROSTATE CANCER USING PRIMARY AND METASTATIC CANCEROIDS
Sofia Karkampouna, Bern, Switzerland, Federico la Manna, Leiden, Netherlands, Eugenio Zoni, Bern, Switzerland, Lijkele Beimers, Peter Kloen, Amsterdam, Netherlands, Antoinette Wetterwald, Joel Grosjean, Irena Klima, Marco G. Cecchini, Martin Spahn, George N. Thalmann, Marianna Kruithof-de Julio*, Bern, Switzerland

MP41-11 A PILOT CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL WITH RIBAVIRIN IN PATIENTS WITH PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER TARGETING STEM-CELL RELATED GENE NETWORK.
Takeo Kosaka*, Takahiro Maeda, Hirohiko Nagata, Shunsuke Yoshimine, Hiroshi Hongo, Toshiaki Shinjima, Mototsugu Oya, Tokyo, Japan

MP41-12 INDUCTION OF PROSTATE CANCER STEM CELL PROPERTIES IN MOUSE INDUCED PLURIPOTENT STEM CELLS VIA DEFINED CARCINOMA NICHE AND TRACKING DRUG RESPONSE IN PRECLINICAL RESEARCH
Naijin Xu*, Okayama, Japan, Xiezhao Li, Albai Xu, Guangzhou, China, People’s Republic of, Masami Watanabe, Okayama, Japan, Peng Huang, Guangzhou, China, People’s Republic of, Yasutomo Nasu, Okayama, Japan, Chunxiao Liu, Guangzhou, China, People’s Republic of

MP41-13 AMNIOTIC FLUID FOR THE TREATMENT OF ERECTILE DYSFUNCTION
Michael Zahalsky*, Gina Dessources, Melissa Marchand, Coral Springs, FL, Jason Levy, Philadelphia, PA

MP41-14 HUMAN URINE-DERIVED STEM CELLS GENETICALLY-MODIFIED WITH PEDF IMPROVE CAVERNOUS NERVE INJURY-INDUCED ERECTILE DYSFUNCTION IN A RAT MODEL
Qiyun Yang*, Xin Chen, Tao Zheng, Kai Xia, Xiangzou Sun, Guihua Liu, Guangzhou, China, People’s Republic of, Yuanjuan Zhang, Winston-Salem, NC, Chunhua Deng, Guangzhou, China, People’s Republic of

MP41-15 STEM CELL ACTIVATION IN THE MAJOR PELVIC GANGLION IS ENHANCED BY STROMAL DERIVED FACTOR-1 PENILE INJECTIONS FOLLOWING NERVE INJURY
Nikolai Sopko*, Baltimore, MD, Hotaka Matsui, Tokyo, Japan, Takahiro Yoshida, Xiaopu Liu, Max Kates, Trinity Bivalacqua, Baltimore, MD

MP41-16 THE EFFICACY OF HUMAN TESTICULAR STEM CELL AND NEURONAL PRECURSOR CELL IN A MOUSE MODEL OF CAVERNOUS NERVE INJURY
Kyung Hwa Choi, Byeong Seong Ki, Seung Ryeol Lee, Young Kwon Hong, Dong Soo Park*, Dong Ryul Lee, Seongnam, Korea, Republic of

MP41-17 SAFETY AND POTENTIAL EFFECT OF A SINGLE INTRACAVERNOUS INJECTION OF AUTOLOGOUS ADIPOSE-DERIVED REGENERATIVE CELLS IN PATIENTS WITH ERECTILE DYSFUNCTION FOLLOWING RADICAL PROSTATECTOMY: A 12-MONTH FOLLOW-UP
Martha Haahr*, Charlotte Harken Jensen, Jens Ahm Sørensen, Søren Paludan Sheikh, Lars Lund, Odense, Denmark
**MP41-18**  KDM5A INHIBITS GONOCYTE DIFFERENTIATION TO SPERMATOGONIAL STEM CELLS BY SUPPRESSING RET GENE FUNCTION VIA EPIGENETIC REGULATION
Hidenori Nishio*, Taiki Kato, Kentaro Mizuno, Yoshinobu Moritoki, Hideyuki Kamisawa, Satoshi Kurokawa, Akihiro Nakane, Tetsuji Maruyama, Yutaro Hayashi, Takahiro Yasui, Nagoya, Japan

**MP41-19**  IN VITRO DIFFERENTIATION OF HUMAN SPERMATOGONIAL STEM CELLS IN A THREE DIMENSIONAL (3D) TESTICULAR ORGANOID SYSTEM
Kara E. McAbee*, Nima Pourhabibi Zarandi, Anthony Atala, Hooman Sadri-Ardekani, Colin Bishop, Winston Salem, NC

---

**MP42-01**  QUANTITATIVE STUDY OF INWARD RECTIFYING ION CHANNEL IN DETRUSOR INSTABILITY
Chitaranjan Mahapatra*, Rohit Manchanda, Mumbai, India

**MP42-02**  MORPHOLOGICAL CHANGES OF DIFFERENT POPULATIONS OF BLADDER AFFERENT NEURONS DETECTED BY HERPES SIMPLEX VIRUS (HSV) VECTORS WITH CELL TYPE-SPECIFIC PROMOTERS IN MICE WITH SPINAL CORD INJURY

**MP42-03**  EFFECTS OF NERVE GROWTH FACTOR NEUTRALIZATION ON HYPEREXCITABILITY OF CAPSAICIN SENSITIVE BLADDER AFFERENT NEURONS IN MICE WITH SPINAL CORD INJURY
Takahiro Shimizu*, Nankoku, Japan, Tsuyoshi Majima, Takahisa Suzuki, Nobutaka Shimizu, Naoki Wada, Shun Takai, Ei-ichiro Takaoka, Joonbeom Kwon, Pradep Tyagi, Pittsburgh, PA, Motoaki Saito, Nankoku, Japan, Naoki Yoshimura, Pittsburgh, PA

**MP42-04**  CHARACTERIZING DEVELOPMENT OF THE HUMAN LOWER URINARY TRACT: ANATOMIC FEATURES AND MOLECULAR EXPRESSION OF THE URETIC BUD AND CLOACA
Alexander C Small*, Julia B Finkelstein, Alejandra Perez, Alessia Casale, Ekatherina Batourina, Cathy L Mendelsohn, New York, NY

**MP42-05**  CHRONIC ORAL ADMINISTRATION OF THE GUANYLATE CYCLASE-C AGONIST LINACLOTIDE ATTENUATES COLITIS INDUCED BLADDER AFFERENT AND DORSAL ROOT GANGLION HYPERACTIVITY

**MP42-06**  EXPRESSION AND FUNCTION OF SEROTONIN PARANEURONAL CELLS IN THE URETHRAL EPITHELIUM OF HUMAN AND RODENTS
Ana Coelho, Raquel Oliveira, Helena Cavaleiro, Celia Duarte Cruz, Francisco Cruz*, Porto, Portugal

**MP42-07**  SONIC HEDGEHOG REGULATION OF Rhabdosphinicter Muscle
Marah Hehemann*, Shawn Choe, Chicago, IL, Danuta Dynda, Shaheen Alane, Tobias Kohler, Kevin McVary, Springfield, IL, Carol Podlasek, Chicago, IL

*Presenting author
MP42-08 MALE URETHRAL SPHINCTER COMPLEX REVISITED USING NOVEL MR IMAGING TECHNIQUES
Kyoko Sakamoto*, Valmik Bhargava, Vadim Malis, M. Raj Rajasekaran, Shantanu Sinha, San Diego, CA

MP42-09 ATROGIN IS A NOVEL MARKER OF AGE-RELATED URETHRAL SPHINCTER MUSCLE ATROPHY
M. Raj Rajasekaran*, Johnny Fu, My-Uyen (Lilly) Nguyen, Valmik Bhargava, San Diego, CA

MP42-10 AUGMENTED BLADDER SMOOTH MUSCLE RESPONSIVENESS TO HYPERGLYCEMIA THROUGH A CAVEOLAE-DEPENDENT ACTIVATION OF RHO KINASE PATHWAY
Vivian Cristofaro*, Josephine A. Carew, Suhas P. Dasari, Raj K. Goyal, Maryrose P. Sullivan, Boston, MA

MP42-11 BLADDER NERVE-SMOOTH MUSCLE FUNCTION REMAINS INTACT AFTER LONG-TERM DECENTRALIZATION
Danielle M Salvadeo*, Eka Tiwari, Nagat Frara, Alan S. Braverman, Mary F. Barbe, Michael Ruggieri, Philadelphia, PA

MP42-12 MUSCARINIC RECEPTOR ANTAGONIST REGULATES THE EXTRACELLULAR MATRIX OF BLADDER IN RAT PARTIAL BLADDER OUTLET OBSTRUCTION MODEL
Tong-Xin Yang*, De-Yi Luo, Yi-Fei Lin, Qiang Liu, Xiang Cai, Hong Li, Kun-Jie Wang, Chengdu, China, People’s Republic of

MP42-13 MODULATION OF NICOTINIC RECEPTOR FUNCTION BY BLADDER DECENTRALIZATION AND REINNERVATION
Danielle M Salvadeo*, Nagat Frara, Alan S. Braverman, Mary F. Barbe, Michael Ruggieri, Philadelphia, PA

MP42-14 PURINERGIC P2X4 RECEPTOR EXPRESSION AND FUNCTION IN RODENT BLADDER SMOOTH MUSCLE
Vivian Cristofaro*, Josephine A. Carew, Sean D. Carey, Raj K. Goyal, Maryrose P. Sullivan, Boston, MA

MP42-15 THE UROTHELIUM IS THE MOST PREDOMINANT TISSUE IN THE BODY FOR SUPEROXIDE PRODUCTION: KEY ROLE OF NADPH OXIDASES
Max Roberts, Josephine Amosah, Lisa Adjei, Guildford, United Kingdom, Guipiu Sui, London, United Kingdom, Rui Wu, Coventry, United Kingdom, Simon Archer, Jonathan Johnston, Guildford, United Kingdom, Michael Ruggieri, Philadelphia, PA, Changhao Wu*, Guildford, United Kingdom

MP42-16 INNERVATION OF GENITOURINARY STRUCTURES: A NEURONAL TRACING STUDY IN FEMALE DOGS

MP42-17 AGE RELATED URETHRAL SPHINCTER MUSCLE DYSFUNCTION AND FIBROSIS: POSSIBLE ROLE OF WNT SIGNaling PATHWAYS
M. Raj Rajasekaran*, Johnny Fu, My-Uyen (Lilly) Nguyen, Valmik Bhargava, San Diego, CA

MP42-18 ENDOCANNABINOID 2-ARACHIDONOYL GLYCEROL DECREASES VISCERAL PAIN ASSOCIATED WITH EXPERIMENTAL CYSTITIS
Zunyi Wang*, Peiqing Wang, Dale Bjorling, Madison, WI

MP42-19 IS TRANSIENT RECEPTOR POTENTIAL CHANNEL INVOLVED IN WARMING INDUCED CONTRACTION OF HUMAN AND PIG URETHRAL SMOOTH MUSCLE?
Ken Lee*, Tomoko Maki, Ryosuke Takahashi, Masatoshi Eto, Shunichi Kajioka, Fukuoka, Japan

MP42-20 IDENTIFICATION OF NOVEL IRRITANT SENSING MECHANISMS IN THE BLADDER
Luke Grundy*, Ashlee Caldwell, Sonia Garcia-Caraballo, Grigori Rychkov, Stuart Brierley, Adelaide, Australia

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT
NUMBER TITLE
MP43-01 CAN FREQUENCY OF PROSTATE BIOPSY ON ACTIVE SURVEILLANCE BE REDUCED WITHOUT SIGNIFICANTLY INCREASING RISK?
Christine Barnett*, Gregory Auffenberg, Zian Cheng, Fan Yang, Jiachen Wang, John Wei, David Miller, James Montie, Ann Arbor, MI, Mufaddal Marnawala, Baltimore, MD, Brian Denton, Ann Arbor, MI

MP43-02 VARIATION IN USE OF CONFIRMATORY TESTING AMONG ACTIVE SURVEILLANCE CANDIDATES
Gregory Auffenberg*, Zaojun Ye, Ann Arbor, MI, Brian Lane, Grand Rapids, MI, Susan Linsell, Nikola Rakic, Andrew Brachulis, Ann Arbor, MI, Michael Cher, Detroit, MI, David Miller, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP43-03 DO PROSTATE BIOPSY-ASSOCIATED COMPLICATIONS INFLUENCE TREATMENT SELECTION FOR PATIENTS WITH NEWLY DIAGNOSED, CLINICALLY LOCALIZED PROSTATE CANCER?
Melanie Adamsky*, Jacob Tallman, Chicago, IL, Kristine Kuchta, Brian Helfand, Evanston, IL

MP43-04 IMPACT OF USPSTF RECOMMENDATION ON RATES OF NON-DEFINITIVE MANAGEMENT IN LOW RISK PROSTATE CANCER UTILIZING THE NATIONAL CANCER DATABASE
John F. Burns*, John P. Flores, Mazen Alsinnawi, Sydney Akapame, John Massman III, Christopher Porter, Seattle, WA

MP43-05 COMPARING PRACTICE-VERSUS PROVIDER-LEVEL VARIATION IN USE OF ACTIVE SURVEILLANCE FOR MEN WITH LOW-RISK PROSTATE CANCER
Gregory Auffenberg*, Apoorv Dhir, Susan Linsell, Ann Arbor, MI, Brian Lane, Grand Rapids, MI, David Miller, Ann Arbor, MI, Michael Cher, Detroit, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP43-06 THE EFFECT OF TARGETED ANTIBIOTIC PROPHYLAXIS IN MEN UNDERGOING TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY
Carling Cheung*, Hiten Patel, Patricia Landis, H. Ballentine Carter, Misop Han, Baltimore, MD

ABSTRACT
NUMBER TITLE
MP43-07 CLINICAL UTILITY OF MRI/FUSION BIOPSY IN PROSTATE CANCER PATIENTS ON ACTIVE SURVEILLANCE
Zachary Hamilton*, Unwanaobong Nseyo, Brittney Cotta, Natalie Schenen-Ahmed, David Karow, A Karim Kader, Christopher Kane, J Kellogg Parsons, San Diego, CA

MP43-08 IMPACT OF HIGH VOLUME CENTERS ON MANAGEMENT OF HIGH AND LOW RISK PROSTATE CANCER
John F. Burns*, John P. Flores, Mazen Alsinnawi, Sydney Akapame, Elliot Blau, John Massman III, Christopher Porter, Seattle, WA

MP43-09 “ACTIVE SURVEILLANCE” IN THE EVERYDAY CARE: RESULTS FROM HAROW-A PROSPECTIVE, NON-INTERVENTIONAL STUDY WITH A MEAN FOLLOW-UP OF 66.7 MONTHS.
Jan Herden*, Cologne, Germany, Dietrich Schnell, Berlin, Germany, Axel Heidenreich, Cologne, Germany, Lothar Weissbach, Berlin, Germany

MP43-10 THE ROLE OF SURVEILLANCE BIOPSY WITH NO CANCER AS A PROGNOSTIC MARKER FOR RECLASSIFICATION: RESULTS FROM THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS)

MP43-11 REFINED ANALYSIS OF PROSTATE SPECIFIC ANTIGEN (PSA) VELOCITY TO PREDICT OUTCOMES IN ACTIVE SURVEILLANCE: RESULTS FROM THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS)

*Presenting author
MP43-12 PREDICTING PROGRESSION IN ACTIVE SURVEILLANCE; EXTERNAL VALIDATION OF THE CANARY PASS RISK CALCULATOR WITH THE SPANISH UROLOGICAL ASSOCIATION REGISTRY ON AS
Angel Borque-Fernando*, Zaragoza, Spain, Jose Rubio-Briones, Valencia, Spain, Luis M. Esteban-Escario, Zaragoza, Spain, Argimiro Collado-Serra, Ana Soto, Valencia, Spain, Pedro A. López González, Murcia, Spain, Jordi Huguet Pérez, Barcelona, Spain, Jose I. Sanz Velez, Huesca, Spain, Jesús Gil Fabra, Zaragoza, Spain, Enrique Gómez Gómez, Córdoba, Spain, Cristina Quicios Dorado, Madrid, Spain, Lluís Fumadó, Barcelona, Spain, Sara Martínez-Briej, A Coruña, Spain, Juan Soto Villalba, Cádiz, Spain, In behalf of rest of Al of AEU/PIEM/2014/0001, Madrid, Spain

MP43-13 COMPARISON OF BIOCHEMICAL RECURRENCE FREE SURVIVAL AFTER RADICAL PROSTATECTOMY AMONG MEN IN ACTIVE SURVEILLANCE FOLLOWING GRADE RECLASSIFICATION AND MEN NEWLY DIAGNOSED WITH SIMILAR GRADE DISEASE
Clarissa Diniz*, Ballentine Carter, Jonathan Epstein, Mufaddal Mamawala, Baltimore, MD

MP43-14 UTILITY OF A NOVEL BIOPSY INSTRUMENT WITH LONG SIDE-NOTCH NEEDLE IN THE SELECTION OF PATIENTS FOR ACTIVE SURVEILLANCE
Kent Kanao*, Keishi Kajikawa, Ikuo Kobayashi, Hiroyuki Muramatsu, Shingo Morinaga, Hiroshi Saiki, Genya Nishikawa, Yoshiharu Kato, Masahito Watanabe, Kogenta Nakamura, Makoto Sumitomo, Nagakute, Japan

MP43-15 CLINICAL SIGNIFICANCE OF DETECTION OF PERINEURAL INVASION (PNI) ON A SURVEILLANCE BIOPSY IN FAVORABLE RISK MEN ON ACTIVE SURVEILLANCE
Mufaddal Mamawala*, Patricia Landis, Jonathan Epstein, Bruce Trock, H. Ballentine Carter, Baltimore, MD

MP43-16 VARIATION IN ACTIVE SURVEILLANCE UTILIZATION FOR THE MANAGEMENT OF PROSTATE CANCER IN A REGIONAL COLLABORATIVE
Adam Reese*, Claudette Fonshell, Serge Ginzburg, Thomas Guzzo, Thomas Lanchoney, Bret Marfow, Marc Smaldone, Edouard Trabulsy, Robert Uzzo, on behalf of the Pennysylvanina Urologic Regional Collaborative, Philadelphia, PA

MP43-17 MPMRI FOR PREDICTING PROSTATE CANCER PROGRESSION IN MEN ON ACTIVE SURVEILLANCE: A COMPARISON TO PSA KINETICS

MP43-18 FOR MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER, OLDER AGE AT DIAGNOSIS AND AT RADICAL PROSTATECTOMY PORTENDS POOR OUTCOMES
Sasha Druskin*, Mufaddal Mamawala, Jeffrey Tosoian, H. Ballentine Carter, Bruce Trock, Baltimore, MD

MP43-19 ACTIVE SURVEILLANCE FOR FAVORABLE-RISK PROSTATE CANCER IN AFRICAN CARIBBEAN MEN: RESULTS OF A PROSPECTIVE STUDY
Matthias Meunier*, Rémi Eyraud, Cédric Sénéchal, Gilles Gourlaud, Virginie Roux, Pointe-à-Pitre, France, Cécilia Lanchon, Grenoble, France, Laurent Brureau, Pascal Blanchet, Pointe-à-Pitre, France

MP43-20 RATES OF NON-DEFINITIVE MANAGEMENT FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER ARE SIMILAR BETWEEN AFRICAN AMERICANS AND CAUCASIANS
John Burns*, John P. Flores, Mazen Alsinnawi, Sydney Akapame, John Massman III, Christopher Porter, Seattle, WA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT
NUMBER TITLE
MP44-01 IN VIVO FLUORESCENCE IMAGING OF AN ORTHOTOPIC RAT BLADDER TUMOR MODEL INDICATES DIFFERENTIAL UPTAKE OF INTRAVESICALLY INSTILLED NEAR-INFRARED LABELED 2-DEOXYGLUCOSE ANALOG BY NEOPLASTIC URINARY BLADDER TISSUES
Joel Slaton*, Carole Davis, Robert Hurst, Oklahoma City, OK, Daqing Piao, Stillwater, OK

MP44-02 IDENTIFICATION AND VALIDATION OF C10RF198 AS AN INDEPENDENT MARKER OF BLADDER CANCER METASTASIS IN SEER AND TCGA DATABASE
Beihe Wang*, Fangning Wan, Yijun Shen, Yiping Zhu, Yao Zhu, Dingwei Ye, Shanghai, China, People’s Republic of

MP44-03 LOW GRADE BLADDER TUMORS PROGRESS TO HIGH GRADE VIA TWO DISTINCT MECHANISMS
Ralf Kittler, Christine Shiang, Ryan Hutchinson*, Rahul Kollipara, Payal Kapur, Franto Francis, Yair Lotan, Dallas, TX

MP44-04 SIGNIFICANCE OF SERUM N-GLYCAN PROFILING AS A DIAGNOSTIC BIOMARKER IN UROTHELIAL CARCINOMA

MP44-05 OVEREXPRESSION OF IMMUNE CO-STIMULATORY MOLECULE B7-H4 IS ASSOCIATED WITH POOR SURVIVAL IN BLADDER UROTHELIAL CARCINOMA
Alexander Glaser*, Joseph Podolj, Stephen Miller, Joshua Meeks, Chicago, IL

MP44-06 IMMUNOHISTOCHEMICAL EVALUATION OF BASAL AND LUMINAL MARKERS IN NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF BLADDER (NMIBC)

MP44-07 A CIRCULAR RNA (CIRCULAR1) AS A NOVEL BIOMARKER OF PROGNOSIS FOR BLADDER CANCER
Guo-Wen Lin*, Hao-Yue Sheng, Hu-Yang Xie, Yi-Jun Shen, Guo-Hai Shi, Ding-Wei Ye, Shanghai, China, People’s Republic of

MP44-08 THE LANDSCAPE OF HER2 ALTERATIONS IN MUSCLE-INVASIVE BLADDER CANCER: IMPACT ON PATIENT SELECTION FOR TARGETED THERAPIES?
Bernhard Kiss, Bern, Switzerland, Alexander Wyatt, Vancouver, Canada, James Douglas, Hampshire, United Kingdom, Veronika Skugina, Bern, Switzerland, Fan Mo, Shawn Anderson, Vancouver, Canada, Diana Rotzer, Achim Fleischmann, Vera Genitsch, Bern, Switzerland, Tetsutaro Hayashi, Hiroshima, Japan, Maja Neuenschwander, Bern, Switzerland, Christine Buerki, Elaiv Davicionie, Colin Collins, Vancouver, Canada, George Thalmann, Bern, Switzerland, Peter Black, Roland Seiler*, Vancouver, Canada

MP44-09 GERMLINE COPY NUMBER POLYMORPHISM IDENTIFIED AS POTENTIAL PROGNOSTIC MARKER FOR PROGRESSION OF NON-MUSCLE INVASIVE BLADDER CANCER
Yoshiaki Yamamoto*, Yutaka Suehiro, Yoshishisa Kawai, Ryo Inoue, Hiroaki Matsumoto, Hideyasu Matsuyama, Ube, Japan

MP44-10 ROLE OF MOLECULAR CLASSIFICATION IN HIGH GRADE (HG) NON MUSCLE INVASIVE BLADDER CANCER(NMIBC)
Marina Gándara-Cortés, Manuel Carballo-Quinta*, Maria Elena López-Diez, Maria Pilar San Miguel-Fraile, José Antonio Ortiz-Rey, Máximo Castro-Iglesias, C Gómez de María, Sheila Dominguez-Almúster, Miguel Pérez-Schoch, Joaquín González-Carrerón, Vigo, Spain

MP44-11 BIOMARKER-DRIVEN TARGETED ORAL TREATMENT STRATEGY FOR BLADDER CANCER
Daley Schimmelpfennig, Michael W. Kemper*, Soum D. Lokeshwar, Augusta, GA, Andre Jordan, Vinata B. Lokeshwar, Miami, FL

MP44-12 APOBEC-MEDIATED MUTAGENESIS IS ASSOCIATED WITH EXPRESSION OF IMMUNE-RELATED GENES AND OVERALL SURVIVAL IN BLADDER CANCER
Alexander Glaser*, Damiano Fantini, Kalen Rimar, Joshua Meeks, Chicago, IL

*Presenting author
MP44-13 MOLECULAR TRACKING OF BLADDER CANCERUSING MUTATIONS DETECTED IN PLASMA CELL-FREE DNA THROUGH RADICAL CYSTECTOMY AND CHEMOTHERAPY.


MP44-14 DOWNREGULATION OF MIR-200B IS ASSOCIATED WITH CISPLATIN-RESISTANCE IN BLADDER CANCER CELLS

Tetsuya Shindo*, Naotaka Nishiyama, Takeshi Niinuma, Hiroshi Kitajima, Masahiro Kai, Takashi Tokino, Nobuo Shinkai, Hiromu Suzuki, Naoya Masumori, Sapporo, Japan

MP44-15 ANXA10 AND ATP7A ARE THE MTOR PATHWAY DOWNSTREAM TO PREDICT THE RECURRENCE AND PROGRESSION IN NON-MUSCLE INVASIVE HIGH GRADE UROTHELIAL CARCINOMA OF THE BLADDER

Byung Hoon Chi, Subin Jin, Young Mi Whang, Seung Hyun Ahn, Jae Duck Choi, Shin Young Lee, In Ho Chang, Bongsuk Shim*, Seoul, Korea, Republic of

MP44-16 NBR1 AND KIF14 ARE THE MTOR PATHWAY DOWNSTREAM TO PREDICT THE RECURRENCE IN NON-MUSCLE INVASIVE LOW GRADE UROTHELIAL CARCINOMA OF THE BLADDER

Byung Hoon Chi*, Subin Jin, Young Mi Whang, Seung Hyun Ahn, Jae Duck Choi, Shin Young Lee, In Ho Chang, Seoul, Korea, Republic of

MP44-17 PATIENT DERIVED XENOGRAFTS AS PRECLINICAL MODELS OF UROLOGICAL MALIGNANCIES

Sofia Karkampouna, Eugenio Zoni, Federico la Manna, Letizia Astrologo, Bern, Switzerland, Lijkele Beimers, Peter Kloen, Amsterdam, Netherlands, Joel Grosjean, Irena Klima, Martin Spahn, Marianna Knuithof-de Julio*, George N. Thalmann, Bern, Switzerland

MP44-18 TUMOR ESCAPE IN THE MICROENVIRONMENT OF PENILE CARCINOMA

Sarah Ottenhof*, Rosa Djadjiningrat, Helene Thypesen, Jeroen de Jong, Simon Horenblas, Ekaterina Jordanova, Amsterdam, Netherlands

MP44-19 HIGH-THROUGHPUT CHEMICAL SCREENING FOR SENSITIZATION OF BLADDER CANCER TO GEMCITABINE AND CISPLATIN CHEMOTHERAPY

Yuki Kita*, Takashi Kobayashi, Atsuro Sawada, Ryouchi Saito, Toshinari Yamasaki, Takahiro Inoue, Osamu Ogawa, Kyoto, Japan

MP44-20 EGFR CELL EXPRESSION IN BLADDER WASHINGS AS A RISK MARKER TOOL IN NON MUSCLE-INVASIVE BLADDER CANCER. PRELIMINARY EXPERIENCE

Fabrizio Di Maida*, Vincenzo Serretta, Cristina Scalici Gasolfo, Marco Vella, Antonella Cangemi, Antonio Russo, Alchised Simonato, GSTU Foundation, Palermo, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
3:50 PD30-03 SAME SESSION BILATERAL URETEROSCOPY FOR MULTIPLE STONES: RESULTS FROM THE CLINICAL RESEARCH OFFICE OF ENDUROLOGICAL SOCIETY (CROES) URETEROSCOPY (URS) GLOBAL STUDY
Kenneth Pace*, Tad Kroczak, Toronto, Canada, Nienke Wijnstok, Guido Kamphuis, Amsterdam, Netherlands, Tarik Eser, Istanbul, Turkey, Chrysovalantis Toutzias, Thessaloniki, Greece, Benjamin Silva, Santiago, Chile, Jean de la Rosette, Amsterdam, Netherlands

4:00 PD30-04 PERIOPERATIVE MANAGEMENT OF LOW-DOSE ASPIRIN IN SURGICAL KIDNEY STONE MANAGEMENT: A SURVEY OF CURRENT ENDOUROLOGIC PRACTICE PATTERNS.
Joshua Ebel*, Columbus, OH, Brian Eisner, Boston, MA, Michael Lipkin, Durham, NC, Ben Chew, Vancouver, Canada, Bodo Knudsen, Columbus, OH

4:10 PD30-05 RISK FACTORS PREDICTING POST-PERCUTANEOUS NEPHROLITHOTOMY TRANSFUSION
Marcelino Rivera*, James Lingeman, Matthew Mellon, Nadya York, Hazem Elmansy, Amy Krambeck, Indianapolis, IN

4:20 PD30-06 TRANSPARENCHYMAL RENAL SURGERY DECREASES KIDNEY FUNCTION IN PATIENTS WITH STONES LARGER THAN 4 CM AND STONES IN MULTIPLE LOCATIONS
Timothy Tran*, New York, NY, Gyan Pareek, Providence, RI

4:30 PD30-07 OUTPATIENT TUBELESS MINI-PCNL FOR MODERATE TO LARGE RENAL STONES: OUR ONGOING EXPERIENCE
Kyle Basham, John Fisher*, Knoxville, TN, Jeremy Archer, Jackson, MS, Ryan Pickens, Knoxville, TN

4:40 PD30-08 DEVICE-RELATED DEVIATION DURING PERCUTANEOUS NEPHROLITHOTOMY: REVIEW OF THE MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE.

4:50 PD30-09 WHICH FLEXIBLE URETEROSCOPIES (DIGITAL VS OPTICAL) CAN EASILY REACH THE DIFFICULT LOWER POLE CALYCES AND HAVE BETTER END-TIP DEFLECTION?
Laurian Dragos*, Timisoara, Romania, Salvatore Buttica, Messina, Italy, Tarik Eser, Istanbul, Turkey, Silvia Proietti, Milan, Italy, Achilles Ploumidis, Athens, Greece, Catalin Iacoboaie, Steve Doizi, Jeremie Berg, Paris, France, Bhaskar Somani, Southampton, United Kingdom, Olivier Traxer, Paris, France

5:00 PD30-10 TIPLESS NITINOL STONE BASKETS: COMPARISON OF PENETRATION FORCE, RADIAL DILATION FORCE, OPENING DYNAMICS, AND DEFLECTION
Nishant Patel*, Arash Akhavein, Bryan Hinck, Rajat Jain, Manoj Monga, Cleveland, OH

5:10 PD30-11 USE OF MOSES PULSE MODULATION TECHNOLOGY TO IMPROVE HOLMIUM LASER LITHOTRIPSY OUTCOMES: A PRECLINICAL STUDY
Mostafa Elhilali*, Montreal, Canada, Shadie Badaan, Haifa, Israel, Ahmed Ibrahim, Sero Andonian, Montreal, Canada

5:20 PD30-12 HOW TO PERFORM THE DUSTING TECHNIQUE FOR CALCIUM OXALATE STONES DURING HO:YAG LITHOTRIPSY
Jeong Woo Lee*, Goyang, Korea, Republic of, Juhyun Park, Min Chul Cho, Hyeon Jeong, Hwancheol Sun, Sung Yong Cho, Seoul, Korea, Republic of
3:50 PD31-03 CONTEMPORARY TRENDS IN THE SURGICAL MANAGEMENT OF PEYRONIE’S DISEASE IN NEW YORK STATE

4:00 PD31-04 ONSET OF PEYRONIE’S DISEASE AFTER DIAGNOSIS AND MANAGEMENT OF PROSTATE CANCER: A POPULATION ANALYSIS
   Phil V. Bach*, New York, NY, Shufeng Li, Stanford, CA, John P. Mulhall, New York, NY, Michael L. Eisenberg, Stanford, CA

4:10 PD31-05 THE DEPRESSION AND RELATIONSHIP IMPACT IN PEYRONIE’S DISEASE STUDY (DRIPD): BASELINE POPULATION CHARACTERISTICS AND PREDICTORS
   Jean-Etienne Terrier*, Lawrence C Jenkins, Christian J Nelson, John P Mulhall, New York City, NY

4:20 PD31-06 THE SAFETY AND EFFICACY OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN COMBINATION WITH VACUUM THERAPY FOR THE TREATMENT OF PEYRONIE’S DISEASE
   David Ralph*, Amir Abdel Raheem, London, United Kingdom, Gennzhuo Liu, Malvern, PA

4:30 PD31-07 CONCURRENT PENILE TRACTION THERAPY IN MEN UNDERGOING COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR PEYRONIE’S DISEASE
   Matthew Ziegelmann*, Boyd Viers, Brian Montgomery, Joshua Savage, Landon Trost, Rochester, MN

4:40 PD31-08 SUCCESSFUL TREATMENT OF RESIDUAL CURVATURE IN PEYRONIE’S DISEASE IN MEN PREVIOUSLY TREATED WITH INTRALESIONAL COLLAGENASE HISTOLYTICUM

4:50 PD31-09 PENILE PROSTHESIS IMPLANTATION (PPI) PLUS CORPOREAL RECONSTRUCTION WITH COLLAGEN-FLEECE GRAFTING IN THE TREATMENT OF PEYRONIE’S DISEASE (PD) WITH OR WITHOUT ED
   Claudio Martínez Ballesteros*, Juan Ignacio Martínez-Salamanca, Eugenio Cerezo, Agustín Fraile, Esaú Fernández Pascual, Luis Del Portillo, Joaquín Carballido, Madrid, Spain

5:00 PD31-10 HYDROXYAPATITE IN PEYRONIE’S PLAQUES
   Thomas Schmid*, Robin Pourzal, Joseph Temple, Laurence Levine, Chicago, IL

5:10 PD31-11 THE ORIGINS OF CALCIFIED PEYRONIE’S PLAQUE
   Matthew Hernefarth*, Ling Chen, Misun Kang, San Francisco, CA, Ryan Hsi, Nashville, TN, Amanda Reed-Maldonado, Guiling Lin, Marshall Stoller, Tom Lue, Sunita Ho, San Francisco, CA

5:20 PD31-12 WHOLE EXOME SEQUENCING IDENTIFIES GENES AND PATHWAYS WITH POTENTIAL INVOLVEMENT IN PEYRONIE’S AND DUPUYTREN’S DISEASES
   Alexander W. Pastuszak*, Yofre Cabeza-Arvelaiz, Suman Maity, Larry I. Lipshtultz, Dolores J. Lamb, Cristian Coarfa, Houston, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 13, 2017 3:30 pm - 5:30 pm
Podium Session 32
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: VALUE OF CARE: COST AND OUTCOMES MEASURES III
Room 205 BC @ Boston Convention & Exhibition Center
Moderators: John Hollingsworth and C.J. Stimson
PD32-03 IMPACT OF MEDICARE SHARED SAVINGS PROGRAM ACCOUNTABLE CARE ORGANIZATIONS ON PROSTATE CANCER TREATMENT
Tudor Borza*, Samuel R. Kaufman, Phyllis Yan, Lindsey Herrel, Amy N. Luckebaugh, David C. Miller, Ted A. Skolarus, Ann Arbor, MI, Bruce L. Jacobs, Pittsburgh, PA, Edward Norton, Vahakn B. Shahinian, Brent K. Hollenbeck, Ann Arbor, MI

PD32-04 SURGEON ENGAGEMENT IN EARLY ACCOUNTABLE CARE ORGANIZATIONS
Matthew Resnick*, Amy Graves, Melinda Buntin, Michael Richards, David Penson, Nashville, TN

PD32-05 PROSTATE CANCER SCREENING: EFFECT OF EARLY MEDICAID EXPANSION
Jesse Sammon, Emily Serrel*, Portland, ME, Patrick Karabon, Detroit, MI, Gregory Mills, Portland, ME, Mani Menon, Firas Abdollah, Detroit, MI, Quoc-Dien Trinh, Boston, MA

PD32-06 THE STATE OF UROLOGIC MALPRACTICE: AN ANALYSIS OF RECENT CLAIMS DATA AND TRENDS
M. Ryan Farrell*, Christopher Coogan, Chicago, IL

PD32-07 EVIDENCE IN SUPPORT OF USING A SINGULAR SCORE TO CHARACTERIZE A SURGEON’S OPERATIVE SPENDING BEHAVIOR
Matthew Truesdale*, Christy Boscardin, Thomas Chi, San Francisco, CA

PD32-08 CAUSES, TIMING, AND HOSPITAL COSTS OF INDEX VS. NON-INDEX HOSPITAL READMISSIONS FOLLOWING RADICAL PROSTATECTOMY: IMPLICATIONS FOR COST CONTAINMENT STRATEGIES
Meera Chappidi*, Max Kates, C.J. Stimson, Heather Chaffin, Jeffrey Tosolian, Misop Han, Mohamad Allaf, Ashley Ross, H. Ballentine Carter, Phillip Pierorazio, Alan Partin, Trinity Bivalacqua, Baltimore, MD

PD32-09 DOWNSTREAM PROCEDURES FOLLOWING THE USE OF BONE SCAN IN THE STAGING OF MUSCLE-INVASIVE BLADDER CANCER
Robert Turner II*, Jonathan Yabes, Benjamin Davies, Dwight Heron, Bruce Jacobs, Pittsburgh, PA

PD32-10 DATA FEEDBACK AFFORDS MODEST EFFECT IN DRIVING PHYSICIAN BEHAVIOR TOWARD VALUE-BASED CARE FOR BPH SURGERY
Alan L Kaplan*, Vishnukamal Golla, Catherine M. Crespi, Jamal Nabhani, Mark S. Litwin, Christopher Saigal, Los Angeles, CA

PD32-11 IMPACT OF PRETREATMENT SMALL RENAL MASS BIOPSY ON COSTS FOR PATIENTS CONSIDERING SURGERY
Amy H. Lim*, Maria Rozo, Sara L Best, Shane A Wells, Meghan G Lubner, Timothy J Ziemlewicz, Fred T Lee, Louis J Hinshaw, Stephen Y. Nakada, E. Jason Abel, Madison, WI

PD32-12 UNDERSTANDING THE EFFECT OF THE HOSPITAL READMISSION REDUCTION PROGRAM ON SURGICAL READMISSIONS
Tudor Borza*, Mary K. Oerline, Ted A. Skolarus, Ann Arbor, MI, Bruce L. Jacobs, Pittsburgh, PA, Amy N. Luckebaugh, Matthew Lee, Rita Jen, Vahakn B. Shahinian, Brent K. Hollenbeck, Ann Arbor, MI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 13, 2017 3:30 pm - 5:30 pm
Podium Session 33
PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY I
Room 251 @ Boston Convention & Exhibition Center
Moderators: Benyi Li and Jill Macoska
3:50 PD33-03 PHARMACOLOGIC TARGETING OF TGF-β MEDIATED EMT IN PROSTATE CANCER
Zheng Cao*, Lexington, KY, Shahriar Koochekpour, Buffalo, NY, Stephen Strup, Natasha Kyrianou, Lexington, KY

4:00 PD33-04 TARGETED NEXT-GENERATION SEQUENCING ANALYSIS OF PRIMARY PROSTATE CANCER IDENTIFIES POTENTIAL THERAPEUTIC TARGETS
Matthew Jeffery*, Adam Cox, Alan Clarke, Howard Kynaston, Cardiff, United Kingdom

4:10 PD33-05 TARGETED NEXT GENERATION SEQUENCING TO CHARACTERIZE MAGNETIC RESONANCE IMAGING VISIBLE AND INVISIBLE PROSTATE CANCER: BIOLOGICAL INSIGHTS AND THERAPEUTIC IMPLICATIONS
Simpa Salami, Daniel Hovelson, Aaron Udager, Matthew Lee*, Nicole Curci, Jeremy Kaplan, Arvin George, Matthew Davenport, Scott Tomlins, Ganesh Palapattu, Ann Arbor, MI

4:20 PD33-06 MCAM SUPPORTS THE AGGRESSIVE PHENOTYPE IN HUMAN PROSTATE CANCER
Eugenio Zoni, Letizia Astrologo, Bern, Switzerland, Janine Melsen, Leiden, Netherlands, Irena Klima, Joel Grosjean, Bern, Switzerland, Gabri van der Pluijm, Leiden, Netherlands, Marco G. Cecchini, Marianna Kruithof-de Julio*, George N. Thalhammer, Bern, Switzerland

4:30 PD33-07 CCRL2 REGULATES PROSTATE CANCER ORGAN SPECIFIC METASTASIS THROUGH THE INTERACTION WITH CCR5
Chia-Ling Hsieh, Taipei, Taiwan, Kuan-Chou Chen, New Taipei, Taiwan, Shian-Ying Sung*, Taipei, Taiwan

4:40 PD33-08 EXPRESSION PROFILES OF ERG AND SPINK1 IN LATENT, INCIDENTAL, AND METASTATIC PROSTATE CANCER
Takahiro Kimura*, Hiroyuki Inaba, Haruhisa koide, Shun Sato, Yasutoshi Yoshiyama, Toshihiro Yamamoto, Jun Miki, Hiroyuki Takahashi, Shin Egawa, Tokyo, Japan

4:50 PD33-09 EXPRESSION OF NEUROPILIN 2 AS PROGNOSTIC FACTOR IN PATIENTS WITH PROSTATE CANCER
Angelika Borkowetz*, Marieta Toma, Michael Froehnner, Pia Hoenscheid, Susanne Fussel, Katli Erdmann, Dresden, Germany, Kaustubh Datta, Omaha, NE, Michael Muters, Manfred Wirth, Dresden, Germany

5:00 PD33-10 PREOPERATIVE SEX HORMONES PROFILES AND PATHOLOGICAL FEATURES OF LOCALIZED PROSTATE CANCER ARE RELATED TO BOTH TOTAL AND BIOAVAILABLE TESTOSTERONE

5:10 PD33-11 REAL-TIME MONITORING OF TUMOR PROGRESSION AND DRUG RESPONSES IN A PRECLINICAL MOUSE MODEL OF PROSTATE CANCER
Peng Huang*, Okayama, Japan, Peng Xu, xiezhaoli Li, Guangzhou, China, People’s Republic of, Naijin Xu, Okayama, Japan, Abai Xu, Guangzhou, China, People’s Republic of, Masami Watanabe, Hiromi Kumon, Okayama, Japan, Chunxiao Liu, Guangzhou, China, People’s Republic of, Yasutomo Nasu, Okayama, Japan

5:20 PD33-12 THE ROLE OF FATTY ACID BINDING PROTEIN 4 IN PROSTATE STROMAL TUMOR MICROENVIRONMENT AND PROSTATE CANCER PROGRESSION
Mingguo Huang*, Atsushi Koizumi, Takamitsu Inoue, Shintaro Narita, Tomonori Habuchi, Akita, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Saturday, May 13, 2017

Video Session 5

3:30 pm - 5:30 pm

BPH AND VOIDING DYSFUNCTION

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 254 @ Boston Convention & Exhibition Center
Moderators: Jairam Eswara, Una Lee and Andrea Tubaro

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V5-01</td>
<td>HOLMIUM LASER ENucleATION OF THE PROSTATE AS RETREATMENT AFTER UROLIFT DEVICE: FEASIBILITY AND TECHNICAL CONSIDERATIONS</td>
</tr>
<tr>
<td>V5-02</td>
<td>VOIDING URETHROCYSTOSCOPY: A NEW CONCEPT FOR BENIGN PROSTATIC OBSTRUCTION CHARACTERIZATION.</td>
</tr>
</tbody>
</table>

*Presenting author
V5-03 ROBOT-ASSISTED PERIPROSTATIC ARTIFICIAL URINARY SPHINCTER IMPLANTATION IN MALE PATIENT WITH NEUROGENIC STRESS URINARY INCONTINENCE
Benoit Peyronnet*, Sébastien Vincendeau, Pierre Grison, Quentin Aliimi, Lucas Freton, Lauranne Tondut, Baptiste Gires, Karim Bensalah, Nelly Senal, Jacques Kerdraon, Andrea Manunta, Rennes, France

V5-04 COMBINED PHOTOVAPORIZATION OF PROSTATE AND LASER CYSTOLITHOTRIPSY USING GREENLIGHT LASER
Darren Ow*, Marlon Perera, Damien Bolton, Nathan Lawrentschuk, Melbourne, Australia

V5-05 PROSTATE ARTERY EMBOLIZATION PRIOR TO ROBOTIC SIMPLE PROSTATECTOMY IN A PATIENT WITH HIGH BLEEDING RISK
Craig Rogers, Dan Pucherill*, Kaila Wilcher, Riaz Rehan, Maria Zanini, Scott Schwartz, Detroit, MI

V5-06 ROBOT-ASSISTED SIMPLE PROSTATECTOMY IN PATIENTS WITH LARGE VOLUME BPH (100 ML): INDICATIONS, TECHNIQUE AND RESULTS BASED ON 81 PROCEDURES
Paolo Umari*, Nicola Fossati, Alexander Heinze, Aalst, Belgium, Ruben De Groote, Aalst, Belgium, Geert De Naeyer, Peter Schatteman, Alexandre Mottrie, Aalst, Belgium

V5-07 PERINEAL ARTIFICIAL URINARY SPHINCTER (AUS) WITH HIGH SUBMUSCULAR (HSM) PLACEMENT OF PRESSURE REGULATING BALLOON (PRB)
Billy Cordon*, MIAMI BEACH, FL, Allen Morey, Dallas, TX

V5-08 "TOP-DOWN" HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP) TECHNIQUE
Nadya E. York*, Indianapolis, IN, Casey A. Dauw, Ann Arbor, MI, Michael S. Borofsky, Minneapolis, MN, James E. Lingeman, Indianapolis, IN

V5-09 HOLMIUM LASER ENUCLEATION OF A PROSTATIC ABSCESS
Marcelino Rivera*, James Lingeman, Amy Krambeck, Indianapolis, IN

V5-10 EXTRAPERITONEAL SIMPLE PROSTATECTOMY: A SURGERY FOR BEGINNERS?
Paulo Mota*, Nuno Carvalho, Emanuel Carvalho-Dias, Agostinho Cordeiro, João Torres, Nuno Morais, Mário Cerqueira-Alves, Riccardo Autorino, Estevão Lima, Braga, Portugal

V5-11 ROBOTIC SIMPLE PROSTATECTOMY: THE RETROPUBIC APPROACH
Unwanaobong Nseyo*, Yahir Santiago-Lastra, Jill Buckley, San Diego, CA

V5-12 HOLMIUM LASER ENUCLEATION OF THE PROSTATE AFTER PROSTATIC URETHRAL LIFT
Andrew Navetta*, Erin Bird, Marawan El Tayeb, Temple, TX
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Sunday, May 14, 2017  Plenary: Prime Time, Sunday Morning Session  7:30 am - 11:45 am

Ballroom West @ Boston Convention & Exhibition Center

7:30  HIGHLIGHTS: SEXUAL MEDICINE SOCIETY OF NORTH AMERICA
  Hossein Sadeghi-Nejad

7:40  POINT-COUNTERPOINT DEBATE: ERECTILE DYSFUNCTION AND THE SHOCKING TRUTH: IS SHOCKWAVE THERAPY EFFECTIVE?
  Moderator: Ranjith Ramasamy  
  Debater-Pro: Irwin Goldstein  
  Debater-Con: Tom Lue

8:00  CROSSFIRE: CONTROVERSIES IN UROLOGY: ADULT ONSET HYPOGONADISM IS A TRUE MEDICAL CONDITION
  Moderator: Wayne Hellstrom  
  Debaters-Pro: Luiz Torres, Abraham Morgentaler  
  Debaters-Con: Ravi Kacker, Allen Seftel

8:30  SECOND OPINION CASES: PEYRONIE’S DISEASE
  Moderator: Thomas Walsh  
  Panelists: William Brant, Ty Higuchi

9:00  SURGICAL TECHNIQUES: BENIGN PROSTATIC HYPERPLASIA (BPH)
  Moderator: Claus Roehrborn  
  Convective Radiofrequency Water Vapor Thermal Therapy: Tobias Kohler  
  Prostatic Urethral Lift: Shahin Tabatabaei  
  Plasma Vaporization with Precision in BPH: Kevin McVary  
  Photoselective Vaporization of the Prostate (PVP): A Systematic Approach to Treating a Large Median Lobe: Matthew Rutman  
  Holmium Laser Vaporization of the Prostate - Going To Capsule with Confidence: Lori Lerner

10:30  PANEL DISCUSSION: NOVEL TREATMENT STRATEGIES FOR PRIAPISM
  Moderator: Rafael Carion  
  Panelists: Gregory Broderick, Arthur Burnett, Laurence Levine

10:50  PPTLBA-01: LATE-BREAKING ABSTRACT–QUALITY OF LIFE AFTER PENILE PROSTHESIS IMPLANTATION – 1 YEAR FOLLOW-UP DATA OF THE ITALIAN PROSPECTIVE REGISTRY INSIST-ED
  Paolo Capogrosso

10:55  CRITICAL DISCUSSION: LIFESTYLE CHANGES TO IMPROVE FERTILITY
  Moderator: Harris Nagler  
  Discussants: Kirk Lo, Jay Sandlow

11:15  PANEL DISCUSSION: HPV: A PREVENTABLE CAUSE OF CANCER
  Moderator: Ira Sharlip  
  Panelists: Michael Eisenberg, Joel Palefsky, Landon Trost

11:45  SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017  Plenary: Next Frontier, Sunday Morning Session  8:00 am - 11:30 am

Ballroom East @ Boston Convention & Exhibition Center

8:00  HIGHLIGHTS: BENIGN UROLOGIC RESEARCH
  Rosalyn Adam

8:15  HIGHLIGHTS: SOCIETY FOR PEDIATRIC UROLOGY
  Elizabeth Yerkes

8:30  JOURNAL OF UROLOGY HIGHLIGHTS: PEDIATRICS
  Julian Wan

8:40  POINT-COUNTERPOINT DEBATE: MANAGING THE ADOLESCENT VARICOCELE
  Moderator: Ahmad Bani Hani, Debater-Observation: Guy Bogaert, Debater-Surgery: Kenneth Glassberg

9:00  CRITICAL DISCUSSION: TUNICA VAGINALIS FLAP FOR LATE SALVAGE OF TESTICULAR TORSION
  Moderator: Wald Farhat, Debater-Con: Nicol Bush, Debater-Pro: Doug Canning

9:20  POINT-COUNTERPOINT DEBATE: ANTIBIOTIC PROPHYLAXIS FOR REFLUX
  Moderator: Anthony Caldamone, Debater-Con: Andrew Kirsch, Debater-Pro: Hans Pohl

*Presenting author
9:40 STATE-OF-THE-ART LECTURE: SYNTHETIC BIOLOGY DEVICES - THE FUTURE DIAGNOSIS OF UTIS
   James Collins

10:00 JOHN DUCKETT MEMORIAL LECTURE: INTERNATIONAL VOLUNTEERISM: HANDS ACROSS THE WORLD
   Catherine deVries

10:20 CRITICAL DISCUSSION: THE TRANSGENDER PATIENT
   Moderator: Dana Ohl; Panelist-Male to Female: Stanton Honig, Panelist-The UK Experience: David Ralph,
   Panelist- Female to Male: Lee Zhao

10:40 STATE-OF-THE-ART LECTURE: FUNGAL URINARY TRACT INFECTIONS
   Francisco Marty

11:00 PNFLBA-01: LATE-BREAKING ABSTRACT - CURRENT ANTI-RETROVIRAL TREATMENTS DO NOT ELIMINATE HIV FROM SEMEN
   Robert Eyre

11:05 PNFLBA-02: LATE-BREAKING ABSTRACT - A HEAD TO HEAD COMPARATIVE PHASE II TRIAL OF STANDARD URINE CULTURE AND SENSITIVITY VERSUS DNA NEXT GENERATION SEQUENCING TESTING FOR URINARY TRACT INFECTIONS
   Michael McDonald

11:10 PANEL DISCUSSION: FEMALE SEXUAL DYSFUNCTION
   Moderator: Stanley Althof
   Brain Reorganization with Multisensory (MiS) Perceptions of Sexual Pain: Melissa Farmer
   New Medical and Psychological Treatments for HSDD in Women: Marita McCabe

11:30 SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
2:50 PNFLBA-07: LATE-BREAKING ABSTRACT – BLADDER INJURY ACTIVATES INNATE IMMUNITY DURING SHORT-TERM FOLEY CATHETERIZATION IN A SWINE MODEL
Carlos Puyo

2:55 PNFLBA-08: LATE-BREAKING ABSTRACT – IS GROUP LEARNING BEHAVIORAL MODIFICATION PROGRAM EFFECTIVE AND SAFE IN REDUCING GERIATRIC URINARY INCONTINENCE? A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL
Ananias Diokno

3:00 PNFB-03: BEST ABSTRACT – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AUTOLOGOUS MUSCLE DERIVED CELLS FOR URINARY SPHINCTER REPAIR
Roger Dmochowski

3:05 PNFB-04: BEST ABSTRACT – ASSOCIATION BETWEEN URINARY SYMPTOM SEVERITY AND AUTOMATED SEGMENTATION OF WHITE MATTER PLAQUE IN WOMEN WITH MULTIPLE SCLEROSIS
Siobhan Hartigan

3:10 PNFB-05: BEST ABSTRACT – SPECIFIC CHANGES IN BRAIN ACTIVITY IN WOMEN WITH OVERACTIVE BLADDER AFTER SUCCESSFUL SACRAL NEUROMODULATION WITH INTERSTIM®: AN FMRI STUDY
Steven Weissbart

3:15 PNFLBA-09: LATE-BREAKING ABSTRACT – LONG-TERM COMBINATION TREATMENT WITH SOLIFENACIN AND MIRABEGRON IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH OVERACTIVE BLADDER
Christian Gratzke

3:20 AUA GUIDELINES 2017: STRESS URINARY INCONTINENCE
Kathleen Kobashi

3:35 PANEL DISCUSSION: VESICOVAGINAL FISTULA: WHAT IS YOUR STRATEGY?
Moderator: Sherif Mourad
Panelists: Jacques Corcos, Dirk De Ridder, Christopher Payne

4:00 SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017  Plenary: Prime Time, Sunday Afternoon Session  1:00 pm - 4:00 pm

Ballroom West @ Boston Convention & Exhibition Center

1:00 CROSSFIRE: CONTROVERSIES IN UROLOGY: TRANSPERINEAL PROSTATE BIOPSY: ARE WE MOVING THE NEEDLE?
Moderator: Declan Murphy
Debaters-Pro: Mark Emberton, Jeremy Grummet
Debaters-Con: Ben Davies, Christopher Porter

1:30 SECOND OPINION CASES: RENAL HILAR MASS
Moderator: Robert Uzzo
Panelists: Georges Pascal Haber, Misop Han

2:00 SURGICAL TECHNIQUES: ENDOSCOPIC DIAGNOSIS AND TRANSURETHRAL RESECTION OF SUPERFICIAL BLADDER CANCER
Blue Light Cytoscopy: Trinity Bivalacqua
Intermittent Resection Technique: Sia Daneshmand
See More MIBC: Mitchell Humphreys

3:00 PPTLBA-02: LATE-BREAKING ABSTRACT - BLUE LIGHT FLEXIBLE CYSTOSCOPY (BLFC) WITH HEXAMINOLEVULINATE (HAL) AND WHITE LIGHT FLEXIBLE CYSTOSCOPY: A PROSPECTIVE, COMPARATIVE, WITHIN-PATIENT CONTROLLED MULTI-CENTER PHASE 3 STUDY IN THE DETECTION OF BLADDER CANCER DURING SURVEILLANCE
Sia Daneshmand

3:05 PANEL DISCUSSION: ADVANCES IN IMAGING IN UROLOGIC ONCOLOGY
Moderator: Badrinath Konety
Panelists: Deepak Bedi, Mihir Desai, Nathan Lawrentschuk

3:30 SETBACKS AND OPERATIVE SOLUTIONS: ROBOTIC HEMORRHAGE CONTROL
Moderator: Monish Aron
Panelists: Stephen Boorjian, Erik Castle, Li-Ming Su

4:00 SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Sunday, May 14, 2017 6:30 am - 10:00 am

SOCIETY OF WOMEN IN UROLOGY (SWIU)
Grand Ballroom CDE @ Westin Waterfront

6:30 BREAKFAST BUFFET
6:45 PRESIDENT'S WELCOME
   Society President: Dolores Lamb
6:50 AUA UPDATE
   J. Brantley Thrasher
7:00 WOMEN IN UROLOGY: CHANGING THE STATISTICS
   Kathleen Cooney

8:00 SWIU AWARD PRESENTATIONS
   Elisabeth Pickett
8:20 ANNUAL BUSINESS MEETING
8:45 NETWORKING
10:00 ADJOURN

Sunday, May 14, 2017 7:00 am - 9:00 am

Moderated Poster Session 45
SEXUAL FUNCTION/DYSFUNCTION: BASIC RESEARCH & PATHOPHYSIOLOGY I
Room 151 @ Boston Convention & Exhibition Center
Moderators: Maarten Albersen, Trinity Bivalacqua and Tom Lue

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-01</td>
<td>POST-TRANSLATIONAL MODIFICATION OF NEURONAL NITRIC OXIDE SYNTHASE IN THE HUMAN ERECTILE TISSUE FOLLOWING RADICAL PROSTATECTOMY</td>
</tr>
<tr>
<td>Serkan Karakus*, Biljana Musicik, Arthur L. Burnett, Baltimore, MD</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-02</td>
<td>ALTERATIONS OF MICRORNA EXPRESSION IN A CAVERNOUS NERVE INJURY RAT MODEL</td>
</tr>
<tr>
<td>Chunhui Liu*, Yanma Cao, Tien C Ko, Run Wang, Houston, TX</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-03</td>
<td>AGE RELATED PENILE HEMODYNAMIC IMPAIRMENT AND FIBROSIS: POSSIBLE ROLE OF GIV-WNT SIGNALING PATHWAYS</td>
</tr>
<tr>
<td>Tung-Chin (Mike) Hsieh*, Sadhna Kanoo, Jay Parikh, Valmik Bhargava, M. Raj Rajasekaran, San Diego, CA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-04</td>
<td>BENEFICIAL EFFECTS OF QUERCETIN ON RAT CORPUS Cavernosum AFTER CISPLATIN TREATMENT</td>
</tr>
<tr>
<td>Iker Tinay*, Selin Cadirci, Istanbul, Turkey, Ozge Cevik, Sivas, Turkey, Feritha Ercan, Kutay Koroglu, Goksel Sener, Istanbul, Turkey</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-05</td>
<td>ACTIVATION OF NRF2 IMPROVES ENDOTHELIAL FUNCTION IN CORPUS Cavernosum FROM AGED RATS AND IN CORPUS Cavernosum AND PENILE ARTERIES FROM ED PATIENTS</td>
</tr>
<tr>
<td>Juan Ignacio Martinez-Salamanca*, Mariam El Assar, Argentina Fernandez, Alberto Sanchez-Ferrer, Agustin Fraile, Leocardio Rodriguez-Mañas, Joaquin Cardallido, Javier Angulo, Madrid, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-06</td>
<td>OPTIMIZATION OF SONIC HEDGEHOG DELIVERY FROM SELF-ASSEMBLED NANOFIBER HYDROGELS TO PREVENT ED AND PENILE MORPHOLOGY CHANGES IN A RAT PROSTATECTOMY MODEL</td>
</tr>
<tr>
<td>Shawn Choe, Chicago, IL, Daniel Harrington, Houston, TX, Samuel Stupp, Chicago, IL, Kevin McVary, Springfield, IL, Carol Podlasek*, Chicago, IL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-07</td>
<td>SONIC HEDGEHOG PROMOTES CAVERNOUS NERVE REGENERATION BY INDUCING SPROUTING OF NEURONS IN THE PELVIC GANGLIA AND CAVERNOUS NERVE</td>
</tr>
<tr>
<td>Ryan Dobbs*, Shawn Choe, Gail Prins, Chicago, IL, Daniel Harrington, Houston, TX, Samuel Stupp, Chicago, IL, Kevin McVary, Springfield, IL, Carol Podlasek, Chicago, IL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-08</td>
<td>CAVERNOUS NERVE CRUSH INJURY INDUCES APOPTOSIS IN THE PELVIC PLEXUS INCLUDING PELVIC AND HYPOGASTRIC NERVES</td>
</tr>
<tr>
<td>Marah Hehemann*, Shawn Choe, Chicago, IL, Kevin McVary, Springfield, IL, Carol Podlasek, Chicago, IL</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-09</td>
<td>RADIATION INCREASED APOPTOSIS OF NITRERGIC NEURONS CULTURED FROM THE MAJOR PELVIC GANGLIA</td>
</tr>
<tr>
<td>Elena Pak, Greenville, NC, Bridget Koontz, Durham, NC, Johanna Hannan*, Greenville, NC</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP45-10</td>
<td>HISTOMORPHOMETRICAL EVALUATION OF THE CORPUS Cavernosum OF HYPERTENSIVE RATS TREATED WITH 5-α-REDUCTASE INHIBITORS</td>
</tr>
<tr>
<td>Marcello Da Silva, Waldemar Costa, Bianca Gregorio, Francisco Sampaio, Diogo De Souza*, Rio De Janeiro, Brazil</td>
<td></td>
</tr>
</tbody>
</table>
MP45-11 DICKKOPF2 PROMOTES ANGIOGENESIS AND NEURAL REGENERATION THROUGH AN ANGIPOIETIN-1-TIE2 PATHWAY AND RESCUES ERECTILE FUNCTION IN THE DIABETIC MOUSE
Guo Nan Yin*, Hai-Rong Jin, Jiyeon Ock, Min Ji Choi, Kang-Moon Song, Anita Limanjaya, Kalyan Ghatak, Nguyen Nhat Minh, Soo-Hwan Park, Ji-Kan Ryu, Jun-Kyu Suh, Incheon, Korea, Republic of

MP45-12 CHRONIC ADMINISTRATION OF A LIMK2 INHIBITOR IMPROVES CAVERNOUS VENO-OCCCLUSIVE DYSFUNCTION THROUGH SUPPRESSION OF CAVERNOUS FIBROSIS IN A RAT MODEL OF ERECTILE DYSFUNCTION AFTER CAVERNOUS NERVE INJURY
Juhyun Park*, Chu Hong Park, Inyoung Sun, Sung Yong Cho, Seoul, Korea, Republic of, Seung Baik, Sang Jun Chun, Gwangju, Korea, Republic of, Kwang Ho You, Gwanmyeong, Korea, Republic of, Kwangjin Park, Hwancheol Son, Hyeon Jeong, Soo Woong Kim, Jae-Seung Paick, Min Chul Cho, Seoul, Korea, Republic of

MP45-13 INTRACAVERNOUS DELIVERY OF DICKKOPF3 GENE OR PEPTIDE RESCUES ERECTILE FUNCTION THROUGH ENHANCED CAVERNOUS ANGIOGENESIS IN THE DIABETIC MOUSE
Kang-Moon Song*, Woo-Jean Kim, Min Ji Choi, Anita Limanjaya, Kalyan Ghatak, Nguyen Nhat Minh, Guo Nan Yin, Soo-Hwan Park, Ji-Kan Ryu, Jun-Kyu Suh, Incheon, Korea, Republic of

MP45-14 EVALUATION OF THE THERAPEUTIC TARGETING POTENTIAL OF MICRORNA-93 IN THE TREATMENT OF VASCULOGENIC ERECTILE DYSFUNCTION
Nathan Starke*, Ryan Smith, Jeffrey Lysiak, Charlottesville, VA

MP45-15 EFFECT OF ICARIIN IN COMBINATION WITH DAILY SILDENAFIL ON PENILE ATROPHY AND ERECTILE DYSFUNCTION IN A RAT MODEL OF BILATERAL CAVERNOUS NERVES INJURY
Yongde Xu*, Yuanyi Wu, Yong Yang, Zhongcheng Xin, Beijing, China, People’s Republic of

MP45-16 PIOGLITAZONE MEDIATES IMPROVEMENT OF ERECTILE FUNCTION AFTER CAVERNOUS NERVE CRUSH INJURY VIA INSULIN GROWTH FACTOR TYPE 1

MP45-17 MAINTENANCE OF CONTRACTILE PHENOTYPE IN CORPUS Cavernosum SMOOTH MUSCLE CELLS BY OVEREXPRESSION OF MYOCARDIN AMELIORATES ERECTILE DYSFUNCTION IN BILATERAL CAVERNOUS NERVE INJURY RATS
Anyang Wei*, Haibo Zhang, Shuhua He, Zhiqiang Wang, Fengzhi Chen, Wei Ding, Wenbin Liu, Zerong Chen, Guangzhou, China, People’s Republic of

MP45-18 CALORIE RESTRICTION REVERSES THE AGE-RELATED ALTERATION OF CAVERNOUS NEUROVASCULAR STRUCTURE IN THE RAT
Anita Limanjaya*, Kang Moon Song, Min Ji Choi, Kalyan Ghatak, Nhat Minh Nguyen, Guo Nan Yin, Ji Kan Ryu, Jun Kyu Suh, Incheon, Korea, Republic of

MP45-19 SOLUBLE EPOXIDE HYDROLASE INHIBITION IMPROVES ERECTILE FUNCTION IN DIABETIC MICE THROUGH ATTENUATION OF FIBROSIS AND APOPTOSIS
Hao Li*, Liping Chen, Tao Wang, Shaogang Wang, Jihong Liu, wuhan, China, People’s Republic of

MP45-20 IMPROVEMENT OF PENILE HISTOMORPHOLOGICAL STRUCTURE AND FUNCTION WITH STEM CELLS IN A RAT MODEL OF NEUROVASCULAR ERECTILE DYSFUNCTION
Ting Long, Liren Zhong, Hua Shi, Yuanyuan Zhang, Wei Li, Dong Chen, Hyunchul Chung, Cara Clouse, Sandy Sink, sunil George, Winston Salem, NC, Tom Lue, San Francisco, CA, James Yoo, Anthony Atala, John Jackson*, Winston Salem, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
MP46-01 IS THE ICIQ-SF QUESTIONNAIRE RELIABLE IN A REAL-LIFE SETTING? RESULTS OF A PROSPECTIVE SINGLE-CENTER STUDY
Manuela Tutolo*, Youri Bekhuis, Wouter Everaerts, Leuven, Belgium, Alberto Briganti, Milan, Italy, Steven Joniau, Ben Van Cleynenbreugel, Leuven, Belgium, Giulia Castagna, Milan, Italy, Enrico Ammirati, Turin, Italy, Emanuele Zaffuto, Milan, Italy, Dirk De Ridder, Frank Van Der Aa, Leuven, Belgium

MP46-02 RADICAL PROSTATECTOMY AND RECOVERY OF URINARY CONTINENCE IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
Jung Keun Lee*, In Jae Lee, Tae Jin Kim, Hakmin Lee, Jong Jin Oh, Sangchul Lee, Seongnam, Korea, Republic of, Jeong Hyun Kim, Chunchon, Korea, Republic of, Sung Kyu Hong, Seok-Soo Byun, Sang Eun Lee, Seong Jin Jeong, Seongnam, Korea, Republic of

MP46-03 URINARY FUNCTION IN 656 HYPOGONADAL MEN IMPROVES OVER 8 YEARS WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) IN COMPARISON TO AN UNTREATED CONTROL GROUP INDEPENDENT OF PROSTATE VOLUME
Ahmad Haider*, Karim Sultan H, Bremerhaven, Germany, Gheorghe Doros, Abdalmageed Traish, Boston, MA

MP46-04 HIGH PREVALENCE OF LOW SERUM TESTOSTERONE LEVELS AMONG ARTIFICIAL URINARY SPHINCTER PATIENTS
Travis Pagliara*, Jeremy Scott, Boyd Viers, Allen Morey, Dallas, TX

MP46-05 PREDICTING URETHRAL ATROPHY IN PATIENTS UNDERGOING PRIMARY PLACEMENT OF ARTIFICIAL URINARY SPHINCTER
Matthew Ziegelmann*, Brian Linder, Boyd Viers, Laureano Rangel, Marcelino Rivera, Daniel Elliott, Rochester, MN

MP46-06 COMPARISON OF ADJUVANT RADIATION THERAPY BEFORE OR AFTER ARTIFICIAL URINARY SPHINCTER PLACEMENT: A MULTI-INSTITUTIONAL ANALYSIS

MP46-07 MULTICENTER ANALYSIS OF ARTIFICIAL URINARY SPHINCTER OUTCOMES IN PATIENTS AFTER BOTH RADICAL PROSTATECTOMY AND ANASTOMOTIC URETHROPLASTY
Jonathan Wingsate*, Tacoma, WA, Jeremy Myers, Salt Lake City, UT, Gregory Murphy, San Francisco, CA, Nejd Alsikafi, Gurnee, IL, Bradley Erickson, Iowa City, IA, Benjamin Breier, San Francisco, CA, Bryan Voelzke, Seattle, WA

MP46-08 URETHRAL STRICTURES ARE NOT AS FREQUENT AS THOUGHT AFTER ARTIFICIAL URINARY SPHINCTER CUFF EROSION
Ramiro Madden-Fuentes*, Stephanie Sexton, Andrew Peterson, Durham, NC

MP46-09 PREVIOUS INCONTINENCE SURGERY AND SURGICAL VOLUME PREDICT SOCIAL CONTINENCE AND SURGICAL REVISION: RESULTS OF A LARGE MULTI-INSTITUTIONAL STUDY
Manuela Tutolo*, Leuven, Belgium, Giulia Castagna, Milan, Italy, Enrico Ammirati, Turin, Italy, Marcus Drake, Bristol, United Kingdom, Nikshe Thiruchelvam, Cambridge, United Kingdom, Kari Tikkinen, Helsinki, Finland, Alexander Bachmann, Basel, Switzerland, Ignacio Martinez-Salamanca, Madrid, Spain, Giorgio Bozzini, Milan, Italy, Ricardo Bauer, Munich, Germany, John Heesakkers, Nijmegen, Netherlands, Michele Favro, Novara, Italy, Richard Lee, New York, NY, Stéphane Larre´, Reims, France, Cosimo De Nunzio, Rome, Italy, François Haab, Paris, France, Sascha Ayhai, Hamburg, Germany, Thomas Pichon, Angers, France, Jean-Nicolas Cornu, Paris, France, Frank Van Der Aa, Leuven, Belgium
MP46-10 PREDICTING SUCCESS AFTER AUS: WHICH PREOPERATIVE FACTORS DRIVE PATIENT SATISFACTION POSTOPERATIVELY?
Nathan Chertack*, Bradley Gill, Tianming Gao, Kenneth Angenmeier, Drogo Montague, Hadley Wood, Cleveland, OH

MP46-11 CAN TIME TO FAILURE PREDICT ARTIFICIAL URINARY SPHINCTER COMPONENT FAILURE?
David Y. Yang*, Brian J. Linder, Laureano J. Rangel, Daniel S. Elliott, Rochester, MN

MP46-12 EFFECTS OF PERIOPERATIVE COMPLICATIONS ON FAVORABLE OUTCOMES AFTER PRIMARY ARTIFICIAL URINARY SPHINCTER IMPLANTATION FOR MALE NON-NEUROGENIC STRESS URINARY INCONTINENCE
Alexander Kretschmer*, Munich, Germany, Tanja Hünsch, Mainz, Germany, Frauke Thomsen, Dominik Kronlachner, Frankfurt, Germany, Ralf Anding, Bonn, Germany, Tobias Pottek, Hamburg, Germany, Alice Obaje, Hildesheim, Germany, Achim Rose, Duisburg, Germany, Roberto Olanitas, Lüneburg, Germany, Alexander Friedl, Vienna, Austria, Wilhem Hübner, Korneuburg, Austria, Roland Homberg, Hamm, Germany, Jesco Pfitznermaier, Bielefeld, Germany, Fabian Queisser, Münster, Germany, Carsten M. Naumann, Kiel, Germany, Josef Schweiger, Erfurt, Germany, Carola Wotzka, Stuttgart, Germany, Joanne N. Nyarangi-Dix, Heidelberg, Germany, Torben Hofmann, Schwäbisch-Hall, Germany, Alexander Buchner, Munich, Germany, Axel Haferkamp, Mainz, Germany, Ricarda M. Bauer, Munich, Germany

MP46-13 EVALUATING THE ROLE OF PERIOPERATIVE ANTIBIOTICS IN PREVENTING ARTIFICIAL URINARY SPHINCTER EXPLANTATION: ANALYSIS OF A LARGE NATIONAL PROSPECTIVE DATABASE
Melanie Adamsky*, William Boysen, Andrew Cohen, Sandra Ham, Joseph Rodriguez, Chicago, IL, Roger Dmochowski, Nashville, TN, Sarah Faris, Gregory Bales, Chicago, IL, Joshua Cohn, Nashville, TN

MP46-14 INVALIDATION OF THE PRACTICE OF ADDING FLUID TO THE AMS 800 ARTIFICIAL URINARY SPHINCTER PRESSURE REGULATING BALLOON
Zachary Koloff*, Paholo Barboglio Romo, Yooni Yi, Bahaa Malaeb, Ann Arbor, MI

MP46-15 REFINED SELECTIVITY USING STANDING COUGH TEST IMPROVES OUTCOMES OF MALE SLING SURGERY
Travis Pagliara*, Maia VanDyke, Boyd Viers, Jeremy Scott, Allen Morey, Dallas, TX

MP46-16 POST-OPERATIVE TRANSOBTURATOR MALE SLING URINARY RETENTION RESOLVES SPONTANEOUSLY WITH TIME AND MAY BE ASSOCIATED WITH HIGHER LONG-TERM SUCCESS
Divya Ajay*, Bryce Allio, Ramiro Madden-Fuentes, Andrew Peterson, Durham, NC

MP46-17 ASSOCIATION BETWEEN EARLY POSTOPERATIVE URINARY RETENTION AND OUTCOMES AFTER TRANSOBTURATOR SLING INSERTION FOR TREATMENT OF MALE STRESS URINARY INCONTINENCE
Amanda Chung*, Jack Zuckerman, Oscar Suarez, Ramon Virasoro, Jeremy Tonkin, Jessica DeLong, Kurt McCammon, Norfolk, VA

MP46-18 A LOGISTIC REGRESSION PREDICTION MODEL FOR THE SUCCESS OF THE MALE TRANSOBTURATOR SLING; VALSALVA LEAK-POINT PRESSURE (VLPP) GREATER THAN 70 CM H2O IS AN INDICATOR FOR SLING SUCCESS
Divya Ajay*, Andrew Peterson, Durham, NC

MP46-19 MID-TERM FOLLOW UP OF THE ADVANCE XP SLING IN THE TREATMENT OF POST-PROSTATECTOMY STRESS URINARY INCONTINENCE – FIRST 4-YEAR RESULTS FROM A PROSPECTIVE MULTICENTER TRIAL
Markus Grabbert*, Benedikt Klehr, Alexander Kretschmer, Munich, Germany, Christian Gozzi, Bolzano, Italy, Peter Rehder, Innsbruck, Austria, Roland Homberg, Hamm, Germany, Florian May, Dachau, Germany, Peter Gebhartl, Voecklabruck, Austria, Christian Stief, Ricarda Bauer, Munich, Germany

MP46-20 DEVELOPMENT OF A NOVEL ARTIFICIAL URINARY SPHINCTER (AUS): THE PRECISION MEDICAL DEVICES (PMD) FLOW CONTROL DEVICE (FCD) FOR MANAGEMENT OF SPHINCTERIC DEFICIENCY USING BLUETOOTH TECHNOLOGY
Michael Ahdoot*, Miami, FL, Angelo Gousse, Miramar, FL, Peter Sayet, Fort Lauderdale, FL, Christopher Gomez, Miami, FL

*Presenting author
### Moderated Poster Session 47

**PROSTATE CANCER: LOCALIZED: SURGICAL THERAPY IV**

Room 156 @ Boston Convention & Exhibition Center

**Moderators:** Jeffrey Michalski, Vipul Patel and Shahrokh Shariat

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP47-01</strong></td>
<td>ULTRASOUND-GUIDED TRANSVERSUS ABDOMINIS PLANE (TAP) BLOCK FOR ROBOT-ASSISTED RADICAL PROSTATECTOMY</td>
</tr>
<tr>
<td><strong>MP47-02</strong></td>
<td>SENTINEL NODE TECHNIQUE IN RADICAL PROSTATECTOMY FOR PROSTATE CANCER PATIENTS: TOWARD AN INDIVIDUALIZED LYMPHADENECTOMY</td>
</tr>
<tr>
<td><strong>MP47-03</strong></td>
<td>IMPACT OF ADDITIONAL RADIATION AND/OR ADT ON FUNCTIONAL OUTCOMES AFTER RADICAL PROSTATECTOMY</td>
</tr>
<tr>
<td><strong>MP47-04</strong></td>
<td>OBESITY WAS ASSOCIATED WITH IMPROVED METASTASES-FREE SURVIVAL AFTER SURGERY IN 13,667 PROSTATE CANCER PATIENTS</td>
</tr>
<tr>
<td><strong>MP47-05</strong></td>
<td>A SYSTEMATIC REVIEW OF INSTRUMENTAL VARIABLE ANALYSES USING GEOGRAPHIC REGION AS AN INSTRUMENT IN PROSTATE CANCER STUDIES</td>
</tr>
<tr>
<td><strong>MP47-06</strong></td>
<td>ONCOLOGICAL OUTCOMES OF PATHOLOGIC NODE POSITIVE PATIENTS, FOLLOWING RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP47-07</strong></td>
<td>SALVAGE ROBOTIC-ASSISTED RADICAL PROSTATECTOMY: ONCOLOGIC AND FUNCTIONAL OUTCOMES FROM TWO HIGH-VOLUME INSTITUTIONS</td>
</tr>
<tr>
<td><strong>MP47-08</strong></td>
<td>COMPARISON OF ONCOLOGICAL AND FUNCTIONAL OUTCOMES FOLLOWING RADICAL PROSTATECTOMY IN CLINICAL T2 AND CLINICAL T3 PROSTATE CANCERS: FINDINGS FROM THE SA-PCOCC DATABASE</td>
</tr>
<tr>
<td><strong>MP47-09</strong></td>
<td>TIMING OF PSA NADIR AFTER RADICAL PROSTATECTOMY AND RISK OF BIOCHEMICAL RECURRENCE: DOES IT MATTER? RESULTS FROM THE SEARCH DATABASE</td>
</tr>
<tr>
<td><strong>MP47-10</strong></td>
<td>MRI USE ALTERS PROSTATE CANCER MANAGEMENT PATTERNS: TREATMENT TRENDS IN THE IMAGE-GUIDED BIOPSY ERA</td>
</tr>
<tr>
<td><strong>MP47-11</strong></td>
<td>EXTENDED PELVIC LYMPH NODE DISSECTION FOR INTERMEDIATE-HIGH RISK PROSTATE CANCER: FREQUENCY AND DISTRIBUTION OF NODAL METASTASES</td>
</tr>
</tbody>
</table>

---

**Sunday, May 14, 2017 7:00 am - 9:00 am**

---

164
MP47-12 IMPACT OF PROXIMITY TO NCI- AND NCCN-DESIGNATED CANCER CENTERS ON OUTCOMES FOR PATIENTS WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
Cameron Ghaffary*, Galveston, TX, Zhigang Duan, Brian Chapin, Houston, TX, Tamer Dafashy, Christopher Kosareck, Galveston, TX, Karim Chamie, Los Angeles, CA, Simon Kim, Cleveland, OH, Thomas Ahlering, Irvine, CA, John Davis, Sharon Giordano, Houston, TX, Stephen Williams, Galveston, TX

MP47-13 COMPARISON BETWEEN MID-TERM OUTCOMES OF HIGH-DOSE-RATE BRACHYTHERAPY WITH EXTERNAL-BEAM RADIOThERAPY COMBINED WITH LONG-TERM ANDROGEN DEPRIVATION THERAPY AND RADICAL PROSTATECTOMY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER.
Hajime Onuma*, Takahiro Kimura, Kojiro Tashiro, Yasutoshi Yoshiyama, Masahito Kido, Yoshitomo Yamamoto, Hiroshi Sasaki, Jun Miki, Yusuke Koike, Tatsuya Shimomura, Hiroki Hamada, Kenta Miki, Manabu Aoki, Shin Egawa, Tokyo, Japan

MP47-14 ASSESSMENT OF ONCOLOGICAL OUTCOMES AFTER RADICAL PROSTATECTOMY ACCORDING TO PREOPERATIVE AND POSTOPERATIVE CAPRA RISK SCORES: RESULTS OF A LARGE, TWO-CENTER EXPERIENCE
Sami-Ramzi Leyh-Bannurah*, Hamburg, Germany, Paolo Dell'Oglio, Emanuele Zaffuto, Milan, Italy, Raisa Pompe, Hans Heinzer, Hartwig Huland, Markus Graefen, Derya Tilki, Hamburg, Germany, Francesco Montorsi, Alberto Briganti, Milan, Italy, Lars Budäus, Hamburg, Germany

MP47-15 REGIONAL VARIATION IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER IN A MEDICARE POPULATION
Rachel A. Moses*, Andrea M. Austin, Donald Carmichael, Elias S. Hyams, Lebanon, NH

MP47-16 CURRENT DELAYS FROM BIOPSY TO RADICAL PROSTATECTOMY DO NOT APPEAR TO AFFECT PATHOLOGIC OUTCOMES IN LOW, INTERMEDIATE, OR HIGH-RISK DISEASE
Premal Patel*, Winnipeg, Canada, Leanne Ross, Kiril Trpkov, Geoffrey Gotto, Calgary, Canada

MP47-17 CAPRINI SCORE PREDICTS VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL PROSTATECTOMY
Jason K. Frankel*, Matthew Belanger, Farmington, CT, Joseph Tortora, Tara McLaughlin, Ilene Staff, Joseph Wagner, Hartford, CT

MP47-18 CONTRIBUTORS TO THE OCCURRENCE OF INGUINAL HERNIA AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY.
Tsuyoshi Majima*, Yasushi Yoshihisa, Yoshitohi Funahashi, Naoto Sassa, Masashi Kato, Tokunori Yamamoto, Momokazu Gotoh, Nagoa, Japan

MP47-19 OPEN VS ROBOTIC PROSTATECTOMY BETWEEN 2009-2014: A CONTEMPORARY ANALYSIS OF NSQIP OUTCOMES
Erwin A. Tieva*, George J.S. Kallingal, San Antonio, TX

MP47-20 PREDICTING EXTRACAPSULAR EXTENTION TO GRADUATE NERVE SPARING DURING RADICAL PROSTATECTOMY: A NOVEL PREDICTING TOOL DEVELOPED ON NEARLY 6360 PATIENTS
Bernardo Rocco*, Modena, Italy, Marco Sandri, Brescia, Italy, Elisa De Lorenzo, Angelica Anna Chiara Grasso, Franco Palmisano, Giancarlo Albo, Milan, Italy, Rafael Coelho, Sao Paulo, Brazil, Alexander Mottrie, Aalst, Belgium, Tadzia Harvey, Darian Kameh, Orlando, FL, Peter Wiklund, Stockholm, Sweden, Silvano Bosari, Milan, Italy, Paola Zuccolotto, Brescia, Italy, Giampaolo Bianchi, Modena, Italy, Vipul Patel, Orlando, FL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT

MP48-01  EXPRESSION AND FUNCTION OF A NOVEL CHONDROITINASE IN BLADDER CANCER
Marie Hupe*, Luebeck, Germany, Soun Lokeshwar, Miami, FL, Martin Hennig, Luebeck, Germany, Daley Schimmelpfennig, Augusta, GA, Mario Kramer, Axel Merseburger, Luebeck, Germany, Mark Soloway, Aventura, FL, Vinata Lokeshwar, Augusta, GA

MP48-02  MELANOMA-ASSOCIATED ANTIGEN-A AND PROGRAMMED DEATH-LIGAND 1 EXPRESSION IN UROTHELIAL CARCINOMA
Izak Faiena*, Los Angeles, CA, Nils Kroeger, Sebastian Fussek, Greifswald, Germany, Stephanie Astrow, Rajul Jain, Adrian Bot, Santa Monica, CA, Alexandra Drakaki, Los Angeles, CA

MP48-03  INTRATUMORAL HETEROGENEITY OF ERBB2 AMPLIFICATION AND HER2 EXPRESSION IN MICROPAPILLARY UROTHELIAL CARCINOMA

MP48-04  EXPRESSION AND FUNCTION OF LYSOPHOSPHATIDIC ACID RECEPTOR 1 IN BLADDER CANCER
Masao Kataoka*, Tomoyuki Koguchi, Michihiro Yabe, Yuuichi Satoh, Nobuhiro Haga, Kei Ishibashi, Ken Aikawa, Yoshiyuki Kojima, Fukushima, Japan

MP48-05  IDENTIFICATION OF CCDC34 AS AN ONCOGENE IN BLADDER CANCER AND ITS FUNCTION DURING BLADDER CARCINOCENESIS
Yanqing Gong*, Xianghui Ning, Xinyu Yang, Jian Lin, Xuesong Li, Yinglu Guo, Beijing, China, People’s Republic of

MP48-06  3D TISSUE ENGINEERING BLADDER MODEL FOR CANCER INVASION STUDY
Cassandra R Goulet, Geneviève Bernard, Stéphane Chabaud, Frédéric Pouliot, Stéphane Bolduc*, Québec, Canada

MP48-07  ESTABLISHMENT AND ANALYSIS OF BLADDER MUCOSA RECONSTRUCTION RABBIT MODEL WITH AUTLOGOUS PERITONEAL FREE GRAFT
Wenjia Wang*, Shengwen Li, Beijing, China, People’s Republic of

MP48-08  HEAT SHOCK PROTEIN 70 MEDIATED SILIBININ-ACTIVATED MITOCHONDRIAL APOPTOTIC SIGNALING PATHWAY IN BLADDER CANCER
Jin Zeng*, Yule Chen, Kaijie Wu, Yi Sun, Lei Li, Dalin He, Xi’an, China, People’s Republic of

MP48-09  INTEGRIN SIGNALING MODULATION DEMONSTRATES POTENTIAL THERAPEUTIC STRATEGY IN BLADDER CANCER USING THREE-DIMENSIONAL ORGANOID CULTURE
LaMont Barlow*, Rebecca Meyer, Ethan Shelkey, David Golombos, Tomasz Owczarek, Lijie Rong, Corinne Abate-Shen, Michael Shen, Bishoy Faltas, Mark Rubin, New York, NY

MP48-10  VALIDATION OF NRF2 PATHWAY DYSREGULATION IN UROTHELIAL CARCINOMA
Natalia Leva*, Thomas Sanford, Maxwell Meng, Sima Porten, San Francisco, CA

MP48-11  THE EFFECT OF MORPHINE AND ITS INHIBITORS ON RT112 BLADDER CANCER CELL GROWTH
Brian Birch*, Bashir Lwaleed, Alan Cooper, Phil Harper, Southampton, United Kingdom, Iliana Giatsidou, Portsmouth, United Kingdom

MP48-12  EXTRAORDINARY ELEVATION OF SERPINB2 GENE AFTER ANTI-CANCER DRUG TREATMENT IN BLADDER CANCER
Miho Hiraki*, Naoko Arichi, Hirofumi Kishi, Haruki Anjiki, Hiroaki Yasumoto, Hiroaki Shiina, Izumo, Japan

MP48-13  LOSS OF FORKHEAD BOX PROTEIN O1 IN BLADDER CANCER INDUCES TUMOR PROGRESSION AS WELL AS CHEMRESISTANCE
Hiroki Ide*, Tokyo, Japan, Satoshi Inoue, Taichi Mizushima, Rochester, NY, Eiji Kashiwagi, Fukuoka, Japan, Mototsugu Oya, Tokyo, Japan, Alexander Baras, Baltimore, MD, Hiroshi Miyamoto, Rochester, NY

MP48-14  LONG NONCODING RNA LNCRNA-BNCA PROMOTES THE PROGRESSION OF BLADDER CANCER VIA REGULATING TRANSLATION OF P53
Changhao Chen*, Jian Huang, Feng Sun, Tianxin Lin, Guangzhou, China, People’s Republic of
**MP48-15** CIRCULAR RNA ITCH INHIBITS BLADDER CANCER PROGRESSION BY SPONGING MIR-17 AND REGULATING P21 EXPRESSION  
*Pengchao Li, Jun Tao, Xiao Yang, Xiaoheng Deng, Qiang Lu*, Nanjing, China, People’s Republic of

**MP48-16** TARGETING ERBB2 MUTATIONS IN UROTHELIAL CARCINOMA  
François Audenet*, Sumit Isharwal, Maria Arcila, Samuel Funt, Jonathan Rosenberg, Dean Bajorin, Eugene Cha, Timothy Donahue, Machele Donat, Harry Herr, Guido Dalbagni, Bernard Bochner, Michael Berger, Hikmat Al-Ahmadi, David Sollt, Gopa Iyer, New York, NY

**MP48-17** PHENOTYPIC-GENOTYPIC CORRELATION OF TP53 AND RB1 IN UROTHELIAL CARCINOMA  

**MP48-18** GERMLINE DNA REPAIR SINGLE NUCLEOTIDE POLYMORPHISMS IN UROTHELIAL CANCER PATIENTS.  
Panagiotis Vlachostergios*, Bishopy Faltas, Tuo Zhang, Linda Lam, Olivier Elemento, Mark Rubin, New York, NY

**MP48-19** MOLECULAR SUBTYPE CLASSIFICATION OF N-METHYL-N-NITROSOUREA-INDUCED UROTHELIAL CANCERS AND EX-VIVO CULTURED SPHEROIDS IN RATS  
Takahiro Yoshida*, Max Kates, Nikolai Sopko, Alexander Baras, George Netto, Xiaopu Liu, Charles Drake, Noah Hahn, David McConkey, Trinity Bivalacqua, Baltimore, MD

**MP48-20** EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TIL) FROM PRIMARY BLADDER TUMORS  
Michael Poch*, Maclean Hall, Krithika Kodumudi Kodumudi, Cortlin Croft, Mayer Fishman, John Mullinax, Amod Sarmiak, James Mule, Shari Pilon-Thomas, Tampa, FL

---

**Moderated Poster Session 49**

**KIDNEY CANCER: LOCALIZED: SURGICAL THERAPY II**  
Room 252 @ Boston Convention & Exhibition Center  
**Moderators:** Jose Karam, Stephen Savage and Hendrik Van Poppel

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP49-01</strong></td>
<td>PHASE 3 RANDOMISED TRIAL OF INTRAVENOUS MANNITOL VERSUS PLACEBO PRIOR TO RENAL ISCHEMIA DURING NEPHRON-SPARING SURGERY: IMPACT ON RENAL FUNCTIONAL OUTCOMES</td>
</tr>
<tr>
<td>Massimiliano Spaliviero*, Nicholas E. Power, Katie S. Murray, Daniel D. Sjoberg, Nicole E. Benfante, Melanie L. Bernstein, James D. Wren, Paul Russo, Jonathan A. Coleman, New York, NY</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP49-02</strong></td>
<td>PERIOPERATIVE MORBIDITY OF CLAMP VS OFF-CLAMP ROBOTIC PARTIAL NEPHRECTOMY: PRELIMINARY RESULTS FROM A MULTICENTRE RANDOMIZED CLINICAL TRIAL (THE CLOCK STUDY)</td>
</tr>
<tr>
<td>Alessandro Antonelli*, Brescia, Italy, Luca Cindolo, Vasto, Italy, Marco Sandri, Maria Furlan, Alessandro Veccia, Carlotta Palumbo, Claudio Simeone, Brescia, Italy, Francesco Sessa, Davide Facchiano, Sergio Semin, Marco Carini, Florence, Italy, Bernardino De Concilio, Guglielmo Zeccolzino, Antonio Celia, Bassano del Grappa, Italy, Manuela Ingrosso, Vasto, Italy, Valentina Giommoni, Filippo Annino, Arezzo, Italy, Valero Pizzuti, Roberto Nuccitelli, Grosseto, Italy, Matteo Dandrea, Angelo Porreca, Abano Terme, Italy, Andrea Minervini, Florence, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP49-03</strong></td>
<td>THE SUPERIOR PRESERVATION OF POSTOPERATIVE RENAL FUNCTION IN ROBOTIC PARTIAL NEPHRECTOMY, COMPARED WITH THE LAPAROSCOPIC PROCEDURE, IS ASSOCIATED WITH LESS PARENCHYMAL VOLUME LOSS, NOT SHORTER RENAL ISCHEMIA TIME: A PROPENSITY SCORE-MATCHED ANALYSIS</td>
</tr>
<tr>
<td>Hidekazu Tachibana*, Toshio Takagi, Tsunenori Kondo, Kazunari Tanabe, Tokyo, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP49-04</strong></td>
<td>EXCISED PARENCHYMAL MASS AND DEVASCULARIZED PARENCHYMAL MASS ASSOCIATED WITH PARTIAL NEPHRECTOMY: IMPACT ON FUNCTIONAL RECOVERY</td>
</tr>
<tr>
<td>Wen Dong*, Jitao Wu, Chalairat Suk-Ouchhai, Elvis Carabello, Diego Aguilar Palacios, Erick Remer, Jianbo Li, Joseph Zabell, Sudhir Isharwal, Steven Campbell, Cleveland, OH</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP49-05</strong></td>
<td>IMPACT OF PROLONGED ISCHEMIC TIME ON CHRONIC KIDNEY DISEASE FOLLOWING PARTIAL NEPHRECTOMY: A MATCHED-PAIR COMPARISON</td>
</tr>
</tbody>
</table>
| Jung Keun Lee*, In Jae Lee, Tae Jin Kim, Hakmin Lee, Jong Jin Oh, Sangchul Lee, Seong Jin Jeon, Seok-Soo Byun, Sang Eun Lee, Sung Kyu Hong, Seongnam, Korea, Republic of

*Presenting author
MP49-06 WHEN PARTIAL NEPHRECTOMY IS UNSUCCESSFUL: UNDERSTANDING THE REASONS FOR CONVERSION FROM ROBOTIC PARTIAL TO RADICAL NEPHRECTOMY AT A TERTIARY REFERRAL CENTER

MP49-07 INCIDENCE AND RISK FACTORS OF POSTOPERATIVE HYPERTENSION AFTER PARTIAL NEPHRECTOMY FOR RENAL TUMORS
Masaharu Inoue*, Yasuhisa Fiji, Masaya Ito, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Tokyo, Japan

MP49-08 ON-CLAMP VERSUS OFF-CLAMP PARTIAL NEPHRECTOMY: PROPENSITY SCORE MATCHED COMPARISON OF LONG TERM FUNCTIONAL OUTCOMES
Giuseppe Simone, Rome, Italy, Umberto Capitanio, Alessandro Larcher, Milan, Italy, Mariaconsiglia Ferriero, Leonardo Misuraca*, Gabriele Tuderti, Giuseppe Romeo, Francesco Minisola, Salvatore Guaglianone, Rome, Italy, Fabio Muttin, Alessandro Nini, Francesco Trevisani, Francesco Montorsi, Roberto Bertini, Milan, Italy, Michele Gallicci, Rome, Italy

MP49-09 COMPARISONS OF SURGICAL OUTCOMES BETWEEN THE RESECTION AND THE ENucleATION IN ROBOT ASSISTED LAPAROSCOPIC PARTIAL NEPHRECTOMY FOR RENAL TUMORS ACCORDING TO THE SURFACE-INTERMEDIATE-BASE MARGIN SCORE
Toshio Takagi*, Tsunenori Kondo, Junpei Iizuka, Hirohito Kobayashi, Hidekazu Tachibana, Kazuhiko Yoshida, Hideki Ishida, Kazunari Tanabe, Tokyo, Japan

MP49-10 ISCHEMIA AND FUNCTIONAL RECOVERY FROM PARTIAL NEPHRECTOMY: REFINED PERSPECTIVES
Chalairat Suk-Ouichai*, Wan Dong, Jitao Wu, Elvis R Carabalbo, Erick Remer, Jianbo Li, Joseph Zabell, Sudhir Isharwal, Steven C Campbell, Cleveland, OH

MP49-11 RENAL ISCHEMIA AND VOLUME LOSS HAVE A COMPOUNDING EFFECT ON ACUTE RENAL DYSFUNCTION AFTER PARTIAL NEPHRECTOMY
Julien Dagenais*, Matthew Maurice, Pascal Mouracade, Onder Kara, Ryan Nelson, Ercan Malkoc, Jihad Kaouk, Cleveland, OH

MP49-12 RETROPERITONEAL VERSUS TRANSPERITONEAL ROBOTIC PARTIAL NEPHRECTOMY FOR POSTERIOR TUMORS: A MULTICENTER MATCH-PAIRED CASE-CONTROL STUDY

MP49-13 COMPARATIVE ANALYSIS OF THE OUTCOMES OF TRANSPERITONEAL AND RETROPERITONEAL ROBOT-ASSISTED PARTIAL NEPHRECTOMY: RESULTS FROM A MULTI-INSTITUTIONAL HIGH-VOLUME CENTERS EXPERIENCE
Giovanni Lughazzani*, Nicola' Buffi, Giuliana Lista, Davide Maffei, Giovanni Forni, Milano, Italy, Nicola Fossati, Alessandro Larcher, Aalst, Belgium, Massimo Lazzari, Alberto Saita, Paolo Casale, Rodolfo Hurle, Giorgio Guazzoni, Milano, Italy, Alex Mottrie, Aalst, Belgium, Jim Porter, Seattle, WA

MP49-14 LAPAROSCOPIC NEPHRON-SPARING SURGERY AFTER SUPERSELECTIVE TUMORAL EMBOLIZATION IN A HYBRID OPERATING ROOM: FEASIBILITY AND IMMEDIATE ONCOLOGICAL AND FUNCTIONAL RESULTS OF THE FIRST 30 PATIENTS.
Paul Panayotopoulous*, Louis Besnier, Antoine Bouvier, Pierre Bigot, Angers, France

MP49-15 SAFETY AND EARLY EFFECTIVENESS OF ROBOTIC PARTIAL NEPHRECTOMY FOR LARGE ANGIOMYOLIPOMAS
Shay Golan*, Scott Johnson, Chicago, IL, Matthew Maurice, Jihad Kaouk, Clevelaned, OH, Wei Lai, Benjamin Lee, New Orleans, LA, Steve Kheyfets, Chandru Sundaram, Bloomington, IN, David Cahn, Robert Uzzo, Philadelphia, PA, Arieh Shalhav, Chicago, IL

MP49-16 MODIFIED LAPAROSCOPIC SIMPLE ENucleATION WITH SINGLE LAYER SUTURE TECHNIQUE VERSUS STANDARD LAPAROSCOPIC PARTIAL NEPHRECTOMY FOR TREATING LOCALIZED RENAL CELL CARCINOMA
Qun Lu*, Xiaozhi Zhao, Changwei Ji, Guangxiang Liu, Hongqian Guo, Nanjing, China, People's Republic of

MP49-17 ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR SELECTED RENAL MASS USING OFF-CLAMP APPROACH OFFERED RENAL FUNCTIONAL ADVANTAGE OVER ON-CLAMP
Pascal Mouracade*, Julien Dagenais, Onder Kara, Matthew Maurice, Ryan Nelson, Khaled Fareed, Robert Stein, Amr Fergany, Jihad Kaouk, Cleveland, OH
MP49-18 OFF-CLAMP ROBOT-ASSISTED PARTIAL NEPHRECTOMY: HOW FAR SHALL WE PROCEED?
Ali Abdel Raheem*, Glen Denmer Santok, Lawrence HC Kim, Kidon Chang, Trenton GH Lum, Young Eun Yoon, Woong Kyu Han, Young Doek Choi, Koon Ho Rha, Seoul, Korea, Republic of

MP49-19 OFF-CLAMP VS. ON-CLAMP ROBOTIC PARTIAL NEPHRECTOMY: A MULTICENTER MATCH-PAIRED ANALYSIS

MP49-20 MULTIVARIATE ASSESSMENT OF ROBOTIC PARTIAL NEPHRECTOMY LEARNING CURVE
Benoit Peyronnet*, Clara Locher, Khene Zineddine, Benjamin Pradere, Romain Mathieu, Gregory Verhoest, Eric Bellissant, Karim Bensalah, Rennes, France

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017
Podium Session 34
TRAUMA/RECONSTRUCTION/DIVERSION: URETHRAL RECONSTRUCTION (INCLUDING STRICTURE, DIVERTICULUM) III
Room 159 @ Boston Convention & Exhibition Center
Moderators: Prem Nath Dogra, Jerilyn Latini and Jordan Siegel

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD34-01</td>
<td>ANASTOMOTIC BULBAR URETHROPLASTY: TO TRANSECT OR NOT TO TRANSECT?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dave Chapman*, Adam Kinnaird, Jon Witten, Keith Rourke, Edmonton, Canada</td>
</tr>
<tr>
<td>7:10</td>
<td>PD34-02</td>
<td>HE LONG-TERM RESULTS OF NON-TRANSECTING BULBAR URETHROPLASTY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stacey Frost*, Stella Iva, Simon Bugeja, Mariya Dragova, Daniela E Andrich, Anthony R Mundy, London, United Kingdom</td>
</tr>
<tr>
<td>7:20</td>
<td>PD34-03</td>
<td>POST-TURP URETHRAL STRICTURES CAN BE MANAGED SUCCESSFULLY WITH URETHROPLASTY</td>
</tr>
<tr>
<td>7:30</td>
<td>PD34-04</td>
<td>ONE-STAGE URETHROPLASTY USING DORSAL AND VENTRAL BUCCAL MUCOSAL GRAFT: LONG-TERM VALIDATED OUTCOMES</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kristi Hebert*, Martin Hofmann, Joel Gelman, Orange, CA</td>
</tr>
<tr>
<td>7:40</td>
<td>PD34-05</td>
<td>EFFECT OF PATIENT AND SURGICAL CHARACTERISTICS ON TREATMENT FAILURE IN 491 ONE-STAGE VENTRAL ONLAY BUCCAL MUCOSAL GRAFT URETHROPLASTIES</td>
</tr>
<tr>
<td>7:50</td>
<td>PD34-06</td>
<td>CALCULATING THE RISK OF URETHRAL STRicture RECURRENT After ANTERIOR URETHROPLASTY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Christopher Tam*, Amy Hahn, Jacob Oleson, Iowa City, IA, Sean Elliott, Minneapolis, MN, Bryan Voelzke, Seattle, WA, Benjamin Breyer, San Francisco, CA, Jeremy Myers, Salt Lake City, UT, Alex Vanni, Burlington, MA, Bradley Erickson, Iowa City, IA</td>
</tr>
</tbody>
</table>

*Presenting author
8:00 PD34-07 COMPLICATIONS OF URETHRAL RECONSTRUCTION ARE MINIMAL COMPARED TO OTHER UROLOGICAL PROCEDURES
Boyd Viers*, Travis Pagliara, Charles Rew, Dallas, TX, Lauren Folgosa-Cooley, Richmond, VA, Alexander Rozanski, Christine Shiang, Jeremy Scott, Allen Morey, Dallas, TX

8:10 PD34-08 REAL-WORLD EFFECTIVENESS OUTCOMES FOR URETHROPLASTY
Robert Goldfarb*, Steven Brandes, New York, NY, Peter Kirk, Tudor Borza, Yongmei Qin, Ted Skolarus, Ann Arbor, MI

8:20 PD34-09 THE UTILITY OF UROFLOWMETRY PARAMETERS IN URETHROPLASTY SURVEILLANCE IS LIMITED
Yooni Yi*, Paholo Barboglio Romo, Bahaa Malaeb, Ann Arbor, MI

8:30 PD34-10 VALUE OF EARLY SURVEILLANCE CYSTourethroSCOPY AFTER BULBAR URETHROPLASTY ON RECURRENCE RISK: A TURNS STUDY
Darshan Patel*, Salt Lake City, UT, Ragheed Al-Dulaimi, salt lake city, UT, Sean Elliott, Minnesota, MN, Alexander Vanni, Burlington, MA, Bradley Erickson, Iowa City, IA, Bryan Voelzke, Seattle, WA, Benjamin Breyer, San Francisco, CA, Christopher McClung, Columbus, OH, Thomas Smith, III, Houston, TX, Angela Presson, Jeremy Myers, Salt Lake City, UT

8:40 PD34-11 MULTI-INSTITUTIONAL OUTCOMES OF ENDOSCOPIC MANAGEMENT OF STRICTURE RECURRENCE AFTER URETHROPLASTY
Shyam Sukumar*, Sean Elliott, Minneapolis, MN, Jeremy Myers, Salt Lake City, UT, Bryan Voelzke, Seattle, WA, Thomas Smith, Houston, TX, Alexandra Carolan, Minneapolis, MN, Michael Maidaa, Bradley Erickson, Iowa City, IA

8:50 PD34-12 TERTIARY URETHROPLASTY: IS THE THIRD TIME A CHARM?
Travis Pagliara*, Boyd Viers, Charles Rew, Dallas, TX, Lauren Folgosa-Cooley, Richmond, VA, Alexander Rozanski, Christine Shiang, Jeremy Scott, Allen Morey, Dallas, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017
Podium Session 35
STONE DISEASE: SURGICAL THERAPY IV
Room 157 @ Boston Convention & Exhibition Center
Moderators: David Duchene, R. John Honey and Eduardo Mazzucchi

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD35-01</td>
<td>A RANDOMIZED DOUBLE-BLIND CONTROLLED STUDY ASSESSING ELECTRO-ACUPUNCTURE FOR THE MANAGEMENT OF POST-OPERATIVE PAIN AFTER PERCUTANEOUS NEPHROLITHOTOMY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Egor Parkhomenko*, Rohit Chugh, Jillian Capodice, Timothy Tran, Julie Thai, Kyle Blum, Mantu Gupta, NY, NY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:10</td>
<td>PD35-02</td>
<td>COSTS VARIATIONS FOR PERCUTANEOUS NEPHROLITHOTOMY IN THE UNITED STATES FROM 2003 TO 2013: A CONTEMPORARY ANALYSIS OF AN ALL-PAYER DISCHARGE DATABASE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jeffrey Leow*, Christian Meyer, Boston, MA, Benjamin Chung, Stanford, CA, Steven Chang, Quoc Dien Trinh, Boston, MA, Naeem Bhojani, Montreal, Canada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td>PD35-04</td>
<td>A RANDOMIZED CONTROL TRIAL OF PREOPERATIVE PROPHYLACTIC ANTIBIOTICS PRIOR TO PERCUTANEOUS NEPHROLITHOTOMY IN THE LOW RISK POPULATION: A REPORT FROM THE EDGE CONSORTIUM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Seth Bechis*, San Diego, CA, Joel Abbott, Glen Burnie, MD, Ben Chew, Vancouver, Canada, Nicole Miller, Nashville, TN, Amy Krambeck, Indianapolis, IN, Mitchell Humphreys, Phoenix, AZ, Vernon Pais, Jr, Lebanon, NH, Manoj Monga, Cleveland, OH, Roger Sur, San Diego, CA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:40</td>
<td>PD35-05</td>
<td>PROSPECTIVE RANDOMIZED TRIAL OF ANTIBIOTIC PROPHYLAXIS DURATION FOR PERCUTANEOUS NEPHROLITHOTOMY: PRELIMINARY RESULTS</td>
</tr>
</tbody>
</table>
7:40 PD35-05 HOW DO YOU LIKE YOUR POPCORN? AN EVALUATION OF LASER SETTINGS AND LOCATION IN THE EFFICIENCY OF THE POPCORN EFFECT
Daniel Wollin*, Ruiyang Jiang, Westin Tom, Daniela Radvak, W. Neal Simmons, Glenn Preminger, Michael Lipkin, Durham, NC

7:50 PD35-06 CAN CT IMAGING PREDICT STONE IMPACTION?
Egor Parkhomenko*, Timothy Tran, Sumit De, Julie Thai, Kyle Blum, Mantu Gupta, NY, NY

8:00 PD35-07 PRELIMINARY RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL OF SAFETY GUIDEWIRE USE IN URETEROSCOPIC STONE SURGERY: TO USE OR NOT TO USE
Yiloren Tanidir*, Bahadir Sahin, Tarik Emre Sener, Muhammed Sulukaya, Cagri Akin Sekerci, Ilker Tinay, Ferruh Simsek, Istanbul, Turkey

8:10 PD35-08 UTILIZATION OF PRESSURIZED VS NON-PRESSURIZED IRRIGATION DURING URETEROSCOPY IN THE ABSENCE OF URETERAL ACCESS SHEATH: COMPARATIVE RETROSPECTIVE STUDY
Karen Doersch*, Amr Elmekresh, Preston A. Milburn, Graham Machen, Kyle Hart, Marawan El Tayeb, Temple, TX

8:20 PD35-09 COMPARISON OF A NOVEL SINGLE-USE FLEXIBLE URETEROSCOPE TO CURRENTLY EXISTING REUSABLE AND SINGLE-USE FLEXIBLE URETEROSCOPIES
Daniel Wollin*, Ruiyang Jiang, Daniela Radvak, Charles Scales, Michael Ferrandino, W. Neal Simmons, Glenn Preminger, Michael Lipkin, Durham, NC

8:30 PD35-10 A PROSPECTIVE CASE COHORT STUDY DEMONSTRATES THAT LITHOVUE™, A SINGLE-USE FLEXIBLE DISPOSABLE URETEROSCOPE, REDUCES OPERATIVE TIME
Manint Usawachintachit*, Dylan Isaacson, Kazumi Taguchi, David Tzou, Ryan Hsi, Benjamin Sherer, Marshall Stoller, Thomas Chi, San Francisco, CA

8:40 PD35-11 NEW DIGITAL SINGLE-USE FLEXIBLE URETEROSCOPE (PUSEN™): FIRST CLINICAL EXPERIENCE
José A. Salvadó*, Alfredo Velasco, Rubén Olivares, José M. Cabello, Manuel Díaz, Sergio Moreno, Santiago, Chile

8:50 PD35-12 UNPLANNED EMERGENCY DEPARTMENT VISITS AND HOSPITAL ADMISSIONS FOLLOWING URETEROSCOPY: DO URETERAL STENTS MAKE A DIFFERENCE?
Harsha R. Mittakanti*, Simon Conti, Alan C. Pao, Joseph Liao, John T. Leppert, Paloo Alto, CA, Christopher S. Elliott, San Jose, CA

ABSTRACT
**TIME** | **NUMBER** | **TITLE**
---|---|---
7:00 | PD36-01 | THE VALIDATED LACE SCORE IDENTIFIES PATIENTS AT INCREASED RISK OF 90-DAY READMISSION AND MORTALITY FOLLOWING RADICAL CYSTECTOMY
Jennifer L. Saluk, Robert H Blackwell*, William S Gange, Matthew AC Zapf, Anai N Kothari, Marcus L Quek, Paul C Kuo, Gopal N Gupta, Robert C Flanigan, Maywood, IL

7:10 | PD36-02 | IMPACT OF NON-MODIFIABLE PATIENT FACTORS ON PERIOPERATIVE OUTCOME FOLLOWING RADICAL CYSTECTOMY WITH ENHANCED RECOVERY PROTOCOL
Daniel Zainfeld*, Bahadir Sahin, Tarik Emre Sener, Muhammed Sulukaya, Cagri Akin Sekerci, Ilker Tinay, Ferruh Simsek, Istanbul, Turkey

7:20 | PD36-03 | PERIOPERATIVE OUTCOMES OF OPEN RADICAL CYSTECTOMY IN OCTOGENARIANS: RESULTS FROM TWO HIGH-VOLUME CENTRES
Vito Palumbo*, Padua, Italy, Fabio Zattoni, Padua and Udine, Italy, Afrovita Kungalli, Sabrina La Falce, Padua, Italy, Mattia Calandrillo, Alessandro Crestani, Giuselena Giannarini, Udine, Italy, Giacomo Novara, Filiberto Zattoni, Padua, Italy, Vincenzo Ficarra, Udine, Italy

7:30 | PD36-04 | DOES SARCOPENIA IMPACT ONCOLOGIC OUTCOMES IN PATIENTS UNDERGOING ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL CYSTECTOMY?
Taylor Peak*, Marc Colaco, Ashok Hemal, Winston-Salem, NC

*Presenting author
7:40  PD36-05 THE PROGNOSTIC VALUE OF POSTOPERATIVE CLINICAL AND LABORATORY PARAMETERS REGARDING THE ONCOLOGICAL OUTCOME OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CELL CARCINOMA OF THE BLADDER
Jan-Friedrich Jokisch*, Tobias Grimm, Munich, Germany, Alexander Buchner, Alexander Kretschmar, Gerald Schulz, Birte Schneeweigt, Christian Stief, Alexander Karl, Munich, Germany

7:50  PD36-06 IS FOUR DAYS HOSPITAL STAY AFTER ROBOTIC ASSISTED RADICAL CYSTECTOMY FEASIBLE? A MULTIDISCIPLINARY ENHANCED RECOVERY PROGRAM CHALLENGE
Dimitrios Moschonas*, Ricardo Soares, Murthy Kusuma, Alison Roodhouse, Chris Jones, Hugh Mostafid, Michael Swinn, Simon Woodhams, Matthew Perry, Krishnaji Patil, Guildford, United Kingdom

8:00  PD36-07 RESTRICTIVE TRANSFUSION IN RADICAL CYSTECTOMY IS SAFE
Sumeet Syan-Bhanvadia*, Swar Shah, Jie Cai, Gus Miranda, Siamak Daneshmand, Los Angeles, CA

8:10  PD36-08 PERIOPERATIVE ALLOGENEIC BLOOD TRANSFUSION DOES NOT ADVERSELY IMPACT SURVIVAL AFTER RADICAL CYSTECTOMY FOR URINARY BLADDER CANCER - A COMPETING-RISKS ANALYSIS FROM A MULTI-INSTITUTIONAL EUROPEAN SERIES
Malte W. Vetterlein*, Philipp Gild, Luis A. Kluth, Hamburg, Germany, Michael Gierth, Hans-Martin Fritsche, Maximilian Burger, Regensburg, Germany, Chris Protzel, Oliver Hakenberg, Rostock, Germany, Nicolas von Landenberg, Florian Roghmann, Joachim Noldus, Herne, Germany, Philipp Nuhn, Mannheim, Germany, Michael Rink, Felix K.H. Chun, Hamburg, Germany, Matthias May, Straubing, Germany, Margit Fisch, Aliquillaah Aziz, Hamburg, Germany

8:20  PD36-09 INSTITUTIONAL VOLUME IS ASSOCIATED WITH REDUCED 90 DAY MORTALITY RATES FOR BOTH OPEN AND ROBOTIC RADICAL CYSTECTOMY
Kaitlin Kosinski, Melissa Fazzari, Michael Kongnyuy, Daniel Halpem, Mineola, NY, Marc Smaldone, Philadelphia, PA, Jeffrey Schiff, Aaron Katz, Anthony Corcoran*, Mineola, NY

8:30  PD36-10 VENOUS THROMBOEMBOLISM RATES FOLLOWING RADICAL CYSTECTOMY STRATIFIED BY METHOD OF PROPHYLAXIS.
Cory Hugen*, Alexander Stern, Jie Cai, Gus Miranda, Anne Schuckman, Hooman Djaladat, Siamak Daneshmand, Los Angeles, CA

8:40  PD36-11 COMPARISON OF TOTAL 90 DAY COSTS FOR OPEN VERSUS ROBOTIC CYSTECTOMY
Michael Metcalfe*, Zachary Compton, Roger Li, James Ferguson, Debashish Sundi, Justin Nguyen, Ashish Kamat, Jay Shah, Colin Dinney, Neema Navai, Houston, TX

8:50  PD36-12 COMPARING COMPLICATIONS AND SURVIVAL OF PRIMARY CYSTECTOMY VS. SALVAGE CYSTECTOMY AFTER TRIMODAL THERAPY
Matthew Mossanen*, Ross E. Krasnow, Alberto C. Pieretti, Adam S. Feldman, Jason A. Efstathiou, Michael L. Blute, Niall M. Heney, Matthew F. Wszolek, Boston, MA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
<th>TIME</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD37-01</td>
<td>7:50</td>
<td>PD37-06</td>
</tr>
</tbody>
</table>
|      | **FOUR VS TEN MONTHS OF INDUCTION ADT FOR INTERMITTENT THERAPY: A PROSPECTIVE CURC RANDOMIZED TRIAL.**
|      | Laurence Klotz*, Andrew Loblaw, Toronto, Canada, Rob Siemens, Kingston, Canada, Paul Ouellette, Montreal, Canada, Anil Kapoor, Hamilton, Canada, Fred Saad, Montreal, Canada |
|      | **A NEW ERA: AUTOMATED EXTRACTION OF DETAILED PROSTATE CANCER INFORMATION FROM NARRATIVELY WRITTEN HEALTH RECORDS. PIONEER WORK FROM A EUROPEAN TERTIARY CARE CENTER**
|      | Sami-Ramzi Leyh-Bannurah*, Hamburg, Germany, Zhe Tian, Pierre Karakiewicz, Montreal, Canada, Dirk Pehrke, Hartwig Huland, Markus Graefen, Lars Budäus, Hamburg, Germany |
| 7:10 | PD37-02  | 8:00 | PD37-07  |
|      | **PHASE III STUDY OF INTERMITTENT MONOTHERAPY VERSUS CONTINUOUS COMBINED ANDROGEN DEPRIVATION**
|      | Fernando Calais da Silva Junior*, Fernando Calais da Silva Senior, Lisboa, Portugal, Frederico Gonçalves, Bratislava, Slovakia(Slovak Republic), Jan Klement, Martin, Slovakia(Slovak Republic), Américo Santos, Braga, Portugal, Spiros Pasidis, Athens, Greece, Antonio Queimadelos, Santiago Compostela, Spain, Chris Robertson, Glasgow, United Kingdom |
|      | **TREATMENT TRENDS FOR METASTATIC PROSTATE CANCER OVER THE LAST DECADE: INSIGHTS FROM THE NATIONAL CANCER DATABASE**
|      | Jared P. Schober*, Kristian D. Stensland, Karim Hamawy, Alireza Moinzadeh, David Canes, Burlington, MA |
| 7:20 | PD37-03  | 8:10 | PD37-08  |
|      | **ANDROGEN DEPRIVATION THERAPY AND THE INCIDENCE OF AUTOIMMUNE DISEASES IN 17,168 PATIENTS WITH PROSTATE CANCER**
|      | Jui-Ming Liu*, Heng-Chang Chuang, Taoyuan, Taiwan, Chun-Te Wu, Keelung, Taiwan, Ren-Jun Hsu, Taipei, Taiwan |
|      | **ENHANCING THE EFFICACY OF VALPROIC ACID IN PROSTATE CANCER CELLS WITH NUTRITIONAL SUPPLEMENTS**
|      | Wasis H. Chowdhury*, Anna-Barbara O’James, San Antonio, TX, Abhinav Sidana, Jatindar Goyal, Daniel Oh, Baltimore, MD, Grace I. Todd, Miazunor Rahman, Ronald Rodriguez, San Antonio, TX |
| 7:30 | PD37-04  | 8:20 | PD37-09  |
|      | **STATINS AND ORAL TREATMENTS IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC): REAL-WORLD OUTCOMES**
|      | Nicole Engel-Nitz, Eden Prairie, MN, Ajay Behl*, Horsham, PA, Cori Blauer-Peterson, Eden Prairie, MN, Nancy Dawson, D.C., MD |
|      | **IDENTIFICATION OF EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) SELECTIVE CYTOTOXIC COMPOUNDS IN PROSTATE CANCER CELLS**
|      | Marion Vanneste, Iowa City, IA, Qin Huang, Coralville, IA, Meng Wu, James Brown*, Michael Henry, Iowa City, IA |
| 7:40 | PD37-05  | 8:30 | PD37-10  |
|      | **IMPACT OF STAGE MIGRATION ON METASTATIC PROSTATE CANCER: EVIDENCE OF MORE FAVOURABLE DISEASE CHARACTERISTICS OVER TIME**
|      | Emanuele Zaffuto*, Milan, Italy, Helen Davis Bondarenko, Montreal, Canada, Raisa S. Pompeo, Hamburg, Germany, Paolo Dell'Oglio, Giorgio Gandaglia, Nicola Fossati, Armando Stabile, Marco Bandini, Francesco Montorsi, Alberto Briganti, Milan, Italy, Pierre l. Karakiewicz, Montreal, Canada |
|      | **BIOCHEMICAL VALIDATION OF PIPERLONGUMINE AS A POTENT THERAPEUTIC AGAINST NEUROENDOCRINE PROSTATE CANCER**
|      | Kamlesh K Yadav*, Khader Shameer, Jennifer Stockert, Cordelia Elaio, Benjamian Readhead, Shalini S Yadav, Joel Dudley, Ashutosh Tewari, Brooklyn, NY |
| 7:50 | PD37-06  | 8:40 | PD37-11  |
|      | **A NEW ERA: AUTOMATED EXTRACTION OF DETAILED PROSTATE CANCER INFORMATION FROM NARRATIVELY WRITTEN HEALTH RECORDS. PIONEER WORK FROM A EUROPEAN TERTIARY CARE CENTER**
|      | Sami-Ramzi Leyh-Bannurah*, Hamburg, Germany, Zhe Tian, Pierre Karakiewicz, Montreal, Canada, Dirk Pehrke, Hartwig Huland, Markus Graefen, Lars Budäus, Hamburg, Germany |
|      | **CHEK2 MUTATIONS INCREASE RISK FOR PROSTATE CANCER BUT DO NOT DIFFERENTIATE RISK OF LETHAL FROM INDOLENT DISEASE**
|      | S. Lily Zheng, Evanston, IL, Rong Na, Shanghai, China, People’s Republic of, Misop Han, Baltimore, MD, Kristian Novakovic, Evanston, IL, Kathleen Wiley, Sarah Isaacs, Alan Partin, Baltimore, MD, Michael McGuire, Evanston, IL, Patrick Walsh, Baltimore, MD, Charles Brendler, Brian Heffand, Evanston, IL, William Isaacs, Baltimore, MD, Jianfeng Xu*, Evanston, IL |
8:50 PD37-12 EVALUATION OF NICLOSAAMIDE AS A POTENT INHIBITOR OF ANDROGEN RECEPTOR VARIANTS TO OVERCOME RESISTANCE TO ABIRATERONE AND ENZALUTAMIDE IN ADVANCED PROSTATE CANCER
Chengfei Liu*, Wei Lou, Joy Yang, Chong-Xian Pan, Primo Lara, Christopher Evans, Allen Gao, Sacramento, CA

Video Session 6

MISC. GU ONCOLOGY AND TRANSPLANT

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 254 @ Boston Convention & Exhibition Center
Moderators: Jay Bishoff, Alberto Breda and James Porter

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V6-01</td>
<td>MIDLINE EXTRAPERITONEAL RPLND IN TESTIS CANCER: MINIMIZING SURGICAL MORBIDITY</td>
</tr>
<tr>
<td>Sumeet Syan-Bhanvadia*, Soroush Bazargani, Thomas Cliftord, Hooman Djalilat, Anne Schuckman, Siamak Daneshmand, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>V6-02</td>
<td>POST CHEMOTHERAPY ROBOTIC RETROPERITONEAL LYMPH NODE DISSECTION FOR NON-SEMINOMATOUS GERM CELL TUMOR</td>
</tr>
<tr>
<td>James Porter*, Gerald Heulitt, Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>V6-03</td>
<td>SYNCHRONOUS AND SIMULTANEOUS POSTERIOR REROPERITONEOSCOPIC BILATERAL ADRENALECTOMY.</td>
</tr>
<tr>
<td>Patricio Garcia Marchiirenas, Miguel Basualdo, Oscar Damia, Guillermo Gueglio, Alberto Jurado*, Ciudad Autónoma de Buenos Aires, Argentina</td>
<td></td>
</tr>
<tr>
<td>V6-04</td>
<td>RETROPERITONEAL COMPARTMENT SYNDROME IN RENAL TRANSPLANTATION —HOW DO WE SALVAGE THE GRAFT?</td>
</tr>
<tr>
<td>V6-05</td>
<td>ROBOTIC PARTIAL ADRENALECTOMY FOR SYMPTOMATIC ALDOSTERONE-SECRETING ADENOMAS: TECHNIQUE AND OUTCOMES</td>
</tr>
<tr>
<td>Giuseppe Simone, Gabriele Tuderti, Leonardo Misurac*, Rome, Italy, Antonio Celia, Bernardino De Concilio, Bassano del Grappa, Italy, Antonio Stigliano, Francesco Minisola, Mariaconsiglia Ferriero, Giuseppe Romeo, Salvatore Guaglianone, Michele Gallucci, Rome, Italy</td>
<td></td>
</tr>
<tr>
<td>V6-06</td>
<td>ROBOTIC-ASSISTED THORACOSCOPIC TRANSDIAPHRAGMATIC ADRENALECTOMY: A NOVEL SURGICAL APPROACH</td>
</tr>
<tr>
<td>V6-07</td>
<td>INTRACORPOREAL PARTLY STAPLED PADUA ILEAL BLADDER USING ROBOTIC STAPLERS: SURGICAL TECHNIQUE, PERIOPERATIVE AND EARLY FUNCTIONAL OUTCOMES OF A PROSPECTIVE SINGLE CENTER SERIES</td>
</tr>
<tr>
<td>Giuseppe Simone, Salvatore Guaglianone, Francesco Minisola*, Mariaconsiglia Ferriero, Leonardo Misuraca, Gabriele Tuderti, Giuseppe Romeo, Michele Gallucci, Rome, Italy</td>
<td></td>
</tr>
<tr>
<td>V6-08</td>
<td>ROBOTIC URETERAL RECONSTRUCTION FOR URETERAL COMPLICATIONS OF KIDNEY TRANSPLANTS</td>
</tr>
<tr>
<td>Kevin Yang*, David Canes, Alireza Moinzadeh, Andrea Sorcini, Burlington, MA</td>
<td></td>
</tr>
<tr>
<td>V6-09</td>
<td>NOVEL ROBOTIC APPROACH TO INGUINAL AND PELVIC LYMPHADENECTOMY FOR METASTATIC MELANOMA IN A 44 YEAR OLD MALE</td>
</tr>
<tr>
<td>Nathan Jung*, Hugh Smith, Alan Hyde, Alvare Valles, Chris Keel, Chattanooga, TN</td>
<td></td>
</tr>
<tr>
<td>V6-10</td>
<td>ROBOTIC KIDNEY TRANSPLANT – OUR INITIAL EXPERIENCE AND TECHNIQUE.</td>
</tr>
<tr>
<td>Anant Kumar*, Anil Gulia, Samit Chaturvedi, Manoj Kumar, Ruchir Maheshwari, Karamveer Singh Sabharwal, New Delhi, India</td>
<td></td>
</tr>
</tbody>
</table>
V6-11 LAPAROSCOPIC RADICAL HEMINEPHROURETERECTOMY IN HORSESHOE KIDNEY WITH HIGH-GRADE UROTHELIAL CELL CARCINOMA AND SINGLE-PORT BLADDER CUFF MANAGEMENT: FIRST CASE REPORT.  
Marino Cabrera*, Jose Gustavo Ramos, Claudia Lucia Ochoa, Angie Ramirez, Rodolfo Varela, Jorge Forero, German Godoy, Bogota, Colombia

V6-12 TRANSVESICOSCOPIC BLADDER CUFF EXCISION IN LAPAROSCOPIC NEPHROURETERECTOMY  
Young Eun Yoon, Sang Woon Kim*, Hyung Ho Lee, Jang He Han, Seung Hwan Lee, Won Sik Ham, Koon Ho Rha, Woong Kyu Han, Seoul, Korea, Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017  7:00 am - 2:30 pm
UROLOGIC CARE FOR THE ADVANCED PRACTICE PROVIDER  
Room 206AB @ Boston Convention & Exhibition Center

7:00  REGISTRATION  10:45  ADVANCED PROSTATE CANCER TREATMENT  
7:30  WELCOME  11:30  Q&A ON MALE HEALTH  
7:35  PANEL DISCUSSION: WORKFORCE SURVEY RESULTS  11:45  POST-TEST  
Heather Schultz, Josh Langston, Brad Hornberger  12:00  LUNCH BREAK  
8:20  SESSION III: MALE HEALTH  1:00  SESSION IV: URODYNAMICS  
MALE SEXUAL HEALTH – ED AND CARDIOVASCULAR DISEASE  
Martin Miner  1:45  BASIC CONCEPTS IN URODYNAMICS  
Martin Miner  2:30  ADJOURN  
8:40  PATIENT COMMUNICATION IN TESTOSTERONE REPLACEMENT THERAPY  
Martin Miner  3:00  APPROVED FOR AMA PRA CATEGORY 1 CREDIT™  
Martin Miner

8:00  WELCOME REMARKS  9:40  KEYNOTE: NAVIGATING REGULATORY AND LEGAL CONSIDERATIONS  
Aria Olumi  Ed Goldman

8:05  INTRODUCTION  10:10  BREAK  
John Wei

8:10  POINT AND COUNTERPOINT: QUALITY IMPROVEMENT DATA: IS IT RESEARCH?  10:25  USING MEDICARE DATA FOR RESEARCH ON HEALTHCARE DELIVERY INNOVATIONS  
John Wei, Peter Carroll, David Miller  Christine Vogeli

8:40  Q & A  10:50  PANEL DISCUSSION: EXAMPLE CLINICAL REGISTRIES: MUSIC, AQUA AND CROES  
Panelists: Khurshid Ghani, Matthew R. Cooperberg, Jean de la Rosette

8:50  TYPES OF DATA AND THEIR USE FOR RESEARCH  11:20  Q & A  
Quoc-Dien Trinh  John Gore

9:15  COLLECTING AND SHARING EMR DATA  11:30  USING RESEARCH RESULTS TO DEVELOP PATIENT-CENTERED TOOLS FOR CANCER CARE: PATIENT ACCESS TO DATA  
Steven Schlossberg  

*Presenting author

175
**Sunday, May 14, 2017**

**9:30 am - 11:30 am**

**Moderated Poster Session 50**

**STONE DISEASE: SURGICAL THERAPY V**

*Room 151 @ Boston Convention & Exhibition Center*  
**Moderators:** Bodo Knudsen and Ojas Shah

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP50-01         | **EFFECT OF DIFFERENT POSTOPERATIVE PAIN MEDICATIONS ON RETURN FOR UNPLANNED CARE AFTER URETEROSCOPY**  
Preston Milburn*, Graham Machen, Amr Elmekresh, Kristofer Wagner, Erin Bird, Marawan El Tayeb, Temple, TX | MP50-09         | **ROBOTIC FLEXIBLE URETEROSCOPIC TREATMENT OF RENAL AND URETERAL CALCULI: FIRST-IN-MAN EXPERIENCE WITH A NOVEL ROBOTIC SYSTEM**  
Mihir Desai*, Los Angeles, CA, Shashikant Mishra, Abhishek Singh, Ravindra Sabnis, Arvind Ganpule, Mahesh Desai, Nadiad, India |
| MP50-02         | **THE IMPACTED URETERAL STONE: FACTORS PREDICTING FOR SUCCESSFUL OUTCOME WITH ENDOSCOPIC MANAGEMENT**  
Sumit De*, Sarina Gupta, Megan Singh, Rohit Chugh, Harrison Bell, Mantu Gupta, New York, NY | MP50-10         | **PREDICTING POSTOPERATIVE FEVER AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME AFTER URETEROSCOPY**  
Andrew Higgins, Amanda Young, Korey Kost, Brielle Schreiter, Marisa Clifton, Brant Fulmer, Tulika Garg*, Danville, PA |
| MP50-03         | **THE URETERIC "RENDEZVOUS PROCEDURE" TO TREAT COMPLEX DISCONTINUITIES**  
Francesco Berardinelli*, Piergustavo De Francesco, Luca Cindolo, Vasto, Italy, Silvia Proietti, Milano, Italy, Orietta Dalpiaz, Graz, Austria, Derek Hennessy, Melbourne, Australia, Cecilia Cracco, Cesare Scoppone, Torino, Italy, Luigi Schips, Vasto, Italy, Guido Giusti, Milano, Italy |
| MP50-04         | **PREOPERATIVE DJ STENT PLACEMENT VS. DIRECT URETEROSCOPY: A RETROSPECTIVE COMPARATIVE STUDY**  
Andrew Navetta*, Trey Durdin, Amr Elmekresh, Adam Cohen, Marawan El Tayeb, Temple, TX | MP50-12         | **PERCUTANEOUS NEPHROLITHOTOMY IN LOW BODY MASS INDEX PATIENTS: CAN THINNESS INFLUENCE PERIOPERATIVE OUTCOMES AND COMPLICATIONS?**  
Jose Agudelo*, Euro Arias, Jhonan Chirinos, Nasser Ktech, Luis Urdanella, Juan Bustamante, Manuel Riveros, Maracaibo, Venezuela |
| MP50-05         | **IMPACT OF LASER FIBER TIP CLEAVAGE ON POWER OUTPUT FOR URETEROSCOPY AND STONE TREATMENT**  
Mattieu Haddad*, Esteban Emiliani, Steeve Doizi, Yann Rouchausse, Frederic Coste, Laurent Berthe, Olivier Traxter, Paris, France | MP50-13         | **INITIAL LOWER POLE ACCESS FOR COMPLETE STAGHORN CALCULI: IS IT FEASIBLE WITHOUT COMPROMISING SUCCESS?**  
Kyle A. Blum*, Egor Parkhomenko, Julie Thai, Timothy Y. Tran, Mantu Gupta, New York, NY |
| MP50-06         | **HYDRONEPHROSIS AFTER URETERAL ACCESS SHEATH USE**  
Brandon Otto*, Stephanie Stillings, VINCENT BIRD, Gainesville, FL | MP50-14         | **PERCUTANEOUS NEPHROLITHOTOMY IN A FREE-STANDING AMBULATORY SURGERY CENTER: FIRST 100 CASES REPORTED**  
Julio Davalos*, Joel Abbott, Baltimore, MD |
| MP50-07         | **COMPARISON OF PARAMETERS OF STANDARD REUSABLE FLEXIBLE URETERO-RENOSCOPES WITH A SINGLE USE URETERO-RENOSCOPE (LITHOVUE)**  
Grzegorz Fojeccki, Derek Hennessy, Nathan Lawrencechuk, Damien Bolton*, Melbourne, Australia |                |                                                                    |
| MP50-08         | **LIMITATIONS OF THE LITHOVUE SINGLE USE DIGITAL FLEXIBLE URETEROSCOPE**  
Saum Ghodoussipour*, Eli Thompson, Adit Shah, Anirban Mitra, Sameer Deshmukh, Matthew Dunn, Los Angeles, CA |                |                                                                    |
MP50-15 ASSESSING THE VOLUME-OUTCOME RELATIONSHIP FOR PCNL IN 2014 AND 2015 - ANALYSIS USING NATIONAL REGISTRY DATA OF OVER 4000 CASES
John Withington*, Sarah Fowler, London, United Kingdom, James Armitage, Cambridge, United Kingdom, Jonathan Glass, London, United Kingdom, William Finch, Stuart Irving, Neil Burgess, Norwich, United Kingdom, Oliver Wiseman, Cambridge, United Kingdom

MP50-16 INITIAL CLINICAL EXPERIENCE WITH A SINGLE-USE DIGITAL FLEXIBLE URETEROSCOPE

MP50-17 A REVIEW OF PERCUTANEOUS NEPHROLITHOTOMY FOR SMALL (LESS THAN 1CM) AND STAGHORN RENAL STONES: OUTCOMES FROM THE UK NATIONAL DATA REGISTRY
Ben Pullar*, Cambridge, United Kingdom, John Withington, London, United Kingdom, James Armitage, Cambridge, United Kingdom, Sarah Fowler, London, United Kingdom, William Finch, Stuart Irving, Norwich, United Kingdom, Jonathan Glass, London, United Kingdom, Neil Burgess, Norwich, United Kingdom, Oliver Wiseman, Cambridge, United Kingdom

MP50-18 SINGLE SESSION BILATERAL VERSUS STAGED BILATERAL URETEROSCOPY FOR NEPHROLITHIASIS: AN ASSESSMENT OF SAFETY AND EFFICACY
Gabriel Fiscus*, Tracy Marien, Teerayut Tangpaitoon, Joseph Kuebker, Duke Herrell, Nicole Miller, Nashville, TN

MP50-19 INTRA-RENAL PRESSURES DURING RA-RIRS (ROBOTIC ASSISTED RETROGRADE INTRA-RENAL SURGERY): A CRITICAL EVALUATION BASED ON URETERAL ACCESS SHEATH (UAS) SIZE AND IRRIGATION FLOW RATE
Nida Zafer Tokatli, Ankara, Turkey, Kemal Sarica*, Istanbul, Turkey, Ahmet Sinan Kabakci, Remzi Saglam, Ankara, Turkey, Anup Patel, London, United Kingdom

MP50-20 DOES PREOPERATIVE ALPHA BLOCKERS FACILITATES URETEROSCOPE INSERTION AT VESICO URETIC JUNCTION? AN ANSWER FROM A PROSPECTIVE RANDOMIZED STUDY
Ashok Sokhal*, Satyanarayan Sankhwar, Apul Goel, kawaljit Singh, Lucknow, India

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017
9:30 am - 11:30 am
Moderated Poster Session 51
SURGICAL TECHNOLOGY & SIMULATION: TRAINING & SKILLS ASSESSMENT I
Room 153 @ Boston Convention & Exhibition Center
Moderators: Michael Borofsky, Thomas Londvay and Prem Rashid

ABSTRACT NUMBER TITLE
MP51-01 CONCURRENT VALIDATION OF AUTOMATED EVALUATION OF ROBOTIC SURGERY PERFORMANCE: CORRELATION OF PERFORMANCE METRICS TO GLOBAL EVALUATIVE ASSESSMENT OF ROBOTIC SURGERY (GEARS)
Andrew Hung*, Los Angeles, CA, Jian Chen, Los Angeles, CA, Anthony Jarc, Sunnyvale, CA, Hooman Djaladat, Inderbir Gill, Los Angeles, CA

ABSTRACT NUMBER TITLE
MP51-03 OLDER AND WISER? CHANGES IN UNPROFESSIONAL CONTENT ON UROLOGISTS' SOCIAL MEDIA FROM RESIDENCY TO PRACTICE
Max Schmidt-Bowman*, Hanover, NH, Kevin Koo, Zita Ficko, E. Ann Gormley, Lebanon, NH

ABSTRACT NUMBER TITLE
MP51-04 A DECADE OF ROBOT-ASSISTED RADICAL PROSTATECTOMY TRAINING: TIME-BASED METRICS FROM FELLOWS AND RESIDENTS
Muammer Altok, Mary Achim, Surena Matin, Curtis Pettaway, John Davis*, Houston, TX

*Presenting author
MP51-05 DOES TRAINEE PERFORMANCE IMPACT SURGEON’S STRESS DURING ROBOT-ASSISTED SURGERY?
Somayeh Shafiei*, Ahmed Hussein, Youssef Ahmed, Justen Kozlowski, Khurshid Guru, Buffalo, NY

MP51-06 ASSESSMENT OF FLEXIBLE URETEROSCOPIC STONE EXTRACTION SKILLS OF UROLOGY POSTGRADUATE TRAINEES DURING OBJECTIVE STRUCTURED CLINICAL EXAMINATIONS: IS THERE A PLACE FOR VIRTUAL REALITY SIMULATORS?
Mehdi Aloosh*, Félix Couture, Sero Andonian, Montreal, Canada

MP51-07 TEACHING COMMUNICATION SKILLS IN UROLOGY RESIDENCY PROGRAMS: A MISSED OPPORTUNITY FOR IMPROVEMENT?
Jorge Whitley*, Houston, TX, Geolani Dy, Seattle, WA, Marcy Rosenbaum, Iowa City, IA, Byron Joyner, Kathleen Kieran, Seattle, WA

MP51-08 GENDER-BASED DIFFERENCES ASKED OF UROLOGY APPLICANTS DURING RESIDENCY INTERVIEWS
Mary Kate Keeter, Ashima Singal*, Nirali Shah, Stephanie Kielb, Chicago, IL

MP51-09 THE “PENANA”: A NOVEL, COST EFFECTIVE, AND HIGHLY EFFICACIOUS MODEL FOR TEACHING MALE URETHRAL ANATOMY AND SAFE FOLEY CATHETER TECHNIQUE
Matthew Truesdale*, Maya Overland, Christy Boscardin, Kirsten Greene, San Francisco, CA

MP51-10 ASSESSING SURGICAL SKILLS AMONG UROLOGY RESIDENT APPLICANTS: CAN CROWD-SOURCING IDENTIFY THE NEXT GENERATION OF SURGEONS?
Zhamshid Okhunov*, Simone L. Vernez, Victor Huynh, Kathryn Osann, Jaime Landman, Ralph V. Clayman, Orange, CA

MP51-11 UTILIZATION OF A SURGICAL VIDEO CURRICULUM TO AUGMENT RESIDENT LEARNING
Wayne Brisbane*, Marc Rogers, Kevin Ostrowski, Robert Sweet, Hunter Wessells, Thomas Walsh, Seattle, WA

MP51-12 A TRAINING COURSE FOR THE UROLOGIST IMPROVES THEIR ABILITY TO INTERPRET CLINICALLY SIGNIFICANT PROSTATE CANCER ON MULTIPARAMETRIC MRI
Veeru Kasivisvanathan*, Susan Charman, Jan van der Meulen, Lina Carmona, Vasillis Stavrinides, Clare Allen, Alex Kirkham, Shonit Punwani, Mark Emberton, Caroline Moore, London, United Kingdom

MP51-13 SURGICAL SKILL QUALITY IMPROVEMENT: UTILIZING A PEER VIDEO REVIEW WORKSHOP FOR SURGEONS PERFORMING ROBOTIC PROSTATECTOMY
Richard Sarle*, Dearborn, MI, Nikola Rakic, Tae Kim, Andrew Brachulis, Ann Arbor, MI, Brian R. Lane, Grand Rapids, MI, Benjamin Stockton, St. Joseph, MI, Susan Linsell, David C. Miller, Ann Arbor, MI, James O. Peabody, Detroit, MI, Khurshid R. Ghani, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP51-14 THE CURRENT STATE OF ROBOTIC SURGERY TRAINING CURRICULA IN UNITED STATES UROLOGY RESIDENCY PROGRAMS
Daniel Verges*, Costas Lallas, Philadelphia, PA

MP51-15 SURGICAL TECHNICAL PERFORMANCE IMPACTS PATIENT OUTCOMES IN ROBOTIC-ASSISTED RADICAL PROSTATECTOMY
Mitchell G. Goldenberg*, Toronto, Canada, S. Larry Goldenberg, Vancouver, Canada, Teodor P. Grantcharov, Toronto, Canada

MP51-16 DEVELOPMENT AND CONTENT VALIDATION OF A TRAINING AND ASSESSMENT TOOL FOR RAPN
Catherine Lovegrove*, Eilidh Bruce, Nicholas Raison, Benjamin Chellacombe, London, United Kingdom, Giacomo Novara, Alex Mottre, Aalst, Belgium, Jaques Hubert, Brabois, France, Declan Murphy, Melbourne, Australia, Prokar Dasgupta, Kamran Ahmed, London, United Kingdom

MP51-17 THE ROBOTIX SIMULATOR: FACE AND CONTENT VALIDATION USING THE FUNDAMENTALS OF ROBOTIC SURGERY (FRS) CURRICULUM
Ismail Omar*, James Dilley, Philip Pucher, Philip Pratt, Torah Ameen, Justin Vale, Ara Darzi, Erik Mayer, London, United Kingdom

MP51-18 DEVELOPMENT AND VALIDATION OF A NOVEL COGNITIVE TRAINING TOOL FOR LAPAROSCOPIC SUTURING
Nicholas Raison*, Lauren Wallace, Takashige Abe, Fehmi Haflz, Matin Sherriff, Christian Brown, Prokar Dasgupta, Kamran Ahmed, London, United Kingdom

MP51-19 MULTI-COMPONENT VIDEO-BASED FEEDBACK USING ADDITIONAL WEBCAM INPUTS IMPROVES DAVINCI SURGICAL SKILLS SIMULATOR (DVSSS) PERFORMANCE
Scott Quarrier, Aisha Siebert, Ahmed Ghazi*, Rochester, NY
**MP51-20 PROSTATE SPECIFIC COMMUNICATIONS: WHAT THE NEXT GENERATION OF UROLOGY TRAINEES ARE TELLING PATIENTS ABOUT PROSTATE CANCER SCREENING, DIAGNOSIS, AND TREATMENT DURING A VIRTUAL OBJECTIVE STRUCTURED CLINICAL ENCOUNTER**

Bruce Kava*, Miami, FL, Allen Andrade, New York, NY, Robert Marcovich, Jorge Ruiz, Miami, FL

---

**ABSTRACT NUMBER TITLE**

**MP52-01 DEVELOPMENT OF NEW SURGICAL DEVICE: A PIEZO-ACTUATOR PULSED WATER JET SYSTEM REDUCES RENAL DAMAGES AFTER OFF-CLAMP PARTIAL NEPHRECTOMY IN A RAT MODEL**

Yoshihiro Kamiyama*, Shinichi Yamashita, Atsushi Nakagawa, Shinnji Fuji, Koji Mitsuoka, Yasuhiro Kaido, Akhiro Ito, Takaaki Abe, Teiji Tominaga, Yoichi Arai, Sendai, Japan

**MP52-02 DOES PNEUMOPERITONEUM CAUSE TRANSIENT RENAL INJURY IN CHILDREN?**

Julia Finkelstein*, New York, NY, Solomon Woldu, Dallas, TX, Alexander Small, Nina Mikkiilineni, Sarah Lambert, Pasquale Casale, New York, NY

**MP52-03 CLASSIFICATION OF KIDNEY TUMORS WITH 1064 NM DISPERSIVE RAMAN SPECTROSCOPY**


**MP52-04 THE DECLINE OF LAPAROENDOSCOPIC SINGLE-SITE SURGERY: A SURVEY OF THE ENDOUROLOGICAL SOCIETY TO IDENTIFY SHORTCOMINGS AND GUIDANCE FOR FUTURE DIRECTIONS.**

Igor Sorokin*, Dallas, TX, Abhay Rane, Redhill, United Kingdom, Brian Inwin, Burlington, VT, Ricardo Autorino, Cleveland, OH, Evangelos Liatsikos, Athens, Greece, Noah Carvasser, Jeffrey Cadeddu, Dallas, TX

---

**ABSTRACT NUMBER TITLE**

**MP52-05 DIFFERENTIAL FLUORESCENCE FOR INTRAOPERATIVE MARGIN ASSESSMENT WITH NEAR-INFRARED FLUORESCENCE IMAGING DURING ROBOTIC PARTIAL NEPHRECTOMY**

Ronney Abaza*, Janice Rosenthal, Jatin Gupta, Dublin, OH

**MP52-06 LAPAROENDOSCOPIC SINGLE SITE SURGERY (LESS) AND MINILAPAROSCOPY (ML): AN OBJECTIVE EVALUATION THROUGH A PROSPECTIVE RANDOMIZED TRIAL**

Ahmed Galal*, Ahmed shoma, Ahmed Mansour, Nasr Eltabei, Mansoura, Egypt

**MP52-07 DOES THE USE OF 5 MM INSTRUMENTS AFFECT THE OUTCOMES OF ROBOT-ASSISTED LAPAROSCOPIC PYELOPLASTY IN SMALLER WORKING SPACES? A COMPARATIVE ANALYSIS OF INFANTS AND OLDER CHILDREN**

Minki Baek*, Seoul, Korea, Republic of, M. Selcuk Silay, Istanbul, Turkey, Jason Au, Gene Huang, Abhishek Seth, Nicolette Janzen, David Roth, Chester Koh, Houston, TX

**MP52-08 TECHNIQUE AND CASE SERIES OF MRI GUIDED IN-BORE BIOPSY FOR PATIENTS WITHOUT RECTUM**

Dordaneh Sugano*, Abhinav Sidana, Collier Wright, Brian Calio, Mahir Maruf, Amit Jain, Maria Merino, Peter Choyke, Baris Turkbey, Bradford Wood, Peter Pinto, Bethesda, MD

**MP52-09 INTRAOPERATIVE IDENTIFICATION OF NERVES USING A MYELIN-BINDING FLUOROPHORE: COMPARATIVE EFFICACY OF INTRAVENOUS VS. TOPICAL ADMINISTRATION**

Pedro Recabal*, Takeshi Hashimoto, Jozefina Casuscelli, Aditya Bagrodia, Katie S. Murray, Jonathan Coleman, Timothy Donahue, Vincent P. Laudone, New York, NY

*Presenting author
MP52-10 A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL FOR ASSESSMENT OF PERINEAL HYDRODISSECTION TECHNIQUE FOR NERVESPARING ROBOT ASSISTED RADICAL PROSTATECTOMY
Gencay Hatiboglu*, Tobias Simpfendörfer, Lorenz Uhlmann, Stephan Macher-Göppinger, Joanne Nyarangi-Dix, Sascha Pahemnik, Boris Hadaschik, Markus Hohenfellner, Dogu Teber, Heidelberg, Germany

MP52-11 PROSPECTIVE RANDOMIZED TRIAL COMPARING ENDOSHEATH WITH VISERA ELITE SYSTEM FOR CLINICAL USE & IMPROVED COST-EFFECTIVENESS
Thomas Watkins, Joao Zambon*, Ashok Hemal, Robert Evans, Ryan Terlecki, Jorge Gutierrez, Majid Mirzazadeh, Gopal Badlani, Winston-Salem, NC

MP52-12 ACCURATE TRANURETHRAL RESECTION OF BLADDER TUMOR LOCATED IN LATERAL BLADDER WALL: A NOVEL TECHNIQUE OBTAINING EN BLOC RESECTION AND OBVIATING OBTRATOR NERVE STIMULATION.
Shengkun Sun*, Axiang Xu, Guangfu Chen, Xu Zhang, Beijing, China, People’s Republic of

MP52-13 TRANSPERINEAL MR-GUIDED PROSTATE NEEDLE INTERVENTIONS USING A PATIENT-SPECIFIC TEMPLATE
Dordaneh Sugano*, Sheng Xu, Reza Seifabadi, Ivane Bakhutashvili, Bethesda, MD, Neil Glossop, Kingston, Canada, Peter Choyke, Peter Pinto, Bethesda, MD, Reto Bale, Innsbruck, Austria

MP52-14 TRUS ROBOT-ASSISTED PROSTATE BIOPSY: A FEASIBILITY STUDY
Misop Han*, Sunghwan Lim, Changhan Jun, Doru Petrisor, Dan Stoianovici, Baltimore, MD

MP52-15 COMPARATIVE ASSESSMENT OF CORE BIOPSY NEEDLES
Carling Cheung*, Changhan Jun, Doru Petrusor, Bruce Trock, Misop Han, Dan Stoianovici, Baltimore, MD

MP52-16 INTRAPARENCHYMAL THERAPY DELIVERY IN THE PROSTATE: THE ROLE OF IMAGING AND DEVICE DESIGN
Hoang-Kim Le*, Temple, TX, Martin Brady, Baltimore, MD, King Scott Coffield, Thomas Kuehl, Temple, TX, Raghu Raghavan, Baltimore, MD, V. O. Speights, Jr., Beul Patel, Temple, TX, Scott Wilson, Mike Wilson, Lexington, KY, Rick Odland, Minneapolis, MN

MP52-17 EVALUATION AND COMPARISON OF CONTEMPORARY ENERGY-BASED SURGICAL VESSEL SEALING DEVICES
Zhamshid Okhunov*, Renai Yoon, Kyle Spradling, Achim Lusch, Christina Hwang, Kathryn Osann, Orange, CA, Jiaot Huang, Jaime Landman, Los Angeles, CA

MP52-18 EVALUATION OF A NOVEL THREE-DIMENSIONAL FUNNEL MESH FOR PARASTOMAL HERNIA REPAIR AFTER ILEAL CONDUIT DIVERSION
Karl Tully*, Bochum, Germany, Florian Roghmann, Jobst Pastor, Rein Jüri Palisaar, Joachim Noldus, Christian von Bodman, Herne, Germany

MP52-19 THE EXPERIENCE OF USING A DUAL CHANNELIZED FLEXIBLE CYSTOSCOPE WITH AN IMPACT SHOOTER FOR RESECTION OF BLADDER TUMORS IN HUMAN CADavers EMBALMED BY THIEL’S MODEL.
Shuichi Morizane*, Toshihiro Maeda, Ryoma Nishikawa, Masashi Honda, Yuichiro Ikebuchi, Kazuya Matsumoto, Masaru Ueki, Yonago, Japan, Naoya Masumori, Mineko Fujimiya, Sapporo, Japan, Atsushi Takenaka, Yonago, Japan

MP52-20 SAFETY OF SPONTANEOUS DETACHMENT OF THE NO-FLIP SHANGRING CIRCUMCISION FOR ADOLESCENTS & ADULTS: A RANDOMIZED CLINICAL TRIAL (RCT) IN KENYA.
Omar Al Hussein Alawamlh*, Quentin Awori, Benjamin V Stone, Phil V Bach, Ryan Flannigan, Marc Goldstein, Mark Barone, Philip S Li, Richard K Lee, New York, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP53-01</td>
<td>DOES BASELINE SERUM TESTOSTERONE INFLUENCE ANDROGEN DEPRIVATION THERAPY OUTCOMES FOR ADVANCED PROSTATE CANCER PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Anup Patel*</td>
</tr>
<tr>
<td></td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>MP53-02</td>
<td>SERUM TESTOSTERONE LEVEL IS A USEFUL BIOMARKER TO AID OPTIMAL TREATMENT SELECTION IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Kohei Hashimoto*</td>
</tr>
<tr>
<td></td>
<td>Tetsuya Shindo</td>
</tr>
<tr>
<td></td>
<td>Hidetoshi Tabata, Toshiaki Tanaka</td>
</tr>
<tr>
<td></td>
<td>Jiro Hashimoto, Ryuta Inoue, Takashi Shimizu, Takashi Muranaka</td>
</tr>
<tr>
<td></td>
<td>Sapporo, Japan, Hiroshi Hotta, Asahikawa, Japan, Atsushi Takahashi, Hakodate, Japan, Masahiro Yanase, Sunagawa, Japan, Naoya Masumori, Sapporo, Japan</td>
</tr>
<tr>
<td>MP53-03</td>
<td>IMPACT OF LOWER CASTRATE-LEVEL TESTOSTERONE ON PROGRESSION TO CASTRATE-RESISTANT PROSTATE CANCER FOR PATIENTS UNDERGOING CONTINUOUS ANDROGEN DEPRIVATION THERAPY: A PROSPECTIVE COHORT STUDY</td>
</tr>
<tr>
<td></td>
<td>Taehyoung Lee*</td>
</tr>
<tr>
<td></td>
<td>Hamilton, Canada, Stuti Tanya, London, Canada, Bobby Shayegan, Hamilton, Canada</td>
</tr>
<tr>
<td>MP53-04</td>
<td>COMPARISON OF THE LENGTH OF TIME FROM INITIATION OF ANDROGEN DEPRIVATION THERAPY TO SALVAGE CHEMOTHERAPY IN AFRICAN AMERICAN MALES AND CAUCASIAN MALES WITH CASTRATE RESISTANT PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Maria Uloko*</td>
</tr>
<tr>
<td></td>
<td>Yunhua Fan, Minneapolis, MN, Stephanie Jarosek, Barinath Konety, Minneapolis, MN</td>
</tr>
<tr>
<td>MP53-05</td>
<td>TESTOSTERONE RECOVERY AFTER LONG TIME DEPRIVATION THERAPY: PREDICTIVE FACTORS AND MODELS (NOMOGRAMS)</td>
</tr>
<tr>
<td></td>
<td>Fernando Estrada*, Ángel García de Jalón, Angel Borque, Luis Esteban, M* Jesús Gil, Gerardo Sanz, Zaragoza, Spain</td>
</tr>
<tr>
<td>MP53-06</td>
<td>THE EFFECTIVE PERIOD OF FIRST ANDROGEN DEPRIVATION THERAPY BECOMES AN PROGNOSTIC THE EFFECTIVE PERIOD OF FIRST ANDROGEN-DEPRIVATION THERAPY BECOMES AN PROGNOSTIC FACTOR IN DOCETAXEL CHEMOTHERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Keisuke Shigeta*, Takeo Kosaka, Ryuichi Mizuno, Toshiaki Shinojima, Eiji Kikuchi, Akira Miyajima, Tokyo, Japan, Hitoshi Tanoguchi, Kanagawa, Japan, Shintaro Hasegawa, Utsunomiya, Japan, Mototsugu Oya, Tokyo, Japan</td>
</tr>
<tr>
<td>MP53-07</td>
<td>IMPACT OF METFORMIN ON PROSTATE CANCER PC OUTCOMES IN THE E3805 CHAARTED TRIAL</td>
</tr>
<tr>
<td></td>
<td>David Jarrard*, Madison, WI, Yu-Hui Chen, Boston, MA, Glenn Liu, Madison, WI, Michael Carducci, Mario Eisenberger, Baltimore, MD, Yu-Ning Wong, Philadelphia, PA, Noah Hahn, Indianapolis, IN, Manish Kohli, Rochester, MI, Matthew Cooney, Cleveland, OH, Robert Dreicer, Charlottesville, VA, Nicholas Vogelzang, Las Vegas, NV, Joel Picus, St. Louis, MO, Daniel Shevlin, Evanston, IL, Maha Hussain, Ann Arbor, MI, Jorge Garcia, Cleveland, OH, Robert DiPaola, New Brunswick, NJ, Christopher Sweeney, Boston, MA</td>
</tr>
<tr>
<td>MP53-08</td>
<td>METFORMIN USE IS ASSOCIATED WITH IMPROVED SURVIVAL IN VETERANS WITH ADVANCED PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY</td>
</tr>
<tr>
<td></td>
<td>Kyle Richards*, Jinn-ing Liou, Vincent Cynx, Tracy Downs, Jason Abel, David Jarrard, Madison, WI</td>
</tr>
<tr>
<td>MP53-09</td>
<td>THE NUMBER OF LYMPH NODES SAMPLED DURING RADICAL PROSTATECTOMY DOES NOT IMPACT THE RISK OF BIOCHEMICAL RECURRENT IN PATIENTS WITH SEMINAL VESICLE INVASION</td>
</tr>
<tr>
<td></td>
<td>Ketan Badani*, Balaji Reddy, David Paulucci, New York, NY, Michael Whalen, Yale, CT, Douglas Skarecky, Thomas Ahlering, Irvine, CA</td>
</tr>
</tbody>
</table>

*Presenting author
MP53-10 ROBOT-ASSISTED SALVAGE NODE DISSECTION FOR OLIGOMETASTATIC NODAL DISEASE DETECTED BY 68GALLIUM-PSMA PET/CT: A MULTICENTRE RETROSPECTIVE SERIES
Amila Siriwardana, James Thompson, Sydney, Australia, Shaela Doig, Brisbane, Australia, Pim van Leeuwen, Rotterdam, Netherlands, Anton Kalsbeek*, Louise Emmett, Warick Delprado, Sydney, Australia, Hemamali Samaratunga, Brisbane, Australia, Anne-Marie Haynes, Sydney, Australia, Geoff Coughlin, Brisbane, Australia, Phillip Stricker, Sydney, Australia

MP53-11 SALVAGE EXTENDED PELVIC LYMPH NODE DISSECTION IN PATIENTS WITH RECURRENT PROSTATE CANCER: 5-YEAR FOLLOW-UP
Alexey V. Aksenov*, Carsten M. Naumann, Moritz F. Hamann, Diethild A. Melchior, Klaus-Peter Juenemann, Daniar K. Osmonov, Kiel, Germany

MP53-12 STANDARD OF CARE VERSUS METASTASIS-DIRECTED THERAPY FOR NODAL OLIGORECURRENT PROSTATE CANCER FOLLOWING MULTIMODALITY TREATMENT: A CASE-CONTROL STUDY
Thomas Steuber, Hamburg, Germany, Vidit Sharma*, Rochester, MN, Piet Ost, Karel Decaestecker, Gent, Belgium, Thomas Zilli, Geneva, Switzerland, Barbara A Jereczek-Fossa, Milan, Italy, Cordula Jilg, Freiburg, Germany, R. Jeffrey Karnes, Rochester, MN

MP53-13 FREEDOM FROM ANDROGEN DEPRIVATION AND RADIOTHERAPY THERAPY AFTER UPFRONT MINIMALLY INVASIVE SURGERY FOR HIGH-RISK PROSTATE CANCER

MP53-14 MULTIMODAL TREATMENT FOR HIGH-RISK PROSTATE CANCER WITH HIGH-DOSE INTENSITY-MODULATED RADIATION THERAPY, CONCURRENT INTENSIFIED-DOSE DOCETAXEL AND LONG-TERM ANDROGEN DEPRIVATION THERAPY AFTER RADICAL PROSTATECTOMY AND LYMPHADENECTOMY: RESULTS OF A PROSPEC
Fabio Zattoni*, Padua, Italy, Roberto Bortolus, Aviano, Italy, Alessandro Morfacco, Padua, Italy, Mauro Arcicasa, Fabio Matrone, Aviano, Italy, Filliberto Zattoni, Padua, Italy

MP53-15 LOCAL THERAPY IN METASTATIC PROSTATE CANCER: DOES THE BURDEN OF DISEASE MATTER? RESULTS FROM A NATIONAL POPULATION-BASED CANCER REGISTRY
Vivek Venkatramani*, Tulay Koru-Sangul, Feng Miao, Bruno Nahar, Nachiketh Sooddana Prakash, Mahmoud Alameddine, Sanjaya Swain, Chad Ritch, Mark Gonzalez, Dipen Parekh, Sanoj Punnen, Miami, FL

MP53-16 LONG-TERM ONCOLOGIC OUTCOMES OF ADDING RADICAL PROSTATECTOMY TO CASTRATION FOR PATHOLOGICAL NODE-POSITIVE PROSTATE CANCER
Bimal Bhindi*, Laureano Rangel, Ross Mason, Matthey Gettman, Igor Frank, Eugene Kwon, Matthew Tollefsen, R. Houston Thompson, Stephen Boorjian, R. Jeffrey Karnes, Rochester, MN

MP53-17 CURRENT MANAGEMENT OF PROSTATE CANCER WITH NODE-POSITIVE DISEASE AFTER RADICAL PROSTATECTOMY AND ITS IMPACT ON OVERALL SURVIVAL
Alaa Hamada*, Cleveland, OH, Simon Kim, Cleveland, OH, Hui Zhu, Cleveland, OH, Robert Abuassaly, Cleveland, OH

MP53-18 EFFICACY OF LOCAL TREATMENT IN PROSTATE CANCER PATIENTS WITH CLINICALLY PELVIC LYMPH NODE-POSITIVE DISEASE AT INITIAL DIAGNOSIS
Thomas Seisen*, Malte W. Vetterlein, Patrick Karabon, Tarun Jindal, Akshay Sood, Luigi Nocera, Detroit, MI, Paul L. Nguyen, Toni K. Choueiri, Quoc-Dien Trinh, Boston, MA, Mani Menon, Firas Abdullah, Detroit, MI

MP53-19 CYTOREDUCTIVE RADICAL PROSTATECTOMY (CRP) IS FEASIBLE IN MEN WITH HORMONE-NAIVE, METASTATIC PROSTATE CANCER (MPCA).
Axel Heidenreich*, Köln, Germany, Jeff. R. Karnes, Rochester, MN, Alberto Briganti, Milan, Italy, Shahrokh Shariat, Vienna, Austria, Daniel Porres, Köln, Germany, Nicola Fossati, Francesco Montorsi, Nazareno Suardi, Milan, Italy, David Pfister, Köln, Germany

MP53-20 RADIUM-223(RAD) IN MEN WITH SYMPTOMATIC CASTRATION-RESISTANT PROSTATE CANCER: GUIDELINE VERSUS CLINICAL REALITY.
Isabel Heidegger*, Saskia Kanzelmeyer, David Pfister, Daniel Porres, Pia Paffenholz, Axel Heidenreich, Köln, Germany
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**ABSTRACT**

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP54-01</td>
<td>EVALUATION OF POSTOPERATIVE COMPLICATIONS AFTER RADICAL CYSTECTOMY USING THE COMPREHENSIVE COMPLICATION INDEX</td>
</tr>
<tr>
<td>MP54-02</td>
<td>POST-OPERATIVE OUTCOMES AFTER RADICAL CYSTECTOMY IN RADIATED PATIENTS</td>
</tr>
<tr>
<td>MP54-03</td>
<td>BENEFITS AND COMPLICATIONS DURING INPATIENT FOLLOW-UP TREATMENT AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER</td>
</tr>
<tr>
<td>MP54-04</td>
<td>HOSPITALIZATION AND READMISSION COSTS AFTER RADICAL CYSTECTOMY IN A NATIONALLY REPRESENTATIVE SAMPLE: NEOBLADDER VS. ILEAL CONDUIT</td>
</tr>
<tr>
<td>MP54-05</td>
<td>VALIDATION OF NATIONAL SURGERY QUALITY IMPROVEMENT PROGRAM (NSQIP) RISK CALCULATOR OF POST-OP COMPLICATIONS AND READMISSION AFTER RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td>MP54-06</td>
<td>IMPACT OF SURGICAL VOLUME ON SURVIVAL FOLLOWING RARC IN A LARGE, NATIONAL COHORT</td>
</tr>
<tr>
<td>MP54-07</td>
<td>PENTAFECTA AND TRIFECTA CRITERIA FOR REPORTING OUTCOMES OF RADICAL CYSTECTOMY FOR MUSCLE INVASIVE UROTHELIAL BLADDER CANCER (MIIBC)</td>
</tr>
</tbody>
</table>

*Presenting author*
MP54-14 BLADDER CARCINOMAS ARE NOT ALL THE SAME: DE NOVO MUSCLE INVASIVE DISEASE HAS IMPROVED SURVIVAL COMPARED TO INVASIVE DISEASE PROGRESSING AFTER INTRAVESICAL THERAPY
Raj Bhanvadia*, Chicago, IL, Kristine Kuchta, Sangfai Park, Evanston, IL

MP54-15 PURE BUT NOT MIXED HISTOLOGICAL VARIANTS ARE ASSOCIATED WITH POOR SURVIVAL AT RADICAL CYSTECTOMY IN BLADDER CANCER PATIENTS
Marco Moschini*, Renzo Colombo, Giorgio Gandaglia, Ettore Di Trapani, Giusy Burgio, Milan, Italy, Rocco Damiano, Catanzaro, Italy, Agostino Mattei, Lucerne, Switzerland, Shahrokhi Shariat, Vienna, Austria, Andrea Salonìa, Alberto Briganti, Francesco Montorsi, Andrea Gallina, Milan, Italy

MP54-16 SURVIVAL ANALYSIS OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER NOT SUITABLE FOR TREATMENT WITH A CURATIVE INTENT
Félix Guerrero Ramos*, Madrid, Spain, Santiago Pérez Cadavid, Ponferrada, Spain, Angel Tejido Sánchez, Esther García Rojo, Daniel Antonio González Padilla, Raquel Sopeña Sutil, Felipe Villacampa Aubé, José Manuel Durante Ojeda, Federico de la Rosa Kehrmann, Juan Passas Martínez, Madrid, Spain

MP54-17 DO PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER UNDERGOING BLADDER-PRESERVING RADIOThERAPY/CHEmORADIOThERAPY AT ACADEMIC CENTERS HAVE IMPROVED SURVIVAL OUTCOMES COMPARED TO THOSE TREATED AT NON-ACADEMIC CENTERS?
Amishi Bajaj*, Robert Blackwell, Brendan Martin, Alec Block, Mark Korpics, Ellen Gaynor, Elizabeth Henry, Matthew Harkenrider, Gopal Gupta, Abhishek Solanki, Maywood, IL

MP54-18 THE USE OF URETHRAL FROZEN SECTION DURING RADICAL CYSTECTOMY MAY IMPROVE CANCER-SPECIFIC AND RECURRENCE-FREE SURVIVAL
Benoît Peyronnet*, Gregory Verhoest, Quentin Alimi, Lauranne Tonduit, Vivien Graffieille, Romain Mathieu, Andrea Manunta, Karim Bensalah, François Guille, Solene-Florence Kammerer-Jacquet, Nathalie Rioux-Leclercq, Rennes, France

MP54-19 IMPACT OF PROSTATE INVOLVEMENT ON OUTCOMES IN PATIENTS TREATED WITH RADICAL CYSTOEPIDIDYMECTOMY FOR BLADDER CANCER
Marco Moschini*, Andrea Gallina, Giusy Burgio, Paolo Dell’Oglio, Emanuele Zaffuto, Milan, Italy, Agostino Mattei, Lucerne, Switzerland, Rocco Damiano, Catanzaro, Italy, Shahrokhi Shariat, Vienna, Austria, Vincenzo Mirone, Naples, Italy, Andrea Salonìa, Alberto Briganti, Francesco Montorsi, Renzo Colombo, Milan, Italy

MP54-20 DO MEN WITH A HISTORY OF PROSTATE CANCER HAVE WORSE BLADDER CANCER OUTCOMES?
David Golombos*, Abimbola Ayangbesan, Patrick Lewicki, LaMont Barlow, New York, NY, Padraic O’Malley, Halifax, Canada, Douglas Scherr, New York, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
MP55-03 DOES HISTOLOGY SUBTYPE NEED TO BE CONSIDERED AFTER PARTIAL NEPHRECTOMY IN PATIENTS WITH PATHOLOGIC T1A RENAL CELL CARCINOMA? PAPILLARY VS. CLEAR CELL RENAL CELL CARCINOMA
Sangjun Yoo, Jeman Ryu*, Han-Ryu Chae, Jae Hyeon Han, Se Young Choi, In Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn, Choung-So Kim, Seoul, Korea, Republic of

MP55-04 PERINEPHRIC VERSUS SINUS FAT INVASION IN PT3A TUMORS MANAGED BY PARTIAL NEPHRECTOMY
Pascal Mouracade*, Onder Kara, Matthew Maurice, Julien Dagenais, Ercan Malkoc, Ryan Nelson, Jeremy Reese, Jihad Kaouk, Cleveland, OH

MP55-05 PARTIAL NEPHRECTOMY IN THE TREATMENT OF RENAL TUMORS WITH CONCOMITANT VENOUS TUMOR THROMBOSIS (VTT) OF RENAL VEIN BRANCHES: RETROSPECTIVE, MULTI-CENTER ANALYSIS OF PERIOPERATIVE, FUNCTIONAL, AND ONCOLOGIC OUTCOMES

MP55-06 PRE-OPERATIVE PREDICTORS OF INCIDENTAL PT3A UPSTAGING FOLLOWING PARTIAL NEPHRECTOMY FOR CLINICAL T1 RENAL CELL CARCINOMA
Christopher M. Russell*, Amir H. Lebastchi, Adam Niemann, Rohit Mehra, Todd M. Morgan, David C. Miller, Ganesh S. Palapattu, Khaled S. Hafez, J. Stuart Wolf, Alan Z. Weizer, Ann Arbor, MI

MP55-07 LONG TERM OUTCOMES OF PATIENTS WITH CYSTIC CLEAR CELL RENAL CELL CARCINOMA
Mary E. Westerman*, Vidit Sharma, Christine M. Lohse, Stephen A. Boorjian, Bradley C. Leibovich, John C. Cheville, R. Houston Thompson, Rochester, MN

MP55-08 DIAGNOSIS, MANAGEMENT, AND CLINICAL OUTCOMES OF CYSTIC RENAL CELL CARCINOMA
Mahyar Kashan*, Mazyar Ghanaat, Maria Becerra, Andreas M. Hötker, Michael Chiok, Brandon Manley, Nicole Benfante, Manhattan, NY, Jozefina Casuscelli, Munich, Germany, Shawn Mendonca, Satish Tickoo, Oguz Akın, Paul Russo, Jonathan Coleman, A Ari Hakimi, Manhattan, NY

MP55-09 OPEN PARTIAL NEPHRECTOMY VS. ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR CYSTIC RENAL MASSES: IMPACT OF PEROPERATIVE CYSTIC SPILLAGE AND ONCOLOGICAL RESULTS.

MP55-10 INCREASED B4GALT7 EXPRESSION IS ASSOCIATED WITH ADVERSE ONCOLOGIC OUTCOME IN LOCALIZED CLEAR CELL RENAL CELL CARCINOMA
Huyang Xie*, Zewei Wang, Qiang Fu, Jiejie Xu, Dingwei Ye, Shanghai, China, People’s Republic of

MP55-11 PROGNOSTIC VALUE OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), VEGF RECEPTOR 2, PLATELET-DERIVED GROWTH FACTOR-β (PDGF-β), AND PDGF-β RECEPTOR EXPRESSION IN PAPILLARY RENAL CELL CARCINOMA
Myong Kim*, Jong Keun Kim, Seoul, Korea, Republic of, Myungchan Park, Sang Hyun Park, Busan, Korea, Republic of, In Gab Jeong, Cheryn Song, Jun Hyuk Hong, Choung-Soo Kim, Tai Young Ahn, Hanjong Ahn, Seoul, Korea, Republic of

MP55-12 LONG-TERM ASSESSMENT OF MORTALITY PATTERNS AFTER SURGICAL TREATMENT FOR NON-METASTATIC KIDNEY CANCER: A COMPETING RISK ANALYSIS
Alessandro Larcher*, Alessandro Nini, Fabio Muttin, Francesco Trevisani, Francesco Ripa, Milan, Italy, Zachary Hamilton, Ilhaar Derweshe, San Diego, CA, Cristina Carenzi, Domenico Fichera, Patrizio Rigatti, Federico Dehò, Francesco Montorsi, Umberto Capitanio, Roberto Bertini, Milan, Italy

*Presenting author
**MP55-13** COMPARING PREDICTIVE ACCURACY FOR FOUR PROGNOSTIC MODELS OF RECURRENCE FOLLOWING SURGERY IN NON-METASTATIC RENAL CELL CARCINOMA WITH THROMBUS USING CONTEMPORARY DATA FROM SIX INSTITUTIONS

Shivashankar Damodaran*, Madison, WI, Jose A. Karam, Dallas, TX, Timothy A. Masterson, Indianapolis, IN, Viraj A. Master, Atlanta, GA, Vitaly Margulis, Dallas, TX, Datta Patel, Atlanta, GA, Tyler Bauman, Michael Blute, Jr., Evan Bloom, Madison, WI, Haley Robyak, Matthew Kaag, Jay D. Raman, Hershey, PA, Christopher G. Wood, Dallas, TX, E. Jason Abel, Madison, WI

**MP55-14** THE ABILITY OF THREE COMORBIDITY INDECES TO PREDICT POSTOPERATIVE MORTALITY IN RENAL CELL CARCINOMA PATIENTS: THE IMPENDING NEED OF A NEW DISEASE-SPECIFIC INDEX

Paolo Dell’Oglio*, Alessandro Larcher, Fabio Muttin, Francesco Cianflone, Alessandro Nini, Milan, Italy, Zachary Hamilton, Ilhaar Derweesh, San Diego, CA, Francesco Trevisani, Cristina Carenzi, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Roberto Bertini, Umberto Capitanio, Milan, Italy

**MP55-15** IMPACT OF INTRAOPERATIVE BLOOD TRANSFUSIONS ON SURVIVAL AFTER SURGERY FOR RENAL CELL CARCINOMA

Giovanni La Croce*, Fabio Muttin, Marco Moschini, Alessandro Larcher, Paolo Dell’Oglio, Alessandro Nini, Francesco Ripa, Francesco Cianflone, Ettore Di Trapani, Cristina Carenzi, Federico Dehò, Francesco Montorsi, Roberto Bertini, Umberto Capitanio, Milan, Italy

**MP55-16** RADICAL NEPHRECTOMY WITH OR WITHOUT LYMPH NODE DISSECTION FOR NON-METASTATIC RENAL CELL CARCINOMA: A MULTI-INSTITUTIONAL ANALYSIS


**MP55-17** ASSESSMENT OF METASTASECTOMY COMPLICATIONS IN RENAL CELL CARCINOMA


**MP55-18** COMPARATIVE EFFICACY OF EXTIRPATIVE SURGERY, THERMAL ABLATION, AND ACTIVE SURVEILLANCE FOR PATIENTS WITH SMALL RENAL MASSES: RESULTS FROM THE DISSRM REGISTRY

Ridwan Alam*, Hiten D. Patel, Alice Semerjian, Mark F. Riffon, Bruce J. Trock, Baltimore, MD, Peter Chang, Andrew A. Wagner, Boston, MA, James M. McKiernan, New York City, NY, Mohamad E. Altif, Phillip M. Pierorazio, Baltimore, MD

**MP55-19** MINIMALLY INVASIVE CONSERVATIVE TREATMENT OF LOCALIZED RENAL TUMORS: A SINGLE CENTER EXPERIENCE ON PERCUTANEOUS ABLATIONS AND ROBOT-ASSISTED PARTIAL NEPHRECTOMY

Yohann Grassano*, Francois Cornelis, Nicolas Grenier, Clement Michiels, Gregoire Capon, Henri Bensadoun, Gilles Pasticier, Gregoire Robert, Jean-Marie Ferriere, Jean-Christophe Bernhard, Bordeaux, France

**MP55-20** ADOPTION OF ROBOTIC PARTIAL NEPHRECTOMY: ITS EFFECT ON RENAL CANCER SURGERY AND KAISER PERMANENTE SOUTHERN CALIFORNIA PRACTICE PATTERNS

Ramzi Jabaji*, Los Angeles, CA, Heidi Fischer, Pasadena, CA, Gary Chien, Los Angeles, CA

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
## ABSTRACT

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD38-01</td>
<td>NATURAL HISTORY AND PREDICTORS OF URETERO-ENTERIC STRICTURES AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td>9:40</td>
<td>PD38-02</td>
<td>UTILIZATION OF INDOCYANINE GREEN FLUORESCENCE ANGIOGRAPHY PRIOR TO INTRACORPOREAL URETEROILEAL ANASTOMOSIS FOLLOWING ROBOTIC RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td>9:50</td>
<td>PD38-03</td>
<td>URETEROENTERIC ANASTOMOSIS IN ORTHOTOPIC NEOBLADDER CREATION: DOES PERIOPERATIVE UTI IMPACT STRicture RATE?</td>
</tr>
<tr>
<td>10:00</td>
<td>PD38-04</td>
<td>OBJECTIVELY DEFINED URINARY CONTINENCE AFTER RADICAL CYSTECTOMY AND ILEAL ORTHOTOPIC NEOBLADDER: EFFECTS ON HEALTH-RELATED QUALITY OF LIFE</td>
</tr>
<tr>
<td>10:10</td>
<td>PD38-05</td>
<td>PREDICTORS OF URINARY RETENTION AFTER RADICAL CYSTECTOMY AND ORTHOTOPIC NEOBLADDER</td>
</tr>
<tr>
<td>10:20</td>
<td>PD38-06</td>
<td>CYSTECTOMY AND URINARY DIVERSION FOR BENIGN DISEASE: PATIENT CHARACTERISTICS AND PREDICTORS OF POST-OPERATIVE OUTCOMES FROM A CONTEMPORARY NATIONAL COHORT</td>
</tr>
<tr>
<td>10:30</td>
<td>PD38-07</td>
<td>ROBOT-ASSISTED INTRACORPOREAL RIGHT COLON CONTINENT CUTANEOUS URINARY DIVERSION AND AUGMENTATION CYSTOPLASTY: A SINGLE INSTITUTION EXPERIENCE</td>
</tr>
<tr>
<td>10:40</td>
<td>PD38-08</td>
<td>DOES THE USE OF RECREATIONAL KETAMINE POSE A CHALLENGE ON BLADDER RECONSTRUCTIVE SURGERY?</td>
</tr>
<tr>
<td>10:50</td>
<td>PD38-09</td>
<td>PROSPECTIVE EVALUATION OF CONTINENCE FOLLOWING OPEN RADICAL CYSTECTOMY AND ORTHOTOPIC URINARY DIVERSION AND THE EFFECT OF PELVIC FLOOR PHYSICAL THERAPY</td>
</tr>
<tr>
<td>11:00</td>
<td>PD38-10</td>
<td>FACTORS INFLUENCING INTRAOPERATIVE CONVERSION FROM PLANNED ORTHOTOPIC TO NON-ORTHOTOPIC URINARY DIVERSION DURING RADICAL CYSTECTOMY</td>
</tr>
<tr>
<td>11:10</td>
<td>PD38-11</td>
<td>KIDNEY TRANSPLANTATION IN PATIENTS WITH BLADDER AUGMENTATION: LONG TERM OUTCOMES</td>
</tr>
<tr>
<td>11:20</td>
<td>PD38-12</td>
<td>THE EFFECT OF RADIOTHERAPY ON THE OUTCOME OF THE REPAIR OF URORECTAL FISTULAE</td>
</tr>
</tbody>
</table>

*Presenting author*
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD39-01</td>
<td>LOW INCIDENCE OF CLEAN INTERMITTENT CATHETERIZATION WITH ONABOTULINUMTOXINA IN DIVERSE AGE GROUPS OF OVERACTIVE BLADDER PATIENTS WITH SUBSTANTIAL IMPROVEMENTS IN TREATMENT RESPONSE</td>
<td>Victor Nitti*, New York, NY, Eric Rovner, Charleston, SC, Marcus Drake, Bristol, United Kingdom, Karel Everaert, Ghent, Belgium, Sidney Radomski, Toronto, Canada, Christopher R. Chapple, Sheffield, United Kingdom, David Ginsberg, Los Angeles, CA, Tamer Aboushwareb, Irvine, CA, Cheng-Tao Chang, Bridgewater, NJ, Roger Dmochowski, Nashville, TN</td>
</tr>
<tr>
<td>9:40</td>
<td>PD39-02</td>
<td>THE IMPACT OF DETRUSOR UNDERACTIVITY ON PATIENT SATISFACTION AFTER HOLMIUM LASER ENucleATION OF THE PROSTATE: A PROSPECTIVE STUDY</td>
<td>Young Ju Lee, Chu Hong Park*, Chihyun Ahn, Bum Sik Tae, Seung-June Oh, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>9:50</td>
<td>PD39-03</td>
<td>URODYNAMIC ANALYSIS OF THE IMPACT OF DIABETES MELLITUS ON BLADDER FUNCTION</td>
<td>Tsuyoshi Majima*, Yoshihisa Matsukawa, Yasuhiro Funahashi, Tokunori Yamamoto, Momokazu Gotoh, Nagoya, Japan</td>
</tr>
<tr>
<td>10:00</td>
<td>PD39-04</td>
<td>SACRAL NEUROMODULATION FOR DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY</td>
<td>Derek Hennessey*, Nathan Hoag, Johan Gani, Melbourne, Australia</td>
</tr>
<tr>
<td>10:30</td>
<td>PD39-07</td>
<td>PELVIC FLOOR PHYSICAL THERAPY SIGNIFICANTLY IMPROVES PAIN AND VOIDING SYMPTOMS IN WOMEN WITH PELVIC PAIN</td>
<td>Natalie Gaines*, Royal Oak, MI, Jacob Henrichsen, Rochester, MI, Laura Nguyen, Larry T. Siris, Jason Gilleran, Jamie Bartley, Royal Oak, MI, Priyanka Gupta, Ann Arbor, MI, Kim A. Killeger, Royal Oak, MI, Robert Petrossian, Rochester, MI, Lisa Odabachian, Judith A. Boura, Kenneth M. Peters, Royal Oak, MI</td>
</tr>
<tr>
<td>10:40</td>
<td>PD39-08</td>
<td>ARE NOMOGRAMS BASED ON FREE UROFLOWS HELPFUL TO EVALUATE URETHRAL OBSTRUCTION IN MEN?</td>
<td>Francoise Valentini*, Montreuil, France, Peter Rosier, Utrecht, Netherlands, Pierre Nelson, Paris, France</td>
</tr>
<tr>
<td>10:50</td>
<td>PD39-09</td>
<td>BLADDER FUNCTION RECOVERY AFTER TREATMENT IN MALE PATIENTS WITH DETRUSOR UNDERACTIVITY – CLINICAL RESULTS AND PREDICTIVE FACTORS</td>
<td>Kau Han Lee*, Tainan City, Taiwan, Hain-Chorng Kuo, Hualien, Taiwan</td>
</tr>
<tr>
<td>11:00</td>
<td>PD39-10</td>
<td>DEVELOPMENT AND VALIDATION OF A NOVEL PICTOGRAM-BASED URINARY SYMPTOM SCORE: THE VISUAL URINARY SYMPTOM SCORE (VUSS) FOR WOMEN</td>
<td>Catherine Lovatt*, Lynn Stothers, Andrew Macnab, Darren Lazare, Vancouver, Canada</td>
</tr>
<tr>
<td>11:20</td>
<td>PD39-12</td>
<td>RISK FACTORS RELATED TO POST-PROSTATECTOMY INCONTINENCE AND DEVELOPMENT OF PREDICTIVE NOMOGRAMS</td>
<td>Liang Dong*, Jiayi Li, Yinjie Zhu, Jiahua Pan, Bajun Dong, Wei Xue, Yiran Huang, Shanghai, China, People's Republic of</td>
</tr>
</tbody>
</table>
**Podium Session 40**

**PROSTATE CANCER: DETECTION & SCREENING V**

Room 162 @ Boston Convention & Exhibition Center

**Moderators:** Adam Kibel, Marc Smaldone and Carlo Terrone

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 9:30 | PD40-01 | ARE THERE REGIONAL TENDENCIES TOWARD CONTROVERSIAL SCREENING PRACTICES? A STUDY OF PROSTATE AND BREAST CANCER SCREENING IN A MEDICARE POPULATION  
Eric Raffin*, Tracy Onega, Julie Bynum, Andrea Austin, Donald Carmichael, Philip Goodney, Elias Hyams, Lebanon, NH |
| 9:40 | PD40-02 | RE-EXAMINING PSA DENSITY: DEFINING THE OPTIMAL PSA RANGE AND PATIENTS FOR USING PSA DENSITY TO PREDICT PROSTATE CANCER USING EXTENDED TEMPLATE BIOPSY  
Joshua Jue*, Marcelo Panizzutti, Nachiketh Prakash, Vivek Venkatramani, Varsha Sinha, Nicola Pavan, Bruno Nahar, Pratik Kanabur, Michael Ahdoot, Ramgopal Satyanarayana, Dipen Parekh, Sanoj Punnen, Miami, FL |
| 9:50 | PD40-03 | EFFECT OF 5-ALFA REDUCTASE INHIBITOR USAGE ON OUTCOMES OF PROSTATE CANCER SCREENING  
Teemu Murtola*, Annina Virku, Tampere, Finland, Kirsi Talala, Ulf-Håkan Stenman, Kimmo Taari, Helsinki, Finland, Teuvo Tammela, Anssi Auvinen, Tampere, Finland |
| 10:00 | PD40-04 | COMMUNITY-BASED PROSTATE CANCER SCREENING IN JAPAN: PREDICTING FACTORS FOR POSITIVE REPEAT BIOPSY  
So Ushijima, Koji Okihara*, Koji Kitamura, Kazumi Kamoi, Osamu Ukimura, Kyoto, Japan |
| 10:10 | PD40-05 | DETERMINANTS OF DEFAULT FROM FOLLOW-UP CARE IN A PROSTATE CANCER SCREENING PROGRAM  
Mark Ferretti*, New York, NY, Michael Goltzman, Akhil Saji, Neel Patel, Denton Allman, Sean Fullerton, Gerald Matthews, John Phillips, Valhalla, NY |
| 10:20 | PD40-06 | A FOUR-KALLIKREIN PANEL IN PREDICTING HIGH-GRADE PROSTATE CANCER ON BIOPSY: AN INDEPENDENT REPPLICATION FROM THE FINNISH SECTION OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER  
| 10:30 | PD40-07 | DOES EARLY PSADT (EPSADT) AFTER RADICAL PROSTATECTOMY, CALCULATED PRIOR TO PSA RECURRENCE, CORRELATE WITH PROSTATE CANCER (PC) OUTCOMES? RESULTS FROM THE SEARCH DATABASE  
Anna Teeter, Kirkland, WA, Kagan Griffin*, Lauren Howard, Durham, NC, William Aronson, Los Angeles, CA, Martha Terris, Augusta, GA, Christopher Kane, San Diego, CA, Christopher Amling, Portland, OR, Matthew Cooperberg, San Francisco, CA, Stephen Freedland, Los Angeles, CA |
| 10:40 | PD40-08 | COMBINING 4KSCORE AND MRI FOR PROSTATE BIOPSY DECISION MAKING  
Karim Marzouk*, Behfar Ehdai, New York City, NY, Stephen Zappala, Andover, MA, Andrew Vickers, New York City, NY |
| 10:50 | PD40-09 | EVALUATION OF PREBIOPSY MAGNETIC RESONANCE IMAGING COMBINED WITH PROSTATE-SPECIFIC ANTIGEN DENSITY IN THE DIAGNOSIS OF PROSTATE CANCER IN MEN AGED 75 YEARS AND OLDER WITH ELEVATED PSA  
Yoshinori Yanai*, Takeo Kosaka, Yu Teranishi, Seiya Hattori, Kazuhiro Matsumoto, Shinya Morita, Kazunobu Shioda, Toshiaki Shinojima, Ryuichi Mizuno, Eiji Kikuchi, Shuji Mikami, Masahiro Jinzaki, Akira Miyajima, Mototsugu Oya, Tokyo, Japan |
| 11:00 | PD40-10 | EFFECTS OF THE 2012 USPSTF PSA SCREENING RECOMMENDATIONS ON PROSTATE BIOPSY PRACTICES IN AN INNER CITY HOSPITAL WITH A HIGH RISK PATIENT POPULATION  
| 11:10 | PD40-11 | IMPACT OF PRIMARY CARE PHYSICIAN FACTORS ON ADHERENCE TO UNITED STATES PREVENTATIVE SERVICES TASK FORCE RECOMMENDATIONS AGAINST PSA SCREENING  
Ryan Hutchinson*, Nirmish Singla, Solomon Woldu, Abdulhadi Akhtar, Justin Haridas, Deepa Bhat, Claus Roehrborn, Yair Lotan, Dallas, TX |
11:20 PD40-12 DO SICKER PEOPLE HAVE WORSE PROSTATE CANCER-SPECIFIC OUTCOMES AFTER RADICAL PROSTATECTOMY? RESULTS FROM SEARCH

Anna Teeter, Kirkland, WA, Xia Sun, Lauren Howard*, Durham, NC, William Aronson, Los Angeles, CA, Christopher Kane, San Diego, CA, Christopher Amling, Durham, NC, Matthew Cooperberg, San Francisco, CA, Martha Terris, Augusta, GA, Stephen Freedland, Los Angeles, CA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017 10:15 am - 4:15 pm

Forums

15TH INTERNATIONAL PROSTATE FORUM
Room 205BC @ Boston Convention & Exhibition Center

10:15 15TH IPF INTRODUCTIONS AND AUA PCA PROGRAMS
Session Co-Chairs: John Davis, Neal Shore

10:20 SESSION I: PROSTATE CANCER DIAGNOSTICS
Moderator: Badar Mian, Cihan Demirel
WHO TO BIOPSY AND REPEAT BIOPSY: MRI, BIOMARKERS, AND THE COST EFFECTIVE QUESTIONS
Alan Partin

10:40 NEWLY DIAGNOSED PROSTATE CANCER: OPTIMAL UTILIZATION OF TISSUE BIOMARKERS AND IMAGING
Robert Reiter

11:00 DISCUSSION
Discussants: Badar Mian, Alan Partin, Robert Reiter, Cihan Demirel

11:10 SESSION II: NON-LETHAL DISEASE
Moderators: Stacy Loeb, Monique Roobol

11:10 ACTIVE SURVEILLANCE AND DIETARY/SUPPLEMENT STRATEGIES
Neil Fleshner, Mark Moyad

11:30 BUILDING AN ACTIVE SURVEILLANCE PROGRAM FOR COMMUNITY PRACTICE
Benjamin Lowentratt, Neal Shore

11:50 DISCUSSION
Moderators: Stacy Loeb, Monique Roobol
Discussants: Neil Fleshner, Benjamin Lowentratt, Mark Moyad, Neal Shore

12:00 BREAK AND VISIT SCIENCE/TECHNOLOGY HALL

1:00 SESSION III: SURGICAL TECHNIQUE
Moderator: John Davis

PANEL DISCUSSION: “THE UBER PROSTATECTOMIST: WHY DID YOU DO THAT AND WHAT CAN YOU PROVE?”
Moderator: John Davis
Panelists: Anthony Costello, Mani Menon, Peter Wiklund

SESSION IV: PCA COMPARATIVE OUTCOMES RESEARCH
Moderator: Derya Tilki, Derya Balbay

INTRODUCTION TO COMPARATIVE OUTCOMES RESEARCH
Jim Hu

BEST OF HEALTH SERVICES RESEARCH
Quoc-Dien Trinh

BEST OF TERTIARY CARE CENTER AND COLLABORATIVE RESEARCH
Andrew Vickers

RP VS XRT—WHAT ABOUT PROPENSITY WEIGHTED STUDIES?
Robert Nam

BEST OF RANDOMIZED TRIALS
John Yaxley

SESSION V: THE BEST OF BOSTON!
Moderators: Richard Babayan, Neal Shore Anthony D’Amico, Jason Efstathiou, Matthew Smith, Christopher Sweeney

ADJOURN
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
### AUA/AMERICAN ASSOCIATION OF CLINICAL UROLOGISTS (AACU) HEALTH POLICY FORUM

**Room 205A @ Boston Convention & Exhibition Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>AUA GUEST SPEAKERS: TELEMEDICINE: STATE OF THE INDUSTRY AND PRACTICAL IMPLICATIONS FOR UROLOGY</td>
<td>Alexis Gilroy and Yulun Wang</td>
</tr>
<tr>
<td>2:00</td>
<td>AACU HOFFMAN LECTURER: MEDICARE PHYSICIAN PAYMENT REFORM: OPPORTUNITIES AND CHALLENGES FOR UROLOGY</td>
<td>Robert Mechanic</td>
</tr>
<tr>
<td>3:00</td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

### FUNDING OPPORTUNITIES AND GRANT WRITING GUIDANCE FOR EARLY-CAREER INVESTIGATORS

**Room 210C @ Boston Convention & Exhibition Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>OVERVIEW AND GOALS</td>
<td>Carolyn Best</td>
</tr>
<tr>
<td>1:05</td>
<td>NIDDK TRAINING AND RESEARCH MECHANISMS</td>
<td>Tracy L. Rankin</td>
</tr>
<tr>
<td>1:20</td>
<td>NIA FUNDING OPPORTUNITIES FOR UROLOGIC RESEARCH AND TRAINING</td>
<td>Candace Kerr</td>
</tr>
<tr>
<td>1:35</td>
<td>DOD/CDMRP FUNDING OPPORTUNITIES AND THE APPLICATION REVIEW PROCESS</td>
<td>Donna M. Kimark</td>
</tr>
<tr>
<td>1:50</td>
<td>AMERICAN CANCER SOCIETY FUNDING OPPORTUNITIES</td>
<td>Ellie Daniels</td>
</tr>
<tr>
<td>2:05</td>
<td>AUA AND UROLOGY CARE FOUNDATION OPPORTUNITIES AND EXTERNAL FUNDING SOURCES</td>
<td>Krystal N. Brinson</td>
</tr>
<tr>
<td>2:20</td>
<td>GRANTWRITING 101</td>
<td>Erika Wolff</td>
</tr>
<tr>
<td>2:35</td>
<td>PERSPECTIVES FROM A SENIOR INVESTIGATOR</td>
<td>Dolores J. Lamb</td>
</tr>
<tr>
<td>2:50</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

### SOCIETY FOR INFECTION AND INFLAMMATION IN UROLOGY (SIIU)

**Room 207 @ Boston Convention & Exhibition Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>MEMORIAL FOR JOE DOWNEY</td>
<td></td>
</tr>
<tr>
<td>1:15</td>
<td>THE ROLE OF ORGAN CROSSTALK AND INCREASED PERMEABILITY IN INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME</td>
<td>Robert Hurst</td>
</tr>
<tr>
<td>2:15</td>
<td>RESEARCH PRESENTATIONS</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP56-01</td>
<td>Racial Variations in Response to Intralesional Collagenase Clostridium Histolyticum in Men with Peyronie's Disease</td>
</tr>
<tr>
<td>MP56-02</td>
<td>Safety and Efficacy of Collagenase Clostridium Histolyticum in the Treatment of Active Phase Peyronie's Disease</td>
</tr>
<tr>
<td>MP56-03</td>
<td>Intralesional Collagenase Clostridium Histolyticum Does Not Change Penile Vascular Parameters in Men with Peyronie's Disease</td>
</tr>
<tr>
<td>MP56-04</td>
<td>Safety and Effectiveness of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease Using a New Shortened Protocol</td>
</tr>
<tr>
<td></td>
<td>Amr Abdel Rahem*, Marco Capece, Ayo Kaljaiye, Amr Mobasher, Giulio Garaffa, Nim Christopher, David Ralph, London, United Kingdom</td>
</tr>
<tr>
<td>MP56-05</td>
<td>Towards Standardization of Protocols for Intralesional Collagenase Clostridium Histolyticum (CCH): Survey Results of SMSMA Membership</td>
</tr>
<tr>
<td></td>
<td>Campbell Bryson*, Stanton Honig, New Haven, CT</td>
</tr>
<tr>
<td>MP56-06</td>
<td>Clinical Outcomes of the Use of Collagenase Clostridium Histolyticum (CCH) for Peyronie's Disease (PD)</td>
</tr>
<tr>
<td></td>
<td>Juan Ignacio Martinez-Salamanca*, Natalia Carballo, Eugenio Cerezo, Agustín Fraile, Francois Peinado, Esaú Fernández Pascual, Joaquín Carballo, Madrid, Spain</td>
</tr>
<tr>
<td>MP56-07</td>
<td>Outcomes of Intralesional Collagenase Clostridium Histolyticum (CCH) in Men with Peyronie's Disease</td>
</tr>
<tr>
<td></td>
<td>Jean-Étienne Terrier*, Christian J Nelson, John P Mulhall, New York City, NY</td>
</tr>
<tr>
<td>MP56-08</td>
<td>Candidates for Collagenase Clostridium Histolyticum Therapy: A Retrospective Review of the Structural and Hemodynamic Characteristics of Men with Peyronie's Disease (PD)</td>
</tr>
<tr>
<td></td>
<td>Ram Pathak*, Gregory Broderick, Jacksonville, FL</td>
</tr>
<tr>
<td>MP56-09</td>
<td>Intermediate Outcomes of Concurrent TachoSil Grafting with Inflatable Penile Prosthesis Placement</td>
</tr>
<tr>
<td></td>
<td>Neil Patel*, Kevin McVary, Nikhil Gupta, Springfield, IL, Michael Butcher, Minneapolis, MN, Tobias Kohler, Springfield, IL</td>
</tr>
<tr>
<td>MP56-10</td>
<td>National Trends in Utilization of Penile Prosthesis Surgery in the Treatment of Peyronie's Disease</td>
</tr>
<tr>
<td></td>
<td>Michael Benson*, Newark, NJ, David Shin, Hackensack, NJ, Fatima Elgammal, West Indies, Grenada, Dongfeng Qi, Guanghui Liu, Minnetonka, MN</td>
</tr>
<tr>
<td>MP56-11</td>
<td>Outcome Analysis of Patients with Peyronie's Disease Who Elect for Non-Invasive Management</td>
</tr>
<tr>
<td></td>
<td>Landan MacDonald, St. John, Canada, Kyle Lehmann*, Halifax, Canada, Luke Armstrong, Gavin Langille, St. John, Canada</td>
</tr>
<tr>
<td>MP56-12</td>
<td>Concerns of Female Peyronie's Disease Partners: A Narrative Analysis</td>
</tr>
<tr>
<td></td>
<td>Barbara Chubak*, Fort Lauderdale, FL, Lawrence Hakim, Weston, FL</td>
</tr>
<tr>
<td>MP56-13</td>
<td>Clinical Factors Negatively Impacting Sexual Relationships in Men with Peyronie's Disease</td>
</tr>
<tr>
<td></td>
<td>Matthew Ziegelmann*, Mary Westerman, Brett Watson, Francisco Maldonado, Landon Trost, Rochester, MN</td>
</tr>
<tr>
<td>MP56-14</td>
<td>Predictors of Penile Instability in Men with Peyronie's Disease (PD)</td>
</tr>
<tr>
<td>MP56-15</td>
<td>Beyond Curvature: Prevalence and Characteristics of Penile Volume Loss Deformities in Men with Peyronie's Disease</td>
</tr>
</tbody>
</table>
MP56-16 PATIENT'S CHOICE OF HEALTH INFORMATION AND TREATMENT MODALITY FOR PEYRONIE'S DISEASE
Raevti Bole*, Matthew Ziegelmann, Ross Avant, Jack Andrews, Kevin Hebert, Manaf Alom, Landon Trost, Rochester, MN

MP56-17 THE HISTOPATHOLOGIC EFFECTS OF INTRACAVERNOSAL MITOMYCIN-C INJECTION IN A RAT PEYRONIE'S DISEASE MODEL
Engin Kaya*, Yusuf Kibar, Sercan Yılmaz, Ankara, Turkey, Ayhan Ozcan, Istanbul, Turkey, Burak Kopru, Konya, Turkey, Hasan Cem Irkilata, Turgay Ebioglu, Ankara, Turkey

MP56-18 THE MOUSE CORPUS Cavernosum GLANDUS IS BIOMECHANICALLY ANALOGOUS TO THE HUMAN CORPUS Cavernosum
Matthew Hennefarth*, Ling Chen, San Francisco, CA, Ryan Hsi, Nashville, TN, Misun Kang, Amanda Reed-Maldonado, Guiting Lin, Marshall Stoller, Tom Lue, Sunita Ho, San Francisco, CA

MP56-19 COMPARING PLAQUE MORPHOLOGY BETWEEN MEN DEVELOPING PEYRONIE'S DISEASE (PD) AFTER RADICAL PROSTATECTOMY (RP) TO THAT OF DE NOVO PEYRONIE'S DISEASE PATIENTS
John Sullivan*, Yanira Ortega, Kelly Chiles, Lawrence Jenkins, John Mulhall, New York, NY

MP56-20 COMPARISON OF CLINICIAN AND PATIENT MEASUREMENTS USING A MOBILE PHONE APPLICATION TO ASSESS PENILE ANGULATION
Wayne Brisbane*, Seattle, WA, Ryan Hsi, Nashville, TN, Marc Rogers, Kevin Ostrowski, Hunter Wessells, Thomas Walsh, Seattle, WA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017 1:00 pm - 3:00 pm

Moderated Poster Session 57

PROSTATE CANCER: ADVANCED (INCLUDING DRUG THERAPY) IV
Room 153 @ Boston Convention & Exhibition Center
Moderators: Marcelo Bendhack, Daniel Petrylak and Edward Schaeffer

ABSTRACT NUMBER TITLE
MP57-01 GERMLINE MUTATIONS IN DNA REPAIR GENES ARE SIGNIFICANTLY ENRICHED IN LETHAL PROSTATE CANCER AND ARE ASSOCIATED WITH DISEASE SURVIVAL
Rong Na*, Shanghai, China, People’s Republic of, S. Lilly S. Lilly, Evanston, IL, Misop Han, Baltimore, MD, Hongjie Yu, Deke Jiang, Sameep Shah, Evanston, IL, Charles Ewing, Lili Zhang, Baltimore, MD, Kristian Novakovic, Jacqueline Petkewicz, Kamalakar Gulkota, Donald Helseth Jr, Margo Quinn, Evanston, IL, Elizabeth Humphries, Kathleen Wiley, Sarah Isaacs, Baltimore, MD, Yishuo Wu, Shanghai, China, People’s Republic of, Xu Liu, Evanston, IL, Ning Zhang, Shanghai, China, People’s Republic of, Chi-Hsiung Wang, Janardan Khandekar, Peter Hulick, Daniel Shevrin, Evanston, IL, Kathleen Cooney, Salt Lake City, UT, Zhoujun Shen, Shanghai, China, People’s Republic of, Alan Alan, H. B. Carter, Michael Carducci, Mario Eisenberger, Sam Denmeade, Baltimore, MD, Michael McGuire, Evanston, IL, Patrick Walsh, Baltimore, MD, Brian Helfand, Charles Brendler, Evanston, IL, Qiang Ding, Shanghai, China, People’s Republic of, Jianfeng Xu, Evanston, IL, William Isaacs, Baltimore, MD

MP57-02 TET, SENSITIZES CRPC CELLS TO ENZALUTAMIDE BY PROMOTING CELL DEATH IN PART BY DECREASING LEVELS OF AR AND ARV7
Kashyap Koul, Sweaty Koul, Quin Dong, Hari Koul*, Shreveport, LA

MP57-03 IDENTIFICATION AND CHARACTERIZATION OF SELECTIVE ANDROGEN RECEPTOR DEGRADERS (SARDS) FOR THE TREATMENT OF ENZALUTAMIDE UNRESPONSIVE AND/OR RESISTANT PROSTATE CANCER
Suriyan Ponnusamy, Robert Geltenberg, Thirumagal Thiyagarajan, Dong-Jin Hwang, Yali He, Memphis, TN, Iain McEwan, Carolyn Watt, Aberdeen, United Kingdom, Tudor Moldoveanu, Duane Miller, Ramesh Narayanan*, Memphis, TN

MP57-04 NOVEL THERAPIES TARGETING ANDROGEN RECEPTOR VARIANTS IN AN IN VITRO MODEL OF CASTRATE RESISTANT PROSTATE CANCER
Joseph A. Baiocco*, Michael Moses, Matthew J. Watson, Raju Chelluri, Bethesda, MD, Jason Gestwicki, San Francisco, CA, Jane Trepel, Len Neckers, Bethesda, MD

*Presenting author
MP57-05 LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

MP57-06 MANAGEMENT OF ENZALUTAMIDE-RELATED ADVERSE EVENTS FOR CRPC PATIENTS BY USING PATIENT REPORTED OUTCOMES LEADS BETTER PROGNOSIS
Taro Iguchi*, Sayaka Yasuda, Minoru Kato, Takeshi Yamasaki, Yasuomi Shimizu, Yuji Takeyama, Satoshi Tamada, Tatsuya Nakatani, Osaka, Japan

MP57-07 PATIENT-IDENTIFIED FACTORS AFFECTING TREATMENT DECISIONS FOR ADVANCED PROSTATE CANCER
Kelvin Moses*, Liping Du, Nashville, TN, Ivy Ahmed, Bowling Green, KY, David Penson, Alicia Morgans, Nashville, TN

MP57-08 POPULATION-BASED ANALYSIS OF TREATMENT TOXICITY AMONG MEN WITH CASTRATION-RESISTANT PROSTATE CANCER
Robert Nam*, Christopher Wallis, Refik Sasaki, Symron Bansal, Urban Emmenegger, Raj Sathkunisivam, Toronto, Canada

MP57-09 CHEMICAL CASTRATION DECREASED THE RISK OF DEMENTIA IN PATIENT WITH PROSTATE CANCER - FROM 13368 PATIENTS, TAIWAN NATIONAL HEALTH INSURANCE RESEARCH DATABASE
Chieh-Chun Liao, Jian-Hua Hong, Yu-Chuan Lu*, Chao-Yuan Huang, Taipei, Taiwan

MP57-10 RELATIONSHIP BETWEEN QUALITY OF LIFE AND OVERALL SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN ALSYMPCA: ANALYSIS BY PRIOR DOCETAXEL SUBGROUP
Neal D. Shore*, Myrtle Beach, SC, Sten Nilsson, Stockholm, Sweden, Oliver Sartor, New Orleans, LA, Nicholas J. Vogelzang, Las Vegas, NV, Robert E. Coleman, Sheffield, United Kingdom, Joe M. O’Sullivan, Belfast, United Kingdom, Daniel Heinrich, Larenoskog, Norway, David Bottomley, Leeds, United Kingdom, Peter Hoskin, Middlesex, United Kingdom, Lars Franzen, Sundsvall and Umeå, Sweden, Arne Solberg, Trondheim, Norway, Jonathan Reunng-Scherer, New Haven, CT, Lin Zhan, Whippany, NJ, Christopher Parker, Sutton, United Kingdom

MP57-11 ANDROGEN-DEPRIVATION THERAPY AND CARDIOVASCULAR RISK (ADTCR): A NATIONWIDE POPULATION-BASED COHORT STUDY
Lucie-Marie Scailteux*, Sébastien Vincendeau, Frédéric Balusson, Christophe Leclercq, André Happe, Béranger Le Nautout, Elisabeth Polard, Emmanuel Nowak, Emmanuel Oger, Rennes, France

MP57-12 SHORT-TERM ANDROGEN DEPRIVATION THERAPY INCREASES BRAIN-TYPE NATRIURETIC PEPTIDE LEVELS IN PATIENTS WITH PROSTATE CANCER: POSSIBLE ADVERSE IMPACT ON CARDIAC FUNCTION
Masaya Ito*, Masaharu Inoue, Hajime Tanaka, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Noboru Numao, Yoh Matsuoka, Kazutaka Saito, Kazunori Kihara, Yasuhisa Fuji, Tokyo, Japan

MP57-13 EARLY CARDIVASCULAR MORBIDITY IN A PILOT PROSPECTIVE RANDOMIZED TRIAL COMPARING LH-RH AGONIST AND ANTAGONIST AMONG PATIENTS WITH ADVANCED PROSTATE CANCER
David Margel, Petah-Tikva, Israel, Avivit Peer, Haifa, Israel, Yaara Ber, Petah-Tikva, Israel, Marina Shaparberg, Haifa, Israel, Sivan Sela, Rachel Ozalvo, Jack Baniel, Petah-Tikva, Israel, Wilhelmima Duivenvoorden, Jehonathan Finthus*, Hamilton, Canada

MP57-14 THE ASSOCIATION OF BMI AND DM WITH SURVIVAL AMONG PATIENTS WITH METASTATIC OR CASTRATION-RESISTANT PROSTATE CANCER
Zachary A Glaser*, Svetlana Avulova, Blair Stocks, David F Penson, Kelvin A Moses, Nashville, TN

MP57-15 PREDICTIVE FACTORS OF DYSLIPIDEMIA IN PATIENTS WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER: A PROSPECTIVE STUDY
Oka Ryo*, Sakura, Japan, Takanobu Utumi, Chapel Hill, NC, Takumi Endo, Masashi Yano, Syuichi Kamijma, Daisuke Nishimi, Naoto Kamiya, Hiroyoshi Suzuki, Sakura, Japan

MP57-16 METABOLIC SYNDROME IN PATIENTS WITH PROSTATE CANCER UNDERGOING INTERMITTENT ANDROGEN-DEPRIVATION THERAPY
Mohammadali Mohammadzadeh Rezaei, Alireza Ghorbati*, Mohammadhadi Mohammadzadeh Rezaei, Behzad Feyzadeh Kerigh, Mashhad, Islamic Republic of Iran
MP57-17 POLYMER DELIVERED, SUBCUTANEOUSLY ADMINISTERED LEUPROLIDE ACETATE PROVIDES STABLE AND LONG-TERM DRUG DELIVERY AND TESTOSTERONE SUPPRESSION ACROSS 4 PIVOTAL TRIALS
Franklin Chu*, San Bernardino, CA, John McLane, Fort Collins, CO, Stuart Atkinson, Debbie Boldt-Houle, Lincolnshire, IL, Christopher Pieczonka, Syracuse, NY

MP57-18 DEVELOPMENT AND VALIDATION OF NOVEL GENOMIC CLASSIFIERS FOR PREDICTION OF ADVERSE PATHOLOGY AFTER PROSTATECTOMY
Firas Abdollah*, Detroit, MI, Hussam Al-Deen Ashab, Vancouver, Canada, R. Jeffrey Karnes, Rochester, MN, John W. Davis, Houston, TX, Nicholas Erho, Qiqi Wang, Ewan A. Gibb, Zaid Haddad, Voleak Cheoumg, Kasra Yousefi, Elai Davicioni, Vancouver, Canada, Christopher J. Kane, San Diego, CA, Robert Den, Philadelphia, PA, Ashley E. Ross, Baltimore, MD, Eric A. Klein, Cleveland, OH

MP57-19 TARGETING AKR1C3 ACTIVATION BY INDOMETHACIN OVERCOMES RESISTANCE TO ENZALUTAMIDE AND ABIRATERONE
Chengfei Liu*, Wei Lou, Joy Yang, Chong-Xian Pan, Marc Dall’Era, Christopher Evans, Allen Gac, Sacramento, CA

MP57-20 DIFFERENTIATING CLINICALLY SIGNIFICANT FROM INSIGNIFICANT BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
Alexandr Pinkhasov, Ruben Pinkhasov*, Ahmed Hussein, Kristopher Atwood, Elena Pop, Gaybrielle James, James Mohler, Buffalo, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017 1:00 pm - 3:00 pm
Moderated Poster Session 58
BLADDER CANCER: INVASIVE V
Room 156 @ Boston Convention & Exhibition Center
Moderators: Eugene Lee, Arturo Medoza-Valdes and Dipen Parekh

ABSTRACT NUMBER TITLE
MP58-01 INCOMPLETENESS OF THE TRANSURETHRAL RESECTION AS A PREDICTOR OF ADVERSE PATHOLOGICAL FEATURES AT THE TIME OF RADICAL CYSTECTOMY: IMPLICATIONS FOR NEOADJUVANT CHEMOTHERAPY SELECTION
Marco Moschini*, Marco Bandini, Giusy Burgio, Giovanni La Croce, Emanuele Zaffuto, Andrea Gallina, Milan, Italy, Agostino Mattei, Lucerne, Switzerland, Rocco Damiano, Catanzaro, Italy, Vincenzo Mirone, Naples, Italy, Shahrokh Shariat, Vienna, Austria, Alberto Briganti, Francesco Montorsi, Renzo Colombo, Milan, Italy

MP58-02 GENOMIC DIFFERENCES BETWEEN “PRIMARY” AND “SECONDARY” MUSCLE INVASIVE BLADDER CANCER: IMPLICATIONS FOR NEOADJUVANT CHEMOTHERAPY
Eugene Pietzak*, New York, NY, Aditya Bagrodia, Dallas, TX, Hikmat Al-Ahmadie, Harry Herr, Emily Zabor, David Barron, Qiang Li, Francois Audenet, Samuel Funt, Ahmet Zehir, Maria Arcila, Priscilla Baex, Michael Berger, Nikolaus Schultz, David Solit, Dean Bajorin, Jonathan Rosenberg, Eugene Cha, Bernard Bochner, Gopa Iyer, New York, NY

ABSTRACT NUMBER TITLE
MP58-03 DOSE DENSE MVAC PRIOR TO RADICAL CYSTECTOMY: A RETROSPECTIVE MULTI-INSTITUTIONAL EXPERIENCE
Homayoun Zargar*, Vancouver, Canada, Jay B Shah, Houston, TX, Elisabeth E Fransen van de Putte, Amsterdam, Netherlands, Kylea R. Polvin, London, Canada, Kamran Zargar-Shoshtari, Tampa, FL, Bas W van Rhijn, Amsterdam, Netherlands, Siamak Daneeshmand, LA, CA, Jeff M Holzbeierlein, Kansas City, KS, Philippe E Spiess, Tampa, FL, Eric Winquist, London, Canada, Simon Horenblas, Amsterdam, Netherlands, Colin Dinney, Houston, TX, Peter C Black, Vancouver, Canada, Wassim Kassouf, Montreal, Canada, Homayoun Zargar, Vancouver, Canada

*Presenting author
MP58-04 DENSE DOSE MVAC VERSUS GC IN PATIENTS WITH CT3-4A BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: A REAL WORLD EXPERIENCE
Homayoun Zargar*, Vancouver, Canada, Jay B Shah, Houston, TX, Elisabeth E Fransen van de Putte, Amsterdam, Netherlands, Kylene R Potvin, London, Canada, Kamran Zargar-Shoshtari, Tampa, FL, Bas W. van Rhijn, Amsterdam, Netherlands, Siemak Daneshmand, LA, CA, Jeff M Holzbeierlein, Kansas City, KS, Philippe E Spiess, Tampa, FL, Eric Winquist, London, Canada, Simon Horenblads, Amsterdam, Netherlands, Colin Dinney, Houston, TX, Adrian S. Fairey, LA, CA, Evan Kovac, Cleveland, OH, Laura-Maria Krabbe, Dallas, TX, Michael S Cookson, Oklahoma City, OK, Niels-Erik Jacobsen, Edmonton, Canada, Nilay Gandhi, Baltimore, MD, Joshua Griffin, Kansas City, KS, Jeffrey S Montgomery, Ann Arbor, MI, Nikhil Vasdev, Newcastle Upon Tyne, United Kingdom, Evan Y. Yu, Seattle, WA, Evangelos Xylinas, New York, NY, Nicholas J. Campain, Exeter, United Kingdom, Jo-An Seah, Toronto, Canada, Cesar E Ercole, Cleveland, OH, Srikala S. Sridhar, Toronto, Canada, John S McGarth, Exeter, United Kingdom, Jonathan Aning, Newcastle Upon Tyne, United Kingdom, Shahrrokh F. Shariat, Vienna, Austria, Jonathan L. Wright, Toronto, Canada, Andrew C. Thorpe, Newcastle Upon Tyne, United Kingdom, Todd M. Morgan, Ann Arbor, MI, Petros Grivas, Andrew J Stephenson, Cleveland, OH, Trinity J Bivalacqua, Baltimore, MD, Scott North, Edmonton, Canada, Daniel A. Barocas, Nashville, TN, Yair Lotan, Dallas, TX, Peter C. Black, Vancouver, Canada, Wassim Kassouf, Montreal, Canada

MP58-05 BASAL AND LUMINAL IMMUNOHISTOCHEMICAL PHENOTYPES IN MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMAS (MIBC) TREATED WITH NEOADJUVANT CHEMOTHERAPY (NAC)
Aline C Tregnago*, Maria Del Carmen Rodriguez Pena, Marie-Lisa Eich, Diana Taheri, Hirofumi Nonogaki, Rajni Sharma, David McConkey, Trinity J. Bivalacqua, George J. Netto, Alexander Baras; Baltimore, MD

MP58-06 THE BENEFITS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY WITH PELVIC LYMPH NODE DISSECTION IN PATIENTS WITH UROTHELIAL CARCINOMA OF BLADDER ACCORDING TO THE LYMPH NODE DENSITY ON FINAL PATHOLOGY
Myong Kim*, Jong Keun Kim, Seoul, Korea, Republic of, Myungchan Park, Sang Hyun Park, Busan, Korea, Republic of, In Gab Jeong, Ceryn Song, Jun Hyuk Hong, Choung-Soo Kim, Tai Young Ahn, Hanjong Ahn, Seoul, Korea, Republic of

MP58-07 USE OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH ADVANCED BLADDER CANCER AFTER NEOADJUVANT CHEMOTHERAPY
Wilson Sul*, Emerson Lim, Guarionex DeCastro, James McKiernan, Christopher Anderson, New York, NY

MP58-08 THE B4GALT1 EXPRESSION IS PROGNOSTIC AND PREDICTIVE FOR POSTOPERATIVE ADJUVANT CHEMOTHERAPY BENEFIT IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER
Huyang Xie*, Yu Zhu, Zewei Wang, Qiang Fu, Jiejie Xu, Dingwei Ye, Shanghai, China, People’s Republic of China

MP58-09 PREDICTING LOCAL FAILURE AFTER RADICAL CYSTECTOMY IN BLADDER CANCER PATIENTS: IMPLICATIONS FOR THE SELECTION OF CANDIDATES AT ADJUVANT RADIATION THERAPY
Marco Moschini*, Andrea Gallina, Nicola Fossati, Stefano Luzzago, Milan, Italy, Rocco Damiano, Catanzaro, Italy, Agostino Mattei, Lucerne, Switzerland, Shahrokh Shariat, Vienna, Austria, Vincenzo Mirone, Naples, Italy, Giusy Burgio, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Renzo Colombo, Milan, Italy

MP58-10 PREOPERATIVE HEMOGLOBIN TO PLATELET RATIO AS A PREDICTOR OF SURVIVAL AFTER RADICAL CYSTECTOMY
Giovanni La Croce*, Marco Moschini, Alessandro Nini, Dell’Oglio Paolo, Eugenio Ventimiglia, Ettore Di Trapani, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Andrea Gallina, Renzo Colombo, Milan, Italy

MP58-11 IMPACT OF INTRA- AND POST-OPERATIVE BLOOD TRANSFUSION ON THE INCIDENCE, TIMING AND PATTERN OF DISEASE RECURRENCE AFTER RADICAL CYSTECTOMY
Marco Moschini*, Andrea Gallina, Marco Bandini, Paolo Dell’Oglio, Giovanni La Croce, Giusy Burgio, Milan, Italy, Agostino Mattei, Lucerne, Switzerland, Rocco Damiano, Catanzaro, Italy, Vincenzo Mirone, Naples, Italy, Alberto Briganti, Francesco Montorsi, Andrea Gallina, Renzo Colombo, Milan, Italy, Shahrokh Shariat, Vienna, Austria

MP58-12 CLINICAL DESTINY OF INDETERMINATE PULMONARY NODULES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER

196
MP58-13 IS TRANSURETHRAL RESECTION ALONE ENOUGH FOR DIAGNOSIS HISTOLOGICAL VARIANTS? A SINGLE CENTER STUDY
Marco Moschini*, Renzo Colombo, Milan, Italy, Shahrokh Shariat, Vienna, Austria, Giuse Burgio, Milan, Italy, Rocco Damiano, Catanzaro, Italy, Agostino Mattei, Lucerne, Switzerland, Marco Bandini, Paolo Dell’Oglio, Emanuele Zaffuto, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Andrea Gallina, Milan, Italy

MP58-14 LIMITS OF TRANSURETHRAL RESSECTION IN DETECTING UNCOMMON HISTOLOGICAL VARIANTS WITHIN BULKY BLADDER TUMORS IN REAL-LIFE CLINICAL PRACTICE
Cristina Scalici Gesolfo*, Alessio Guarneri, Sandro Billone, Palermo, Italy, Marco Moschini, Renzo Colombo, Matteo Ferro, Ottavio De Cobelli, Milan, Italy, Alchide Simonato, Vincenzo Serretta, Palermo, Italy

MP58-15 IMPACT OF TUMOR HISTOPATHOLOGIC TYPES ON PATTERN OF TUMOR RECURRENCE AFTER RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER (MIBC)
Ahmed Mansour*, Mahmoud Laymon, Mohamed M. Elsadadany, Ahmed Mosbah, Shaaban A.A., Hassan Abol-enein, Mansoura, Egypt

MP58-16 ONCOLOGIC OUTCOMES OF SQUAMOUS CELL CARCINOMA VERSUS UROTHELIAL CARCINOMA WITH SQUAMOUS DIFFERENTIATION AFTER RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER (MIBC)
Mahmoud Laymon*, Ahmed Mansour, Mohamed M. Elsadadany, Ahmed Mosbah, Shaaban A.A., Hassan Abol-enein, Mansoura, Egypt

MP58-17 PREVALENCE OF ADVANCED BLADDER CANCER IN SQUAMOUS CELL VS. UROTHELIAL CELL CARCINOMA-IMPLICATIONS FOR DIFFERENCES IN ONCOLOGIC OUTCOME
Gerald Schulz*, Tobias Grimm, Alexander Buchner, Friedrich Jokisch, Markus Grabbert, Birte-Swantje Schneevoigt, Alexander Kretschmer, Christian Stief, Alexander Karl, 81377 Munich, Germany

MP58-18 UNRELIABILITY OF COMPARING LYMPH NODE YIELDS BETWEEN INSTITUTIONS
Ronney Abaza*, Janice Rosenthal, Jatin Gupta, Dublin, OH

MP58-19 SURGICAL TREATMENT FOR CLINICAL NODE POSITIVE BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY
Marco Moschini*, Andrea Gallina, Giovanni La Croce, Ettore Di Trapani, Giuse Burgio, Milan, Italy, Agostino Mattei, Lucerne, Switzerland, Shahrokh Shariat, Vienna, Austria, Rocco Damiano, Catanzaro, Italy, Vincenzo Mirone, Naples, Italy, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Renzo Colombo, Milan, Italy

MP58-20 PATTERN OF POSITIVE NODE METASTASES IN PATIENTS TREATED WITH EXTENDED AND SUPER EXTENDED PELVIC LYMPH NODE DISSECTION AND RADICAL CYSTECTOMY DUE TO BLADDER CANCER
Marco Moschini*, Renzo Colombo, Nazareno Suardi, Giuse Burgio, Marco Bandini, Emanuele Zaffuto, Milan, Italy, Rocco Damiano, Catanzaro, Italy, Agostino Mattei, Lucerne, Switzerland, Vincenzo Mirone, Naples, Italy, Shahrokh Shariat, Vienna, Austria, Alberto Briganti, Francesco Montorsi, Renzo Colombo, Milan, Italy

APPROVED FORAMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017
1:00 pm - 3:00 pm
Moderated Poster Session 59
KIDNEY CANCER: LOCALIZED: SURGICAL THERAPY IV
Room 160 @ Boston Convention & Exhibition Center
Moderators: Monish Aron, Umberto Capitanio and R. Houston Thompson

ABSTRACT NUMBER TITLE
MP59-01 IS RETRO THE WAY FORWARD? RETROPERITONEAL ROBOTIC-ASSISTED PARTIAL Nephrectomy: SINGLE INSTITUTION EXPERIENCE
Muddassar Hussain*, Joanne Oakley, Georg Muller, Amr Emara, Neil Barber, Surrey, United Kingdom

ABSTRACT NUMBER TITLE
MP59-02 ANALYSIS OF THE IMPACT OF ASSISTANT SURGEON EXPERIENCE ON PERI-OPErATIVE OUTCOMES OF ROBOTIC PARTIAL Nephrectomy

*Presenting author
MP59-03 MAY ROBOT-ASSISTED PARTIAL NEPHRECTOMY BE TAUGHT TO FELLOWS WITHOUT AFFECTING PERIOPERATIVE OUTCOMES?  
Zine-Eddine Khene*, Benoit Peyronnet, Elise Bosquet, Benjamin Pradère, Gregory Verhoest, Romain Mathieu, Solène-Florenc Kammerer-Jacquet, Nathalie Rioux-Leclercq, Karim Bensalah, Rennes, France

MP59-04 CONVERSION OF ROBOTIC PARTIAL TO RADICAL NEPHRECTOMY; A PROSPECTIVE MULTI-INSTITUTIONAL STUDY  
Brian Chun*, Deepansh Dalela, Mouafak Tourojman, Detroit, MI, Ronney Abaza, Dublin, OH, Rajesh Ahlewat, Gurgaon, India, James Adshead, Stevenage, UK, Prokar Dasgupta, London, UK, Daniel Moon, Melbourne, Australia, Giacomo Novara, Padua, Italy, Francesco Porpiglia, Orbassano, Italy, Mahendra Bhandari, Detroit, MI, Alexander Mottrie, Aalst, Belgium, Craig Rogers, Detroit, MI

MP59-05 CRITICAL ANALYSIS AND ASSESSMENT OF CLINICAL UTILITY OF NEPHROMETRY SCORES FOR THE PREDICTION OF COMPLICATIONS AFTER NEPHRON SPARING SURGERY  
Alessandro Larcher*, Fabio Muttin, Nicola Fossati, Paolo Dell'Oglio, Francesco Ripa, Francesco Trevisani, Cristina Caranzi, Milano, Italy, Alexandre Mottrie, Aalst, Belgium, Zachary Hamilton, Ithaca Derweesh, San Diego, CA, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Roberto Bertini, Umberto Capitanio, Milan, Italy

MP59-06 ANALYSIS OF PREDICTIVE FACTORS ASSOCIATED WITH PROLONGED OPERATIVE TIME DURING ROBOT-ASSISTED PARTIAL NEPHRECTOMY  
Hidekazu Tachibana*, Toshio Takagi, Tsunenori Kondo, Kazunari Tanabe, Tokyo, Japan

MP59-07 POST-OPERATIVE COMPLICATIONS INCREASE THE RISK OF CHRONIC KIDNEY DISEASE AFTER ELECTIVE NEPHRON SPARING SURGERY  
Eugenio Ventimiglia*, Alessandro Larcher, Fabio Muttin, Paolo Dell'Oglio, Nini Alessandro, Francesco Ripa, Francesco Trevisani, Cristina Caranzi, Milano, Italy, Ithaca Derweesh, Zachary Hamilton, San Diego, CA, Federico Deho, Andrea Salonia, Francesco Montorsi, Roberto Bertini, Umberto Capitanio, Milano, Italy

MP59-08 EXTERNAL VALIDATION OF RENAL TUMOUR CONTACT SURFACE AREA (CSA) IN PATIENTS WHO UNDERWENT PARTIAL NEPHRECTOMY  
Marta Rossanese, Udine, Italy, Valeria Lami, Padua, Italy, Fabio Zattoni*, Padua and Udine, Italy, Alessandro Crestani, Barbara Grossetti, Gianluca Giannarini, Vincenzo Ficarra, Udine, Italy

MP59-09 FUNCTIONAL CHANGE OF CONTRALATERAL KIDNEY AFTER PARTIAL NEPHRECTOMY USING DIETHYLENE TRIAMINE PENTACARBOXYLIC ACID (DTPA) RENAL SCINTIGRAPHY: LONG TERM ANALYSIS  
Se Young Choi, Jeman Ryu*, Jae Hyeon Han, Wonchul Lee, Han Kyu Chae, Sangjun Yoo, Dalsan You, In Gab Jeong, Cheryn Song, Bumsik Hong, Hanjong Ahn, Cheong-Soo Kim, Seoul, Korea, Republic of

MP59-10 EVALUATING KIDNEY VOLUME LOSS AFTER PARTIAL NEPHRECTOMY: COMPARING IMMEDIATE POSTOPERATIVE TO 6 MONTH VOLUME LOSS USING THREE-DIMENSIONAL MODELING  
Clinton Bahler*, Chandru Sundaram, Indianapolis, IN, Tsunenori Kondo, Tokyo, Japan

MP59-11 CLINICAL APPLICATION OF CALCULATED SPLIT RENAL VOLUME USING COMPUTED TOMOGRAPHY-BASED VOLUMETRY AFTER PARTIAL NEPHRECTOMY: CORRELATION WITH 99mTc-DMSA RENAL SCAN DATA  
Chan Ho Lee*, Ja Yoon Ku, Hong Koo Ha, Busan, Korea, Republic of

MP59-12 VALIDATION OF A MATHEMATICAL MODEL TO PREDICT RENAL FUNCTION AFTER NEPHRON SPARING SURGERY  

MP59-13 A USEFUL METHOD FOR ASSESSING DIFFERENCES OF COMPENSATORY HYPERPLASIA IN THE CONTRALATERAL KIDNEY BEFORE AND AFTER RADICAL NEPHRECTOMY IN PATIENTS WITH RENAL CELL CARCINOMA: ELLIPSOID FORMULA ON COMPUTED TOMOGRAPHY  
Bong Hee Park, Sung Hak Kang*, Joon Se Jung, Sang Rak Bae, Yong Seok Lee, Chang Hee Han, Uijeongbu-Si, Korea, Republic of

MP59-14 RENAL FUNCTIONAL OUTCOMES IN PATIENTS UNDERGOING PARTIAL NEPHRECTOMY OR PERCUTANEOUS CRYOABlation FOR A SOLITARY RENAL MASS  
Ross Mason*, Thomas Atwell, Bimal Bhindi, Grant Schmit, Adam Weisbrod, Christine Lohse, Stephen A. Boorjian, Bradley Leibovich, R. Houston Thompson, Rochester, MN

MP59-15 LONG-TERM OUTCOMES AFTER RENAL CANCER SURGERY: PREDICTORS OF CHRONIC KIDNEY DISEASE AND NON-RENAL CANCER MORTALITY  
Joseph Zabell*, Sevag Demirjian, Steven C. Campbell, Cleveland, OH
MP59-16 VASCULARIZED PARENCHYMAL MASS PRESERVATION WITH PARTIAL NEPHRECTOMY: FUNCTIONAL IMPACT AND PREDICTIVE FACTORS
Jitao Wu*, Wen Dong, Chalairat Suk-Ouchai, Elvis Antonio Carabello, Erick Remer, Jianbo Li, Joseph Zabell, Sudhir Ishwarwal, Steven Campbell, Cleveland, OH

MP59-17 SUBCLINICAL Rhabdomyolysis: An Under-Recognized Contributor to Postoperative Acute Kidney Injury in Patients Undergoing Minimally Invasive Urologic Surgery
Jim Shen, Mohamed Kheilla, Samuel Abourbih*, Patrick Yang, Ingrid Wahjudi, Liang Ji, Salim Cheriyani, Nazih Khater, D. Duane Baldwin, Loma Linda, Ca

MP59-18 IMPACT OF MAYO ADHESIVE PROBABILITY SCORE ON THE COMPLEXITY OF ROBOT-ASSISTED PARTIAL NEPHRECTOMY
Ryo Ishiyama*, Tsunenori Kondo, Toshio Takagi, Junpei Izuka, Hirohito Kobayashi, Kenji Omae, Norihiro Fukuda, Hiroki Ishihara, Kazunari Tanabe, Tokyo, Japan

MP59-19 OUTCOME OF KIDNEY FUNCTION AFTER ISCHAEMIC AND ZERO-ISCHAEMIC LAPAROSCOPIC AND OPEN NEPHRONSPARING SURGERY FOR RCC
Jan Ebbing*, Basel, Switzerland, Kurt Miller, Frank Friedersdorff, Florian Fuller, Jonas Busch, Berlin, Germany, Hans H. Seifert, Peter Ardelt, Christian Wetterauer, Basel, Switzerland, Justin Collins, Christofer Adding, Paolo Frumento, Stockholm, Sweden, Carsten Kempensteffen, Berlin, Germany

MP59-20 MULTICENTER ANALYSIS OF ONCOLOGIC AND RENAL FUNCTIONAL OUTCOMES OF RADICAL AND PARTIAL NEPHRECTOMY IN STAGE II RENAL CELL CARCINOMA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017
Moderated Poster Session 60
1:00 pm - 3:00 pm

KIDNEY CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY II
Room 252 @ Boston Convention & Exhibition Center
Moderators: Peter Clark and Gopal Gupta

ABSTRACT NUMBER TITLE
MP60-01 DAB2IP STABILIZES P27 VIA SUPPRESSING PI3K/AKT SIGNALING IN RENAL CELL CARCINOMA
Jiancheng Zhou*, Yongyi Cheng, Kaijie Wu, Dalin He, Xi’an, China, People’s Republic of, Jer-Tsong Hsieh, Dallas, TX

MP60-02 IRON DEPRIVATION DOWNREGULATES HIF2-α AND INDUCES CANCER-SPECIFIC APOPTOSIS IN CLEAR CELL RENAL CELL CARCINOMA
Christopher Greene*, Nitika Sharma, Gary Smith, Kenneth Gross, Eric Kauffman, Buffalo, NY

MP60-03 NF2/MERLIN AS A MODULATOR OF INVASIVENESS AND METASTASIS IN RENAL CELL CARCINOMA
Juan Hernandez*, Jason Scovell, Richard Link, Houston, TX

MP60-04 ERK2 PHOSPHORYLATE T-LAK CELL-ORIGINATED PROTEIN KINASE AT SER32 PROMOTES TUMORIGENESIS OF RENAL CANCER
Huimin Sun*, Xi’an, China, People’s Republic of, Juanjuan Xiao, Wuhan, China, People’s Republic of, Lei Zhang, Juntao Yue, Shijie Liu, Junshen Wu, Rongliang Qin, Lijun Yang, Full Wang, Bo Yang, Xi’an, China, People’s Republic of, Feng Zhu, Wuhan, China, People’s Republic of, Chen Shao, Xi’an, China, People’s Republic of

MP60-05 ERYTHROPOIETIN RECEPTOR MAY BECOME A TARGET FOR RENAL CELL CARCINOMA
Teng Li*, Kang Gong, Pengjie Wu, Shengjie Liu, Xianghui Ning, Shuanghe Peng, Jiangyi Wang, Beijing, China, People’s Republic of

MP60-06 HAI-2 REGULATES THE INVASIVE GROWTH OF RCC CELLS IN BONE METASTASIS THROUGH SUPPRESSION OF Matriptase-Induced HGF Activation
Koji Yamasaki*, Toyoharu Kamibeppu, Shoichiro Mukai, Toshiyuki Kamoto, Miyazaki, Japan

*Presenting author
MP60-07 THE CALCIUM-SENSING RECEPTOR (CASR) IS RESPONSIBLE FOR THE DEVELOPMENT OF BONE METASTASIS IN RENAL CANCER
Sebastian Frees*, Vancouver, Canada, Tobias Haber, Mainz, Germany, Igor Moskalev, Vancouver, Canada, Ines Breuksch, Mainz, Germany, Werner Struss, Vancouver, Canada, Joachim Thüroff, Mainz, Germany, Martin Gleave, Vancouver, Canada, Dirk Prawitt, Mainz, Germany, Alan So, Vancouver, Canada, Walburgis Brenner, Mainz, Germany

MP60-08 INTRACRINE ANDROGEN BIOSYNTHESIS IN RENAL CELL CARCINOMA

MP60-09 LIM1 ONCOGENE AS A NEW THERAPEUTIC TARGET IN ADVANCED HUMAN RENAL CELL CARCINOMA
Imène Hamaidi, Sabrina Danilin, Strasbourg, France, Valérien Dormoy, Reims, France, Sylvie Rothhut, Catherine Coquard, Claire Béraud, Mariette Barthelmebs, Véronique Lindner, Hervé Lang, Thierry Massfielder*, Strasbourg, France

MP60-10 LOSS OF PBRM1 INCREASES PROLIFERATION AND INVASION IN RENAL CELL CARCINOMA BY REGULATING CHEMOKINE/Chemokine RECEPTOR INTERACTION PATHWAY SHORT TITLE: PBRM1 AND CHEMOKINE PATHWAYS IN KIDNEY CANCER
Hongkai Wang*, HaiLiang Zhang, DingWei Ye, Shanghai, China, People’s Republic of

MP60-11 EPIGENETIC INACTIVATION OF HOXA11 AS A NOVEL FUNCTIONAL TUMOR SUPPRESSOR FOR RENAL CELL CARCINOMA
Wang Lu*, Cui Yun, Jingdong Sheng, Guanyu Kuang, Yang Yang, Fan Yu, Jin Jie, Zhang Qian, Beijing, China, People’s Republic of

MP60-12 FOLLICULIN TUMOR SUPPRESSOR BINDS TO TRANSLATION INITIATION FACTORS EIF2G & EIF5B AND SUPPRESSES PROTEIN SYNTHESIS
Meike Schneider*, Taha Hagar, Katja Dinkelborg, Syed I.A. Bukhari, Charlestown, MA, Axel Haferkamp, Mainz, Germany, Shobha Vasudevan, Othon Illopolous, Charlestown, MA

MP60-13 LOSS OF FAT MASS AND OBESITY ASSOCIATED GENE (FTO) DECREASES PROLIFERATION AND INVASION IN RENAL CELL CARCINOMA CELL-LINE BY UPREGULATION OF NF-KAPPA B SIGNALING PATHWAY
Hongkai Wang*, JunLong Wu, Hai Liang Zhang, GuoHai Shi, Yao Zhu, DingWei Ye, Shanghai, China, People’s Republic of

MP60-14 THE VON HIPPEL-LINDAU (VHL) TUMOR SUPPRESSOR INHIBITS P53 TARGET GENE EXPRESSION TO PROMOTE APOPTOSIS-RESISTANCE IN CANCER
Adam Kinnaird*, Peter Dromparis, Aristides Boukouris, Vikram Gurtu, Bruno Saleme, Sotiris Zervopoulos, Gopinath Sutendra, Evangelos Michelakis, Edmonton, Canada

MP60-15 MICRORNA-224 PROMOTES TUMOR GROWTH AND PROGRESSION IN CLEAR CELL RENAL CELL CARCINOMA BY DOWN-REGULATION OF EYES ABSENT 4 AS A NEW TUMOR SUPPRESSOR GENE
Nakanori Fuji*, Hiroshi Hirata, Koji Ueno, Junichi Mori, Kosuke Shimizu, Yoshihisa Kawai, Ryo Inoue, Yoshiaki Yamamoto, Hiroaki Matsumoto, Tomoyuki Shimabukuro, Hideyasu Matsuyama, Ube, Japan

MP60-16 CRISPR/CAS9-MEDIATED MIR-210-3P DEPLETION PROMOTED TUMORIGENESIS THROUGH REVIVAL OF TWIST1 IN RENAL CELL CARCINOMA
Hirofumi Yoshino*, Masaya Yonemori, Kazutaka Miyamoto, Kagoshima, Japan, Satoshi Kofuji, Cincinnati, OH, Nijiro Nohata, La Jolla, CA, Hideki Enokida, Masayuki Nakagawa, Kagoshima, Japan

MP60-17 OVEREXPRESSION OF CYP1B1 MEDIATED BY LOSS OF MIR-200C PROMOTES RENAL CELL CARCINOMA TUMORIGENESIS VIA ALTERED EXPRESSIONS OF CDC20 AND DAPK1

MP60-18 LONG NON-CODING RNA HOTAIR PROMOTES CELL MIGRATION VIA UP-REGULATION OF INSULIN GROWTH FACTOR BINDING PROTEIN 2 IN CLEAR CELL RENAL CARCINOMA
Hiromichi Katayama*, Sendai, Japan, Keiichi Tamai, Sadafuni Kawamura, Tatsuo Tochigi, Natori, Japan, Rajvir Dahlia, Yuichiro Tanaka, San Francisco, CA

MP60-19 LONG NONCODING RNA BX357664 REGULATES CELL PROLIFERATION AND EPITHELIAL-TO-MESENCHYMAL TRANSITION VIA INHIBITING TGF-BETA 1/P38/HSP27 SIGNALING IN RENAL CELL CARCINOMA
Yiyang Liu, Zengjun Wang*, Nanjing, China, People’s Republic of
ABSTRACT NUMBER TITLE

MP60-20 IDENTIFICATION OF MICRORNA REGULATING SUNITINIB RESISTANCE IN RENAL CELL CARCINOMA CELLS
Noriya Yamaguchi*, Tetsuya Yumioka, Kunishige Onuma, Hisato Iwamoto, Toshihiko Masago, Shuichi Morizane, Masashi Honda, Mitsuhiko Osaki, Futoshi Okada, Atsushi Takenaka, Yonago, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017 1:00 pm - 3:00 pm

Moderated Poster Session 61

PEdiATRICS: Urinary TrACT INFECTION AND VesiCOuRETERAL REFLUX

Room 253 AB @ Boston Convention & Exhibition Center

Moderators: Hillary Copp, Abdol-Muhammad Kajbafzadeh and Caleb Nelson

ABSTRACT NUMBER TITLE

MP61-01 IMPACT OF POSITIVE PREOPERATIVE URINE CULTURES BEFORE PEDIATRIC LOWER URINARY TRACT RECONSTRUCTIVE SURGERY UTILIZING BOWEL
Alexander C Small*, Alejandra Perez, Stanley Desire, Michael J. Lipsky, Justin T. Matulay, Lisa Creelman, Pasquale Casale, Shumyle Alam, New York, NY

MP61-02 MINIMALLY INVASIVE VERSUS OPEN URETERAL REIMPLANTATION: IS THERE A DIFFERENCE IN RATES OF REOPERATION? COMPARISON FROM A LARGE NATIONAL DATABASE
Eric D. Schadler*, William R. Boysen, Christopher Lyttle, Vignesh T. Packiam, Charles U. Nottingham, Mohan S. Gundeti, Chicago, IL

MP61-03 QUALITY OF REPORTING AND FRAGILITY INDEX FOR RANDOMIZED CONTROLLED TRIALS IN THE VESICOURETERAL REFLUX LITERATURE – WHERE DO WE STAND?
Michele Gnech, Toronto, Canada, Mandy Rickard, Hamilton, Canada, Armando J. Lorenzo, Toronto, Canada, Stephanie Sanger, Luis Braga*, Hamilton, Canada

MP61-04 THE IPSILATERAL URETERO-URETEROSTOMY: DOES FUNCTION OF THE OBSTRUCTED MOIETY MATTER?

MP61-05 URINARY CARBOHYDRATE ANTIGEN 19-9 LEVEL AS A NOVEL BIOMARKER FOR EARLY DETECTION OF ACUTE PYELONEPHRITIS
Seyyedeh Sanam Ladi-Seyedian*, Seyyedeh Maryam Kameli, Maslaineh Moghtaderi, Abdol-Mohammad Kajbafzadeh, Tehran, Islamic Republic of Iran

MP61-06 CLINICAL AND PATIENT-CENTERED OUTCOMES ASSOCIATED WITH CHRONIC INTERMITTENT CATHETERIZATION IN THE CHRONIC KIDNEY DISEASE IN CHILDREN COHORT STUDY
J Michael Winer*, Albuquerque, NM, Matthew Matheson, Arlene C. Gerson, Baltimore, MD, Jessica Ming, Toronto, Canada, Bradley A. Warady, Kansas City, MO, Susan L. Furth, Philadelphia, PA, Craig S. Wong, Albuquerque, NM, Jennifer L. Dodson, Baltimore, MD

MP61-07 NATIONAL TRENDS IN VCUG UTILIZATION AFTER THE RELEASE OF THE 2011 AAP GUIDELINES
Ted Lee*, Chandy Ellimmoottil, John Park, Kate Kraft, Vesna Ivancic, Kathryn Marchetti, Tanima Banejee, David Bloom, Julian Wan, Ann Arbor, MI

MP61-08 VOIDING CYSTOURETHROGRAM AND ANTIBIOTIC PROPHYLAXIS FOR PRENATAL HYDRONEPHROSIS: SURPRISING RESULTS FROM A SURVEY OF SFU MEMBERS’ PRACTICE PATTERNS
Adriana Dekirmendjian, Mandy Rickard*, Hamilton, Canada, CD Anthony Herndon, Richmond, VA, Christopher S. Cooper, Iowa City, IA, Armando J. Lorenzo, Toronto, Canada, Bethany Easterbrook, Hamilton, Canada, Rebecca S. Zee, Charlottesville, VA, Natasha Brownrigg, Luis H. Braga, Hamilton, Canada

MP61-09 DISTAL URETERAL DIAMETER RATIO IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH FEBRILE URINARY TRACT INFECTION
Angela M. Arlen*, Siobhan E. Alexander, Paul J. Guidos, Iowa City, IA, Traci Leong, Atlanta, GA, Christopher S. Cooper, Iowa City, IA

*Presenting author
USE OF SINGLE POINT DOSIMETER TO EVALUATE RADIATION DOSE WITH FLUOROSCOPIC VOIDING CYSTOURETHROGRAM IN PEDIATRIC PATIENTS: A PROSPECTIVE PILOT STUDY
Rajeev Chaudhry*, Patrick J Fox, Pankaj Dangle, Wael Abdalla, Helen Bradley, Mark Duranko, Michael Sheetz, Francis X Schneck, Glenn M Cannon, Michael C Ost, Heidi A Stephany, Pittsburgh, PA

A REEVALUATION OF THE RIVUR TRIAL WITH A VALIDATED RISK STRATIFICATION MODEL
Zhan Tao (Peter) Wang*, Yasaman Alam, Irene McAleer, Ahmed Ali, Josh Chamberlin, Orange, CA, Guy Hidas, Jerusalem, Israel, Antoine Khoury, Orange, CA

A CRITICAL REVIEW OF RECENT CLINICAL PRACTICE GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC URINARY TRACT INFECTION USING THE AGREE II TOOL
Michael Chua*, Jessica Ming, Joana Dos Santos, Toronto, Canada, Shang-Jen Chang, Taipei, Taiwan, Jan Michael Silangcruz, Quezon City, Philippines, Mark Bayley, Martin Koyle, Toronto, Canada

COMPLIANCE WITH THE 2011 AAP UTI GUIDELINES FOR VCUG ORDERING BY PROVIDER SPECIALTY

EFFECT OF NEWBORN CIRCUMCISION ON URINARY TRACT INFECTIONS IN PATIENTS WITH AN EARLY DIAGNOSIS OF HYDRONEPHROSIS
Jonathan Ellison*, Geolani Dy, Ben Fu, Sarah Holt, John Gore, Paul Merguerian, Seattle, WA

TECHNICAL VARIABILITY IN ROBOT-ASSISTED LAPAROSCOPIC URETERAL REIMPLANTATION: FEASIBILITY OF A MULTI-INSTITUTIONAL COLLABORATIVE
Emilie Johnson*, Chicago, IL, Michael Kurtz, Boston, MA, Ilina Rosoklija, Edward Gong, Chicago, IL, Duong Tu, Sheila Ryan, Houston, TX, Trudy Kawal, Aseem Shukla, Arun Srinivasan, Philadelphia, PA, Richard Yu, Boston, MA, Bruce Lindgren, Chicago, IL, Chester Koh, Houston, TX

VARIATIONS IN ADHERENCE TO AUA GUIDELINES FOR VESICOURETERAL REFUX
Vijaya Vemulakonda*, Aurora, CO, Nicolette Janzen, Houston, TX, Carter Sevick, Aurora, CO, George Chiang, San Diegp, CA

SPLIT-CUFF NIPPLE URETERONEOCYSTOTOMY FOR REPAIR OF PRIMARY OBSTRUCTED MEGAURETER IN SMALL CAPACITY BLADDER OF INFANTS
Moneer Hanna*, Great Neck, NY

EVOLUTION IN ENDOSCOPIC MANAGEMENT OF URETEROCOELE: LONG-TERM OUTCOMES OF URETEROCOELE DOUBLE PUNCTURE AS A PROMISING TECHNIQUE
Behnam Nabavizadeh, Tehran, Islamic Republic of Iran, Reza Nabavizadeh*, Richmond, VA, Abdol-Mohammad Kajbafzadeh, Tehran, Islamic Republic of Iran

AN INGUINAL APPROACH TO COMPLEX EXTRAVESICAL URETERAL REIMPLANTATION
Adam S. Howe*, Lane S. Palmer, Long Island, NY

ACUTE URETERAL JET ANGLED MEASURED BY PREOPERATIVE ULTRASOUND CORRELATES WITH RESOLUTION OF VESICOURETERAL REFUX TREATED WITH ENDOSCOPIC INJECTION OF SUBURETERIC BULKING AGENTS
Kevin Ginsburg*, Jesse Jacobs, Kahill Saad, Detroit, MI, Theodore Barber, Brian Roelof, Kirstan Meldrum, George Steinhardt, Grand Rapids, MI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD41-01</td>
<td>IMPROVISED SURGICAL OUTCOMES AFTER PREOPERATIVE REHEARSAL USING 3D PRINTED PATIENT SPECIFIC SIMULATION FOR PERCUTANEOUS NEPHROLITHOTOMY (PCNL)</td>
<td>Jonathan Stone*, Rebecca Bonamico, Erdal Erturk, Ahmed Ghazi, Rochester, NY</td>
</tr>
<tr>
<td>1:30</td>
<td>PD41-04</td>
<td>DEVELOPMENT AND VALIDATION OF A NON-TECHNICAL SKILLS ASSESSMENT TOOL FOR ROBOTIC SURGERY</td>
<td>Nicholas Raison*, Thomas Wood, Oliver Brunckhorst, Takashige Abe, Abdullatif Aydin, London, United Kingdom, Andrea Gavazzi, Florence, Italy, Giacomo Novara, Padua, Italy, Nico Buffi, Milan, Italy, Declan Murphy, Melbourne, Australia, Shamim Khan, Ben Challacombe, London, United Kingdom, Henk Van Der Poel, Amsterdam, Netherlands, Craig McIlhenny, Larbert, United Kingdom, Prokar Dasgupta, Kamran Ahmed, London, United Kingdom</td>
</tr>
<tr>
<td>1:40</td>
<td>PD41-05</td>
<td>TRANSFER OF FLEXIBLE URETEROSCOPIC STONE-EXTRACTION SKILL FROM A VIRTUAL REALITY SIMULATOR TO THE OPERATING THEATRE: A PILOT STUDY</td>
<td>Mehdi Aloosh*, Yasser A Noureldin, Sero Andonian, Montreal, Canada</td>
</tr>
<tr>
<td>1:50</td>
<td>PD41-06</td>
<td>ROBOT-ASSISTED TRAINING - EXPERT PERFORMANCE IN FULL IMMERSION SIMULATION, SETTING THE BENCHMARK (CONCURRENT VALIDITY)</td>
<td>Talisa Ross, Nicholas Raison*, Lauren Wallace, Thomas Wood, Catherine Lovegrove, London, United Kingdom, Henk Van der Poel, Amsterdam, Netherlands, Prokar Dasgupta, Kamran Ahmed, London, United Kingdom</td>
</tr>
<tr>
<td>2:00</td>
<td>PD41-07</td>
<td>THE EVALUATION OF A SILICONE RENAL TUMOR MODEL FOR PARTIAL NEPHRECTOMY TRAINING</td>
<td>Steven Monda*, Jonathan Weese, Barrett Anderson, Ramakrishna Venkatesh, Baisong Cheng, Robert Figenhau, St. Louis, MO</td>
</tr>
<tr>
<td>2:20</td>
<td>PD41-09</td>
<td>TEACHING AND EVALUATION OF BASIC URODYNAMIC SKILLS: QUEBEC UROLOGY RESIDENT EXPERIENCE</td>
<td>Samer Shamout*, Sero Andonian, Hani Kabbara, Lysanne Campeau, Montreal, Canada</td>
</tr>
<tr>
<td>2:40</td>
<td>PD41-11</td>
<td>SAFETY OF LIVE SURGERY IN UROLOGY. PROPENSITY SCORED MATCHED ANALYSIS</td>
<td>Gabriel Ogaya*, Eduardo Hernandez-Cardona, Hariharan Palayapalayam, Celebration, FL, Xavier Bonet, L’Hospitalet de Llobregat, Spain, Cathy Jenson, Vipul Patel, Celebration, FL</td>
</tr>
<tr>
<td>2:50</td>
<td>PD41-12</td>
<td>THE QUANTIFIED SURGEON: DEFINING AND VALIDATING CLINICAL PERFORMANCE METRICS DURING ROBOTIC RADICAL PROSTATECTOMY</td>
<td>Andrew Hung*, Los Angeles, CA, Jian Chen, Los Angeles, CA, Anthony Jarc, Sunnyvale, CA, Inderbir Gill, Los Angeles, CA</td>
</tr>
<tr>
<td>Time</td>
<td>Number</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>1:00</td>
<td>PD42-01</td>
<td>IMPACT OF PREOPERATIVE ALPHA-ADRENERGIC ANTAGONISTS ON URETERAL ACCESS SHEATH INSERTION FORCE AND THE UPPER LIMIT OF FORCE TO AVOID URETERAL MUCOSAL INJURY: A RANDOMIZED-CONTROLLED STUDY</td>
<td>Kyo Chul Koo*, Joon Ho Yoon, No-Cheol Park, Jongsoo Lee, Jong Won Kim, Jae Yong Jeong, Sung Ku Kang, Jong Chan Kim, Kwang Suk Lee, Do Kyung Kim, Chang Hee Hong, Byung Ha Chung, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>1:10</td>
<td>PD42-02</td>
<td>DEVELOPMENT AND VALIDATION OF A HOMEMADE DEVICE FOR THE MEASUREMENT OF URETERAL ACCESS SHEATH INSERTION FORCE</td>
<td>Kyo Chul Koo*, Joon Ho Yoon, No-Cheol Park, Kwang Suk Lee, Do Kyung Kim, Jong Chan Kim, Sung Ku Kang, Jae Yong Jeong, Jong Won Kim, Jongsoo Lee, Chang Hee Hong, Byung Ha Chung, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>1:20</td>
<td>PD42-03</td>
<td>EFFICACY OF SINGLE URETRAL STENT VERSUS TWO STENT INSERTIONS AFTER BILHARZIAL URETRAL STRICTURE MANAGED BY LASER ENDOURETROTOMY: A RANDOMIZED CONTROLLED STUDY</td>
<td>Khaled Mohyelden*, Mahmoud Shoukry, Hussein Aldaqadossi, Hossam Shaker, Hamdy Ibrahim, Fayoum, Egypt</td>
</tr>
<tr>
<td>1:40</td>
<td>PD42-05</td>
<td>FIRST CLINICAL EVALUATION OF A NEW SINGLE USE FLEXIBLE CYSTOSCOPE DEDICATED TO DOUBLE-J STENT REMOVAL (ISIRIS™): A EUROPEAN PROSPECTIVE MULTICENTER STUDY</td>
<td>Steeve Doizi*, Paris, France, Guido Kamphuis, Amsterdam, Netherlands, Guido Giusti, Milan, Italy, Jose Luis Palmero, Valencia, Spain, Jake Patterson, Sheffield, United Kingdom, Silvia Proietti, Milan, Italy, Michael Straub, Munich, Germany, Jean de la Rosette, Amsterdam, Netherlands, Olivier Traxer, Paris, France</td>
</tr>
<tr>
<td>1:50</td>
<td>PD42-06</td>
<td>ASSESSMENT OF NEW TECHNOLOGY IN URETEROSCOPY: A COMPARISON OF DIGITAL, FIBEROPTIC, AND DISPOSABLE DIGITAL URETEROSCOPES USING A NOVEL EVALUATION INSTRUMENT</td>
<td>John Roger Bell*, Sara L Best, Kristina L Perrin, Stephen Y Nakada, Madison, WI</td>
</tr>
<tr>
<td>2:00</td>
<td>PD42-07</td>
<td>COMPARATIVE IN VITRO STUDY OF HO:YAG AND TM FIBER LASER LITHOTRIPTERS IN DUSTING MODE OF OPERATION</td>
<td>Petr Glybochko, Moscow, Russian Federation, Gregory Alfschuler, Ilya Yaroslavsky, Marlborough, MA, Andrey Vinarov, Leonid Rapoport, Dmitry Enikeev*, Nikolay Sorokin, Alym Dymov, Moscow, Russian Federation, Victoria Vinnichenko, Fryazino, Russian Federation</td>
</tr>
<tr>
<td>2:10</td>
<td>PD42-08</td>
<td>INTRODUCING A COMBINED ULTRASOUND AND ELECTROMAGNETIC TRACKING DEVICE FOR NAVIGATED SONOGRAPHIC KIDNEY PUNCTURE</td>
<td>Tobias Simpofendörfer*, Alfred Franz, Alexander Seitel, Nasrin Bopp, Claudia Gasch, Markus Hohenfellner, Lena Maier-Hein, Dogu Teber, Heidelberg, Germany</td>
</tr>
<tr>
<td>2:30</td>
<td>PD42-10</td>
<td>COMPARISON OF LONG-TERM NON-METALLIC STENTS FOR MALIGNANT VS. NON-MALIGNANT URETERAL OBSTRUCTION</td>
<td>Amar P. Patel*, Jeffrey Pearl, John G. Pattaras, Atlanta, GA</td>
</tr>
<tr>
<td>2:50</td>
<td>PD42-12</td>
<td>DESIGN, FABRICATION, AND TESTING OF PATIENT-SPECIFIC CONCENTRIC TUBE ROBOTS FOR NONLINEAR RENAL ACCESS AND MASS ABLATION</td>
<td>Tania Morimoto, Joseph Greer, Elliot Hawkes, Allison Okamura, Stanford, CA, Michael Hsieh*, Washington, DC</td>
</tr>
</tbody>
</table>
Podium Session 43
PROSTATE CANCER: DETECTION & SCREENING VI
Room 162 @ Boston Convention & Exhibition Center
Moderators: William Aiken, Chris Bangma and Robert Weiss

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>PD43-01</td>
<td>ASSESSMENT OF TUMOUR-AGGRESSIVENESS IN TRANSPERINEAL MRI/ULTRASOUND-FUSION BIOPSY IN COMPARISON TO TRANSRECTAL SYSTEMATIC PROSTATE BIOPSY IN PATIENTS WITH AND WITHOUT PRIOR BIOPSY</td>
<td>Angelika Borkowetz*, Ivan Platzek, Marieta Toma, Theresa Renner, Martin Baunacke, Michael Froehner, Stefan Zastrow, Manfred Wirth, Dresden, Germany</td>
</tr>
<tr>
<td>1:10</td>
<td>PD43-02</td>
<td>MULTICENTRE COMPARISON OF TARGET AND SYSTEMATIC BIOPSY USING MAGNETIC RESONANCE AND ULTRASOUND IMAGE-FUSION GUIDED TRANSPERINEAL PROSTATE BIOPSY IN PATIENTS WITH A PREVIOUS NEGATIVE BIOPSY</td>
<td>Claudia Kesch*, Heidelberg, Germany, Nienke Lynn Hansen, Tristan Barett, Cambridge, United Kingdom, Jan Philipp Radtke, David Bonekamp, Heinz-Peter Schlemmer, Heidelberg, Germany, Anne Warren, Cambridge, United Kingdom, Kathrin Wieczorek, Markus Hohenfellner, Heidelberg, Germany, Christoph Kastner, Cambridge, United Kingdom, Boris Hadaschik, Heidelberg, Germany</td>
</tr>
<tr>
<td>1:20</td>
<td>PD43-03</td>
<td>RISK OF PROSTATE CANCER DIAGNOSIS FOLLOWING A LOW-SUSPICIOUS PROSTATE MRI OR BENIGN MRI-TARGETED BIOPSY: A 3-YEAR FOLLOW-UP STUDY OF MEN WITH PRIOR NEGATIVE TRANSRECTAL ULTRASOUND GUIDED BIOPSY</td>
<td>Lars Boesen*, Nis Nørgaard, Vibeke Løgager, Ingegerd Balslev, Henrik S. Thomsen, Herlev, Denmark</td>
</tr>
<tr>
<td>1:30</td>
<td>PD43-04</td>
<td>COMBINATION OF VERSION 2.0 PROSTATE IMAGING REPORTING AND DATA SYSTEM (PI-RADS) AND PERIPROSTATIC FAT THICKNESS ON MULTIPARAMETRIC MRI TO PREDICT THE PRESENCE OF PROSTATE CANCER</td>
<td>Yudong Cao*, Min Cao, Yuke Chen, Wei Yu, Xiaoying Wang, Jio Jin, Beijing, China, People’s Republic of China</td>
</tr>
<tr>
<td>1:40</td>
<td>PD43-05</td>
<td>ABSENCE OF EVIDENCE IS NOT EVIDENCE OF ABSENCE: NORMAL AREAS ON MRI COULD HARBOUR SIGNIFICANT TUMOUR</td>
<td>Ashwin Sridhar*, Ben Lamb, Gerald Busuttil, London, United Kingdom, Mohammed Zahran, Mansoura, Egypt, Keren Zaccai, Maria Davari, London, United Kingdom, Imran Ahmad, Glasgow, United Kingdom, Anna Mohmed, Greg Shaw, Prabhakar Rajan, Senthil Nathan, Timothy Briggs, Navin Ramachandran, Clare Allen, John Kelly, London, United Kingdom</td>
</tr>
<tr>
<td>1:50</td>
<td>PD43-06</td>
<td>A MULTIVARIATE LOGISTIC REGRESSION INVESTIGATING WHICH FACTORS INFLUENCE DETECTION OF CLINICALLY SIGNIFICANT CANCER BY MRI-TARGETED PROSTATE BIOPSY</td>
<td>Veeru Kasivisvanathan*, Osayuki Nehikhare, Sara Renshaw, Susan Charman, Jan van der Meulen, Shonit Punwani, Alistair Grey, Henrietta Mair, Esmee van der Saar, Ross Warner, Hashim Ahmed, Mark Emberton, Caroline Moore, London, United Kingdom</td>
</tr>
<tr>
<td>2:00</td>
<td>PD43-07</td>
<td>RECTAL SWAB CULTURES AND TARGETED PROPHYLACTIC ANTIMICROBIAL REGIMES DO NOT REDUCE THE RISK OF SEPSIS FOLLOWING TRANSRECTAL PROSTATE BIOPSY</td>
<td>Waseem Mulhem, Marios Hadjipavlou, Mazin Eragat, Charlott Kenny, Martino Dallantonia, Christopher Wood, Mohamed Hammadeh*, London, United Kingdom</td>
</tr>
<tr>
<td>2:10</td>
<td>PD43-08</td>
<td>COMPLICATION RATES FOR OUTPATIENT, TRANSRECTAL, IN-BORE MRI-GUIDED BIOPSY: SEVEN YEARS’ EXPERIENCE</td>
<td>John Feller*, Bernadette Greenwood, Stuart May, Indian Wells, CA</td>
</tr>
<tr>
<td>2:20</td>
<td>PD43-09</td>
<td>COST ANALYSIS OF DIFFERENT PROSTATE BIOPSY MODALITIES</td>
<td>Muammer Altok, John Ward, Brian Chapin, Louis Pisters, Curtis Pettaway, John Davis*, Houston, TX</td>
</tr>
<tr>
<td>2:30</td>
<td>PD43-10</td>
<td>REPEAT PROSTATE BIOPSY PRACTICE PATTERNS IN A STATEWIDE QUALITY IMPROVEMENT COLLABORATIVE</td>
<td>Jonathan C. Hu*, Royal Oak, MI, Khurshid R. Ghani, Ann Arbor, MI, Dinesh Telang, Royal Oak, MI, Alice Liu, Scott Hawken, Zack Montgomery, Susan Linsell, James E. Montie, David C. Miller, Ann Arbor, MI, Frank N. Burks, Royal Oak, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI</td>
</tr>
</tbody>
</table>

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V7-01</td>
<td>INTRAOPERATIVE MRI-GUIDED NAVIGATION OF THE PELVIC FLOOR DURING EXSTROPHY CLOSURE</td>
</tr>
<tr>
<td>V7-02</td>
<td>ROBOTIC ASSISTED ILEOVESICOSTOMY &amp; CECOSTOMY TUBE</td>
</tr>
<tr>
<td>V7-03</td>
<td>ROBOTIC PARTIAL NEPHRECTOMY WITH SELECTIVE CLAMPING FOR RENAL MASS IN</td>
</tr>
<tr>
<td>V7-04</td>
<td>MONS PLASTY: A TECHNIQUE FOR OPTIMAL AESTHETIC OUTCOME</td>
</tr>
<tr>
<td>V7-05</td>
<td>ROBOTIC ASSISTED LAPAROSCOPIC ADRENALECTOMY IN THE SETTING OF AN INCIDENTAL ADRENAL MASS</td>
</tr>
<tr>
<td>V7-06</td>
<td>PERCUTANEOUS EXTERNALLY ASSEMBLED LAPAROSCOPIC (PEAL) SURGERY FOR FOWLER-STEPHENS ORCHIOPEXY: A VIDEO PRESENTATION</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V7-07</td>
<td>ROBOTIC BLADDER NECK RECONSTRUCTION WITH SLING AND SPLIT APPENDIX TECHNIQUE FOR APPENDICOVESICOSTOMY AND MACE</td>
</tr>
<tr>
<td>V7-08</td>
<td>LAPAROSCOPIC NEPHRECTOMY FOR PRENATALLY DIAGNOSED WILMS’ TUMOR</td>
</tr>
<tr>
<td>V7-09</td>
<td>PEDIATRIC ROBOT-ASSISTED LOWER POLE HEMINEPHRECTOMY WITH INTRAURETERAL INDOCYANINE GREEN IN A Duplicated COLLECTING SYSTEM NOT FOLLOWING WEIGERT-MEYER LAW</td>
</tr>
<tr>
<td>V7-10</td>
<td>ROBOTIC ASSISTED LAPAROSCOPIC DISMEMBERED TAPERED URETERAL REIMPLANTATION FOR MEGAURETER</td>
</tr>
<tr>
<td>V7-11</td>
<td>ROBOTIC-ASSISTED LAPAROSCOPIC PARTIAL NEPHRECTOMY FOR A RENAL MASS IN A TWO-YEAR-OLD</td>
</tr>
<tr>
<td>V7-12</td>
<td>ROBOTIC-ASSISTED LAPAROSCOPIC LEFT NEPHROURETERECTOMY OF AN ECTOPIC KIDNEY IN THE MALE</td>
</tr>
</tbody>
</table>

Sunday, May 14, 2017
1:00 pm - 3:00 pm

Video Session 7

PEDIATRICS

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 254 @ Boston Convention & Exhibition Center

Moderators: Gregory Dean, Edward Diaz and David Winkle

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
KOREAN WORLD UROLOGIC CONGRESS (KWUC)
Room 210AB @ Boston Convention & Exhibition Center

1:00 LUNCH AND NETWORKING
1:20 WELCOME ADDRESS
   KUA President: Jun Cheon
   AUA Representative: TBD
1:30 RENAL CELL CARCINOMA: DIAGNOSIS AND TREATMENT OF SMALL RENAL MASS
   Moderators: Monish Aron, Jun Cheon, Isaac Y. Kim
   DISCREPANCY IN RATE OF UNEXPECTED BENIGN HISTOLOGY AFTER RADICAL OR PARTIAL NEPHRECTOMY FOR SMALL RENAL TUMOR BETWEEN KOREA AND THE US
   Seong Il Seo
1:45 BIOPSY AND ACTIVE SURVEILLANCE OF SMALL RENAL MASS
   Christopher G. Wood
2:00 UPDATE ON NON-CLAMPING PARTIAL NEPHRECTOMY: TECHNIQUES AND OUTCOMES
   Monish Aron
2:15 PANEL DISCUSSION
   Case Presenter: Hong Koo Ha
   Panelists: Benjamin Chung, Seong Il Seo, Christopher G. Wood, Monish Aron
2:30 BENIGN PROSTATIC HYPERPLASIA: UPDATES
   Moderators: Myung-Soo Choo, Daniel Eun
   A NEW INSIGHT INTO THE HOLEP
   Seung-June Oh
2:45 UROLIFT SYSTEM: A CRITICAL APPRAISAL
   Eugene Y. Rhee
3:00 OVERACTIVE BLADDER IN BPH: UPDATED PATHOPHYSIOLOGY AND IMPACT OF SURGERY
   Toby C. Chai
3:15 PANEL DISCUSSION
   Case Presentation: Jang Hwan Kim
   Panelists: Kyu-Sung Lee, Toby C. Chai, Eugene Rhee, Seung-June Oh
3:30 PROSTATE CANCER: STATE-OF-THE-ART DIAGNOSIS OF LOW RISK PROSTATE CANCER
   Moderators: Hanjong Ahn, Jonathan Hwang
3:45 COMPARISON OF MR-FUSION PROSTATE BIOPSY TECHNOLOGIES
   Peter A. Pinto
4:00 ROLE OF MRI AND MR-FUSION BIOPSY FOR RECLASSIFICATION OF ACTIVE SURVEILLANCE CANDIDATE
   Chang Wook Jeong
4:15 GENETIC BIOMarkers FOR RISK STRATIFICATION OF LOW-RISK PROSTATE CANCER
   Matthew R. Cooperberg
4:30 PANEL DISCUSSION
   Case Presenter: Sung Gu Kang
   Panelists: Misop Han, Peter A. Pinto, Matthew R. Cooperberg, Chang Wook Jeong
4:45 KUA/SKAU FELLOW/RESIDENT PRESENTATIONS
   TBD
4:51 TBD
5:00 ADJOURN

SOCIETY OF UROLOGIC ROBOTIC SURGERY (SURS)
Marina Ballroom @ Westin Waterfront

1:00 WELCOME AND INTRODUCTION OF PROGRAM
   Chairs: Ashok Hemal, Stephen Nakada
1:10 SESSION I: ROBOTIC SURGERY: FUTURE PERSPECTIVE
   Moderators: Ali Kural, Chandru Sundaram
   NEWER ROBOTIC SYSTEMS IN HORIZON FOR CLINICAL USE
   Koon Rha
1:23 SINGLE-SITE ROBOTIC UROLOGIC SURGERY ON HORIZON FOR CLINICAL USE
   Jihad Kaouk
1:36 HOW TO MAKE AN EFFECTIVE ROBOTIC UROLOGY PROGRAM
   Alex Mottrie
1:50 LESSONS FROM CASEY STENGEL AND YOGI BERRA?
   Mani Menon
2:10 SESSION II: ROBOTIC SURGERY-PROSTATE CANCER
   Moderators: David Lee, Jean Joseph
2:23 TECHNICAL ART OF NERVE SPARING DURING ROBOTIC PROSTATECTOMY
   Ashutosh Tewari

*Presenting author
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:25</td>
<td>HOW TO IMPROVE ONCOLOGIC OUTCOMES</td>
<td>Joseph Smith</td>
</tr>
<tr>
<td>2:40</td>
<td>HOW TO ACHIEVE BEST CONTINENCE OUTCOMES?</td>
<td>Peter Carroll</td>
</tr>
<tr>
<td>2:55</td>
<td>ROBOTIC PROSTATECTOMY FOR LOCAL ADVANCED / OLIGOMETASTATIC PROSTATE CANCER</td>
<td>Francesco Montorsi</td>
</tr>
<tr>
<td>3:10</td>
<td>SESSION III: ROBOTIC SURGERY - KIDNEY CANCER</td>
<td>Moderators: Ketan Badani, Benjamin Lee</td>
</tr>
<tr>
<td>3:21</td>
<td>ROBOTIC PARTIAL NEPHRECTOMY FOR HEREDITARY, MULTIPLE &amp; RECURRENT TUMOURS</td>
<td>Adam Metwalli</td>
</tr>
<tr>
<td>3:33</td>
<td>ROBOTIC IVC THROMBECTOMY</td>
<td>Inderbir Gill</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:48</td>
<td>SHOULD RADICAL NEPHRECTOMY BE THE STANDARD OF CARE</td>
<td>Ronney Abaza</td>
</tr>
<tr>
<td>4:00</td>
<td>SESSION IV: ROBOTIC SURGERY – BLADDER &amp; RECONSTRUCTION</td>
<td>Moderators: Erik Castle, Raju Thomas</td>
</tr>
<tr>
<td>4:15</td>
<td>ROBOTIC RPLND</td>
<td>James Porter</td>
</tr>
<tr>
<td>4:30</td>
<td>ADVANCES IN ROBOTIC URETERAL SURGERY</td>
<td>Michael Stifelman</td>
</tr>
<tr>
<td>4:45</td>
<td>ROBOTIC RADICAL CYSTECTOMY – IMPACT OF CURRENT EVIDENCE</td>
<td>Dipen Parekh</td>
</tr>
<tr>
<td>5:00</td>
<td>SHOULD INTRACORPOREAL DIVERSION BE STANDARD OF CARE?</td>
<td>Khurshid Guru</td>
</tr>
</tbody>
</table>

Sunday, May 14, 2017

SOCIETY FOR THE STUDY OF MALE REPRODUCTION (SSMR)
Room 204 @ Boston Convention & Exhibition Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>INTRODUCTION</td>
<td>James Smith</td>
</tr>
<tr>
<td>1:05</td>
<td>SESSION I: MEASUREMENT OF MALE REPRODUCTION: OPPORTUNITIES FOR TODAY AND TOMORROW</td>
<td>Matthew Cooperberg</td>
</tr>
<tr>
<td>1:20</td>
<td>THE REPRODUCTIVE RISKS OF CHEMO AND RADIATION THERAPY FOR BOYS: LESSONS LEARNED FROM U.S. &amp; GLOBAL COHORTS (AND DATA NEEDS FOR FUTURE)</td>
<td>Daniel Green</td>
</tr>
<tr>
<td>1:35</td>
<td>HEALTH RISKS AND MALE INFERTILITY: UTAH POPULATION DATABASE, ANDROLOGY RESEARCH CONSORTIUM, REPRODUCTIVE MEDICINE NETWORK, NSFG, ET AL. STRENGTHS, WEAKNESSES, AND NEEDS FOR FUTURE</td>
<td>James Hotaling</td>
</tr>
<tr>
<td>1:50</td>
<td>CDC AND SART/NASS DATA: HOW DID WE GET TO 2017? WHAT DATA DO WE HAVE TODAY?</td>
<td>Ajay Nangia</td>
</tr>
<tr>
<td>2:00</td>
<td>CDC, SART – HOW TO UTILIZE THE DATA</td>
<td>Thomas Walsh</td>
</tr>
<tr>
<td>2:10</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>2:20</td>
<td>SESSION II: FERTILITY PRESERVATION: STATE OF THE ART AND VISION OF THE FUTURE</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:20</td>
<td>SESSION III: ACCESS TO REPRODUCTIVE CARE: THE ELEPHANT IN THE ROOM</td>
<td>Akanksha Mehta</td>
</tr>
<tr>
<td>2:40</td>
<td>PHYSICIAN-LEVEL BARRIERS IN PROVIDING REPRODUCTIVE CARE: RVU-BASED INCENTIVE PLANS, INSURANCE COVERAGE FOR REPRODUCTIVE CARE</td>
<td>R. Matthew Coward</td>
</tr>
<tr>
<td>3:20</td>
<td>OUTCOMES OF ONCOTESE: USE OF TISSUE, FRESH, FROZEN, AND RISKS OF BIRTH DEFECTS. CURRENT DATA AND NEEDS FOR THE FUTURE</td>
<td>Sukhinder Minhas</td>
</tr>
<tr>
<td>3:30</td>
<td>PEDIATRIC FERTILITY PRESERVATION AND ETHICAL, MORAL, AND RELIGIOUS IMPLICATIONS: CLINICAL OPTIONS PRESENT AND FUTURE, ASRM, ASCO, AAP GUIDELINES, AUTOLOGOUS TRANSPLANT, CULTURE. ARE OUR TECHNICAL ADVANCES OUTSTRIPPING OUR ETHICAL AND MORAL UNDERSTANDING?</td>
<td>James Smith</td>
</tr>
<tr>
<td>3:45</td>
<td>ADULT MALE FERTILITY PRESERVATION CASE DISCUSSION PANEL</td>
<td>Moderator: Robert Brannigan</td>
</tr>
<tr>
<td>3:45</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>3:45</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>4:00</td>
<td>SESSION III: ACCESS TO REPRODUCTIVE CARE: THE ELEPHANT IN THE ROOM</td>
<td>Akanksha Mehta</td>
</tr>
<tr>
<td>4:05</td>
<td>PHYSICIAN-LEVEL BARRIERS IN PROVIDING REPRODUCTIVE CARE: RVU-BASED INCENTIVE PLANS, INSURANCE COVERAGE FOR REPRODUCTIVE CARE</td>
<td>R. Matthew Coward</td>
</tr>
<tr>
<td>4:20</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Presenter(s)</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>4:30</td>
<td>SESSION IV: DEBATE: ACCESS TO FERTILITY PRESERVATION IS A PRIVILEGE NOT A</td>
<td>Kathleen Hwang</td>
</tr>
<tr>
<td></td>
<td>RIGHT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PATIENTS SHOULD NOT GET UNIVERSAL ACCESS TO FERTILITY PRESERVATION CARE</td>
<td>James Dupree</td>
</tr>
<tr>
<td>4:50</td>
<td>HOW CAN YOU ACTUALLY ACHIEVE UNIVERSAL ACCESS TO FERTILITY PRESERVATION? HEALTH POLICY</td>
<td>Joyce Reinecke</td>
</tr>
<tr>
<td>4:40</td>
<td>PATIENTS SHOULD ALL GET UNIVERSAL ACCESS TO FERTILITY PRESERVATION CARE</td>
<td></td>
</tr>
</tbody>
</table>

Sunday, May 14, 2017

GERIATRIC UROLOGICAL SOCIETY (GUS)
Room 208 @ Boston Convention & Exhibition Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>WELCOME AND INTRODUCTION</td>
<td>Tomas Griebling</td>
</tr>
<tr>
<td>1:10</td>
<td>SESSION I: UNDERACTIVE BLADDER (UAB) UPDATE 2017: WHERE ARE WE AND WHERE</td>
<td>Michael B. Chancellor, Ananias C. Diokno, Noaki Yoshimura, Michelle J. Lajiness, Nitya Abraham</td>
</tr>
<tr>
<td></td>
<td>ARE WEヘADED?</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>SESSION II: ROUNDTABLE DISCUSSION I</td>
<td>Ananias Diokno</td>
</tr>
<tr>
<td>2:00</td>
<td>URODYNAMIC AND MOLECULAR CHARACTERISTICS OF DETRUSOR UNDERACTIVITY IN A</td>
<td>Yao-Chi Chuang</td>
</tr>
<tr>
<td></td>
<td>RATE CRYOINJURY BLADDER MODEL AND EFFECTS OF LOW ENERGY SHOCK WAVE THERAPY</td>
<td></td>
</tr>
<tr>
<td>2:15</td>
<td>EFFECTS OF TRPV4 CHANNEL ACTIVATION IN A RATE MODEL OF UAB AND DHIC</td>
<td>Eiichiro Takaoka</td>
</tr>
<tr>
<td></td>
<td>INDUCED BY PELVIC NERVE INJURY</td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td>HOLEP IN PATIENTS OVER 75 YEARS OF AGE</td>
<td>Jessica Paonessa</td>
</tr>
<tr>
<td>2:45</td>
<td>THIRD LINE THERAPIES FOR OVERACTIVE BLADER (OAB) IN A GERIATRIC POPULATION</td>
<td>Jason Gilleran</td>
</tr>
<tr>
<td></td>
<td>SEEN IN A TERTIARY CARE SPECIALTY CLINIC</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>WISER USE OF PSA IN ASIAN POPULATION FOR PROSTATE CANCER DIAGNOSIS</td>
<td>Anthony C.F. Ng</td>
</tr>
<tr>
<td>3:15</td>
<td>NEITHER PSAD AND CLINICAL T STAGE, NOR ALPHA REDUCTASE INHIBITOR USE</td>
<td>Ibrahim Cevik</td>
</tr>
<tr>
<td></td>
<td>SIGNIFICANTLY AFFECTS PATHOLOGICAL PROGRESS IN GERIATRIC PATIENTS UNDER</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER</td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>3:40</td>
<td>ROUNDTABLE DISCUSSION II</td>
<td>Tomas Griebling</td>
</tr>
<tr>
<td></td>
<td>EFFECT OF AGE ON BLADDER UROTHELIAL HOMEOSTASIS</td>
<td>Lori Birder</td>
</tr>
<tr>
<td>3:55</td>
<td>OVERALL SURVIVAL IN ELDERLY WITH PROSTATE CANCER: A HUNGARIAN POPULATION</td>
<td>Peter Nyirady</td>
</tr>
<tr>
<td></td>
<td>BASED STUDY ANALYZING THE NATIONAL HEALTH INSURANCE FOUND DATABASE</td>
<td></td>
</tr>
<tr>
<td>4:10</td>
<td>URODYNAMIC FINDINGS IN OLDER ADULTS WITH LUTS</td>
<td>Peter Rosier</td>
</tr>
<tr>
<td>4:25</td>
<td>DEVELOPMENT AND IMPLEMENTATION OF A URO-GERIATRICS CLINICAL LIAISON SERVICE</td>
<td>Lewis Chan</td>
</tr>
<tr>
<td>4:40</td>
<td>TREATMENT PATTERNS FOR OVERACTIVE BLADDER AMONG MEDICARE BENEFICIARIES</td>
<td>Charles Scales</td>
</tr>
<tr>
<td>4:55</td>
<td>MINOR UROLOGIC SURGERY AMONG FRAIL ELDERLY PATIENTS</td>
<td>Anne Suskind</td>
</tr>
<tr>
<td>5:10</td>
<td>EVIDENCE BASED CHOICES FOR ANTIBIOTICS FOR UTI IN GERIATRIC UROLOGY</td>
<td>Philippe Zimmer</td>
</tr>
<tr>
<td>5:25</td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
### Forums

#### COMBINED SPU CONGENITALISM WORKING GROUP PROGRAM

Atlantic 3 @ Renaissance Waterfront

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30</td>
<td>PANEL: USE OF BOWEL FOR RECONSTRUCTION</td>
</tr>
<tr>
<td></td>
<td>Moderators: Stephanie Kielb, Jairam Eswara</td>
</tr>
<tr>
<td></td>
<td>Mark Cain, Steve Brandes, Samuel Nurko</td>
</tr>
<tr>
<td></td>
<td>2:15 DEBATE: MANAGEMENT OF NEUROGENIC BOWEL EMPTYING</td>
</tr>
<tr>
<td></td>
<td>Moderator: John Wiener</td>
</tr>
<tr>
<td></td>
<td>Alan Goldstein, Belinda Dickie, Fiona Paul</td>
</tr>
<tr>
<td>2:45</td>
<td>ADJOURN</td>
</tr>
</tbody>
</table>

#### APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

### British Association of Urological Surgeons (BAUS), BJUI and Urological Society of Australia and New Zealand (USANZ)

Grand Ballroom CDE @ Westin Waterfront

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00</td>
<td>PERSONALISED MEDICINE</td>
</tr>
<tr>
<td></td>
<td>Chair: Prokar Dasgupta</td>
</tr>
<tr>
<td></td>
<td>PERSONALISED MEDICINE FOR BLADDER CANCER</td>
</tr>
<tr>
<td></td>
<td>Bernard Bochner</td>
</tr>
<tr>
<td></td>
<td>PERSONALISED MEDICINE FOR PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Ian Vela</td>
</tr>
<tr>
<td>2:20</td>
<td>PERSONALISED MEDICINE FOR BPH</td>
</tr>
<tr>
<td></td>
<td>Wade Bushman</td>
</tr>
<tr>
<td>2:40</td>
<td>IMMUNOTHERAPY FOR UROLOGICAL CANCERS</td>
</tr>
<tr>
<td></td>
<td>Jennifer Mataraza</td>
</tr>
<tr>
<td>3:00</td>
<td>BREAK</td>
</tr>
<tr>
<td>3:50</td>
<td>UROLOGICAL TRAINING FOR THE FUTURE</td>
</tr>
<tr>
<td></td>
<td>Chair: Peter Heathcote</td>
</tr>
<tr>
<td></td>
<td>TRAINING AND INSPIRING THE NEXT GENERATION OF UROLOGISTS</td>
</tr>
<tr>
<td></td>
<td>Kieran O'Flynn</td>
</tr>
<tr>
<td>4:10</td>
<td>THE ROLE OF COGNITIVE TRAINING IN SURGERY</td>
</tr>
<tr>
<td></td>
<td>Khurshid Guru</td>
</tr>
<tr>
<td>4:30</td>
<td>COFFEY-KRANE AWARD PRESENTATION</td>
</tr>
<tr>
<td></td>
<td>Prokar Dasgupta</td>
</tr>
<tr>
<td>5:00</td>
<td>ADJOURN</td>
</tr>
</tbody>
</table>

#### APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

### Japanese Urological Association (JUA)

Grand Ballroom A @ Westin Waterfront

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00</td>
<td>OPENING REMARKS: AUA REPRESENTATIVE</td>
</tr>
<tr>
<td>2:05</td>
<td>PROSTATE CANCER - NEW MARKERS, IMAGING MODALITIES FOR BETTER DIAGNOSIS</td>
</tr>
<tr>
<td></td>
<td>Moderators: Yasutomo Nasu, Andrew Stephenson</td>
</tr>
<tr>
<td></td>
<td>GLYCOBIOLOGY OF PSA FOR EARLY DETECTION OF PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Chikara Ohyama</td>
</tr>
<tr>
<td>2:15</td>
<td>INCORPORATING MMRI IN THE DIAGNOSTIC DECISION MAKING FOR SIGNIFICANT CANCER</td>
</tr>
<tr>
<td></td>
<td>Andrew Stephenson</td>
</tr>
<tr>
<td>2:30</td>
<td>PANEL DISCUSSION ON CLINICAL CASES: WHAT IS YOUR CHOICE OF TREATMENT?</td>
</tr>
<tr>
<td></td>
<td>Moderators: Yoshiyuki Kojima, Andrew Stephenson</td>
</tr>
<tr>
<td></td>
<td>Panelists: Takashi Kobayashi, Tetsuya Shindo</td>
</tr>
<tr>
<td></td>
<td>AUA Faculty: Scott Eggener, Edouard Trabulsi</td>
</tr>
<tr>
<td>3:00</td>
<td>RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td>Moderators: Masatoshi Eto, Chandru Sundaram</td>
</tr>
<tr>
<td>3:10</td>
<td>IMMUNE CHECKPOINT BLOCKADE FOR MRCC</td>
</tr>
<tr>
<td></td>
<td>Chandra Sundaram</td>
</tr>
<tr>
<td>3:20</td>
<td>PANEL DISCUSSION ON CLINICAL CASES: HOW TO APPROACH THIS SITUATION?</td>
</tr>
<tr>
<td></td>
<td>Moderators: Masatoshi Eto, Chandru Sundaram</td>
</tr>
<tr>
<td></td>
<td>Panelists: Hideaki Miyake, Katsunori Tatsugami</td>
</tr>
<tr>
<td></td>
<td>AUA Faculty: Surena Matin, Eric Singer</td>
</tr>
<tr>
<td>4:05</td>
<td>INTERSTITIAL CYSTITIS</td>
</tr>
<tr>
<td></td>
<td>Moderators: Yasuhiko Igawa, Howard Goldman</td>
</tr>
<tr>
<td>4:10</td>
<td>PATHOPHYSIOLOGY OF INTERSTITIAL CYSTITIS</td>
</tr>
<tr>
<td></td>
<td>YoShiyuki Akiyama</td>
</tr>
</tbody>
</table>
### Sunday, May 14, 2017 2:00 pm - 6:00 pm

**Sociedad Argentina de Urología (SAU)**

**Grand Ballroom B @ Westin Waterfront**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00</td>
<td><strong>Apertura (Opening)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Directors: Miguel Angel Costa, Roberto Hernández</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Secretaries: Norberto Lafos, José Rozanec</td>
<td></td>
</tr>
<tr>
<td>2:15</td>
<td><strong>Geriatría y cáncer: cuál es el límite del tratamiento? (Geriatrics and cancer: what are the treatment limits?)</strong></td>
<td>Alejandro Nolazco</td>
</tr>
<tr>
<td></td>
<td>Moderator: Alejandro Nolazco, Osvaldo Mazza</td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td><strong>Xofigo® en el tratamiento del cáncer de próstata avanzado: maximizando beneficios. (Xofigo® for the treatment of advanced prostate cancer: maximizing benefits)</strong></td>
<td>Miguel Angel Costa</td>
</tr>
<tr>
<td></td>
<td>Moderator: Miguel Angel Costa, Mauricio Castaneda</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td><strong>Valor de la linfadenectomía de rescate pos prostatectomía radical (Value of salvage lymph node dissection post-radical prostatectomy)</strong></td>
<td>Wenceslao Villamil</td>
</tr>
<tr>
<td></td>
<td>Moderator: Wenceslao Villamil, Fernando Pablo Secin</td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td><strong>Tratamiento de la incontinencia de orina masculina (Treatment of male urinary incontinence)</strong></td>
<td>Martín del Sordo</td>
</tr>
<tr>
<td></td>
<td>Moderator: Martín del Sordo, Leandro Capiel</td>
<td></td>
</tr>
<tr>
<td>3:45</td>
<td><strong>Discusión de casos clínicos (Discussion of clinical cases)</strong></td>
<td>Patricio Alvarez</td>
</tr>
<tr>
<td></td>
<td>Moderator: Patricio Alvarez, Ricardo Nardone, Carlos Palazzo</td>
<td></td>
</tr>
<tr>
<td>4:15</td>
<td><strong>Cómo resolver la disfunción sexual producida por las comorbilidades (How to treat sexual dysfunction caused by comorbidities)</strong></td>
<td>Miguel Rivero</td>
</tr>
<tr>
<td></td>
<td>Moderator: Miguel Rivero, Malen Pijoan</td>
<td></td>
</tr>
<tr>
<td>4:30</td>
<td><strong>Consejos prácticos para la cirugía laparoscópica de los tumores retroperitoneales (Tips for laparoscopic surgery of retroperitoneal tumors)</strong></td>
<td>Adrian Momesso</td>
</tr>
<tr>
<td></td>
<td>Moderator: Adrian Momesso, Gonzalo Vitagliano</td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td><strong>Litiásis infectada en adulto mayor: resolución endourológica (Inherited lithiasis in elderly patients: endourologic resolution)</strong></td>
<td>Horacio Sanguinetti</td>
</tr>
<tr>
<td></td>
<td>Moderator: Horacio Sanguinetti, Norberto Bernardo</td>
<td></td>
</tr>
<tr>
<td>4:55</td>
<td><strong>Closing remarks</strong></td>
<td>Masato Fujisawa</td>
</tr>
</tbody>
</table>

---

### Sunday, May 14, 2017 2:00 pm - 6:30 pm

**R. Frank Jones Urological Society (RFJ)**

**Room 209 @ Boston Convention & Exhibition Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00</td>
<td><strong>Welcome and President’s update</strong></td>
<td>Jacqueline Hamilton</td>
</tr>
<tr>
<td>2:05</td>
<td><strong>Welcome from the AUA</strong></td>
<td></td>
</tr>
<tr>
<td>2:15</td>
<td><strong>Questions and answers</strong></td>
<td></td>
</tr>
<tr>
<td>2:20</td>
<td><strong>AUA Public Policy Council liaison update</strong></td>
<td>Robert Waterhouse, Jr.</td>
</tr>
<tr>
<td>2:00</td>
<td><strong>Welcome and president’s update</strong></td>
<td>Jacqueline Hamilton</td>
</tr>
<tr>
<td>2:05</td>
<td><strong>Welcome from the AUA</strong></td>
<td></td>
</tr>
<tr>
<td>2:15</td>
<td><strong>Questions and answers</strong></td>
<td></td>
</tr>
<tr>
<td>2:20</td>
<td><strong>AUA public policy council liaison update</strong></td>
<td>Robert Waterhouse, Jr.</td>
</tr>
</tbody>
</table>

*Presenting author*
2:30 MIDLEVEL PROVIDERS IN UROLOGY: HISTORICAL PERSPECTIVE AND FUTURE CONSIDERATIONS
Kenneth Mitchell

2:50 QUESTIONS & ANSWERS/AUDIENCE RESPONSE TECHNOLOGY

3:00 INTRODUCTION AND PRETEST

3:10 RACE AND THE ENVIRONMENT: EFFECTS ON REPRODUCTIVE HEALTH AND GENITOURINARY CANCER
Mark Mitchell

3:40 AUDIENCE RESPONSE/QUESTIONS AND ANSWERS

3:45 USE OF NOVEL GENETIC TESTS TO HELP INDIVIDUALIZE PATIENT SELECTION FOR PROSTATE CANCER SCREENING AND TREATMENT
Marc Garnick

4:15 QUESTIONS & ANSWERS/AUDIENCE RESPONSE TECHNOLOGY

4:20 DIET AND ITS RELATIONSHIP TO PROSTATE CANCER
Terry Mason

4:50 QUESTIONS & ANSWERS/AUDIENCE RESPONSE TECHNOLOGY

5:15 ROUND TABLE: IMPACT OF “REPEALING AND REPLACING” THE AFFORDABLE HEALTH CARE ACT ON ACCESS TO HEALTH CARE FOR UNDERSERVED POPULATIONS
Moderator: Chiledum Ahaghotu

5:40 USE OF NOVEL GENETIC TESTS TO HELP INDIVIDUALIZE PATIENT SELECTION FOR PROSTATE CANCER SCREENING AND TREATMENT
Marc Garnick

6:10 AUDIENCE RESPONSE/QUESTIONS AND ANSWER/POSTTEST

6:20 CONCLUDING REMARKS

6:30 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14 2017 3:00 pm - 5:30 pm

RESEARCH FORUM: EARLY-CAREER INVESTIGATORS SHOWCASE
Room 210C @ Boston Convention & Exhibition Center

3:00 EARLY CAREER INVESTIGATORS POSTER VIEWING
4:35 MOLECULAR PROFILING OF MULTI-FOCAL PROSTATE CANCER AND CONCOMITANT LYMPH NODE METASTASIS: IMPLICATIONS FOR TISSUE-BASED PROGNOSTIC BIOMARKERS
Simpa Salami

3:30 PROGRAM INTRODUCTION
Carolyn Best

4:45 STUDIES IN THE CONTEMPORARY MANAGEMENT OF GENITOURINARY TRAUMA UTILIZING THE MULTI-INSTITUTIONAL TRIALS COMMITTEE OF THE AMERICAN ASSOCIATION FOR THE SURGERY OF TRAUMA (AAST)
Jeremy Myers

3:35 ORAL ANTIBIOTIC EXPOSURE AND INCIDENT KIDNEY STONE DISEASE
Gregory Tasian

4:55 INHIBITION OF THE P63-MYC SIGNALING AXIS TO OVERCOME CISPLATIN RESISTANCE IN MUSCLE INVASIVE BLADDER CANCER
John Sfakianos

3:55 THE ROLE OF THE SUCCINATE RECEPTOR IN THE TREATMENT OF VOIDING DYSFUNCTION ASSOCIATED WITH METABOLIC SYNDROME
Lysanne Campeau

5:05 TRENDS IN THE USE OF INTRACYTOPLASMIC SPERM INJECTION: INDICATIONS AND OUTCOMES
Akanksha Mehta

4:05 MARKERS OF CENTRAL SENSITIZATION IN WOMEN UNDERGOING THIRD-LINE OAB THERAPY
William Stuart Reynolds

5:15 AUA/UROLOGY CARE FOUNDATION RESEARCH ACTIVITIES
Krystal Brinson

4:15 IMMUNE CORRELATES OF PATHOLOGIC RESPONSE IN BLADDER CANCER PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY
Philip Abbosh

5:25 PRESENTATION OF AWARDS
Carolyn Best

4:25 SUBFERTILITY HEALTH ASSISTED REPRODUCTION AND THE ENVIRONMENT (SHARE): TRANS-GENERATIONAL IMPACTS OF MALE INFERTILITY
James Hotaling

5:30 ADJOURN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
3:30 WELCOME BY THE AFU DELEGATE OF THE INTERNATIONAL MEMBER COMMITTEE OF THE AUA
Emmanuel Chartier-Kastler

5:25 CONCLUSION OF THE MEETING AND SUMMARY BY THE PRESIDENT OF AFU
Thierry Lebret

3:35 PROSTATE BIOPSIES
Pierre Mozer, Jonathan Coleman

5:30 PROLAPSE MANAGEMENT FROM EUROPE TO USA
Elise De, Gilles Karsenty

Sunday, May 14, 2017
3:30 pm - 5:30 pm
Moderated Poster Session 62
STONE DISEASE: SHOCK WAVE LITHOTRIPSY
Room 151 @ Boston Convention & Exhibition Center
Moderators: Michael Bailey and John Denstedt

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP62-01</td>
<td>PREDICTION FOR SUCCESS RATE OF SHOCK WAVE LITHOTRIPSY USING MEAN STONE DENSITY-STONE HETEROGENEITY INDEX RATIO CALCULATING HOUNSFIELD UNIT ON NON-CONTRAST COMPUTED TOMOGRAPHY</td>
</tr>
<tr>
<td>Dong Hyuk Kang*, Kang Su Cho, Won Sik Ham, Jong Kyou Kwon, Seung Hwan Lee, Young Deuk Choi, Joo Yong Lee, Seoul, Korea, Republic of</td>
<td></td>
</tr>
<tr>
<td>MP62-02</td>
<td>VARIATION COEFFICIENT OF STONE DENSITY: A NOVEL PREDICTOR OF TREATMENT OUTCOME FOLLOWING EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY</td>
</tr>
<tr>
<td>Shimpei Yamashita*, Yasuo Kohjimoto, Takashi Iguchi, Akinori Iba, Isao Hara, Wakayama, Japan</td>
<td></td>
</tr>
<tr>
<td>MP62-03</td>
<td>PREDICTING ESWL OUTCOME USING CLASSIFICATION AND REGRESSION TREE (CART) ANALYSIS</td>
</tr>
<tr>
<td>Yasuo Kohjimoto*, Shimpei Yamashita, Takashi Iguchi, Satoshi Nishizawa, Akinori Iba, Kazuro Kikkawa, Isao Hara, Wakayama, Japan</td>
<td></td>
</tr>
<tr>
<td>MP62-04</td>
<td>IDENTIFICATION OF THE RECOMMENDED TECHNIQUES, CASE SELECTION, AND INVENTION TO IMPROVE EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY SUCCESS RATES</td>
</tr>
<tr>
<td>Atsushi Okada*, Teruaki Sugino, Rei Unno, Kazumi Taguchi, Shuzo Hamamoto, Ryosuke Ando, Keichi Tozawa, Takahiro Yasui, Nagoya, Japan</td>
<td></td>
</tr>
<tr>
<td>MP62-05</td>
<td>DOES BOWEL PREPARATION OR FASTING IMPROVE STONE VISUALISATION AND CLEARANCE IN THOSE UNDERGOING SHOCK WAVE LITHOTRIPSY FOR INTRA-RENAL CALCULI?</td>
</tr>
<tr>
<td>Athina Pirpiris*, Bentleigh East, Australia, Debbie Siew, Antonio de Sousa, Shekib Shahbaz, Philip McCahy, Melbourne, Australia</td>
<td></td>
</tr>
<tr>
<td>MP62-06</td>
<td>ADVANCEMENTS IN ULTRASONIC PROPULSION TECHNOLOGY FOR PUSHING KIDNEY STONES</td>
</tr>
<tr>
<td>MP62-07</td>
<td>IDENTIFICATION OF FACTORS AFFECTING IN VITRO LITHOTRIPSY EXPERIMENTS TOWARDS AN IMPROVED MODEL</td>
</tr>
<tr>
<td>Justin Ahn*, Wayne Kreider, Christopher Hunter, Theresa Zwaschka, Michael Bailey, Mathew Sorensen, Jonathan Harper, Adam Maxwell, Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>MP62-08</td>
<td>MARKERS OF RENAL INJURY DURING SHOCK WAVE LITHOTRIPSY WITH NARROW VS. WIDE FOCAL ZONES</td>
</tr>
<tr>
<td>RJ D’A Honey, Daniela Ghiculete, Monica A. Farcas*, Kenneth T. Pace, Toronto, Canada</td>
<td></td>
</tr>
<tr>
<td>MP62-09</td>
<td>RANDOMIZED CONTROL TRIAL COMPARING NARROW VERSUS WIDE FOCAL ZONES FOR SHOCK WAVE LITHOTRIPSY OF RENAL CALCULI</td>
</tr>
<tr>
<td>RJ D’A Honey, Daniela Ghiculete, Monica A. Farcas*, Kenneth T. Pace, Toronto, Canada</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP62-10 PRELIMINARY REPORT ON STONE BREAKAGE AND LESION SIZE EVALUATION OF A NEW ELECTROHYDRAULIC (SPARKER ARRAY) DISCHARGE DEVICE Bret Connors*, Indianapolis, IN, Ray Schaefer, John Gallagher, Chelmsford, MA, Cynthia Johnson, Andrew Evan, Indianapolis, IN

MP62-11 EXTRACORPOREAL SHOCK-WAVE LITHOTRIPSY (ESWL) FOR RENAL STONES IS ASSOCIATED WITH DECREASED KIDNEY FUNCTION AFTER LONG TERM FOLLOW-UP Christian Fankhauser*, Josias Grogg, Alexander Holenstein, Qing Zhong, Johann Steurer, Thomas Hermanns, Tullio Sulser, Cédric Poyet, Zurich, Switzerland

MP62-12 URETEROSCOPY AND SHOCKWAVE LITHOTRIPSY UTILIZATION PATTERNS IN WISCONSIN: AN ANALYSIS OF SOCIODEMOGRAPHIC FACTORS John Roger Bell*, Brett Johnson, Kristina Penniston, Stephen Y Nakada, Madison, WI

MP62-13 COMPARISON OF PATIENT SATISFACTION FOR TREATMENT EFFICACY AND ASSOCIATED FACTORS BETWEEN SWL AND URS FOR URINARY STONE: ANALYSIS FROM PATIENTS’ VIEW Yoshikazu Sato*, Musashi Tobe, Kosuke Uchida, Kazunori Haga, Ichiya Honna, Keigo Akagashi, Toshikazu Nitta, Hisao Nakajima, Tatsuo Hanzawa, Sapporo, Japan

MP62-14 URETERAL STENTING CAN BE A NEGATIVE PREDICTOR FOR SUCCESSFUL OUTCOME FOLLOWING SHOCK WAVE LITHOTRIPSY IN PATIENTS WITH URETERAL STONES Dong Hyuk Kang*, Kang Su Cho, Won Sik Ham, Jong Kyou Kwon, Seung Hwan Lee, Young Deuk Choi, Joo Yong Lee, Seoul, Korea, Republic of

MP62-15 EMERGENCY EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY FOR UPPER URETERIC STONES WITH OR WITHOUT PRE-STENTING: A RANDOMIZED CLINICAL TRIAL Tarek El-Ghazaly*, Shameem Vita, Salam Hussain, Abdulkader Al-Obaidy, Doha, Qatar

MP62-16 SHOCK WAVE LITHOTRIPSY IS EFFICACIOUS FOR TREATING OBESE PATIENTS WITH UPPER URETERIC STONES DISTANCE OF MORE THAN 14CM William K M Gietzmann, Abishek Sharma, Edward Mains, ismail El-Mokadem, Ben G Thomas, Simon Phips, David A Tolley, Mark L Cutress*, Edinburgh, United Kingdom

MP62-17 LISTENING TO MUSIC DURING SHOCK WAVE LITHOTRIPSY DECREASES ANXIETY, PAIN AND DISSATISFACTION: A RANDOMIZED CONTROLLED STUDY Ozgur Cakmak, Izmir, Turkey, Sertac Cimen, Halifax, Canada, Huseyin Tarhan, Mugla, Turkey, Rahmi Gokhan Ekin, Batuham Ergan, Taha Cetin, Volkan Ulker, Ilker Akarken, Zafer Koziaciglu*, Izmir, Turkey

MP62-18 AMBULATORY SHOCK WAVE LITHOTRIPSY IS AN EFFICACIOUS AND COST-EFFECTIVE TREATMENT FOR LOWER POLE RENAL STONES BETWEEN 10-20MM IN SIZE: A PROSPECTIVE LARGE SINGLE CENTRE STUDY Daniel Good, Luke Chan, Karina Laing, Simon Phips, Ben Thomas, Julian Keanie, David Tolley, Mark Cutress*, Edinburgh, United Kingdom

MP62-19 CROSS VALIDATION OF A PREDICTIVE ANALYTIC MODEL WHICH PREDICTS SUCCESS AND COMPLICATIONS OF SHOCKWAVE LITHOTRIPSY Blake Hamilton*, Salt Lake City, UT, Ryan Seltzer, Donald Gleason, Tucson, AZ, Stephen Nakada, Madison, WI, Glenn Gerber, Chicago, IL


APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
## ABSTRACT

**MP63-01** ADVANCED MATERNAL AGE AT FIRST DELIVERY DOES NOT AFFECT PATIENT-REPORTED URINARY OUTCOMES: RESULTS FROM A NATIONWIDE SAMPLE
Michael Daugherty*, Natasha Ginzburg, Syracuse, NY

**MP63-02** PURE STRESS URINARY INCONTINENCE: ANALYSIS OF THE PREVALENCE, ESTIMATION OF COSTS AND FINANCIAL IMPACT
Emanuele Rubilotta, Matteo Balzarro*, Silvia Bassi, Paolo Corsi, Marco Pirozzi, Trabacchin Nicolò, Antonio Benito Porcaro, Antonio D’Amico, Walter Artibani, Verona, Italy

**MP63-03** THE TIMED ASSESSMENT OF MOBILITY FOR URINARY FUNCTION (TAM-U): A MEASURE FOR FUNCTIONAL INCONTINENCE IN THE ELDERLY
Lynn Stothers*, Vancouver, Canada

**MP63-04** OAB SCORE. A CLINICAL MODEL THAT OPTIMIZES THE PROBABILITY OF PRESENTING OVERACTIVE DETRUSOR IN URODYNAMIC STUDY
Leandro Arribillaga*, Ariel Montedoro, Rubén Guillermo Bengió, Marta Ledesma, Florencia Pisano, Aldana Pientrantozzi, Ruben Hugo Bengió, Córdoba, Argentina

**MP63-05** NOVEL URODYNAMIC FINDINGS IN FEMALE PATIENTS WITH URGENCY URINARY INCONTINENCE
Liang Dong*, Jiayi Li, Jianwei Lv, Jing Leng, Wei Xue, Yiran Huang, Shanghai, China, People’s Republic of

**MP63-06** CATEGORIZATION OF REAL-TIME SENSATION PATTERNS DURING URODYNAMICS
Zachary Cullingsworth*, Adam Klausner, Anna Nagle, William Simmons, Jacqueline Morin, Randy Vince, David Rapp, John Speich, Richmond, VA

**MP63-07** CHARACTERIZATION OF LOW AMPLITUDE RHYTHMIC CONTRACTIONS DURING URODYNAMICS
Zachary Cullingsworth*, Brooks Kelly, William Simmons, Andrew Colhoun, Anna Nagle, Randy Vince, John Speich, Adam Klausner, Richmond, VA

**MP63-08** CAN URODYNAMIC PARAMETERS PREDICT SLING REVISION FOR VOIDING DYSFUNCTION IN WOMEN UNDERGOING SYNTHETIC MIDURETHRAL SLING PLACEMENT?
Brian Linder*, Emanuel Trabuco, John Gebhart, Christopher Klingele, John Occhino, Daniel Elliott, Deborah Lightner, Rochester, MN

**MP63-09** PREDICTION OF THE LONG-TERM DURABILITY OF SUBURETHRAL SLING BASED ON POSTOPERATIVE URODYNAMICS
Hsain-Ho Liu*, Taichung, Taiwan, Hann-Chorg Kuo, Hualien, Taiwan

**MP63-10** DO URODYNAMICS PREDICT URINARY RETENTION AFTER SLING PLACEMENT IN THE COMPLEX PATIENT: VALUE OF REPRODUCING SYMPTOMS OF URODYNAMICS
Alyssa Greiman*, Lauren Rittenberg, Lindsey Cox, Ross Rames, Eric Rovner, Charleston, SC

**MP63-11** IS IT MANDATORY TO PERFORM URODYNAMICS TO IDENTIFY OCCULT STRESS URINARY INCONTINENCE?
Susane Hwang*, Luis Gustavo Toledo, Silvia Carramao, Armando Frade, Raquel Richetti, Sao Paulo, Brazil, Andre Matos, Salvador, Brazil, Antonio Auge, Sao Paulo, Brazil

**MP63-12** RELIABILITY OF VALSALVA LEAK POINT PRESSURE IN FEMALE STRESS URINARY INCONTINENCE
Jun Seok Kim*, Dong Hoon Yoo, Dong Hoon Lim, Gwangju, Korea, Republic of, Myung Ki Kim, Jeonju, Korea, Republic of, Hee Jong Jeong, Iksan, Korea, Republic of, Eun Mi Yang, Seong Woon Park, Joon Hwa Noh, Gwangju, Korea, Republic of

**MP63-13** DOES VIDEOURODYNAMIC CLASSIFICATION DEPEND ON PATIENT POSITIONING IN PATIENTS WITH STRESS URINARY INCONTINENCE?
Hazel Ecclestone*, Eskinder Solomon, Rizwan Hamid, Mahreen Paksad, Daniel Wood, Tamsin Greenwell, Jeremy Ockrim, London, United Kingdom

**MP63-14** OVERNIGHT AMBULATORY URODYNAMICS FINDINGS IN PATIENTS WITH NOCTURIA AND/OR NOCTURNAL ENURESIS
Eskinder Solomon, Megan Duffy, Sachin Malde, Hazel Ecclestone*, Mahreen Paksad, Rizwan Hamid, Tamsin Greenwell, Jeremy Ockrim, London, United Kingdom

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP63-15</td>
<td>CONCORDANCE OF URODYNAMIC DEFINITIONS OF FEMALE BLADDER OUTLET OBSTRUCTION</td>
</tr>
<tr>
<td>MP63-16</td>
<td>EFFECTS OF RADIATION ON MALE STRESS INCONTINENCE</td>
</tr>
<tr>
<td>MP63-17</td>
<td>ROLES OF URODYNAMICS IN THE ASSESSMENT OF POST RADICAL PROSTATECTOMY INCONTINENCE: DO FINDINGS CHANGE PATIENT MANAGEMENT?</td>
</tr>
<tr>
<td>MP63-18</td>
<td>DO SYMPTOMS CORRELATE WITH URODYNAMIC FINDINGS FOR MEN WITH POST-PROSTATECTOMY INCONTINENCE?</td>
</tr>
<tr>
<td>MP63-19</td>
<td>THE VALUE OF URODYNAMICS PRIOR TO SACRAL NEUROMODULATION IN MEN</td>
</tr>
<tr>
<td>MP63-20</td>
<td>SYMPTOMATIC URINARY TRACT INFECTIONS' RATE POST-URODYNAMIC STUDIES AND RISK FACTORS</td>
</tr>
</tbody>
</table>

Moderated Poster Session 64
PROSTATE CANCER: LOCALIZED: SURGICAL THERAPY V
Room 156 @ Boston Convention & Exhibition Center
Moderators: Christopher Amling, Herbert Lepor and Francesco Montorsi

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP64-01</td>
<td>EXTERNAL VALIDATION OF THE CAPRA-S SCORE TO PREDICT BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE K-CAP DATABASE</td>
</tr>
<tr>
<td>MP64-02</td>
<td>ONCOLOGICAL OUTCOMES OF SALVAGE RADICAL PROSTATECTOMY: A MULTICENTRE SERIES OF 243 PATIENTS</td>
</tr>
</tbody>
</table>
MP64-03 TUMOR AND MRI FEATURES PREDICTIVE OF EXTRACAPSULAR EXTENSION IN HIGH RISK PROSTATE CANCER
Pooya Banapour*, Andrew Schumacher, Rex Parker, David Finley, Los Angeles, CA

MP64-04 PROSTATE SPECIFIC ANTIGEN NADIR: THE OPTIMAL LEVEL TO DEFINE BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY
Seyed Yousef Hosseini, Erfan Amini*, Naser Riazi, Mohsen Ayali, Tehran, Islamic Republic of Iran

MP64-05 CONTEMPORARY EXTENDED PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER IN THE UK – AN ANALYSIS OF NATIONAL PRACTICE AND LYMPH NODE INVASION RATES
Edward Calleja, Sarah Fowler, John McGrath, Prasanna Sooriakumaran, Jonathan Aning*, London, United Kingdom

MP64-06 LYMPHADENECTOMY IN GLEASON 7 PROSTATE CANCER: UTILIZATION AND ADHERENCE TO GUIDELINES
Thenappan Chandrasekar*, Hanan Goldberg, Zachary Klaassen, Robert J. Hamilton, Girish S. Kulkarni, Neil E. Fleshner, Toronto, Canada

MP64-07 LYMPH NODE YIELD AND POSITIVITY RATE BY LOCATION IN 1000 ROBOTIC PROSTATECTOMY PATIENTS THAT UNDERWENT EXTENDED PELVIC LYMPH NODE DISSECTIONS AT A SINGLE INSTITUTION
Paul Gellhaus*, Nora Ruel, Avinash Chennamsetty, William Chu, Justin Emtage, Jonathan Yamzon, Clayton Lau, Pasadena, CA, Timothy Wilson, Santa Monica, CA, Bertram Yuh, Pasadena, CA

MP64-08 SYMPTOMATIC LYMPHOCELE FORMATION AFTER EXTRAPERITONEAL VS. TRANSPERITONEAL ROBOT ASSISTED RADICAL PROSTATECTOMY AND BILATERAL PELVIC LYMPHADENECTOMY
David Horovitz*, Xiang Lu, Changyong Feng, Edward Messing, Jean Joseph, Rochester, NY

MP64-09 THE IMPACT OF OF LYMPH NODES COUNT AND ADJUVANT THERAPY ON ONCOLOGIC OUTCOMES IN MEN WITH LYMPH NODE METASTASIS AT THE TIME OF RADICAL PROSTATECTOMY
Hao Nguyen*, Janet Cowan, Matthew Cooperberg, Peter Carroll, San Francisco, CA

MP64-10 IS THERE AN AGE LIMIT FOR THE INDICATION OF EXTENDED PELVIC LYMPH NODE DISSECTION DURING RADICAL PROSTATECTOMY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER?
Alessandro Larcher*, Nicola Fossati, Giorgio Gandaglia, Umberto Capitanio, Paolo Dell’Oglio, Emanuele Zaffuto, Nazareno Suardi, Marco Bandini, Milan, Italy, Shahroksh Shariat, Vienna, Austria, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP64-11 ZONAL DISTRIBUTION OF PROSTATE CANCER IS IMPORTANT PROGNOSTIC FACTOR IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER TREATED ROBOT ASSISTED RADICAL PROSTATECTOMY(RARP)
Makoto Ohori*, Tatsuo Gondo, Yosuke Hirasawa, Takeshi Hashimoto, Yoshihiro Nakagami, Rie Inoue, Takashi Nagao, Tokyo, Japan

MP64-12 ASSESSING DECIPHER FOR PREDICTING LYMPH NODE POSITIVE DISEASE AMONG MEN DIAGNOSED WITH INTERMEDIATE RISK DISEASE TREATED WITH PROSTATECTOMY AND EPLND
Mary Achim, Surena Matin, Brian Chapin, Patricia Troncoso, Elsa Li Ning Tapia, Mikeya Guernero, Ina Prokhorova, Houston, TX, Anders Olson, Zaid Haddad, Jennifer Margrave, Jijimon Chelliserry, Lucia Lam, Kasra Yousefi, Christine Buerki, Elai Davicioni, Vancouver, Canada, John Davis*, Houston, TX

MP64-13 DECREASING OVERTREATMENT OF LOCALIZED PROSTATE CANCER WITH RADICAL PROSTATECTOMY: 10-YEAR TRENDS
Ilhan Gokhan*, Tracy Han, Ghalib Jibara, Robert Qi, Judd Moul, Durham, NC

MP64-14 SIMPLE PROGNOSTIC MODEL FOR HIGH-RISK PROSTATE CANCER AFTER RADICAL PROSTATECTOMY
Yasuhiro Kohjimoto*, Takahito Wakamiya, Takashi Iguchi, Shimpei Yamashita, Satoshi Nishizawa, Akinori Iba, Kazuro Kikkawa, Isao Hara, Wakayama, Japan

MP64-15 ROBOTIC ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY IN ISUP GRADE 5 PROSTATE CANCER: ONCOLOGICAL OUTCOMES
Itay Sagy*, Charles Nottingham, Shay Golan, Matt Galocy, Arieh Shalhav, Chicago, IL

MP64-16 ADVERSE FEATURES AND COMPETING RISK MORTALITY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER
Valerio Vagnoni, Lorenzo Bianchi, Marco Borghesi, Cristian Vincenzo Pultrone, Hussam Dababneh, Marco Giampaoli, Martina Sofia Rossi, Francesco Chessa, Daniele Romagnoli, Andrea Angiolini, Giuseppe Martorana, Riccardo Schiavina*, Eugenio Brunocilla, Bologna, Italy
MP65-07 TREATMENT WITH THE HISTONE DEACETYLASE INHIBITOR, CI-994, IN COMBINATION WITH PD-1 BLOCKADE LEADS TO REGRESSION OF INTRAVESICAL MURINE TUMORS
Catherine Eden*, Cynthia Perez-Fournier, Gopal Gupta, Jose Guevara-Patino, Maywood, IL

MP65-08 HEAT-TARGETED DRUG DELIVERY USING THE COMBAT BRS DEVICE FOR TREATING BLADDER CANCER
Steven C. Brousell*, Thomas A. Longo, Joseph J. Fantony, Wiguins Etienne, David Needham, Mark W. Dewhirst, Paolo F. Maccarini, Ivan Spasojevic, Brant A. Inman, Durham, NC

MP65-09 MOLECULAR TUMOUR GRADING AND OUTCOME PROGNOSTICATION OF NON MUSCLE INVASIVE BLADDER CANCER BASED ON WHOLE TRANSCRIPTOME ANALYSIS

MP65-10 RECURRENT NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA TUMORS HAVE COMMON ANCESTRAL CLONE

MP65-11 MUCIN 16 IS A MUTATIONAL HOTSPOT FOR NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
Sumeet Syan-Bhanvadia*, Christopher Duymich, Yong June Kim, Won Tae Kim, Wun-Jae Kim, Peter Jones, Siamak Daneshmand, Gangning Liang, Los Angeles, CA

MP65-12 TARGETING ESTROGEN/ESTROGEN RECEPTOR SIGNAL PATHWAYS TO ENHANCE THE EFFICACY OF BACILLUS CALMETTE-GUÉRIN TREATMENT IN BLADDER CANCER

*Presenting author
<p>| MP66-01 | EMERGENCY DEPARTMENT REVISITS FOR CHILDREN FOLLOWING AN ACUTE URINARY STONE EPISODE |
| MP66-02 | PRE-OPERATIVE TAMSULOSIN AND URETERAL ORIFICE NAVIGATION IN PEDIATRIC PATIENTS: IS THERE ANY BENEFIT? |
| MP66-03 | PRESCRIBING NARCOTIC SHOULD BE SELECTIVE AFTER MANY PEDIATRIC UROLOGIC SURGERIES |
| MP66-04 | GONADAL FUNCTION AND REPRODUCTIVE SYSTEM ANATOMY IN POST PUBERAL PRUNE BELLY SYNDROME PATIENTS |
| MP66-05 | TESTICULAR HISTOLOGY IN INFANTS WITH PRADER-WILLI SYNDROME |
| MP66-06 | IS SURGICAL ANTIBiotic PROPHYLAXIS NECESSARY FOR PEDIATRIC ORCHIOPEXY? |</p>
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP66-12</td>
<td>PERCUTANEOUS EXTERNALLY ASSEMBLED LAPAROSCOPIC INSTRUMENTS FOR FOWLER-STEPHENS ORCHIOPEXY: THE FEASIBILITY OF A NEW SURGICAL SYSTEM</td>
<td>Isaac Kelly*, Samuel Abourbih, Minh Chau, Loma Linda, CA, Nazih Khter, Los Angeles, CA, Mohamed Kheilla, Salim Cherian, Patrick Yang, Jim Shen, Matthew Pierce, D. Duane Baldwin, Loma Linda, CA</td>
<td></td>
</tr>
<tr>
<td>MP66-14</td>
<td>TESTICULAR MICROLITHIASIS: A CASE-BASED, MULTINATIONAL SURVEY OF CLINICAL MANAGEMENT PRACTICES</td>
<td>Katie Brodie*, Amanda Saltzman, Nicholas Cost, Aurora, CO</td>
<td></td>
</tr>
<tr>
<td>MP66-16</td>
<td>IMMEDIATE POST-OPERATIVE COURSE FOLLOWING OPEN AND LAPAROSCOPIC ORCHIOPEXY OF ABDOMINAL TESTES: IS THERE A DIFFERENCE?</td>
<td>Kristina Suson*, Yegappan Lakshmanan, Detroit, MI</td>
<td></td>
</tr>
<tr>
<td>MP66-17</td>
<td>RISK FACTORS FOR REPEAT SURGICAL INTERVENTION IN PEDIATRIC NEPHROLITHIASIS: A PEDIATRIC HEALTH INFORMATION SYSTEM® DATABASE STUDY</td>
<td>Jonathan Ellison*, Thomas Lendvay, Kathleen Kieran, Assaf Oron, Margaret Shnorhavorian, Paul Merguerian, Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>MP66-18</td>
<td>DECELLULARIZED WHOLE TESTIS AS A POTENTIAL BIOSCAFFOLD FOR TESTIS TISSUE-ENGINEERING</td>
<td>Aram Akbarzadeh*, Maral Kianimanesh, Maryam Ebadi, Ahmad Masoomi, Fereshteh Ghazisaeedi, Reza Seyed Hosein Beigi, Arash Fallahi, Reyhane Sheikh, Abdol-Mohammad Kajbafzadeh, Tehran, Islamic Republic Of Iran</td>
<td></td>
</tr>
<tr>
<td>MP66-19</td>
<td>THE DECLINING RATE OF PEDIATRIC VARIPOCELECTOMY IN NEW YORK STATE</td>
<td>Michael J Lipsky*, Wilson Sui, Julia B Finkelstein, Alexander C Small, Dennis J Robbins, Sarah M Lambert, Pasquale Casale, New York, NY</td>
<td></td>
</tr>
<tr>
<td>MP66-20</td>
<td>PEDIATRIC MODIFIED SUPINE PERCUTANEOUS NEPHROLITHOTOMY: AN AUSTRALIAN CASE SERIES</td>
<td>Athina Pirpiris*, Bentleigh East, Australia, Debbie Siew, Antonio de Sousa, Shekib Shabbaz, Philip McCahy, Nathalie Webb, Melbourne, Australia</td>
<td></td>
</tr>
</tbody>
</table>

Sunday, May 14, 2017 3:30 pm - 5:30 pm

**Moderated Poster Session 67**

**KIDNEY CANCER: EPIDEMIOLOGY & EVALUATION/STAGING II**

**Room 252 @ Boston Convention & Exhibition Center**

**Moderators:** Sean Stroup, Tracey Krupski and Simon Tanguay

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP67-01</td>
<td>TELOMERE LENGTH AND GENETIC ANTICIPATION IN A LARGE COHORT OF CHINESE VON HIPPLE-LINDAU DISEASE</td>
<td>Jiangyi Wang*, Shuanghe Peng, Xianghui Ning, Teng Li, Jiayuan Liu, Shengjie Liu, Kan Gong, Beijing, China, People’s Republic of</td>
<td></td>
</tr>
<tr>
<td>MP67-02</td>
<td>INCREASED HP1-GAMMA EXPRESSION ASSOCIATES WITH ADVERSE OUTCOME IN PATIENTS WITH NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA</td>
<td>Yu Zhu*, Zewei Wang, Dingwei Ye, Shanghai, China, People’s Republic of</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author*
MP67-04 EVALUATION OF THE DE RITIS (ASPARTATE TRANSMINASE/ALANINE TRANSAMINASE) RATIO AS A PREDICTOR OF ONCOLOGICAL OUTCOMES IN PATIENTS WITH UPPER URINARY TRACT UROTHELIAL CARCINOMA AFTER SURGERY

Eu Chang Hwang*, Yang Hyun Cho, Ho Seok Chung, Seung Il Jung, Taek Won Kang, Dong Deuk Kwon, Gwangju, Korea, Republic of, Myung Ki Kim, Jeonju, Korea, Republic of, Sung Gu Kang, Jun Cheon, Seoul, Korea, Republic of, Ja Yoon Ku, Hong Koo Ha, Busan, Korea, Republic of, Chang Wook Jeong, Ja Hyeon Ku, Cheol Kwak, Seoul, Korea, Republic of, Tae Gyun Kwon, Tae-Hwan Kim, Seock Hwan Choi, Daegu, Korea, Republic of

MP67-05 CLINICOPATHOLOGIC ANALYSIS OF RENAL EPITHELIOID ANGIOMYOLIPOMA: A SINGLE INSTITUTE EXPERIENCE OF 21 CASES

Han-Yu Tsai*, Cheng-Keng Chuang, Kwan-Fong Ng, Kun-Han Lee, Taoyuan City, Taiwan

MP67-06 COLLECTING (BELLINI) DUCT CARCINOMA: DISEASE CHARACTERISTICS AND TREATMENT OUTCOMES

Wilson Sui*, Justin Matulay, Dennis Robins, Maxwell James, Ifeanyi Onyeji, Marissa Theofanides, Arindam RoyChoudhury, Sven Wenske, Guarionex DeCastro, New York, NY

MP67-07 PATHOLOGICAL DETERMINANTS OF ONCOLOGIC OUTCOMES IN STAGE II RENAL CELL CARCINOMA: AN INTERNATIONAL MULTICENTER ANALYSIS


MP67-08 PREOPERATIVE SYSTEMIC INFLAMMATORY MARKERS IN UPPER TRACT UROTHELIAL CELL CARCINOMA: WHICH IS BETTER AS A PROGNOSTIC FACTOR?

Eu Chang Hwang*, Yang Hyun Cho, Ho Seok Chung, Seung Il Jung, Taek Won Kang, Dong Deuk Kwon, Gwangju, Korea, Republic of, Myung Ki Kim, Jeonju, Korea, Republic of, Sung Gu Kang, Seok Ho Kang, Jun Cheon, Seoul, Korea, Republic of, Ja Yoon Ku, Hong Koo Ha, Busan, Korea, Republic of, Chang Wook Jeong, Ja Hyeon Ku, Cheol Kwak, Seoul, Korea, Republic of, Tae Gyun Kwon, Tae-Hwan Kim, Seock Hwan Choi, Daegu, Korea, Republic of, II Young Seo, Iksan, Korea, Republic of

MP67-09 SURVEILLANCE STRATEGY AND OUTCOME AFTER PARTIAL NEPHRECTOMY

Pascal Mouracade*, Julien Dagenais, Matthew Maurice, Onder Kara, Ryan Nelson, Jaya Sai Chavali, Jihad Kaouk, Cleveland, OH

MP67-10 ACCURATE RISK ASSESSMENT OF PATIENTS WITH LOCALIZED PATHOLOGIC T3A RENAL CELL CARCINOMA

Jung Keun Lee*, In Jae Lee, Tae Jin Kim, Hakmin Lee, Jong Jin Oh, Sangchul Lee, Seong Joon Jeong, Seok-Soo Byun, Sung Eun Lee, Sung Kyu Hong, Seongnam, Korea, Republic of

MP67-11 THE IMPACT OF MODIFIED INTERNATIONAL METASTATIC RENAL CELL CARCINOMA DATABASE CONSORTIUM MODEL USING A TWO-STEP STRATIFICATION PROCESS

Suguru Shirotake*, Hideyuki Kondo, Yota Yasumizu, Koshiro Nishimoto, Saitama Pref., Japan, Nobuyuki Tanaka, Tokyo, Japan, Koji Ito, Saitama Pref., Japan, Kent Kanao, Aichi Pref., Japan, Mototsugu Oya, Tokyo, Japan, Masafumi Oyama, Saitama Pref., Japan

MP67-12 CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH ACQUIRED CYSTIC DISEASE-ASSOCIATED RENAL CELL CARCINOMA: CENTRAL PATHOLOGY RESULTS ACCORDING TO THE 2016 WHO CLASSIFICATION IN A MULTI-INSTITUTIONAL STUDY

Tsunenori Kondo*, Tokyo, Japan, Toyko Tsuzuki, Nagakute, Japan, Naoto Sassa, Hiroshi Yamada, Nagoya, Japan, Toshio Takagi, Kenji Omae, Junpei Iizuka, Kazuhiyo Yoshida, Hironori Fukuda, Kazunari Tanabe, Tokyo, Japan

MP67-13 PURE HOST-RELATED RISK FACTORS FOR ADHHERENT PERINEPHRIC FAT IN HEALTHY INDIVIDUALS DURING LAPAROSCOPIC RENAL SURGERY

Shintaro Narita*, Takamitsu Inoue, Mitsuru Saito, Taketoshi Nara, Koichiro Takayama, Kazuyuki Numakura, Hiroshi Tsuruta, Atsushi Maeno, Shigeru Satoh, Tomonori Habuchi, Akita, Akita, Japan

MP67-14 CHARACTERIZATION OF RENAL CELL CARCINOMA IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS COMPARED TO OTHER SOFT TISSUE SARCOMAS

Shawn Mendonca*, Mazyar Ghanati, Mahyar Kashan, Maria Becerra, Brandon Manley, Nicole Benfante, Paul Russo, Jonathan Coleman, Aimee Crago, A. Ari Hakimi, New York, NY
MP67-15 SURGICAL TREATMENT FOR STAGE I RENAL CELL CARCINOMA: DOES TREATMENT FACILITY MATTER?
Kyle Plante, Telisa Stewart, Dongliang Wang, Syracuse, NY, Thomas Schwabb, Buffalo, NY, Gennady Bratslavsky, Margaret Formica*, Syracuse, NY

MP67-16 UTILITY OF PREOPERATIVE MRI IN CHARACTERIZING THE PARENCHYMAL-TUMOR INTERFACE OF RENAL MASSES PRIOR TO SURGICAL INTERVENTION
Shalin Desai*, Connor Snarskis, Gopal Gupta, Maywood, IL

MP67-17 IS A PREOPERATIVE LOW EJECTION FRACTION A RISK FACTOR FOR COMPLICATIONS AND IMPAIRED SURVIVAL IN RENAL CANCER PATIENTS WHO UNDERGO SURGERY? RESULTS FROM A PROPENSITY-SCORE MATCHING WITH NON CARDIOPATHIC COUNTERPARTS
Alessandro Nini*, Alessandro Larcher, Fabio Muttin, Emanuele Zaffuto, Paolo Dell'Oglio, Francesco Ripa, Cristina Carenci, Giovanni La Croce, Gabriele Fragasso, Francesco Montorsi, Umberto Capitanio, Roberto Bertini, Milan, Italy

MP67-18 THE COMPREHENSIVE COMPLICATION INDEX (CCI) IS SUPERIOR TO THE CLAVIEN-DINDO GRADING SYSTEM IN PREDICTING LENGTH OF STAY AND HOSPITAL READMISSION FOLLOWING RADICAL NEPHROURETERECTOMY
Scott Geiger*, Neil Kocher, Dan Illinsky, Hershey, PA, Evanguelos Xylinas, Paris, France, Peter Chang, Lauren Dewey, Andrew A. Wagner, Boston, MA, Firas Petros, Surena F. Matin, Houston, TX, Conrad Tobert, Chad Tracy, Iowa City, IA, Patard Pierre-Marie, Mathieu Roumiguie, Toulouse, France, Leonardo Lima Monteiro, Wassim Kassouf, Montreal, Canada, Jay D. Raman, Hershey, PA

MP67-19 THE NUCLEAR GRADE AND PROGNOSIS ARE UNRELATED TO THE TNM STAGE IN MULTILOCULAR CYSTIC RENAL CELL NEOPLASM OF LOW MALIGNANT POTENTIAL
Teng Li*, Kan Gong, Xianghui Ning, Shuanghe Peng, Jiangyi Wang, Qun He, Xinyu Yang, Beijing, China, People's Republic of

MP67-20 IDENTIFYING BARRIERS TO THE ADOPTION OF PERCUTANEOUS RENAL TUMOUR BIOPSY IN THE MANAGEMENT OF SMALL RENAL MASSES
Patrick O. Richard*, Sherbrooke, Canada, Lisa Martin, Toronto, Canada, Luke Lavallée, Ottawa, Canada, Phil Violette, Woodstock, Canada, Maria Komissarenko, Kunal Jain, Michael Jewett, Antonio Finelli, Toronto, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017
Podium Session 44
SEXUAL FUNCTION/DYSFUNCTION: FEMALE
Room 157 @ Boston Convention & Exhibition Center
Moderators: Melissa Farmer, Irwin Goldstein and Marita McCabe

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 3:30 | PD44-01 | CHARACTERISTICS AND OUTCOMES OF WOMEN PRESENTING TO A MULTIDISCIPLINARY WOMEN'S UROLOGY CLINIC
Laura Nguyen, Kim Killinger, Natalie Gaines*, Royal Oak, MI, Priyanka Gupta, Ann Arbor, MI, Larry Sirls, Jason Gilleran, Jamie Bartley, Judith Boura, Kenneth Peters, Royal Oak, MI |
| 3:40 | PD44-02 | SEXUAL FUNCTION OUTCOMES IN PATIENTS AND PATIENTS' SPOUSES AFTER MIDURETHRAL SLING PROCEDURE FOR STRESS URINARY INCONTINENCE: DATA FROM A MINIMUM OF 3 YEARS OF FOLLOW-UP
Phil Hyun Song*, Jae Young Choi, Young Hwi Ko, Ki Hak Moon, Hee Chang Jung, Daegu, Korea, Republic of |
| 3:50 | PD44-03 | THE IMPACT OF CYCLING ON WOMEN'S SEXUAL AND URINARY FUNCTIONS
Mohannad Awad*, Thomas Gaither, Thanabhudee Chumnamsongkhroh, Ian Metzler, Thomas Sanford, Gregory Murphy, San Francisco, CA, E. Charles Osterberg, Austin, TX, Benjamin Breyer, San Francisco, CA |
| 4:00 | PD44-04 | SUCCESSFUL TREATMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/PBS) IN WOMEN WITH PROVOKED VESTIBULODYNIA (PVD)

*Presenting author
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD45-01</td>
<td>CHANGE OF CATEGORIES OF THE INTERNATIONAL PROSTATE SYMPTOM SCORE (IPSS) IN HYPOGONADAL PATIENTS WITH AND WITHOUT TESTOSTERONE THERAPY FOR UP TO 12 YEARS: REAL-WORLD DATA FROM TWO POOLED CONTROLLED REGISTRY STUDIES</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aksam Yassin*, Dany-Jan Yassin, Norderstedt-Hamburg, Germany, Karim Haider, Ahmad Haider, Bremerhaven, Germany</td>
</tr>
<tr>
<td>3:40</td>
<td>PD45-02</td>
<td>VALIDATION STUDY OF THE MALE ANDROGEN DEFICIENCY SYNDROME (MADS) SCREENING QUESTIONNAIRE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nelson Stone*, New York, NY, Martin Miner, Providence, RI, Wendy Poage, E. David Crawford, Aurora, CO</td>
</tr>
<tr>
<td>3:50</td>
<td>PD45-03</td>
<td>VOIDING FUNCTION IMPROVES UNDER LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) IN HYPOGONADAL MEN FOR UP TO 12 YEARS INDEPENDENT OF PROSTATE SIZE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aksam Yassin*, Dany-Jan Yassin, Norderstedt-Hamburg, Germany, Gheorge Doros, Abdulmaged Traish, Boston, MA</td>
</tr>
<tr>
<td>4:00</td>
<td>PD45-04</td>
<td>SERUM ESTRADIOL IS INDEPENDENTLY ASSOCIATED WITH ERECTILE FUNCTION</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anka Ackerman*, Ezra Margolin, Peter Stahl, New York, NY</td>
</tr>
<tr>
<td>4:10</td>
<td>PD45-05</td>
<td>THE IMPACT OF CYCLING ON MEN’S SEXUAL AND URINARY FUNCTIONS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mohammad Awad*, Thomas Gaiter, Thanabuddee Chumnamsongkhroh, Ian Metzler, Thomas Sanford, Gregory Murphy, San Francisco, CA, E. Charles Osterberg, Austin, TX, Benjamin Breyer, San Francisco, CA</td>
</tr>
</tbody>
</table>
4:20 PD45-06 A LARGE-SCALE INVESTIGATION OF THE PREVALENCE AND PATTERNS OF DEPRESSION AND ANXIETY IN OUTPATIENTS IN THE CLINICS OF ANDROLOGY
Dong Fang*, Yiming Yuan, Zhichao Zhang, Wei Zheng, Yuan Tang, Wanshou Cui, Jing Pang, Weidong Song, Bing Gao, Zhongcheng Xin, Liqun Zhou, Beijing, China, People’s Republic of

4:30 PD45-07 CRITICAL ANALYSIS OF PENILE DUPLEX DOPPLER ULTRASOUND (PDDU) IN ERECTILE DYSFUNCTION (ED): TECHNICAL AND INTERPRETATION DEFICIENCIES
Eduardo P. Miranda*, Jean E. Terrier, Bruno Nascimento, John P. Mulhall, New York, NY

4:40 PD45-08 INTERNATIONAL VARIABILITY IN PENILE DUPLEX ULTRASOUND PRACTICE PATTERNS, TECHNIQUE AND INTERPRETATION
Mark Hockenberry*, Will Kirby, Alexander Pastuszak, Larry Lipshultz, Houston, TX

4:50 PD45-09 EARLY DETECTION OF CARDIOVASCULAR DISEASE (CVD) RISK IN MEN WITH ERECTILE DYSFUNCTION (ED) IS FACILITATED USING NEXT GENERATION IMMUNODIAGNOSTICS
Amin Herati*, Houston, TX, Peter Butler, Houston, TX, Alexander Pastuszak, David Skutt, Larry Lipshultz, Houston, TX

5:00 PD45-10 EXTRACORPOREAL SHOCK-WAVE THERAPY (ESWT) IN TREATMENT OF ED: FIRST RESULTS OF ONGOING SHAM-CONTROLLED STUDY
Andrei Vinarov, Leonid Spivak*, Darina Platonova, Yury Demidko, Moscow, Russian Federation

5:10 PD45-11 IMPROVED DIAGNOSIS AND TREATMENT OF PATIENTS THROUGH ACCURATE AND STANDARDIZED TESTOSTERONE TESTS
Julianne Cook Botelho*, Krista Poynter, Ashley Ribera, Oloke Sugahara, Hubert W Vesper, Atlanta, GA

5:20 PD45-12 SEXUAL HEALTH CARE PRACTITIONER’S EVALUATION OF MEN WHO HAVE SEX WITH MEN
Amin Herati*, Houston, TX, Billy Cordon, Miami, FL, Peter Butler, Houston, TX, Mark Hockenberry, Larry Lipshultz, Houston, TX

Sunday, May 14, 2017
Podium Session 46
3:30 pm - 5:30 pm

SURGICAL TECHNOLOGY & SIMULATION: TRAINING & SKILLS ASSESSMENT III
Room 161 @ Boston Convention & Exhibition Center
Moderators: Richard Grills, Ty Higuchi and B. Price Kerfoot

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIME NUMBER TITLE</td>
<td>TIME NUMBER TITLE</td>
</tr>
<tr>
<td>3:30 PD46-01 CAN SURGICAL MENTOR’S TRUST HOLD THE KEY TO TRAINEE PERFORMANCE?</td>
<td>4:00 PD46-04 VIDEO ANALYSIS OF SKILL AND TECHNIQUE (VAST): MACHINE LEARNING TO ASSESS SURGEONS PERFORMING ROBOTIC PROSTATECTOMY</td>
</tr>
<tr>
<td>3:40 PD46-02 LOOKING FOR YOUR OWN REFLECTION: ASSESSING BRAIN FUNCTIONAL STATE OF SURGICAL MENTOR DURING ROBOT-ASSISTED SURGERY</td>
<td>4:10 PD46-05 A RANDOMISED CONTROLLED TRIAL OF COGNITIVE TRAINING FOR TECHNICAL AND NON-TECHNICAL SKILLS IN ROBOTIC SURGERY</td>
</tr>
<tr>
<td>3:50 PD46-03 IS CROWDSOURCING SURGICAL SKILL ASSESSMENT RELIABLE? AN ANALYSIS OF ROBOTIC PROSTATECTOMIES</td>
<td></td>
</tr>
<tr>
<td>Thomas S. Lendvay*, Seattle, WA, Khurshid R. Ghani, Ann Arbor, MI, James O. Peabody, Detroit, MI, Susan Linsell, David C. Miller, Ann Arbor, MI, Bryan Comstock, Seattle, WA</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author

225
### Podium Session 47

**PROSTATE CANCER: EPIDEMIOLOGY & NATURAL HISTORY III**  
Room 162 @ Boston Convention & Exhibition Center  
Moderators: Scott Eggener, Neil Fleshner and Ashley Ross

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD47-01</td>
<td>THE EFFECT OF PROSTATE CANCER TREATMENT ON PATIENT REPORTED URINARY</td>
<td>Mark Tyson*, JoAnn Alvarez, Tatsuki Koyama, Matthew Resnick, David Penson, Daniel Barocas, Nashville, TN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AND SEXUAL FUNCTION VARIES BY DISEASE SEVERITY: 3-YEAR RESULTS FROM THE CEASAR STUDY</td>
<td></td>
</tr>
<tr>
<td>3:40</td>
<td>PD47-02</td>
<td>FASTING BLOOD GLUCOSE AND PROSTATE CANCER RISK IN THE FINNISH RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER</td>
<td>Teemu Murtola*, Ville Vihervuori, Tampere, Finland, Kirsi Talala, Kimmo Taari, Helsinki, Finland, Teuvo Tammela, Anssi Auvinen, Tampere, Finland</td>
</tr>
<tr>
<td>3:50</td>
<td>PD47-03</td>
<td>FAMILY HISTORY AND INCREASED RISK OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN THE PLCO CANCER SCREENING TRIAL</td>
<td>Adrien Bernstein*, Ron Golan, Jonathan Shoag, Brian Dinerman, Jim C. Hu, NEW YORK, NY</td>
</tr>
<tr>
<td>4:00</td>
<td>PD47-04</td>
<td>STATIN USE, SERUM LIPID LEVELS AND PROSTATE INFLAMMATION: RESULTS FROM THE REDUCE STUDY</td>
<td>Emma Allott*, Chapel Hill, NC, Lauren Howard, Durham, NC, Adriana Vidal, Los Angeles, CA, Daniel Moreira, Chicago, IL, Ramiro Castro-Santamaria, King of Prussia, PA, Gerald Andriole, St Louis, MO, Stephen Freedland, Los Angeles, CA</td>
</tr>
<tr>
<td>4:10</td>
<td>PD47-05</td>
<td>ELDERLY PROSTATE CANCER PATIENTS HAVE A WORSE PROGNOSIS THAN YOUNGER PATIENTS: A POPULATION-BASED STUDY IN THE NETHERLANDS</td>
<td>Robin W.M. Vernooij, Utrecht, Netherlands, Inge M. van Oort, Nijmegen, Netherlands, Theo M. de Reijijk*, Amsterdam, Netherlands, Katja K.H. Aben, Utrecht, Netherlands</td>
</tr>
<tr>
<td>4:20</td>
<td>PD47-06</td>
<td>LOWER RISK OF PROSTATE CANCER IN ASIAN MEN: FROM LESS SCREENING OR TRUE RACIAL DIFFERENCES?</td>
<td>Tom Feng*, Alexis Freedland, Los Angeles, CA, Lauren Howard, Durham, NC, Adriana Vidal, Los Angeles, CA, Daniel Moreira, Chicago, IL, Ramiro Castro-Santamaria, King of Prussia, PA, Gerald Andriole, St Louis, MO, Stephen Freedland, Los Angeles, CA</td>
</tr>
</tbody>
</table>

**Sunday, May 14, 2017**  
3:30 pm - 5:30 pm
4:30 PD47-07 THE EFFECT OF A PREFERENCE SENSITIVE ONLINE DECISION AID ON LOCALIZED PROSTATE CANCER TREATMENT: FIRST RESULTS OF A RANDOMIZED CLUSTER CONTROLLED TRIAL
Romy Lamers*, Maarten Cuypers, Tilburg, Netherlands, Marieke de Vries, Nijmegen, Netherlands, Ronneke vd Poll-Franse, Tilburg, Netherlands, Ruud Bosch, Utrecht, Netherlands, Paul Kl, Tilburg, Netherlands

4:40 PD47-08 VARIATION AND TRENDS IN PROSTATE CANCER CARE AT COMMISSION ON CANCER DESIGNATED FACILITIES
Björn Löppenberg*, Akshay Sood, Deepansh Dalela, Patrick Karabon, Detroit, MI, Jesse Sammon, Portland, ME, Malte Vetterlein, Detroit, MI, Joachim Noldus, Heine, Germany, James Peabody, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Mani Menon, Firas Abdollah, Detroit, MI

4:50 PD47-09 INFLUENCE OF STATIN INTAKE ON PSA VALUES, RISK OF PROSTATE CANCER DEVELOPMENT AND SURVIVAL IN A PROSPECTIVE SCREENING TRIAL COHORT (ERSPC AARAU)
Maciej Kwiatkowski*, Aarau, Switzerland, Elena Lang, Ashkan Mortezavi, Zurich, Switzerland, Lukas Praise, Stephen Wyler, Rainer Grobholz, Andreas Huber, Aarau, Switzerland, Lukas Manka, Braunsgweig, Germany, Tuilio Sulser, Zurich, Switzerland, Franz Recker, Aarau, Switzerland, Daniel Eberli, Zurich, Switzerland

5:00 PD47-10 THE RESEARCH IMPLICATIONS OF PSA REGISTRY ERRORS

5:10 PD47-11 OPTIMUM TOOLS FOR PREDICTING CLINICAL OUTCOMES IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY: A SYSTEMATIC REVIEW OF PROGNOSTIC ACCURACY AND VALIDITY
Jared Campbell, Elspeth Raymond, Michael O’Callaghan*, Andrew Vincent, Keri Beckmann, David Roder, Adelaide, Australia, Sue Evans, John McNeil, Jeremy Millar, John Zalcberg, Melbourne, Australia, Martin Borg, Kim Moretti, Adelaide, Australia

5:20 PD47-12 INCIDENCE RATES AND CANCER CONTROL OUTCOMES OF CONTEMPORARY PRIMARY NEUROENDOCRINE PROSTATE CANCER: ANALYSIS OF SEER DATABASE
Emanuele Zaffuto*, Milan, Italy, Marc Zanaty, Helen Davis Bondarenko, Montreal, Canada, Raisa S. Pompe, Hamburg, Germany, Paolo Dell'Oglio, Giorgio Gandaglia, Nicola Fossati, Armando Stabile, Milan, Italy, Kevin C. Zom, Montreal, Canada, Francesco Montorsi, Alberto Briganti, Milan, Italy, Pierre I. Karakiewicz, Montreal, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017
3:30 pm - 5:30 pm
Podium Session 48
BLADDER CANCER: NON-INVASIVE III
Room 251 @ Boston Convention & Exhibition Center
Moderators: Paolo Gontero, Cheryl Lee and Sanjay Patel

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD48-01</td>
<td>3:30</td>
<td>IS RESTAGING TRANSURETHRAL RESECTION (TUR) NECESSARY IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) AND FOCAL LAMINA PROPRIA INVASION?</td>
<td></td>
</tr>
</tbody>
</table>
Francois AUDENET*, Caitlyn RETINGER, Christine CHIEN, Nicole BENFANTE, Bernard BOCHNER, Machele DONAT, Harry HERR, Guido DALBAGNI, New York, NY

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD48-02</td>
<td>3:40</td>
<td>THE EFFECT OF IMMEDIATE SECOND RESECTION OF TUMOR BED AFTER COMPLETE TRANSURETHRAL RESECTION OF BLADDER TUMOR: A COMPARATIVE STUDY USING PROPENSITY SCORE MATCHING</td>
<td></td>
</tr>
</tbody>
</table>
Myungchan Park*, Sang Hyun Park, Busan, Korea, Republic of, Myung Kim, Jong Keun Kim, Cheryn Song, Bumsik Hong, Hanjung Ahn, Seoul, Korea, Republic of

*Presenting author
3:50 PD48-03 RISK FACTORS FOR RESIDUAL DISEASE AT RE-TUR IN T1G3 BLADDER CANCER
Joan Palou*, Barcelona, Spain, Richard Sylvester, Brussels, Belgium, Francesca Pisano, Turin, Italy, Steven Joniau, Baptiste Eeck, Leuven, Belgium, Marco Oderda, Turin, Italy, Vinzenz Serretta, palermo, Italy, Stephane Larré, Oxford, United Kingdom, Savino Di Stasi, Rome, Italy, Bas Van Rhijn, Amsterdam, Netherlands, Alfred J Witjes, Anne Grotenhuis, Nijmegen, Netherlands, Renzo Colombo, Alberto Briganti, Milan, Italy, Amreik Babjuk, Viktor Soukup, Orague, Czech Republic, Per Uno Malmstrom, Uppsala, Sweden, Jaques Irani, Poitiers, France, Nuria Malats, madrid, Spain, Jack Daniel, Roy Mano, Tel Aviv, Israel, Tommaso Cai, Trento, Italy, Eugene Cha, New York, NY, Peter Ardelat, Freiburg, Germany, John Varkarakis, Athene, Greece, Riccardo Bartoletti, florence, Italy, Martin Sphan, Wurtzburg, Germany, Guido Dalbagni, New York, NY, Shahrokh F Shariat, Vienna, Austria, Evangelos Xylinas, New York, NY, R Jeffrey Barnes, Rochester, NY, Paolo Goontero, Turin, Italy

4:00 PD48-04 CLINICAL BENEFITS OF COMBINED TECHNIQUE TRANSURETHRAL EN-BLOC + ENDOSCOPIC MUCOSAL RESECTION FOR NON-MUSCLE INVASIVE BLADDER CANCER, ESPECIALLY IN LARGE TUMOR
Yasushi Hayashida*, Ureshino, Japan, Yasuyoshi Miyata, Tomohiro Matsu, Nagasaki, Japan, Keisuke Taniguchi, Ureshino, Japan, Hideki Sakai, Nagasaki, Japan

4:10 PD48-05 METRIC SUB-STAGE ACCORDING TO MICRO AND EXTENSIVE LAMINA PROPRIA INVASION IMPROVES PROGNOSTICS IN T1 BLADDER CANCER
Elisabeth Fransen van de Putte*, Amsterdam, Netherlands, Theodorus van der Kwast, Toronto, Canada, Simone Bertz, Erlangen, Germany, Stefan Denzinger, Regensburg, Germany, Quentin Manach, Eva Compérat, Paris, France, Joost Boomans, Rotterdam, Netherlands, Michael Jewett, Toronto, Canada, Robert Stöhr, Erlangen, Germany, Alexandre Zlotta, Toronto, Canada, Kees Hendriksen, Amsterdam, Netherlands, Morgan Rouprét, Paris, France, Wolfgang Otto, Maximilian Burger, Regensburg, Germany, Arndt Hartmann, Erlangen, Germany, Bas van Rhijn, Amsterdam, Netherlands

4:20 PD48-06 2 YEAR CLINICAL AND IMMUNOLOGIC OUTCOMES OF INTRADERMAL BCG PRIMING PRIOR TO INTRAVESICAL INDUCTION IMMUNOTHERAPY FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER

4:30 PD48-07 RECURRENCE AND PROGRESSION ACCORDING TO STAGE AT RE-TUR IN T1G3 BLADDER CANCER PATIENTS TREATED WITH BCG: NOT AS BAD AS PREVIOUSLY THOUGHT

4:40 PD48-08 CLINICAL AND PATHOLOGICAL OUTCOMES FOR PATIENTS WITH HIGH RISK T1HG BLADDER CANCER MANAGED WITH EITHER UPFRONT CYSTECTOMY OR PRIMARY BCG AND DELAYED CYSTECTOMY
Michael Metcalfe*, James Ferguson, Roger Li, Xiao Lianchun, Neema Navai, Ashish Kamat, Jay Shah, Colin Dinney, Houston, TX

4:50 PD48-09 PURIFIED PROTEIN DEPRIVATION SKIN TEST REACTION IS ASSOCIATED WITH CLINICAL OUTCOME OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS-CALMETTE-GUERIN
Naoya Niwa*, Eiji Kikuchi, Kazuhiro Matsumoto, Koichiro Oghihara, Hiroshi Hongo, Takeo Kosaka, Ryuichi Mizuno, Akira Miyajima, Mototsugu Oya, Tokyo, Japan

5:00 PD48-10 PREOPERATIVE NEUTROPHIL-TO-LYMPHOCYTE RATIO AND SMOKING HISTORY ARE INDEPENDENTLY ASSOCIATED WITH BCG RELAPSING TUMOR RECURRENT IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
Koichiro Oghihara*, Eiji Kikuchi, Yoshinori Yanai, Tokyo, Japan, Kimiharu Takamatsu, Suguru Shirotake, Saitama, Japan, Kazuhiro Matsumoto, Tokyo, Japan, Masafumi Oyama, Saitama, Japan, Hirohiko Nagata, Akira Miyajima, Mototsugu Oya, Tokyo, Japan
NEXT GENERATION SEQUENCING OF NON-MUSCLE INVASIVE BLADDER CANCER REVEALS POTENTIAL BIOMARKERS AND RATIONAL THERAPEUTIC TARGETS

Eugene Pietzak*, Eugene Cha, New York, NY, Aditya Bagrodia, Dallas, TX, Esther Drill, Gopa Iyer, Priscilla Baez, Sumit Isharwal, Qiang Li, Ahmet Zehir, Maria Arcila, Michael Berger, Nikolaus Schultz, Irina Ostrovnaya, Jonathan Rosenberg, Dean Bajorin, Guido Dalbagni, Hikmat Al-Ahmadie, David Solt, Bernard Bochner, New York, NY

METHOD OF DETECTING BLADDER CANCER BY OPTICAL ANALYSIS OF BODILY FLUIDS

Danny Rabah*, Riyadh, Saudi Arabia

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Sunday, May 14, 2017 3:30 pm - 5:30 pm

Video Session 8

PROSTATE AND RENAL ONCOLOGY

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 254 @ Boston Convention & Exhibition Center

Moderators: Duane Baldwin, David Lee and Manish Patel

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V8-01</td>
<td>FOCAL LASER ABLATION: PATH TO A CLINIC TREATMENT FOR PROSTATE CANCER</td>
</tr>
<tr>
<td><em>Leonard Marks</em>, Shyam Natarajan, Alan Priester, Los Angeles, CA, Daniel Margolis, New York, NY</td>
<td></td>
</tr>
</tbody>
</table>

| V8-02 | APPLICATION OF CHITOSAN MEMBRANES ON THE NEUROVASCULAR BUNDLES AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: PRELIMINARY RESULTS OF A PHASE II STUDY |
| Francesco Porpiglia*, Riccardo Bertolo, Enrico Checucci, Matteo Manfredi, Sabrina De Cillis, Roberta Aimer, Stefano Geuna, Cristian Fiori, Orbassano, Italy |

| V8-03 | ROBOT ASSISTED RADICAL NEPHRECTOMY AND INFERIOR VENA CAVA THROMBECTOMY: SURGICAL TECHNIQUE, PERIOPERATIVE AND ONCOLOGIC OUTCOMES |
| *Giuseppe Simone*, Leonardo Misuraca, Gabriele Tuderti, Rome, Italy, David Hatcher, Los Angeles, CA, Mariaconsiglia Ferriero, Rome, Italy, Andre Luis De Castro Abreu, Los Angeles, CA, Francesco Minisola, Rome, Italy, Monish Aron, Los Angeles, CA, Salvatore Guaglianone, Rome, Italy, Mihir Desai, Inderbir Singh Gill, Los Angeles, CA, Michele Gallucci, Rome, Italy |

| V8-04 | PERCUTANEOUS EXTERNALLY ASSEMBLED LAPAROSCOPIC (PEAL) NEPHRECTOMY |
| Jerry Thomas, Mohamed Keheila*, Samuel Abourbih, Patrick Yang, Nazih Khater, Jim Shen, Salim Cheriyian, D. Duane Baldwin, LOMA LINDA, CA |

| V8-05 | SUCCESSFUL ENDOVASCULAR CONTROL OF RENAL ARTERY IN A TRANSPLANT KIDNEY DURING NEPHRON SPARING SURGERY FOR LARGE CENTRALLY LOCATED TUMOR |
| Sagi Shprits*, Boaz Moskovits, Robert Sachnner, Ofer Nativ, Haifa, Israel |

| V8-06 | ADVANCED RECONSTRUCTION OF VESICO-URETHRAL SUPPORT DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY: EXPERIENCE WITH 526 CASES |
| Vladimir Jr. Student, Igor Hartmann, Ales Vidlar, Michal Grepl, Eva Buresova, Vladimir Student*, Olomouc, Czech Republic |

| V8-07 | MODIFIED MILAN SLING TECHNIQUE DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY FOR EARLY RECOVERY OF URINARY CONTINENCE WITHOUT NERVE-SPARING: A PILOT STUDY |
| Yuji Maeda*, Hakusan, Japan, Toshimitsu Misaki, Osamu Ueki, Kanazawa, Japan, Tetsuyuki Kurokawa, Yukinosuke Oshinoaya, Hakusan, Japan, Ken-Ichi Nagano, Haruo Hisazumi, Kanazawa, Japan |

| V8-08 | PURELY OFF-CLAMP ROBOTIC PARTIAL NEPHRECTOMY |
| Giuseppe Simone, Leonardo Misuraca, Gabriele Tuderti*, Francesco Minisola, Mariaconsiglia Ferriero, Giuseppe Romeo, Manuela Costantini, Salvatore Guaglianone, Michele Gallucci, Rome, Italy |

*Presenting author
V8-09 ROBOT ASSISTED RADICAL PROSTATECTOMY FOR PROSTATES OVER 100 GRAMS: TECHNIQUE AND OUTCOMES
Harihara Palayapalayam Ganapathi*, Gabriel Ogaya-Pinies, Eduardo Hernandez, Travis Rogers, Vipul Patel, Celebration, FL

V8-10 ROBOTIC SALVAGE RETROPERITONEAL AND PELVIC LYMPH NODE DISSECTION FOR “NODE-ONLY” RECURRENT PROSTATE CANCER
Carlos Fay*, Andre Abreu, Daniel Park, Niero Rajarubendra, Daniel Melecchi Freitas, Giovanni Cacciamani, Inderbir Gill, Los Angeles, CA

V8-11 THE USE OF A NOVEL CURVED-TIP SUCTION DEVICE IN LAPAROSCOPIC AND ROBOTIC UROLOGIC SURGERY
Mina Fam*, Pittsburgh, NJ, Michael Esposito, Gregory Lovallo, Thomas Christiano, Christopher Wright, Mutahar Ahmed, Hackensack, NJ

V8-12 COMBINING ANTEGRADE AND RETROGRADE DISSECTION DURING SALVAGE ROBOTIC RADICAL PROSTATECTOMY
Mariaconsiglia Ferriero*, Giuseppe Simone, Riccardo Mastroianni, Gabriele Tuderti, Leonardo Misuraca, Francesco Minisola, Salvatore Guaglanone, Michele Gallucci, Rome, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
### Plenary: Prime Time, Monday Morning Session

**Plenary: Prime Time, Monday Morning Session**  
**Ballroom West @ Boston Convention & Exhibition Center**  
*Monday, May 15, 2017 8:00 am - 11:30 am*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>HIGHLIGHTS: GENITOURINARY RECONSTRUCTIVE SURGEONS (GURS)</td>
<td>Benjamin Breyer</td>
</tr>
<tr>
<td>8:10</td>
<td>STATE-OF-THE-ART LECTURE: WHAT’S NEW IN WOUND HEALING?</td>
<td>Dennis Orgill</td>
</tr>
</tbody>
</table>
| 8:30  | CROSSFIRE: CONTROVERSIES IN UROLOGY: GRADE 4 RENAL TRAUMA SHOULD BE MANAGED CONSERVATIVELY  
Moderator: Andre Cavalcanti  
Debaters-Pro: Jeff Carney, Richard Santucci  
Debaters-Con: Hunter Wessells, Frank Burks |
| 9:00  | SECOND OPINION CASES: MANAGING ARTIFICIAL SPHINCTER MALFUNCTION             | Brian Christine                                  |
| 9:30  | SURGICAL TECHNIQUES: ANTERIOR URETHROPLASTY                                 | Sean Elliott                                     |
|       | Surgeons: Kurt McCammon, Sanjay Kulkarni, Kenneth Angermeier                |                                                  |
| 10:30 | COMPLEX CASES: PAN-URETHRAL STRICTURE DISEASE                              | Michael Coburn                                   |
|       | Panelists: Daniela Andrich, Pankaj Joshi, Alex Vanni                        |                                                  |
| 11:00 | POINT-COUNTERPOINT DEBATE: THE DEVASTATED BLADDER NECK: SALVAGE OR CLOSE?  | Marc Cendron                                     |
| 11:30 | SESSION CONCLUDES                                                           |                                                  |

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**

---

### Plenary: Next Frontier, Monday Morning Session

**Plenary: Next Frontier, Monday Morning Session**  
**Ballroom East @ Boston Convention & Exhibition Center**  
*Monday, May 15, 2017 8:00 am - 11:30 am*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>HIGHLIGHTS OF UROLOGIC ONCOLOGY RESEARCH</td>
<td>Aria Olumi</td>
</tr>
</tbody>
</table>
| 8:15  | SOCIÉTÉ INTERNATIONALE D’UROLOGIE (SIU) LECTURE: OPTICAL COHERENCE TOMOGRAPHY IN UROLOGIC ONCOLOGY  
Jean de la Rosette |
| 8:30  | EUROPEAN ASSOCIATION OF UROLOGY (EAU) LECTURE: GENOMIC REVOLUTION IN BLADDER CANCER:  
FAST APPROACHING OR A DISTANT DREAM?  
James Catto |
| 8:45  | STATE-OF-THE-ART LECTURE: IMMUNOTHERAPY FOR BLADDER CANCER                  | Peter Black                                      |
| 9:00  | STATE-OF-THE-ART LECTURE: RACIAL DISPARITIES AND GENETIC VARIABILITY IN PROSTATE CANCER  
Isaac Kim |
| 9:30  | STATE-OF-THE-ART LECTURE: IMPLANTABLE MICRO DEVICE FOR HIGH-THROUGHPUT IN VIVO DRUG TESTING  
Oliver Jonas |
| 9:45  | STATE-OF-THE-ART LECTURE: CIRCULATING TUMOR CELLS                           | Mehmet Toner                                     |
| 10:00 | PNFB-A06: BEST ABSTRACT - ASKMUSIC®: LEVERAGING A CLINICAL REGISTRY TO INFORM PATIENTS  
Gregory Auffenberg |
| 10:05 | PNFB-A07: BEST ABSTRACT - THE CURRENT MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES:  
DATA FROM THE AQUA REGISTRY  
Matthew Cooperberg |

*Presenting author*
10:10 PNFBA-08: BEST ABSTRACT - NOVEL IN VITRO ORGANOID TECHNOLOGY TO FACILITATE A PRECISION MEDICINE APPROACH IN THE MANAGEMENT OF MEN WITH BIOCHEMICAL RECURRENCE OF PROSTATE CANCER
Andre Joshi

10:15 PNFBA-09: BEST ABSTRACT - THE DIVERSE GENOMIC LANDSCAPE OF LOW-RISK PROSTATE CANCER
Matthew Cooperberg

10:20 PNFBA-10: BEST ABSTRACT - FOCAL THERAPY OF PROSTATE CANCER: DEFINING APPROPRIATE TREATMENT MARGINS USING MRI: WHOLE MOUNT CO-REGISTRATION
Tonye Jones

10:25 PNFBA-11: BEST ABSTRACT - E-CIGARETTE SMOKE IS POTENTIALLY BLADDER CARCINOGENIC – IT INDUCES TUMORIGENIC DNA ADDUCTS AND INHIBITS DNA REPAIR IN UROTHELIAL CELLS
Hyun-wook Lee

10:30 PNFBA-12: BEST ABSTRACT - LIQUID BIOPSY FOR RENAL CELL CARCINOMA
Usama Al-Qassab

10:35 PNFBA-13: BEST ABSTRACT - ARE THE CURRENT FOLLOW-UP GUIDELINES AFTER TREATMENT FOR ORGAN CONFINED RENAL SEBINUS
Sebastian Frees

10:40 PNFLBA-10: LATE-BREAKING ABSTRACT - A PHASE III BLINDED STUDY OF IMMEDIATE POST-TURBT INSTILLATION OF GEMCITABINE VERSUS SALINE IN PATIENTS WITH NEWLY DIAGNOSED OR OCCASIONALLY RECURRING GRADE I/II NON-MUSCLE INVASIVE BLADDER CANCER: SWOG S0337
Edward Messing

10:45 PNFLBA-11: LATE-BREAKING ABSTRACT - RADICAL PROSTATECTOMY VERSUS OBSERVATION FOR EARLY PROSTATE CANCER: FOLLOW-UP RESULTS OF THE PROSTATE CANCER INTERVENTION VERSUS OBSERVATION TRIAL
Timothy Wilt

10:50 PNFLBA-12: LATE-BREAKING ABSTRACT - TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 EXPRESSING BLADDER CANCER USING COMBINATION PHOTOIMMUNOTHERAPY (PIT)
Mohammad Siddiqui

10:55 PNFLBA-13: LATE-BREAKING ABSTRACT - INTERIM RESULTS FROM A SINGLE-ARM MULTICENTER PHASE II TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
Vignesh Packiam

11:00 PNFLBA-14: LATE-BREAKING ABSTRACT - EARLY IN VIVO DETECTION OF METASTATIC BLADDER CANCER IN MICE USING MOLECULAR MRI
Joel Slaton

11:05 PNFLBA-15: LATE-BREAKING ABSTRACT - INTERIM RESULTS OF A NOVEL ADAPTIVE REGISTRATION-UTILITY TRIAL ASSESSING THE PERFORMANCE OF EXODX® (PROSTATE) INTELLISCORE (EPI); A NON-DRE URINE EXOSOME GENE EXPRESSION ASSAY TO PREDICT HIGH GRADE DISEASE ON INITIAL BIOPSY
James McKiernan

11:10 PNFLBA-16: LATE-BREAKING ABSTRACT - FIRST RESULTS OF A-PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY
Grant Stewart

11:15 PNFLBA-17: LATE-BREAKING ABSTRACT - DETECTION OF CIRCULATING TUMOR CELL IN THE PATIENTS WITH PROSTATE CANCER USING NOVEL VIRAL MARKER OBP-1101
Nobuyuki Hinata

11:20 PNFLBA-18: LATE-BREAKING ABSTRACT - A PROSPECTIVE, MULTICENTER, RANDOMIZED TRIAL OF OPEN VERSUS ROBOTIC RADICAL CYSTECTOMY (RAZOR)
Dipen Parekh

11:30 SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Monday, May 15, 2017 1:00 pm - 4:30 pm

Plenary: Prime Time I, Monday Afternoon Session

Ballroom West @ Boston Convention & Exhibition Center

1:00  CROSSFIRE: CONTROVERSIES IN UROLOGY: FOCAL THERAPY FOR PROSTATE CANCER IS THE FUTURE AND THE FUTURE IS NOW

Moderator:  Laurence Klotz
Debaters-Pro:  Thomas Polascik, Inderbir Gill
Debaters-Con:  James Eastham, Dipen Parekh

1:30  SECOND OPINION CASES: NON-MUSCLE INVASIVE BLADDER CANCER

Moderator:  John Seigne
Panelists:  Colin Dinney, Yair Lotan

2:00  SURGICAL TECHNIQUES: ROBOT-ASSISTED LAPAROSCOPIC RETROPERITONEAL LYMPH NODE DISSECTION (RPLND)

Surgeons:  James Porter, Sean Stroup, Lou Kavoussi

3:00  PANEL DISCUSSION: DO WE NEED EXTENDED NODE DISSECTIONS FOR BLADDER AND RENAL CANCER?

Moderator:  Hendrik Van Poppel
Panelists:  Umberto Capitanio, Seth Lerner, Alexandre Zlotta

3:20  POINT-COUNTERPOINT DEBATE: ADJUVANT THERAPY FOR HIGH RISK RENAL CANCER

Debater-Con:  Lauren Harshman
Debater-Pro:  Christopher Wood

3:40  PANEL DISCUSSION: HOW TO DEFINE LOW RISK PROSTATE CANCER?

Moderator:  Marc Dall’Era
Panelist: Confirmatory Biopsy:  Peter Carroll
Panelist: Genomics:  Eric Klein
Panelist: MRI:  Samir Taneja

4:00  SETBACKS AND OPERATIVE SOLUTIONS (SOS): ROBOTIC PROSTATECTOMY

Moderator:  Raju Thomas
Panelists:  Ketan Badani, Matthew Gettman, Ashok Hemal, Robert Stein

4:30  SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 15, 2017 1:00 pm - 4:00 pm

Plenary: Prime Time II, Monday Afternoon Session

Ballroom East @ Boston Convention & Exhibition Center

1:00  HIGHLIGHTS: SOCIETY OF URODYNAMICS, FEMALE PELVIC MEDICINE & UROGENITAL RECONSTRUCTION (SUFU) PROGRAM

Ryan Krlin

1:10  PANEL DISCUSSION: DEMENTIA, COGNITION AND THE AGING BLADDER

Moderator:  Eric Rovner
Panelists:  Sender Herschorn, George Kuchel

1:30  CROSSFIRE: CONTROVERSIES IN UROLOGY: VAGINAL MESH SHOULD BE REMOVED BY RADICAL MESTECTOMY

Moderator:  Victor Nitti
Debaters-Pro:  Shlomo Raz, Christian Twiss
Debaters-Con:  Elizabeth Takacs, Howard Goldman

2:00  SECOND OPINION CASES: URINARY INCONTINENCE

Moderator:  Gopal Badlani
Panelists:  Fiona Burkhard, Una Lee, Nissrine Nakib

2:30  SURGICAL TECHNIQUES: AUTOLOGOUS PUBOVAGINAL SLINGS

Moderator:  Roger Dmochowski
Surgeons:  Philip Zimmern, Melissa Kaufman, Donna Deng

3:30  SETBACKS AND OPERATIVE SOLUTIONS (SOS): PROLAPSE SURGERY

Moderator:  Sandip Vasavada
Panelists:  Brian Flynn, Paulo Palma, Mauricio Plata

4:00  SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT

MP68-01  EFFECTS AND OUTCOMES OF URETERAL STENTING PRIOR TO URETEROSCOPY VERSUS PRIMARY URETEROSCOPY IN URINARY STONE TREATMENT
Ilgar Akbarov*, Mustafa Al-Mahmid, Ali Tok, Vahudin Zugor, Melanie Von Brandenstein, David Pfister, Axel Heidenreich, Cologne, Germany

MP68-02  URETERAL STRICTURE RATES ASSOCIATED WITH URETERAL ACCESS SHEATH USE FOR RETROGRADE RENAL STONE SURGERY
Brian Jordan, Sang Gune Yoo, Aziz Khambati*, Kent Perry, Robert Nadler, Chicago, IL

MP68-03  UROSEPSIS FOLLOWING URETERORENOSCOPY FOR THE TREATMENT OF UROLITHIASIS OR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA: A FOCUS ON UNDERESTIMATED AND HARMFUL POSTOPERATIVE COMPLICATION
Luca Villa*, Filippo Pederzoli, Francesco Trevisani, Alberto Briganti, Andrea Salonia, Francesco Montorsi, Milan, Italy

MP68-04  SUCTIONING FLEXIBLE URETEROSCOPIC LITHOTRIPSY IN THE OBLIQUE SUPINE LITHOTOMY POSITION AND SUPINE LITHOTOMY POSITION: A COMPARATIVE STUDY
Leming Song*, Xiaolin Deng, Ganzhou, China, People’s Republic of, Donghua Xie, Fort Lauderdale, FL, Jianrong Huang, Ganzhou, China, People’s Republic of

MP68-05  SINGLE SURGEON EXPERIENCE WITH RETAINED ENCRUSTED STENTS: COMBINED ENDOUROLOGICAL APPROACH AND MODIFIED GRADING SYSTEM
Roberto Lopes, Carlos Watranabe-Silva*, Fabricio Beltame, Alexandre Danilovic, Joaquim Claro, Fabio Vicentini, São Paulo, Brazil

MP68-06  A PROSPECTIVE RANDOMIZED STUDY EVALUATING SAFETY AND EFFICACY OF BILATERAL SIMULTANEOUS RETROGRADE INTRARENAL SURGERY FOR ENDOSCOPIC MANAGEMENT OF BILATERAL RENAL CALCULI.
Hemendra Shah*, Rashmi Shah, Mumbai, India

MP68-07  1-BILATERAL SIMULTANEOUS RETROGRADE INTRARENAL SURGERY IN CHILDREN: IS IT SAFE AND FEASIBLE?
Ahmed Fahmy*, Mostafa Elsaywy, Amr Kamal, hazem Rhasad, Alexandria, Egypt

MP68-08  POSITIONAL MANIPULATIONS TO FACILITATE SUCCESS DURING RETROGRADE INTRARENAL SURGERY IN CHILDREN USING SEMI RIGID URETEROSCOPY
Ahmed Fahmy*, Moustafa Elsaywy, Amr Kamal, hazem Rhasad, Abdelrahman Zahrani, Alexandria, Egypt

MP68-09  CONTINUING ASPIRIN DOES NOT INCREASE BLOOD LOSS FROM PERCUTANEOUS NEPHROLITHOTOMY
Timothy Tran*, Egor Pankhomenko, Julie Thai, Kyle Blum, Mantu Gupta, New York, NY

MP68-10  PERIOPERATIVE ASPIRIN USE DURING PERCUTANEOUS NEPHROLITHOTOMY (PCNL): OUR SINGLE CENTER EXPERIENCE.
Joshua Ebel*, Bodo Knudsen, Columbus, OH

MP68-11  A PROSPECTIVE, RANDOMIZED TRIAL EVALUATING THE EFFICACY OF TWO DIFFERENT HEMOSTATIC SEALANT IN TUBELESS PERCUTANEOUS NEPHROLITHOTOMY
Yang Sun Choi, Kyu Won Lee*, Woong Jin Bae, Seoul, Korea, Republic Of, Sung-Dae Kim, Jeju, Korea, Republic Of, Sung-Hoo Hong, Ji Youl Lee, Sae Woong Kim, Hyuk Jin Cho, Seoul, Korea, Republic Of

MP68-12  STONE MORPHOMETRY: TRACT (S) AND STAGE (S) PREDICTOR FOR PERCUTANEOUS NEPHROLITHOTOMY
Jorge Sedano-Basilio*, Luis Trujillo-Ortiz, Carlos Martinez-Arroyo, Carlos Pacheco-Gahbler, Mexico City, Mexico

MP68-13  OUTCOMES OF PATIENTS WITH RADIOGRAPHIC XANTHOGRANULOMATOUS PYELONEPHRITIS MANAGED WITH PERCUTANEOUS NEPHROLITHOTOMY
Noah Canvasser, Aaron Lay, Shuvro De, Arti Satyanarayan, Elysha Kolitz, Margaret Pearle, Jodi Antonelli*, Dallas, TX

MP68-14  SUPINE MINI PCNL – ARE WE LOOKING AT A RECURSE TO STANDARD PCNL? - A SINGLE CENTER EXPERIENCE
Anunkurmal Balakrishnan*, Chennai, India, Kulthe Ramesh Seetharam Bhat, Bangalore, India, Priyank Shah R, Gaurav Gyvi, Chennai, India
MP68-15 SUPINE PERCUTANEOUS NEPHROLITHOTOMY FOR STAGHORN CALCULI – PROSPECTIVELY RECORDED EXPERIENCE IN A SINGLE TERTIARY REFERRAL ENDUROLOGY UNIT


MP68-16 PERCUTANEOUS NEPHROLITHOTOMY ACCESSED BY SVOF TWO-STEP DILATION WITH ULTRASOUND-GUIDED PRONE POSITION PUNCTURE FOR 11 507 PATIENTS

Xiao Yu*, Ejun Peng, Shaogang Wang, Zhangqun Ye, Wuhan, China, People’s Republic Of

MP68-17 THE CLINICAL SAFETY AND FEASIBILITY FOR ULTRASOUND GUIDED PARAVERTEBRAL BLOCK ANESTHESIA OF PERCUTANEOUS NEPHROLITHOTOMY

Jia Hu*, Xiao Yu, Shaogang Wang, Wuhan, China, People’s Republic Of

MP68-18 “DOES SPLITTING OF PAPILLA MATTER DURING PCNL?” A PROSPECTIVE STUDY

Venkatesh Krishnamoorthy*, MG Pradeepa, Maneesh Sinha, Bangalore, India

MP68-19 BILATERAL SINGLE SESSION PERCUTANEOUS NEPHROLITHOTOMY: IS IT WORTH THE RISK?

Oleg Goldin*, Sergiu Bistrich, Tareq Aro, Ariel Zisman, Gilad E. Amiel, Michael Mullerad, Haifa, Israel

MP68-20 INTEROBSERVER VARIABILITY AMONG SURGEONS AND RADIOLOGISTS IN ASSESSMENT OF GUY’S STONE SCORE AND S.T.O.N.E. NEPHROLITHOMETRIC SCORE: A PROSPECTIVE EVALUATION

Aneesh Srivastava*, Priyank Yadav, Sanjoy Sureka, Uday Singh, Rakesh Kapoor, M S Ansari, Hira Lal, Prabhakar Mishra, Lucknow, India

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 15, 2017 7:00 am - 9:00 am

Moderated Poster Session 69

GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, QUALITY OF LIFE AND SHARED DECISION MAKING III

Moderators: J. Quentin Clemens, Christopher Gonzalez and J. Kellogg Parsons

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP69-01</td>
<td>ANTIMUSCARINIC USE IN THE ELDERLY: A POISONED APPLE?</td>
</tr>
<tr>
<td>Daniel Pucheril*, Detroit, MI, Christian P. Meyer, Boston, MA, Patrick Karabon, Humphrey Asiemo, Mani Menon, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Bilal Chughtai, New York, NY</td>
<td></td>
</tr>
<tr>
<td>MP69-02</td>
<td>VARIATION IN CARE INTENSITY FOR OVERACTIVE BLADDER SYMPTOMS AMONG MEDICARE BENEFICIARIES</td>
</tr>
<tr>
<td>Charles Scales Jr*, Melissa Greiner, Lesley Curtis, Brad Hammill, Andrew Peterson, Cindy Amundsen, Kenneth Schmader, Durham, NC</td>
<td></td>
</tr>
<tr>
<td>MP69-03</td>
<td>USE OF PELVIC FLOOR REHABILITATION IN A STATEWIDE QUALITY IMPROVEMENT COLLABORATIVE: PATIENT AND COST CHARACTERISTICS</td>
</tr>
<tr>
<td>Deborah R. Kaye*, John Syrijamaki, Chad Ellismo01it, M Hugh Solomon, Take Kim, Susan Linsell, Khurshid R. Ghani, David C. Miller, James E. Montie, James M. Dupree, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI</td>
<td></td>
</tr>
<tr>
<td>MP69-04</td>
<td>IDENTIFICATION OF MODIFIABLE RISK FACTORS ASSOCIATED WITH PATIENT-REPORTED ERECTILE DYSFUNCTION TO ENHANCE PATIENT HEALTH COUNSELING AND SEXUAL QUALITY OF LIFE</td>
</tr>
<tr>
<td>MP69-05</td>
<td>TWITTER MENTIONS AND ACADEMIC CITATIONS IN UROLOGY LITERATURE</td>
</tr>
<tr>
<td>Solomon Hayon*, Ian Stormont, Meagan Dunne, Michael Naslund, Mohammad Minhaj Siddiqi, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>MP69-06</td>
<td>AUTHOR SELF-CITATION IN THE UROLOGY LITERATURE</td>
</tr>
<tr>
<td>Katherine Carlisle*, Joseph Sterbis, Phuong Do, Leah McMann, Honolulu, HI</td>
<td></td>
</tr>
<tr>
<td>MP69-07</td>
<td>HASHTAG PEER-REVIEW: DOES EARLY SOCIAL MEDIA SUCCESS CORRELATE WITH CONVENTIONAL METRICS OF PUBLICATION IMPACT?</td>
</tr>
</tbody>
</table>

*Presenting author
MP69-08 PHARMACEUTICAL INDUSTRY PAYMENTS AND PHYSICIAN PRESCRIBING OF UROLOGIC DRUGS
Parth Modi*, New Brunswick, NJ, Matthew Ingham, Boston, MA, Eric Singer, New Brunswick, NJ, Steven Chang, Boston, MA

MP69-09 SURVIVAL OUTCOMES OF ORGAN SPARING SURGERY, PARTIAL PENECTOMY AND TOTAL PENECTOMY IN T1/T2 PENILE CANCER
Benjamin Schurhamer*, Jun Tao, Mark Campbell, Judy Farias, Alfred Hall, Rodney Davis, Joseph Su, Mohamed Kamel, Little Rock, AR

MP69-10 TRENDS IN STAGE I NON-SEMINOMATOUS GERM CELL TUMORS IN THE UNITED STATES
Nahid Punjani*, London, Canada, Thomas Seisen, Claire Beard, Christopher Sweeney, Quoc-Dien Trinh, Jennifer Rider, Mark Preston, Boston, MA

MP69-11 PATTERNS OF SURVEILLANCE INTENSITY IN KIDNEY CANCER
Suzanne Merrill*, Eric Schaefer, Chris Hollenbeak, Hershey, PA

MP69-12 UNDERUTILIZATION OF PALLIATIVE SERVICES IN ADVANCED GENITOURINARY MALIGNANCIES
Adrien Bernstein*, Ron Golan, Brian Dinerman, Jonathan Fainberg, Bashir Al Husseins Al Awamith, Jim C. Hu, NEW YORK, NY

MP69-13 PATIENT REPORTED HEALTH AND QUALITY OF LIFE AFTER NEOADJUVANT CHEMOTHERAPY AND CYSTECTOMY: RESULTS FROM BLADDER CANCER OUTCOMES AND IMPACT STUDY
Dominic Tang*, Andrew Leone, Juan Chipollini, Tampa, FL, Paul Crispen, Carl Henrikson, Gainesville, FL, Michael Poch, Wade Sexton, Scott Gilbert, Tampa, FL

MP69-14 ACADEMIC AND HIGH-VOLUME HOSPITALS ARE ASSOCIATED WITH IMPROVED OUTCOMES IN THE MANAGEMENT OF RETROPERITONEAL SARCOMA
Jessica Yih*, Matthew Maurice, Robert Abouassaly, John Ammori, Cleveland, OH

MP69-15 RECEIPT OF Mannitol USE IN PARTIAL NEPHRECTOMY AND RATES OF CONVERSION TO RADICAL NEPHRECTOMY AFTER MANNITOL ADMINISTRATION
Yash Khandwala*, San Diego, CA, In Gab Jeong, Palo Alto, CA, Ye Wang, Boston, MA, Dek Hyun Han, Seoul, Korea, Republic of, Jae Heon Kim, Seol, Korea, Republic of, Shufeng Li, Palo Alto, CA, Steven L Chang, Boston, MA, Benjamin Chung, Palo Alto, CA

MP69-16 THE ASSOCIATION OF HEALTH LITERACY AND NUMERACY ON UNDERSTANDING OF PROSTATE CANCER TERMINOLOGY
Jeremiah Umoh*, Shaquille Brown, Daniel Heslop, Ken Walliston, Kelvin Moses, Nashville, TN

MP69-17 INCIDENCE OF PROSTATE CANCER STRATIFIED BY COUNTY EDUCATION, POVERTY, AND URBANIZATION LEVELS: A POPULATION BASED ANALYSIS OF SEER
Daniel Au*, Johar Syed, Sameer Siddiqui, Saint Louis, MO

MP69-18 A PATIENT-CENTERED PRACTICE CHANGE: FINDING THE BEST APPROACH FOR PROSTATE CANCER DECISION SUPPORT
Donna Berry*, Barbara Halpenny, Meghan Underhill, Boston, MA, Martin Senda, Viraj Master, Christopher Filson, Atlanta, GA, Peter Chang, Boston, MA, Gary Chien, Los Angeles, CA, Seth Wolpin, Seattle, WA

MP69-19 THE IMPACT OF RACE ON PERCEPTIONS OF ANXIETY AFTER LOCAL THERAPY FOR PROSTATE CANCER
Shilajit Kundu, Vincent Wong, Channa Amarasekera*, Kevin Lewis, Edward Schaeffer, Anthony Schaeffer, Joshua Meeks, David Victorson, James Burns, Sandra Gutierrez, Chicago, IL, Kevin McVary, Springfield, IL, Sarah Psutka, David Cella, Chicago, IL

MP69-20 THE IMPACT OF STATE LAWS LIMITING MALPRACTICE AWARDS ON DIFFUSION OF SURGICAL INNOVATION: THE CASE OF MINIMALLY INVASIVE RADICAL PROSTATECTOMY
Shyam Sukumar*, Oluwakayode Adejoro, Badrinath Konety, Minneapolis, MN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP70-01</td>
<td>Utility of Multiparametric MRI on Patient Selection for Focal Therapy in Intermediate Risk Prostate Cancer</td>
<td>Brian Calio*, Abhinav Sidana, Dordaneh Sugano, Sonia Gaur, Amit Jain, Mahir Maruf, Maria Merino, Baris Turkbey, Peter Choyke, Bradford Wood, Peter Pinto</td>
<td>Bethesda, MD</td>
</tr>
<tr>
<td>MP70-03</td>
<td>Clinical Performance of Multi-parametric Magnetic Resonance Imaging in the Follow-Up of Partial Gland Ablation for Prostate Cancer</td>
<td>Arjun Sivaraman*, Melissa Assel, Andreas Hoetker, Govindarajan Srimathveeravalli, Behfar Ehdai, Oguz Akin, Jonathan Coleman</td>
<td>New York, NY</td>
</tr>
<tr>
<td>MP70-04</td>
<td>3-T Multiparametric MRI Characteristics of Prostate Cancer Patients Suspicious for Biochemical Recurrence After Primary Focal Cryosurgery.</td>
<td>Daniel Halpern*, Michael Kongnyuy, Kaitlin Kosinski, Jeffrey Schiff, Anthony Corcoran, Aaron Katz</td>
<td>Mineola, NY</td>
</tr>
<tr>
<td>MP70-06</td>
<td>Predicting Oncological Control Following Focal Ablation(FA) of Prostate Cancer(PCA)</td>
<td>Alexander Kenigsberg*, Elton Lukuani, Fang-Ming Deng, Jonathan Melamed, Herbert Lepor</td>
<td>New York, NY</td>
</tr>
</tbody>
</table>
MP70-12 PREDICTING EXTENSIVE DISEASE AMONG POTENTIAL CANDIDATES FOR HEMI-ABLATIVE FOCAL THERAPY FOR PROSTATE CANCER
Toshikazu Takeda*, Amy Tin, Renato Corradi, Maha Mamoor, Nicola Robertson, Hebert Vargas, Nicole Benfante, Daniel Sjoberg, Samson Fine, James Eastham, Peter Scardino, Karim Touijer, New York, NY

MP70-13 CRYOSURGICAL ABLATION OF THE PROSTATE: LOCAL DISEASE CONTROL FOR INTERMEDIATE /HIGH-GRADE GLEASON PROSTATE CANCER
Ahmed El Shafei, Mohamed Eltemamy*, Yaw Nyame, Hans Arora, J Stephen Jones, Cleveland, OH

MP70-14 PSA NADIR AND PSA FLARE ARE THE PREDICTORS OF BIOCHEMICAL FAILURE AFTER HIGH-INTENSITY FOCUSED ULTRASOUND TREATMENT OF LOCALIZED PROSTATE CANCER
Naokazu Ibuki*, Teruo Inamoto, Yudai Nishimoto, Kiyoshi Takahara, Toshikazu Watsuji, Haruhito Azuma, Osaka, Japan

MP70-15 INTRA-PROSTATIC PRX302 FOCAL THERAPY IN TREATING CLINICALLY SIGNIFICANT LOW-INTERMEDIATE PROSTATE CANCER: AN OPEN LABEL, PROOF-OF-CONCEPT STUDY
Edward Bass*, Yaalini Shanmugabavan, London, United Kingdom, Allison Hulme, La Jolla, CA, Alex Freeman, Chris Brew-Graves, Ingrid Potyka, Navin Ramachandran, Mark Emberton, Hashim Ahmed, London, United Kingdom

MP70-16 SAFETY AND FEASIBILITY OF REAL-TIME MRI-GUIDED FOCUSED ULTRASOUND FOR FOCAL THERAPY OF LOCALIZED PROSTATE CANCER USING THE EXABLADE 2100 DEVICE: PHASE 1 STUDY
Nathan Portis*, Eugen Hlasny, Walter Kucharczyk, Masoom Haider, Antonio Finelli, Alexandre Zlotka, Girish Kulkarni, John Trachtenberg, Sangeet Ghai, Toronto, Canada

MP70-17 DOES PRIOR INTERVENTIONAL THERAPY FOR BPH INCREASE THE RISK OF COMPLICATIONS AFTER PRIMARY WHOLE GLAND PROSTATE CRYOABLATION?
Ahmed El Shafei*, Cleveland, OH, Kae Jack Tay, Durham, NC, Asmaa Hatem, Cleveland, OH, Thomas Polascik, Durham, NC, Ashley Ross, Baltimore, MD, J. Kellogg Parsons, San Diego, CA, Vladimir Mouraviev, Celebration, FL, Robert Given, Norfolk, VA, J Stephen Jones, Cleveland, OH

MP70-18 PROSTATE RADIOFREQUENCY ABLATION FOCAL TREATMENT (PRORAF): INTERIM RESULTS OF A PROSPECTIVE DEVELOPMENT STUDY
Clement Orczyk*, Chris Brew-graves, Norman Williams, Ingrid Potika, Navin Ramachandran, Alex Freeman, Mark Emberton, Hashim U Ahmed, London, United Kingdom

MP70-19 LOCAL IMMUNE MODULATION BY INCREASING T CYTOTOXIC / T HELPER RATIO AFTER PROSTATE CANCER HEMI-CRYOABLATION
Karen L. Ferrara, Michael Cerqueira, Athanase Bills, Mário J. A. Saad, Amilcar Castro, Leonardo O. Reis*, Campinas - SP, Brazil

MP70-20 PREDICTORS AND UTILIZATION OF ABLATIVE THERAPIES IN NEW YORK STATE
Maxwell B James*, Dennis J Robins, Wilson Sui, Ifeanyi C Onyeji, Justin T Matulay, Marissa C Theofanides, Sven Wenske, New York, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT

NUMBER TITLE
MP71-01 COMPREHENSIVE GENOMIC CHARACTERIZATION OF UPPER TRACT UROTHELIAL CARCINOMA (UTUC)
Tyler Moss, Yuan Qi, Bo Peng, Liu Xi, Maribel Mosqueda, Charles Guo, Michael Ittmann, David Wheeler, Seth Lerner, Surena Matin*, Houston, TX

MP71-02 DISTINCT GENOMIC LANDSCAPE OF UPPER URINARY TRACT UROTHELIAL CARCINOMA
Yoichi Fuji*, Yusuke Sato, Tokyo, Japan, Hiromichi Suzuki*, Tetsuichi Yoshizato, Kyoto, Japan, Yushiuke Shozawa, Tokyo, Japan, Kenichi Yoshida, Kyoto, Japan, Yuichi Shiraisi, Tohru Nakagawa, Haruki Kume, Hiroaki Nishimatsu, Toshikazu Okaneya, Tokyo, Japan, Masashi Sanada, Nagoya, Japan, Hideki Makishima, Tokyo, Japan, Satoru Miyano, Tokyo, Japan, Seishi Ogawa, Hiroki Ide, Tatani, Japan, Yukio Homma, Tokyo, Japan

MP71-03 PROGNOSTIC VALUE OF PD-1 AND PD-L1 EXPRESSION IN PATIENTS WITH HIGH-GRANDE UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT
Laura-Maria Krabbe*, Dallas, TX, Barbara Heitzplatz, Muenster, Germany, Ryan Hutchinson, Solomon Woldu, Nirmish Singla, Dallas, TX, Sina Preuss, Martin Boegemann, Muenster, Germany, Christopher Wood, Jose Karam, Houston, TX, Alon Weizer, Ann Arbor, MI, Jay Raman, Hershey, PA, Nirmish Singla, Fukuoka, Japan, Eiji Kashiwagi, Tokyo, Japan, Hiroshi Miyamoto, Netto, Birmingham, AL, Norio Nonomura, Suita, Japan, Hiroki Miyamoto, Rochester, NY

MP71-04 GATA3 IMMUNOHISTOCHEMISTRY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT AS A UROTHELIAL MARKER AS WELL AS A PROGNOSTICATOR
Satoshi Inoue*, Rochester, NY, Kazutoshi Fujita, Suita, Japan, Hiroki Ide, Tokyo, Japan, Seiji Yamaguchi, Hiroaki Fushimi, Osaka, Japan, George Netto, Birmingham, AL, Norio Nonomura, Suita, Japan, Hiroki Miyamoto, Rochester, NY

MP71-05 PROGNOSTIC SIGNIFICANCE OF BAP1 EXPRESSION IN UPPER TRACT UROTHELIAL CARCINOMA
Nirmish Singla, Dallas, TX, Ahmet Aydin*, Ankara, Turkey, Nirmish Singla, Fukuoka, Japan, Solomon Woldu, Dallas, TX, Christopher Wood, Jose Karam, Houston, TX, Alon Weizer, Ann Arbor, MI, Jay Raman, Hershey, PA, Nirmish Singla, Osaka, Japan, Kazutoshi Fujita, Suita, Japan, Hiroki Miyamoto, Netto, Birmingham, AL, Norio Nonomura, Suita, Japan, Hiroki Miyamoto, Rochester, NY

MP71-06 PROGNOSTIC SIGNIFICANCE OF EZH2 EXPRESSION IN UPPER TRACT UROTHELIAL CARCINOMA
Ahmet Aydin*, Ankara, Turkey, Nirmish Singla, Fukuoka, Japan, Solomon Woldu, Dallas, TX, Christopher Wood, Jose Karam, Houston, TX, Alon Weizer, Ann Arbor, MI, Jay Raman, Hershey, PA, Nirmish Singla, Osaka, Japan, Kazutoshi Fujita, Suita, Japan, Hiroki Miyamoto, Netto, Birmingham, AL, Norio Nonomura, Suita, Japan, Hiroki Miyamoto, Rochester, NY

MP71-07 SERUM CORE FUCOSYLATED N-GLYCAN CARRYING IMMUNOGLOBRIN IS A DIAGNOSTIC AND PRE-OPERATIVE PROGNOSTIC MARKER OF UPPER TRACT UROTHELIAL CARCINOMA
Toshikazu Tanaka*, Yukie Tobisawa, Shingo Hatayama, Kazuyuki Mori, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama, Tohru Yoneyama, Hiroaki Fushimi, Osaka, Japan

MP71-08 EXPRESSION OF TRANSCRIPTION FACTORS, ELK1, FOXO1, NFATC1, AND ZKSCAN3, IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT AS PROGNOSTICATORS
Taichi Mizushima*, Rochester, NY, Kazutoshi Fujita, Suita, Japan, Satoshi Inoue, Rochester, NY, Hiroki Ide, Tokyo, Japan, Takashi Kawahara, Yokohama, Japan, Mehrsa Jalalizadeh, Baltimore, MD, Seiji Yamaguchi, Hiroaki Fushimi, Osaka, Japan, Eiji Kashiwagi, Fukukika, Japan, George Netto, Birmingham, AL, Norio Nonomura, Suita, Japan, Hiroki Miyamoto, Rochester, NY

*Presenting author
MP71-09  EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL NEPHROURETERECTOMY FOR LOCALLY ADVANCED AND/OR POSITIVE REGIONAL LYMPH NODE UPPER TRACT UROTHELIAL CARCINOMA
Thomas Seisen*, Ross E. Krasnow, Joaquim Bellmunt, Boston, MA, Morgan Rouprêt, Paris, France, Jeffrey J. Leow, Stuart R. Lipsitz, Malte Vetterlein, Mark A. Preston, Nawar Hanna, Adam S. Kibel, Maxine Sun, Toni K. Choueiri, Quoc-Dien Trinh, Steven Lee Chang, Boston, MA

MP71-10  ADJUVANT THERAPY FOR T3B OF THE UPPER TRACT UROTHELIAL CARCINOMA
Jong Keun Kim*, Seoul, Korea, Republic of, Myungchan Park, Busan, Korea, Republic of, Myong Kim, Dalsan You, In Gab Jeoung, Cheryn Song, Bumsik Hong, Young Seek Kim, Seoul, Korea, Republic of, Seong-Ho Lee, Hwaseong-si, Korea, Republic of, Sang Hyun Park, Busan, Korea, Republic of, Choung-Soo Kim, Tai Young Ahn, Hanjong Ahn, Seoul, Korea, Republic of

MP71-11  CLINICAL RESPONSE RATES OF NEOADJUVANT CHEMOTHERAPY IN HIGH GRADE UPPER TRACT UROTHELIAL CARCINOMA: A SINGLE INSTITUTIONAL EXPERIENCE
Hayley R. Silver*, Marc A. Bjurlin, William C. Huang, New York, NY

MP71-12  CLINICAL BENEFIT OF PLATINUM-BASED NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED UPPER TRACT UROTHELIAL CARCINOMA
Shingo Hatakeyama*, Shogo Hosogoe, Masaki Momota, Koichi Kido, Hayato Yamamoto, Yasuhiro Hashimoto, Takahiro Yoneyama, Takuya Kole, Chikara Ohyama, Hirosaki, Japan

MP71-13  EFFICACY OF CHEMOTHERAPY ADMINISTRATION IN ELDERLY PATIENTS WITH METASTATIC UPPER TRACT UROTHELIAL CARCINOMA AFTER RADICAL NEPHROURETERECTOMY.
Keisuke Shigeta*, Eiji Kikuchi, Keishiro Fukumoto, Nozomi Hayakawa, Takeo Kosaka, Akira Miyajima, Mototsugu Oya, Tokyo, Japan

MP71-14  SIGNIFICANCE OF BUTTYRYLCHOLINESTERASE BEFORE CHEMOTHERAPY AS AN INDEPENDENT PREDICTOR OF OVER-ALL SURVIVAL IN PATIENTS WITH ADVANCED UPPER-TRACT UROTHELIAL CANCER
Takahiro Yoneyama*, Masaaki Oikawa, Kazuhsa Hagiwara, Takuma Narita, Tosihikazu Tanaka, Kengo Imanishi, Tohru Yoneyama, Kazuuki Mori, Atsushi Imai, Shingo Hatakeyama, Yasuhiro Hashimoto, Takuya Kole, Chikara Ohyama, hirosaki, Japan

MP71-15  PREDICTIVE ABILITY OF RENAL CORTEX ENHANCEMENT IN DYNAMIC CT FOR RESIDUAL RENAL FUNCTION AFTER NEPHROURETERECTOMY: COMPARATIVE STUDY WITH RENOGRAPHY
Yuma Waseda*, Kazutaka Saito, Masaharu Inoue, Masaya Ito, Toshih Kiijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoaka, Kazunori Khara, Yasuhisa Fujii, Tokyo, Japan

MP71-16  RISK STRATIFICATION BY MEANS OF THE BIOLOGICAL AGE RELATED FACTORS BETTER PREDICTS CANCER-SPECIFIC SURVIVAL THAN THE CHRONOLOGICAL AGE IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA (UTUC): A MULTI-INSTITUTIONAL DATABASE STUDY
Teruo Inamoto*, Kiyoshi Takahara, Naokazu Ibuki, Takatsuki, Japan, Hideyasu Matsuyama, Ube, Japan, Kiyohide Fujimoto, Kashiwara, Japan, Hiroaki Shiina, Shimane, Japan, Shigeru Sakano, Kazuhiro Nagao, Ube, Japan, Yoshihiro Tatsumi, Kashiwara, Japan, Hiroaki Yasumoto, Shimane, Japan, Haruhito Azuma, Takatsuki, Japan, Nishinohon Uro-Oncology Collaborative Group, Ube, Japan

MP71-17  COMPARATIVE STUDY OF ONCOLOGICAL OUTCOMES OF LAPAROSCOPIC AND OPEN RADICAL NEPHROURETERECTOMY FOR PATIENTS WITH UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT UNDERGOING REGIONAL LYMPH NODE DISSECTION
Takashige Abe*, Sapporo, Japan, Tsunenori Kondo, Tokyo, Japan, Toru Harabayashi, Nonikata Takada, Ryuji Matsumoto, Ataru Sazawa, Takahiro Osawa, Keita Minami, Satoshi Nagamori, Naoto Miyajima, Kunihiko Tsuchiya, Satoru Manyayama, Sachio Murai, Sapporo, Japan, Kazunari Tanabe, Tokyo, Japan, Nobuo Shinohara, Sapporo, Japan
MP71-18 DISTRIBUTION OF LYMPH NODE METASTASIS IN UPPER URINARY TRACT UROTHELIAL CANCER, SUB-ANALYSIS OF JCOG1110A STUDY
Junichi Inokuchi*, Fukuoka, Japan, Kentaro Kuroiwa, Miyazaki, Japan, Yoshiyuki Kakehi, Mikio Sugimoto, Kagawa, Japan, Toshiki Tanikawa, Niigata, Japan, Hiroyuki Fujimoto, Tokyo, Japan, Momokazu Gotoh, Nagoya, Japan, Naoya Masumori, Sapporo, Japan, Osamu Ogawa, Kyoto, Japan, Masatoshi Eto, Fukuoka, Japan, Chikara Ohyama, Hirotsuki, Japan, Akito Yamaguchi, Fukuoka, Japan, Hideyasu Matsuyama, Ube, Japan, Tomohiko Ichikawa, Chiba, Japan, Tomohiko Asano, Tokorozawa, Japan, Atsushi Takenaka, Yonago, Japan, Kiyohide Fujimoto, Kashiwara, Japan, Raizo Yamaguchi, Tokyo, Japan, Tomonori Habuchi, Akita, Japan, Katsuyoshi Hashine, Matsuyama, Japan, Yoichi Arai, Sendai, Japan, Nonhiko Tsuchiya, Yamagata, Japan, Hiroyuki Nishiyama, Ibaraki, Japan, Nobuo Shinohara, Sapporo, Japan, Masashi Nishikawa, Shizuoka, Japan, Shin Egawa, Tokyo, Japan, Seiichiro Ozono, Hamamatsu, Japan, Tomomi Kamba, Kumamoto, Japan, Osamu Ishizuka, Matsumoto, Japan, Kazuo Nishimura, Osaka, Japan, Tatsuo Tochigi, Natomi, Japan, Yoshiki Sugimura, Tsu, Japan, Junki Mizusawa, Koriichi Miyamoto, Tokyo, Japan, Seiji Naito, Fukuoka, Japan

MP71-19 PREOPERATIVE PREDICTORS OF MUSCLE INVASION IN UPPER TRACT UROTHELIAL CARCINOMA
Ezra J. Margolin*, Justin T. Matulay, Xiaosong Meng, Brian Chao, Varun Vijay, Hayley Silver, William C. Huang, Marc A. Bjurlin, Qjas Shah, Christopher B. Anderson, New York, NY

MP71-20 PROGNOSTIC SIGNIFICANCE OF ERYTHROCYTE PROTEIN BAND 4.1-LIKE5 EXPRESSION IN UPPER URINARY TRACT UROTHELIAL CARCINOMA
Tatsuki Daimon*, Takeo Kosaka, Eiji Kikuchi, Shuji Mikami, Yasumasa Miyazaki, Ryuchi Mizuno, Akira Miyajima, Yasunori Okada, Tokyo, Japan, Hisataka Sabe, Hokkaido, Japan, Mototsugu Oya, Tokyo, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 15, 2017 7:00 am - 9:00 am
Moderated Poster Session 72
KIDNEY CANCER: LOCALIZED: SURGICAL THERAPY V
Room 252 @ Boston Convention & Exhibition Center
Moderators: Casey Ng, Alejandro Rodriguez and Li-Ming Su

ABSTRACT NUMBER TITLE
MP72-01 PREDICTING RENAL CELL CARCINOMA PROGRESSION AFTER SURGERY

MP72-02 FAVORABLE PROGNOSIS OF PATIENTS WITH END-STAGE RENAL DISEASE PATIENTS AND RENAL CELL CARCINOMA: A LONG-TERM FOLLOW-UP STUDY AT A SINGLE INSTITUTION
Shunichi Namiki*, Sendai, Japan, Yoshihiro Ikeda, Osaki, Japan, Takashi Kudo, Masatake Aizawa, Naoomasu Ioritani, Sendai, Japan

MP72-03 COMPARATIVE ANALYSIS OF RADICAL AND PARTIAL NEPHRECTOMY IN PATIENTS WITH PREOPERATIVE STAGE 2 CHRONIC KIDNEY DISEASE: A MULTICENTER STUDY

*Presenting author
MP72-04 CAN PARTIAL NEPHRECTOMY PROVIDE EQUAL ONCOLOGICAL EFFICIENCY AND SAFETY COMPARED WITH RADICAL NEPHRECTOMY IN PATIENTS WITH RENAL CELL CARCINOMA (≥ 4 CM)? A PROPENSITY SCORE MATCHED STUDY


MP72-05 PATTERNS AND PREDICTORS OF RECURRENCE AFTER PARTIAL NEPHRECTOMY FOR KIDNEY TUMORS

Pascal Mourouac*, Onder Kara, Matthew Maurice, Julien Dagenais, Ercan Malkoc, Jaya Sai Chavali, Ryan Nelson, Khaled Fareed, Robert Stein, Amr Fergany, Jihad Kaouk, Cleveland, OH

MP72-06 MULTI-INSTITUTIONAL SURVIVAL ANALYSIS OF INCIDENTAL PATHOLOGIC T3A UPSTAGING IN CLINICAL T1 RENAL CELL CARCINOMA FOLLOWING PARTIAL NEPHRECTOMY


MP72-07 HISTOPATHOLOGIC ANALYSIS OF TUMOR BED AFTER IN VITRO TUMOR ENucleATION ON RADICAL NEPHRECTOMY SPECIMEN

Qun Lu*, Changwei Ji, Xiaozhi Zhao, Guangxiang Liu, Hongqian Guo, Nanjing, China, People’s Republic of

MP72-08 SEVERITY OF PREOPERATIVE PROTEINURIA IS A RISK FACTOR FOR OVERALL MORTALITY IN PATIENTS UNDERGOING NEPHRECTOMY

David Y Yang*, R Houston Thompson, Harras B Zaid, Christine M Lohse, Andrew D Rule, Bradley C Leibovich, John C Cheville, Matthew K Tollefson, Rochester, MN

MP72-09 TRENDS IN UTILIZATION AND QUALITY OUTCOMES OF PARTIAL NEPHRECTOMY IN CT1B AND CT2A RENAL CELL CARCINOMA: ANALYSIS OF THE NATIONAL CANCER DATABASE

Katherine Fero*, Zachary Hamilton*, Daniel Han, Aaron Bloch, Charles Field, Ithaar Derweesh, San Diego, CA

MP72-10 THE PROGNOSTIC IMPLICATION OF BODY MASS INDEX ON POSTOPERATIVE SURVIVAL OUTCOMES IN NON-METASTATIC RENAL CELL CARCINOMA

Hyung Suk Kim*, Chang Wook Jeong, Cheol Kwak, Ja Hyeon Ku, Hyeon Hoe Kim, Seoul, Korea, Republic of, Hae Won Lee, Goyang, Korea, Democratic People’s Republic of

MP72-11 MODIFIED 5-ITEM FRAILTY INDEX IS ASSOCIATED WITH INCREASED HEALTHCARE RESOURCE UTILIZATION FOLLOWING ELECTIVE MINIMALLY INVASIVE RADICAL NEPHRECTOMY

Benjamin Taylor*, Leilei Xia, Jose Pulido, Jeremy Bonzo, George Drach, Thomas Guzzo, Philadelphia, PA

MP72-12 SURVEILLANCE AFTER SURGERY FOR RENAL CELL CARCINOMA: A RISK-ADAPTED APPROACH

William Parker*, Rochester, MN, Suzanne Merrill, Hershey, PA, Phillip Schulte, Ross Mason, R. Houston Thompson, Christine Lohse, Igor Frank, Rochester, MN

MP72-13 MODIFIED ROBOT-ASSISTED SIMPLE ENucleATION WITH SINGLE LAYER SUTURE TECHNIQUE IN LOCALIZED RENAL TUMORS: A PROPENSITY SCORE-MATCHING ANALYSIS

Xiaozi Zhao*, Qun Lu, Guangxiang Liu, Guitian Zhang, Xiaogong Li, Weidong Gan, Hongqian Guo, Nanjing, China, People’s Republic of

MP72-14 IMPACT OF CHRONIC KIDNEY DISEASE AND HYPERTENSION ON DECLINE IN REMAINING KIDNEY FUNCTION AFTER RADICAL NEPHRECTOMY

Minato Yokoyama*, Fumitsuka Koga, Yukihiro Otsuka, Tetsu Osako, Tetsuo Tsukamoto, Tokyo, Japan, Tetsuo Okuno, Toride, Japan, Katsushi Nagahama, Ichikawa, Japan, Yukio Kageyama, Ina, Japan, Akira Noro, Saitama, Japan, Yoshikiko Tsuji, Tokyo, Japan, Shinji Morimoto, Tsuchiura, Japan, Satoshi Kitahara, Tama, Japan, Kazunori Kihara, Yasuhsa Fujii, Tokyo, Japan

MP72-15 ROBOTIC PARTIAL NEPHRECTOMY IN PATIENTS WITH CHRONIC KIDNEY DISEASE: OBJECTIVE MEASUREMENT OF SHORT AND LONG TERM RENAL FUNCTIONAL OUTCOMES


MP72-16 PREDICTORS OF POSITIVE SURGICAL MARGINS IN PATIENTS UNDERGOING PARTIAL NEPHRECTOMY: A SINGLE-CENTER EXPERIENCE

MP72-17 ROBOT-ASSISTED PARTIAL NEPHRECTOMY FOR COMPLEX CASES (PADUA SCORE ≥ 10): RESULTS FROM A MULTICENTER EXPERIENCE AT THREE HIGH-VOLUME CENTERS
Giovanni Lughezzani*, Nicolo’ Buffi, Giuliana Lista, Davide Maffei, Giovanni Forni, Milano, Italy, Nicola Fossati, Alessandro Larcher, Aalst, Belgium, Massimo Lazzeri, Alberto Saita, Paolo Casale, Giorgio Guazzoni, Milano, Italy, Jim Porter, Seattle, WA, Alex Mottrie, Aalst, Belgium

MP72-18 ONCOLOGICAL OUTCOMES OF POSITIVE SURGICAL MARGINS IN PATIENTS WHO UNDERWENT PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA
Henrique Nonemacher*, Mauricio Cordeiro, George Lins de Albuquerque, João Brunhara, Paulo Afonso Carvalho, Fabio Gallucci, Leonardo Borges, Rafael Coelho, Sao Paulo, Brazil, Vipul Patel, Orlando, FL, William Nahas, Sao Paulo, Brazil

MP72-19 PHASE II STUDY OF AXITINIB FOR DOWNSTAGING Ct2a TO CT1 RENAL TUMORS FOR ALLOWING PARTIAL NEPHRECTOMY (AXIPAN)

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 15, 2017
7:00 am - 9:00 am

Moderated Poster Session 73
KIDNEY CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY III
Room 253 AB @ Boston Convention & Exhibition Center
Moderators: Mark Gonzalgo and Guan Wu

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP73-01</td>
<td>IMMUNE CHECKPOINT INHIBITOR COMBINED WITH THE GROWTH INHIBITOR LYCORINE SYNERGISTICALLY FUNCTION TO MEDIATE ANTI-TUMOR EFFECTS IN A MOUSE MODEL OF RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>Xiezhao Li*, Guangzhou, China, People’s Republic of, Naijin Xu, Okayama, Japan, Aibai Xu, Guangzhou, China, People’s Republic of, Masami Watanabe, Peng Huang, Yasutomo Nasu, Okayama, Japan, Chunxiao Liu, Guangzhou, China, People’s Republic of</td>
<td></td>
</tr>
<tr>
<td>MP73-02</td>
<td>IMMUNOLOGICAL CLASSIFICATION IN RENAL CELL CARCINOMA BASED ON IMMUNOCHECKPOINT MOLECULES: THE RELATIONSHIP WITH TUMOR AGGRESSIVENESS AND THE PRESENCE OF INTRA-TUMOR DIVERSITY</td>
</tr>
<tr>
<td>Atsunari Kawashima*, Takayuki Kanazawa, Kumiko Goto, Mitsuobu Matsumoto, Yu Ishizuya, Cong Wang, Yoshiyuki Yamamoto, Tokuji Hayashi, Toshiro Kinouchi, Kyosuke Matsuzaki, Norihiko Kawamura, Takeshi Ujike, Akira Nagahara, Kazutoshi Fujita, Motohide Uemura, Hisashi Wada, Norio Nonomura, Suita, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP73-03</td>
<td>PD-L1 EXPRESSION IN XP11.2 TRANSLOCATION RENAL CELL CARCINOMA: INDICATOR OF TUMOR AGGRESSIVENESS</td>
</tr>
<tr>
<td>Yuan-Yuan Qu*, Kun Chang, Bo Dai, Yao Zhu, Hai-Liang Zhang, Ding-Wei Ye, Shanghai, China, People’s Republic of</td>
<td></td>
</tr>
<tr>
<td>MP73-04</td>
<td>TUMOR INFILTRATING MAST CELLS (TIMS) CONFRS A MARKED SURVIVAL ADVANTAGE IN NON-METASTASIS CLEAR-CELL RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>Hangcheng Fu*, Yu Zhu, Dingwei Ye, Shanghai, China, People’s Republic of</td>
<td></td>
</tr>
<tr>
<td>MP73-05</td>
<td>ACTIVATION OF SERINE BIOSYNTHESIS PATHWAY IN HIF2a ANTAGONIST-RESISTANT RENAL CELL CARCINOMA CELLS AFTER ACQUIRING SUNITINIB RESISTANCE: RESULTS FROM THE GENOME EDITING TECHNOLOGY</td>
</tr>
<tr>
<td>Hideki Enokida*, Hirofumi Yoshino, Kazutaka Miyamoto, Masaya Yonemori, Satoru Sugita, Takashi Sakaguchi, Masayuki Nakagawa, Kagoshima, Japan</td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP73-06 DRUG RESISTANCE CONSEQUENCES OF TUMOR HETEROGENEITY IN METASTATIC RENAL CELL CARCINOMA USING ULTRA-FAST PATIENT DERIVED XENOGRAPHS AND MULTIREGIONAL GENOMIC SEQUENCING

MP73-07 INVOLVEMENT OF ANGIOPHENIN IN SUNITINIB RESISTANCE IN HUMAN RENAL CELL CARCINOMA
Laure Pierard, Sébastien Bergerat, Claire Béraud, Pascal Mourad, Imène Hamaidi, Catherine Coquard, Sylvie Rothny, Véronique Lindner, Hervé Lang, Thierry Massfield*, Strasbourg, France

MP73-08 METFORMIN DRIVES SYNERGISTIC EFFECT AND OVERCOMES THE TREATMENT RESISTANCE OF MOLECULAR TARGETED DRUGS FOR RENAL CELL CARCINOMA
Hiroaki Matsumoto*, Juiichi Mori, Kosuke Shimizu, Nakanori Fujii, Yoshiihisa Kawai, Ryo Inoue, Yoshiaki Yamamoto, Hiroshi Hirata, Tomoko Shimabukuro, Hideyasu Matsuyama, Ube, Japan

MP73-09 NELFINAVIR ACTS SYNERGISTICAL WITH PANOBINOSTAT TO INDUCE ENDOPOLASMIC RETICULUM STRESS AND INHIBIT RENAL CANCER GROWTH
Kazuki Okubo*, Akinori Sato, Takako Asano, Makoto Isono, Tomohiko Asano, Tokorozawa, Saitama, Japan

MP73-10 RITONAVIR, A POTENT INHIBITOR OF CYP3A4, ENHANCES THE ANTICANCER EFFECTS OF ENTINOSTAT IN RENAL CANCER CELLS IN VITRO AND IN VIVO
Takako Asano*, Akinori Sato, Kazuki Okubo, Makoto Isono, Tomohiko Asano, Tokorozawa, Japan

MP73-11 GINSENOSIDE COMPOUND K ENHANCES TRAIL-MEDIATED RENAL CANCER CELL APOPTOSIS THROUGH CHOP SIGNALING
Yu Ren, Shuahai Huang, Xue Wang, Xuping Yao, Guobin Weng*, Ningbo, China, People's Republic of

MP73-12 LOPINAVIR SYNERGIZES WITH RITONAVIR TO CAUSE RENAL CANCER APOPTOSIS VIA INDUCING ENDOPOLASMIC RETICULUM STRESS
Kazuki Okubo*, Akinori Sato, Takako Asano, Makoto Isono, Tomohiko Asano, Tokorozawa, Saitama, Japan

MP73-13 PHENOXODIOL, A NOVEL SOY ISOFLAVONE ANALOG, INHIBITS AKT PATHWAY AND INDUCES RENAL CANCER APOPTOSIS
Makoto Isono*, Akinori Sato, Takako Asano, Kazuki Okubo, Tomohiko Asano, Tokorozawa, Japan

MP73-14 CAPABILITY OF ELECTRICAL IMPEDANCE SPECTROSCOPY SENSOR ON A NEEDLE AS A NOVEL TOOL TO ESTIMATE MALIGNANT RENAL TUMOR MARGIN: EX-VIVO DEMARCATION OF TUMOR AND SURGICAL MARGIN
Hyeon Woo Kim*, John Yun, Gwangju, Korea, Republic of, Dong Gil Shin, Jeong Zoo Lee, Tae Nam Kim, Wan Lee, Chang Yell Lee, Chul Soo Yoon, Seong Choi, Busan, Korea, Republic of, Jong-Hyun Lee, Gwangju, Korea, Republic of

MP73-15 PROTECTIVE EFFECT OF ETHYL PYRUVATE ON OXIDATIVE RENAL CELL INJURY: IMPLICATION IN PREVENTION OF RENAL ISCHEMIA/REPERFUSION INJURY
Jonathan Bloom*, Mark Ferretti, Matthew Chaimowitz, Muhammad Choudhury, Majid Esghi, Sensuke Konno, Valhalla, NY


MP73-17 BENIGN AND TUMOR PARENCHYMA METABOLIC PROFILES AFFECT COMPENSATORY RENAL GROWTH IN RENAL CELL CARCINOMA SURGICAL PATIENTS

MP73-18 HISTOLOGIC ABNORMALITIES IN NON-NEOPLASTIC RENAL PARENCHYMA AFTER RADICAL NEPHRECTOMY: A NOMOGRAM TO PREDICT CHRONIC KIDNEY DISEASE
Ricardo Brandina*, Miguel Srougi, Katia Ramos Moreira Leite, Sao Paulo, Brazil, Emerson Pereira Gregorio, Londrina, Brazil

MP73-19 PREOPERATIVE PROTEINURIA PREDICTS INCREASED RATES OF ACUTE KIDNEY INJURY AFTER PARTIAL NEPHRECTOMY
Önder Kara*, Matthew J. Maurice, Pascal Mourad, Ercan Malkoc, Julien Dagenais, Ryan J. Nelson, Jaya Sai Chavali, Jihad H. Kaouk, Cleveland, OH
MP73-20 NOVEL CULTURE METHOD FOR RENAL CELL CARCINOMA: MODIFIED ORGANOID CULTURE
Hyung Ho Lee*, Sook Young Kim, Young Eun Yoon, Sung Ku Kang, Jae Yong Jeong, Kwang Hyun Kim, Seoul, Korea, Republic of, Kyung Hwa Choi, Seongnam, Korea, Republic of, Joong Shik Lee, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Woong Kyu Han, Seoul, Korea, Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 15, 2017 7:00 am - 9:00 am
Podium Session 49
SEXUAL FUNCTION/DYSFUNCTION: PENIS/TESTIS/URETHRA: BENIGN DISEASE & MALIGNANT DISEASE I
Room 159 @ Boston Convention & Exhibition Center
Moderators: Jeffrey Holzbeierlein and Andrew James

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 7:00 | PD49-01 | ADJUVANT PELVIC RADIATION IS ASSOCIATED WITH IMPROVED SURVIVAL AND DECREASED DISEASE RECURRENCE IN PELVIC NODE-POSITIVE PENILE CANCER AFTER LYMPH NODE DISSECTION: A MULTI-INSTITUTIONAL STUDY
Dominic Tang*, Tampa, FL, Rosa Djadiadiningrat, Amsterdam, Netherland, Gregory Diorio, Zhenjun Ma, Braydon Schaal, Tampa, FL, Mario Catanzaro, Milano, Italy, Dingwei Ye, Yao Zhu, Shanghai, China, People’s Republic of, Nicola Nicolai, Milano, Italy, Simon Horenblas, Amsterdam, Netherlands, Peter Johnstone, Philippe Spiess, Tampa, FL |
| 7:10 | PD49-02 | PREDICTION OF POSTOPERATIVE COMPLICATIONS AFTER INGUINAL LYMHPHADENECTOMY FOR PENILE CANCER USING A NOVEL CLASSIFICATION TOOL
Yao Zhu*, Wei-Jie Gu, Shanghai, China, People’s Republic of, Philippe Spiess, FL, FL, Ding-Wei Ye, Shanghai, China, People’s Republic of |
| 7:20 | PD49-03 | ADHERENCE TO GUIDELINES: SURGICAL STAGING OF INGUINAL LYMPH NODES IN HIGH-RISK CLINICALLY LOCALIZED PENILE CANCER AND SURVIVAL IMPLICATIONS
Solomon Woldu*, Ryan Hutchinson, Nirmish Singla, Boyd Viers, Laura-Maria Krabbe, Arthur Sagalowsky, Yair Lotan, Aditya Bagrodia, Vitaly Margulis, Dallas, TX |
| 7:30 | PD49-04 | ONCOLOGICAL OUTCOMES AND PATTERNS OF RECURRENCE OF PENILE SPARING APPROACHES FOR CARCINOMA OF THE PENIS: A RETROSPECTIVE, MULTICENTER COHORT ANALYSIS
Juan Chipollini*, Adam Baumgarten, Dominic Tang, Tampa, FL, Sylvia Yan, London, United Kingdom, Sarah Ottenhof, Amsterdam, Netherlands, Yao Zhu, Ding-wei Ye, Shanghai, China, People’s Republic of, Chris Protzel, Rostock, Germany, Simon Horenblas, Amsterdam, Netherlands, Nicholas Watkin, London, United Kingdom, Philippe Spiess, Tampa, FL |
| 7:40 | PD49-05 | PATHOLOGICAL NODAL INVOLVEMENT IN PATIENTS WITH PENILE CANCER IN THE NATIONAL CANCER DATA BASE (NCDB) USING THE UPDATED AJCC STAGING GUIDELINES FOR T2 AND T3 DISEASE
James Kearns*, Brian Winters, Daniel Lin, Jonathan Wright, Seattle, WA |
| 7:50 | PD49-06 | THE ADHERENCE TO THE EAU GUIDELINES ON PENILE CANCER TREATMENT COULD INFLUENCE THE SURVIVAL: MULTICENTER, RETROSPECTIVE, EUROPEAN STUDY.
Luca Cindolo, Maida Bada*, Vasto, Italy, Péter Nyirády, James Varga, Budapest, Hungary, Pasquale Ditonno, Stefano Boccaasile, Michele Battaglia, Bari, Italy, Paolo Chiodini, Naples, Italy, Francesco Berardinelli, Vasto, Italy, Cosimo De Nunzio, Giorgia Terna, Rome, Italy, Andrea Veccia, Alessandro Antonelli, Claudio Simeone, Brescia, Italy, Stefano Puliatti, Salvatore Miceli, Baggiovara, Italy, Luigi Schips, Vasto, Italy |

*Presenting author
8:00 PD49-07 ENGINEERING OF CORPORAL TISSUE CONSTRUCTS USING NON-HUMAN PRIMATE CORPUS Cavernosal Smooth Muscle and Endothelial Cells for Clinical Applications
Joao Zambon*, Young-Min Ju, Koudy Williams, Ryan Terlecki, Sita Somara, Alexander Baume, Ashley Dean, John Jackson, Julie Allickson, James Yoo, Anthony Atala, Winston-Salem, NC

8:10 PD49-08 THE IMPACT OF ROUTINE FROZEN SECTION ANALYSIS DURING PENECTOMY ON SURGICAL MARGIN STATUS AND LONG-TERM ONCOLOGIC OUTCOMES
Alexandra Danakas, Caroline Bsirini, Hiroshi Miyamoto*, Rochester, NY

8:20 PD49-09 SURVIVAL ANALYSIS OF PATIENTS WITH T2 PENILE CANCER WHO RECEIVED INGUINAL LYMPH NODE DISSECTION: RESULTS FROM THE NATIONAL CANCER DATABASE

8:30 PD49-10 CHANGES IN PENILE LENGTH AFTER RADICAL PROSTATECTOMY: INVESTIGATION OF ANATOMICAL MECHANISM
Yoshifumi Kadono*, Kazuaki Machioka, Kazuiki Nakashima, Masashi Iijima, Kazuyoshi Shigehara, Takahiro Nohara, Kazutaka Narimoto, Kouji Izumi, Yusuhide Kitagawa, Hiroyuki Konaka, Atsushi Mizokami, Kanazawa, Japan

8:40 PD49-11 SURVIVAL AMONG FEMALE URETHRAL CANCER PATIENTS 2004-2013, A NATIONAL CANCER DATABASE ANALYSIS
Mary E. Westerman*, Vidit Sharma, Derek J. Gearman, Matthew K. Tollefson, Stephen A. Boorjian, Deborah J. Lightner, R. Jeffrey Karmes, Rochester, MN

8:50 PD49-12 PRIMARY MALIGNANT MELANOMA OF THE FEMALE URETHRA: MANAGEMENT AND LONG-TERM OUTCOMES AT A TERTIARY REFERRAL CENTER
Brian Montgomery*, Derek Lomas, Vidit Sharma, Deborah Lightner, Rochester, MN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
8:00 PD50-07 LOW SERUM TESTOSTERONE IS ASSOCIATED WITH INCREASED STRESS AND MIXED INCONTINENCE IN WOMEN
Michelle Kim*, Boston, MA, Zaid Chaudhry, Janine Oliver, Evgeniy Kreydin, Los Angeles, CA

8:10 PD50-08 AUTOLOGOUS MUSCLE DERIVED CELLS FOR URINARY SPHINCTER REPAIR FOR RECURRENT OR PERSISTENT STRESS URINARY INCONTINENCE AFTER CONTINENCE SURGERY
Lesley Carr, Toronto, Canada, Le Mai Tu, Sherbrooke, Canada, Magali Robert, Calgary, Canada, David Quinlan, Victoria, Canada, Kevin Carlson, Calgary, Canada, Sender Herschorn, Toronto, Canada, Roger Dmochowski, Nashville, TN, Kenneth Peters, Royal Oak, MI, Melissa Kaufman, Nashville, TN, Ron Jankowski, Pittsburgh, PA, Michael Chancellor*, Royal Oak, MI

8:20 PD50-09 A POTENTIAL NEW TARGET FOR STRESS URINARY INCONTINENCE: A μ-OPIOID RECEPTOR IN THE SPINAL CORD BY TRAMADOL, IN RATS
Asuka Ashikari*, Minoru Miyazato, Takuma Oshiro, Seiichi Saito, Okinawa, Japan

8:30 PD50-10 GENE EXPRESSION AND PATTERNS OF SCARRING RESPONSE IN HUMAN FIBROBLASTS IN RESPONSE TO MESH AND CATHETER MATERIALS USING A NOVEL 3-D COLLAGEN MODEL
Li Yunyuan, Lynn Sloaters*, Aziz Ghahtary, Vancouver, Canada

8:40 PD50-11 MANAGEMENT OF URINARY INCONTINENCE FOLLOWING SUB-URETHRAL SLING REMOVAL
Nirmish Singla*, Himanshu Aggarwal, Jeannine Foster, Feras Alhalabi, Gary Lemack, Philippe Zimmerman, Dallas, TX

8:50 PD50-12 HIGH CATASTROPHIZING IN PATIENTS WITH SELF-REPORTED PAINFUL MESH COMPLICATIONS HAVE POORER OUTCOMES
Juzar Jammagerwalla*, Karyn S. Eliber, Jennifer T. Anger, A. Lenore Ackerman, Los Angeles, CA

*Presenting author
7:30 PD51-04 THE IMPACT OF ANXIETY AND DEPRESSION ON FUNCTIONAL OUTCOME IN PATIENTS WHO UNDERWENT RADICAL PROSTATECTOMY
Raisa Sinaida Pompe*, Alexander Krueger, Hamburg, Germany, Pierre I. Karakiewicz, Montreal, Canada, Philipp Mandel, Philipp Gild, Sami-Ramzi Leyh-Bannurah, Georg Salomon, Hartwig Huland, Markus Graefen, Derya Tilki, Hamburg, Germany

7:40 PD51-05 SURVIVAL ASSOCIATED WITH RADICAL PROSTATECTOMY VERSUS RADIOTHERAPY FOR HIGH-RISK PROSTATE CANCER: A CONTEMPORARY, NATIONALWIDE OBSERVATIONAL ANALYSIS
Tarun Jindal*, Deeoansh Dalela, Patrick Karabon, Malte Vetterlein, Thomas Seisen, Akshay Sood, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Wook Jeong, Mani Menon, Firas Abdollah, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Wooju Jeong, Mani Menon, Firas Abdollah, Detroit, MI

7:50 PD51-06 SALVAGE ROBOT ASSISTED RADICAL PROSTATECTOMY AFTER PRIMARY RADIATION OR ABLATION TREATMENT: WHAT HAVE WE LEARNED? ASSESSING THE LEARNING CURVE IN TERMS OF MORBIDITY, ONCOLOGICAL AND FUNCTIONAL OUTCOMES.
Xavier Bonet*, Gabriel Ogaya, Tracey Woodlief, Eduardo Hernández-Cardona, Hariharan Ganapathi, Travis Rogers, Rafael Coelho, Bernardo Rocco, Vipul Patel, Celebration, FL

8:00 PD51-07 IMPACT OF THE TIME INTERVAL BETWEEN BIOPSY AND ROBOTIC-ASSISTED RADICAL PROSTATECTOMY ON BIOCHEMICAL RECURRENCE: A PROPENSITY SCORE MATCHING ANALYSIS
Yosuke Hirasawa*, Makoto Ohori, Naoto Kaburagi, Takashi Mima, Tatsuo Gondo, Tokyo, Japan, Kunihiko Yoshioka, Kanagawa, Japan, Jun Nakashima, Yoshio Ohno, Tokyo, Japan

8:10 PD51-08 ASSESSING THE 20-YEAR OUTCOMES OF RADICAL PROSTATECTOMY FOR HIGH RISK PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES
Marco Bianchi*, Catanzaro, Italy, Michele Colicchia, Rochester, NY, Giorgio Gandaglia, Milan, Italy, Stefania Munegato, Turin, Italy, Nicola Fossati, Marco Bandini, Armando Stabile, Paolo Dell’Oglio, Nazareno Suardi, Milan, Italy, Paolo Gontero, Turin, Italy, R. Jeffrey Karnes, Rochester, NY, Steven Joniau, Leuven, Belgium, Martin Spahn, Bern, Switzerland, Francesco Montorsi, Alberto Briganti, Milan, Italy

8:20 PD51-09 CONDITIONAL PROBABILITY OF BIOCHEMICAL RECURRENCE-FREE SURVIVAL AND CANCER-SPECIFIC MORTALITY AFTER RADICAL PROSTATECTOMY AT LONG TERM FOLLOW-UP
Silvia Garcia-Barreras*, Rafael Sanchez-Salas, Igor Nunes-Silva, Paris, France, Fernando Secin, Buenos Aires, Argentina, Victor Srougi, Mohammed Baghdi, Eric Barret, François Rozet, Marc Galiano, Xavier Cathelineau, Paris, France

8:30 PD51-10 SURVIVAL AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PSA PERSISTENCE: THE IMPACT OF COMPETING CAUSES OF MORTALITY

8:40 PD51-11 PATHOLOGICAL FINDINGS AT RADICAL PROSTATECTOMY AFTER INITIAL ACTIVE SURVEILLANCE IN LOW-RISK PROSTATE CANCER PATIENTS. DID WE MISS THE CHANCE TO CURE?
Nazareno Suardi*, Stefano Luzzago, Paolo Dell’Oglio, Nicola Fossati, Giorgio Gandaglia, Emanuele Zaffuto, Franco Gaboardi, Claudio Doglioni, Massimo Fracchi, Vincenzo Scattoni, Umberto Capitanio, Armando Stabile, Francesco Montorsi, Alberto Briganti, Milan, Italy

8:50 PD51-12 ONCOLOGICAL AND FUNCTIONAL OUTCOMES AFTER RP FOR HIGH OR VERY HIGH-RISK PROSTATE CANCER – EUROPEAN VALIDATION OF THE CURRENT NCCN GUIDELINE
Raisa Sinaida Pompe*, Philipp Gild, Felix K. Chun, Hamburg, Germany, Zhe Tian, Montreal, Canada, Jonas Schiffmann, Braunschweig, Germany, Georg Salomon, Hartwig Huland, Markus Graefen, Hamburg, Germany, Pierre I. Karakiewicz, Montreal, Canada, Derya Tilki, Hamburg, Germany

APPROVED FORAMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| 7:00 | PD52-01 | DIFFERENTIAL GENE EXPRESSION IN PATIENTS WITH INDOLENT VERSUS AGGRESSIVE CHROMOPHOBE RENAL CELL CARCINOMA: AN ANALYSIS OF THE CANCER GENOME ATLAS DATABASE  
Aip Tuna Beksac*, David Paulucci, John Stakianos, Ketan Badani, New York, NY |
| 7:10 | PD52-02 | RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLLOCATION/TFE3 GENE FUSIONS: DIFFERENTIAL DIAGNOSIS WITH CLEAR CELL RENAL CELL CARCINOMA ON CONTRAST-ENHANCED ULTRASOUND  
Zhang Fan*, Wang Wei, Gan Weidong, Guo Hongqian, Nanjing, China, People's Republic of |
| 7:20 | PD52-03 | PATIENTS WITH RCC AND PATHOLOGIC NODAL DISEASE SHOULD BE RECLASSIFIED AS STAGE IV  
Kai-Jie Yu*, Linkou, Taiwan, Sarp K. Keskin, Firas G. Petros, Xuemei Wang, Leonardo D. Borregales, Yara Aboshady, Cindy Gu, Surena F. Matin, Christopher G. Wood, Jose A. Karam, Houston, TX |
| 7:30 | PD52-04 | SURGICAL HISTOPATHOLOGY FOR SUSPECTED ONCOCYTOMA ON RENAL MASS BIOPSY: RETROSPECTIVE INSTITUTIONAL COHORT WITH SYSTEMATIC REVIEW AND META-ANALYSIS  
Hiten Patel*, Sasha Druskin, Steven Rowe, Phillip Pierorazio, Michael Gorin, Mohamad Allaf, Baltimore, MD |
| 7:40 | PD52-05 | WHEN TO PERFORM PREOPERATIVE BONE SCINTIGRAPHY FOR KIDNEY CANCER STAGING  
Fabio Muttin*, Alessandro Larcher, Nicola Fossati, Paolo Dell'Oglio, Alessandro Nini, Armando Stabile, Francesco Ripa, Francesco Trevisani, Cristina Carenzi, Alberto Briganti, Andrea Salonia, Milan, Italy, Alexandre Mottier, Aalst, Belgium, Roberto Bertini, Francesco Montorsi, Umberto Capitanio, Milan, Italy |
| 7:50 | PD52-06 | CAPTURING RENAL CELL CARCINOMA RECURRENCES WHEN ASYMPTOMATIC IMPROVES PATIENT SURVIVAL  
Suzanne Merrill*, Ashiya Hamirani, Matthew Kaag, Erik Lehman, Kathleen Lehman, Jay Raman, Hershey, PA |
| 8:00 | PD52-07 | MEDICATION USE AND KIDNEY CANCER RISK: A POPULATION-BASED STUDY  
Madhur Nayan*, David Juurlink, Peter Austin, Erin Macdonald, Antonio Finelli, Girish Kulkarni, Robert Hamilton, Toronto, Canada |
| 8:10 | PD52-08 | CAN LOOKS DECEIVE? NOT ALL CLINICALLY "CYSTIC" RENAL MASSES HARBOR INDOLENT BIOLOGY  
| 8:20 | PD52-09 | THROMBOEMBOLIC EVENTS DURING TREATMENT FOR RENAL CELL CARCINOMA: MUST WE PREVENT?  
Jamie Olsen*, Steven Jubelirer, Charleston, WV, Samuel Umstot, Morgantown, WV, Samuel Deem, Charleston, WV |
| 8:30 | PD52-10 | SHORTER TELOMERE LENGTH INCREASES AGE-RELATED TUMOR RISKS IN CHINESE VON HIPPEL-LINDAU DISEASE  
Jiangyi Wang*, Shuanghe Peng, Xianghui Ning, Teng Li, Jiayuan Liu, Shengjie Liu, Kan Gong, Beijing, China, People’s Republic of |
| 8:40 | PD52-11 | A MOLECULAR SCORING ALGORITHM TO PREDICT SURVIVAL IN METASTATIC RENAL CELL CARCINOMA  
| 8:50 | PD52-12 | A NOVEL PRE-OPERATIVE MODEL TO PREDICT 90-DAY SURGICAL MORTALITY IN PATIENTS BEING CONSIDERED FOR EXTIRPATIVE SURGERY FOR RENAL CELL CARCINOMA  
Adam Calaway*, Maria Francesca Morn, Clint Bahler, Clint Cary, Ronald Boris, Indianapolis, IN |

*Presenting author
Monday, May 15, 2017 8:30 am - 9:30 am

AMERICAN BOARD OF UROLOGY TOWN HALL
Room 208 @ Boston Convention & Exhibition Center

8:30 ABU/AUA PANEL DISCUSSION
Program Chair: Ballentine Carter

9:30 ADJOURN

Monday, May 15, 2017 9:30 am - 11:30 am

Moderated Poster Session 74

TRANSPLANTATION & VASCULAR SURGERY: RENAL TRANSPLANTATION & VASCULAR SURGERY III
Room 151 @ Boston Convention & Exhibition Center


<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP74-01</td>
<td>ARTERIOLAR HYALINIZATION PREDICTS CLINICAL OUTCOME IN RENAL TRANSPLANTATION FROM DONORS AFTER CARDIAC DEATH.</td>
</tr>
<tr>
<td></td>
<td>Masayuki Tasaki*, Kazuhide Saito, Yuki Nakagawa, Naofumi Imai, Yumi Ito, Masato Akiyama, Kota Takahashi, Yoshihiko Tomita, Niigata, Japan</td>
</tr>
</tbody>
</table>

| MP74-02         | ROLE OF EARLY POVIDONE IODINE INSTILLATION IN POST RENAL TRANSPLANT LYMPHORRHOEA: A PROSPECTIVE RANDOMIZED STUDY |
|                 | Sanjoy Sureka, Aneesh Srivastava, Priyank Yadav*, Rakash Kapoor, M S Ansari, Uday Singh, Lucknow, India |

| MP74-03         | TRANSPLANT KIDNEY RETROGRADE URETERAL STENT PLACEMENT AND EXCHANGE: OVERCOMING THE CHALLENGE |
|                 | Daniel Halstuch*, Roy Mano, Chen Shenhar, Ronen Holland, Jack Daniel, David Lifshitz, Petah Tiqva, Israel |

| MP74-04         | IMPACT OF PACKAGE AND STORAGE TECHNIQUES ON KIDNEY TEMPERATURE ENVIRONMENT |
|                 | Luâ Souza Cunha, Gabriela Yale Lima de Oliveira, Laila Gabriely Souza Mota, Diego Henrique Gomes Sobrinho, Porto Velho, Brazil, Leonardo Oliveira Reis, Campinas, Brazil, Alessandro Prudente*, Porto Velho, Brazil |

| MP74-05         | DONOR AGE IS THE MOST IMPORTANT PREDICTOR OF LONGTERM GRAFT FUNCTION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION FROM DONORS AFTER CARDIAC DEATH |

| MP74-06         | FABRICATION OF BIOMIMETIC VASCULAR SCAFFOLDS USING VASCULAR CORROSION CASTS FOR RECONSTRUCTION OF KIDNEY TISSUES |
|                 | Jennifer Huling, In Kap Ko, John Jackson*, James Yoo, Anthony Atala, Winston Salem, NC |

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP74-07</td>
<td>RENAL PROTECTION BY APPLYING ISCHEMIC PRECONDITIONING.</td>
</tr>
<tr>
<td></td>
<td>Valter Torezan Gouveia Junior*, Cervantes Caporossi, Rafael Morais De Assis, Maisa Pavana Dos Santos, Thiago Rachid Jaudy, Luiz Molina, Rafael Amaral, Cuiaba, Brazil, Amanda Martins; Baviera, Araraquara, Brazil, Nair Honda Kawashita, Damiana Luisa Pereira Souza, Claudia Bonadiman De Lima, Maikon Adriano Ticianel, Cuiaba, Brazil, Felipe De Souza Bouret, Cuiabá, Brazil, Nicole Gabrielle Hernandez, Thulio Fernandes De Souza, Gabriel Silva De Lima, João Henrique Aleixo, Cuiaba, Brazil</td>
</tr>
</tbody>
</table>

| MP74-08         | GLUCOCORTICOID RECEPTOR POLYMORPHISM AFFECTS RECIPIENTS’ SUSCEPTIBILITY TO DYSLIPIDEMIA 1 YEAR AFTER KIDNEY TRANSPLANTATION |
|                 | Kazuyuki Numakura*, Hideaki Kagaya, Naoki Komine, Nobuhiro Fujiyama, Mitsuji Saito, Takamitsu Inoue, Hiroshi Tsrnuta, Atsushi Maeno, Shitarno Narita, Takenorit Nioka, Masatomo Miura, Tomonori Habuchi, Shigeru Satoh, Akita, Japan |

| MP74-09         | FOCAL ABLATIVE THERAPY FOR SOLID RENAL MASSES IN TRANSPLANT ALLOGRAFT KIDNEYS |
|                 | John Griffith*, Aaron Fischman, Nikhil Wajingankar, Michael Palese, John Sfakianos, Ketan Badani, Reza Mehrzarin, New York, NY |

| MP74-10         | THE FATE OF POSTOPERATIVE PERINEPHRIC FLUID COLLECTIONS WITHIN 1 MONTH AFTER PEDIATRIC RENAL TRANSPLANTATION: ETIOLOGY AND THERAPEUTIC INTERVENTIONS |
|                 | Frank J. Penna*, Hanover, NH, Armando J. Lorenzo, Walid A. Farhat, Martin A. Koyle, Toronto, Canada |

| MP74-11         | ADVERSE EVENTS IN THERAPEUTIC PLASMA EXCHANGE USING FRESH-FROZEN PLASMA IN KIDNEY TRANSPLANT RECIPIENTS |
|                 | Mitsuji Saito*, Takamitsu Inoue, Shitarno Narita, Atsushi Maeno, Hiroshi Tsrnuta, Kazuyuki Numakura, Shigero Satoh, Tomonori Habuchi, Akita, Japan |
**Title**: Antibody Titer Against BK Polyomavirus of Renal Transplant Recipients’ Serum and Intravenous Immunoglobulin 3 Products Derived from Donated Blood in Japan and Its Clinical Implications

*Mitsuru Saito*, Akita, Japan, Takeru Urayama, Kobe, Japan, Kazuyuki Numakura, Takamitsu Inoue, Shintaro Narita, Hiroshi Tsuruta, Atsushi Maeno, Akita, Japan, Kaoru Sakai, Kobe, Japan, Shigeru Satoh, Tomonori Habuchi, Akita, Japan

**Title**: Association of PCK2 Gene Polymorphism with Impaired Glucose Tolerance after Kidney Transplantation

*Naoki Yokoyama*, Teruyuki Oda, Satoshi Ogawa, Takeshi Ishimura, Masato Fujisawa, Kobe, Japan

**Title**: Is it Possible to Predict Success of Renal Auto-Transplantation for Chronic Kidney Pain? Development of an Algorithm Utilizing Celiac Plexus Block


**Title**: A Novel NF-κB Inhibitor Dehydroxymethyleneepoxyquinomicin Prevents Acute Rejection of Kidney Allografts in a Rat Model

*Kazunobu Shinoda*, Shinya Morita, Kazuhiro Matsumoto, Takeo Kosaka, Ryuichi Mizuno, Toshiaki Shinojima, Eiji Kikkuchi, Hiroshi Asanuma, Akira Miyajima, Tokyo, Japan, Kazuo Umezawa, Archi, Japan, Mototsugu Oya, Tokyo, Japan

**Title**: Transurethral Resection or Incision of the Prostate After Renal Transplantation: Is There a Safer Time for the Procedure?

*Alfonso Celso Piovesan*, Sao Paulo, Brazil, Rafael Fagionato Locali, Sao Paulo, Brazil, Marcos Mello, Kleilton G R Yamacak, Hideki Kanashiro, Gustavo Xavier Ebaid, Ioannis Antonopoulos, Flavio Jota de Paula, William Carlos Nahas, Sao Paulo, Brazil

**Title**: Renal Artery Diameter is a Surrogate Marker for Kidney Volume in Living Kidney Donors

*Arshvin Kesavan*, Bee Choo Tai, Singapore, Singapore, Arun B, Dublin, Ireland, Benjamin Goh, Lata Raman, Vathsala Anantharaman, Ho Yee Tiong, Singapore, Singapore

**Title**: The Effect of Thymoquinone on the Renal Functions Following Ischemia-Reperfusion Injury

*Fayez Hammad*, Loay Lubbad, Al Ain, United Arab Emirates

**Title**: Variation in National Opioid Prescribing Patterns Following Outpatient Nephrolithiasis Procedures

*Tudor Borza*, Rodney L. Dunn, Yongmei Qui, Tyler N. Winkelman, Ted A. Skolarus, David C. Miller, Brent K. Hollenbeck, Gregory B. Auffenberg, Ann Arbor, MI

---

**Abstract Table**

<table>
<thead>
<tr>
<th>Abstract Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP75-01</td>
<td>Paravertebral Block for Percutaneous Nephrolithotomy: A Prospective, Randomized, Double-Blind Placebo-Controlled Study</td>
</tr>
<tr>
<td></td>
<td>Kristin G. Baldea*, Grace Delos Santos, Chicago, IL, Chandy Ellimoottil, Ann Arbor, MI, Ahmer Farooq, Elizabeth R. Mueller, Scott Byram, Thomas M.T. Turk, Chicago, IL</td>
</tr>
<tr>
<td>MP75-02</td>
<td>Predictors of ED Visits Following Ureteroscopy</td>
</tr>
<tr>
<td></td>
<td>Graham Machen*, Lawrence Tsai, Patrick Lowry, Erin Bird, Marawan El Tayeb, Temple, TX</td>
</tr>
<tr>
<td>MP75-03</td>
<td>Unplanned 30-Day Encounters After Uretero-Renoscopy for Urolithiasis</td>
</tr>
<tr>
<td></td>
<td>Kefu Du*, Robert Wang, Joel Vetter, Alethea Paradis, Alana Desai, Robert Figenshau, Ramakrishna Venkatesh, St. Louis, MO</td>
</tr>
<tr>
<td>MP75-04</td>
<td>Variation in National Opioid Prescribing Patterns Following Outpatient Nephrolithiasis Procedures</td>
</tr>
<tr>
<td></td>
<td>Tudor Borza*, Rodney L. Dunn, Yongmei Qui, Tyler N. Winkelman, Ted A. Skolarus, David C. Miller, Brent K. Hollenbeck, Gregory B. Auffenberg, Ann Arbor, MI</td>
</tr>
</tbody>
</table>

*Presenting author*
MP75-05 FAST TRACK STENT STUDY (FAST): SHORT TERM EXTERNAL URETER STENTING SHOWS SIGNIFICANT BENEFIT IN COMPARISON TO ROUTINE DJ STENT PLACEMENT AFTER URETERORENOSCOPIC STONE EXTRACTION – A PROSPECTIVE-RANDOMIZED TRIAL
Peter Bach*, Alina Reicherz, Lisa Dahlkamp, Nicolas von Landenberg, Rein-Jueri Palisaar, Joachim Noldus, Christian von Bodman, Herne, Germany

MP75-06 A PROSPECTIVE OBSERVATIONAL STUDY ABOUT STENT-RELATED SYMPTOMS AFTER URETEROSCOPY ASSESSED THROUGH A VALIDATED QUESTIONNAIRE.
Andrea Bosio*, Eugenio Alessandria, Ettore Dalmasso, Dario Peretti, Alessandro Biasonti, Paolo Destefanis, Paolo Gontero, Turin, Italy

MP75-07 INTRAVESICAL INSTILLATION OF LEVOBUPIVACAINE AS AN ADJUNCT TO REDUCE THE URETERAL STENT ASSOCIATED DISCOMFORT: A DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL.
José A. Salvadó*, Gaston Astroza, Alvaro Saavedra, Santiago, Chile

MP75-08 USE OF NON-METALLIC LONG TERM STENTS FOR URETERAL OBSTRUCTION
Amar P. Patel*, Jeffrey Pearl, John G. Pattaras, Atlanta, GA

MP75-09 RISK FACTORS FOR RE-INFECTION IN PATIENTS DRAINED WITH DJ STENT FOR URETEROLITHIASIS AND SEPSIS
Eyal Kord*, Yoram Siegel, Amir Cooper, zerifin, Israel, Sivan Hirsh, Tel aviv, Israel, Galina Goltsman, Amnon zisman, zerifin, Israel

MP75-10 TAILORING ANTIBiotic PROPHylaxis FOR URETEROSCOPIC PROCEDURES BASED ON LOCAL RESISTANCE PROFILES MAY LEAD TO REDUCED RATES OF INFECTIONS AND UROSEPSIS
Ariel Zisman, Shadie Badaan, Alexander Kastin, Alexander Kravtsov, David Kakiashvili, Gilad E. Amiel, Michael Mullerad*, Haifa, Israel

MP75-11 RENAL STONE CULTURE AND SENSITIVITY IS A BETTER PREDICTOR OF POTENTIAL UROSEPSIS THAN PELVIC OR MIDSTREAM URINE CULTURE AND SENSITIVITY
Karthik Tanneru*, Gunter, India, Rahul Devraj, Ramreddy Ch, Hyderabad, India

MP75-12 PROSPECTIVE EVALUATION OF STONE FREE RATES BY COMPUTED TOMOGRAPHY AFTER AGGRESSIVE URETEROSCOPY
Noah Canvasser*, Aaron Lay, Elysha Kolitz, Jodi Antonelli, Margaret Pearle, Dallas, TX

MP75-13 THE C.R.E.A.M. NEPHROLITHOMETRY SCORE: A COMPREHENSIVE GRADING SYSTEM BASED ON NON-ENHANCED CT SCAN TO PREDICT SUCCESS OF FLEXIBLE URETEROSCOPIC LITHOTRIPSY FOR RENAL CALCULI
Ke Liu*, Chunlei Xiao, Yichang Hao, Lulin Ma, Beijing, China, People’s Republic of

MP75-14 THE IMPACT OF ONE WEEK OF PRE-OPERATIVE TAMSOlUSIN ON DEPLOYMENT OF 16-FRENCH URETERAL ACCESS SHEATHS
Kamaljot S. Kaler*, Shoaib M. Safiullah, Roshan M. Patel, Daniel Lama, Young H. Ko, Zhamshid Okhunov, Jaime Landman, Ralph V. Clayman, Orange, CA

MP75-15 REAL TIME WHOLE COURSE MONITORED ULTRASOUND GUIDED PERCUTANEOUS RENAL ACCESS ESTABLISHMENT USING BALLOON DILATION: 135 CASES IN A SINGLE CENTER
Shu Wang*, Xin Zhang, Bo Xiao, Weiguo Hu, Song Chen, Jianxing Li, Beijing, China, People’s Republic of

MP75-16 SUPRACOSTAL ACCESS TUBELESS PERCUTANEOUS NEPHROLITHOTOMY: MINIMIZING COMPLICATIONS
Michael Sourial*, Nathaly Francois, Hiroko Miyagi, Geoffrey Box, Bodo Knudsen, Columbus, OH

MP75-17 C-REACTIVE PROTEIN AND ERYTHROCYTE SEDIMENTATION RATE PREDICTS SIRS AFTER PERCUTANEOUS NEPHROLITHOTOMY
Vishnu Ganesh*, Robert Brown, Juan Jimenez, Cleveland, Ohio, Shubha De, Edmonton, Canada, Manoj Monga, Cleveland, OH

MP75-18 COMPARISON OF COSTS AND OUTCOMES OF PERCUTANEOUS NEPHROLITHOTOMY BASED ON PERCUTANEOUS ACCESS
Rutveej Patel*, Kushan Radadia, Christopher Han, Ephrem Oweny, Sammy Elsamra, New Brunswick, NJ

MP75-19 NATIONAL TRENDS IN IMAGING FOLLOWING URETEROSCOPY & SHOCKWAVE LITHOTRIPSY
Justin Ahn*, Sarah Holt, Philip May, Jonathan Harper, Seattle, WA

MP75-20 EVALUATION OF THE TREATMENT OF DISTAL URETRAL STONES CAUSING RENAL COLIC IN A HIGH INTERVENTION SETTING
Bruce Gao*, Taylor Remondini, Premal Patel, Navraj Dhalwal, Ramneet Dhalwal, Adrian Frusec, Anthony Cook, Grant Innes, Bryce Weber, Calgary, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP76-01</td>
<td>SHARP DECREASE IN PROSTATE BIOPSY INCIDENCE WITH WIDE GEOGRAPHIC VARIATION FOLLOWING TASK FORCE PROSTATE CANCER SCREENING RECOMMENDATIONS</td>
<td>Mark Henry*, David Howard, Dattatraya Patil, Atlanta, GA, Benjamin Davies, Pittsburgh, PA, Christopher Filson, Atlanta, GA</td>
</tr>
<tr>
<td>MP76-02</td>
<td>UROLOGIST PRACTICE AFFILIATION AND INTENSITY MODULATED RADIATION THERAPY FOR PROSTATE CANCER</td>
<td>Lindsey Hernel*, Brent Hollenbeck, Samuel Kaufman, Phyllis Yan, Tudor Borza, Ann Arbor, MI, Florian Schroock, Hanover, NH, Bruce Jacobs, Pittsburgh, PA, Ted Skolarus, Vahako Shahinian, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP76-03</td>
<td>SMALL EFFECT OF PHARMACEUTICAL INDUSTRY PAYMENTS TO PHYSICIANS ON MEDICARE PRESCRIPTION HABITS: USING ABRIRATONE AND ENZALUTAMIDE</td>
<td>Omar Ayyash*, Jathin Bandari, Robert Turner, Bruce Jacobs, Benjamin Davies, Pittsburgh, PA</td>
</tr>
<tr>
<td>MP76-04</td>
<td>RECENT TRENDS IN FUNDING OF CLINICAL TRIALS FOR UROLOGICAL MALIGNANCIES.</td>
<td>Ariel Schulman*, Ghalib Jibara, Christina Sze, Kae Jack Tay, Efrat Tsivian, Thomas Polascik, Durham, NC</td>
</tr>
<tr>
<td>MP76-05</td>
<td>RADICAL CYSTECTOMY: THE ASSOCIATION BETWEEN DISTANCE TO TREATING FACILITY AND QUALITY OF CARE</td>
<td>Stephen Ryan*, Portland, ME, Patrick Karabon, Detroit, MI, Gregory Mills, Moritz Hansen, Matthew Hayn, Portland, ME, Mani Menon, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Firas Abdullah, Detroit, MI, Jesse Sammon, Portland, ME</td>
</tr>
<tr>
<td>MP76-06</td>
<td>TRENDS IN USE OF ANDROGEN DEPRIVATION THERAPY WITH RADIATION IN HIGH AND VERY HIGH RISK PROSTATE CANCER PATIENTS</td>
<td>John DeLancey*, Richard Matulewicz, Oliver Ko, Edward Schaeffer, Chicago, IL</td>
</tr>
<tr>
<td>MP76-08</td>
<td>THE IMPACT OF PATHOLOGICAL RISK FACTORS AND THE MANAGEMENT OF STAGE I NON SEMINOMATOUS GERM CELL TESTICULAR CANCER</td>
<td>Mazen Alsinnawi*, Sydney Akapame, John Burns, John Paul Flores, Christopher Porter, Seattle, WA</td>
</tr>
<tr>
<td>MP76-09</td>
<td>PREDICTORS OF METASTASIS AT TIME OF DIAGNOSIS AND OVERALL SURVIVAL IN METASTATIC TESTICULAR CANCER</td>
<td>Marshall Shaw*, Andrew Bachman, Alexander Parker, Brian Cross, Kelly Stratton, Michael Cookson, Sanjay Patel, Oklahoma City, OK</td>
</tr>
<tr>
<td>MP76-10</td>
<td>BURNOUT IN UROLOGY: RESULTS FROM THE 2016 AUA CENSUS</td>
<td>Amanda C. North*, Bronx, NY, Patrick H. McKenna, Madison, WI, Raymond Fang, Linthicum, MD, Alp Sener, London, Canada, Brian K. McNeil, Brooklyn, NY, Julie Franc-Guimond, Montreal, Canada, William Meeks, Linthicum, MD, Steven Schlossberg, Walnut Creek, CA, Chris M. Gonzalez, Cleveland, OH, James Q. Clemens, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP76-11</td>
<td>IS YOUR CAREER HURTING YOU? THE ERGONOMIC CONSEQUENCES OF SURGERY OVER TIME IN 701 GLOBAL UROLOGISTS</td>
<td>Granville Lloyd*, Denver, CO, Amanda Chung, Concord, NSW, Australia, Mark Sawyer, Steve Steinberg, Denver, CO, Daniel Williams, Madison, WI, Douglas Overbey, Denver, CO</td>
</tr>
<tr>
<td>MP76-12</td>
<td>THE RISING TREND OF ADVANCED PRACTICE PROVIDER ASSISTANCE IN UROLOGIC SURGERY</td>
<td>Amanda Swanton*, Ahmad Alzubaidi, Bradley Erickson, Iowa City, IA</td>
</tr>
<tr>
<td>MP76-13</td>
<td>SCRIBES IN AMBULATORY UROLOGIC PRACTICE: FINANCIAL ANALYSIS AND PRACTICE MANAGEMENT CONSIDERATIONS</td>
<td>Madeline Cancian*, Gyan Pareek, Stephen Schiff, Simone Thavaseelan, Providence, RI</td>
</tr>
<tr>
<td>MP76-14</td>
<td>PATIENT PORTAL USAGE IN PEDIATRIC UROLOGY: IS IT MEANINGFUL USE TO EVERYONE?</td>
<td>Diana Cardona-Grau*, Ruth Bush, Hena Din, Andrew Richardson, Cynthia Kuebels, George Chiang, San Diego, CA</td>
</tr>
</tbody>
</table>
MP76-15 SURGICAL OUTCOMES CENTER FOR KIDS: A RESEARCH MODEL FOR PEDIATRIC UROLOGY
Chelsea Lauderdale*, Madison Shultz, Douglass Clayton, Stacy Tanaka, John Thomas, John Pope, Mark Adams, John Brock, Chevis Shannon, Nashville, TN

MP76-16 PATTERNS OF MEDICAL MANAGEMENT OF OVERACTIVE BLADDER (OAB) AND BENIGN PROSTATIC HYPERPLASIA (BPH) IN THE US: WHO DOES BETTER?
Jennifer Anger*, Los Angeles, CA, Howard Goldman, Cleveland, Oht, Xuemei Luo, Martin Carlsson, Douglass Chapman, Kelly Zou, Fady Ntanios, David Russell, Canan Esinduy, New York, NY, J. Quentin Clemens, Ann Arbor, MI

MP76-17 PATTERNS OF CARE FOR THE EVALUATION OF HEMATURIA AMONG INSURED NON--ELDERLY PATIENTS
Alyssa Greiman*, Kit Simpson, Charleston, SC, Amit Patel, DuPage, IL, Sandip Prasad, Charleston, SC

MP76-18 VARIABILITY IN INTENSIVE CARE UNIT USE IN PATIENTS WITH RENAL TRAUMA
Judith C. Hagedorn*, D. Alex Quistberg, Saman Arbabi, Monica S. Vavilala, Hunter Wessells, Seattle, WA

MP76-19 ASSESSMENT OF PHYSICIANS' PRACTICES IN SCREENING AND TREATING WOMEN WITH BACTERIURIA

MP76-20 UTILIZATION OF RADIATION THERAPY FOR T2/T3 BLADDER UROTHELIAL CARCINOMA: A 25-YEAR POPULATION-BASED ANALYSIS
Matthew Kaufman*, Augusta, GA, Zachary Klaassen, Toronto, Canada, Chris Ellington, Alan K. Barnes, Michael Kemper, Rabii Madi, Martha K. Terris, Durwood E. Neal, Jr., Augusta, GA

Approved for AMA PRA Category 1 Credit™

Monday, May 15, 2017 9:30 am - 11:30 am
Moderated Poster Session 77
Prostate Cancer: Detection & Screening VII
Room 160 @ Boston Convention & Exhibition Center
Moderators: William Catalona and Quoc-Dien Trinh

ABSTRACT NUMBER TITLE
MP77-01 11C-CHOLINE VERSUS 68GA-PSMA PET/CT SCAN FOR THE DETECTION OF NODAL RECURRENCE FROM PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SALVAGE LYMPH NODE DISSECTION SERIES

ABSTRACT NUMBER TITLE
MP77-02 FIRST CLINICAL EXPERIENCE OF TRIMODAL (18)F-CHOLINE-PET/MPMRI/TRUS TARGETED PROSTATE BIOPSIES: A PILOT STUDY FOR A NEW CONCEPT.
Jean-Louis Bonnal*, Arnaud Marien, Aurelien ROCK, Khaled El maadarani, Brigitte Mauroy, Delphine Bessard, Arnaud Delebarre, Pierre Gosset, Tanguy Blaire, Lille, France

MP77-03 TARGETED 11C-CHOLINE PET/CT/TRUS SOFTWARE FUSION--GUIDED PROSTATE BIOPSY HAS IN MEN WITH PERSISTENTLY ELEVATED PSA AFTER PREVIOUS NEGATIVE BIOPSY
Egesta Lopci, Rozzano, Italy, Massimo Lazzeri*, Giovanni Lughezzani, NicolòMaria Buffi, Paolo Casale, Rodolfo Hurle, Alberto Saita, Giuliana Lista, Luisa Pasini, Silvia Zandegiacomo, Alessio Benetti, Roberto Peschechera, Pasquale Cardone, Milano, Italy, Arturo Chiti, Giorgio Guazzaroni, Rozzano, Italy
**MP77-04** IMPLICATIONS OF RECURRENCE SITES IDENTIFICATION FOLLOWING SALVAGE TREATMENTS FOR PROSTATE CANCER USING C-11 CHOLINE PET AND MULTIPARAMETRIC MRI

**MP77-05** SIMPLE PROSTATE BIOPSY PROTOCOL WITH AUGMENTED ANTIBIOTICS DECREASES COMPLICATIONS AND ADMISSIONS IN VETERANS
Kimberly A Maciolek*, Sara L Best, Wade A Bushman, David F Jarrard, Tracy M Downs, E Jason Abel, Kyle A Richards, Madison, WI

**MP77-06** ANTIMICROBIAL LUBRICANT REDUCES RECTAL BACTERIA AT TRANSRECTAL PROSTATE BIOPSY. RESULTS FROM A LARGE PROSPECTIVE RANDOMIZED TRIAL
Katharina Boehm*, Mainz, Germany, Sandra Prues, Judith Saul, Lars Budäus, Derya Tilki, Hamburg, Germany, Axel Haferkamp, Mainz, Germany, Markus Graefen, Georg Salomon, Hamburg, Germany

**MP77-07** PATHOLOGIC OUTCOMES OF ADDITIONAL 2-CORES IN PROSTATE APEX ANTERIOR COMPARED TO 12-ROUTINE CORES: PROSPECTIVE STUDY
Sung Jin Kim*, Chang Hoo Park, Han Kwon Kim, Jong Yeon Park, Gangneung, Korea, Republic of

**MP77-08** SECULAR TRENDS IN PROSTATE BIOPSY CRITERIA AND OUTCOMES: THE DARTMOUTH EXPERIENCE
Lael Reinstatler*, West Lebanon, NH, Cody Rissman, John Seigne, Elias Hyams, Lebanon, NH

**MP77-09** CURRENT PRACTICE OF PROSTATE BIOPSY IN AUSTRALIA AND NEW ZEALAND: AN UPDATED SURVEY
Arveen Kalapara*, Paul Davis, Eldho Paul, Jeremy Grummet, Melbourne, Australia

**MP77-10** THE EFFECT OF ULTRASOUND-GUIDED COMPRESSION PERFORMED IMMEDIATELY AFTER TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY ON POSTBIOPSY BLEEDING
Bong Hee Park, Sung Hak Kang, Joon Se Jung*, Sang Rok Bae, Yong Seok Lee, Chang Hee Han, Ulleungbu-Si, Korea, Republic of

**MP77-11** ASSESSMENT OF DISCOMFORT AND PAIN IN PATIENTS UNDERGOING FUSION-MRI-GUIDED VERSUS TRUS-GUIDED PROSTATE BIOPSY
Dennis Robins*, Michael Lipsky, Sven Wenske, New York, NY

**MP77-12** HEAD-TO-HEAD COMPARISON OF COMMONLY USED INTERNATIONAL PROSTATE CANCER RISK CALCULATORS FOR PROSTATE BIOPSY
Nuno Pereira-Azevedo*, Porto, Portugal, Jan Verbeek**, Daan Nieboer, Ewout Steyerberg, Monique Roobol, Rotterdam, Netherlands

**MP77-13** A PROSPECTIVE EVALUATION ON THE PERFORMANCE OF THE DRE BASED ROTTERDAM PROSTATE CANCER RISK CALCULATOR
Nuno Pereira-Azevedo*, Rotterdam, Netherlands, Isaac Braga, Braga, Portugal, Jan F.M. Verbeek, Rotterdam, Netherlands, Luis Osorio, Vitor Cavadas, Avelino Fraga, Eduardo Carrasquinho, Eduardo Cardoso de Oliveira, Porto, Portugal, Daan Nieboer, Monique J. Roobol, Rotterdam, Netherlands

**MP77-14** DIABETES MELLITUS, METFORMIN AND PROSTATE CANCER: RESULTS OF A PROSTATE CANCER DATABASE ANALYSIS
Seyed Behzad Jazayeri*, Brittany Weissman, David Samadi, New York, NY

**MP77-15** INCLUSION OF MPMRI INTO THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) RISK CALCULATOR: A NEW PROPOSAL TO IMPROVE THE ACCURACY OF PROSTATE CANCER DETECTION
Paolo Dell’Oglio*, Armando Stabile, Giorgio Gandaglia, Giorgio Brembilla, Tommaso Maga, Giulia Cristel, Ella Kinzikeeva, Andrea Losa, Antonio Esposito, Gianpiero Cardone, Francesco De Cobelli, Alessandro Del Maschio, Franco Gaboardi, Francesco Montorsi, Alberto Briganti, Milan, Italy

**MP77-16** FIRST REPEATED BIOPSY REPRESENTS THE MOST INFORMATIVE PREDICTOR OF PROGRESSION-FREE SURVIVAL AT 3 YEARS FOLLOW-UP IN PATIENTS INCLUDED IN AN ACTIVE SURVEILLANCE PROTOCOL FOR LOW-RISK PROSTATE CANCER
Stefano Luzzago*, Nazareno Suardi, Paolo Dell’Oglio, Nicola Fossati, Umberto Capitanio, Giorgio Gandaglia, Emanuele Zaffuto, Milan, Italy, Vincenzo Mirone, Naples, Italy, Roberto Bertini, Milan, Italy, Rocco Damiano, Catanzaro, Italy, Massimo Freschi, Franco Gaboardi, Francesco Montorsi, Alberto Briganti, Milan, Italy

**MP77-17** IMPACT OF TIME FROM BIOPSY TO SURGERY ON COMPLICATIONS, FUNCTIONAL AND ONCOLOGIC OUTCOMES FOLLOWING RADICAL PROSTATECTOMY
Mary E. Westerman*, Vidit Sharma, George C. Bailey, Stephen A. Boorjian, Igor Frank, Matthew T. Gettman, R. Houston Thompson, Matthew K. Tollefsen, R. Jeffrey Karnes, Rochester, MN

---

*Presenting author
MP77-18 WHAT FALSE NEGATIVE RATE OF NON-INVASIVE TESTING ARE ACTIVE SURVEILLANCE PATIENTS AND URO-Oncologists WILLING TO ACCEPT IN ORDER TO AVOID PROSTATE BIOPSY?
Rashid Sayyid*, Dharmendra Dingar, Katherine Fleshner, Toronto, Canada, Taylor Thorburn, Wolfville, Canada, Joshua Diamond, Montreal, Canada, Erikk Yao, Karen Hersey, Karen Chadwick, Nathan Perlis, Laurence Klotz, Antonio Finelli, Alexandre Zlotta, Robert Hamilton, Girish Kulkarni, Neil Fleshner, Toronto, Canada

MP77-19 TIMING OF CONFIRMATORY BIOPSIES INFLUENCES ELIGIBILITY FOR ACTIVE SURVEILLANCE
Jessica Armstrong, Farmington, CT, Peter Haddock, Hartford, CT, Scott Wiener*, Farmington, CT, Iline Staff, Joseph Cusano, Joseph Wagner, Hartford, CT

MP77-20 MULTIPARAMETRIC MRI REPRESENTS AN ADDED VALUE BUT NOT A SUBSTITUTE OF FOLLOW-UP BIOPSIES IN PATIENTS ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER
Stefano Luzzago*, Nazareno Suardi, Paolo Dell'Oglio, Gianpiero Cardone, Giorgio Gandaglia, Antonio Esposito, Francesco De Cobelli, Giulia Cristel, Ella Kinzikeeva, Massimo Freschi, Franco Gaboardi, Alessandro Del Maschio, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP78-01 IMPACT OF URETEROSCOPY BEFORE RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMAS ON ONCOLOGIC OUTCOMES: A META-ANALYSIS
Run-Qi Guo*, Peng Hong, Xue-Song Li, Li-Qun Zhou, Beijing, China, People’s Republic Of

MP78-02 RESULTS OF SECOND LINE TOPICAL THERAPY FOR UPPER TRACT UROTHELIAL CARCINOMA (UTUC)
Adityya Balasubramanian*, Michael J Metcalfe, Gavin Wagenheim, Lianchun Xiao, Firas G Petros, John Papadopoulos, Neema Navai, John W Davis, Jose A Karam, Ashish M Kham, Christopher G Wood, Colin P Dinney, Suren F Matin, Houston, TX

MP78-03 IMPACT OF RESIDUAL PERI-ORIFICE UROTHELIUM ON INTRAVESICAL RECURRENT AFTER NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CANCER
Chia-Wei Cheng*, Tainan, Taiwan, Ze-Hong Lu, Weng-Horng Yang, Chien-Hui Ou, Tainan, Taiwan

MP78-04 EFFICACY OF EARLY URETERAL LIGATION ON PREVENTION OF INTRAVESICAL RECURRENT AFTER RADICAL NEPHROURETERECTOMY FOR UPPER URINARY TRACT UROTHELIAL CARCINOMA: A PROSPECTIVE SINGLE-ARM MULTICENTER CLINICAL TRIAL
Shinichi Yamashita*, Akishi Ito, Koji Mitsuzuka, Masatuka Aizawa, Naomasa Ioritani, Sendai, Japan, Shigeto Ishidoya, Sendai, Japan, Yoshiihiro Ikeda, Osaki, Japan, Kenji Numahata, Yamagata, Japan, Kazuhiko Orikasa, Kesennuma, Japan, Tatsuo Toghi, Natori, Japan, Fumihiko Soma, Hachinohe, Japan, Takashige Namima, Hideo Sato, Sendai, Japan, Makoto Sato, Rifu, Japan, Shimosuke Kato, Yuzawa, Japan, Shozo Ota, Sendai, Japan, Atsushi Kyan, Shirakawa, Japan, Atsushi Takeda, Ichinoseki, Japan, Yasuhiro Kaiho, Yoichi Arai, Sendai, Japan

MP78-05 INTRAVESICAL IRRIGATION PREVENTS BLADDER CARCINOMA RECURRENT AFTER NEPHROURETERECTOMY
Satoshi Yamamoto*, Shinichi Sakamoto, Tomokazu Sazuka, Chiba, Japan, Toshihito Inoue, Kazuyoshi Nozumi, Kazuto Chiba, Kanetaka Miyazaki, Atsushi Inoue, Maki Nagata, Yokohama, Japan, Tomohiko Ichikawa, Chiba, Japan
MP78-06 PHASE II STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR METASTATIC UPPER TRACT UROTHELIAL CANCER PATIENTS REFRACTORY TO THE STANDARD CHEMOTHERAPY
Shigetaka Suekane*, Kousuke Ueda, Kiyoaki Nishihara, Tsukasa Igawa, Masanori Noguchi, Kurume, Japan, Tetsuro Sasada, Yokohama, Japan, Takuto Yamashita, Shigeru Yutani, Shigeki Shichijo, Kyogo Itoh, Kurume, Japan

MP78-07 GENDER-SPECIFIC DIFFERENCES IN CANCER-SPECIFIC SURVIVAL AFTER NEPHROURETERECTOMY WITH BLADDER CUFF FOR PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA
Teruo Inamoto*, Kiyoshi Takahara, Naokazu Ituki, Takatsuki, Japan, Hideyasu Matsuyama, Ube, Japan, Kiyohide Fujimoto, Kashihara, Japan, Hiroaki Shinya, Shimane, Japan, Shigeru Sakano, Kauhiro Nagao, Ube, Japan, Yoshhiro Tatsumi, Kashihara, Japan, Haruhito Azuma, Takatsuki, Japan, Nishinohon Uro-Oncology Collaborative Group, Ube, Japan

MP78-08 IMPROVED SURVIVAL OF CYTOREDUCTIVE SURGERY IN ADDITION TO CHEMOTHERAPY FOR METASTATIC UPPER TRACT UROTHELIAL CARCINOMA: RESULTS FROM THE NATIONAL CANCER DATA BASE
Leilei Xia*, Benjamin Taylor, Jose Pulido, Jeremy Bonzo, Thomas Guzzo, Philadelphia, PA

MP78-09 EXTERNAL VALIDATION OF A PREOPERATIVE NOMOGRAM TO PREDICT LIKELIHOOD OF ALL COMPLICATIONS FOLLOWING RADICAL NEPHROURETERECTOMY

MP78-10 HIGHER RISK OF RECURRENCE AT EXTRAREGIONAL NODES AFTER RADICAL NEPHROURETERECTOMY IN PATIENTS WITH LEFT THAN IN PATIENTS WITH RIGHT URETERAL CANCER
Tsunenori Kondo*, Tokyo, Japan, Isao Hara, Wakayama, Japan, Toshio Takagi, Tokyo, Japan, Yoshiki Kodama, Wakayama, Japan, Kenji Omae, Junpei Iizuka, Kazuhiro, Yoshida, Hironori Fukuda, Kazunari Tanabe, Tokyo, Japan

MP78-11 POSITIVE PREDICTIVE VALUE OF CT UROGRAPHY FOR UPPER TRACT UROTHELIAL CARCINOMA DIAGNOSIS USING DIAGNOSTIC URETEROSCOPY AS THE REFERENCE STANDARD
Timothy Chan Chang*, Stanford, CA, Ishay Mintz, Yuval Bar-Yosef, Tel Aviv, Israel, Simon Conti, Stanford, CA, Sophie Barnes, Diego Mercier, Nicola Mabjeeesh, Tel Aviv, Israel, Joseph Liao, Stanford, CA, Mario Sofer, Tel Aviv, Israel

MP78-12 PREOPERATIVE CONTROLLING NUTRITIONAL STATUS (CONUT) SCORE AS A NOVEL PREDICTIVE BIOMARKER OF SURVIVAL IN PATIENTS WITH LOCALIZED UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT TREATED WITH RADICAL NEPHROURETERECTOMY
Hiroki Ishihara*, Tsunenori Kondo, Kazuhiko Yoshida, Kenji Omae, Toshio Takagi, Junpei Iizuka, Kazunari Tanabe, Tokyo, Japan

MP78-13 IMPAIRED BASELINE PERFORMANCE STATUS AND CHRONIC KIDNEY DISEASE ARE SIGNIFICANTLY ASSOCIATED WITH MAJOR COMPLICATIONS FOLLOWING RADICAL NEPHROURETERECTOMY
Neil Kocher*, Jay Raman, Hershey, PA, David Canes, Burlington, MA, Karim Bensalah, Rennes, France, Morgan Roupret, Paris, France, Costas Lallas, Philadelphia, PA, Vitaly Margulis, Dallas, TX, Shahrokh Shariat, Vienna, Austria, Pierre Colin, Lille, France, Surena Matin, Houston, TX, Chad Tracy, Iowa City, IA, Evanguelos Xylinas, Paris, France, Andrew Wagner, Boston, MA, Mathieu Roumigie, Toulouse, France, Wassim Kassouf, Montreal, Canada, Tobias Klatte, Vienna, Austria

MP78-14 IMPORTANCE OF TUMOR SIZE AS RISK STRATIFICATION PARAMETER IN UPPER TRACT UROTHELIAL CARCINOMA (UTUC)
Beat Foerster*, Vienna, Austria, Thomas Seisen, Paris, France, Marco Bandini, Milan, Italy, Kees Hendriksen, Amsterdam, Netherlands, Anna K. Czeck, Krakow, Poland, Marco Moschini, Mohammad Abufaraj, Vienna, Austria, Marco Bianchi, Milan, Italy, Donald Schweitzer, Amsterdam, Netherlands, Kilian M. Gust, Vienna, Austria, Morgan Roupret, Paris, France, Alberto Briganti, Milan, Italy, Bas G. van Rhijn, Amsterdam, Netherlands, Pirot Chilosta, Krakow, Poland, Pierre Colin, Lille, France, Hubert John, Winterthur, Switzerland, Shahrokh F. Shariat, Vienna, Austria
### Podium Session 53

**SEXUAL FUNCTION/DYSFUNCTION: PENIS/TESTIS/URETHRA: BENIGN DISEASE & MALIGNANT DISEASE II**

**Room 157 @ Boston Convention & Exhibition Center**

**Moderators:** Phillip Pierorazio and William Bedford Waters

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD53-01</td>
<td>NON-GUIDELINE CONCORDANT TREATMENT OF TESTICULAR CANCER Pia Paffenholz*, David Pfister, Axel Heidenreich, Cologne, Germany</td>
</tr>
<tr>
<td>9:40</td>
<td>PD53-02</td>
<td>HISTOLOGY AND CLINICAL OUTCOMES IN PATIENTS WITH ELEVATED SERUM TUMOR MARKERS AT THE TIME OF POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR ADVANCED GERM CELL MALIGNANCY Qiang Li #*, Piotr Zareba #, Brett Carver, George Bost, Darren Feldman, Dean Bajorin, Robert Motzer, Joel Sheinfeld, New York, NY</td>
</tr>
<tr>
<td>9:50</td>
<td>PD53-03</td>
<td>TOTAL LYMPH NODE YIELD IMPACTS ON OVERALL SURVIVAL FOLLOWING POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR NON-SEMINOMATOUS TESTICULAR CANCER Raj Bhanvadia*, Joseph Rodriguez III, Scott Eggener, Chicago, IL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>PD53-04</td>
<td>THE FEATURES AND MANAGEMENT OF LATE RELAPSE OF NON-SEMINOMATOUS GERM CELL TUMOURS Alexander Jay*, London, United Kingdom, Mohammed Aldiwan, Suranga Wijayarathna, Robert Huddart, Erik Mayer, David Nicol, London, United Kingdom</td>
</tr>
<tr>
<td>10:10</td>
<td>PD53-05</td>
<td>RISK OF SECONDARY MALIGNANCY AND CAUSES OF DEATH AFTER RADIATION THERAPY FOR TESTICULAR SEMINOMAS Hilen Patel*, Amav Srivastava, Ridwan Alam, Gregory Joice, Zeyad Schwen, Alice Semerjian, Mohamad Allaf, Phillip Pierorazio, Baltimore, MD</td>
</tr>
<tr>
<td>10:20</td>
<td>PD53-06</td>
<td>HISTOLOGIC FINDINGS OF LATE RELAPSED SEMINOMA MANAGED WITH RETROPERITONEAL LYMPH NODE DISSECTION Clint Cary*, Joseph Jacob, Richard Foster, Indianapolis, IN</td>
</tr>
</tbody>
</table>
PD53-07 CONDITIONAL RISK OF RELAPSE IN 3,601 PATIENTS MANAGED WITH SURVEILLANCE FOR STAGE I TESTICULAR CANCER
Madhur Nayan*, Toronto, Canada, Gedske Daugaard, Copenhagen, Denmark, Michael Jewett, Toronto, Canada, Jakob Lauritsen, Mikkel Bandak, Mette Saksoe Mortensen, Maria Gry Gundgaard Kier, Copenhagen, Denmark, Philippe Bedard, Aaron Hansen, Padraig Warde, Peter Chung, Eshetu Atanafu, Robert Hamilton, Toronto, Canada

PD53-08 CLINICAL IMPLICATIONS OF SERUM N-GLYCAN PROFILING AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN GERM-CELL TUMORS

PD53-09 MEN WITH TESTICULAR CANCER HAVE LOWER SEMEN QUALITY COMPARED TO THOSE WITH OTHER MALIGNANCIES
Daisuke Noro*, Shingo Hatakeyama, Itsuto Hamano, Toshikazu Tanaka, Takuma Nairita, Tohru Yoneyama, Atsushi Imai, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama, Hiroaki, Japan

PD53-10 IMPACT OF ADJUVANT TREATMENT ON LONG-TERM QUALITY OF LIFE OF TESTICULAR CANCER SURVIVORS
Trung Q Ngo*, Jeremy R Goad, Anthony J Dowling, Lih-Ming Wong, Fitzroy, Victoria, Australia

PD53-11 PRIMARY RETROPERITONEAL LYMHP NODE DISSECTION (RPLND) IN STAGE II A/B SEMINOMA PATIENTS WITHOUT ADJUVANT TREATMENT: A PHASE II TRIAL (PRIMETEST)
Achim Lusch*, Laura Gerbaulet, Christian Winter, Peter Albers, Duesseldorf, Germany

PD53-12 CENTRALIZATION OF CARE PROMOTES TRAINING DISPARITIES WITH REGARD TO THE TEACHING OF RETROPERITONEAL LYMHPADENECTOMY
Ryan Owen*, Stephanie Dresner, James Bienvenu, W. Bedford Waters, Knoxville, TN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 15, 2017 9:30 am - 11:30 am
Podium Session 54
URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: FEMALE INCONTINENCE: THERAPY III
Room 159 @ Boston Convention & Exhibition Center
Moderators: Michael DiSanto, Mauricio Plata and Anne Suskind

ABSTRACT
TIME NUMBER TITLE
9:30 PD54-01 BRAIN ACTIVITY CHANGES ON FUNCTIONAL MAGNETIC RESONANCE IMAGING DURING SACRAL NERVE STIMULATION FOR OVERACTIVE BLADDER
Bradley Gill*, Cleveland, OH, Javier Pizarro-Berdichevsky, Santiago, Chile, Pallab Bhattacharyya, Cleveland, OH, Brian Marks, Concord, NH, Adrienne Quirouet, Ottawa, Canada, Sandip Vasavada, Stephen E Jones, Howard B Goldman, Cleveland, OH

9:40 PD54-02 REMOVAL OF SACRAL NERVE STIMULATION DEVICES FOR MAGNETIC RESONANCE IMAGING: WHAT HAPPENS NEXT
Jessica Lloyd*, Bradley Gill, Cleveland, OH, Javier Pizarro-Berdichevsky, Santiago, Chile, Elodi Dielubanza, Juan Guzman, Henry Okafor, Cleveland, OH, Howard Goldman, Cleveland, OH

9:50 PD54-03 OPTIMIZING LEAD PLACEMENT DURING STAGED SACRAL NEUROMODULATION (SNM): FACTORS ASSOCIATED WITH PROGRESSION TO STAGE 2
Sarah A Adelstein*, Kevin Gioia, Jonathan Wingate, Alvano Lucioni, Kathleen C Kobashi, Una J Lee, Seattle, WA

10:00 PD54-04 NEUROMODULATION FOR CHRONIC UROGENITAL PAIN: A COMPARISON OF PUDENDAL AND SACRAL NERVE STIMULATION
Austin Fan, Rochester, MI, Kim A. Killinger, Kenneth M. Peters*, Judith Boura, Royal Oak, MI

*Presenting author
10:10 PD54-05 DEMOGRAPHIC AND CLINICAL VARIABLES ASSOCIATED WITH TREATMENT RESPONSE IN WOMEN UNDERGOING ONABOTULINUMTOXINA AND SACRAL NEUROMODULATION
Holly E Richter*, Birmingham, AL, Cindy Amundson, Durham, NC, Eric Jelovsek, Cleveland, OH, Stephen Erickson, Reserach Triangle Park, NC, Yuko Komesu, Albuquerque, NM, Christopher Chemmansky, Pittsburgh, PA, Norbert Kadima, Reserach Triangle Park, NC, Deborah Myers, Providence, RI, Heidi Harvie, Philadelphia, PA, Michael Albo, San Diego, CA, Dennis Wallace, Reseach Triangle Park, NC

10:20 PD54-06 A PROSPECTIVE RANDOMIZED CLINICAL TRIAL COMPARING TWO DOSES OF ONABOTULINUMTOXINA FOR IDIOPATHIC OVERACTIVE BLADDER
Danielle de Sa Dantas Bezerra*, Luis Gustavo Morato Toledo, Jose Eduardo Veitorazzo Filho, Antonio Pedro Flores Auge, Sao Paulo, Brazil

10:30 PD54-07 EXPRESSION OF MIR221 AND MIR125B IN BLADDER BIOPSY PREDICT THE RISK OF HIGH PVR FOLLOWING INTRADETRUSOR ONABOTULINUMTOXIN-A INJECTION: IMPLICATIONS FOR CLINICAL DECISION MAKING
Christopher J Chermansky*, Brian T Kadow, Mahendra Kashyap, Pradeep Tyagi, Pittsburgh, PA

10:40 PD54-08 WHAT IS THE IDEAL ANTIBIOTIC PROPHYLAXIS FOR INTRAVESICAL BOTOX INJECTION? A COMPARISON OF TWO DIFFERENT REGIMENS
Justin Houman*, Juzar Jamnagerwalla, Ariel Moradzadeh, Kian Asand, Devin Patel, Jennifer Anger, Karyn Eilber, Los Angeles, CA

10:50 PD54-09 FIRST RESULTS – THE URG 1 STUDY - RANDOMIZED TRIAL TO COMPARE SOLIFENACIN AND BILATERAL MESH REPLACEMENT OF THE UTEROSACRAL LIGAMENTS IN THE TREATMENT OF URGENCY URINARY INCONTINENCE
Sebastian Ludwig*, Martin Sturim, Peter Mallmann, Wolfram Jäger, Cologne, Germany

11:00 PD54-10 THE VALUE OF COMBINING LOW DOSE TROSPUMI CHLORIDE WITH TRANSCUTANEOUS POSTERIOR TIBIAL NERVE STIMULATION IN THE TREATMENT OF OVERACTIVE BLADDER IN FEMALES
Amr Abulseoud*, Gaber Ali, Mohamed Hassouna, Ahmed Moussa, Ibrahim Ibrahim, Emmanuel Saba, Alexandria, Egypt

11:10 PD54-11 ELECTRICAL STIMULATION OF AFFERENT NERVES IN THE FOOT WITH TRANSCUTANEOUS ADHESIVE PAD ELECTRODES IN WOMEN WITH REFRACTIVE OVERACTIVE BLADDER: DEFINING IDEAL STIMULATION DURATION
Christopher J Chermansky*, Bing Shen, Janet Okonski, William C de Groat, Changfeng Tai, Pittsburgh, PA

11:20 PD54-12 STATEWIDE TRENDS OF INTERSTIM® IMPLANTATION ACROSS DIFFERENT SURGICAL SPECIALTIES IN NEW YORK
Wai Lee*, Andrew Chen, Olga Povcher, Kailash Kapadia, Wei Hou, Jason Kim, Stony Brook, NY

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
9:50 PD55-03 ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER IN MEN UNDER 60 YEARS OF AGE
Keyan Salari*, David Kuppermann, Mark Preston, Douglas Dahl, Jason Efstathiou, Michael Blute, Boston, MA, Danny Vesprini, Andrew Loblaw, Toronto, Canada, Anthony Zietman, Boston, MA, Laurence Kotz, Toronto, Canada, Adam Feldman, Boston, MA

10:00 PD55-04 THE ERSPC VERSUS THE PROTECT STUDY: OUTCOMES AFTER ACTIVE SURVEILLANCE COMPARED TO SURGERY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER.
Frank-Jan Drost*, Arnout Alberts, Chris Bangma, Monique Roobol, for the ERSPC Rotterdam group, Rotterdam, Netherlands

10:10 PD55-05 ACTIVE SURVEILLANCE IS A VIABLE OPTION FOR MEN WITH BORDERLINE LOW-RISK PROSTATE CANCER
Keyan Salari*, David Kuppermann, Mark Preston, Douglas Dahl, Aria Olumi, Jason Efstathiou, Richard Lee, Chin-Lee Wu, Michael Blute, Anthony Zietman, Adam Feldman, Boston, MA

10:20 PD55-06 PSA VELOCITY IN MEN STARTING 5-ALPHA-REDUCTASE INHIBITORS AT THE TIME OF STARTING ACTIVE SURVEILLANCE IS A PREDICTOR OF PATHOLOGICAL PROGRESSION IN LOW-RISK PROSTATE CANCER
Narhari Timilshina*, Shabbir Alibhai, Maria Komisarenko, Lisa Martin, Ruby Grewal, Rob Hamilton, Girish kulkarni, Alexandre Zlotta, Neil Fleshner, Antonio Finelli, Toronto, Canada

10:30 PD55-07 VERY LOW RISK AND LOW RISK PATIENTS IN ACTIVE SURVEILLANCE: IS THE DISTINCTION RELEVANT?
R. Yates Coley*, Seattle, WA, Scott Zeger, Mufaddal Mamawala, H. Ballentine Carter, Baltimore, MD

10:40 PD55-08 INTRODUCING MPMRI INTO CONTEMPORARY UK ACTIVE SURVEILLANCE FOR LOCALISED PROSTATE CANCER
Richard Bryant*, Bob Yang, Yiannis Philippou, Karla Lam, Maureen Obiakor, Jennifer Ayers, Fergus Gleeson, Ruth MacPherson, Clare Verrill, Ian Roberts, Thomas Leslie, Jeremy Crew, Prasanna Sooriakumar, Freddie Hamdy, Simon Brewster, Oxford, United Kingdom

10:50 PD55-09 ROLE OF MPMRI PSA DENSITY AND PIRADS SCORE IN PREDICTING UPSTAGING IN MEN ON ACTIVE SURVEILLANCE
Michelle Van Kuiken*, Robert H. Blackwell, Bryan Bisanz, Joseph Yacoub, Ari Goldberg, Steven Shea, Marcus Quek, Gopal N. Gupta, Maywood, IL

11:00 PD55-10 ONCOLOGIC OUTCOMES AFTER RADICAL PROSTATECTOMY IN FAVORABLE INTERMEDIATE RISK GROUP ACTIVE SURVEILLANCE CANDIDATES
Monty Aghazadeh*, Hartford, CT, Jason K Frankel, Matthew Belanger, Farmington, CT, Tara McLaughlin, Ilene Staff, Joseph Wagner, Hartford, CT

11:10 PD55-11 IS FAVORABLE INTERMEDIATE RISK PROSTATE CANCER REALLY FAVORABLE? IMPLICATIONS FOR ACTIVE SURVEILLANCE STRATEGIES
Samuel Haywood*, Yaw Nyame, Helen Liang, Eric Klein, Andrew Stephenson, Cleveland, OH

11:20 PD55-12 OLDER AGE AT DIAGNOSIS AND DISEASE VOLUME PREDICT UPGRADING ON CONFIRMATORY BIOPSY IN PROSTATE CANCER PATIENTS BEING CONSIDERED FOR ACTIVE SURVEILLANCE

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
## Video Session 9

**INFERTILITY, ED, AND RECONSTRUCTION LOWER TRACT (II)**

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 254 @ Boston Convention & Exhibition Center

**Moderators:** Bobby Najari and Justin Parker

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>V9-01</strong></td>
<td><strong>THREE-DIMENSIONAL PHOTOGRAPHY AS A TOOL FOR CHARACTERIZATION OF PENILE DEFORMITY IN PEYRONIE’S DISEASE</strong> Ezra Margolin*, Carrie Mlynarczyk, Doron Stember, Peter Stahl, New York, NY</td>
<td><strong>V9-07</strong></td>
<td><strong>MICROSURGICALLY-ASSISTED INGUINAL HERNIA REPAIR</strong> Ryan Flannigan*, Brian Dinerman, New York, NY, Phil Bach, New York, NY, Michael Shulster, Philip Li, Marc Goldstein, New York, NY</td>
</tr>
<tr>
<td><strong>V9-03</strong></td>
<td><strong>RANDOMIZED CLINICAL TRIAL OF THE NO-FLIP SHANGRING CIRCUMCISION FOR ADOLESCENTS AND ADULTS IN AFRICA</strong> Benjamin V Stone*, Omar Al Hussein Alawamith, Phil V Bach, Ryan Flannigan, Quentin Awori, Marc Goldstein, Mark Barone, Philip S Li, Richard K Lee, New York, NY</td>
<td><strong>V9-09</strong></td>
<td><strong>ROBOT-ASSISTED LAPAROSCOPIC MANAGEMENT OF INFLATABLE PENILE PROSTHESIS RESERVOIR MIGRATION INTO BLADDER WITH UTILIZATION OF CRYOPRESERVED AMNIOTIC MEMBRANE AND UMBILICAL TISSUE</strong> Mark Ferretti*, New York, NY, Gregory Lovallo, Michael Stifelman, Mutahar Ahmed, Hackensack, NJ</td>
</tr>
<tr>
<td><strong>V9-04</strong></td>
<td><strong>ONE-STAGE TRANSVESICAL LAPAROENDOSCOPIC SINGLE-SITE SURGERY (T-LESS) FOR REMOVAL OF TWO BLADDER DIVERtICULA IN A FEMALE PATIENT.</strong> Marek Roslan*, Maciej Przudzik, Michal Borowik, Mirosław Łęślow, Olsztyn, Poland</td>
<td><strong>V9-10</strong></td>
<td><strong>TRANSURETHRAL RESECTION OF EJACULATORY DUCTS: A STEP-BY-STEP GUIDE</strong> Luis Savio*, Joseph Palmer, Nachiketh S Prakash, Raul Clavijo, Desmond Adamu, Ranjith Ramasamy, Miami, FL</td>
</tr>
<tr>
<td><strong>V9-05</strong></td>
<td><strong>LAPAROSCOPIC VARICOCELECTOMY USING INTRAOPERATIVE NAVIGATION: INDOCYANINE GREEN ANGIOGRAPHY AND INDIGO CARMINE LYMPHATIC DYE</strong> Keiji Tomita*, Eiki Hanada, Susumu Kageyama, Kazuyoshi Johnin, Mitsuhiro Narita, Akihiro Kawauchi, Otsu, Japan</td>
<td><strong>V9-11</strong></td>
<td><strong>SUPRAPUBIC FAT PAD EXCISION WITH SIMULTANEOUS PLACEMENT OF INFLATABLE PENILE PROSTHESIS</strong> Adam Baumgarten*, Jonathan Beilain, Michael Bickell, Justin Parker, Tampa, FL, Gerard Henry, Shreveport, LA, Rafael Carrion, Tampa, FL</td>
</tr>
<tr>
<td><strong>V9-06</strong></td>
<td><strong>ROBOT ASSISTED PENILE INVERSION VAGINOPLASTY: A NOVEL TECHNIQUE</strong> Temitope Rude*, New York, NY, Kiranpreet Khurana, Cleveland, OH, Aaron Weinberg, Jamie Levine, New York, NY, Michael Stifelman, Hackensack, NJ, Lee C. Zhao, New York, NY</td>
<td><strong>V9-12</strong></td>
<td><strong>FERTILITY RECOVERY AFTER LAPAROSCOPIC REMOVAL OF HYPERtROPHIC SEMINAL VESICLE</strong> Gaetano Chiapparone, Giovanni Liguori, Nicola Pavan*, Grazia Bianchi, Andrea Lissiani, Carlo Trombetta, Trieste, Italy</td>
</tr>
</tbody>
</table>

**APPROVED FOR AMA PRA CATEGORY 1 CREDIT™**
YOUNG UROLOGISTS FORUM
Room 205A @ Boston Convention & Exhibition Center

10:30 WORK-LIFE BALANCE AND PURSUITS OF MEANINGFUL METRICS: WELCOME & INTRODUCTIONS
Committee Chair: John Lam

10:35 RECOGNITION OF YU OF THE YEAR AWARD RECIPIENTS
Committee Chair: John Lam

11:45 PRESENTATION
Robert Cerfolio

12:00 ADJOURN

TRAUMA/RECONSTRUCTION/DIVERSION: EXTERNAL GENITALIA RECONSTRUCTION AND UROTRAUMA (INCLUDING TRANSGENDER SURGERY) I
Room 151 @ Boston Convention & Exhibition Center
Moderators: Sanjay Kulkarni, Bahaa Malaeb and Alex Vanni

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-01</td>
<td>NEPHRECTOMY AFTER HIGH-GRADE RENAL TRAUMA: RESULTS FROM THE AMERICAN ASSOCIATION FOR THE SURGERY OF TRAUMA (AAST) GENITOURINARY TRAUMA STUDY</td>
</tr>
<tr>
<td>Sorena Keihani*, Yizhe Xu, Angela P. Presson, Salt Lake City, UT, Brian P. Smith, Patrick M. Reilly, Philadelphia, PA, Xian Luo-Owen, Kaushik Mukherjee, Loma Linda, CA, Bradley J. Morris, Sarah Majercik, Murray, UT, Peter B. Thomsen, Bradley A. Erickson, Iowa City, IA, Benjamin N. Breyer, Gregory Murphy, San Francisco, CA, Barbara A. Shaffer, Matthew M. Carrick, Plano, TX, Brandi Miller, Richard A. Santucci, Detroit, MI, Timothy Hewitt, Frank N. Burks, Royal Oak, MI, Erik S. DeSoucy, Scott A. Zakaluzny, Sacramento, CA, LaDonna Allen, Jurek F. Kocik, Tyler, TX, Raminder Nirula, Jeremy B. Myers, Salt Lake City, UT</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-03</td>
<td>SIMULTANEOUS COLON AND RENAL TRAUMA IN THE ERA OF CONSERVATIVE MANAGEMENT: A SINGLE INSTITUTION STUDY</td>
</tr>
<tr>
<td>James Furr*, Jared Higley, Byron Dubow, Babawale Oluborode, Tabitha Garwe, Sanjay Patel, Alisa Cross, Brian Cross, Oklahoma City, OK</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-05</td>
<td>SINGLE-STAGE DELAYED PRIMARY CLOSURE OF FOURNIER'S GANGRENE: OUR EXPERIENCE AT THE UNIVERSITY OF PUERTO RICO MEDICAL CENTER</td>
</tr>
<tr>
<td>Jose Antonio Saavedra-Belaunde*, Timoteo Torres, Antonio Puras-Baez, Magaly Cabrera-Beauchamp, San Juan, PR</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-06</td>
<td>SURGICAL MANAGEMENT OF GENITOPERINEAL HIDRADENITIS SUPPURATIVA: A 12 YEAR EXPERIENCE</td>
</tr>
<tr>
<td>Brandi Miller*, Sarah Martin, Richard Santucci, Detroit, MI</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP79-07</td>
<td>INDICATIONS FOR NOVEL INTERPOSITION MYOCUTANEOUS FLAP FOR THE REPAIR OF RECTO-URINARY FISTULA</td>
</tr>
<tr>
<td>Alyssa Greiman*, Lawrence Dagrosa, Nima Baradaran, Eric Rovner, Harry Clarke, Charleston, SC</td>
<td></td>
</tr>
</tbody>
</table>
MP79-08 UPDATED OUTCOMES OF EARLY ENDOSCOPIC REALIGNMENT FOR PELVIC FRACTURE URETHRAL INJURIES AT A LEVEL 1 TRAUMA CENTER
Paul H Chung*, Hunter Wessells, Bryan B Voelzke, Seattle, WA

MP79-09 TITLE: ROBOT ASSISTED PENILE INVERSION VAGINOPLASTY A DESCRIPTION OF A NOVEL TECHNIQUE
Brenton Armstrong*, Aaron Weinberg, NEW YORK, NY, Kiranpreet Khurana, cleveland, OH, Jamie Levine, Lee Zhao, New York, NY

MP79-10 URINARY–CUTANEOUS FISTULAE: A RARE BUT MORBID COMPLICATION OF NON-OPERATIVELY MANAGED EXTRAPERITONEAL BLADDER RUPTURES
Niels Johnsen, Rachel Sosland*, Jason Young, Joshua Cohn, W. Stuart Reynolds, Melissa Kaufman, Doug Milam, Oscar Guillamondegui, Roger Dmochowski, Nashville, TN

MP79-11 COMPARISON OF OUTCOMES BETWEEN ULNAR AND RADIAL FREE FLAPS FOR NEOPHALLUS CONSTRUCTION
Katherine Smentkowski*, Norfolk, VA, Jack Zuckerman, San Diego, CA, Oscar Suarez Fernandez de Lara, Monterrey, Mexico, David Gilbert, Ramon Virasoro, Jessica Delong, Jeremy Tonkin, Kurt McCammon, Norfolk, VA

MP79-12 SKIN GRAFT GLANULOPLASTY AFTER TOTAL GLANSECTOMY OR PARTIAL PENECTOMY.
André Cavalcanti*, Carlos Felipe Restreppo, Henrique Florindo, Roberto Medeiros, Túlio Rojas, Rio de Janeiro, Brazil, Neildo Chaves, Rio de Janeiro, Brazil

MP79-13 GENITOURINARY INJURY IN MALE VETERANS RECEIVING VA HEALTH CARE: THE IMPORTANCE OF LINKING DOD AND VA DATA
Steven Hudak*, Jean Orman, Megan Amuan, Mary Jo Pugh, Nina Nnamani, Douglas Soderdahl, Judson Janak, Michael Liss, San Antonio, TX

MP79-14 PENILE FRACTURE INCIDENCE AND PHYSICIAN COMPLIANCE WITH UROTRAUMA GUIDELINES IN NEW YORK STATE
Michael J Lipsky*, Wilson Sui, Alexander C Small, Dennis J Robins, Carrie M Mlynarczyk, Steven B Brandes, Peter J Stahl, New York, NY

MP79-15 DEVELOPMENT OF HYPERTENSION AFTER RENAL TRAUMA
E. Charles Osterberg, Austin, TX, Mohannad Awad*, Gregory Murphy, Thomas Gaither, Jennie Yoo, Thanahhudee Chumnamsongkhroh, Benjamin Breyer, San Francisco, CA

MP79-16 COMPLICATIONS OF GENITAL ENLARGEMENT SURGERY
Kristi Hebert*, Eric Wisenbaugh, Joel Gelman, Orange, CA

MP79-17 IDIOPATHIC URETHRAL STRICTURES – SIMILAR CHARACTERISTICS TO THOSE FOLLOWING RECOGNIZED TRAUMA
Boyd Viers*, Travis Pagliara, Charles Rew, Dallas, TX, Lauren Folgosa-Cooley, Richmond, VA, Christine Shiang, Jeremy Scott, Allen Morey, Dallas, TX

MP79-18 INJURY SEVERITY SCORE ASSOCIATED WITH CONCURRENT BLADDER INJURY IN PATIENTS WITH BLUNT URETHRAL INJURY
Eric Eidelman*, Ian Stormont, Gauthami Churukanti, Deborah M Stein, Mohummad Minhaj Siddiqui, Baltimore, MD

MP79-19 THE WALKING PATIENT WITH GRADE IV – V RENAL INJURY
Efraim Serafetinides*, Graham Haesketh, Georgia Galani, Alexia Balanika, Andreas Fildisis, Nikolaos Moumouaras, Athileas Karafotias, Dimitrios Delakas, Athens, Greece

MP79-20 RISK STRATIFICATION FOR ERECTILE DYSFUNCTION AFTER PELVIC FRACTURE URETHRAL INJURIES: A PILOT STUDY
Paul H Chung*, Cody Gehring, Reza Firoozabadi, Bryan B Voelzke, Seattle, WA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT NUMBER | TITLE
--- | ---
MP80-01 | THE USE OF INTRA-OPERATIVE FROZEN SECTION DURING ORGAN SPARING SURGERY FOR PENILE CANCER GREATLY REDUCES THE LOCAL RECURRENCE RATE. LONG TERM FOLLOW UP DATA
Ayman Younis, Dawn Cave, John Dormer, Timothy Terry, Jonathan Goddard, Duncan Summerton*, Leicester, United Kingdom

MP80-02 | INCREASING AGE OF PATIENTS WITH TESTICULAR CANCER: 1980-2016 SINGLE-CENTER EXPERIENCE
Shinichi Yamashita*, Shinji Fuji, Shigeyuki Yamada, Yoshihide Kawasaki, Hideaki Izumi, Naoki Kawamorita, Koji Mitsuzuka, Hisanobu Adachi, Yasuhiro Kaiho, Akihiro Ito, Yoichi Arai, Sendai, Japan

MP80-03 | DISTRESS SCREENING IN PATIENTS WITH UROGENITAL MALIGNANCIES
Pia Paffenholz*, Cologne, Germany, Maria Angerer-Shipilena, Aachen, Germany, Johannes Salem, David Pfister, Axel Heidenreich, Cologne, Germany

MP80-04 | EFFECT OF ALVIMOPAN ON GASTROINTESTINAL RECOVERY AND HOSPITAL LENGTH OF STAY AFTER RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTICULAR CANCER

MP80-05 | IS THERE BENEFIT TO ADJUVANT RADIATION IN STAGE III PENILE CANCER AFTER LYMPH NODE DISSECTION? FINDINGS FROM THE NATIONAL CANCER DATABASE.
Brian Winters*, James Keams, Sarah Holt, Matthew Mossanen, Daniel Lin, Jonathan Wright, Seattle, WA

MP80-06 | EVALUATION OF ‘PROGRAMMED DEATH-1’ / ‘PROGRAMMED DEATH LIGAND 1 AND 2’ PATHWAY IN TUMOR SAMPLES OF SEMINOMA AND NON-SEMINOMA, AND ITS PROGNOSTIC ROLE IN TESTICULAR CANCERS
Asgar Garayev*, Emin Bozkurtlan, Deniz Filinto, Haydar Kamal Cam, Ferruh Sypsak, Ilker Tinay, Istanbul, Turkey

MP80-07 | SEX CORD-GONADAL STROMAL TUMORS OF THE TESTICLE ARE FAR MORE LETHAL THAN GERM CELL TESTICULAR NEOPLASMS
Joel Slaton*, Oklahoma City, OK, Jet Li, Oklahoma City, OK, Ngoc Duong, Kai Ding, Oklahoma City, OK

MP80-08 | DIAGNOSTIC VALUE OF FROZEN SECTION EXAMINATION (FSE) DURING INGUINAL EXPLORATION IN PATIENTS WITH INCONCLUCIVE TESTICULAR LESIONS
Christian Fankhauser*, Joerg Beyer, Lisa Roth, Peter-Karl Bode, Holger Moch, Tullio Sulser, Thomas Hermanns, Zurich, Switzerland

MP80-09 | 2-18FLUORO-DEOXY-D-GLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN SEMINOMA: IS AN OBJECTIVE SCORING SYSTEM USEFUL?
Clint Cary*, Antoin Dougwall, Ryan Zukerman, Costantine Albany, Mark Tann, Richard Foster, Indianapolis, IN

MP80-10 | MIDLINE EXTRAPERITONEAL APPROACH TO RETROPERITONEAL LYMPH NODE DISSECTION IN TESTICULAR CANCER: MINIMIZING SURGICAL MORBIDITY
Sumeet Syan-Bhanavadia*, Soroush Bazargani, Thomas Clifton, Jie Cai, Gus Miranda, Hooman Djaladat, Anne Schuckman, Slamak Daneshmand, Los Angeles, CA

MP80-11 | PENILE SPARING SURGERY FOR PENILE CANCER: A MULTICENTER INTERNATIONAL RETROSPECTIVE COHORT
Adam Baumgarten*, Tampa, FL, Sylvia Yan, London, United Kingdom, Sarah Offenhofer, Amsterdam, Netherlands, Juan Chipollini, Dominic Tang, Barrett McCormick, Tampa, FL, Yao Zhu, Ding-Wei Ye, Shanghai Shi, China, People's Republic of, Chris Protzel, Rostock, Germany, Simon Horenblas, Amsterdam, Netherlands, Nicholas Watkin, London, United Kingdom, Philippe Spiess, Tampa, FL

MP80-12 | RETINAL TOXICITY AFTER CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH TESTICULAR CANCER

MP80-13 | MANAGING THE HIGH INCIDENCE OF GENITAL PAIN AND PATHOLOGY IN THE MALE PRISON POPULATION WITH TELEMEDICINE
Brenton Sherwood*, Yu Han, Kenneth Nepple, Bradley Erickson, Iowa City, IA

*Presenting author
MP80-14 LYMPH NODE YIELD AS A PREDICTOR OF OVERALL SURVIVAL FOLLOWING REGIONAL LYMPHADENECTOMY FOR PENILE CANCER
Chad Ritch*, Nachiketh Soodana Prakash, Varsha Sinha, Diana M Lopategui, Katherine Almengo, Micheal Ahdoot, David Alonzo, Mahmoud Alameddine, Sanoj Punnen, Dipen Parekh, Mark Gonzalgo, Miami, FL

MP80-15 RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTICULAR SEMINOMAS: POPULATION-BASED STAGE-BY-STAGE SURVIVAL OUTCOMES
Hiten Patel*, Gregory Joice, Zeyad Schwen, Alice Semerjian, Ridwan Alami, Arnav Srivastava, Mohamad Aliaf, Phillip Pierorazio, Baltimore, MD

MP80-16 NEUTROPHIL-TO-LYMPHOCYTE RATIO – A SIMPLE BIOMARKER IN TESTICULAR CANCER
Ahmet Aydin*, Ankara, Turkey, Solomon Woldu, Thomas Lowrey, Ryan Hutchinson, Laura-Maria Krabbe, Nirmish Singla, Arthur Sagalowsky, Vitaly Margulis, Aditya Bagrodia, Dallas, TX

MP80-17 CXCL12 IS A PREDICTOR FOR DISEASE RECURRENCE IN PATIENTS WITH METASTATIC NON-SEMINOMA
Christian Fankhauser*, Lisa Roth, Joerg Beyer, Tullio Sulser, Holger Moch, Thomas Hermanns, Peter-Karl Bode, Zurich, Switzerland

MP80-18 KIDNEY INJURY MOLECULE-1 STAINING HELPS TO DIFFERENTIATE MIXED GERM CELL NEOPLASMS OF TESTIS FROM CLASSIC SEMINOMAS
Chirag Dave*, Alia Gupta, Miutal Amin, Ping Zhang, Jason Hafron, Royal Oak, MI

MP80-19 TREATMENT TRENDS AND OUTCOMES FOR LYMPH NODE POSITIVE PENILE CANCER PATIENTS

MP80-20 COMPLICATIONS AND ADJUNCTIVE SURGICAL PROCEDURES IN POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) TO DEFINE A TERTIAL REFERRAL CENTER
Achim Lusch*, Laura Gerbaulet, Christian Winter, Peter Albers, Duesseldorf, Germany

ABSTRACT NUMBER TITLE
MP81-01 CENTRAL TUMOR NECROSIS FACTOR-ALPHA BLOCKADE INCREASED NNOS EXPRESSION IN THE HYPOTHALAMIC PARAVENTRICULAR NUCLEUS AND IMPROVED SEXUAL BEHAVIOR DISORDER IN MALE DIABETIC RATS
Ting Long*, Winston-Salem, NC, Huanhuan Wang, Xiaohong Ye, Wenwen Lin, shantou, China, People’s Republic of, Yuan yuan Zhang, Winston-Salem, NC, Danian Qin, shantou, China, People’s Republic of

MP81-02 OXYGEN SATURATION AFTER VACUUM ERECTILE DEVICE AS IMPORTANT FACTOR IN PENILE REHABILITATION.
Sergey Kotov*, Alexander Osadchinsky, Moscow, Russian Federation

MP81-03 ERECTILE DYSFUNCTION IS INDEPENDENTLY ASSOCIATED WITH APNEA HYPOPNEA INDEX & OXYGEN DESATURATION INDEX IN ELDERLY, BUT NOT YOUNGER, COMMUNITY-DWELLING MEN
Sean Martin*, Sarah Appleton, Robert Adams, Anne Taylor, Nicholas Brook, Peter Catcheside, Douglas McEvoy, Gary Wittert, Adelaide, Australia

MP81-04LEYDIG STEM CELL ISOLATION AND DIFFERENTIATION FROM HUMAN TESTIS BIOPSIES: POTENTIAL MODALITY TO INCREASE SERUM TESTOSTERONE
Himanshu Arora*, Manlla Sanches Santos Rizzo Zutti, Bruno Nahar, Joshua M. Hare, Ranjith Ramasamy, Miami, Fl
MP81-05 PELVIC AUTONOMIC DYSFUNCTION: A NEW CONCEPT IN PATIENTS HAVING LOWER URINARY TRACT SYMPTOMS WITH COEXISTENCE OF ERECTILE DYSFUNCTION
Onder Kayigil*, Ankara, Turkey, Yucel Altay, Diyarbakir, Turkey, Emrah Okulu, Ankara, Turkey

MP81-06 IS BARIATRIC SURGERY THE ANSWER TO SEXUAL DYSFUNCTION IN OBESE MEN?
Ahmed Fahmy, Moustafa Elsawy, Amr Kamal, Abdelrahman Zahran, hazem Rhasad*, Alexandria, Egypt

MP81-07 PENILE CARCINOMA: GENETICALLY ENGINEERED MODELS FOR NOVEL THERAPEUTICS IDENTIFICATION
Ahmed Sarhan*, Xiaoying Shang, Pherose Tamboli, Priya Rao, Curtis Pettaway, Alan Wang, Ronald DePinho, Xin Lu, Houston, TX

MP81-08 ENCLOMIPHENE CITRATE VS. TOPICAL TESTOSTERONE GEL: EFFECTS ON REPRODUCTIVE HORMONES AND SPERM PARAMETERS
Greg Fontenot*, Joseph Podolski, The Woodlands, TX

MP81-09 THE NERVES IN THE GLANS PENIS: ANATOMICAL AND HISTOLOGICAL STUDY
Nobuyuki Hinata*, Kobe, Japan, Ahmed Aly Hussein, Buffalo, NY, Tomoki Terakawa, Yukari Bando, Kobe, Japan, Gen Murakami, Iwamizawa, Japan, Khurshid Guru, Buffalo, NY, Masato Fujisawa, Kobe, Japan

MP81-10 ERECTILE DYSFUNCTION IN 45-YEAR-OLD GERMAN MEN IN ASSOCIATION WITH RISK FACTORS AND COMORBIDITIES; RESULTS OF THE GERMAN MALE SEX-STUDY
Kathleen Herkommer*, Jacqueline Hallanzy, Munich, Germany, Martina Kron, Ulm, Germany, F.-M. Köhn, Maximilian Schmautz, Munich, Germany, Peter Albers, Christian Arsov, Dusseldorf, Germany, Boris A. Hadaschik, Markus Hohenfellner, Heidelberg, Germany, Florian Imkamp, Martin Kuczyn, Hannover, Germany, Jürgen E. Gschwend, Munich, Germany

MP81-11 SACUBITRIL/VALSARTAN (ENTRESTO®) AND VALSARTAN/SILDENAFIL COMBINATION IMPROVES FUNCTIONAL RESPONSES ON ISOLATED RAT CORPUS CAVERNOSUM FROM NERVE-CRUSH INJURY MODEL
Serap Gur, Ankara, Turkey, Suresh C Sikka, Philip J Kadowitz, Nora Haney, Kenneth DeLay*, Wayne JG Hellstrom, New Orleans, LA

MP81-12 FUNCTIONAL BRAIN IMAGING SHOWS A CORRELATION BETWEEN DISTENDED SEMINAL VESICLES AND SPECIFIC BRAIN ACTIVITY IN HEALTHY MEN
Christian Weistamner, Manuela Wapp, Martin Schmitt, Stefan Puig, Bern, Switzerland, Livio Mordasini, Luzern, Switzerland, Roland Wiest, George N. Thalmann, Bern, Switzerland, Frédéric D. Birkhäuser*, Luzern, Switzerland

MP81-13 EFFECT OF VAGINAL ESTROGEN DELIVERY ON THE VAGINAL MUSCULARIS IN A RODENT MODEL OF VULVOVAGINAL ATROPHY WITH MENOPAUSE.
Nicole Pepe*, Lauren Doda, Sarah Stewart, Millie Mattox, Maureen Basha, Lewisburg, WV

MP81-14 HUMAN TISSUE KALLIKREIN 1 AMELIORATES ERECTILE FUNCTION VIA MODULATING AUTOPHAGY AND ACTIVATING HIF-1α/COX-2 PATHWAY IN AGED TRANSGENIC RATS
Zhe Tang*, Kai Cui, Yang Luan, Yajun Ruan, Tao Wang, Jun Yang, Shaogang Wang, Jihong Liu, Wuhan, China, People’s Republic of China

MP81-15 THE ROLE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN MEN WITH ERECTILE DYSFUNCTION – PRELIMINARY FINDINGS OF A REAL-LIFE CROSS-SECTIONAL STUDY
Eugenio Ventimiglia*, Walter Cazzaniga, Paolo Capogrosso, Filippo Pederzoli, Luca Boeri, Nicola Frego, Alberto Briganti, Massimo Alfano, Federico Dehò, Milan, Italy, Alessandro Palmieri, Naples, Italy, Lorenzo Piemonti, Francesco Montorsi, Andrea Salonia, Milan, Italy

MP81-16 THREE-DIMENSIONAL RECONSTRUCTION OF MALE PELVIC ANATOMY FROM MAGNETIC RESONANCE IMAGING
M. Raj Rajasekaran*, Ishika Trivedi, Shantanu Sinha, Valmik Bhargava, San Diego, CA

MP81-17 DEVELOPING IMPROVED E-LEARNING ANATOMY RESOURCES FOR UNDERGRADUATE MEDICAL STUDENTS: MALE REPRODUCTIVE ANATOMY, A CASE STUDY
Matthew A Williams*, Jessica Caterson, Christopher Horton, Tom Cosker, Oxford, United Kingdom

MP81-18 EFFECTS OF SEX HORMONES ON CELL PROLIFERATION IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS
Yasumasa Miyazaki*, Takeo Kosaka, Eiji Kikuchi, Akira Miyajima, Mototsugu Oya, Tokyo, Japan
MP81-19 ANDROGEN RECEPTOR CAG REPEAT LENGTH AS A RISK FACTOR OF LATE ONSET HYPOGONADISM IN A KOREAN MALE POPULATION
Sun Tae Ahn*, Hyeong Guk Jeong, Ji Yun Chae, Jong Wook Kim, Mi Mi Oh, Hong Seok Park, Je Jong Kim, Du Geon Moon, Seoul, Korea, Republic of

MP81-20 THE ROLE OF SYSTEMIC INFLAMMATION IN DETERMINING HEALTH STATUS IN MEN WITH SEXUAL DYSFUNCTION – A WORRISOME SCENARIO IN YOUNG MEN
Eugenio Ventimiglia, Walter Cazzaniga*, Filippo Pederzoli, Paolo Capogrosso, Luca Boeri, Nicola Frego, Federico Deho, Massimo Alfano, Lorenzo Piemonti, Milan, Italy, Alessandro Palmieri, Naples, Italy, Francesco Montorsi, Andrea Salonia, Milan, Italy

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 15, 2017
1:00 pm - 3:00 pm
Moderated Poster Session 82
URODYNAMICS/LOWER URINARY TRACT DYSFUNCTION/FEMALE PELVIC MEDICINE: BASIC RESEARCH & PATHOPHYSIOLOGY II
Room 252 @ Boston Convention & Exhibition Center
Moderators: Margot Damaser and Henry Lai

ABSTRACT NUMBER TITLE
MP82-01 A GENETIC FEMALE MOUSE MODEL WITH CONGENITAL GENITOURINARY ANOMALIES AND URINARY INCONTINENCE
Akbari Pedram, Toronto, Canada, Ali Fathollahi, New York, NY, Rong Mo, Michael Chua*, Toronto, Canada, Michael Kavran, Cleveland, OH, Nicole Episalla, Washington DC, WA, Chi-Chung Hu, Wald Farhat, Toronto, Canada, Adonis Hijaz, Cleveland, OH

MP82-02 DECREASED URINARY FUNGAL BURDEN AND DIVERSITY IN OVERACTIVE BLADDER
A. Lenore Ackerman*, Jie Tang, Karyn Eilber, Jayoung Kim, Jennifer Anger, David Underhill, Michael Freeman, Los Angeles, CA

MP82-03 NEUTRALIZATION OF BRAIN-DERIVED NEUROTROPHIC FACTOR INCREASES SYNERGISTIC ACTIVITY OF EXTERNAL URETHRAL SPHINCTER WITH REDUCTION OF ACID-SENSING ION CHANNELS IN MICE WITH SPINAL CORD INJURY
Naoki Wada*, Takahiro Shimizu, Nobutaka Shimizu, Pradeep Tyagi, William de Groat, Anthony Kanai, Pittsburgh, PA, Hidetohiro Kakizaki, Asahikawa, Japan, Naoki Yoshimura, Pittsburgh, PA

MP82-04 TRANSCRIPTIONAL REGULATION OF CORTICOTROPIN RELEASING FACTOR
Lizath Aguiniga*, Anthony Schaeffer, David Klumpp, Chicago, IL

MP82-05 PSYCHOSOCIAL FACTORS, SLEEP, AND PHYSICAL FUNCTION IN WOMEN WITH LOWER URINARY TRACT SYMPTOMS
Nazema Y. Siddiqui*, Durham, NC, Anne P. Cameron, Ann Arbor, MI, David Celia, Chicago, IL, Catherine S. Bradley, Iowa City, IA, H. Henry Lai, Saint Louis, MO, Margaret E. Helmuth, Jonathan Wiseman, Ann Arbor, MI, James W. Griffith, Chicago, IL, Cindy L. Amundsen, Durham, NC, Kimberly Kenton, Chicago, IL, J. Quentin Clemens, Ann Arbor, MI, Karl J. Kreder, Iowa City, IA, Robert M. Merion, Ann Arbor, MI, Ziya Kirkali, John W. Kusek for the LURN, Bethesda, MD

MP82-06 DETRUSOR UNDERACTIVITY IN AN OBSESE-PRONE RAT MODEL
Eric Gonzalez*, Warren Grill, Durham, NC

MP82-07 UROTHELIAL GENES MODULATING MICTURITION BEHAVIOR INDUCED BY A REPETITIVE LIPOPOLYSACCHARIDE (LPS) EXPOSURE IN AN OVARIECTOMIZED (OVX) MOUSE MODEL
Marian Acevedo-Alvarez*, Judy Yeh, Lery Alvarez-Lugo, Ming Lu, Nilton Sukumar, New Haven, CT, Warren Hill, Boston, MA, Toby Chai, New Haven, CT

MP82-08 THE POTENTIAL OF 2 MICRORNAs CLUSTERS IN ELUCIDATION OF BIOLOGICAL FUNCTIONS OF SIGNALLING PATHWAYS REGULATED BY MICRORNAs IN UNDERACTIVE BLADDER
Ali Hashemi Gheinani*, Fiona C. Burkhard, Katia Monastyrskaya, Bern, Switzerland

MP82-09 ENHANCEMENT OF SNEEZE-INDUCED URETHRAL CONTINENCE Reflex VIA SEROTONIN TYPE 7 RECEPTORS IN RATS
Takahisa Suzuki*, Pittsburgh, PA, Takahiro Shimizu, Nankoku, Japan, Joombeom Kwon, Eiichiro Takaoka, Shun Takai, Nobutaka Shimizu, Pittsburgh, PA, Naoki Wada, Asahikawa, Japan, Naoki Yoshimura, Pittsburgh, PA
**MP82-10** CHARACTERIZATION OF THE “ONE-PAD PATIENT” AT LONG-TERM FOLLOW-UP AFTER RADICAL PROSTATECTOMY

Björn Löppenberg*, Guido Müller, Peter Bach, Christian von Bodman, Marko Brock, Florian Rogmann, Joachim Noldus, Jüri Palisaar, Herne, Germany

**MP82-11** THE MOLECULAR BIOLOGIC STUDY ABOUT THE CIRCADIAN RHYTHMIC CONTROL OF MICTURITION FUNCTION

Su Jin Kim*, Young Sam Cho, Seoul, Korea, Republic of, Khae Hawn Kim, Incheon, Korea, Republic of

**MP82-12** THE EFFECT OF GSMTX4, AN INHIBITOR OF STRETCH-ACTIVATED CHANNELS, ON NOCTURIA IN MICE.

Tatsuya Ihara*, Takahiko Mitsui, Yuki Nakamura, Yuki Imai, Satoru Kira, Hirushi Nakagomi, Norifumi Sawada, Atushiko Nakao, Masayuki Takeda, yamanashi, Japan

**MP82-13** BLADDER DISTENSION REGULATES PANNEXIN 1 EXPRESSION IN THE BLADDER UROTHELIUM

Melissa Laudano*, Marcia Urban-Maldonado, Hui Sun, Mia Thi, Sylvia Suadicani, Bronx, NY

**MP82-14** DETECTION OF RAC ACTIVITY AND INHIBITION OF SMOOTH MUSCLE CONTRACTION BY THE RAC INHIBITOR EHT1864 IN THE HUMAN TRIGONE: IMPLICATIONS FOR RAC GTPASE IN BLADDER SMOOTH MUSCLE CONTRACTION

Yiming Wang*, Christian Gratze, Qingfeng Yu, Frank Strittmatter, Annika Herlemann, Beata Rutz, Christian G. Stief, Martin Hennenberg, Munich, Germany

**MP82-15** THE AMELIORATIVE POTENTIAL OF TAMSULOSIN ON BLADDER FUNCTION IN A RAT MODEL OF CHRONIC PELVIC ISCHEMIA

Norifumi Sawada*, Satoru Kira, Tatsuya Ihara, Takahiro Mochizuki, Yuki Imai, Hiroshi Nakagomi, Takahiko Mitsui, Chuo-shi, Japan, Karl-Erik Andersson, Winston-Salem, NC, Masayuki Takeda, Chuo-shi, Japan

**MP82-16** BLADDER SMOOTH MUSCLE CONTRACTILITY IS INHIBITED BY HC030031 INDEPENDENTLY OF TRPA1

Karel Dewulf*, Jan Franken, Pieter Vulin, Yves Deruyver, Wouter Everaerts, Dirk De Ridder, Thomas Voets, Leuven, Belgium

**MP82-17** A NEURO-MODULATIVE SLING IMPROVES MIXED URINARY INCONTINENCE IN AN ACUTE ANIMAL MODEL

Ling Qin*, Xiang-xiang Ye, Qi Ling, Wenzhou, China, People’s Republic of, Qi-Xiang Song, Shanghai, China, People’s Republic of, Limin Liao, Beijing, China, People’s Republic of, Hai-Yan Li, Wenzhou, China, People’s Republic of

**MP82-18** SHARED ALTERATIONS IN URINARY BACTERIAL COMMUNITIES IN PATIENTS WITH INTERSTITIAL CYSTITIS AND OVERACTIVE BLADDER

A. Lenore Ackerman, Jie Tang, Karyn Elber, Jayyoung Kim, Los Angeles, CA, J. Curtis Nickel, Ontario, Canada, Garth Ehrlich, Philadelphia, PA, James Ackerman*, David Underhill, Michael Freeman, Jennifer Anger, Los Angeles, CA, MAPP Research Network, Washington, DC

**MP83-01** HIGH-GRADE PROSTATE CANCER HAS INCREASED MITOCHONDRIAL CONTENT

Anton Kalsbeek*, Eva Chan, Judith Grogan, Desiree Petersen, Weerachai Jaratlerdsiri, Ruta Gupta, Ruth Lyons, Anne-Maree Haynes, Lisa Horvath, James Kench, Phillip Stricker, Vanessa Hayes, Sydney, Australia

**MP83-02** OVERCOMING PI3K/MTOR INHIBITOR RESISTANCE BY PIM1 INHIBITOR THROUGH REGULATION OF TYROSINE KINASE EXPRESSION.

Takeo Kosaka*, Hiroshi Hongo, Yota Yasumizu, Yasumasa Miyazaki, Eiji Kikuchi, Akira Miyajima, Mototsugu Oya, Tokyo, Japan

---

271

Monday, May 15, 2017

**Moderated Poster Session 83**

1:00 pm - 3:00 pm

**PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY II**

Room 253 AB @ Boston Convention & Exhibition Center

**Moderators:** Christopher Filson and Shuyuan Yeh

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP83-01</strong></td>
<td>HIGH-GRADE PROSTATE CANCER HAS INCREASED MITOCHONDRIAL CONTENT</td>
</tr>
<tr>
<td><strong>MP83-02</strong></td>
<td>OVERCOMING PI3K/MTOR INHIBITOR RESISTANCE BY PIM1 INHIBITOR THROUGH REGULATION OF TYROSINE KINASE EXPRESSION.</td>
</tr>
</tbody>
</table>

*Presenting author
MP83-03 NOVEL SELECTIVE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITORS EFFECTIVELY IMPAIR CASTRATION RESISTANT PROSTATE CANCER GROWTH
Toshiki Etani*, Taku Naiki, Nagoya, Japan, Takayoshi Suzuki, Kyoto, Japan, Takashi Nagai, Keitaro Iida, Ryosuke Ando, Noriyasu Kawai, Keiichi Tazawa, Tohru Mogami, Takahiro Yasui, Nagoya, Japan

MP83-04 SUPPRESSION OF HUMAN PROSTATE CANCER (CAP) BY ADOPTIVE TRANSFER OF PATIENT-DERIVED PSMA-SPECIFIC, TGF-β-INSSENSITIVE CD8+ T CELLS
Qiang Zhang*, Timothy Kuzel, Brian Helfand, Ximing J Yang, Weijun Qin, Chicago, IL, Chung Lee, Benebito Carneiro, Francis J Giles, Chicago, IL

MP83-05 27-HYDROXYCHOLESTEROL INHIBITS PROSTATE CANCER GROWTH BY REDUCING STAT3 SIGNALING
Shweta Dambal, Everardo Macias*, Sergio Sanders, Stephen Freedland, Los Angeles, CA

MP83-06 COMBINATION THERAPY WITH EPI-002 AND PARP INHIBITOR FOR CASTRATION-RESISTANT PROSTATE CANCER
Yusuke Ito*, C. Adriana Banuelos, Marianne D. Sadar, Vancouver, Canada

MP83-07 N-TERMINAL TARGETING OF ANDROGEN RECEPTOR BY EPI-001 IN COMBINATION WITH AUTOPHAGY INHIBITORS ENHANCES THE ANTI-TUMOR EFFECT IN LNCAP PROSTATE CANCER CELLS
Benedikt Kranzbu̇hler*, Souzan Salemi, Tullio Sulser, Daniel Eberli, Zurich, Switzerland

MP83-08 COMBINATION OF METFORMIN AND SODIUM VALPROATE FOR PROSTATE CANCER: A RAPID APPROACH FROM BENCH TO CLINICAL TRIAL.
Linh N.K. Tran*, Ganessian Kichenadasse, Rebecca J. Ormsby, Katherine L. Morel, Lisa M. Butler, Margaret M. Centenera, Pamela J. Sykes, Adelaide, Australia

MP83-09 ELUCIDATING CROSS-RESISTANCE BETWEEN DOCETAXEL AND CABAZITAXEL IN CASTRATION RESISTANT PROSTATE CANCER
Alan Lombard, Chengfei Liu, Cameron Armstrong, Wei Lou, Christopher Evans, Allen Gao*, Sacramento, CA

MP83-10 CORRELATION BETWEEN CABAZITAXEL RESISTANCE AND EMT IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Hiroshi Hongo*, Takoe Kosaka, Yota Yasumizu, Yasumasa Miyazaki, Eiji Kikuchi, Akira Miyajima, Mototsugu Oya, Tokyo, Japan

MP83-11 Y*LATZ2 (SLC7A6) EXPRESSION IN CASTRATION RESISTANT PROSTATE CANCER
Hideo Otsuki*, Toru Kimura, Takeo Kosaka, Takashi Yamaga, Jun-ichi Suehiro, Hiroyuki Sakurai, Tokyo, Japan

MP83-12 TISSUE-SPECIFIC RADIATION SENSITIZATION OF PROSTATE CANCER BY APTAMER TARGETED SIRNA KNOCK-DOWN OF DNA REPAIR PATHWAY
Kenji Zennami*, Yonggang Zhang, Haoming Zhou, Daniel Thorek, Theodore DeWeese, Shawn Lupold, Baltimore, MD

MP83-13 ZOLEDRONIC ACID SENSITIZES CASTRATION-RESISTANT PROSTATE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY BY DOWNREGULATING STAT1
Takayuki Nakayama*, Toshiki Kijima, Soichiro Yoshida, Fumitaka Koga, Kazunori Kihara, Yasuhisa Fuji, Tokyo, Japan

MP83-14 COMBINATION USE OF EK2K AND VPS34 INHIBITORS WITH ANTI-ANDROGEN AGAINST DRUG-RESISTANT CASTRATION RESISTANT PROSTATE CANCER
Joy Yang, Vito Cucchiara*, Allen Gao, Christopher Evans, Sacramento, CA

MP83-15 A NOVEL THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER THROUGH INHIBITION OF ONCOGENIC MICRORNAs
Tyler Sheetz*, Darío Palmieri, Vincenzo Coppola, Anna Tessari, Joseph Mills, Ashley Braddom, Erika Reese, Claudia Foray, Karesema Parbhoo, Carlo M. Croce, Columbus, OH

MP83-16 EXPLORING 2D AND 3D CULTURE ON RESPONSES TO COMBINATORIAL DRUG THERAPY IN HUMAN PROSTATE CELL LINES
Yana Filipovich, Omar Franco, Simon Hayward*, Evanston, IL

MP83-17 EFFECT OF COMBINATION THERAPY OF DESMOPRESSIN AND DOCETAXEL ON PROSTATE CANCER CELL DU145 PROLIFERATION, MIGRATION AND GROWTH
Azik Hoffman*, Hiroshi Sasaki, Domenica Roberto, Michelle J Mayer, Laurence Klotz, Vasundara Venkateswaran, Toronto, Canada

MP83-18 A 21-CARBON STEROIDAL METABOLITE FROM PROGESTIN, 20β-DIHYDRO-5α-DIHYDROPROGESTERONE, STIMULATES THE ANDROGEN RECEPTOR IN PROSTATE CANCER CELLS
Takashi Ando*, Itsuhiro Takizawa, Tatsuhiko Hoshiti, Niigata City, Japan, Yoshimichi Miyashiro, Kawasaki City, Japan, Noboru Harra, Tsutomu Nishiya, Yoshihiko Tomita, Niigata City, Japan
MP83-19 CO-TREATMENT WITH L-METHADONE SIGNIFICANTLY INCREASES THE EFFICACY OF CYTOSTATIC DRUGS IN PROSTATE CANCER CELLS
Birgit Stadlbauer, Munich, Germany, Detlef Koziars, Frankfurt, Germany, Christian Stief, Alexander Buchner*, Munich, Germany

MP83-20 ENDOGENOUS SULFUR DIOXIDE, A NOVEL GASOTRANSMITTER, PLAYS TUMOR SUPPRESSOR ROLE IN PROSTATE CANCER
Yun Cui*, Shuai Hu, Yang Yang, Lu Wang, Jindong Sheng, Yu Fan, Junbao Du, Hongfang Jin, Jie Jin, Beijing, China, People’s Republic of

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 15, 2017 1:00 pm - 3:00 pm

Podium Session 56
PROSTATE CANCER: LOCALIZED: ABLATIVE THERAPY II
Room 157 @ Boston Convention & Exhibition Center
Moderators: Christian Chaussy and Alexander Kutikov

ABSTRACT
TIME NUMBER TITLE
1:00 PD56-01 LONG-TERM OUTCOMES OF SALVAGE CRYOABLATION FOR RECURRENT PROSTATE CANCER FOLLOWING RADIATION THERAPY: A COMBINED ANALYSIS OF TWO CENTERS
Michael Metcalfe*, Houston, TX, Khurram Siddiqui, Malcolm Dewar, London, Canada, John Ward, Houston, TX, Joseph Chin, London, Canada, Louis Pisters, Houston, TX

1:10 PD56-02 AVOIDANCE OF ANDROGEN DEPRIVATION THERAPY IN RADIORECURRENT PROSTATE CANCER AS A CLINICALLY MEANINGFUL ENDPOINT FOR SALVAGE CRYOABLATION
Kevin Ginsburg*, Detroit, MI, Ahmed ElShafei, Changhong Yu, J. Stephen Jones, Cleveland, OH, Michael Cher, Detroit, MI

1:20 PD56-03 PREDICTORS OF RECTO-URETHRAL FISTULA AFTER PRIMARY, WHOLE GLAND CRYOABLATION OF PROSTATE CANCER: RESULTS FROM THE CRYO-ONLINE DATABASE (COLD) REGISTRY

1:30 PD56-04 SALVAGE PROSTATE CRYOABLATION IN OLDER MEN
J. Kellogg Parsons, San Diego, CA, Ashley Ross, Baltimore, MD, Ahmed El Shafei, Asmaa Hatem, Cleveland, OH, Britney Cotta*, San Diego, CA, Kae Jack Tay, Thomas Polascik, Durham, NC, Robert Given, Norfolk, VA, Vladimir Mouraviev, Celebration, FL, J Stephen Jones, Cleveland, OH

1:40 PD56-05 ELIMINATING RISK OF UPGRADE FROM MRI-TRUS FUSION BIOPSY TO RADICAL PROSTECTOMY: COULD SATURATION BIOPSY OF THE INDEX TUMOR BE THE SOLUTION?
Brian Call*, Abhishek Sidana, Dordaneh Sugano, Amit Jain, Mahir Maruf, Maria Merino, Peter Choyke, Bradford Wood, Peter Pinto, Baris Turkbey, Bethesda, MD

1:50 PD56-06 NEW FRONTIERS AHEAD FOCAL THERAPY POSTOPERATIVE FOLLOW-UP: WHAT IS THE REAL ROLE OF MRI IN THIS SETTING?
Igor Nunes-Silva*, Eric Barret, Mohammed Baghdadi, Victor Srougi, Silvia Garcia-Barreras, Paris, France, Arié Carneiro, São Paulo, Brazil, Paolo Capogrosso, Milan, Italy, Gregorie Rembeyo, Rafael Sanchez-Salas, François Rozet, Marc Galiano, Xavier Cathelineau, Paris, France

2:00 PD56-07 CAN FOCAL THERAPY IMPACT ON PERIOPERATIVE, ONCOLOGICAL AND FUNCTION OUTCOMES IN MEN UNDERWENT FOCAL THERAPY SALVAGE ROBOTIC-ASSISTED RADICAL PROSTATECTOMY? A RETROSPECTIVE MATCHED-PAIR COMPARATIVE STUDY
Igor Nunes-Silva*, Eric Barret, Victor Srougi, Mohammed Baghdadi, Silvia Garcia-Barreras, Paris, France, Paolo Capogrosso, Milan, Italy, Gregorie Rembeyo, Paris, France, Arié Carneiro, São Paulo, Brazil, Rafael Sanchez-Salas, François Rozet, Marc Galiano, Xavier Cathelineau, Paris, France

*Presenting author

273
THE PART TRIAL - A PHASE III STUDY COMPARING PARTIAL PROSTATE ABLATION VERSUS RADICAL PROSTATECTOMY (PART) IN INTERMEDIATE RISK PROSTATE CANCER – EARLY DATA FROM THE FEASIBILITY STUDY

Tom Leslie*, Lucy Davies, Oxford, United Kingdom, Daisy Elliott, Bristol, United Kingdom, Simon Brewster, Prasanna Sooriakumaran, Oxford, United Kingdom, Derek Rosario, Jim Catho, Sheffield, United Kingdom, Tim Dudderidge, Southampton, United Kingdom, Hashim Ahmed, Mark Emberton, London, United Kingdom, Richard Hindley, Basingstoke, United Kingdom, Jenny Donovan, Bristol, United Kingdom, Richard Gray, Freddie Hamdy, Oxford, United Kingdom

PSA TRENDS FOLLOWING PRIMARY FOCAL CRYOSURGERY FOR EARLY STAGE PROSTATE CANCER

Michael Kongnyuy*, Shahidul Islam, Daniel Halpern, Kaitlin Kosinski, Jose Salcedo, Jeffrey Schiff, Anthony Corcoran, Aaron Katz, Mineola, NY

HEMATURIA RISK INDEX - RISK OF UROTHELIAL MALIGNANCY IN PATIENTS WITH ASYMPOTOMATIC MICROSCOPIC HEMATURIA

Ronald Loo*, Casey Ng, Jeff Slezak, Steven Jacobsen, Pasadena, CA

CHARACTERIZATION OF UROTHELIAL CANCER CIRCULATING TUMOR CELLS WITH A NOVEL SELECTION-FREE METHOD

Heather Chalfin*, Max Kates, Emma van der Toom, Stephanie Glavaris, James Verdone, Noah Hahn, Kenneth Pienta, Michael Gorin, Trinity Bivalacqua, Baltimore, MD

ASSESSMENT OF THE ECOCLOGICAL ASSOCIATION BETWEEN TOBACCO SMOKING EXPOSURE AND BLADDER CANCER INCIDENCE OVER THE PAST HALF-CENTURY IN THE UNITED STATES

Thomas Seisen*, Stuart R. Lipsitz, Joaquim Bellmunt, Boston, MA, Mani Menon, Detroit, MI, Nicolas von Landenberg, Philipp Gild, Boston, MA, Morgan Rouprêt, Paris, France, Toni K. Choueiri, Quoc-Dien Trinh, Maxine Sun, Boston, MA

PROGNOSTIC VALUE OF THE WHO 1973 AND 2004 CLASSIFICATION SYSTEMS FOR GRADE IN NON-MUSCLE-INVASIVE T1 BLADDER CANCER

Elisabeth Fransen van de Putte*, Amsterdam, Netherlands, Theodorus van der Kwast, Toronto, Canada, Simone Bertz, Erlangen, Germany, Stefan Denzinger, Regensburg, Germany, Quentin Manach, Eva Compérat, Paris, France, Joost Boormans, Rotterdam, Netherlands, Michael Jewett, Toronto, Canada, Robert Stöhr, Erlangen, Germany, Alexandre Zlotta, Paris, France, Wolfgang Otto, Maximilian Burger, Regensburg, Germany, Arndt Hartmann, Erlangen, Germany, Bas van Rhijn, Amsterdam, Netherlands

UNIVERSAL POINT OF CARE TESTING FOR LYNCH SYNDROME IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA

Michael Metcalfe*, Firas Petros, Priya Rao, Maureen Mork, Xiao Lianchun, Russell Broaddus, Sarena Matin, Houston, TX

UPROLOGIST’S PRACTICE PATTERNS AND PREFERENCES REGARDING FOCAL THERAPY FOR PROSTATE CANCER

Amit L Jain*, Abhinav Sidana, Mahr Maruf, Brian Calio, Dordaneh Sugano, Bradford Wood, Peter Pinto, Bethesda, MD

DEVELOPMENT OF CONVECTIVE WATER VAPOR ENERGY FOR TREATING LOCALIZED PROSTATE CANCER: FIRST-IN-MAN EARLY CLINICAL EXPERIENCES.

Christopher Dixon*, Sleepy Hollow, NY, Ramon Rodriguez Lay, Panama City, Panama, Cesar Cabanas, Asuncion, Paraguay, Edwin Rijo, La Romana, Dominican Republic, Thayne Larson, Scottsdale, AZ

SURVEY OF ABDOMINAL ACCESS AND ASSOCIATED MORBIDITY FOR ROBOT-ASSISTED RADICAL PROSTATECTOMY (RARP)- DOES PALMER’S POINT WARRANT FURTHER AWARENESS AND STUDY?

William K Johnston III*, Northville, MI, David Miller, Susan Linsell, Khurshid Ghani, Ann Arbor, MI

Approved for AMA PRA Category 1 Credit™
1:50 PD57-06 OUTCOMES OF UROTHELIAL BLADDER CANCER PATIENTS WHO HAD PREVIOUS UPPER TRACT UROTHELIAL DISEASE
Hanan Goldberg*, Thenappan Chandrasekar, Zachary Klaassen, Robert Hamilton, Girish Kulkarni, Neil Fleshner, Toronto, Canada

2:00 PD57-07 RACE AND FINASTERIDE USE: DIFFERENTIAL IMPACT ON BLADDER CANCER RISK
Abhishek Srivastava*, Ethan Fram, Ilir Agalli, Mark Schoenberg, Alexander Sankin, Bronx, NY

2:10 PD57-08 CENTRALIZATION OF RADICAL CYSTECTOMY FOR BLADDER CANCER IN A UNIVERSAL HEALTHCARE SYSTEM: EARLY RESULTS FROM A CANADIAN ACADEMIC CENTER
Jan Rudzinski*, Niels Jacobsen, Eric Estey, Naveen Basappa, Michael Kolinsky, Edmonton, Canada, Adrian Fairey, Edmonton, Canada

2:20 PD57-09 NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM SURGICAL RISK CALCULATOR POORLY PREDICTS COMPLICATIONS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY WITH URINARY DIVERSION: THE CASE FOR A PROCEDURE-SPECIFIC RISK CALCULATOR
Melanie Adamsky*, Shay Golan, Chuanhong Liao, Scott Johnson, Norm Smith, Gary Steinberg, Arieh Shalhav, Chicago, IL

2:30 PD57-10 A PROSPECTIVE STUDY ON THE IMPACT OF RADICAL CYSTECTOMY ON SEXUAL FUNCTION IN FEMALES WITH BLADDER CANCER
Karim Marzouk*, Bruce Rapkin, Yuelin Li, Thomas Atkinson, Alan Thong, Leah Goldstein, Dahlia Speerling, New York City, NY, Carolyn Schwartz, Concord, MA, Harry Herr, Machele Donat, Vincent Laudone, Jonathan Coleman, Guido Dalbagni, Bernard Bochner, New York City, NY

2:40 PD57-11 CROSS-SECTIONAL STUDY EVALUATING LONG-TERM BOWEL ISSUES IN BLADDER CANCER PATIENTS: DIARRHEA AS A LIMITING FACTOR OF QUALITY OF LIFE AFTER RADICAL CYSTECTOMY
Marie Hupe*, Luebeck, Germany, Winfried Vahlensieck, Bad Nauheim, Germany, Martin Hennig, Tomasz Ozimek, Julian Struck, Luebeck, Germany, Hossein Tezval, Hannover, Germany, Axel Mersberger, Luebeck, Germany, Markus Kuczyk, Hannover, Germany, Mario Kramer, Luebeck, Germany

2:50 PD57-12 A COMPARISON OF POST-CYSTECTOMY RECURRENCE AND SURVIVAL IN NAC-RESPONSIVE MIBC VS. HIGH-RISK NMIBC PATIENTS: SIMILAR PATHOLOGIC STAGE YET DIFFERENT OUTCOMES
Aaron Brant*, Max Kates, Meera Chappidi, Nikolai Sopko, Trinity Bivalacqua, Baltimore, MD

ABSTRACT
TIME NUMBER TITLE
1:00 PD58-01 VALIDATION OF VENOUS THROMBOEMBOLISM RISK ASSESSMENT SCORE IN MAJOR UROLGIC CANCER SURGERY: A POPULATION BASED STUDY
Ross Krasnow*, Mark Preston, Boston, MA, Benjamin Chung, Stanford, CA, Adam Kibel, Steven Chang, Boston, MA

1:10 PD58-02 A QUALITY IMPROVEMENT FOLEY PROJECT TO REDUCE CATHETER RELATED TRAUMA IN A LARGE COMMUNITY HOSPITAL
Kassem Faraj, Rochester, MI, Chirag Dave*, Royal Oak, MI, Paras Vakharia, Rochester, MI, Judy Boura, Jay Hollander, Royal Oak, MI

1:20 PD58-03 IS COMPLIANCE TO AN ENHANCED RECOVERY PROTOCOL AFTER RADICAL CYSTECTOMY ASSOCIATED WITH IMPROVED POST OPERATIVE OUTCOMES?
Saum Ghodoussipour*, Brian Cameron, Clara Wang, Jie Cai, Nariman Ahmadi, Siamak Daneshmand, Hooman Djaladat, Los Angeles, CA

1:30 PD58-04 THE ROLE OF PATIENT FACTORS ON UROLOGY OPERATING ROOM TURNOVER
1:40 PD58-05 CONTRIBUTING TO A CRISIS? DEFINING NATIONAL PATTERNS IN OPIOID PRESCRIBING AFTER OUTPATIENT VASECTOMY
Gregory Auffenberg*, Rodney Dunn, Yongmei Qin, Tyler Winkelman, James Dupree, Brent Hollenbeck, Ted Skolarus, David Miller, Tudor Borza, Ann Arbor, MI

1:50 PD58-06 SURGICAL SKILL AND PATIENT OUTCOMES AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY
James O. Peabody*, Detroit, MI, Rodney L. Dunn, Andrew Brachulis, Tae Kim, Susan Linsell, Ann Arbor, MI, Brian R. Lane, Grand Rapids, MI, Richard Sarle, Dearborn, MI, James Montie, David C. Miller, Khurshid R. Ghani, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

2:00 PD58-07 MUSIC OCTAVE – COMPOSITE MEASURES TO ASSESS SURGEON PERFORMANCE FOR ROBOTIC PROSTATECTOMY
Rodney L. Dunn*, Ann Arbor, MI, James O Peabody, Detroit, MI, Brian R. Lane, Grand Rapids, MI, Richard Sarle, Dearborn, MI, Tae Kim, Andrew Brachulis, Todd Morgan, Ann Arbor, MI, Benjamin Stockton, St. Joseph, MI, Khurshid R Ghani, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

2:10 PD58-08 THE UTILITY OF STANDARDIZED WEEKLY INTRADEPARTMENTAL CONFERENCE IN DETECTING PREOPERATIVE ISSUES AND CONCERNS
Al-Qassab Usama*, Jeffrey Pearl, Louis Aliperti, Dean Laganosky, Vitaly Zhoudev, Lorenz Adam, Maggie Dear, Jennifer Lindelow, Donald Finnerty, John Petros, Filson Christopher, Muta Issa, Decatur, GA

2:20 PD58-09 THE IMPACT OF A TEACHING HOSPITAL ON FUNDAMENTAL GENERAL UROLOGIC PROCEDURES: DO RESIDENTS HELP OR HURT?
Carrie Mlynarczyk*, Maxwell James, Henry Tran, Doreen E Chung, New York, NY

2:30 PD58-10 QUALITY IMPROVEMENT EDUCATION AND PARTICIPATION IN UROLOGY RESIDENCY PROGRAMS: PRELIMINARY SURVEY RESULTS OF PROGRAM DIRECTORS
Justin Ziemba*, Brian Matlaga, Baltimore, MD, Christopher Tessier, Portland, OR

2:40 PD58-11 THE FRAGILITY OF STATISTICALLY SIGNIFICANT RESULTS FROM RANDOMIZED TRIALS IN UROLOGY
Vikram Narayan*, Minneapolis, MN, Shreyas Gandhi, Hamilton, Canada, Kristin Chrouser, Minneapolis, MN, Nathan Evanieh, Hamilton, Canada, Philipp Dahm, Minneapolis, MN

2:50 PD58-12 PSA SCREENING AT THE INTERSECTION OF POLITICS AND POLICY
Jesse Sammon, Emily Serrel*, Portland, ME, Malte Vetterlein, Patrick Karabon, Detroit, MI, Gregory Mills, Moritz Hansen, Portland, ME, Mani Menon, Detroit, MI, Quoc-Dien Trinh, Boston, MA, Firas Abdollah, Detroit, MI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
1:20  PD59-03 GROWTH KINETICS IN VON HIPPEL-LINDAU-ASSOCIATED RENAL TUMORS: DEFINING THE INFLUENCE OF GERMINE MUTATION TYPE
Mark Ball*, Shawna Boyle, Bethesda, MD, Kiranpreet Khurana, Cleveland, OH, Rabindra Gautam, Bethesda, MD, Gennady Bratslavsky, Syracuse, NY, W. Marston Linehan, Adam Metwalli, Bethesda, MD

1:30  PD59-04 NATURAL HISTORY AND PREDICTORS OF GROWTH OF SMALL RENAL MASSES IN A PROSPECTIVE COHORT WITH A MEDIAN FOLLOW-UP OF FIVE-YEARS
Emily Whelan*, Jeffrey Himmelman, Ross Mason, Kara Thompson, Ricardo Rendon, Halifax, Canada

1:40  PD59-05 ACTIVE SURVEILLANCE FOR RENAL MASSES WITH 5 YEARS OF FOLLOW-UP: TUMOR GROWTH, DELAYED INTERVENTION RATES, AND CLINICAL OUTCOMES
Andrew McIntosh*, Pranav Parikh, Anthony Tokarski, Eric Ross, David Chen, Richard Greenberg, Alexander Kutikov, Marc Smaldone, Rosalia Viterbo, Robert Uzzo, Philadelphia, PA

1:50  PD59-06 QUALITY OF LIFE SCORES IN PATIENTS WITH SMALL RENAL MASSES WHO HAVE UNDERGONE RENAL MASS BIOPSY COMPARED TO THOSE WHO HAVE NOT: ANALYSIS OF THE DISRM REGISTRY.
Alice Semerjian*, Ridwan Alam, Hiten Patel, Mark Rifton, Michael Johnson, Baltimore, MD, Peter Chang, Andrew Wagner, Boston, MA, James McKiernan, New York, NY, Bruce Trock, Mohamad Allaf, Phillip Pierorazio, Baltimore, MD

2:00  PD59-07 USING MATHEMATICAL MODELING TO DEFINE THE ROLE OF ACTIVE SURVEILLANCE IN THE MANAGEMENT OF PATIENTS WITH CLINICAL T1 RENAL MASSES
Devang Sharma*, Jennifer Lobo, Noah Schenman, Tracey Krupski, Charlottesville, VA

2:10  PD59-08 PROPOSAL AND VALIDATION OF A DYNAMIC CRITERION FOR PATIENT INCLUSION IN KIDNEY CANCER ACTIVE SURVEILLANCE PROTOCOLS
Alessandro Larcher*, Fabio Muttin, Francesco Rizzi, Armando Stabile, Francesco Trevisani, Alessandro Nitti, Francesco Cianflone, Cristina Carensi, Milan, Italy, Alexandre Mottie, Aalst, Belgium, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Roberto Bertini, Umberto Capitanio, Milan, Italy

2:20  PD59-09 MANAGEMENT OF SMALL RENAL MASSES IN RENAL TRANSPLANT RECIPIENT CANDIDATES: A MULTI-INSTITUTIONAL SURVEY ANALYSIS
Alp Tuna Beksaç*, David Paulucci, John Sfakianos, Balaji Reddy, Susan Lemer, Jared Winoker, Harry Anastos, Jorge Pereira, Ketan Badani, New York, NY

2:30  PD59-10 THE NATURAL HISTORY OF LARGE RENAL MASSES ON ACTIVE SURVEILLANCE & EXPECTANT MANAGEMENT
Karim Marzouk*, Amy Tin, Nick Liu, Daniel Sjoberg, A. Art Hakimi, Paul Russo, Jonathan Coleman, New York City, NY

2:50  PD59-12 PREDICTING LOW METASTATIC POTENTIAL TUMORS USING CLINICAL RADIOGRAPHIC SIZE: A SYSTEMATIC REVIEW OF THE LITERATURE.
Alice Semerjian*, Hiten D. Patel, Michael A. Gorin, Michael H. Johnson, Mohamad Allaf, Phillip M. Pierorazio, Baltimore, MD

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
### AUA/BRAZILIAN PORTUGUESE UROLOGY PROGRAM (BPUP)

**Room 205BC @ Boston Convention & Exhibition Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>WELCOME AND INTRODUCTIONS: INTRODUCTION OF SBU-AUA SCHOLARS, APU &amp; ALU LEADERSHIP</td>
<td>Course Director: Fernando J. W. Kim, Moderators: Gopal Badlani, Archimedes Nardozza, Luiz Torres</td>
</tr>
<tr>
<td>1:15</td>
<td>EMERGING THERAPIES FOR BPH: AN UPDATE</td>
<td>Ricardo Gonzalez</td>
</tr>
<tr>
<td>1:35</td>
<td>COMPLICATIONS OF ROBOTIC PARTIAL NEPHRECTOMY</td>
<td>Ashok Hemal</td>
</tr>
<tr>
<td>1:55</td>
<td>SURGICAL MANAGEMENT OF FEMALE SUI IN 2017</td>
<td>Brian Flynn</td>
</tr>
<tr>
<td>2:15</td>
<td>TESTOSTERONE THERAPY: EFFICACY AND SAFETY 2017</td>
<td>Larry Lipshultz</td>
</tr>
<tr>
<td>2:35</td>
<td>PROSTATE CANCER SCREENING/ACTIVE SURVEILLANCE/ROLE OF GENETIC TESTING</td>
<td>James Eastham</td>
</tr>
<tr>
<td>2:55</td>
<td>ROBOTIC CYSTECECTOMY</td>
<td>Mihir Desai</td>
</tr>
<tr>
<td>3:15</td>
<td>CASTRATION RESISTANT PROSTATE CANCER</td>
<td>Badrinath Konety</td>
</tr>
<tr>
<td>3:35</td>
<td>URETEROSCOPY: QUALITY IMPROVEMENT PROCESS</td>
<td>Timothy Averch</td>
</tr>
<tr>
<td>3:55</td>
<td>IDEAL ACCESS FOR PCNL</td>
<td>Mantu Gupta</td>
</tr>
<tr>
<td>4:15</td>
<td>GLOBAL TRENDS IN ERECTILE RESTORATION: IMPLICATIONS FOR PRACTICE</td>
<td>Ryan Terlecki</td>
</tr>
<tr>
<td>4:35</td>
<td>FEMALE UROLOGY/INCONTINENCE - CASE BASED LEARNING</td>
<td>Gopal Badlani</td>
</tr>
<tr>
<td>4:55</td>
<td>CLOSING REMARKS/ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>

**UROLOGIC SOCIETY FOR TRANSPLANTATION & RENAL SURGERY (USTRS)**

**Room 206 @ Boston Convention & Exhibition Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00</td>
<td>WELCOME REMARKS</td>
<td>Society President: Anil Kapoor</td>
</tr>
<tr>
<td>1:05</td>
<td>INTERNATIONAL HOUR: PERSPECTIVES ON KIDNEY TRANSPLANTITION: NEPAL</td>
<td>Asarfi Shah</td>
</tr>
<tr>
<td>1:20</td>
<td>INTERNATIONAL HOUR: PERSPECTIVES ON KIDNEY TRANSPLANTITION: EGYPT</td>
<td>Hassan Abol-Enein</td>
</tr>
<tr>
<td>1:35</td>
<td>INTERNATIONAL HOUR: PERSPECTIVES ON KIDNEY TRANSPLANTITION: VIETNAM</td>
<td>Tran Ngoc Sinh</td>
</tr>
<tr>
<td>1:50</td>
<td>INTERNATIONAL HOUR: PERSPECTIVES ON KIDNEY TRANSPLANTITION: IRAN</td>
<td>Nasser Simforoosh</td>
</tr>
<tr>
<td>2:05</td>
<td>RESIDENT AND FELLOW ABSTRACT PRESENTATIONS</td>
<td></td>
</tr>
<tr>
<td>3:05</td>
<td>BREAK</td>
<td>HOW TO AVOID AND DEAL WITH ROBOTIC RENAL SURGICAL DISASTERS</td>
</tr>
<tr>
<td>3:20</td>
<td>HOW TO AVOID AND DEAL WITH ROBOTIC RENAL SURGICAL DISASTERS</td>
<td>James Porter</td>
</tr>
<tr>
<td>4:00</td>
<td>PANEL: LAPAROSCOPIC AND ROBOTIC RENAL SURGERY COMPLICATIONS AND MANAGEMENT</td>
<td>Anil Kapoor, Nicolas Muruve, Christopher Nguan, James Porter, Alp Senar, , Evan Vapnek</td>
</tr>
<tr>
<td>5:00</td>
<td>PRESENTATION OF NOVICK AWARD</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td>ADJOURN</td>
<td>APPROVED FOR AMA PRA CATEGORY 1 CREDIT™</td>
</tr>
<tr>
<td>TIME</td>
<td>NUMBER</td>
<td>TITLE</td>
</tr>
<tr>
<td>------</td>
<td>--------</td>
<td>-------</td>
</tr>
<tr>
<td>1:00</td>
<td>FRI-01</td>
<td>FROM A VERY SELECT CLUB TO AN UNIVERSAL AND POWERFUL EUROPEAN ASSOCIATION OF UROLOGY (EAU)</td>
</tr>
<tr>
<td>1:10</td>
<td>FRI-02</td>
<td>AGAINST ALL ODDS: THE BEGINNING OF EXPERIMENTAL RENAL PHYSIOLOGY</td>
</tr>
<tr>
<td>1:20</td>
<td>FRI-03</td>
<td>KIDNEY OR CONSPIRACY? WAS RENAL FAILURE THE CAUSE OF MOZART'S DEATH? A BRIEF REVIEW OF THE COMPOSER'S KNOWN ILLNESSES AND THEORIES SURROUNDING HIS DEATH.</td>
</tr>
<tr>
<td>1:30</td>
<td>FRI-04</td>
<td>FIRST FEMALE AUTHORS IN THE JOURNAL OF UROLOGY</td>
</tr>
<tr>
<td>1:40</td>
<td>FRI-05</td>
<td>M. L. GANNON: PIONEER IN UROLOGY</td>
</tr>
<tr>
<td>2:00</td>
<td>FRI-07</td>
<td>A RACE TO IMAGING REVOLUTION: PIONEERS IN FIBER OPTICS</td>
</tr>
<tr>
<td>2:20</td>
<td>FRI-09</td>
<td>MORE THAN JUST STORING AND EMPTYING: THE BLADDER'S FUNCTIONS IN THE KITCHEN</td>
</tr>
<tr>
<td>2:40</td>
<td>FRI-11</td>
<td>OBSTRUCTIVE PYOHYDRONEPHROSIS AND LIFE SAVING INTERVENTION OF THE GREATEST STARLET OF ALL TIME - SARAH BERNHARDT</td>
</tr>
<tr>
<td>3:30</td>
<td>FRI-12</td>
<td>MARY HELEN SCHIRM OF SAVANNAH, THE FIRST US PATIENT, WHO UNDERWENT INDICATED NEPHRECTOMY</td>
</tr>
<tr>
<td>3:40</td>
<td>FRI-13</td>
<td>ANATOMY OF THE PROSTATE GLAND: EVOLVING UNDERSTANDING THROUGH LAPAROSCOPIC AND ROBOTIC UROLOGICAL SURGERY</td>
</tr>
<tr>
<td>3:50</td>
<td>FRI-14</td>
<td>REVIEW OF THE EVIDENCE OF THE FEMALE PROSTATE AS A FUNCTIONAL, SEXUALLY-RELEVANT GLAND IN WOMEN</td>
</tr>
<tr>
<td>4:00</td>
<td>FRI-15</td>
<td>CRIME AND PUNISHMENT: GENITOURINARY MUTILATION AS A LEGAL SENTENCING</td>
</tr>
<tr>
<td>4:10</td>
<td>FRI-16</td>
<td>RADIATION EFFECT ON MALE SPERMATOGENESIS AND FERTILITY – THE SCIENCE AND ETHICAL CONSIDERATION OF THE OREGON AND WASHINGTON RADIATION EXPERIMENTS ON PRISON INMATES</td>
</tr>
<tr>
<td>4:20</td>
<td>FRI-17</td>
<td>“WALK LIKE A MAN”: SEX TESTING AND FEMALE GENDER IDENTITY IN INTERNATIONAL ATHLETIC COMPETITION</td>
</tr>
<tr>
<td>4:30</td>
<td>FRI-18</td>
<td>ChangIN GENDER AND ANNULING MARRIAGE – A HISTORICAL PERSPECTIVE ON THE EARLY HISTORY OF HYPOSPADIAS</td>
</tr>
</tbody>
</table>

*Presenting author
4:40 FRII-01 MICHELANGELO’S KIDNEY: A CASE PRESENTATION OF UROLITHIASIS
Kailash Kapadia*, Andrew Chen, Kirk Redger, Felix Cheung, Howard L Adler, Stony Brook, NY

4:43 FRII-02 HOW A UROLOGY CAREER-ENDING HAND INJURY PRODUCED A PIONEER OF UORADIOLOGY
Steven Brandes, Stephanie Thompson*, Robert Goldfarb, New York, NY

4:46 FRII-03 MAX WILMS: A TRIPHASIC HISTORY OF THE MAN, HIS EPONYMOUS TUMOR, AND ITS EVOLVING TREATMENT
Kristina Suson*, Yegappan Lakshmanan, Janae Preece, Detroit, MI

4:49 FRII-04 LITTLE BIG MAN WITH A SHORT THUMB: J BENTLEY SQUIER AS UROLOGIC GIANT AND THE FOUNDING OF THE WORLD’S FIRST ACADEMIC MEDICAL CENTER
Robert Goldfarb*, Stephanie Thompson, Steven Brandes, New York, NY

4:52 FRII-05 TOBIAS GOODMAN AND THE NEW ENGLAND ORIGIN OF URETEROSCOPY.
Joseph Yared*, Vernon Pais, Lebanon, NH

4:55 FRII-06 BOSTON, MA: THE HOME OF DR. JOSEPH E. MURRAY AND THE FIRST ORGAN TRANSPLANT
Alexandra Rehfuss*, Albany, NY

4:58 FRII-07 HOW CHESTER ALAN ARTHUR BRIGHTENED FROM A POLITICAL SPOILSMAN TO A CIVIL SERVICE REFORMER
Daniel Canter, Hailey Silverii*, Stephen Carriere, New Orleans, LA

5:01 FRII-08 WALLWERK MEETS STONE WORK: THE BLADDER MEETS THE MOON IN THE EYES OF FRANZ VON PAULA GRUITHUISEN
Joseph Mahon*, Charles Welliver, Mark White, Albany, NY

5:04 FRII-09 CONSERVATIVE KIDNEY TRAUMA MANAGEMENT AND CONSERVATIVE POLITICS: HOW SIR WINSTON CHURCHILL’S PHYSICIANS MAY HAVE SAVED THE WESTERN WORLD
Alan Carnes*, Augusta, GA, Zach Klaassen, Toronto, Canada, Michael Kemper, Arthur Smith, Durwood Neal, Augusta, GA

5:07 FRII-10 HM3 LITHOTRIPTER AT UNIVERSITY OF VIRGINIA: 1984-2016, END OF AN ERA
Matthew Clements*, Jay Y Gillenwater, Noah Schenkman, Charlottesville, VA

5:10 FRII-11 RARE AND UNUSUAL UROGENITAL DISEASES
Eleftheria-Foteini Poulakou*, Apostolos Rempelakos, C Tsiamis, M Chrisofos, Athens, Greece

5:13 FRII-12 UROLOGIC DISEASE DURING THE AMERICAN CIVIL WAR
Patrick Fisher*, Sacramento, CA

5:16 FRII-13 WAR AND PEACE: LEO SZILARD’S NUCLEAR LEGACY
Lawrence Wyner*, Huntington, WV

5:19 FRII-14 EVOLUTION OF SOCIAL MEDIA IN PEDIATRIC UROLOGY: THE FIRST LIVE TWEET CHAT ON TESTICULAR TORSION
Christina Ho*, Camden, NJ, T. Ernesto Figueroa, Wilmington, DE

5:22 FRII-15 EVOLUTION OF INNOVATION: HISTORICAL PERSPECTIVES ON THE MANAGEMENT OF URETHRAL STRICTURE DISEASE
Devang Desai*, Pankaj Joshi, Hazem Orabi, Sandesh Surana, Sanjay Kulkarni, Mumbai, India

5:30 ADJOURN
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

1:00 INTRODUCTION
Society President Elect: David Bushinsky

1:05 SESSION 1: UPDATE ON SURGICAL MANAGEMENT OF STONES
Moderators: Erdal Erturk, Marshall Stoller

PROPULSION WAVE LITHOTRIPSY
Michael Bailey

1:25 DEBATE 1: DUSTING VS. ACTIVE FRAGMENT REMOVAL
Debaters: Khurshid Ghani, Vernon Pais

1:55 RISKS & BENEFITS OF BILATERAL STONE SURGERY IN A SINGLE SESSION
James Lingeman
2:15 PCNL - ULTRASOUND VS. FLUOROSCOPY TO
GAIN RENAL ACCESS - USE OF ULTRASOUND
Tom Chi

4:05 BONE DISEASE IN STONE FORMERS
Elaine Worcester

4:25 DEBATE 4: MET FOR URETERAL STONES
Debaters: John Hollingsworth, Matthew Bultitude

4:45 BREAK

Bodo Knudsen

5:05 SESSION 3: SURGICAL CONTROVERSIES IN
STONE DISEASE
Moderators: Stephen Nakada, Amy Krambeck

5:25 DEBATE 5: PCNL: STANDARD VS. MINI
Debaters: Jorge Gutierrez-Aceves, Margaret Pearle

5:45 PRECURSORS TO RANDALL PLAQUES
Marshall Stoller

6:05 ADJOURN

5:55 APPROVED FOR AMA PRA CATEGORY 1
CREDIT™

Monday, May 15, 2017 1:15 pm - 5:00 pm

PAN AFRICAN UROLOGICAL SURGEONS ASSOCIATION/CARIBBEAN UROLOGICAL SURGEONS ASSOCIATION (PAUSA/CURA)
Room 207 @ Boston Convention & Exhibition Center

1:15 WELCOME REMARKS
Program Chair: E. Oluwabunmi Olapade-Olaopa

1:30 SESSION 1: GUEST LECTURES
Session Chairs: Elijah Kehinde, Shingai Mutambirwa

1:45 THE EBOLA EPIDEMIC: A UROLOGIST’S
EXPERIENCE
Punga Maole

2:00 SESSION 2: ON THE SCIENTIFIC FRONTIER
Session Chairs: Serigne Gueye, Robin Roberts

2:10 PAIRED KIDNEY EXCHANGE: UTILITY OF
INCOMPATIBLE DONOR
Obi Ekwenna

2:20 UPDATE ON PROSTATE CANCER IN
AFRICANS
Mohamed Jalloh

2:30 CONTROVERSIES ON ANTIBIOTIC
PROPHYLAXIS FOR TRUS GUIDED PROSTATE
BIOPSY
Elijah Kehinde

2:40 UPDATE ON ERECTILE DYSFUNCTION
Luc Valiquette

2:50 PATHOLOGICAL UPGRADING AND
UPSTAGING AT RADICAL PROSTATECTOMY
IN JAMAICAN MEN WITH LOW RISK
PROSTATE CANCER
Belinda Morrison
PHILIPPINE UROLOGICAL ASSOCIATION (PUA)
Douglass @ Westin Waterfront

2:00 WELCOME REMARKS
Society President: Gavino Mercado
Program Chair: Wilfredo Tagle
Moderator: Samuel Vincent Yrastorza

2:30 STONES, BPH, PROSTATE CANCER
Eduardo Gatchalian, Dennis Serrano

Monday, May 15, 2017 2:00 pm - 5:00 pm

SOCIETA ITALIANA DI UROLOGIA (SIU)
Room 208 @ Boston Convention & Exhibition Center

2:25 WELCOME AND INTRODUCTION
AUA Global Initiative Chairman: Inderbir Gill
SIU Secretary: Vincenzo Mirone
AUA Secretary: Manoj Monga

2:30 SESSION 1
Moderators: Giuseppe Carrieri, Giuseppe Morgia
BLADDER CANCER DIAGNOSIS: THE ROLE OF TUR, MARKERS AND NEW TECHNOLOGIES.
CASE PRESENTATION
Mark Soloway

2:50 BCG FAILURES AND TREATMENT OPTIONS.
CASE PRESENTATION
Andrew Stephenson

3:10 BLADDER SPARING APPROACH IN MUSCLE-INVASIVE BLADDER CANCER: LATE RESULTS
Sam Chang

3:30 FROM CHEMOTHERAPY TO CHECK-POINT INHIBITION IN INVASIVE BLADDER CANCER
Cora Sternberg

3:50 DISCUSSION

4:00 SESSION 2
Moderators: Walter Artibani, Vincenzo Mirone

4:20 CYSTECTOMY FOR LOCALLY ADVANCED BLADDER CANCER
Moderator: Maurizio Brausi

4:40 COMPLICATIONS AFTER ORTHOTOPIC BLADDER SUBSTITUTION: HOW TO AVOID THEM
Richard Hautmann

5:00 ROBOTIC RADICAL CYSTECTOMY: LONG TERM ONCOLOGICAL AND FUNCTIONAL OUTCOMES AND COMPLICATIONS
Peter Wiklund

5:20 DISCUSSION

5:30 AWARD: BEST ITALIAN ABSTRACT PRESENTED AT THE AUA MEETING IN 2017
Presenter: Giuseppe Ludovico

5:35 ADJOURN

Monday, May 15, 2017 3:00 pm - 5:30 pm

CLINICAL CONTROVERSIES IN MEN’S HEALTH
Room 205A @ Boston Convention & Exhibition Center

3:00 INTRODUCTION
Larry Lipshultz, Abraham Morgentaler

DEBATE: PLATELET-RICH PLASMA (PRP) IS A REASONABLE THERAPEUTIC OPTION FOR THE TREATMENT OF ERECTILE DYSFUNCTION
Pro: Irwin Goldstein
Con: Gerald Brock

3:30 Q & A

3:40 GENETIC TESTING FOR PROSTATE CANCER: WHICH TEST, WHEN, AND WHY?
Eric Klein

3:40 Q & A

4:00 Q & A

4:10 DEBATE: MRI SHOULD BE PART OF THE EVALUATION OF THE PATIENT WITH SUSPECTED OR NEWLY DIAGNOSED PROSTATE CANCER
Pro: Peter Pinto
Con: Nelson Stone

4:40 Q & A
### ABSTRACT NUMBER TITLE

**MP84-01** PREDICTORS OF INCREASED INTRACavernosal INJECTION REQUIREMENTS AT PENILE ULTRASOUND  
Ross Avant*, Matthew Ziegelmann, Joshua Savage, Landon Trost, Rochester, MN

**MP84-02** UTILITY OF 2D PHOTOGRAPHY IN THE ASSESSMENT OF PENILE CURVATURE IN MEN WITH PEYRONIE’S DISEASE (PD): THE GOSOFT STUDY  

**MP84-03** DEVELOPMENT OF A CUT-OFF FOR THE PEYRONIE’S DISEASE QUESTIONNAIRE (PDQ) BOTHER SCORE  
Jean-Etienne Terrier*, Christian J Nelson, John P Mulhall, New York City, NY

**MP84-04** PREDICTION OF FUTURE ERECTILE DYSFUNCTION USING COMORBID DISEASE AND MEDICATION PROFILES  
George Bailey*, Joshua Piotrowski, Tanner Miest, Francisco Maldonado, Ziegelmann Matthew, Brian Montgomery, Landon Trost, Rochester, MN

**MP84-05** HOW LONG SHOULD PATIENTS WAIT BEFORE RESUMING SEXUAL ACTIVITY AFTER BPH SURGERY?  
Hanan Goldberg*, Toronto, Canada, Liat Weinzieg, Marc Lubin, Yariv Shlabboltz, Amihai Nevo, Chen Shenhar, Paz Lotan, Roy Mano, Daniel Halstuch, Dov Lask, Yaron Erlich, Daniel Margel, Daniel Kedar, Jack Daniel, Ofer Yossepowitch, Petach Tiqva, Israel

**MP84-06** TERTIARY REFERRAL HOSPITAL EXPERIENCES OF MEN PRESENTING WITH PAINLESS POST-COITAL GROSS HEMATURIA AND A SUGGESTION FOR TENTATIVE MANAGEMENT ALGORITHM  
Dong Hyuk Kang*, Jongsoo Lee, Jong Won Kim, Jae Yong Jeong, Sung Ku Kang, Jong Kyu Kwon, Joo Yong Lee, Dae Chul Jung, Young Deuk Choi, Kang Su Cho, Seoul, Korea, Republic of

---

*Presenting author*
MP84-12 DOES CALCULATED FREE TESTOSTERONE OVERCOME TOTAL TESTOSTERONE IN PROTECTING FROM SEXUAL SYMPTOMS IMPAIRMENT? FINDINGS OF A CROSS-SECTIONAL STUDY
Luca Boeri*, Paolo Capogrosso, Eugenio Ventimiglia, Walter Cazzaniga, Filippo Pederzoli, Davide Oreggia, Nicola Frego, Donatella Moretti, Franco Gaborardi, Milan, Italy, Emanuele Montanari, Milano, Italy, Vincenzo Mirone, Naples, Italy, Francesco Montorsi, Andrea Salonia, Milan, Italy

MP84-13 RISK FACTORS FOR ERECTILE DYSFUNCTION IN A POPULATION BASED COHORT
George Bailey*, Joshua Piotrowski, Tanner Miest, Francisco Maldonado, Ziegelmann Matthew, Brian Montgomery, Landon Trost, Rochester, MN

MP84-14 THE RELATIONSHIPS BETWEEN LIFESTYLE AND TESTOSTERONE; NIGHT WAKING, SMOKING HISTORY, DRINK HABIT AND THE LENGTH OF TIME USING INTERNET AND PLAYING GAMES ARE ASSOCIATED WITH TESTOSTERONE LEVEL
Shinichiro Fukuhara*, Norichika Ueda, Tetsuji Soda, Hiroshi Kiuchi, Yasushi Miyagawa, Suita, Japan, Akira Tsujimura, Urayasu, Japan, Norio Nonomura, Suita, Japan

MP84-15 A NEW METHOD OF QUANTITATIVELY MEASURING PENILE ERECTION HARDNESS IN ERECTILE DYSFUNCTION PATIENTS: REAL-TIME ULTRASONIC SHEAR WAVE ELASTOGRAPHY
Lin Yang*, Hao Cheng, Litao Ruan, Xian, China, People’s Republic of

MP84-16 BASELINE CHARACTERISTICS OF YOUNG MEN WITH ERECTILE DYSFUNCTION: A SINGLE CENTER EXPERIENCE
Peter Tsambarlis*, Chicago, IL, Mark Ehlers, Madison, WI, Adam Wiggins, Laurence Levine, Chicago, IL

MP84-17 EXPLORING THE ASSOCIATION BETWEEN OBSTRUCTIVE SLEEP APNEA AND VENOUS LEAK
Patrick Teloken, Eduardo Miranda, Coskun Kagacari, John Mulhall*, New York, NY

MP84-18 ERECTILE DYSFUNCTION AFTER PROSTATIC RADIOThERAPY: WHY MEASUREMENT MATTERS, A SYSTEMATIC REVIEW AND META-ANALYSIS
Thomas Gaither*, Mohannad Awad, San Francisco, CA, E. Charles Osternberg, Austin, TX, Gregory Murphy, Isabel Allen, Albert Chang, San Francisco, CA, Raymond Rosen, Watertown, MA, Benjamin Breyer, San Francisco, CA

MP84-19 BOTHER ASSOCIATED WITH CLIMACTURIA AFTER RADICAL PROSTATECTOMY: PREVALENCE, DEGREE AND PREDICTORS

MP84-20 RELATION BETWEEN SEVENTEEN SYMPTOM OF AGING MALE SYMPTOMS RATING SCALE AND SERUM CONCENTRATION OF IGF-1, DHEA-S, CORTISOL AND TESTOSTERONE IN PATIENTS WITH LATE ONSET HYPOGONADISM
Akira Tsujimura*, Ippei Hiramatsu, Yusuke Aoki, Hirofumi Shimoyama, Taiki Mizuno, Taiji Nozaki, Masato Shirai, Urayasu, Japan, Yoshiaki Kumamoto, Kazuhiro Kobayashi, Tokyo, Japan, Shigeo Horie, Bunkyo-Ku, Tokyo, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

MP84-01 ROLES OF NERVE GROWTH FACTOR IN BLADDER STORAGE DYSFUNCTION DUE TO DETRUSOR OVERACTIVITY IN SPINAL CORD INJURED MICE – ANALYSIS OF TIME-DEPENDENT RESPONSES
Naoki Wada*, Takahiro Shimizu, Nobutaka Shimizu, Pradeep Tyagi, William de Groat, Anthony Kanai, Pittsburgh, PA, Hidehiro Kakizaki, Asahikawa, Japan, Naoki Yoshimura, Pittsburgh, PA

MP84-02 ABERRANT BLADDER REFLEXES CAN DRIVE HIND LIMB LOCOMOTOR ACTIVITY FOLLOWING COMPLETE SUPRASACRAL SPINAL CORD INJURY
Brian M. Inouye*, Jilleene M. Brooks, Danielle J. Degoski, Francis M. Hughes Jr., J. Todd Purves, Matthew O. Fraser, Durham, NC

284
**MP85-03** THE THERAPEUTIC EFFECT OF TRPV4 ACTIVATION IN THE BLADDER ON UNDERACTIVE BLADDER IN RATS WITH PELVIC NERVE CRUSH

El-ichiro Takaoka*, Shun Takai, Takahisa Suzuki, Nobutaka Shimizu, Joonbeom Kwon, Hiroki Okada, Pittsburgh, PA, Hiroyuki Nishiyama, Tsukuba, Japan, Naoki Yoshimura, Christopher J. Chermansky, Pittsburgh, PA

**MP85-04** DEVELOPMENT OF AN UNDERACTIVE SYNDROME OF PELVIC TARGETS IN LONG-TERM STUDIES AFTER A UNILATERAL AVULSION INJURY OF LUMBOSacRAL VENTRAL ROOTS IN RHESUS MACAQUES

Huiyi Harriet Chang*, Jih-Chao Yeh, Robecca Do, Los Angeles, CA, Jaime H Nieto, Flushing, NY, Kari L Christe, Davis, CA, Leif A. Havton, Los Angeles, CA

**MP85-05** LONG-TERM FOLLOW-UP REVEALS DIFFERENTIAL PHENOTYPES OF NEUROLOGIC IMPAIRMENT AND BLADDER FUNCTION IN A MURINE MODEL OF NEURODEGENERATION

Sanghee Lee*, Balachandar Nedumaran, Joseph Hypolite, Randall Meacham, Anna Malykhina, Aurora, CO

**MP85-06** BRAIN NETWORKS CONTROLLING BLADDER FILLING AND VOIDING

Hanneke Verstegen*, John Mathai, Mark Zeidel, Boston, MA, Joel Geerling, Iowa City, IA

**MP85-07** FUNCTIONAL NEUROIMAGING OF URINE STORAGE AND VOIDING IN MICE

Bryce MacIver*, Aaron Grant, Timothy Pagliaro, David Alsop, John Mathai, Mark Zeidel, Boston, MA

**MP85-08** NON-SURGICAL MANAGEMENT OF DETERUSOR LEAK POINT PressURES ABOVE 40 CM H2O IN ADULTS WITH CONGENITAL NEUROGENIC BLADDER

Giulia Lane*, Ronak Gor, Minneapolis, MN, Jenna Katorski, St. Paul, MN, Sean Elliott, Minneapolis, MN

**MP85-09** COMPARISON OF NEUROGENIC LOWER URINARY TRACT DYSFUNCTIONS IN OPEN VS. CLOSED SPINAL DYSRAPHISM: RESULTS OBSERVED IN A PROSPECTIVE COHORT OF 395 PATIENTS


**MP85-10** HIGH RATES OF ADMISSION SEEN WITH ADULT SPINA BIFIDA PATIENTS PRESENTING TO THE EMERGENCY ROOM

Stephanie Kielb, Richard Matulewicz, Oluwarotimi Nettey*, Chicago, IL

**MP85-11** PREDICTORS OF A RETURN OF VOLITIONAL VOIDING AFTER SPINAL CORD INJURY

Dimitar V. Zlatev*, Stanford, CA, Kazuko Sherr, San Jose, CA, Christopher S. Elliott, Stanford, CA

**MP85-12** UROLOGICAL MANAGEMENT AND COMPLICATIONS IN SPINAL CORD INJURY PATIENTS: A 40- TO 50-YEAR FOLLOW-UP STUDY

Yunliang Gao*, Changsha, China, People’s Republic of, Teresa Danforth, Buffalo, NY, David Ginsberg, Los Angeles, CA

**MP85-13** SEVERITY OF LOWER URINARY TRACT SYMPTOMS PREDICT OVERALL NEUROLOGIC QUALITY OF LIFE AMONG PATIENTS WITH MULTIPLE SCLEROSIS

Aleksandar Blubaua*, Stephen Blakely, Nicholas Westfall, Augusto Miravalle, Brian Flynn, Aurora, CO

**MP85-14** PERISTEEN TRANSANAL IRRIGATION SYSTEM FOR THE TREATMENT OF NEUROPATHIC BOWEL DYSFUNCTION AND ABDOMINAL PAIN

Giovanni Pallieschi*, Antonio Luigi Pastore, Yazan Al Salhi, Andrea Fusch, Gennaro Velotti, Antonino Leto, Vincenzo Petrozza, Antonio Carbone, Latina, Italy

**MP85-15** INTRAVESICAL INJECTION OF HIGHLY PURIFIED BOTULINUM TOXIN [INCUBOTULINUMTOXIN A (XEOMIN)] FOR NEUROGENIC BLADDER

Denise Asafu-Adjei*, New York, NY, Alex Small, Doreen Chung, New York, NY, Glen McWilliams, Cory Harris, Bronx, NY

**MP85-16** COMPARISON OF URODYNAMIC PARAMETERS FOLLOWING INJECTION OF TWO DIFFERENT BOTULINUM TOXIN A PREPARATIONS IN MANAGEMENT OF NEUROGENIC DETRUSOR OVER-ACTIVITY FOLLOWING SPINAL CORD INJURY

Jason Gan, Sarah Rasip*, London, United Kingdom, Sarah Knight, Mohamed Helal, Frank Lee, Julian Shah, Rizwan Hamid, Stanmore, United Kingdom

**MP85-17** FACTORS ASSOCIATED WITH DURABILITY OF THERAPEUTIC BOTULINUM TOXIN A INJECTION FOR OVERACTIVE BLADDER

Kristian Stensland*, Burlington, MA, Jay Vance, Bennett Sluis, Boston, MA, Jared Schober, Arthur Mourtzinos, Lara Maclachlan, Burlington, MA

**MP85-18** GENDER DIFFERENCES IN THE SUCCESS OF SACRAL NERVE STIMULATION IN PATIENTS WITH OVERACTIVE BLADDER

Kristian Stensland*, Burlington, MA, Bennett Sluis, Jay Vance, Boston, MA, Jared Schober, Lara Maclachlan, Arthur Mourtzinos, Burlington, MA

*Presenting author
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP86-01</strong></td>
<td>FRAILTY IS COMMON AMONG PATIENTS PRESENTING TO AN ACADEMIC NON-ONCOLOGIC UROLOGY PRACTICE</td>
</tr>
<tr>
<td><strong>Anne M Suskind</strong>, San Francisco, CA, Jayce Pangilinan, Tuscon, AZ, Kathryn Quanstrom, Mark Bridge, Louise C Walter, Emily Finlayson, San Francisco, CA</td>
<td></td>
</tr>
<tr>
<td><strong>MP86-02</strong></td>
<td>PREVALENCE OF FRAILTY AMONG UROLOGICAL CANCER PATIENTS IN COMPARISON WITH COMMUNITY-DWELLING POPULATION</td>
</tr>
<tr>
<td>Shingo Hatakeyama*, Osamu Soma, Takuma Narita, Kazuhisa Tanaka, Toshikazu Tanaka, Daisuke Noro, Masaaki Okawa, Yoshimi Tanaka, Tepppei Matsumoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama, Hiroaki, Japan</td>
<td></td>
</tr>
<tr>
<td><strong>MP86-03</strong></td>
<td>A PREDICTIVE RISK STRATIFICATION MODEL FOR DELIRIUM AFTER MAJOR UROLOGIC CANCER SURGERIES</td>
</tr>
<tr>
<td>Albert Ha*, Ross Krasnow, Tammy Hsieh, Adam Kibel, Boston, MA, James Rudolph, Providence, RI, Benjamin Chung, Stanford, CA, Steven Chang, Boston, MA</td>
<td></td>
</tr>
<tr>
<td><strong>MP86-04</strong></td>
<td>NEW-ONSET DEPRESSION AND MENTAL HEALTH-RELATED QUALITY OF LIFE FOLLOWING PROSTATE CANCER DIAGNOSIS WITHOUT TREATMENT</td>
</tr>
<tr>
<td>Hankyul Kim*, Dattatraya Patil, Christopher Filson, Atlanta, GA</td>
<td></td>
</tr>
<tr>
<td><strong>MP86-05</strong></td>
<td>THE RELATIONSHIP BETWEEN FINANCIAL TOXICITY AND QUALITY OF LIFE AMONG BLADDER CANCER PATIENTS</td>
</tr>
</tbody>
</table>

**MP85-19** SIDE MATTERS: SACRAL NEUROMODULATION LEAD PLACEMENT ON THE LESS VERSATILE SIDE OFFERS GREATER BENEFIT IN PATIENTS WITH ASYMMETRY  
Usama Al-Qassab*, Lindsey Hartsell, Joy Butterworth, John DeCaro, Atlanta, GA, Niall Galloway, Atlanta, GA

**MP85-20** ACYLOXYACYL HYDROLASE MODULATES PELVIC PAIN SEVERITY  
Wenbin Yang*, Ryan Yaggie, Mingcheng Jiang, Charles Rudick, Joseph Done, Charles Heckman, Anthony Schaeffer, David Klumpp, Chicago, IL

---

Monday, May 15, 2017 3:30 pm - 5:30 pm

**Moderated Poster Session 86**

GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, QUALITY OF LIFE AND SHARED DECISION MAKING V

**Moderators:** Jonathan Bergman, James Dupree and Roderick van den Bergh
MP86-10 RELATIONSHIP BETWEEN OVERACTIVE BLADDER AND METABOLIC SYNDROME: A CROSS-SECTIONAL STUDY AMONG JAPANESE MEN AND WOMEN.
Yoshitaka Aoki*, Chieko Matsumoto, Yosuke Matsui, Hideaki Ito, Yukinori Kusaka, Osamu Yokoyama, Fukui, Japan

MP86-11 PROSPECTIVE ASSESSMENT OF PSYCHOLOGICAL SYMPTOMS IN MEN WITH LATE-ONSET HYPOGONADISM WHO RECEIVED TESTOSTERONE REPLACEMENT THERAPY
Kenta Sumii*, Mikito Tanaka, Takaki Ishida, Noritoshi Enatsu, Koji Chiba, Kei Matsushita, Masato Fujisawa, Kobe, Japan

MP86-12 PSYCHOLOGICAL DISTRESS IN PATIENTS UNDERGOING SURGERY FOR UROLOGICAL CANCER: A PROSPECTIVE SINGLE CENTRE CROSS-SECTIONAL STUDY
Antonio Luigi Pastore*, Giovanni Palleschi, Antonio Carbone, Latina, Italy, Serena Maruccia, Milano, Italy, Ana Mir Bou, Nuria Camps Bellnoch, Juan Palou, Barcelona, Spain

MP86-13 HEALTH RELATED QUALITY OF LIFE OF PATIENTS UNDERGOING ACTIVE SURVEILLANCE – COMPARISON WITH PROSTATE CANCER ACTIVE TREATMENTS
Lluis Fumado*, Barcelona, Spain, Jose Francisco Suárez, l’Hospital de Llobregat, Spain, Olatz Garín, Andrea Sureda, Montse Ferrer, Barcelona, Spain, Manel Castells, l’Hospital de Llobregat, Spain, Jose Maria Abascal, Maria Carme Mir, Barcelona, Spain, Xavier Bonet, Helena Vila, l’Hospital de Llobregat, Spain, Lluis Cecchini, Barcelona, Spain, Francesc Vigués, l’Hospital de Llobregat, Spain

MP86-14 PROSTATE SPECIFIC ANTIGEN AND HEALTH-RELATED QUALITY-OF-LIFE OUTCOMES IN UNINSURED MEN WITH PROSTATE CANCER
Avi Baskin*, Joseph Shirk, Lorna Kwan, Karim Chamie, Los Angeles, CA

MP86-15 EFFECTS OF GROUP REHABILITATION UPON WOMEN UNDERGOING SURGERY FOR OBSTETRIC FISTULA
Pooja Parameshwar*, Los Angeles, CA, Musa Kayondo, Mbarara, Uganda, A. Lenore Ackerman, Jennifer Anger, Christopher Tamay, Los Angeles, CA

MP86-16 A MULTI-CENTER ANALYSIS OF PROSTATE CANCER (PCA) TREATMENT AMONG VETERANS FOLLOWING INTRODUCTION OF THE 17-GENE GENOMIC PROSTATE SCORE (GPS) ASSAY

MP86-17 THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA

MP86-18 GENDER DIFFERENCES IN UROLOGICAL SUBSPECIALTIES
Oluwarotimi Netley*, Joceline Liu, Stephanie Kielb, Edward Schaeffer, Chicago, IL

MP86-19 FEMALE UROLOGY RESIDENT REPRESENTATION AT SECTIONAL MEETINGS – DO WE HAVE A GENDER DISPARITY ISSUE?
Tony Lin*, Hershey, PA, Adam Klausner, Richmond, VA, Jay Raman, Hershey, PA

MP86-20 IMPACT OF NUMERACY ON UNDERSTANDING OF PROSTATE CANCER RISK REDUCTION IN PSA SCREENING
Kevin Koo*, Charles Brackett, Ellen Eisenberg, Kelly Kieffer, Elias Hyams, Lebanon, NH

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author

287
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP87-01</td>
<td>AKT-PHOSPHORYLATED FOXO1 INHIBITS PKM2 NUCLEAR LOCALIZATION AND WARBURG EFFECT IN PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Chun-Wu Pan*, Shanghai, China, People’s Republic of, Jian An, R. Jeffrey Kames, Ligo Wang, Jun Zhang, Rochester, MN, Jun Qi, Shanghai, China, People’s Republic of, Haojie Huang, Rochester, MN</td>
</tr>
<tr>
<td>MP87-02</td>
<td>TUMOR-ASSOCIATED MACROPHAGES PROMOTE PROSTATE CANCER METASTASIS VIA CCL2-CCR2 AXIS-INDUCED CCL22-CCR4 AXIS</td>
</tr>
<tr>
<td></td>
<td>Kouji Izumi*, Aerkken Maolake, Ariunbold Natsagdorj, Kazutaka Narimoto, Yoshifumi Kadono, Atsushi Mizokami, Kanazawa, Japan</td>
</tr>
<tr>
<td>MP87-03</td>
<td>URINARY MMP-9 AS CANDIDATE FOR A NON-INVASIVE PROSTATE CANCER BIOMARKER REVEALED BY QUANTITATIVE PROTEOMICS ANALYSIS</td>
</tr>
<tr>
<td></td>
<td>Rebeca Kawahara, Fabio Ortega*, Sao Paulo, Brazil, Livia Rosa-Fernandes, Odense, Denmark, Vanessa Guimaraes, Katia Leite, William Nahas, Miguel Srougi, Sao Paulo, Brazil, Martin Larsen, Odense, Denmark, Giuseppe Palmisano, Sao Paulo, Brazil</td>
</tr>
<tr>
<td>MP87-04</td>
<td>MEIS PROTEINS AS PREDICTIVE MARKERS OF METASTATIC PROSTATE CANCER PROGRESSION</td>
</tr>
<tr>
<td></td>
<td>Raj Bhavnadivra*, Erin McAuley, Wen-Ching Chan, Hannah Brechka, Gladell Paner, Donald Vander Griend, Chicago, IL</td>
</tr>
<tr>
<td>MP87-05</td>
<td>UPREGULATION OF OPIORPHIN IS ASSOCIATED WITH PROSTATE CANCER; A POTENTIAL NOVEL THERAPEUTIC TARGET</td>
</tr>
<tr>
<td></td>
<td>Amarnath Mukherjee*, Li Wang, Mark Schoenberg, Kelvin Davies, Bronx, NY</td>
</tr>
<tr>
<td>MP87-06</td>
<td>EXPRESSION ANALYSIS OF TUMOR PROMOTING GENES IN CIRCULATING TUMOR CELLS OF PATIENTS WITH LOCALIZED AND METASTATIC PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Simone Bier, Jörg Hennenlotter, Gunthild Beger, Lucretia Pavlenco, Tübingen, Germany, Nathalie Feniuk, Siegfried Hauch, Hilden, Germany, Steffen Rausch, Arnulf Stenzl, Tilman Todenhöfer*, Tübingen, Germany</td>
</tr>
<tr>
<td>MP87-07</td>
<td>THE BIOLOGICAL RAMIFICATIONS OF PROSTATE CANCER ASSOCIATED CELL FREE DNA: EFFECT ON PLATELET FUNCTION AND DISEASE PROGRESSION</td>
</tr>
<tr>
<td></td>
<td>Mackenzie Adams, James Henderson, Matthew Lee, Todd Morgan, Ganesh Palapattu, Alexander Zaslavsky*, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP87-08</td>
<td>ROLE OF THE C-MYC TARGET DNPH1, A NEW N-HYDROLASE, IN KIDNEY AND PROSTATE CANCERS</td>
</tr>
<tr>
<td>MP87-09</td>
<td>DISTINCT EPIGENETIC AND TRANSCRIPTOMIC VARIATIONS IN AFRICAN AMERICAN MEN AS COMPARED TO CAUCASIAN IN PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Richa Rai, Cordelia Elahi, Victoria Hackert, Kamlesh K Yadav, Ashutosh Tewari, Shalini S Yadav*, New York, NY</td>
</tr>
<tr>
<td>MP87-10</td>
<td>GENOMIC ANALYSIS OF A LONGITUDINAL SERIES OF SURGICAL PROSTATE CANCER BONE METASTASES AND XENOGRAFTS FROM THE SAME PATIENT REVEALED SELECTION OF A PROGRESSIVELY THERAPY RESISTANT METASTATIC CLONE</td>
</tr>
<tr>
<td></td>
<td>Christina Jamieson*, Michelle Muldong, Abigail Gallegos, Christina Wu, Theresa Mendoza, LA Jolla, CA, Jin Sung Park, Sego, Daejeon, Korea, Republic of, William Zhu, Omer Raheem, La Jolla, CA, Seung Chol Park, Jeonbuk, Korea, Republic of, Michael Liss, San Antonio, TX, Danielle Burner, Lee Edsall, Olga Miakicheva, La Jolla, CA, Nicholas Cacalano, Los Angeles, CA, Catriona Jamieson, Christopher Kane, Anna Kuldijian, Terry Gaasterland, La Jolla, CA</td>
</tr>
<tr>
<td>MP87-11</td>
<td>INTRINSIC PROSTATE CANCER SUBTYPES DETERMINED IN DIAGNOSTIC PROSTATE BIOPSIES OF MEN WITH METASTATIC DISEASE RESEMBLE CASTRATION-RESISTANT PROSTATE CANCER METASTASES</td>
</tr>
<tr>
<td></td>
<td>Eric Miller*, Santa Monica, CA, Sungyong You, Lorna Kwan, Xinmin Li, Michael Lewis, Beatrice Knudsen, Michael Freeman, Isla Garraway, Los Angeles, CA</td>
</tr>
</tbody>
</table>
MP87-12 ADRENAL ANDROGENS FACILITATE PROSTATE CANCER CELL RESISTANCE TO ANDROGEN DEPRIVATION THERAPY
Michael Fiandalo*, John Stocking, Elena Pop, Krystin Mantione, John Wilton, James Mohler, Buffalo, NY

MP87-13 ESTROGEN RECEPTOR α IN CANCER ASSOCIATED FIBROBLASTS SUPPRESSES PROSTATE CANCER INVASION VIA REDUCING CCL5, IL6 AND MACROPHAGE INFILTRATION IN THE TUMOR MICROENVIRONMENT.
Yang Yang*, Beijing, China, People’s Republic of, Chiuan-Ren Yeh, Spencer Slavin, Jie Luo, Fu-Ju Chou, Keliang Wang, Matthew Truong, Chawnshang Chang, Edward M. Messing, Shuyuan Yeh, Rochester, NY

MP87-14 STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF ERGI-USU, A HIGHLY SELECTIVE INHIBITOR FOR ERG POSITIVE PROSTATE CANCER CELLS
Ahmed Mohamed*, Charles Xavier, Rockville, MD, Gauthaman Sukumar, Bethesda, MD, Samuel Banister, Vineet Kumar, Stanford, CA, Shyh-Han Tan, Shilpa Katta, Lakshmi Ravindranath, Muhammad Jamal, Taduru Sreenath, David McLeod, Gyorgy Petrovics, Albert Dobi, Rockville, MD, Meera Srivastava, Bethesda, MD, Sanjay Malhotra, Stanford, CA, Clifton Dalgard, Bethesda, MD, Shiv Srivastava, Rockville, MD

MP87-15 INHIBITION OF RPS6KB1 AS A POTENTIAL ADJUVANT FOR PROSTATE CANCER RADIATION THERAPY
Suleman Hussain, Roble Bedolla, SAN ANTONIO, TX, Hiroshi Miyamoto, New York, NY, Paul Rivas, Joseph Basler, Gregory Swanson, Nikos Papanikolasou, Robert Reddick, Rita Ghosh, Addanki Kumar*, SAN ANTONIO, TX

MP87-16 INTERFERON-INDUCED MICRORNA TURNOVER LEADING TO EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) IN CANCER
U-Ging Lo*, Rey-Chen Pong, Elizabeth Hernandez, Shi-Hong Ma, Jer-Tsong Hsieh, Dallas, TX

MP87-17 PROSTATE MRI REPRESENTS LEUKOCYTE DENSITY AND NOT THE PRESENCE OF CANCER ON BIOPSY
Eric Kim*, Dengfeng Cao, Russell Pachynski, Robert Grubb III, Gerald Andriole, St. Louis, MO

MP87-18 ASSOCIATION OF GERMLINE GENETIC VARIANTS WITH TMPRSS2-ERG FUSION STATUS IN PROSTATE CANCER
Indu Kohaar*, Lakshmi Ravindranath, Denise Young, Amina Ali, Rockville, MD, Qiyuan Li, Fujian Sheng, China, People’s Republic of, Albert Dobi, David McLeod, Rockville, MD, Inger Rosner, Bethesda, MD, Isabell Sesterhenn, Silver Spring, MD, Matthew Freedman, Cambridge, MA, Shiv Srivastava, Gyorgy Petrovics, Rockville, MD

MP87-19 ETS RELATED GENE (ERG) DRIVEN ANDROGEN RECEPTOR AGGREGATION IS A KEY REGULATOR OF ENDOPLASMIC STRESS AND CELL SURVIVAL DURING PROSTATE CARCINOGENESIS
Taduru Sreenath*, Natalia Mikhailkevich, Shashwat Sharad, Rishita Gupta, Oluwatosin Diaro, Kevin Babcock, Charles Xavier, Ahmed Mohamed, Muhammad Jamal, Shyh-Han Tan, Albert Dobi, Gyorgy Petrovics, Rockville, MD, Isabell Sesterhenn, Silver Spring, MD, David McLeod, Rockville, MD, Inger Rosner, Bethesda, MD, Shiv Srivastava, Rockville, MD

MP87-20 THERAPEUTIC TARGETING OF TRANSCRIPTIONAL REPRESSOR BCL-6 IN ENZALUTAMIDE-RESISTANT CASTRATION-RESISTANT PROSTATE CANCER
Hiroshi Hongo*, Takeo Kosaka, Yota Yasumizu, Yasumasa Miyazaki, Eiji Kikuchi, Akira Miyajima, Mototsugu Oya, Tokyo, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP88-01</strong></td>
<td>The Prognostic Value of Pre-Cystectomy Serum α-GLUTAMYLTRANSFERASE Levels in Patients with Invasive Bladder Cancer</td>
<td>Tina Schubert*, Manuel Alexander Schmid, Thomas Lütfrenk, Markus Renninger, Arnulf Stenzi, Georgios Gakis, Tuebingen, Germany</td>
</tr>
<tr>
<td><strong>MP88-02</strong></td>
<td>Expression of Class III Beta-Tubulin Predicts Prognosis in Cisplatin-Resistant Bladder Cancer Patients Receiving Paclitaxel-Based Second-Line Chemotherapy</td>
<td>Tomohiro Matsuo*, Yasuyoshi Miyata, Yuichiro Nakamura, Takuji Yasuda, Kojiro Ohba, Hideki Sakai, Nagasaki, Japan</td>
</tr>
<tr>
<td><strong>MP88-03</strong></td>
<td>Sequencing of a Cancer Cell Subpopulation Identifies Micrometastases in Bladder Cancer</td>
<td>Kris Prado*, Los Angeles, CA, Kelvin Zhang, Boston, MA, Matteo Pellegrini, Arnold Chin, Los Angeles, CA</td>
</tr>
<tr>
<td><strong>MP88-04</strong></td>
<td>The Adaptor Protein Crk-Induced Erbb2 Expression Promotes Tumor Progression and Metastasis of Bladder Cancer via Exosomes</td>
<td>Kazuhiro Yoshida*, Tokyo, Japan, Masumi Tsuda, Ryuji Matsumoto, Shingo Semba, Taichi Kimura, Mishie Tanino, Hiroshi Nishihara, Sapporo, Japan, Tsunenori Kondo, Kazunari Tanabe, Tokyo, Japan, Shinya Tanaka, Sapporo, Japan</td>
</tr>
<tr>
<td><strong>MP88-05</strong></td>
<td>Comprehensive Immune Transcriptomic Analysis in Bladder Cancer Reveals Subtype Specific Immune Gene Expression Patterns</td>
<td>D. Siemens*, Runhan Ren, Kathrin Tyryshkin, Madhuri Koti, Kingston, Canada</td>
</tr>
<tr>
<td><strong>MP88-06</strong></td>
<td>Nuclear Factor (NF)-κB Signals Promote Urothelial Tumorigenesis through the Androgen Receptor (AR) Pathway</td>
<td>Hiroki Ide*, Tokyo, Japan, Satoshi Inoue, Taichi Mizushima, Rochester, NY, Mototsugu Oya, Tokyo, Japan, Hiroshi Miyamoto, Rochester, NY</td>
</tr>
<tr>
<td><strong>MP88-07</strong></td>
<td>Androgen Receptor Activity Modulates Radiosensitivity in Bladder Cancer Cells</td>
<td>Hiroki Ide*, Tokyo, Japan, Satoshi Inoue, Taichi Mizushima, Rochester, NY, Mototsugu Oya, Tokyo, Japan, Hiroshi Miyamoto, Rochester, NY</td>
</tr>
<tr>
<td><strong>MP88-08</strong></td>
<td>Estrogen Receptor (ER)-β Signals Induce Urothelial Tumorigenesis via Down-Regulation of a Potential Tumor Suppressor</td>
<td>Hiroki Ide*, Tokyo, Japan, Satoshi Inoue, Rochester, NY, Kazutoshi Fujita, Suita, Japan, Yl Li, Rochester, NY, Takashi Kawahara, Yokohama, Japan, Eiji Kashiwagi, Fukuoka, Japan, Taichi Mizushima, Rochester, NY, Seiji Yamaguchi, Hiroaki Fushimi, Osaka, Japan, Mototsugu Oya, Tokyo, Japan, Norio Nonomura, Suita, Japan, Hiroshi Miyamoto, Rochester, NY</td>
</tr>
<tr>
<td><strong>MP88-09</strong></td>
<td>Androgen Receptor Activity Modulates Direct Cytotoxicity of Bacillus Calmette-Guerin (BCG) in Bladder Cancer Cells</td>
<td>Jinbo Chen*, Rochester, NY, Peng Li, Shandong, China, People’s Republic of, Taichi Mizushima, Rochester, NY, Bin Han, Shenyang, China, People’s Republic of, Satoshi Inoue, Rochester, NY, Hiroki Ide, Tokyo, Japan, Mehrsa Jalilizadeh, Baltimore, MD, Leonardo Reis, Campinas, Brazil, Hiroshi Miyamoto, Rochester, NY</td>
</tr>
<tr>
<td><strong>MP88-10</strong></td>
<td>Inhibition of Lim and Sh3 Domain Protein 1 Delays Cisplatin-Resistant Bladder Tumor Progression</td>
<td>Takashi Dejima*, Ario Takeuchi, Masaki Shioti, Masatoshi Eto, Fukuoka, Japan, Martin Gleave, Christopher Ong, Vancouver, Canada</td>
</tr>
</tbody>
</table>
MP88-12 CYTOTOXIC T LYMPHOCYTE CD8+, CD3+, AND IMMUNOSCORE AS PROGNOSTIC MARKER IN PATIENTS AFTER RADICAL CYSTECTOMY
Alice Yu*, Jose Joao Mansure, Shraddha Solanki, Fadi Brimo, Wassim Kassouf, Montreal, Canada

MP88-13 DOES AGGRESSIVENESS OF TUMOR STAGE CORRELATE WITH INTRAOPERATIVE PELVIC WASHINGS & PNEUMO-PERITONEUM DURING ROBOT-ASSISTED RADICAL CYSTECTOMY?
Youssef Ahmed*, Ahmed Hussein, Yingyu Ma, Victoria Cranwell, Gissou Azabdaftari, Wei Luo, Song Liu, Sean Glenn, Candace Johnson, Khurshid Guru, Buffalo, NY

MP88-14 EVALUATION OF E-CIGARETTES USERS URINE FOR KNOWN BLADDER CARCINOGENS
Thomas Fuller*, Abhinav Acharya, Godugu Bhaskar, Michelle Yu, Steven Little, Tatum Tarin, Pittsburgh, PA

MP88-15 DISTINCT EXOSOMAL miRNA PROFILES IN CHEMoresistant BLADDER CARCINOMA CELL LINES
Heba Fanous*, Travis Sullivan, Kimberly Rieger-Christ, Burlington, MA

MP88-16 TARGETED EXOSOME-MEDIATED DELIVERY OF SURVIVIN SIRNA FOR THE TREATMENT OF BLADDER CANCER
Rong Yang*, Xiang Yan, Shiwei Zhang, Hongqian Guo, Nanjing, China, People’s Republic of China

MP88-17 PATIENT DERIVED XENOGRAFTS OF UPPER TRACT UROTHELIAL CARCINOMA: A POTENTIAL TOOL FOR PERSONALIZED MEDICINE

MP88-18 A NOVEL, INTEGRATED GENE EXPRESSION AND DRUG SENSITIVITY APPROACH REVEALS UNIQUE SENSITIVITY OF SQUAMOUS CELL CARCINOMA-LIKE BLADDER CANCERS TO PI3K inhibitors AZD6482
Kevin Shee*, Hanover, NH, Kevin Koo, Lel S. Reinstatler, John D. Seignde, Todd W. Miller, Lebanon, NH

MP88-19 MIR-145 MODULATES WARBURG EFFECT BY TARGETING KLF4/PTB1/PKMS AXIS IN BLADDER CANCER CELLS.
Koichiro Minami*, Koei Taniguchi, Teruo Inamoto, Kyoshi Takehara, Kazumasa Komura, Tomoki Takai, Yuki Yoshikawa, Takatsuki, Japan, Yukihiro Aka, Gifu, Japan, Haruhito Azuma, Takatsuki, Japan

MP88-20 ESTABLISHMENT OF NOVEL MOUSE BLADDER CANCER CELL LINES MIMICKING INTRINSIC SUBTYPE OF HUMAN INVASIVE BLADDER CANCER
Ryoichi Saito*, Kyoto, Japan, Christoph Smith, Jordan Kardos, Lisa Bixby, Shengjie Chai, Jeffrey Damrauer, Takanobu Utsumi, Sara Wobker, Bhavani Krishnan, Chapel Hill, NC, Osamu Ogawa, Kyoto, Japan, Benjamin Vincent, William Kim, Chapel Hill, NC

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 15, 2017

Podium Session 60

TRAUMA/RECONSTRUCTION/DIVERSION: URETHRAL RECONSTRUCTION (INCLUDING STRICTURE, DIVERTICULUM) IV

Room 157 @ Boston Convention & Exhibition Center

Moderators: Frank Burks and Keith Rourke

ABSTRACT
TIME NUMBER TITLE
3:30 PD60-01 INCIDENCE AND PREDICTORS OF complications DUE TO URETHRAL STRicture IN PATIENTS AWAITING URETHROPLASTY
Hoy Nathan*, Nick Dean, Dave Chapman, Jon Witten, Keith Rourke, Edmonton, Canada

3:40 PD60-02 DELAY OF URETHROPLASTY IS ASSOCIATED WITH LONGER STRictures AND MORE Complicated Repairs
Boyd Viers*, Travis Pagliara, Charles Rew, Dallas, TX, Lauren Folgosa-Cooley, Richmond, VA, Christine Shiang, Jeremy Scott, Allen Morey, Dallas, TX

ABSTRACT
TIME NUMBER TITLE
3:50 PD60-03 PRE- AND POST-TREATMENT URETHROGRAMS SHOW THAT transcResTREATMENT TREATMENTS INCREASE THE COMPLEXITY OF URETHRAL STRictures
Akio Horiguchi*, Masayuki Shinchi, Keiici Ito, Ryuichi Azuma, Tomohiko Asano, Saitama, Japan

*Presenting author
4:00 PD60-04 PREDICTIVE FACTORS OF SUCCESS IN ADULT PATIENTS TREATED FOR URETHRAL STRICTURE AFTER PRIMARY HYPOSPADIAS REPAIR FAILURE: A MULTIVARIABLE ANALYSIS OF A SINGLE-SURGEON SERIES
Guido Barbagli, Arezzo, Italy, Nicola Fossati, Alessandro Larcher, Francesco Montorsi, Milano, Italy, Salvatore Sansalone, Roma, Italy, Denis Butnaru, Moscow, Russian Federation, Massimo Lazzeri*, Milano, Italy

4:10 PD60-05 DOUBLE FACED (INLAY AND ONLAY) BUCCAL MUCOSA URETHROPLASTY OFFERS BETTER LONG TERM RESULTS FOR LONG AND NARROW URETHRAL STRICTURES
Ashish Pardeshi*, Vijay Raghoji, Pune, India, Rajesh Rajendran, Tiruchirapally, India

4:20 PD60-06 DOUBLE FACED BUCCAL MUCOSAL GRAFT URETHROPLASTY FOR NEAR OBLITERATIVE INFLAMMATORY URETHRAL STRICTURE: A RETROSPECTIVE STUDY.
Prarthan Joshi*, Tarun Javali, Horahalli Nagaraj, S.M.L. Prakash Babu, Kuldeep Aggarwal, Arjun Nagaraj, Bangalore, India

4:30 PD60-07 OUTCOME OF DORSAL ONLAY BUCCAL MUCOSAL GRAFT VERSUS VENTRAL ONLAY LOCAL PENILE SKIN FLAP IN COMPLEX ANTERIOR URETHRAL STRICTURES: A PROSPECTIVE RANDOMIZED STUDY
Ahmed Tawakol, Mohammed Abdel-Rassoul*, Mohamed El-Ghoneimey, Mohamed El-Gammal, Cairo, Egypt

4:40 PD60-08 INVESTIGATION OF TRAUMATIC URETHRAL CATHETERIZATION AND EVALUATION OF A NOVEL SAFETY SYRINGE AFTER CORRELATING TRAUMA WITH URETHRAL DISTENSION AND CATHETER BALLOON PRESSURE: A PROSPECTIVE MULTI-INSTITUTIONAL STUDY.
Niall Davis*, Dublin, Ireland, Eoghan Cunnane, Limerick, Ireland, Mark Quinlan, Rustom Manecksha, John Thomhill, David Mulvin, Dublin, Ireland, Michael Walsh, Limerick, Ireland

4:50 PD60-09 ANALYSING 5-YEAR MEMOKATH OUTCOMES FOR MALIGNANT AND BENIGN URETERIC OBSTRUCTION: A PROPOSED UPDATE TO CLINICAL GUIDELINES

5:00 PD60-10 SUBSTITUTION URETHROPLASTY WITH CLOSURE VERSUS NON-CLOSURE OF THE BUCCAL MUCOSA GRAFT HARVEST SITE: FINAL RESULTS OF A RANDOMIZED CONTROLLED TRIAL WITH A DETAILED ANALYSIS OF PAIN AND MORBIDITY
Armin Soave*, Roland Dahlem, Hans Pinnenschmidt, Hamburg, Germany, Sascha Ahyai, Goettingen, Germany, Michael Rink, Jessica Langetepe, Oliver Engel, Luis Kluth, Philip Reiss, Margit Fisch, Hamburg, Germany

5:10 PD60-11 POPULATION-BASED MANAGEMENT OF MALE URETHRAL STRICTURE DISEASE
Robert Goldfarb*, Steven Brandes, New York, NY, Peter Kirk, Tudor Borza, Yongmei Qin, Ted Skolarus, Ann Arbor, MI

5:20 PD60-12 GERIATRIC URETHROPLASTY: LESSONS LEARNED FROM URETHRAL RECONSTRUCTION IN ELDERLY MEN
Boyd Viers*, Travis Pagliara, Charles Rew, Dallas, TX, Lauren Folgosa-Cooley, Richmond, VA, Christine Shiang, Jeremy Scott, Allen Morey, Dallas, TX

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD61-01</td>
<td>18F-FLUCICLOVINE PET/CT IN COMPARISON WITH 11C-CHOLINE PET/CT FOR NODAL STAGING IN PROSTATE CANCER PATIENTS: PRELIMINARY DIAGNOSTIC ACCURACY ANALYSIS Cristian Vincenzo Pultrone, Lorenzo Bianchi, Lucia Zanoni, Cristina Nanni, Francesca Giunchi, Michelangelo Fiorentino, Bologna, Italy, Angelo Porreca, Abano Terme (Padua), Italy, Marco Borghesi, Valerio Vagnoni, Stefano Fant, Riccardo Schiavi*, Eugenio Brunocilla, Bologna, Italy</td>
</tr>
<tr>
<td>3:40</td>
<td>PD61-02</td>
<td>68GA-PSMA PET/CT FOR DETECTION OF EARLY RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY WITH PSA VALUES UP TO 1NG/ML Tobias Maurer*, Charlotte Düwel, Berhard Haller, Jürgen E. Gschwend, Markus Schwaiger, Matthias Eiber, Munich, Germany</td>
</tr>
<tr>
<td>3:50</td>
<td>PD61-03</td>
<td>EVALUATION OF RECURRENT PROSTATE CANCER AFTER PRIMARY RADIATION THERAPY AS DEFINED BY PHOENIX CRITERIA BY 68GA-PSMA PET/CT Tobias Maurer*, Ingo Einspieler, Isabel Rauscher, Christoph Rischpler, Charlotte Düwel, Markus Krönke, Gregor Habi, Sabrina Dewes, Jürgen E. Gschwend, Hans-Jürgen Wester, Markus Schwaiger, Matthias Eiber, Munich, Germany</td>
</tr>
<tr>
<td>4:00</td>
<td>PD61-04</td>
<td>COMPARISON OF GLEASON UPGRADING RATES IN TRANSRECTAL ULTRASOUND SYSTEMATIC RANDOM BIOPSIES VERSUS US-MRI FUSION BIOPSIES FOR PROSTATE CANCER. Arie Carneiro, Paulo Kayano*, Tiago Castilho, São Paulo, Brazil, Arjun Sivaraman, New York, NY, Oliver Claros, Ary Neto, Renee Filippi, Ronaldo Baroni, Gustavo Lemos, São Paulo, Brazil</td>
</tr>
<tr>
<td>4:10</td>
<td>PD61-05</td>
<td>OUTCOMES OF REPEAT MRI-US FUSION-TARGETED BIOPSY IN MEN WITH INITIALLY LOW RISK OR NEGATIVE FUSION BIOPSY Xiaosong Meng*, Andrew Rosenkrantz, Fang-Ming Deng, Richard Huang, James Wysock, Marc Bjurtin, William C. Huang, Herbert Lepor, Samir S. Taneja, New York, NY</td>
</tr>
<tr>
<td>4:30</td>
<td>PD61-07</td>
<td>ACCURACY OF PREOPERATIVE MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING FOR PREDICTION OF UNFAVORABLE PATHOLOGY IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY Hakmin Lee, Ohseong Kwon*, Seoul, Korea, Republic of, Sangchul Lee, Sung Kyu Hong, Seok-Soo Byun, Seongnam, Korea, Republic of, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han-Yong Choi, Hyun Moo Lee, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>4:40</td>
<td>PD61-08</td>
<td>DOES GLEASON SCORE AT THE SITE OF POSITIVE SURGICAL MARGIN PREDICT RECURRENCE FOLLOWING RADICAL PROSTATECTOMY? Goran Rac*, Lawrence Dagrosa, Laura Spruill, Thomas Keane, Charleston, SC</td>
</tr>
<tr>
<td>4:50</td>
<td>PD61-09</td>
<td>INDEX TUMOR VOLUME ON MRI AS A PREDICTOR OF PATHOLOGIC OUTCOMES FOLLOWING RADICAL PROSTATECTOMY. Dordaneh Sugano*, Abhinav Sidana, Brian Calio, Sonia Gaur, Amit Jain, Mahir Manuf, Maria Merino, Peter Choyke, Baris Turkbey, Bradford Wood, Peter Pinto, Bethesda, MD</td>
</tr>
<tr>
<td>5:00</td>
<td>PD61-10</td>
<td>DOES THE NUMBER OF GLEASON 6 POSITIVE CORES ON PROSTATE BIOPSY PREDICT ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY IN PATIENTS WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE? François Audenet*, Emily Vertosick, Samson Fine, New York, Ny, Rafael Sanchez-Salas, Marc Galliano, Eric Barret, Xavier Cathelineau, François Roxet, Paris, France, James Eastham, Peter Scardino, Karim Touijer, New York, Ny</td>
</tr>
</tbody>
</table>
5:10  PD61-11  THE NEW EPSTEIN GLEASON SCORE CLASSIFICATION SIGNIFICANTLY REDUCES UPGRADING IN PROSTATE CANCER PATIENTS
Cosimo De Nunzio*, Giuseppe Simone, Costantino Leonardo, Riccardo Mastroianni, Rome, Italy, Devis Collura, Giovanni Muto, Turin, Italy, Michele Gallucci, Riccardo Lombardo, Carlo De Dominicis, Andrea Tubaro, Andrea Vecchione, Rome, Italy

5:20  PD61-12  IMPACT OF SURGICAL TECHNIQUE ON THE PERFORMANCE OF PELVIC LYMPH NODE DISSECTION AT RADICAL PROSTATECTOMY: RESULTS FROM A GERMAN MULTICENTER DATABASE
Alexander Winter*, Lutz Brautmeier, Oldenburg, Germany, Attyla Drabik, Münster, Germany, Tom Fischer, Mario Zacharias, Robert Kössler, Berlin, Germany, Björn Volkmer, Kassel, Germany, Jan Roigas, Berlin, Germany, Ulrich Witzsch, Frankfurt a.M., Germany, Holger Heidenreich, Manfred Beer, Berlin, Germany, Marcus Horstmann, Krefeld-Uerdingen, Germany, Wolfgang Stollhoff, Bendorf, Germany, Wolfgang Diedrichs, Berlin, Germany, Mika Lehsnau, Nauen, Germany, Mark Schrader, Steffen Weikert, Christian Klop, Berlin, Germany, Jan Fichtner, Oberhausen, Germany, Friedhelm Wawroschek, Oldenburg, Germany, Annette Reinecke, Berlin, Germany, Martin Schootak, Magdeburg, Germany, Kurt Miller, Berlin, Germany

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Monday, May 15, 2017 3:30 pm - 5:30 pm
Podium Session 62
BLADDER CANCER: INVASIVE VI
Room 162 @ Boston Convention & Exhibition Center
Moderators: John Gore and Eila Skinner

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>PD62-01</td>
<td>COMPARATIVE EFFECTIVENESS OF SELECTIVE ADJUVANT VERSUS SYSTEMATIC NEOADJUVANT CHEMOTHERAPY-BASED STRATEGY FOR MUSCLE- INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER</td>
</tr>
<tr>
<td>3:50</td>
<td>PD62-03</td>
<td>THE EFFECT OF INTRINSIC SUBTYPE ON RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:40</td>
<td>PD62-02</td>
<td>ADJUVANT CHEMOTHERAPY VS. OBSERVATION FOLLOWING RADICAL CYSTECTOMY FOR PT3-4 AND/OR PN+ UROTHELIAL CARCINOMA OF THE BLADDER PREVIOUSLY TREATED WITH NEOADJUVANT CHEMOTHERAPY</td>
</tr>
<tr>
<td>4:00</td>
<td>PD62-04</td>
<td>SAFETY AND EFFICACY GEMCITABINE-CISPLATIN SPLIT DOSE AS A NEOADJUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:10</td>
<td>PD62-05</td>
<td>NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER: DIFFERENCES IN CLINICAL AND PATHOLOGICAL RESPONSE</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:40</td>
<td>PD62-06</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00</td>
<td>PD62-07</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30</td>
<td>PD62-08</td>
<td></td>
</tr>
</tbody>
</table>

294
4:20  PD62-06  NEOADJUVANT CHEMOTHERAPY FOR ELDERLY PATIENTS WITH LOCALLY ADVANCED OR EARLY NODAL DISEASE: ARE WE DOING ENOUGH?
Andres Correa*, Elizabeth Handorf, Benjamin Ristau, Haifler Haifler, Shreyas Joshi, Robert Uzzo, Rosalia Viterbo, Richard Greenberg, David Chen, Alexander Kutikov, Daniel Geynisman, Marc Smaldone, Philadelphia, PA

4:30  PD62-07  UTILIZATION OF CHEMOTHERAPY AND RADIATION FOR MUSCLE INVASIVE UROTHELIAL CARCINOMA

4:40  PD62-08  CHANGES IN LEAN MUSCLE MASS ASSOCIATED WITH NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
Kalen Rimar*, Alexander Glaser, Edward Schaeffer, Joshua Meeks, Shilajit Kundu, Sarah Psutka, Chicago, IL

4:50  PD62-09  PATHOLOGICAL EXAMINATION EXTEMPORARY OF LYMPH NODES USING FROZEN SECTION (FS) DURING RADICAL CYSTECTOMY (RC) IS USEFUL TO SELECT PATIENTS WHO NEED SUPER EXTENDED LYMPH NODE DISSECTION (SE-LAD): RESULTS OF A PROSPECTIVE STUDY
Maurizio Brausi*, Giancarlo Peracchia, Giuseppe De Luca, Carpi, Italy

5:00  PD62-10  IDENTIFICATION OF MOLECULAR BIOMARKERS OF CISPLATIN-BASED CHEMOSENSITIVITY IN PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER

5:10  PD62-11  PREDICTIVE ROLE OF EPITHELIAL TUMOR MARKER LEVEL ELEVATION AT FOLLOW-UP FOR TUMOR RECURRENCE AND ONCOLOGICAL OUTCOMES IN UROTHELIAL BLADDER CANCER
Soroush T Bazargani*, Hooman Djaladat, Anne Schuckman, Gus Miranda, Jie Cal, Sarmad Sadeghi, Tanya Dorff, David Quinn, siamak Dameshmand, Los Angeles, CA

5:20  PD62-12  COMPARATIVE EFFECTIVENESS OF TRIMODAL THERAPY VERSUS Radical CYSTECTOMY FOR LOCALIZED MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
Thomas Seisen*, Maxine Sun, Stuart R. Lipsitz, Boston, MA, Firas Abdullah, Detroit, MI, Jeffrey J. Leow, Boston, MA, Mani Menon, Detroit, MI, Nicolas von Landenberg, Philipp Gild, Boston, MA, Morgan Rouprêt, Paris, France, Mark Preston, Lauren C. Harshman, Adam S. Kibel, Toni K. Choueiri, Quoc-Dien Trinh, Boston, MA

4:20  PD62-06  NEOADJUVANT CHEMOTHERAPY FOR ELDERLY PATIENTS WITH LOCALLY ADVANCED OR EARLY NODAL DISEASE: ARE WE DOING ENOUGH?
Andres Correa*, Elizabeth Handorf, Benjamin Ristau, Haifler Haifler, Shreyas Joshi, Robert Uzzo, Rosalia Viterbo, Richard Greenberg, David Chen, Alexander Kutikov, Daniel Geynisman, Marc Smaldone, Philadelphia, PA

4:30  PD62-07  UTILIZATION OF CHEMOTHERAPY AND RADIATION FOR MUSCLE INVASIVE UROTHELIAL CARCINOMA

4:40  PD62-08  CHANGES IN LEAN MUSCLE MASS ASSOCIATED WITH NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
Kalen Rimar*, Alexander Glaser, Edward Schaeffer, Joshua Meeks, Shilajit Kundu, Sarah Psutka, Chicago, IL

4:50  PD62-09  PATHOLOGICAL EXAMINATION EXTEMPORARY OF LYMPH NODES USING FROZEN SECTION (FS) DURING RADICAL CYSTECTOMY (RC) IS USEFUL TO SELECT PATIENTS WHO NEED SUPER EXTENDED LYMPH NODE DISSECTION (SE-LAD): RESULTS OF A PROSPECTIVE STUDY
Maurizio Brausi*, Giancarlo Peracchia, Giuseppe De Luca, Carpi, Italy

5:00  PD62-10  IDENTIFICATION OF MOLECULAR BIOMARKERS OF CISPLATIN-BASED CHEMOSENSITIVITY IN PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER

5:10  PD62-11  PREDICTIVE ROLE OF EPITHELIAL TUMOR MARKER LEVEL ELEVATION AT FOLLOW-UP FOR TUMOR RECURRENCE AND ONCOLOGICAL OUTCOMES IN UROTHELIAL BLADDER CANCER
Soroush T Bazargani*, Hooman Djaladat, Anne Schuckman, Gus Miranda, Jie Cal, Sarmad Sadeghi, Tanya Dorff, David Quinn, siamak Dameshmand, Los Angeles, CA

5:20  PD62-12  COMPARATIVE EFFECTIVENESS OF TRIMODAL THERAPY VERSUS Radical CYSTECTOMY FOR LOCALIZED MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
Thomas Seisen*, Maxine Sun, Stuart R. Lipsitz, Boston, MA, Firas Abdullah, Detroit, MI, Jeffrey J. Leow, Boston, MA, Mani Menon, Detroit, MI, Nicolas von Landenberg, Philipp Gild, Boston, MA, Morgan Rouprêt, Paris, France, Mark Preston, Lauren C. Harshman, Adam S. Kibel, Toni K. Choueiri, Quoc-Dien Trinh, Boston, MA

Monday, May 15, 2017  Video Session 10
3:30 pm - 5:30 pm

**RECONSTRUCTION UPPER TRACT**

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 254 @ Boston Convention & Exhibition Center

**ABSTRACT NUMBER**
**TITLE**
V10-01  RECONSTRUCTION OF TWO CONCURRENT IPSILATERAL URETERAL STRICTURES WITH APPENDICEAL ONLAY AND NON-TRANSECTING URETERAL REIMPLANT

**ABSTRACT NUMBER**
**TITLE**
V10-02  ROBOTIC BUCCAL MUCOSAL URETEROPLASTY FOR URETERAL STRICTE AFTER ROBOTIC URETEROLYSIS
Chase Heilbron, Logan Campbell*, Mouafak Tourjman, Dan Pucheril, Lamont Jones, Craig Rogers, Detroit, MI

*Presenting author
V10-03 ROBOT ASSISTED BILATERAL URETERAL REIMPLANTATION ON STUDER NEOBLADDER WITH EXPOSURE OF ILIAC ARTERY PROSTHESIS
Joan Palou*, Lluís Gausa, Ivan Schwartzmann, Barcelona, Spain, Laura González Pérez, La Laguna, Spain, Juan Antonio Peña, Enver Moncada, Pablo Juárez del Dago, Humberto Villavicencio, Barcelona, Spain

V10-04 EARLY ROBOTIC REPAIR OF MULTIFOCAL URETERAL PERFORATION AFTER URETEROSCOPY
Andrew Radtke*, Kenneth Jacobsohn, Milwaukee, WI

V10-05 ROBOTIC SALVAGE PYELOPLASTY WITH BUCCAL MUCOSAL ONLAY GRAFT – A SIMPLIFIED TECHNIQUE
Ryan J. Nelson*, Anna Zampini, Jeremy Reece, Kenneth Angermeier, Georges-Pascal Haber, Cleveland, OH

V10-06 ROBOTIC-ASSISTED LAPAROSCOPIC CALYCEAL DIVERTICULECTOMY
Hugh Smith*, Nathan Jung, Juan Class, Amar Singh, Darryl Turner, Dana Butler, Chris Keel, Chattanooga, TN

V10-07 ROBOTIC REPAIR OF RIGHT URETERO-ILEAL ANASTOMOTIC STRicture FOLLOWING PRIOR ROBOTIC RADICAL CYSTECTOMY AND INTRACORPOREAL CONDUIT DIVERSION
Mehrdad Alemozaffar*, Atlanta, GA

V10-08 TOTAL LAPAROSCOPIC URETERAL SUBSTITUTION USING APPENDIX
Paulo Medeiros*, Cesar Britto, Daniel Ferreira, Mauricio Júnior, Rodolfo Alves, Ronnie Lima, Thiago Grossi, Carla Santos, John Heyder Galvão, Natal RN, Brazil

V10-09 TIPS FOR SURGICAL TECHNIQUE DURING ROBOTIC URETERAL RECONSTRUCTION FOR VARIOUS SEGMENTS OF URETER
Manish Patel*, Ashok Hemal, Winston Salem, NC

V10-10 COMBINATION OF ENDO-GIA WITH LAPAROSCOPIC PYELOPLASTY FOR THE TREATMENT OF A 19 YEAR-OLD MAN OF HORSESHOE KIDNEY WITH URETEROPELVIC JUNCTION OBSTRUCTION
Xuesong Li*, Kunlin Yang, Ligun Zhou, Beijing, China, People’s Republic of

V10-11 INTRACORPOREAL ROBOTIC-ASSISTED LAPAROSCOPIC APPENDICEAL INTERPOSITION FOR URETERAL STRicture DISEASE
Vidhush K Yarlagadda*, Jeffrey W Nix, J Patrick Selph, Birmingham, AL

V10-12 ROBOTIC (DA VINCI XI) URETERAL REIMPLANT WITH BOARI FLAP
John DiBianco*, Christopher Bayne, Washington, DC, Dan Su, Ami Klichevsky, Jeffery Sparenborg, Les Folio, Piyush Agarwal, Bethesda, MD

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Tuesday, May 16, 2017  Plenary: Next Frontier, Tuesday Morning Session  8:00 am - 11:30 am
Ballroom East @ Boston Convention & Exhibition Center

COMPLEX CASES

8:00  PROSTATE CANCER
Presenter:  Ian Thompson
Panelists:  Thomas Guzzo, Francesco Montorsi, Martha Terris, Christopher Warlick

8:30  COMPLICATIONS OF URINARY DIVERSIONS
Presenter:  Margit Fisch
Panelists:  Suzanne Merrill, Jeremy Myers, Andrew Peterson

8:50  MALIGNANCY IN TRANSPLANT PATIENTS
Presenter:  James McKiernan
Panelists:  Ronald Moore, Dicken Ko, Patrick Luke

9:10  BLADDER CANCER
Presenter:  Arthur Sagalowsky
Panelists:  Igor Frank, Kris Gaston, Jay Shah

9:30  STONES
Presenter:  Ben Chew
Panelists:  Brian Eisner, Silvia Proietti, Daron Smith

9:50  FEMALE UROLOGY
Presenter:  Gary Lemack
Panelists:  Stephen Kraus, Anne P. Cameron, John Stoffel

10:00  TRAUMA
Presenter:  Steven Brandes
Panelists:  Leo Doumanian, Jerilyn Latini, Bahaa Malaeb, Jay Simhan

11:00  AUDIENCE VIEWS AND VOTES ON TOP 3 AWARD WINNING VIDEO ABSTRACTS
11:30  SESSION CONCLUDES

Approved for AMA PRA Category 1 Credit™

Tuesday, May 16, 2017  Plenary: Next Frontier, Tuesday Afternoon Session  1:00 pm - 4:00 pm
Ballroom East @ Boston Convention & Exhibition Center

TAKE HOME MESSAGES

1:00  PROSTATE CANCER
Kirsten Greene

1:10  BASIC SCIENCE

1:20  TRAUMA/RECONSTRUCTION
Laura Leddy

1:30  ENDUROLOGY/STONES
Alana Desai

1:40  INFECTION/INFLAMMATION
Sarah Flury

1:50  IMAGING
Rose Khavari

2:00  INFERTILITY/ANDROLOGY
Cigdem Tanrikut

2:10  OUTCOMES
Emilie Johnson

2:20  SEXUAL DYSFUNCTION

2:30  PEDIATRICS
Audrey Rhee

2:40  PENILE/URETHRAL CANCER
Anne Schuckman

*Presenting author
2:50  KIDNEY CANCER
     Megan Merrill

3:00  BLADDER CANCER
     Angela Smith

3:10  TRANSPLANTATION
     Hannah Choate

3:20  FEMALE UROLOGY/INCONTINENCE
     Priya Padmanabhan

3:30  BPH/LUTS
     Doreen E. Chung

3:40  MINIMALLY INVASIVE SURGERY
     Rosalia Viterbo

3:50  QUALITY IMPROVEMENT & PATIENT SAFETY
     Kristin Chrouser

4:00  SESSION CONCLUDES

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Tuesday, May 16, 2017

Moderated Poster Session 89

INFERTILITY: THERAPY I

Moderators: Peter Kolettis, Jay Sandlow and Vincenzo Mirone

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP89-01</td>
<td>TIME TO IMPROVEMENT IN SEMEN ANALYSIS PARAMETERS AFTER VARICOCELECTOMY</td>
</tr>
<tr>
<td></td>
<td>Melissa St.Aubin*, Dane Johnson, Kate Cohen, Jay Sandlow, Milwaukee, WI</td>
</tr>
<tr>
<td>MP89-02</td>
<td>EFFICACY OF INDOCYANINE GREEN FLUORESCENCE ANGIOGRAPHY FOR ARTERIAL SPARING DURING MICROSURGICAL SUBINGUINAL VARICOCELECTOMY</td>
</tr>
<tr>
<td></td>
<td>Yasuhiro Shibata*, Sota Kurihara, Seiji Arai, Takeshi Miyao, Yoshiyuki Miyazawa, Yoshitaka Sekine, Hidekazu Koike, Kazuto Ito, Tetsuya Nakamura, Kazuhiro Suzuki, Maebashi, Japan</td>
</tr>
<tr>
<td>MP89-03</td>
<td>NORMAL PREOPERATIVE FOLLICLE-STIMULATING HORMONE LEVEL IS ASSOCIATED WITH IMPROVEMENT IN SEMEN PARAMETERS FOLLOWING MICROSURGICAL VARICOCELECTOMY</td>
</tr>
<tr>
<td></td>
<td>Lunan Ji*, Samuel A. Shabtaie, Nachiketh Soodana Prakash, Ranjith Ramaamam, Miami, FL</td>
</tr>
<tr>
<td>MP89-04</td>
<td>DOES GRADE MATTER? A SYSTEMATIC REVIEW OF THE IMPACT OF VARICOCELE GRADE ON RESPONSE TO TREATMENT.</td>
</tr>
<tr>
<td></td>
<td>Clark Judge*, New York, NY, Christopher Deibert, Omaha, NE, Doron Stember, Peter Stahl, New York, NY</td>
</tr>
<tr>
<td>MP89-05</td>
<td>THE ASSESSMENT OF HORMONE REPLACEMENT THERAPY SUCCESS DUE TO HYPOGONADOTROPHIC HYPOGONADISM</td>
</tr>
<tr>
<td></td>
<td>Emre Salabas*, Ebubekir Buyuk, Caner Bese, Mazhar Ortac, Ates Kadioglu, Istanbul, Turkey</td>
</tr>
<tr>
<td>MP89-06</td>
<td>PRESERVATION OF NORMAL CONCENTRATIONS OF PITUITARY GONADOTROPINS DESPITE ACHIEVEMENT OF NORMAL SERUM TESTOSTERONE LEVELS IN HYPOGONADAL MEN TREATED WITH A 4.5% NASAL TESTOSTERONE GEL</td>
</tr>
<tr>
<td></td>
<td>William Conners*, Abraham Morgentaler, Boston, MA, Margaux Guidry, Gerwin Westfield, Englewood, CO, Nathan Bryson, Mississauga, Canada, Irwin Goldstein, San Diego, CA</td>
</tr>
<tr>
<td>MP89-07</td>
<td>ARTIFICIAL REPRODUCTIVE TECHNIQUE OUTCOMES IN MALE HYPOGONODOTROPIC HYPOGONODISM REGARDING SPERM SOURCE</td>
</tr>
<tr>
<td></td>
<td>M. Murad Basar*, Caroline Pirkevi-Cetinkaya, Yesim Kumtepe-Colakoglu, Serkan Selimoglu, Semra Kahraman, ISTANBUL, Turkey</td>
</tr>
</tbody>
</table>
ULTRASONOGRAPHICALLY GUIDED PUNCTURE OF THE RETE TESTIS FOR SPERM RECOVERY IN NON-OBSTRUCTED AZOOSPERMIC MEN
Athanasios Zachariou*, Ioannina, Greece, Fotios Dimitriadis, Thessaloniki, Greece, Sotiris Skoulos, Ioannina, Greece, Panagiota Tsounapi, Yonago, Japan, Irene Matthaiou, Ioannina, Greece, Atsushi Takenaka, Yonago, Japan, Nikolaos Sofikitis, Ioannina, Greece

SALVAGE MTESE AFTER PREVIOUS FAILED MTESE: RESULTS AND PREDICTORS FOR SUCCESS.
Amr Moubasher*, Odunayo Kalejaiye, Giovanni Chiriacco, Marco Capece, Pippa Sangster, Amr Raheem, Nim Christopher, Asif Muneer, Giulio Garaffa, David Ralph, London, United Kingdom

CRITICAL ANALYSIS OF MEDICAL TREATMENT BEFORE SURGERY IN NON-OBSTRUCTIVE AZOOSPERMIA: A SYSTEMATIC REVIEW
Thiago Nunes*, Ricardo Saade, Campinas, Brazil, Edson Borges, Sao Paulo, Brazil

LOW SAMPLE VOLUME CASES HAVE HIGH SPERM RETRIEVAL RATES IN MICRODISSECTION TESTICULAR SPERM EXTRACTION.
Satoshi Nozaki*, Tomoki Takeda, Shoichiro Iwatsuki, Hamakawa Takashi, Kazumi Taguchi, Yasuhiro Fujii, Hiroti Kubota, Hiroyuki Kamiya, Yukihito Umemoto, Takahiro Yasui, Nagoya, Japan

EFFICACY OF TREATMENT WITH PSEUDOEPHEDRINE IN MEN WITH RETROGRADE EJACULATION
Nikita Abhyankar*, Chicago, IL, Ohad Shoshany, Tel Aviv, Israel, Jason Elyaguov, Syracuse, NY, Craig Niederberger, Chicago, IL

PRESENTATION AND TREATMENT OUTCOMES OF EJACULATORY DUCT OBSTRUCTION
Pippa Sangster*, Ayo Kalejaiye, Giovanni Chiriacco, Amr Raheem, Asif Muneer, David Ralph, London, United Kingdom

HYPERBARIC OXYGEN THERAPY IN THE TREATMENT OF ELEVATED LEVELS OF ACTIVE OXYGEN RADICALS IN THE SEMEN AND SPERM DNA FRAGMENTATION
Alexey Metelev, Andrey Bogdanov*, Evgeny Ivkin, Evgeny Veliev, Moscow, Russian Federation

PATIENT CHARACTERISTICS OF CHILDLESS MEN UNDERGOING VASECTOMY REVERSAL: RESULTS OF RETROSPECTIVE REVIEW
Christopher Corder*, Omaha, NE, Amy Perkins, Matthew Marks, Sheldon Marks, Tucson, AZ, Christopher Deibert, Omaha, NE

CHARACTERISTICS AND MOTIVATIONS OF MEN WHO SEEK VASECTOMY REVERSAL
John Sigalos*, Mark Hockenberry, Edgar Kirby, Jordan Krieger, Alexander Pastuszak, Larry Lipschultz, Houston, TX

MICROSCOPIC EVALUATION OF THE VASAL FLUID FOR SPERM AT THE TIME OF VASECTOMY REVERSAL – DO WE REALLY NEED TO CHECK?
Ethan Grober*, Sammi Tobe, Toronto, Canada

THE EFFECT OF FELLOWSHIP TRAINING ON OPERATIVE TIMES AND OUTCOMES FOR MICROSURGICAL CASES
Dane Johnson*, Raymond Roewe, Jay Sandlow, Milwaukee, WI

TIMING OF RETURN OF SPERM TO THE EJACULATE AND LATE FAILURES FOLLOWING VASECTOMY RECONSTRUCTION
Ryan Flannigan*, New York, NY, Phil V. Bach, New York, NY, Abimbola Ayangbesan, Andrew Gottesdiener, Marc Goldstein, New York, NY

TARGETED ROBOTIC ASSISTED MICROSURGICAL DENERVATION OF THE SPERMATIC CORD FOR THE TREATMENT OF CHRONIC SCROTAL CONTENT PAIN: SINGLE CENTER, LARGE SERIES REVIEW.
Nahomy Calixte*, Bayo Tojuola, Ibrahim Kartal, Ahmet Gudeloglu, Jamin Brahmbhatt, Sijo Parekattil, Clermont, FL

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
</table>
| MP90-01         | SUCCESSFUL DIABETIC CONTROL AS MEASURED BY HEMOGLOBIN A1C DECREASES URINE RISK FACTORS FOR URIC ACID CALCULI  
|                 | Kimberly A Maciolek*, Kristina L Penniston, Sara L Best, Madison, WI |
| MP90-02         | ORAL DISSOLUTION THERAPY (ODT) FOR LUCENT RENAL CALCULI; CAN WE PREDICT THE OUTCOME?  
| MP90-03         | INVESTIGATING SMART WATER BOTTLE TECHNOLOGY AS A CLINICAL TOOL FOR STONE FORMERS  
|                 | Michael S. Borofsky*, Minneapolis, MN, Casey A. Dauw, Ann Arbor, MI, Nadya E. York, Colin Terry, James E. Lingeman, Indianapolis, IN |
| MP90-04         | A NOVEL USE OF STRUCTURED WATER FOR THE PREVENTION OF RECURRENT STONES IN IDIOPATHIC HYPERCALCIURIA  
|                 | Ali Sami*, Suleimany, Iraq |
| MP90-05         | THE INS AND OUTS OF FLUID MANAGEMENT IN STONE FORMERS: THE IMPACT OF LOWER URINARY TRACT SYMPTOMATOLOGY ON URINE VOLUMES  
|                 | Nathan Hoy*, Jeremy Wu, Nicholas Dean, Timothy Wollin, Shubha De, Edmonton, Canada |
| MP90-06         | DOES THIAZIDE USE FOR STONE PREVENTION AFFECT OUR PATIENTS’ HEALTH-RELATED QUALITY OF LIFE?  
|                 | Eric Raffin*, Lebanon, NH, Kristina Penniston, Stephen Nakada, Madison, WI, Jodi Antonelli, Dallas, TX, Davis Viprakasit, Chapel Hill, NC, Timothy Averch, Pittsburgh, PA, Sri Sivalingham, Cleveland, OH, Roger Sur, San Diego, CA, Ben Chew, Vancouver, Canada, Vincent Bird, Gainesville, FL, Lawrence Dagrosa, Rebecca Smith, Vernon Pais, Lebanon, NH |
| MP90-07         | THE EFFECT OF POTASSIUM CITRATE ON THE HEALTH-RELATED QUALITY OF LIFE OF STONE FORMERS  
|                 | Eric Raffin*, Lebanon, NH, Kristina Penniston, Stephen Nakada, Madison, WI, Jodi Antonelli, Dallas, TX, Davis Viprakasit, Chapel Hill, NC, Timothy Averch, Pittsburgh, PA, Sri Sivalingham, Cleveland, OH, Roger Sur, San Diego, CA, Ben Chew, Vancouver, Canada, Vincent Bird, Gainesville, FL, Lawrence Dagrosa, Rebecca Smith, Vernon Pais, Lebanon, NH |
| MP90-08         | VARIABILITY IN STONE COMPOSITION AND METABOLIC EVALUATION BETWEEN KIDNEYS IN PATIENTS WITH BILATERAL NEPHROLITHIASIS  
|                 | Marcelino Rivera*, Indianapolis, IN, Michael Borofsky, Minneapolis, MN, Suzanne Kissel, Indianapolis, IN, Casey Dauw, Ann Arbor, MI, Nadya York, Amy Krambeck, James Lingeman, Indianapolis, IN |
| MP90-09         | THE METABOLIC SYNDROME AND ITS IMPACT ON CALCIUM OXALATE STONE TYPE  
|                 | Egor Parkhomenko*, Kathleen Kan, Timothy Tran, Julie Thai, Kyle Blum, Mantu Gupta, NY, NY |
| MP90-10         | THIOLA IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH BILATERAL VERSUS UNILATERAL CYSTINE STONE DISEASE  
|                 | Manint Usawachintachit*, Matthew Hudnall, Alexander Rifkind, David Tzou, Ryan Hsi, Benjamin Sherer, Marshall Stoller, Thomas Chi, San Francisco, CA |
| MP90-11         | POTASSIUM CITRATE INCREASES URINARY CITRATE MORE EFFECTIVELY WITHOUT ALTERING CALCIUM PHOSPHATE STONE RISK IN OBESE VS. NON-OBESE PATIENTS  
|                 | Kimberly A Maciolek*, Kristina L Penniston, Stephen Y Nakada, Sara L Best, Madison, WI |
| MP90-12         | DOES THE TIMING OF MAGNESIUM SUPPLEMENTATION AFFECT URINARY OXALATE LEVELS IN PATIENTS WITH NEPHROLITHIASIS?  
|                 | Omar Ayyash*, Timothy Averch, Michelle Semins, Pittsburgh, PA |
| MP90-13         | 24 HOUR URINE UTILIZATION IN NEPHROLITHIASIS TREATMENT: RESULTS FROM M-STONE (MULTICENTER COLLABORATION TO STUDY TREATMENT OUTCOMES IN NEPHROLITHIASIS EVALUATION)  
|                 | Jodi Antonelli*, Dallas, TX, Thomas Bentley, Sara Best, Stephen Nakada, Madison, WI, Chad Tracy, Lewis Thomas, Ryan Steinberg, Iowa City, IA, Tracy Marien, Nicole Miller, Nashville, TN, Adam Cohen, Elysha Kolitz, Xilong Li, Beverley Huet, Margaret Pearle, Yair Lotan, Dallas, TX |
| MP90-14         | DOES SATURATION INDEX PREDICT STONE ACTIVITY IN PATIENTS WITH CALCIUM OXALATE NEPHROLITHIASIS?  
<p>|                 | Noah Canvasser*, Aaron Lay, Elysha Kolitz, Beverley Huet, Xilong Li, John Poindexter, Jodi Antonelli, Margaret Pearle, Dallas, TX |</p>
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP91-01</td>
<td>ELECTROHYDRAULIC LOW-INTENSITY SHOCKWAVE THERAPY FOR PDE5I-REFRACTORY ERECTILE DYSFUNCTION: A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED STUDY</td>
</tr>
<tr>
<td></td>
<td>Jose Vinay*, Daniel Moreno, Alvaro Vives, Osvaldo Rajmil, Eduardo Ruiz-Castané, Josvany Sanchez-Curbelo, Barcelona, Spain</td>
</tr>
<tr>
<td>MP91-02</td>
<td>EFFECTS OF LOW-INTENSITY EXTRACORPOREAL SHOCK WAVE THERAPY ON ERECTILE DYSFUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
</tr>
<tr>
<td></td>
<td>Raul Clavijo*, Miami, FL, Taylor Kohn, Jaden Kohn, Houston, TX, Ranjith Ramasamy, Miami, FL</td>
</tr>
<tr>
<td>MP91-03</td>
<td>ROLE OF LOW-INTENSITY SHOCK WAVE THERAPY IN Penile Rehabilitation Post Nerve Sparing Radical Cystoprostatectomy: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP91-04</td>
<td>ADVERSE EFFECTS OF TESTOSTERONE REPLACEMENT THERAPY FOR MEN, A MATCHED COHORT STUDY</td>
</tr>
<tr>
<td></td>
<td>Julian Hanske*, Nicolas von Landenberg, Philipp Gild, Alexander P. Cole, Wei Jiang, Stuart R. Lipsitz, Martin N. Kathrins, Boston, MA, Peter Leam, Bethesda, MD, Mani Menon, Detroit, MI, Joachim Noldus, Herne, Germany, Maxine Sun, Quoc-Dien Trinh, Boston, MA</td>
</tr>
<tr>
<td>MP91-05</td>
<td>AEROBIC EXERCISE IS BETTER FOR INCREASING SERUM TESTOSTERONE LEVEL THAN STRENGTH EXERCISE IN PATIENTS WITH ERECTILE DYSFUNCTION</td>
</tr>
<tr>
<td></td>
<td>Min Gu Park*, Jung Kyun Yeo, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>MP91-06</td>
<td>INCREASED RISK OF HYPOGONADAL SYMPTOMS IN SHIFT WORKERS WITH SHIFT WORK SLEEP DISORDER</td>
</tr>
<tr>
<td></td>
<td>Will Kirby*, Adithya Balasubramanian, Javier Santiago, Mark Hockenberry, David Skutt, Taylor Kohn, Stephen Pickett, Asad Hasan, Alex Pastuszak, Larry Lipshultz, Houston, TX</td>
</tr>
</tbody>
</table>

*Presenting author
MP91-07 LONGTERM TREATMENT OF HYPOGONADAL MEN: RESULTS FROM A 9-YEAR-REGISTRY
Michael Zitzmann*, Julia Rohayem, Jann-Frederik Cremers, Eberhard Nieschlag, Muenster, Germany, Abdulmaged Traish, Boston, MA, Sabine Klesch, Muenster, Germany

MP91-08 COMBINATION OF METABOLIC SYNDROME COMPONENTS TO PREDICT TESTOSTERONE DEFICIENCY IN MEN
Eduardo P Miranda*, Carina Oliveira, Evanilda Carvalho, Alessandra Rabelo, Aline Xavier, Ricardo Tiraboschi, Victor Paschoalini, Jose Murillo Bastos-Netto, Cristiano Gomes, Jose Bessa Junior, Feira de Santana, Brazil

MP91-09 LOW PSA LEVEL IN MEN DIAGNOSED WITH PROSTATE CANCER PREDICTS TESTOSTERONE DEFICIENCY (TD)

MP91-10 TESTOSTERONE RECOVERY PROFILES AFTER CESSION OF ANDROGEN DEPRIVATION THERAPY (ADT)

MP91-11 POSITIVE EFFECTS OF LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) ON RENAL FUNCTION IN HYPOGONADAL MEN: REAL-LIFE DATA FROM A PROSPECTIVE CONTROLLED REGISTRY STUDY
Aksam Yassin*, Dany-Jan Yassin, Norderstedt-Hamburg, Germany, Gheorge Doros, Abdulmaged Traish, Boston, MA

MP91-12 ERECTILE FUNCTION IN 656 HYPOGONADAL MEN IMPROVES OVER 8 YEARS WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) IN COMPARISON TO AN UNTREATED CONTROL GROUP
Ahmad Haider*, Karim Sultan Haider, Bremerhaven, Germany, Gheorge Doros, Abdulmaged Traish, Boston, MA

MP91-13 THE ASSOCIATION BETWEEN TESTOSTERONE AND VITALITY: THE ROLE OF GENETIC VARIATION IN THE ANDROGEN RECEPTOR
Matthew Panizzon, Tung-Chin Hsieh*, Franz Carol, Richard Hauger, William Kremen, San Diego, CA

MP91-14 CARDIOVASCULAR DISEASE (CVD), HYPOGONADISM & ED: POSITIVE EFFECTS UNDER LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU)
Dany-Jan Yassin*, Akas Yassin, Norderstedt-Hamburg, Germany, Karim Haider, Ahmad Haider, Bremerhaven, Germany

MP91-15 CAN CONCOMITANT DUTASTERIDE REDUCE THE EFFECT OF TESTOSTERONE REPLACEMENT THERAPY IN MEN WITH LATE-ONSET HYPOGONADISM? A 24-WEEK, RANDOMIZED, PARALLEL STUDY
Hyun Jun Park*, Tae Nam Kim, Jong Kil Nam, Busan, Korea, Republic of, Du Geon Moon, Seoul, Korea, Republic of, Nam Cheol Park, Busan, Korea, Republic of

MP91-16 SAFETY AND EFFICACY RESULTS FROM THE PHASE-3, DOUBLE-BLIND, MULTICENTER STEADY TRIAL OF A NOVEL, PRE-FILLED, SUBCUTANEOUS AUTO-INJECTOR FOR TESTOSTERONE REPLACEMENT THERAPY
Jed Kaminetsky*, New York, NY, Christina Wang, Ronald Swerdloff, Torrance, CA, Andrew McCullough, Burlington, MA

MP91-17 DO REPEAT PROSTATE BIOPSIES IMPACT FUNCTIONAL OUTCOMES AFTER RADICAL PROSTATECTOMY? A LONG-TERM ANALYSIS OF 1015 PATIENTS
Marc-Alain Furrer*, Thomas von Ruette, George N. Thalmann, Daniel P. Nguyen, Bern, Switzerland

MP91-18 THE ROLE OF VACUUM ERECTION DEVICES IN PENILE REHABILITATION AFTER POSTERIOR URETHRAL ANASTOMOTIC URETHROPLASTY: A PILOT STUDY
Lujie Song*, Qiang Fu, Shanghai, China, People’s Republic of

MP91-19 NEOCLITORIS SIZE AND LOCATION: CAN THEY AFFECT TRANSEXUAL WOMEN SEXUAL FUNCTION? A PRELIMINARY PELVIC MRI STUDY.
Francesca Vedovo, Nicola Pavan*, Giovanni Liguori, Stefano Bucci, Michele Bertolotto, Carlo Trombetta, Trieste, Italy

MP91-20 A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL ASSESSING THE EFFECT OF TADALAFIL (CIALIS) ON THE CARDIOVASCULAR RESPONSE IN MEN WITH COMPLETE SPINAL CORD INJURY ABOVE THE SIXTH THORACIC LEVEL
Karen Ethans*, Alan Casey, Winnipeg, Canada, Mohamed Tarhoni, St. John’s, Canada

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP92-01</td>
<td>SAFETY AND EFFICACY OF POST-OPERATIVE EXTENDED-DURATION VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HIGH-RISK UROLOGIC ONCOLOGY PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Russell Terry*, Mohit Gupta, Michael Blute, Paul Crispen, Gainesville, FL</td>
</tr>
<tr>
<td>MP92-02</td>
<td>BPA ALERT EFFECT ON CAUTIS HOSPITAL-WIDE AT UIHC</td>
</tr>
<tr>
<td></td>
<td>Colette Gnade*, Douglas Storm, Patrick Ten Eyck, Iowa City, IA</td>
</tr>
<tr>
<td>MP92-03</td>
<td>TRANSVERSUS ABDOMINIS PLANE BLOCKADE AS PART OF A MULTIMODAL POSTOPERATIVE ANALGESIA PLAN IS ASSOCIATED WITH IMPROVED POSTOPERATIVE OUTCOMES IN RADICAL CYSTECTOMY PATIENTS</td>
</tr>
<tr>
<td></td>
<td>Richard Matulewicz*, Mehul Patel, Jacqueline Morano, Brendan Frainey, Yasin Bhanji, Anton Nader, Shilajit Kundu, Joshua Meeks, Chicago, IL</td>
</tr>
<tr>
<td>MP92-04</td>
<td>IMPROVEMENT OF INFORMED CONSENT IN UROLOGICAL SURGERIES: PORTABLE VIDEO MEDIA VERSUS STANDARD VERBAL COMMUNICATION. A RANDOMIZED CONTROLLED TRIAL</td>
</tr>
<tr>
<td></td>
<td>Sebastian Armijos León*, Federico Rodriguez-Rubio, Cadiz, Spain, Jorge Rioja Zuazu, Zaragoza, Spain, Virginia Sanchez Barrios, Guildford, United Kingdom, Juan González Caballero, Cádiz, Spain, Bandi Sanjeev, Brisbane, Australia, Elba Canelon, Cadiz, Spain</td>
</tr>
<tr>
<td>MP92-05</td>
<td>CALCULATING SURGICAL TIME FOR ROBOT-ASSISTED RADICAL CYSTECTOMY BASED ON PATIENT RELATED METRICS &amp; INSTITUTIONAL EXPERIENCE: RESULTS FROM THE INTERNATIONAL ROBOTIC CYSTECTOMY CONSORTIUM</td>
</tr>
<tr>
<td>MP92-06</td>
<td>ANALYSIS OF 30 DAY READMISSION TO AN ADULT UROLOGY SERVICE: ASSESSMENT OF RISK FACTORS AND BASIS FOR A QUALITY INDEX METRIC</td>
</tr>
<tr>
<td>MP92-07</td>
<td>TAKE NOTES: IDENTIFYING DRIVERS OF 30 DAY READMISSION AFTER RADICAL PROSTATECTOMY</td>
</tr>
<tr>
<td></td>
<td>Naveen Kachroo*, Daniel Pucherit, Detroit, MI, Tae Kim, Ji Qi, Anna Johnson, Ann Arbor, MI, Edward Schervish, St. Clair Shores, MI, Mani Menon, Detroit, MI, James Dupree, Ann Arbor, MI, James Peabody, Detroit, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI</td>
</tr>
<tr>
<td>MP92-08</td>
<td>RACIAL DISPARITY AND ADHERENCE TO QUALITY MEASURES FOR RADIATION THERAPY OF PROSTATE CANCER</td>
</tr>
<tr>
<td></td>
<td>Daniel Lee*, Joann Alvarez, Tatsuki Koyama, Matthew Resnick, David Penson, Daniel Barocas, Karen Hoffman, Ceasar Investigators, Nashville, TN</td>
</tr>
</tbody>
</table>

*Presenting author
MP92-09 IMPLICATIONS OF REGIONALIZING CARE IN THE DEVELOPING WORLD: IMPACT OF DISTANCE TO REFERRAL CENTER ON COMPLIANCE TO BIOPSY RECOMMENDATIONS IN A BRAZILIAN PROSTATE CANCER SCREENING COHORT
Alexis Freedland*, Los Angeles, CA, Cathrine Hoyo, Raleigh, NC, Elizabeth Turner, Patricia Moorman, Durham, NC, Roberto Muller, Eliney Faria, Gustavo Carvahal, Barretos, Brazil, Rodolfo Reis, Ribiero Prieto, Brazil, Edmundo Mauad, Andre Carvalho, Barretos, Brazil, Stephen Freedland, Los Angeles, CA

MP92-10 A RECTAL SWAB GUIDED PROPHYLAXIS PROGRAM ON THE INCIDENCE OF INFECTIOUS COMPLICATIONS FOLLOWING TRANS-RECTAL ULTRASOUND GUIDED PROSTATE BIOPSY AND FIDUCIAL MARKER PLACEMENT
Alexander Van Hoof, Nedim Ruhotina, Sarah Faisal, Bashar Omarbasha, Christopher Pieczonka, Yi Yang, David Albala*, Syracuse, NY

MP92-11 UTILIZATION OF RECTAL SWAB CULTURES PRIOR TO PROSTATE BIOPSY: AN INITIAL SURVEY TO ASSESS PRACTICE AND POSSIBLE BARRIERS TO USE
John Graham*, David Silver, Jeffrey Weiss, Brooklyn, NY, Michael Herman, Oceanside, NY

MP92-12 PROSPECTIVE MONITORING OF IMAGING GUIDELINE ADHERENCE IN A STATEWIDE SURGICAL COLLABORATIVE: USE OF STATISTICAL PROCESS METHODS
Michael Inadomi*, Yuqing Gao, Susan Linsell, Matthew Plumlee, Ann Arbor, MI, Patrick Hurley, Southfield, MI, James Montie, Khurshid R. Ghani, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP92-13 IMPROVING ACCESS TO CARE AND GUIDELINE COMPLIANCE IN A VETERANS AFFAIRS CYSTOSCOPY CLINIC
Conrad Tobert*, P. Joseph Guidos, Bradley Erickson, Kenneth Nepple, Iowa City, IA

MP92-14 FACTORS ASSOCIATED WITH STAGE AT PRESENTATION AND SURVIVAL IN PENILE CANCER
Solomon Woldu*, Ryan Hutchinson, Nirmish Singla, Boyd Viers, Laura-Maria Krabbe, Arthur Sagalowsky, Yair Lotan, Aditya Bagrodia, Vitaly Margulis, Dallas, TX

MP92-15 PREDICTING POST-OPERATIVE READMISSIONS IN PEDIATRIC UROLOGY BY USING THREE VALIDATED COMORBIDITY INDICES
Ruiyang Jiang*, Steven Wolf, J. Todd Purves, John S. Wiener, Jonathan C. Routh, Durham, NC

MP92-16 QUALITY IMPROVEMENT FOR UROLOGISTS: CURRICULAR KEYS FOR EDUCATING RESIDENTS (QUICKER)
Eugene Cone*, Durham, NC, Jonathan Bergman, Tannaz Moin, Los Angeles, CA, Ashley Wietsma, Durham, NC, Arlene Fink, Los Angeles, CA, B Price Kerfoot, Boston, MA, Charles Scales, Durham, NC

MP92-17 USE OF GUIDEWIRE DURING PLACEMENT OF PROPHYLACTIC URETERAL LOCALIZATION STENTS (PULSE) FOR COLORECTAL SURGERY (CRS) CASES DECREASES UROLOGIC-INDUCED OPERATIVE COMPLICATIONS
Ram Pathak*, Gregory Broderick, Kasey Cockerill, Ciara Boyne, Todd Igel, Raymond Pak, Steven Petrou, Paul Young, Ryan Frank, Nicolette Chimato, David Thiel, Jacksonville, FL

MP92-18 A STUDY OF UROLOGY RESIDENT SLEEP PATTERNS IN RELATION TO VOLUME AND CATEGORY OF OVERNIGHT PAGES IN A HOME CALL SYSTEM
Adam Ludvigson*, Gregory Mills, Stephen Ryan, Graham VerLee, Moritz Hansen, Portland, ME

MP92-19 NOVEL, NONTOXIC SKIN CARE FORMULATION ASSOCIATED WITH LOWER CAUTI RATES FOR HIGH-RISK ICU, NEURO, C-V AND TRAUMA PATIENTS WHEN USED FOR FOLEY CATHETER INSERTION AND MAINTENANCE
George Turini III*, Providence, RI, Joseph Renzulli II, Saunderstown, RI

MP92-20 FEMALE GENITAL MUTILATION AT A SAFETY-NET HOSPITAL IN DENVER, CO
Diedra Gustafson, Leticia Nogueira, Stephanie Gold, Elizabeth Berry, Rodrigo Donaldisio da Silva*, Fernando J. Kim, Denver, CO

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
**ABSTRACT**

**NUMBER** | **TITLE**
--- | ---
**MP93-01** | MODIFIED ANASTOMOSIS TECHNIQUE DURING ROBOT ASSISTED RADICAL PROSTATECTOMY: PREVENTION OF URETHRAL RETRACTION AND IMPROVEMENT OF EARLY CONTINENCE

Omer Burak Argun*, Mustafa Bilal Tuna, Tunkut Salim Dogancan, Ilter Tufek, Panagiotis Mounmours, Can Obek, Ali Riza Kural, Istanbul, Turkey

**MP93-02** | COMPARISON OF ONCOLOGICAL OUTCOMES BETWEEN OPEN VERSUS ROBOT-ASSISTED SALVAGE RADICAL PROSTATECTOMY: A RETROSPECTIVE MULTICENTRE SERIES.


**MP93-03** | NOMOGRAM PREDICTING BOWEL DYSFUNCTION FOR MEN WITH LOCALIZED PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY, EXTERNAL-BEAM RADIOTHERAPY, OR BRACHYTHERAPY

Joseph Zabel*, Joseph Klink, Cleveland, OH, Mark Litwin, Los Angeles, CA, Martin Sanda, Atlanta, GA, Meredith Regan, Boston, MA, Christopher Saigal, Lorna Kwan Herbert, Los Angeles, CA, Tianming Gao, Eric Klein, Michael Kattan, Andrew J. Stephenson, Cleveland, OH

**MP93-04** | THE RISK OF URINARY RETENTION FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND ITS IMPACT ON EARLY CONTINENCE OUTCOMES

Mansour Alnazari*, Marc Zanaty, Pierre-Alain Hueber, Emad Rajih, Assad El-Hakim, Kevin C. Zorn, Montreal, Canada

**MP93-05** | COMPARISON OF FUNCTIONAL OUTCOMES BETWEEN LAPAROSCOPIC RADICAL PROSTATECTOMY AND ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY: A PROPENSITY SCORE-MATCHED COMPARISON STUDY

JaYoon Ku*, ChanHo Lee, KyungHwan Kim, Pusan, Korea, Republic of, Sang Don Lee, Moon Kee Chung, Yangsan, Korea, Republic of, HongKoo Ha, Pusan, Korea, Republic of

**MP93-06** | TECHNICAL FACTORS PREVENTING FULL NERVE SPARING DURING ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY IN PATIENTS THAT ARE CANDIDATES FOR FULL NERVE SPARING

Harirhanar Palayapalayam Ganapathi*, Gabriel Ogaya-Pinies, Eduardo Hernandez, Travis Rogers, Tracey Woodlief, Vipul Patel, Celebration, FL

**MP93-07** | HOSPITAL STAY IS PREDICTIVE OF FUNCTIONAL OUTCOME AFTER SURGERY FOR HIGH RISK OR CT3 PROSTATE CANCER


**MP93-08** | INTERPRETING PATIENT-REPORTED URINARY AND SEXUAL FUNCTION OUTCOMES ACROSS MULTIPLE VALIDATED INSTRUMENTS

Emily Vertosick, Andrew Vickers*, New York, NY, Janet Cowan, Jeanette Broering, Peter Carroll, Matthew Cooperberg, San Francisco, CA

**MP93-09** | PREDICTORS OF MEMBRANOUS URETHRAL LENGTH MEASUREMENT PRIOR TO RADICAL PROSTATECTOMY

Sean Mungovan*, Westmead, Australia, Petra Graham, Sydney, Australia, Jaspreet Sandhu, Oguz Akin, New York, NY, Manish Patel, Westmead, Australia

**MP93-10** | URINARY, BOWEL, AND SEXUAL FUNCTION AT 2 YEARS FOLLOWING MANAGEMENT OF LOCALIZED PROSTATE CANCER

Shreep Agrawal*, Anna Zampini, Bradley Gill, Sudhir Isharwal, Joseph Zabell, Yaw Nyame, JJ Hailing Zhang, Eric Klein, Andrew J Stephenson, Cleveland, OH

*Presenting author
MP93-11 EVALUATION OF FUNCTIONAL AND ONCOLOGIC OUTCOMES AFTER ROBOTIC RADICAL PROSTATECTOMY: VALIDATION OF THE PROPOSED SURVIVAL, CONTINENCE, AND POTENCY (SCP) SYSTEM
Nicole Dodge, Alexandr Pinkhasov, Ruben Pinkhasov*, Aarti Agarwal, Gaybrielle James, Elena Pop, James Mohler, Buffalo, NY

MP93-12 PROSTATE CANCER IN MEN YOUNGER THAN 55: RATES OF FUNCTIONAL RECOVERY POST-ROBOTIC ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY
Tracey Woodlief*, Hariharan Ganapathi, Gabriel Ogaya-Pinies, Eduardo Hernandez, Travis Rogers, Vipul Patel, Celebration, FL

MP93-13 EXPLORING POSITIVE SURGICAL MARGINS AFTER MINIMALLY INVASIVE RADICAL PROSTATECTOMY: DOES BODY HABITUS REALLY MAKE A DIFFERENCE?
Simone Albisinni*, Julien Grosman, Fouad Aoun, Thierry Quackels, Alexandre Peltier, Roland van Velthoven, Thierry Roumeguère, Bruxelles, Belgium

MP93-14 EXTRAPERITONEAL VS. TRANSPERITONEAL ROBOT-ASSISTED RADICAL PROSTATECTOMY IN THE MORBIDLY OBESE
David Horovitz*, Hao Sun, Changyong Feng, Edward Messing, Jean Joseph, Rochester, NY

MP93-15 FEASIBILITY OF A WEIGHT MANAGEMENT PROGRAM TAILORED FOR OVERWEIGHT MEN WITH LOCALIZED PROSTATE CANCER: A PILOT STUDY
Meredith Metcalf*, Cole Chana, Lauren Hand, Abigail Stanley, Misty Bechtel, Prabhakar Chalise, Tanner Isaacson, Debra K. Sullivan, Jennifer Klemm, Christie Befort, J. Brantley Thrasher, Jill M. Hamilton-Reeves, Kansas City, KS

MP93-16 IMPACT OF OBESITY ON PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY
Vidit Sharma*, Mary E Westerman, Michele Colicchia, Alessandro Morlacco, Matthew K. Tollefsen, Stephen A Boatian, R. Houston Thompson, Igor Frank, Matthew T Gettman, R. Jeffrey Karnes, Rochester, MN

MP93-17 ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS SUBMITTED TO EXTRAPERITONEAL ENDOSCOPIC RADICAL PROSTATECTOMY (EERP) AND TRANSPERITONEAL ENDOSCOPIC RADICAL PROSTATECTOMY (TERP) WITH EXTENDED PELVIC LYMPH NODE DISSECTION
Sebastian Piotrowicz*, Lkasz Nyk, Mieszko Kozikowski, Jan Powrożik, Jakub Dobruch, Otwock, Poland

MP93-18 Cavernous Nerve Reconstruction by Processed Nerve Allograft During Robot-Assisted Radical Prostatectomy

MP93-19 PROSTATE MRI PRIOR TO PROSTATECTOMY DOES NOT IMPACT SURGICAL OUTCOMES
Eric Kim*, Joel Vetter, Michael Glamore, Seth Strope, Robert Grubb III, Gerald Andriole, St. Louis, MO

MP93-20 TUMOR CONTACT LENGTH WITH PROSTATE CAPSULE ON MAGNETIC RESONANCE IMAGING AS A POTENTIAL PREDICTOR FOR BIOCHEMICAL RECURRENCE AFTER ROBOTIC-ASSISTED RADICAL PROSTATECTOMY
Kazumi Kamoi*, Koji Okihara, Fumiya Hongo, Yasuyuki Naitoh, Atsuko Iwata, Motohiro Kanazawa, So Ushijima, Osamu Ukimura, Kyoto, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP94-01</td>
<td>PROTECTIVE EFFECT OF PLATELET-RICH PLASMA ON URETHRAL STRICTURE MODEL OF MALE RATS</td>
</tr>
<tr>
<td>MP94-02</td>
<td>ANALYSIS OF INTRAVESICAL HYALURONIC ACID EFFECTIVENESS ON AVOIDING THE DEVELOPMENT OF ACTINIC CYSTITIS IN PATIENTS DURING PELVIC RADIATION THERAPY</td>
</tr>
<tr>
<td>MP94-03</td>
<td>ANTI-VEGF TREATMENT DECREASES BLADDER PAIN IN CYCLOPHOSPHAMIDE CYSTITIS IN MICE</td>
</tr>
<tr>
<td>MP94-04</td>
<td>MECHANICAL CHARACTERISATION AND RUPTURE PRESSURE OF HUMAN URETHRAS: A FEASIBILITY STUDY PERFORMED IN EXPLANTED TISSUE FROM PATIENTS UNDERGOING GENDER REASSIGNMENT SURGERY</td>
</tr>
<tr>
<td>MP94-05</td>
<td>CHRONIC RAT MODEL FOR TESTING NEW THERAPIES FOR STRESS URINARY INCONTINENCE</td>
</tr>
<tr>
<td>MP94-06</td>
<td>MORPHOLOGICAL AND FUNCTIONAL RESTORATION COMPARISON BETWEEN A NOVEL BILAYER CHITOSAN AND BLADDER ACELLULAR MATRIX GRAFT AS SCAFFOLDS IN A RAT BLADDER AUGMENTATION MODEL.</td>
</tr>
<tr>
<td>MP94-07</td>
<td>PATIENTS WITH NOCTURNAL POLYURIA PRESENTED A DIFFERENT NIGHT-TIME AND DAY-TIME BLADDER CAPACITY: IMPLICATION FOR NOCTURIA</td>
</tr>
<tr>
<td>MP94-08</td>
<td>GROUP III METABOTROPIC GLUTAMATE RECEPTOR-MEDIATED REGULATION OF MICTURITION REFLEX IN URETHANE-ANESTHETIZED RATS</td>
</tr>
<tr>
<td>MP94-09</td>
<td>ROLE OF THE SEROTONERGIC SYSTEM IN URETHRAL CONTINENCE REFLEXES DURING SNEEZING IN RATS</td>
</tr>
<tr>
<td>MP94-10</td>
<td>THE VISCOELASTIC, REVERSIBLY PLASTIC, BEHAVIOR OF DETRUSOR SMOOTH MUSCLE EXPLAINS BLADDER HIGH COMPLIANCE.</td>
</tr>
<tr>
<td>MP94-11</td>
<td>AUTOPHAGY, APOPTOSIS AND CELL PROLIFERATION IN EXTROPHY-EPISPADIAS COMPLEX</td>
</tr>
<tr>
<td>MP94-12</td>
<td>BLADDER OUTLET OBSTRUCTION INDUCED REMODELING OF EXTRACELLULAR MATRIX OF HUMAN BLADDER SMOOTH MUSCLE CELLS VIA IL-6</td>
</tr>
<tr>
<td>MP94-13</td>
<td>THE EFFECT OF FREE RADICAL SCAVENGER ON THE OXIDATION STRESS IN PARTIAL BLADDER OUTLET OBSTRUCTION AND ITS RELIEF IN RAT MODEL</td>
</tr>
<tr>
<td>MP94-14</td>
<td>URODYNAMIC EVALUATION OF DA-8010 IN CONSCIOUS RATS WITH PARTIAL BLADDER OUTLET OBSTRUCTION</td>
</tr>
</tbody>
</table>

*Presenting author
MP94-15 MUSCARINIC M₂- AND M₃- RECEPTOR-ACTIVATED SIGNALING IN THE BLADDER IS INVERSELY REGULATED BY CAVEOLAE.
Vivian Cristofaro*, Maryrose P. Sullivan, Boston, MA

MP94-16 OXIDATIVE STRESS-RELATED ALTERATIONS IN THE BLADDER OF A SHORT-PERIOD DIABETES TYPE-2 RAT MODEL.
Panagiota Tsounapi*, Masashi Honda, Yonago, Japan, Fotios Dimitriadis, Ioannina, Greece, Yusuke Kimura, Yonago, Japan, Shogo Shimizu, Nankoku, Japan, Bunya Kawamoto, Katsuya Hikita, Yonago, Japan, Motoaki Saito, Nankoku, Japan, Nikolaos Sofikitis, Ioannina, Greece, Atsushi Takenaka, Yonago, Japan

MP94-17 DYNAMIC IMAGING OF URINE FLOW AT BLADDER NECK IN RABBIT DURING VOIDING USING TRACER BY WIRELESS CAPSULE ENDOSCOPE
Tokunori Yamamoto*, Hideki Mizuno, Nagoya, Japan, Shigehiro Soh, Koshigaya, Japan, Yasuhiro Funahashi, Yoshihisa Matsukawa, Masanori Nakamura, Momokazu Gotoh, Nagoya, Japan

MP94-18 UROTHELIAL CELLS EXPRESS A FUNCTIONAL SUCCINATE RECEPTOR GPR91
Abubakr Mossa, Monica Velasquez-Flores, Philippe Cammisotto, Lysanne Campeau*, Montreal, Canada

MP94-19 A POTENTIAL NOVEL MECHANISM FOR DETRUSOR UNDER-ACTIVITY MEDIATED BY MYOSIN LIGHT CHAIN PHOSPHORYLATION AND AMP-DEPENDENT KINASE
Randy Vince*, Ramanan Remesh, John Speich, Adam Klausner, Amy Miner, Paul Ratz, Richmond, VA

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Tuesday, May 16, 2017 7:00 am - 9:00 am
Podium Session 63
TRAUMA/RECONSTRUCTION/DIVERSION: EXTERNAL GENITALIA RECONSTRUCTION AND UROTRAUMA (INCLUDING TRANSGENDER SURGERY) II
Room 157 @ Boston Convention & Exhibition Center
Moderators: Steven Brandes, Arnulf Stenzl and Lee Zhao

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD63-01</td>
<td>SEVERE PENILE INJURIES SUSTAINED DURING OPERATIONS IRAQI AND ENDURING FREEDOM: EVALUATING THE TOUGH COHORT FOR PENILE TRANSPLANTATION</td>
</tr>
<tr>
<td>Steve Hudak*, Judson Janak, Jean Orman, Michael Davis, San Antonio, TX</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:10</td>
<td>PD63-02</td>
<td>COMPLIANCE WITH AUA GUIDELINES WITH EXCRETORY PHASE IMAGING FOR EVALUATION OF HIGH-GRADE RENAL TRAUMA: RESULTS FROM THE AMERICAN ASSOCIATION FOR SURGERY OF TRAUMA (AAST) GENITOURINARY TRAUMA STUDY</td>
</tr>
<tr>
<td>Brandi Miller*, Detroit, MI, Sorena Keihani, Salt Lake City, UT, Brian P. Smith, Patrick M. Reilly, Philadelphia, PA, Xian Luo-Owen, Kaushik Mukherjee, Loma Linda, CA, Bradley J. Morris, Sarah Majercik, Murray, UT, Peter B. Thomsen, Bradley A. Erickson, Iowa City, IA, Benjamin N. Breyer, Gregory Murphy, San Francisco, CA, Richard A. Santucci, Detroit, MI, Timothy Hewitt, Frank N. Burks, Royal Oak, MI, Erik S. DeSoucy, Scott A. Zakaluzny, Sacramento, CA, LaDonna Allen, Jurek F. Kocik, Tyler, TX, Raminder Nirula, Jeremy B. Myers, Salt Lake City, UT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
7:30 PD63-04 ROLE OF REPEAT IMAGING IN RENAL TRAUMA MANAGEMENT: RESULTS OF A FRENCH MULTICENTRIC STUDY (TRAUMAFUF)

7:40 PD63-05 BLUNT RENAL TRAUMA: VALIDATION OF A CONSERVATIVE FOLLOW-UP IMAGING STRATEGY

7:50 PD63-06 NONOPERATIVE MANAGEMENT HAS SIGNIFICANTLY INCREASED FOR BOTH BLUNT AND PENETRATING RENAL TRAUMA: DATA FROM THE NATIONAL TRAUMA DATA BANK
Marc Colaco*, Winston-Salem, NC, Susan MacDonald, Hershey, PA, Ryan Terlecki, Winston-Salem, NC

8:00 PD63-07 PERINEPHRIC HEMATOMA SIZE IS INDEPENDENTLY ASSOCIATED WITH THE NEED FOR UROLOGIC INTERVENTION IN BLUNT RENAL TRAUMA
Logan Zemp*, Uday Mann, Keith Rourke, Edmonton, Canada

8:10 PD63-08 EARLY MOBILIZATION IS SAFE AFTER RENAL TRAUMA: A MULTICENTER STUDY

8:20 PD63-09 POSTOPERATIVE COMPLICATIONS FOLLOWING PRIMARY PENILE INVERSION VAGINOPLASTY AMONG 330 MALE-TO-FEMALE TRANSGENDER PATIENTS
Thomas Gaither*, Mohannad Awad, San Francisco, CA, E. Charles Osterberg, Austin, TX, Gregory Murphy, San Francisco, CA, Angelita Romero, Marci Bowers, Burlingame, CA, Benjamin Breyer, San Francisco, CA

8:30 PD63-10 ONE-STAGE GENDER CONFIRMATION SURGERY (METOIDIOLAPLASTY) FOR FEMALE-TO-MALE TRANSEXUALS
Marta Bizic, Borko Stojanovic, Vladimir Kojovic, Miroslav Djordjevic*, Belgrade, Serbia

8:40 PD63-11 SURGICAL AND FUNCTIONAL OUTCOMES FOLLOWING ADULT BURIED PENIS REPAIR WITH LIMITED SUPRAPUBIC PANNICULECTOMY AND SPLITTTHICKNESS SKIN GRAFTING
Lindsay Hampson*, San Francisco, CA, Wade Muncey, C.C. Ma, Jeffrey Friedrich, Hunter Wessells, Bryan Voelzke, Seattle, WA

8:50 PD63-12 EXCISION AND PRIMARY ANASTOMOSIS RECONSTRUCTION FOR TRAUMATIC STRICTURES OF THE PENILE URETHRA
Boyd Viers*, Billy Cordon, Travis Pagliara, Jeremy Scott, Dallas, TX, Noel Armenakas, New York, NY, Allen Morey, Dallas, TX

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD64-01</td>
<td>THE NEUROGENIC BLADDER SYMPTOM SCORE (NBSS): AN ASSESSMENT OF ITS EXTERNAL VALIDITY AND ABILITY TO DETECT CHANGE</td>
<td>Blayne Welk*, London, Canada, Sara Lenherr, Salt Lake City, UT, Sean Elliott, Minneapolis, MN, John Stoffel, Ann Arbor, MI, Angela Presson, Chong Zhang, Salt Lake City, UT, Richard Baverstock, Kevin Carlson, Calgary, Canada, Jeremy Myers, Salt Lake City, UT</td>
</tr>
<tr>
<td>7:10</td>
<td>PD64-02</td>
<td>IS NEUROGENIC BLADDER A RISK FACTOR FOR FEBRILE URINARY TRACT INFECTION AFTER URETEROSCOPY, AND IF SO, WHY?</td>
<td>Craig Stauffer*, Elizabeth Snyder, Tin Ngo, Chris Elliott, Palo Alto, CA</td>
</tr>
<tr>
<td>7:20</td>
<td>PD64-03</td>
<td>DEMONSTRATION OF LEVATOR ANI EMG ACTIVITY BELOW THE LEVEL OF INJURY IN COMPLETE SPINAL CORD INJURY (SCI) USING OVER GROUND ROBOTIC EXOSKELETON WALKING</td>
<td>Lynn Stothers*, Chisholm Amanda, Raid Alamro, A Williams, Tania Lam, Vancouver, Canada</td>
</tr>
<tr>
<td>7:30</td>
<td>PD64-04</td>
<td>QUALITY OF LIFE ASSOCIATED WITH BLADDER MANAGEMENT STRATEGY AFTER SPINAL CORD INJURY</td>
<td>Shyam Sukumar*, Minneapolis, MN, Sara Lenherr, Jeremy Myers, Darshan Patel, Salt Lake City, UT, Ronak Gor, Minneapolis, MN, Amitabh Jha, Angela Presson, Chong Zhang, Jeffrey Rosenbluth, Salt Lake City, UT, John Stoffel, Ann Arbor, MI, Blayne Welk, London, Canada, Sean Elliott, Minneapolis, MN</td>
</tr>
<tr>
<td>7:40</td>
<td>PD64-05</td>
<td>SWITCH TO ABOBOTULINUM TOXIN A MAY BE USEFUL IN THE TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY WHEN INTRADETRUSOR INJECTIONS OF ONABOTULINUM TOXIN A FAILED</td>
<td>Benoit Peyronnet*, Rennes, France, Florie Bottel, Romain Boissier, Marseille, France, Andrea Manunta, Rennes, France, Benédicte Reiss, Nantes, France, Jean-Gabriel Previnaire, Berck, France, Jacques Kerdraon, Rennes, France, Alain Ruffion, Lyon, France, Loïc Lenormand, Brigitte Perrouin-Verbe, Nantes, France, Sarah Gaïlet, Marseille, France, Xavier Gamé, Toulouse, France, Gilles Karsenty, Marseille, France</td>
</tr>
<tr>
<td>7:50</td>
<td>PD64-06</td>
<td>MULTI-INSTITUTIONAL EXPERIENCE WITH ONABOTULINUMTOXIN-A IN PATIENTS WITH PRIOR AUGMENTATION CYSTOPLASTY</td>
<td>Laura Martinez*, Houston, TX, Ryan Tubre, Kansas City, KS, Robyn Roberts, Galveston, TX, Timothy Boone, Julie Steward, Houston, TX, Tomas Griebing, Kansas City, KS, Rose Khavari, Houston, TX, Priya Padmanabhan, Kansas City, KS</td>
</tr>
</tbody>
</table>
8:10 PD64-08 CAN WE AVOID BLADDER AUGMENTATION IN CASE OF FAILURE OF A FIRST INTRADETRUSOR BOTULINUM TOXIN INJECTIONS IN PATIENTS WITH SPINAL DYSRAPHISM?

8:30 PD64-10 LONG TERM OUTCOME FOLLOWING BLADDER NECK ARTIFICIAL URINARY SPHINCTER IMPLANTATION
Simon Bugeja*, Stella Ivaz, Stacey Frost, Mariya Dragova, Daniela E Andrich, Anthony R Mundy, London, United Kingdom

8:40 PD64-11 NEW NOVEL CHRONIC TIBIAL NEUROMODULATION (CTNM) TREATMENT OPTION FOR OAB SIGNIFICANTLY IMPROVES URGENCY (UI)/URGE INCONTINENCE (UUI) AND NORMALIZES SLEEP PATTERNS
Karl-Dietrich Sievert*, Lilliana Milinovic, Esra Foditch, Salzburg, Austria, Stefan DeWachter, Antwerp, Belgium, Anne Roggenkamp, Salzburg, Austria, Thomas Kessler, Zurich, Switzerland

8:50 PD64-12 URODYNAMIC FINDINGS OF PATIENTS WITH BRAIN TUMOR CLASSIFIED BY LOCATION OF AFFECTED AREA
Hee Seo Son*, Mark Benson Gamo, Jongsoo Lee, Jong Won Kim, Seoul, Korea, Republic of, Sang-Hyeon Cheon, Ulsan, Korea, Republic of, Ju Tae Seo, Jang Hwan Kim, Seoul, Korea, Republic of

*Presenting author

8:20 PD64-09 LONG-TERM OUTCOME OF ADENOSINE A2A RECEPTOR ANTAGONIST ON LOWER URINARY TRACT SYMPTOMS IN MALE PARKINSON’S DISEASE PATIENTS
Takeya Kitta*, Ichiro Yabe, Yukiko Kanno, Ouchi Mifuka, Kimihiko Moriya, Ikuko Takahashi, Masaaki Matsushima, Hidenao Sasaki, Nobuo Shinohara, Sarporo, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
Tuesday, May 16, 2017

Podium Session 65

PROSTATE CANCER: MARKERS II
Room 162 @ Boston Convention & Exhibition Center
Moderators: Kirsten Greene and J. Brantley Thrasher

**ABSTRACT**

**PD65-01**
GERMLINE MUTATIONS IN THE KALLIKREIN 6 REGION AND PREDISPOSITION FOR AGGRESSIVE PROSTATE CANCER
Laurent Briollais, Hilmi Ozcelik, Jingxiong Xu, Toronto, Canada, Maciej Kwiatkowski, Aarau, Switzerland, Emilie Lalonde, Dorotea H Sendorak, Neil E Fleshner, Toronto, Canada, Franz Recker, Aarau, Switzerland, Cynthia Kuk, Ekaterina Olkhov-Mitsel, Toronto, Canada, Svetap Savas, St. John’s, Canada, Sally Hanna, Tristan Juvet, Geoffrey A Hunter, Matt Friedlander, Hong Li, Karen Chadwick, Ioannis Prassas, Antoninus Soosaipillai, Toronto, Canada, Marco Randazzo, Aarau, Switzerland, John Trachtenberg, Ants Toi, Yu-Jia Shiah, Michael Fraser, Theodorus van der Kwast, Robert G Bristow, Bharati Bapat, Eleftherios P. Diamandis, Paul C Boutros, Alexandre R Zlotta*, Toronto, Canada

7:00

**PD65-02**
ONCOSOMES AS A NOVEL LIQUID BIOPSY BIOMARKER FOR QUANTIFYING METASTATIC CANCER DYNAMICS IN REAL-TIME
Florence Deng*, Yohan Kim, Andrew Poon, Tom Liao, Hon Leong, London, Canada

7:10

**PD65-03**
DECIPHER GENE EXPRESSION LEVELS DO NOT CORRELATE WITH PATHOLOGIC FEATURES OF AGGRESSIVE PROSTATE CANCER IN AFRICAN AMERICANS
Jordan Alger*, Rohit Patil, Anna Chichura, Filipe La Fuente Carvalho, Jonathan Hwang, Lambros Stamatakis, Washington, DC

7:20

**PD65-04**
NUCLEOLIN STAINING MAY AID IN THE IDENTIFICATION OF CIRCULATING PROSTATE CANCER CELLS
Heather Chalfin*, James Verdone, Emma van der Toom, Stephanie Glavaris, Michael Gorin, Kenneth Pienta, Baltimore, MD

7:30

**PD65-05**
URINE EXPRESSION OF TIMP1, SERPINB1, AND SEMENOGELIN 2 MAY DIFFERENTIATE MEN WITH LOW-RISK OR NO EVIDENCE OF PROSTATE CANCER FROM MEN WITH HIGH-RISK OR METASTATIC DISEASE
Sarah Prophet*, Adam Feldman, Mary Fergus, Bruce Zetter, Boston, MA

7:40

**PD65-06**
PATIENT NCCN RISK CLASSIFICATION BASED ON COMBINED CLINICAL CELL CYCLE RISK (CCR) SCORE
E. David Crawford*, Aurora, CO, Steve Stone, Julia Reid, Michael Brawer, Salt Lake City, UT

7:50

**PD65-07**
ISOPSA™: INTERIM CLINICAL PERFORMANCE EVALUATION OF A NOVEL STRUCTURE-BASED BIOMARKER FOR PROSTATE CANCER IN A MULTICENTER PROSPECTIVE TRIAL FOR GLEASON ≥7
Eric Klein*, Mark Stovsky, Cleveland, OH, Jason Haftron, Kenneth Kernan, Troy, MI, Kanan Manickam, Baltimore, MD, Hui Zhu, Cleveland, OH, Matthew Wagner, Clackamas, OR

8:00

**PD65-08**
DISTINGUISHING LOW VERSUS HIGH RISK PROSTATE CANCER LESIONS USING RADIOMIC FEATURES DERIVED FROM MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING (MRI)
Rakesh Shiradkar*, Soumya Ghose, Cleveland, OH, Robert Villani, Eran Ben-Levi, Ardeshir Rastinehad, New York, NY, Anant Madabhusi, Cleveland, OH

8:10

**PD65-09**
DOES 4K AND/OR MICHIGAN PROSTATE SCORE CHANGE CANCER DETECTION RATES IN MULTI-PARAMETRIC MRI DISCOVERED PIRADS 3 OR LOWER LESIONS?
Wei Phin Tan*, Patrick Whelan, Jessica Phelps, Andrea Strong, Megan Lowe, Stephanie Shors, Gregory White, Shahid Ekbal, Charles McKiel, Leslie Deane, Chicago, IL

8:20

**PD65-10**
USING MP-MRI GUIDED PROSTATE NEEDLE BIOPSY SAMPLES TO IMPROVE PROSTATE CANCER DIAGNOSIS.
Jonathan Olivier*, Jonathan Kay, Vasili Stravides, Freeman Alex, Hashim Ahmed, Caroline Moore, Emberton Mark, Whitaker Hayley, London, United Kingdom

8:30

**PD65-11**
DOES PI-RADS V2 SCORES PREDICT ADVERSE SURGICAL PATHOLOGY AT RADICAL PROSTATECTOMY?
Hao Nguyen*, Antonio Westphalen, Ameli Niloufar, Michael Leapman, Janet Cowan, Jeff Simko, Katsuto Shinohara, Peter Carroll, San Francisco, CA

8:40

**PD65-12**
THE ANDROGEN RECEPTOR BECOMES A NOVEL PREDICTIVE BIOMARKER OF PROSTATE CANCER PROGRESSION WHEN POST TRANSLATIONALLY ACTIVATED BY THE FER KINASE ON TYROSINE 223
Turki Altaylouni*, Fatima Zouanat, Eleonora Scarlata, Tarik Benidir, Lucie Hamel, Fadi Brimo, Louis Bégün, Armen Aprikian, Simone Chevalier, Montreal, Canada

**CREDIT™**
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>PD66-01</td>
<td>RENAL CELL CARCINOMA WITH PERIRENAL FAT INVASION: IS PARTIAL NEPHRECTOMY AS GOOD AS RADICAL SURGERY?</td>
<td>Fabio Gallucci*, Mauricio Cordeiro, Joao Barbosa, Paulo Afonso Carvalho, Henrique Nonemaker, Eder Ilario, Arnaldo Fazoli, Daniel Abe, Valter Cassao, Romulo Mattedi, William Nahas, Sao Paulo, Brazil</td>
</tr>
<tr>
<td>7:10</td>
<td>PD66-02</td>
<td>ARE ALL RENAL ONCOCYTIC NEOPLASMS CREATED EQUALLY?</td>
<td>Chandra K. Flack*, Adam C. Calaway, Indianapolis, IN, Brady L. Miller, Madison, WI, Maria M. Picken, Maywood, IL, E. Jason Abel, Madison, WI, Gopal G. Gupta, Maywood, IL, Ronald S. Boris, Indianapolis, IN</td>
</tr>
<tr>
<td>7:20</td>
<td>PD66-03</td>
<td>SURVIVAL IN PATIENTS WITH END STAGE RENAL DISEASE AS A RESULT OF KIDNEY CANCER</td>
<td>Joseph Rodriguez*, Scott Johnson, Zachary Smith, Gary Steinberg, Chicago, IL</td>
</tr>
<tr>
<td>7:40</td>
<td>PD66-05</td>
<td>USE OF INTRAOPERATIVE MANNITOL DURING PARTIAL NEPHRECTOMY FAILS TO PROVIDE SHORT-TERM OR LONG-TERM RENAL FUNCTION BENEFIT – EVEN IN HIGH RISK POPULATIONS</td>
<td>Jeremy Reese*, Julie Dagenais, Matthew Maurice, Pascal Mouracade, Onder Kara, Ryan Nelson, Jihad Kauuk, Cleveland, OH</td>
</tr>
<tr>
<td>7:50</td>
<td>PD66-06</td>
<td>RANDOMIZED, CONTROLLED, DOUBLE BLINDED, PROSPECTIVE EVALUATION OF RENAL FUNCTION FOLLOWING MANNITOL ADMINISTRATION DURING MINIMALLY INVASIVE ROBOTIC-ASSISTED LAPAROSCOPIC PARTIAL NEPHRECTOMY</td>
<td>Stephen Phillips*, Kellen Choi, Sharon Hill, Deem Samuel, Charleston, WV</td>
</tr>
<tr>
<td>8:00</td>
<td>PD66-07</td>
<td>CREATION OF A PREDICTION TOOL FOR RENAL FUNCTION AFTER PARTIAL AND RADICAL NEPHRECTOMY: PERSONALIZING DECISION-MAKING FOR RENAL CANCER SURGERY</td>
<td>Bimal Bhindi*, Christine Lohse, Ross Mason, John Cheville, Stephen Boorjian, Bradley Leibovich, R. Houston Thompson, Rochester, MN</td>
</tr>
<tr>
<td>8:20</td>
<td>PD66-09</td>
<td>UTILIZATION OF ROBOTIC VERSUS OPEN PARTIAL NEPHRECTOMY FOR MANAGEMENT OF CT1 AND CT2 RENAL MASSES</td>
<td>Mahmoud Alameddine*, Tulay Koru-Sengul, Feng Miao, Luis Felipe Sávio, Ian Zheng, Vivek Venkatramani, Nachiketh Soodana Prakash, Joshua S Jue, Bruno Nahar, Chad Ritch, Sanoj Punnen, Dipen J. Parekh, Mark L. Goncalo, Miami, FL</td>
</tr>
<tr>
<td>8:30</td>
<td>PD66-10</td>
<td>BULB SUCTION DRAINAGE IS NOT NECESSARY AFTER ROUTINE ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY: A LARGE CASE-CONTROL ANALYSIS</td>
<td>Christopher Winter*, Wesley White, Ryan Pickens, Knoxville, TN</td>
</tr>
<tr>
<td>8:40</td>
<td>PD66-11</td>
<td>ONCOLOGICAL OUTCOMES COMPARING INTRAVESICAL AND EXTRAVESICAL BLADDER CUFF EXCISION FOLLOWING RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA</td>
<td>Amir Toussi*, Tanner Miest, Stephen Boorjian, George Chow, R. Houston Thompson, Bradley Leibovich, Matthew Tollefson, Rochester, MN</td>
</tr>
<tr>
<td>8:50</td>
<td>PD66-12</td>
<td>OUTCOMES ON ILEAL MUCOSAL CUFF MANAGEMENT DURING RADICAL NEPHROURETERECTOMY</td>
<td>Amir Toussi*, Vidit Sharma, Tanner Miest, George Chow, Bradley Leibovich, Matthew Tollefson, Rochester, MN</td>
</tr>
</tbody>
</table>

*Presenting author

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
ABSTRACT

7:00 PD67-01 LONG-TERM FUNCTIONAL OUTCOMES AND MORBIDITY OF PROSTATE SPARING CYSTECTOMY VERSUS CYSTOPROSTATECTOMY: A CASE CONTROLLED STUDY.
Mohamed Saad M.*, Rafael Sanchez-Salas, Eric Barret, Marc Galiano, François Rozet, Nathalie Cathala, Annick Mombet, Dominique Prapotnich, Xavier Cathelineau, Paris, France

7:10 PD67-02 CRITICAL EVALUATION OF THE SELECTION CRITERIA FOR PROSTATE SPARING CYSTECTOMY: DO WE NEED TO TIGHTEN THEM?
Mohamed Saad M.*, Rafael Sanchez-Salas, Eric Barret, Marc Galiano, François Rozet, Nathalie Cathala, Annick Mombet, Dominique Prapotnich, Xavier Cathelineau, Paris, France

7:20 PD67-03 THE ONCOLOGICAL IMPACT OF TRANSURETHRAL ENDOSCOPIC RESECTION OF THE PROSTATE VERSUS MILLIN’S ADENOMECTOMY IN PROSTATE SPARING CYSTECTOMY CASES
Mohamed Saad M.*, Rafael Sanchez-Salas, Eric Barret, Marc Galiano, François Rozet, Nathalie Cathala, Annick Mombet, Dominique Prapotnich, Xavier Cathelineau, Paris, France

7:30 PD67-04 EARLY AND LATE COMPLICATIONS OF ROBOTIC RADICAL CYSTECTOMY AND INTRACORPOREAL URINARY DIVERSION
Sameer Chopra*, Fatima Hussain, Andre Abreu, Nariman Ahmadi, Andre Berger, Inderbir Gill, Monish Aron, Mihir Desai, Los Angeles, CA

7:40 PD67-05 FACILITY VOLUME AND TYPE IS ASSOCIATED WITH RECEIPT OF CONTINENT DIVERSION FOR BOTH OPEN AND ROBOTIC RADICAL CYSTECTOMY
Kaitlin Kosinski, Melissa Fazzari, Michael Kongnyuy, Daniel Halpern, Mineola, NY, Marc Smaldone, Philadelphia, PA, Jeffrey Schiff, Aaron Katz, Anthony Corcoran*, Mineola, NY

7:50 PD67-06 PATHOLOGIC METRICS OF SURGICAL QUALITY IN OPEN AND ROBOTIC RADICAL CYSTECTOMY IMPROVED AT HIGHER VOLUME AND ACADEMIC CENTERS
Kaitlin Kosinski, Melissa Fazzari, Michael Kongnyuy, Daniel Halpern, Mineola, NY, Marc Smaldone, Philadelphia, PA, Jeffrey Schiff, Aaron Katz, Anthony Corcoran*, Mineola, NY

8:00 PD67-07 OPEN VERSUS ROBOT ASSISTED RADICAL CYSTECTOMY AND INTRACORPOREAL URINARY DIVERSEIONS: MID-TERM PROPENSITY SCORE MATCHED ANALYSIS OF PERIOPERATIVE AND ONCOLOGIC OUTCOMES

8:10 PD67-08 LONG TERM ONCOLOGICAL OUTCOME OF ROBOTIC ASSISTED VERSUS OPEN CYSTECTOMY
Kawa Omar*, Brian Parsons, Martina Smekal, Rajesh Nair, Ramesh Thairajah, Shamim Khan, London, United Kingdom

8:20 PD67-09 COMPARATIVE EFFECTIVENESS OF ROBOT-ASSISTED VS. OPEN RADICAL CYSTECTOMY
Nawar Hanna*, Jeffrey J. Leow, Maxine Sun, Nicolas von Landenberg, Philipp Gild, Boston, MA, Firas Abdollah, Mani Menon, Detroit, MI, Adam S. Kibel, Joaquim Bellmunt, Tony I. Choueiri, Quoc-Dien Trinh, Boston, MA

8:30 PD67-10 INCIDENCE AND RISK FACTORS FOR PERITONEAL CARCINOMATOSIS FOLLOWING OPEN RADICAL CYSTECTOMY
David Y Yang*, Igor Frank, Ross A Avant, Prabin Thapa, Stephen A Boorjian, Matthew K Tollefson, Rochester, MN

8:40 PD67-11 ENHANCED RECOVERY AFTER RADICAL CYSTECTOMY REDUCES COST AND LENGTH OF STAY: THE JOHNS HOPKINS EXPERIENCE.
Alice Semerjian*, Niv Milbar, Max Kates, Michael Gorin, Heather Chaffin, Cary Stimson, William Yang, Steven Frank, Deb Hobson, Lindsay Robertson, Ken Lee, Michael Johnson, Phillip Pierorazio, Trinity Bivalacqua, Baltimore, MD

8:50 PD67-12 SAFETY & FEASIBILITY OF BLADDER AND PROSTATE ROBOTIC SURGERY AFTER RADIATION THERAPY
Tareq Aro*, David Kakiashvili, Kamil Malschy, Valentín Shabataev, Gilad Amiel, haifa, Israel
Video Session 11

UROLITHIASIS

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 254 @ Boston Convention & Exhibition Center

Moderators: Altan Ilkay, Necole Streeper and Michael Wong

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>V11-01</td>
<td>COMPLICATIONS OF PERCUTANEOUS ACCESS DURING PERCUTANEOUS NEPHROLITHOTOMY</td>
</tr>
<tr>
<td></td>
<td>Vinaya Vasudevan*, Zeph Okeke, Arthur Smith, New Hyde Park, NY</td>
</tr>
<tr>
<td>V11-02</td>
<td>AVICENNA ROBOFLEX, FOR ROBOTIC ASSISTED RETROGRADE INTRARENAL LASER LITHOTRIPSY OF THE KIDNEY STONES, LARGER THAN 2 CM.</td>
</tr>
<tr>
<td></td>
<td>Anup Patel*, London, United Kingdom, Jan Klein, Ulm, Germany, Yasser Farahat, Umm al Quwain, United Arab Emirates, Nida Zafer Tokatl, Ahmet Sinan Kabakci, Remzi Saglam, Ankara, Turkey</td>
</tr>
<tr>
<td>V11-03</td>
<td>APPLYING UROLITHIASIS TECHNIQUES TO BILIARY STONES: PERCUTANEOUS TRANSHEPATIC LITHOTRIPSY</td>
</tr>
<tr>
<td></td>
<td>Brett Johnson*, John Roger Bell, Prasad Dalvie, John McDermott, Stephen Nakada, Madison, WI</td>
</tr>
<tr>
<td>V11-04</td>
<td>DUSTING UTILIZING SUCTION TECHNIQUE (DUST) FOR PERCUTANEOUS NEPHROLITHOTOMY: DEDICATED LASER HANDPIECE TO TREAT A STAGHORN STONE</td>
</tr>
<tr>
<td></td>
<td>Khurshid Ghani*, William Roberts, Ann Arbor, MI</td>
</tr>
<tr>
<td>V11-05</td>
<td>RENAL CALYCEAL DIVERTICULUM WITH STONES - SINGLE-STAGE PERCUTANEOUS APPROACH</td>
</tr>
<tr>
<td></td>
<td>Nadya E. York*, Hazem M. Elmansy, Marcelino E. Rivera, James E. Lingeman, Indianapolis, IN</td>
</tr>
<tr>
<td>V11-06</td>
<td>STEP BY STEP ULTRASOUND-GUIDED PERCUTANEOUS NEPHROLITHOTOMY: A SINGLE HOSPITAL EXPERIENCE</td>
</tr>
<tr>
<td></td>
<td>Yite Chiang, Kaiyi Tzou*, Taipei, Taiwan</td>
</tr>
<tr>
<td>V11-07</td>
<td>ECIRS (ENDOSCOPIC COMBINED INTRARENAL SURGERY) IN THE GALDAKAO-MODIFIED SUPINE VALDIVIA POSITION</td>
</tr>
<tr>
<td></td>
<td>Cesare Marco Scoffone, Manuela Ingrosso, Cecilia Cracco*, Torino, Italy</td>
</tr>
<tr>
<td>V11-08</td>
<td>COMPLETE SUPINE PERCUTANEOUS NEPHROLITHOTOMY FROM THE SURGEON’S POINT OF VIEW WITH A GOPRO®, TEN STEPS FOR SUCCESS.</td>
</tr>
<tr>
<td></td>
<td>Fabio Vicentini*, Hugo Santos, Evaristo Oliveira Neto, Carlos Batagello, Sao Paulo, Brazil, Julia Amundson, Miami, FL, Miguel Srougi, Eduardo Mazzucchi, Sao Paulo, Brazil</td>
</tr>
<tr>
<td>V11-09</td>
<td>THE PARALLEL GUIDEWIRE RAPID RELEASE PERCUTANEOUS TRACT DILATION</td>
</tr>
<tr>
<td></td>
<td>Mohammed Lezrek*, Meknes, Morocco, Hicham Tazi, Fes, Morocco, adil slimani, khali bazine, Amoquarine Beddouch, abdeghani ammanni, mohammed alami, Meknes, Morocco</td>
</tr>
<tr>
<td>V11-10</td>
<td>MINI-PERCUTANEOUS NEPHROLITHOTOMY USING AN INTEGRATED ULTRASONIC AND MECHANICAL LITHOTRIPTER (OLYMPUS SHOCKPULSE-SE LITHOTRIPTER)</td>
</tr>
<tr>
<td></td>
<td>Joshua Ebel*, Nathaly Francois, Bodo Knudsen, Columbus, OH</td>
</tr>
<tr>
<td>V11-11</td>
<td>THULIUM LITHOTRIPSY: FROM EXPERIMENT TO CLINICAL PRACTICE</td>
</tr>
<tr>
<td></td>
<td>Alim Dymov*, Petr Glybochko, Yuri Alyaev, Andrey Vinarov, Moscow, Russian Federation, Gregory Altshuler, Boston, MA, Viktoriya Zamyatin, Fryazino, Russian Federation, Nikolay Sorokin, Dmitri Enikeev, Vladimir Lekarev, Alexandra Proskura, Alexey Koshkarev, Moscow, Russian Federation</td>
</tr>
<tr>
<td>V11-12</td>
<td>HOLMIUM LASER SETTINGS DURING LITHOTRIPSY OF DIFFERENT TYPES OF KIDNEY STONES</td>
</tr>
<tr>
<td></td>
<td>Oriol Angeri*, Juan Manuel Lopez, Pavel Gavrilon, Francisco Sanchez-Martin, Felix Millan, Humberto Villavicencio, Barcelona, Spain</td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

*Presenting author
ABSTRACT NUMBER TITLE
MP95-01 ASSOCIATION BETWEEN ORAL ANTIBIOTICS AND INCIDENT KIDNEY STONES
Gregory Tasian*, Thomas Jemelleta, Philadelphia, PA, David Goldfarb, New York, NY, Qufei Wu, Lawrence Copelovitch, Jeffrey Gerber, Michelle Denburg, Philadelphia, PA

MP95-02 HETEROGENEITY IN CALCIUM-BASED NEPHROLITHIASIS FROM A MATERIALS PERSPECTIVE
Benjamin Sherer*, Ling Chen, Ryan Hsi, San Francisco, CA, David Killilea, Oakland, CA, Sunita Ho, Marshall Stoller, San Francisco, CA

MP95-03 PATIENT RURALITY INFLUENCES TREATMENT MODALITY FOR URINARY STONE DISEASE
Paul Morrison*, George Gharabeb, Thomas Gruca, Craig Jarvie, Bradley Erickson, Iowa City, IA

MP95-04 URBANIZATION MAY AFFECT THE INCIDENCE OF UROLITHIASIS IN SOUTH KOREA
Se Young Choi, Seoul, Korea, Republic of, Seo Yeon Lee, Goyang, Korea, Republic of, Byung Hoon Chi, Seung Hyun Ahn, Jae Duck Choi*, Shin Young Lee, In Ho Chang, Seoul, Korea, Republic of

MP95-05 INCREASING UTILIZATION OF CARE FOR URINARY STONE DISEASE IN OLDER ADULTS
Kevin T. Hobbs*, Brad Hammill, Daniel Wollin, Glenn M. Preminger, Michael E. Lipkin, Kenneth E. Schmader, Charles D. Scales, Jr., Durham, NC

MP95-06 PATIENTS WITH UROLITHIASIS ARE MORE LIKE TO DEVELOP FRACTURE: A NATION-WIDE POPULATION-BASED AND WITH AN 8-YEAR FOLLOW-UP STUDY
Hsiao-Jen Chung*, Alex Tong-Long Lin, Yi-Hsiu Huang, Chih-Chieh Lin, Tseng-Ji Chen, Kuang-Kuo Chen, Taipei, Taiwan

MP95-07 SLEEP APNEA: AN INDEPENDENT RISK FACTOR FOR NEPHROLITHIASIS
Sheng-Han Tsai*, Taipei, Taiwan, Marshall Stoller, Benjamin Sherer, San Francisco, CA, Zi-Hao Chao, New Taipei City, Taiwan, Tao-Hsin Tong, Taipei, Taiwan

MP95-08 PRIMARY HYPERPARATHYROIDISM: A SOMETIMES ELUSIVE DIAGNOSIS
Jodi Antonelli*, Niccolo Passoni, Elysha Kolitz, Aaron Lay, Naim Maalouf, Margaret Pearle, Dallas, TX

ABSTRACT NUMBER TITLE
MP95-09 DECREASING TREND IN STONE DISEASE: ARE MEN DOING SOMETHING RIGHT?
Alan Carnes*, Augusta, GA, Zach Klaassen, Toronto, Canada, Michael Kemper, Durwood Neal, Vinata Lokeshwar, Augusta, GA

Lael Reinstatter*, Sari Khaleel, Vernon Paux, Lebanon, NH

MP95-11 EVALUATION, MANAGEMENT, AND OUTCOMES OF PREGNANT PATIENTS WITH CLINICALLY SYMPTOMATIC NEPHROLITHIASIS AT A LARGE WOMEN’S HOSPITAL
Nabeel Hamoui*, Emily Yura, Mary Kate Keeter, Kaitly Sacotte, Beverely Onyekwuluje, Nirali Shah, Chicago, IL, Granville Lloyd, Denver, CO, Stephanie J. Kielb, Chicago, IL

MP95-12 CHANGING LITHOGENIC TRENDS IN PATIENTS WITH NEUROLOGICALLY DERIVED MUSCULOSKELETAL DEFICIENCIES (NDMD)
Lee Hugar*, Ilan Kafka, Sara Sprauer, Michelle Yu, Thomas Fuller, Hassan Taan, Timothy Averch, Michelle Semins, Pittsburgh, PA

MP95-13 CORRELATION OF STRESS IN KIDNEY STONE PATIENTS WITH THE WISCONSIN STONE QUALITY OF LIFE QUESTIONNAIRE

MP95-14 IMPACT OF RACE AND SOCIOECONOMIC STATUS ON STONE CHARACTERISTICS: RESULTS FROM RESKU – THE REGISTRY FOR STONES OF THE KIDNEY AND URETER
Tuesday, May 16, 2017
9:30 am - 11:30 am
Moderated Poster Session 96
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: QUALITY IMPROVEMENT & PATIENT SAFETY III
Room 153 @ Boston Convention & Exhibition Center
Moderators: Timothy Averch, Howard Goldman and Hassan Razvi

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP96-01</td>
<td>SURGEON LEADERSHIP IN THE OR: THE EFFECTS OF POSITIVE AND NEGATIVE BEHAVIORS ON SURGICAL TEAM PERFORMANCE</td>
<td>MP96-06</td>
<td>TOPICAL RECTAL ANTISEPTIC AT TIME OF PROSTATE BIOPSY: HOW A RESIDENT PATIENT SAFETY PROJECT EVOLVED INTO INSTITUTIONAL PRACTICE</td>
</tr>
<tr>
<td></td>
<td>Julian Barling, Amy Akers, Michael Di Lena, Darren Beiko*</td>
<td>Rosa Park*, Hershey, PA, Kalyan Dewan, Girish Kirimanjeswara, University Park, PA, Joseph Clark, Matthew Kaag, Kathleen Lehman, Jay Raman, Hershey, PA</td>
<td></td>
</tr>
<tr>
<td>MP96-02</td>
<td>THE REACH CLINIC: USE OF THE T STAGING SYSTEM FOR THE TRANSITION OF PEDIATRIC PATIENTS WITH NEUROGENIC BLADDER INTO ADULT CLINICS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bhalajeet Meenakshi-Sundaram*, Jake Klein, Jennifer Lewis, Emily Haddad, Dominic Frimberger, Gennady Slobodov, Oklahoma City, OK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP96-03</td>
<td>FUNCTIONAL OUTCOMES AFTER &quot;MINOR&quot; UROLOGIC SURGERY AMONG NURSING HOME RESIDENTS; A NATIONAL STUDY</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anne M Suskind*, Shujuan Zhao, Louise C Walter, Emily Finlayson, San Francisco, CA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP96-04</td>
<td>DOES ALLOWING RESIDENTS TO OPERATE WORSEN THE OUTCOME OF AN OPEN RADICAL PROSTATECTOMY?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sharon English*, Christchurch, New Zealand</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP96-05</td>
<td>PRE-DISCHARGE PREDICTORS OF READMISSIONS AND POST-DISCHARGE COMPLICATIONS IN ROBOT-ASSISTED RADICAL PROSTATECTOMY</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leilei Xia*, Benjamin Taylor, Jeremy Bonzo, Jose Pulido, Thomas Guzzo, Philadelphia, PA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP96-07</td>
<td>PATIENT TRAVEL DISTANCES TO HIGH-VOLUME CYSTECTOMY CENTERS FOLLOW A COMPLEX RELATIONSHIP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nathan Hale*, Jonathan Yabes, Robert Turner, Mina Fam, Benjamin Davies, Bruce Jacobs, Pittsburgh, PA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP96-08</td>
<td>IS GROSS HEMATURIA MORE LIKELY THAN MICROSCOPIC HEMATURIA TO BE EVALUATED IN A TIMELY FASHION?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kyle Richards*, Madison, WI, Daniel Murphy, Houston, TX, Vania Lopez, Tracy Downs, Jason Abel, David Jarrard, Madison, WI, Hardeep Singh, Houston, TX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP96-09</td>
<td>PREDICTING PROBABILITY OF MISSED CLINIC VISITS AT AN ACADEMIC MULTI-PROVIDER UROLOGY CLINIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jordan Foreman*, Bryan Wilson, Julie Riley, Albuquerque, NM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MP96-10</td>
<td>INITIAL VALIDATION OF AUTOMATED DATA EXTRACTION METHODS IN UROLOGIC ONCOLOGY PRACTICE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renu Eapen*, Samuel Washington III, Annika Herlemann, David Tat, Mark Bridge, Niloufar Ameli, Janet Cowan, Frank Stauf, Peter Carroll, Matthew Cooperberg, San Francisco, CA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Presenting author
MP96-11 IN PATIENTS WITH MICROHEMATURIA, A FOLLOW UP URINALYSIS ADDS INFORMATION ABOUT THE RISK OF BENIGN AND MALIGNANT DIAGNOSES
Richard Matulewicz*, John Oliver DeLancey, Joshua Meeks, Chicago, IL

MP96-12 DOES ROUTINE OVERNIGHT STAY AFTER ROBOTIC PARTIAL NEPHRECTOMY INCREASE COMPLICATIONS?

MP96-13 CONSULTANT OUTCOME PUBLICATION: PATIENTS' OPINIONS OF A NEW MANDATORY HEALTH POLICY
Marc Williams*, Nikki Cotterill, Marcus Drake, Francis Keeley, Bristol, United Kingdom

MP96-14 ANALYSIS OF NATIONAL TRENDS IN HOSPITAL ACQUIRED CONDITIONS FOLLOWING MAJOR UROLOGIC SURGERY BEFORE AND AFTER IMPLEMENTATION OF THE HOSPITAL ACQUIRED CONDITION REDUCTION PROGRAM
Temitope Rude*, New York, NY, Nicholas Donin, Los Angeles, CA, Matthew Cohn, New York, NY, William Meeks, Scott Sullig, Linthicum, MD, James Wysock, Danil Makarov, Marc Bjurlin, New York, NY

MP96-15 SURGICAL PROCEDURAL VOLUME MAY NOT BE SOLE DRIVER OF URINARY FUNCTION OUTCOME FOLLOWING RADICAL PROSTATECTOMY
Daniel Pucheril*, Naveen Kachroo, Detroit, MI, Tae Kim, Rodney Dunn, Greg Auffenberg, Ann Arbor, MI, James Peabody, Detroit, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

MP96-16 ASSOCIATION OF TRAVEL DISTANCE, SOCIOECONOMIC STATUS, AND REFERRAL INSTITUTION ON DELAY TO DEFINITIVE SURGERY IN PATIENTS WITH BLADDER CANCER
David Golombos*, New York, NY, Padraic O'Malley, Halifax, Canada, Patrick Lewicki, Abimbola Ayangbesan, LaMont Barlow, Douglas Scherr, New York, NY

MP96-17 LOWER SERUM ALBUMIN LEVELS ARE ASSOCIATED WITH LONGER LENGTHS OF STAY (LOS) FOLLOWING CYSTECTOMY: THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM
Rohan Bhalla*, Li Wang, Sam Chang, Mark Tyson, Nashville, TN

MP96-18 IMPACT OF PROSTATE CANCER THERAPY ON URINARY INCONTINENCE AND QUALITY OF LIFE
Andrew Wang, Paul McClain*, Robert Given, Norfolk, VA

MP96-19 RETURN TO EMERGENCY DEPARTMENT AFTER PEDIATRIC UROLOGY PROCEDURES
Naimet K Naoum Alsaigh, Michael Chua*, Jessica Ming, Joana Dos Santos, Megan Saunders, Roberto I Lopes, Martin Koyle, Wald Farhat, Toronto, Canada

MP96-20 CHALLENGING THE PARADIGM OF MANDATORY OVERNIGHT OBSERVATION AFTER ELECTIVE PERCUTANEOUS NEPHROSTOMY TUBE PLACEMENT
Jennifer Robles*, Nicole Miller, Nashville, TN

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Tuesday, May 16, 2017
9:30 am - 11:30 am
Moderated Poster Session 97

PROSTATE CANCER: LOCALIZED: SURGICAL THERAPY VIII
Room 156 @ Boston Convention & Exhibition Center
Moderators: Steven Joniau, Simon Kim and Juan Salamanca

**ABSTRACT NUMBER** | **TITLE** |
---|---|
**MP97-01** | EFFICACY OF A NEOADJUVANT LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONIST PLUS LOW-DOSE ESTRAMUSTINE PHOSPHATE IN HIGH-RISK PROSTATE CANCER |
Kazuhisa Hagiwara*, Takuya Koie, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama, Hirosaki, Japan

**MP97-02** | ROBOTIC ASSISTED RADICAL PROSTATECTOMY IN METABOLIC SYNDROME PATIENTS. STRATIFICATION BY NUMBER OF METABOLIC RISK FACTORS. |
Xavier Bonet*, Gabriel Ogaya, Tracey Woodi, Eduardo Hernández-Cartona, Harinanan Ganapathi, Travis Rogers, Renzo Ains, Rafael Coelho, Bernardo Rocco, Vipul Patel, Celebration, FL
MP97-03 APPLICATION OF LOCAL 18F-FLUORO-2-DEOXYGLUCOSE UPTAKE BY THE PROSTATE TO ASSESS PERIOPERATIVE RESULTS OF ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY: Hiroyuki Iio*, Ryotaro Tomida, Kosuke Seto, Takuya Tsujioka, Kenichi Nishimura, Kensuke Shinomori, Shiro Fujikata, Syuji Tanimoto, Kenjiro Okamoto, Sadamu Yamashi, Masaharu Kan, Matsuyama, Japan

MP97-04 URINARY CONTINENCE, SEXUAL FUNCTION AND BIOCHEMICAL RECURRENCE 12 MONTHS FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY: A RANDOMIZED CONTROLLED STUDY COMPARING THE BOCCIARDI AND MENON TECHNIQUES Mani Menon, Deepansh Dalela*, Madhu Ashni-Prasad, Marcus Jamil, Firas Abdollah, Akshay Sood, Patrick Karabon, Mireya Diaz, Stram Eleswarapu, Detroit, MI, Jesse Sammon, Portland, ME, Brad Baize, Andrea Simone, Wooju Jeong, Detroit, MI

MP97-05 OUTCOMES OF PREVENTIVE VS DELAYED LIGATION OF DORSAL VASCULAR COMPLEX DURING RARP: PRELIMINARY RESULTS OF A RANDOMIZED TRIAL Carlotta Palumbo*, Alessandro Antonelli, Irene Mittino, Simone Francavilla, Marco Lattarulo, Mario Sodano, Maria Furlan, Angelo Peroni, Claudio Simeone, Brescia, Italy

MP97-06 INGUINAL HERNIA AFTER RADICAL PROSTATECTOMY: INCIDENCE AND RISKS FACTORS Giacomo Perugia*, Pier Paolo Prontera, Emanuele Corongiu, Giuseppe Borgoni, Milena Polese, Antonio Rossi, Piergiorgio Tuzzolo, Marcello Liberti, Rome, Italy

MP97-07 IMPACT OF REVERSE STAGE MIGRATION ON THE OUTCOME OF NODE POSITIVE PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A LARGE, TWO-CENTER EXPERIENCE Paolo Dell’Oglio*, Milan, Italy, Derya Tilki, Hamburg, Germany, Giorgio Gandaglia, Nicola Fossati, Armando Stabile, Milan, Italy, Thomas Steuber, Hamburg, Germany, Nazareno Suardi, Francesco Montorsi, Milan, Italy, Markus Graefen, Hamburg, Germany, Alberto Briganti, Milan, Italy

MP97-08 PREDICTION OF EXTREME UPGRADE FROM BIOPSY GRADE 1 TO GRADE 4 OR 5 AT RADICAL PROSTATECTOMY: THE IMPORTANCE OF THE EXTENT OF BIOPSY SAMPLING Emanuele Zaffuto*, Giorgio Gandaglia, Marco Bandini, Paolo Dell’Oglio, Nicola Fossati, Francesco Pellegrino, Milan, Italy, Vincenzo Mirone, Naples, Italy, Vito Cucchiara, Milan, Italy, Marco Bianchi, Catanzaro, Italy, Federico Dehò, Emanuele Montanari, Nazareno Suardi, Milan, Italy, Rodolfo Montroni, Ancona, Italy, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP97-09 VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS UNDERGOING OPEN AND MINIMALLY INVASIVE RADICAL PROSTATECTOMY: POPULATION-BASED TIME TREND ANALYSIS Raisa Sinaida Pompe*, Hamburg, Germany, Emanuele Zaffuto, Milan, Italy, Helen Davis Bondarenko, Zhe Tian, Montreal, Canada, Jonas Schiiffmann, Braunschweig, Germany, Sami-Ramzi Leyh-Bannurah, Hartwig Huland, Markus Graefen, Derya Tilki, Hamburg, Germany, Pierre I. Karakiewicz, Montreal, Canada

MP97-10 CAN WE MODULATE THE EXTENT OF NODAL DISSECTION ACCORDING TO THE PREOPERATIVE RISK OF LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY? Giorgio Gandaglia*, Emanuele Zaffuto, Paolo Dell’Oglio, Nicola Fossati, Vincenzo Scattoni, Milan, Italy, Marco Bianchi, Catanzaro, Italy, Andrea Gallina, Umberto Capitanio, Franco Gaboardi, Francesco Montorsi, Alberto Briganti, Milan, Italy

MP97-11 IMPACT OF PREVIOUS EXPERIENCE WITH OPEN SURGERY AND INITIAL ANNUAL ROBOTIC CASELOAD ON POSITIVE SURGICAL MARGIN RATES AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY? Giorgio Gandaglia*, Nazareno Suardi, Paolo Dell’Oglio, Nicola Fossati, Emanuele Zaffuto, Giuseppe Saitta, Marco Bandini, Giorgio Guazzoni, Franco Gaboardi, Milan, Italy, Vincenzo Mirone, Naples, Italy, Rocco Damiano, Catanzaro, Italy, Andrea Gallina, Francesco Montorsi, Alberto Briganti, Milan, Italy
MP97-12 CHANGES OVER TIME IN NODE POSITIVE PROSTATE CANCER RATES AND FEATURES AMONG MEN TREATED WITH RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION AT A SINGLE REFERRAL CENTER

MP97-13 ASSOCIATION OF EXTENDED PELVIC LYMPH NODE DISSECTION WITH THROMBOEMBOLIC EVENTS AND LYMPHOCELE FORMATION AMONG MEN UNDERGOING ROBOTIC ASSISTED LAPAROSCOPIC PROSTATECTOMY WITH PELVIC LYMPH NODE DISSECTION
Jorge Pereira*, Holly Shillan, Christopher Tucci, Gyan Pareek, Dragan Golijanin, Boris Gershman, Joseph Renzulli, Providence, RI

MP97-14 FUNCTIONAL OUTCOME OF RADICAL PROSTATECTOMY AFTER REPEAT BIOPSY
Clemens Rosenbaum*, Philipp Mandel, Pierre Tennstedt, Markus Graefen, Derya Tilki, Georg Salomon, Hamburg, Germany

MP97-15 NEW APPROACH: FROM LAPAROENDOSCOPIC SINGLE-SITE RADICAL PROSTATECTOMY (LESS-RP) TO TRANSURETHRAL-ASSISTED LESS-RP (TU-LESS-RP)
Qingyi Zhu*, Yunfei Wei, Jian Su, Lin Yuan, Yang Zhang, Qingling Zhang, Chen Zhu, Luming Shen, Zijie Lu, Zijie Lu, Zijie Lu, Nanjing, China, People’s Republic of

MP97-16 ROBOTIC SALVAGE-LYMPHADENECTOMY FOR NODAL-ONLY RECURRENCES AFTER RADICAL PROSTATECTOMY: PERIOPERATIVE AND EARLY ONCOLOGICAL OUTCOMES
Johannes Linxweiler*, Matthias Saar, Zaid Al-Kailani, Michael Stöckle, Stefan Siemer, Carsten H. Ohlmann, Homburg Saar, Germany

MP97-17 A COMPARISON OF INTRAPERITONEAL ONLAY MESH REPAIR VS. MINIMALLY INVASIVE SUTURE REPAIR OF INGUINAL HERNIAS DURING ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY

MP97-18 LONGITUDINAL HEALTH-RELATED QUALITY OF LIFE AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY
Yusuke Kimura*, Masashi Honda, Yetsuya Yumioka, Noriya Yamaguchi, Hideto Iwamoto, Bunya Kawamoto, Toshihiko Masago, Shuichi Morizane, Katsuya Hikita, Atsushi Takenaka, Yonago, Japan

MP97-19 SURGICAL OUTCOMES IN THE MANAGEMENT OF HIGH RISK PROSTATE CANCER USING THE SURGICAL OUTCOMES FOR ADVANCED PROSTATE CANCER SCORE
John Francis*, Simon Kim, Cleveland, OH, Hui Zhu, Cleveland, OH, Robert Abouassaly, Cleveland, OH

MP97-20 PREDICTION OF NON-BIOCHEMICAL RECURRENCE RATE AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY (RARP) IN A JAPANESE COHORT: DEVELOPMENT OF A POSTOPERATIVE NOMOGRAM
Kazuki Hasama*, Makoto Ohori, Yosuke Hirasawa, Tatsuo Gondo, Go Nagao, Takashi Mima, Takeshi Kashima, Yoshihiro Nakagami, Yoshio Ono, Kazunori Namiki, Rie Inoue, Takashi Nagao, Tokyo, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MP98-01</strong></td>
<td>PROGRAMMED CELL DEATH-1 EXPRESSION IN BCG RELAPSING TUMORS IS SIGNIFICANTLY ASSOCIATED WITH STAGE PROGRESSION IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS</td>
</tr>
<tr>
<td><strong>MP98-02</strong></td>
<td>A POTENTIAL ROLE OF ABERRANT DNA METHYLATION IN THE CHEMoresistance IN BLADDER CANCER CELLS. DNA METHYLATION INHIBITORS COULD RE-SENSITIZE Drug-Resistance BLADDER CANCER CELLS.</td>
</tr>
<tr>
<td><strong>MP98-03</strong></td>
<td>T-DM1, A NOVEL HER2 ANTIBODY-CYTOTOXIC DRUG CONJUGATE, HAS ANTI-METASTATIC POTENTIAL AND IS EFFECTIVE IN BLADDER CANCER WITH HER2 IHC SCORE 2+/3+</td>
</tr>
<tr>
<td><strong>MP98-04</strong></td>
<td>DEFECTIVE ERCC2 CONFRS INCREASED CISPLATIN AND IONIZING RADIATION SENSITIVITY IN BLADDER CANCER CELLS</td>
</tr>
<tr>
<td><strong>MP98-05</strong></td>
<td>CHECKPOINT INHIBITION WITH SYSTEMIC ANTI-PROGRAMMED CELL DEATH LIGAND-1 AND INTRAVESICAL TMX-101 DECREASE TUMOR BURDEN IN A MOUSE MODEL OF UROTHELIAL CARCINOMA</td>
</tr>
<tr>
<td><strong>MP98-06</strong></td>
<td>EFFICACY OF RECOMBINANT BACILLE CALMETTE-GUERIN SECRETING INTERLEUKIN-15 AGAINST BLADDER CANCER</td>
</tr>
<tr>
<td><strong>MP98-07</strong></td>
<td>LIMD2 EXPRESSION IS UPREGULATED IN BLADDER CANCER LYMPH NODE METASTASES, CORRELATES WITH THE AGGRESSIVE BASAL MOLECULAR PHENOTYPE, AND IS IMPLICATED IN BLADDER CANCER METASTASIS.</td>
</tr>
<tr>
<td><strong>MP98-08</strong></td>
<td>LONG NON-CODING RNA, MEG3, SUPPRESSES BLADDER CANCER INVASION BY COMPETITIVELY BINDING MIR-27A AND PROMOTING PROTEIN TRANSLATION OF PHILP2 TUMOR SUPPRESSOR</td>
</tr>
<tr>
<td><strong>MP98-09</strong></td>
<td>SYNERGISTIC IMMUNO-PHOTOTHERMAL NANTHERAPY (SYMPHONY): A NOVEL TREATMENT FOR LOCALIZED AND METASTATIC BLADDER CANCER</td>
</tr>
<tr>
<td><strong>MP98-10</strong></td>
<td>UTILITY OF HIGH THROUGHPUT SCREENING IN IDENTIFYING AND REPURPOSING SMALL MOLECULE INHIBITORS FOR UROTHELIAL CARCINOMA</td>
</tr>
<tr>
<td><strong>MP98-11</strong></td>
<td>GPX2 IS A PROGNOSTIC MARKER AND HAS A THERAPEUTIC POTENTIAL VIA REGULATION OF OXIDATIVE STRESS IN BLADDER CANCER</td>
</tr>
</tbody>
</table>
MP98-12 FOXA1 KNOCKOUT IS ASSOCIATED WITH INCREASED CARCINOGENIC SUSCEPTIBILITY AND ANDROGEN RECEPTOR EXPRESSION IN MURINE BLADDER CANCER

Lauren Shuman*, Zongyu Zheng, Hironobu Yamashita, Joshua Warrick, Hershey, PA, Klaus Kaestner, Philadelphia, PA, David DeGraff, Hershey, PA

MP98-13 HOTAIR AFFECTS BLADDER CANCER EPITHELIAL-TO-MESENCHYME TRANSITION THROUGH BOTH THE CANONICAL WNT-PATHWAY AND EXTRACELLULAR VESICLES


MP98-14 CATHEPSIN S INHIBITION CHANGES REGULATORY T-CELL ACTIVITY IN REGULATING BLADDER CANCER AND IMMUNE CELL PROLIFERATION AND APOPTOSIS


MP98-15 NUCLEAR PROTHYMOSIN-α CAN ENHANCE PTEN EXPRESSION TRANSCRIPTIONALLY AND NRF2 EXPRESSION THROUGH INHIBITING TRIM-21-MEDIATED UBQUITINATION IN HUMAN BLADDER CANCER

Yuh-Shyan Tsai, Shih-Kai Lan*, Hsin-Tzu Tsai, Tainan, Taiwan, Tzong-Shin Tzai, Tainan, Taiwan

MP98-16 DOWN-REGULATION OF PYRUVATE KINASE 2 BY RNAI AND SMALL MOLECULE INHIBITOR OVERCOMES CISPLATIN RESISTANCE OF BLADDER CANCER CELLS IN VITRO AND IN VIVO

Xing Wang, Fenglin Zhang, Herbert Lepor, Moon-shong Tang, Chuanshu Huang, Xue-Ru Wu*, New York, NY

MP98-17 TARGETING PROTEIN KINASE D2 MAY REPRESENT A THERAPEUTIC STRATEGY FOR BLADDER CANCER

Mohammad Siddiqui*, Lawen Hsu, Quentin Li, Thomas Sanford, Reema Rainkar, Plyush Agarwal, Bethesda, MD

MP98-18 INHIBITION OF HSP90 SYNERGISTICALLY POTENTIATES ANTITUMOR EFFECT OF NVP-BEZ235 AND SATRAPLATIN COMBINATION THERAPY IN CISPLATIN-RESISTANT HUMAN BLADDER CANCER CELLS THROUGH THE DOWN-REGULATION OF AKT AND ERK SIGNALING

Cheol Yong Yoon*, Mi Kyung Gong, Dong Heok Kang, Myung Soo Kim, Won Sik Jung, Seoul, Korea, Republic of, Young Sik Kim, Goyang, Korea, Republic of, In Rae Cho, Gimhae, Korea, Republic of, Young Deuk Choi, Seoul, Korea, Republic of

MP98-19 TUMOR-SUPPRESSIVE MICRONRNA-26A-5P/-26B-5P INHIBIT CANCER CELL MIGRATION AND INVASION THROUGH TARGETING PLOD2 THAT IS A POTENTIAL PROGNOSTIC MARKER IN BLADDER CANCER

Kazutaka Miyamoto*, Kagoshima, Japan, Naohiko Seki, Chiba, Japan, Ryosuke Matsushita, Masaya Yonomori, Hirofumi Yoshino, Takashi Sakaguchi, Satoshi Sugita, Hideki Enokida, Masayuki Nakagawa, Kagoshima, Japan

MP98-20 THE ROLE OF TOLL-LIKE RECEPTOR 4 IN BLADDER CANCER PROGRESSION.

Tomoya Fukawa*, Terumichi Shintani, Kei Daizumoto, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Tokushima, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Tuesday, May 16, 2017
9:30 am - 11:30 am

Moderated Poster Session 99

PROSTATE CANCER: BASIC RESEARCH & PATHOPHYSIOLOGY IV
Room 252 @ Boston Convention & Exhibition Center
Moderators: Mark Garzotto and Ganesh Raj

ABSTRACT NUMBER TITLE

MP99-01 PROTEOMIC ANALYSIS OF URINARY EXTRACELLULAR VESICLES FROM HIGH GLEASON SCORE PROSTATE CANCER

Kazutoshi Fujita*, Suita, Japan, Hideaki Kume, Ibaraki, Japan, Kyosuke Matsuzaki, Atsunari Kawashima, Takeshi Ujike, Akira Nagahara, Motohide Uemura, Yasushi Miyagawa, Suita, Japan, Takeshi Tomonaga, Ibaraki, Japan, Norio Nonomura, Suita, Japan

MP99-02 OVEREXPRESSION OF HSD3B1 CONFRS RESISTANCE TO ENZALUTAMIDE IN PROSTATE CANCER

Cameron Armstrong*, Chengfei Liu, Wei Lou, Christopher Evans, Allen Gao, Sacramento, CA
MP99-03 RIOK2 IS A MEDIATOR OF OBESITY ENHANCED PROSTATE CANCER GROWTH
Everardo Macias*, Los Angeles, CA, David Corcoran, Jen-Tsan Chi, Durham, NC, Stephen Fieldland, Los Angeles, CA

MP99-04 TRUNCATED-CRMP4 BY CALPAIN-2 SUPPRESSES CRMP4 TO PROMOTE METASTASIS OF PROSTATE CANCER VIA PROMOTER METHYLATION THROUGH E2F1/NF-κB/DNMT1 SIGNALING
Xin Gao*, Yunhua Mao, Zheng Chen, Jun Pang, Ke Li, Guangzhou, China, People's Republic of

MP99-05 ELL2 REGULATES DNA DOUBLE-STRAND BREAK REPAIR IN PROSTATE CANCER CELLS
Yachen zang, Yibin Zhou*, Leizhen Wei, Joel B. Nelson, Lan Li, Pittsburgh, PA, Boxin xue, YuXi Shan, Suzhou, China, People's Republic of, Zhou Wang, Pittsburgh, PA

MP99-06 HIGH FAT DIET-INDUCED INFLAMMATION ACCELERATES TUMOR PROGRESSION IN MICE MODEL FOR PROSTATE CANCER
Takuki Hayashi*, Kazutoshi Fujita, Yu Ishizuya, Cong Wang, Yoshiyuki Yamamoto, Toshiro Kinouchi, Kyosuke Matsuzaki, Norihiko Kawamura, Suita, Japan

MP99-07 AP4 PROMOTES PROLIFERATION AND METASTASIS OF CASTRATION-RESISTANT PROSTATE CANCER THROUGH BINDING AND UP-REGULATION OF L-PLASTIN
Changhao Chen*, Tianxin Lin, Guangzhou, China, People's Republic of, Thomas B Lam, Aberdeen, United Kingdom, Yue Zhao, Jian Huang, Guangzhou, China, People's Republic of

MP99-08 SPOP MUTANT PROSTATE CANCER IS NOT DRIVEN BY ERG STABILIZATION
Jonathan Shoag*, Deil Liu, Mirjam Blattner, Andrea Sboner, Juan Miguel Mosquera, Brian Robinson, Yu Chen, Christopher Barbieri, New York, NY

MP99-09 PROSTATE CANCER GENOMICS – IDENTIFICATION OF PROGNOSTIC MARKERS FROM THE BONE MARROW
Simone Bier*, Jörg Hennenlotter, Tübingen, Germany, Ursula Haefer, Reutlingen, Germany, Eleni Karpatsi, Arnulf Stenzl, Tilman Todenhöfer, Tübingen, Germany, Christian Schmees, Reutlingen, Germany

MP99-10 SYNERGISTIC CONTRIBUTIONS OF ABL1 AND ABL2 TO AN α3β1 INTEGRIN – ABL KINASE – HIPPO SUPPRESSOR PATHWAY IN PROSTATE CANCER
Afsrin Varzavand, William Hacker, Deqin Ma, Katherin Gibson-Corley, Maria Hawayek, James Brown*, Michael Henry, Christopher Stipp, Iowa City, IA

MP99-11 ANGIOMOTIN REGULATES PROSTATE CANCER CELL PROLIFERATION BY SIGNALING THROUGH HIPPO-YAP PATHWAY
Pengfei Shen*, Hao Zeng, Chengdu, China, People's Republic of, Angelica Ortiz, Houston, TX, Chien-Jui Cheng, Taipei, Taiwan, Yu-Chen Lee, Guoyu Yu, Song-Chang Lin, Li-Yuan Yu-Le, Sue-Hwa Lin, Houston, TX

MP99-12 IMPACT OF HIPPO PATHWAY PROTEIN EXPRESSION IN RESIDUAL CANCER AFTER NEOADJUVANT CHEMOHORMONAL THERAPY WITH DOCETAXEL FOR HIGH-RISK LOCALIZED PROSTATE CANCER
Shintaro Narita*, Taketoshi Nara, Huang Mingguo, Kazuyuki Numakura, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Shigeru Satoh, Hiroshi Nanjo, Tomonomi Habbuchi, Akita, Akita, Japan

MP99-13 IMPACT OF ANTITUMOR MICRORNA-145-3P REGULATED RNA NETWORKS IN CASTRATION-RESISTANT PROSTATE CANCER
Akira Kurozumi*, Yusuke Goto, Chiba, Japan, Nijiro Nohata, La Jolla, CA, Satoko Kojima, Ichihara, Japan, Takayuki Arai, Atsushi Okato, Mayuko Kato, Chiba, Japan, Yukio Naya, Ichihara, Japan, Tomohiko Ichikawa, Naohiko Seki, Chiba, Japan

MP99-14 PDCD4 IS A CHECK POINT OF MIR-21-1 INDUCED CASTRATION RESISTANCE IN HUMAN PROSTATE CANCER
Kenji Zennami*, Baltimore, MD, Koji Hatano, Osaka, Japan, Ross Liao, Fatima Rafiqi, Su Mi Choi, Shawn Lupold, Baltimore, MD

MP99-15 TAXANE RESISTANCE IN PROSTATE CANCER: A ROLE FOR MRNA 181A REGULATED RNA NETWORKS IN CASTRATION-RESISTANT PROSTATE CANCER VIA REGULATING ANDROGEN RECEPTOR EXPRESSION IN RESIDUAL CANCER
Eugenio Zoni, Bern, Switzerland, Markus Krebs, Philip Herreiner, Charis Kalogiro, Wuerzburg, Germany, Lapeng Chen, Ewa Snaar-Jagalska, Leiden, Netherlands, George N. Thalmann, Marianna Kruthof-de Julio*, Bern, Switzerland, Hubertus Riddermill, Burkhard Kneitz, Wuertzburg, Germany, Martin Spahn, Bern, Switzerland

MP99-16 MIR-221 MODULATES TUMOR GROWTH IN VIVO AND IS A REGULATOR OF TGF-β SIGNALING IN HUMAN PROSTATE CANCER
Angelica Ortiz, Baltimore, MD, Ke Li, Xin Gao*, Yunhua Mao, Zheng Chen, Jun Pang, Ke Li, Guangzhou, China, People's Republic of, Sun Pang, Wei Lou, Fangwen Zhang, Yue Chen, Guangzhou, China, People's Republic of
<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP100-01</td>
<td>PARTIAL NEPHRECTOMY VERSUS CRYOABLATION OR RADIOFREQUENCY ABLATION FOR CLINICAL STAGE T1 RENAL MASSES: SYSTEMATIC REVIEW AND META-ANALYSIS OF MORE THAN 3900 PATIENTS</td>
</tr>
<tr>
<td>MP100-02</td>
<td>BOILING HISTOTRIPSY ABLATION OF RENAL CARCINOMA IN A CHRONIC RAT MODEL</td>
</tr>
<tr>
<td>Wayne Brisbane*, Tatiana Khokhlova, Stella Whang, Kayla Gravelle, Yak-Nam Wang, Joo Ha Hwang, Vera Khokhlova, George Schade, Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>MP100-03</td>
<td>MULTI-POINT THERMAL SENSING NEEDLES: IMPROVED ONCOLOGICAL OUTCOMES FOLLOWING CRYOABLATION</td>
</tr>
<tr>
<td>Jeremy W. Martin*, Roshan Patel, Zhamshid Okhunov, Aashay Vyas, Jaime Landman, Duane Vajgirt, Ralph V. Clayman, Orange, CA</td>
<td></td>
</tr>
<tr>
<td>MP100-04</td>
<td>PERCUTANEOUS MICROWAVE ABLATION FOR CLINICAL T1B RENAL CANCERS</td>
</tr>
<tr>
<td>Brett Johnson*, Shane Wells, Sara Best, Michael Hartung, Timothy Ziemlewicz, Meghan Lubner, J. Louis Hinshaw, Fred Lee, Stephen Y Nakada, E. Jason Abel, Madison, WI</td>
<td></td>
</tr>
<tr>
<td>MP100-05</td>
<td>LONG-TERM OUTCOME DATA FROM 47 TREATED RENAL MALIGNANCIES WITH MRI-GUIDED AND MONITORED LASER ABLATION: A SINGLE CENTER STUDY</td>
</tr>
<tr>
<td>Sherif Nour*, Kareem Elsaffary, Debra Weber, Melinda Lewis, Viraj Master, Atlanta, GA</td>
<td></td>
</tr>
</tbody>
</table>

Moderated Poster Session 100

KIDNEY CANCER: ABLATIVE THERAPY
Room 253 AB @ Boston Convention & Exhibition Center
Moderators: Jihad Kaouk and Hyung Lae Kim

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP100-06</td>
<td>CRYOABLATION OF CT1 RENAL MASSES IN “HEALTHIER” PATIENTS: EARLY OUTCOMES FROM MAYO CLINIC</td>
</tr>
<tr>
<td>Harras Zaid*, Thomas Atwell, Grant Schmit, Stephen Boorjian, William Parker, John Cheville, Bradley Leibovich, R. Houston Thompson, Rochester, MN</td>
<td></td>
</tr>
<tr>
<td>MP100-07</td>
<td>COMPARISON OF ONCOLOGIC RESULTS, FUNCTIONAL OUTCOMES AND COMPLICATIONS AFTER PARTIAL NEPHRECTOMY VERSUS PERCUTANEOUS RADIOFREQUENCY ABLATION IN SMALL SIZED (4CM OR LESS) BOSNIAK III OR IV CYSTIC RENAL LESIONS</td>
</tr>
<tr>
<td>Song Wan*, Byung Kwan Park, Chan Kyo Kim, Young Hyo Choi, Hyun Woo Chung, Chung Un Lee, Jun Phil Na, Hwang Gun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, Hyun Moo Lee, Seoul, Korea, Republic of</td>
<td></td>
</tr>
<tr>
<td>MP100-08</td>
<td>MITOCHONDRIAL – TARGET PEPTIDES ANTIOXIDANTS SS-20 AND SS-31 AS A KIDNEY PROTECTOR AGAINST HIGH DOSE WST-11 VASCULAR TARGET PHOTODYNAMIC THERAPY (VTP)</td>
</tr>
<tr>
<td>Ricardo Alvim*, Barak Rosenzweig, Alexander Somma, Stephen La Rosa, Kwanghee Kim, Jonathan Coleman, New York, NY</td>
<td></td>
</tr>
<tr>
<td>MP100-09</td>
<td>DOES ROUTINE BIOPSY IMPROVE DETECTION OF RESIDUAL RCC POST MICROWAVE ABLATION?</td>
</tr>
<tr>
<td>Brett Johnson*, Amy Lim, Shane Wells, Sara Best, Michael Hartung, Meghan Lubner, Timothy Ziemlewicz, J. Louis Hinshaw, Fred Lee, Wei Huang, Richard Yang, Stephen Y Nakada, E. Jason Abel, Madison, WI</td>
<td></td>
</tr>
</tbody>
</table>
MP100-10 A COST ANALYSIS OF RENAL BIOPSY VS LAPAROSCOPIC CRYOABLATION FOR INITIAL MANAGEMENT OF SMALL RENAL MASSES
Michael Kottwitz*, Thomas Tieu, Joshua Ring, Bradley Schwartz, Springfield, IL

MP100-11 PERCUTANEOUS IRREVERSIBLE ELECTROPORATION OF RENAL TUMORS: OUTCOMES AFTER MEDIAN 2 YEAR FOLLOW-UP
Igor Sorokin*, Noah Canvasser, Aaron Lay, Monica Morgan, Asim Ozay, Jeffrey Gahan, Clayton Trimmer, Jeffrey Cadeddu, Dallas, TX

MP100-12 SHOULD PATHOLOGIC DIAGNOSIS BE OBTAINED PRIOR TO RENAL MASS ABLATION?
Amy H. Lim*, Shane Wells, Matthew Grimes, Tyler Wittmann, Sara Best, James Louis Hinshaw, Fred T. Lee, Meghan Lubner, Timothy Ziemlewicz, Stephen Y. Nakada, E. Jason Abel, Madison, WI

MP100-13 IRREVERSIBLE ELECTROPORATION FOR RENAL MASSES NOT AMENABLE TO THERMAL ABLATION IN NON-SURGICAL CANDIDATES: MID-TERM CLINICAL FOLLOW-UP
Robert Medairos*, Wei Phin Tan, Kelsey Gallo, Kalyan Latchamsetty, Jordan Tasse, Christopher Coogan, Bulent Arslan, Chicago, IL

MP100-14 HIGH INTENSITY FOCUSED ULTRASOUND KIDNEY ABLATION: PRE-CLINICAL SAFETY AND EFFICACY EVALUATION IN A PORCINE MODEL USING A 15MM LAPAROSCOPIC PROBE
Sameer Chopra*, Inderbir Gill, Alfredo Bove, Carlos Fay, Kevin King, Vinay Duddalwar, Toshitaka Shin, Rene Arboleda, Los Angeles, CA, Rodrigo Chaluisan, Jesse Clanton, Jacob Carr, Christie Johnson, Ben Ettinger, Adam Morris, Roy Carlson, Narendra Sanghvi, Mark Carol, Ralf Seip, Charlotte, NC

MP100-15 LONG TERM ONCOLOGICAL OUTCOMES FOLLOWING RADIO FREQUENCY ABLATION OF RENAL MASS
Haritharan Sanapathi, Celebration, FL, Emily Fell Kelly, Boca Ratón, FL, Aysswarya Manoharan, St Louis, MO, Manuel Molina, Miami, FL, Raymond J Leveillee*, Boynton Beach, FL

MP100-16 LAPAROSCOPIC RENAL CRYOABLATION USING REAL-TIME INTRAOPERATIVE THERMAL MONITORING: 15 YEAR EXPERIENCE
Dean Laganosky*, Mark Henry, Frances Kim, Peter McHie, Viraj Master, John Pattaras, Atlanta, GA

MP100-17 PARTIAL NEPHRECTOMY VERSUS CRYOABLATION FOR TUMORS IN SOLITARY KIDNEYS: A PROPENSITY SCORE ANALYSIS
Bimal Bhindi*, Ross Mason, Mustafa Haddad, Stephen Boorjian, Bradley Leibovich, Thomas Atwell, Grant Schmit, R. Houston Thompson, Rochester, MN

MP100-18 LONG-TERM OUTCOMES OF CRYOABLATION FOR BIOPSY-PROVEN RCC: SIZE MATTERS
Sara Best, Brett Johnson*, Shane Wells, Meghan Lubner, Timothy Ziemlewicz, J. Louis Hinshaw, Fred Lee, Stephen Y Nakada, E. Jason Abel, Madison, WI

MP100-19 LAPAROSCOPIC VERSUS PERCUTANEOUS CRYOABLATION OF SMALL RENAL MASS: A META-ANALYSIS OF 1725 CASES
Rodrigo R Pessoa*, Denver, CO, Riccardo Autorino, Cleveland, OH, Maria del Pilar Laguna, Amsterdam, Netherlands, Wilson R Molina, Rodrigo R Donalisio da Silva, Diedra Gustafson, Priya N. Werahera, Fernando J Kim, Denver, CO

MP100-20 CRYOTHERAPY AND THERMAL ABLATION FOR RENAL MALIGNANCY OVER 3 CENTIMETERS - COMPARATIVE ANALYSIS OF SURVIVAL WITH SMALL RENAL MASSES
Alex Jones*, Megan Dinino, Mark Wakefield, Katie Murray, Naveen Pokala, Columbia, MO

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD68-01</td>
<td>PILOT STUDY RESULTS USING FLUORESCENCE ACTIVATED CELL SORTING OF SPERMATOZOA FROM TESTIS TISSUE: A NOVEL METHOD FOR SPERM ISOLATION AFTER TESE</td>
<td>Sameer Mittal*, Anna Mielnik, Alexander Bolyakov, Peter Schlegel, Darius Paduch, New York, NY</td>
</tr>
<tr>
<td>9:40</td>
<td>PD68-02</td>
<td>SPERM EXTRACTION LOCATION CAN AFFECT EARLY EMBRYO MORPHOKINETICS</td>
<td>Nicholas Tadros*, Pavinder Gill, Edmund Sabanegh, Nina Desai, Cleveland, OH</td>
</tr>
<tr>
<td>9:50</td>
<td>PD68-03</td>
<td>IMPACT OF INJECTED TESTICULAR SPERM CHARACTERISTICS ON REPRODUCTIVE OUTCOMES IN INTRACYTOPLASMIC SPERM INJECTION</td>
<td>Phil V. Bach*, Ryan Flannigan, Bobby Najari, Nikica Zaninovic, Gianpiero Palermo, Zev Rosenwaks, Peter Schlegel, New York, NY</td>
</tr>
<tr>
<td>10:00</td>
<td>PD68-04</td>
<td>IMPACT OF CFTR MUTATIONS ON PHENOTYPE AND REPRODUCTIVE OUTCOMES IN MEN WITH CONGENITAL ABSENCE OF THE VAS DEFERENS</td>
<td>Phil V. Bach*, New York, NY, Filipe Neto, Recife, Brazil, Bobby Najari, Ryan Flannigan, Miriam Feliciano, Philip Li, Marc Goldstein, New York, NY</td>
</tr>
<tr>
<td>10:40</td>
<td>PD68-08</td>
<td>EFFICACY OF ANASTROZOLE IN OLIGOZOOSPERMIC HYPOANDROGENIC SUBFERTILE MEN – THE SIGNIFICANCE OF POST TREATMENT TESTOSTERONE TO ESTRADIOL RATIO</td>
<td>Nikita Abhyankar*, Chicago, IL, Ohad Shoshany, Tel Aviv, Israel, Daniel Garvey, Craig Niederberger, Chicago, IL</td>
</tr>
<tr>
<td>10:50</td>
<td>PD68-09</td>
<td>DEMOGRAPHICS, USAGE PATTERNS, AND SAFETY OF MALE USERS OF CLOMIPHENE IN THE UNITED STATES</td>
<td>Dimitar V. Zlatev*, Shufeng Li, Laurence C. Baker, Michael L. Eisenberg, Stanford, CA</td>
</tr>
<tr>
<td>11:00</td>
<td>PD68-10</td>
<td>THE EFFECT OF SPERM MORPHOLOGY ON INTRACYTOPLASMIC INSEMINATION PREGNANCY SUCCESS RATE: A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
<td>Taylor P. Kohn*, Jaden R. Kohn, Houston, TX, Samuel A. Shabtai, Nancy L. Brackett, Charles M. Lynne, Ranjith Ramasamy, Miami, FL</td>
</tr>
<tr>
<td>11:10</td>
<td>PD68-11</td>
<td>FATE OF RECURRENT OR PERSISTENT VARICOCELE IN THE ERA OF ASSISTED REPRODUCTION TECHNOLOGY: MICROSURGICAL SUBINGUINAL REDO VARICOCELECTOMY VERSUS OBSERVATION</td>
<td>Selahiltin Çayan*, Erdem Akbay, Mersin, Turkey</td>
</tr>
<tr>
<td>11:20</td>
<td>PD68-12</td>
<td>STUDY TO ANALYSE THE FERTILITY POTENTIAL OF VARICOCELECTOMY IN NON-OBSTRUCTIVE AZOOSPERMIA (NOA), VIRTUAL AZOOSPERMIA (VA) AND SEVERE OLIGOZOOSPERMIA (SO)</td>
<td>Ashwin Tamhankar*, Mumbai, India, Ajit Sawant, Vijay Kulkarni, Prakash Pawar, Shankar Mundhe, Sunil Patil, Mumbai, India</td>
</tr>
</tbody>
</table>

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD69-01</td>
<td>A PHASE IIA STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF THE SELECTIVE OXYTOCIN RECEPTOR ANTAGONIST, IX-01, IN MEN WITH LIFELONG PREMATURE EJACULATION</td>
<td>10:10</td>
<td>PD69-05</td>
<td>EFFICACY AND SAFETY OF FIXED DOSE COMBINATION OF TAMSULOSIN AND TADALAFIL IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND ERECTILE DYSFUNCTION</td>
</tr>
<tr>
<td>9:40</td>
<td>PD69-02</td>
<td>DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL OF TOPICAL 4% BENZOCAINE WIPES FOR MANAGEMENT OF PREMATURE EJACULATION: INTERIM ANALYSIS</td>
<td>10:20</td>
<td>PD69-06</td>
<td>CLINICAL IMPROVEMENTS IN ERECTILE FUNCTION AND MOOD IN HYPOGONADAL MEN TREATED WITH 4.5% NASAL TESTOSTERONE GEL</td>
</tr>
<tr>
<td>9:50</td>
<td>PD69-03</td>
<td>COMPARISON OF EFFICACY AND SAFETY FOR ERECTILE DYSFUNCTION OF MIRODENALFIL 50MG ONCE DAILY AND 100MG ON-DEMAND IN PATIENTS WITH RADICAL PROSTATECTOMY : MULTICENTER, RANDOMIZED TRIAL.</td>
<td>10:30</td>
<td>PD69-07</td>
<td>ERECTILE FUNCTION OUTCOMES OF PROSTATE CANCER PATIENT TREATED WITH TRIPLE THERAPY</td>
</tr>
<tr>
<td>10:00</td>
<td>PD69-04</td>
<td>SAFETY AND EFFICACY OF LOW-INTENSITY EXTRACORPOREAL SHOCKWAVE IN THE TREATMENT OF VASCULOGENIC ERECTILE DYSFUNCTION: A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED SHAM-CONTROLLED CLINICAL TRIAL</td>
<td>10:40</td>
<td>PD69-08</td>
<td>THE IMPACT OF ANDROGEN DEPRIVATION THERAPY ON COMPLIANCE WITH INTRACAVERNOUS INJECTIONS</td>
</tr>
</tbody>
</table>

*Presenting author*
<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD70-01</td>
<td>EFFECTS OF WATER AVOIDANCE STRESS ON PERIPHERAL AND CENTRAL RESPONSES DURING BLADDER FILLING IN THE RAT</td>
<td>Huiyi Harriet Chang*, Zhuo Wang, Yunliang Gao, Rong Zhang, Daniel P Holschneider, Larissa V Rodriguez, Los Angeles, CA</td>
</tr>
<tr>
<td>9:40</td>
<td>PD70-02</td>
<td>CAMP-DEPENDENT REGULATION OF RHOA/RHO-KINASE ATTENUATES DETRUSOR OVERACTIVITY IN A NOVEL MOUSE EXPERIMENTAL MODEL</td>
<td>William Akakpo*, Biljana Musicki, Arthur Burnett, Baltimore, MD</td>
</tr>
<tr>
<td>9:50</td>
<td>PD70-03</td>
<td>FRESHLY DISSOCIATED SMOOTH MUSCLE CELLS FROM DETRUSOR OVERACTIVE HUMAN BLADDERS SHOW ABNORMAL EXPRESSION OF TREK-1 CHANNELS AND CAVEOLAE MEMBRANE MICRODOMAINS.</td>
<td>Ricardo Pineda*, Balachandar Nedumaran, Joseph Hypolite, Shandra Wilson, Randall B Meachan, Anna P Malykhina, Aurora, CO</td>
</tr>
<tr>
<td>10:00</td>
<td>PD70-04</td>
<td>OPTOGENETIC MODULATION OF BLADDER FUNCTION</td>
<td>Aaron Mickle*, Vijay Samineni, Kate Meacham, St. Louis, MO, Jangyoel Yoon, Champaign, IL, Jose Grajales-Reyes, Melanie Pullen, St. Louis, MO, John Rogers, Evanston, IL, Henry Lai, Robert Gereau, St. Louis, MO</td>
</tr>
<tr>
<td>10:10</td>
<td>PD70-05</td>
<td>MITOCNDRIAL MUTATIONS CONTRIBUTE TO INCREASED VOIDING FREQUENCY AND IMPAIRED CHOLINERGIC CONTRACTION IN A MODEL OF PREMATURE AGING</td>
<td>Shelby A. Powers*, Terence E. Ryan, Michael R. Odom, Joseph M. McClung, Johanna L. Hannan, Greenville, NC</td>
</tr>
<tr>
<td>10:20</td>
<td>PD70-06</td>
<td>THE ROLE OF UROTHELIAL ATP SIGNALING IN MICTURITION REFLEX</td>
<td>Kentaro Takezawa*, Makoto Kondo, Hiroshi Kuchi, Norichika Ueda, Tetsuji Soda, Shinichiro Fukuhara, Tetsuya Takao, Yasushi Miyagawa, Akira Tsujimura, Kazumasa Matsumoto-Miyai, Yusuke Ishida, Suits, Japan, Hiroimitsu Negoro, Kyoto, Japan, Shoichi Shimada, Norio Nomomura, Suits, Japan</td>
</tr>
<tr>
<td>10:30</td>
<td>PD70-07</td>
<td>ROLE OF CANNABINOID RECEPTOR TYPE 1 IN TIBIAL AND PUDENDAL NEUROMODULATION OF BLADDER OVERACTIVITY IN CATS</td>
<td>Xuewen Jian, Michelle Yu*, Jamie Uy, Thomas W. Fuller, Cameron Jones, Bing Shen, Jichen Wang, James R. Roppolo, William C. de Groat, Changfeng Tai, Pittsburgh, PA</td>
</tr>
<tr>
<td>10:50</td>
<td>PD70-09</td>
<td>EFFECTS OF NERVE GROWTH FACTOR (NGF) NEUTRALIZATION ON TRP CHANNEL EXPRESSION IN LASER-CAPTURED BLADDER AFFERENT NEURONS OF MICE WITH SPINAL CORD INJURY (SCI)</td>
<td>Nobutaka Shimizu*, Shun Takai, Naoki Wada, Takahisa Suzuki, Ei-ichiro Takaoka, Takahiro Shimizu, Pittsburgh, PA, Akihide Hirayama, Nara, Japan, Hirotatsu Uemura, Osaka sayama, Japan, Anthony J. Kanai, Naoki Yoshimura, Pittsburgh, PA</td>
</tr>
</tbody>
</table>
11:00 PD70-10 ABNORMAL RESTING-STATE INTER-NETWORK COUPLING IN PATIENTS WITH NON-NEUROGENIC OAB
Lorenz Leitner*, Ulrich Mehrnert, Matthias Walter, Thomas M. Kessler, Spyros Kollias, Lars Michels, Zürich, Switzerland

11:10 PD70-11 CIRCADIAN RHYTHM COORDINATES ATP RELEASE IN THE UROTHELIUM VIA CONNEXIN43 HEMICHANNELS.
Atsushi Sengiku*, Hiromitsu Negoro, Takeshi Sano, Masakatsu Ueda, Jin Kono, Kyoto, Japan, Louis Liu, Cambridge, MA, Hikoshi Okamura, Osamu Ogawa, Kyoto, Japan

11:20 PD70-12 IMPAIRMENT OF MICRO BLOOD FLOW IN THE BLADDER MUCOSA AND DERMIS UP-REGULATES TRPM8 CHANNELS AND INDUCE COLD STRESS RELATED FREQUENCY IN OVARIECTOMIZED RATS.
Tetsuichi Saito*, Takeshi Nagai, Toshio Suzuki, Tomonori Minagawa, Teruyuki Ogawa, Osamu Ishizuka, Matsumoto, Japan

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Tuesday, May 16, 2017 9:30 am - 11:30 am
Podium Session 71
PROSTATE CANCER: MARKERS III
Room 162 @ Boston Convention & Exhibition Center
Moderators: Paul Lange and Douglas Scherr

ABSTRACT ABSTRACT
TIME NUMBER TITLE TIME NUMBER TITLE
9:30 PD71-01 DECIPHER TEST IMPACTS DECISION-MAKING AMONG PATIENTS CONSIDERING ADJUVANT AND SALVAGE TREATMENT FOLLOWING RADICAL PROSTATECTOMY: INTERIM RESULTS FROM THE MULTICENTER PROSPECTIVE PRO-IMPACT STUDY

9:40 PD71-02 PROSTATE HEALTH INDEX DENSITY IMPROVES DETECTION OF CLINICALLY-SIGNIFICANT PROSTATE CANCER
Jeffrey Tosoian, Sasha Druskin*, Baltimore, MD, Darian Andreas, Richmond, VA, Patrick Mullane, Meera Chappidi, Sarah Joo, Kamyar Ghabili, Mufaddal Marzawala, Joseph Agostino, H. Ballentine Carter, Alan Partin, Lori Sokoll, Ashley Ross, Baltimore, MD

9:50 PD71-03 NOVEL DNA METHYLATION MARKERS FOR ACCURATE PROGNOSTIC ASSESSMENT OF PROSTATE CANCER: DISCOVERY AND EARLY VALIDATION

10:00 PD71-04 AN INDEPENDENT, MULTI-INSTITUTIONAL, PROSPECTIVE STUDY IN THE VETERANS AFFAIRS HEALTH SYSTEM CONFIRMS THE 4KSCORE ACCURATELY PREDICTS AGGRESSIVE PROSTATE CANCER

10:10 PD71-05 VALIDATION OF GEMCAP AS A DNA BASED BIOMARKER TO PREDICT PROSTATE CANCER RECURRENT AFTER RADICAL PROSTATECTOMY

*Presenting author
10:20 PD71-06 CTC-BASED GENE EXPRESSION FOR PREDICTING RESISTANCE TO ABIRATERONE AND ENZALUTAMIDE IN MCRPC
   Jae-Seung Chung*, Yugang Wang, Henderson James, Uditi Singhal, Yuanyuan Qiao, Alexander Zaslavsky, Dan Hovelson, Ann Arbor, MI, Felix Feng, San Francisco, CA, Ganesh Palapattu, Taichman Russell, Arul Chinnaian, Scott Tomlins, Todd Morgan, Ann Arbor, MI

10:30 PD71-07 GAS6, KLK2, AND BMP7 DETECTED IN CIRCULATING TUMOR CELLS PREDICT RESISTANCE TO CHEMOTHERAPY IN MCRPC
   Jae-Seung Chung*, Yugang Wang, Henderson James, Uditi Singhal, Yuanyuan Qiao, Alexander Zaslavsky, Dan Hovelson, Ann Arbor, MI, Felix Feng, San Francisco, CA, Ganesh Palapattu, Taichman Russell, Arul Chinnaian, Scott Tomlins, Todd Morgan, Ann Arbor, MI

10:40 PD71-08 ANDROGEN RECEPTOR SPLICE VARIANT 7 (AR-V7) IN PATIENTS WITH LOCAL ADVANCED, METASTATIC AND CRPC: A NOVEL CAPILLARY NANO-INMUNOASSAY TECHNIQUE
   Alvaro Rodriguez*, Juan Luis Garcia, Javier Garcia Garcia, Rebeca Lozano Mejorada, Irena Misiewicz-Krzeminska, Manuel Herrero Polo, Juan Jesus Cruz, Francisco Gomez Veiga, Salamanca, Spain

10:50 PD71-09 QUANTITATIVE DIGITAL IMAGE ANALYSIS AND MACHINE LEARNING ACCURATELY CLASSIFIES PRIMARY PROSTATE TUMORS OF BONE METASTATIC DISEASE BASED ON HISTOMORPHOMETRIC FEATURES IN DIAGNOSTIC PROSTATE NEEDLE BIOPSIES
   Eric Miller*, Santa Monica, CA, Hootan Salemi, Sergey Klimov, Michael Lewis, Isla Garryaway, Beatrice Knudsen, Arkadiusz Gertych, Los Angeles, CA

11:00 PD71-10 SERUM N-GLYCOMICS PREDICTS IN PATIENTS WHO DEVELOPED CASTRATION RESISTANT PROSTATE CANCER
   Tohru Yoneyama*, Yuki Tobisawa, Shingo Hatakeyama, Kazuyuki Mori, Yasuhiro Hashimoto, Takuya Koie, Chikara Ohyama, Hiroaki Kornori, Japan

11:10 PD71-11 P53 FOCAL PROTEIN EXPRESSION IN PRIMARY PROSTATE TUMORS AND LYMPHATIC VESSEL INVASION PREDICT BIOCHEMICAL RECURRENCE AND METASTATIC PROGRESSION
   William Gesztes*, Jennifer Cullen, Denise Young, Yongmei Chen, Rockville, MD, Allen Burke, Silver Spring, MD, Albert Dobi, Gyorgy Petrovics, Rockville, MD, Inger Rosner, Bethesda, MD, Shiv Srivastava, Rockville, MD, Isabell Sesterhenn, Silver Spring, MD

11:20 PD71-12 BIOLOGICAL PATHWAYS IDENTIFIED FROM OUR FUNCTIONAL DRIVER GENE MARKER NETWORK THAT ACTIVATE THE ANDROGEN RECEPTOR
   Isaac Powell*, Detroit, MI

APPROVED FOR AMA PRA CATEGORY 1 CREDIT™

Tuesday, May 16, 2017

Podium Session 72

PROSTATE CANCER: LOCALIZED: RADIATION THERAPY II
Room 205 BC @ Boston Convention & Exhibition Center
Moderators: Mack Roach and A. Oliver Sartor

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 PD72-01</td>
<td>LONG-TERM ANDROGEN DEPRIVATION, WITH OR WITHOUT RADIOTHERAPY, IN LOCALLY-ADVANCED PROSTATE CANCER: RESULTS FROM A PHASE III RANDOMIZED STUDY</td>
<td>Nicolas Mottet, Saint-Etienne, France, Pierre Richaud, Bordeaux, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT</th>
<th>TIME</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40 PD72-02</td>
<td>GENOMIC CLASSIFIER AUGMENTS THE ROLE OF PATHOLOGICAL FEATURES IN IDENTIFYING OPTIMAL CANDIDATES FOR ADJUVANT RADIATION THERAPY IN PATIENTS WITH PROSTATE CANCER: DEVELOPMENT AND INTERNAL VALIDATION OF A MULTIVARIABLE PROGNOSTIC MODEL</td>
<td>Deepansh Dalela*, Detroit, MI, Maria Santiago-Jimenez, Kasra Yousef, Vancouver, Canada, Jeffrey Kames, Rochester, MN, Ashley Ross, Baltimore, MD, Robert Den, Philadelphia, PA, Edward Schaeffer, Chicago, IL, Adam Dicker, Philadelphia, PA, Mani Menon, Detroit, MI, Alberto Briganti, Milan, Italy, Elai Davicinon, Vancouver, Canada, Firas Abdullah, Detroit, MI</td>
<td></td>
</tr>
</tbody>
</table>
9:50 PD72-03 TIMING OF SALVAGE RADIATION THERAPY AND USE OF CONCOMITANT HORMONAL THERAPY FOR PATIENTS WITH PSA RISING AFTER RADICAL PROSTATECTOMY: A LONG-TERM SURVIVAL ANALYSIS

10:00 PD72-04 CANCER-SPECIFIC MORTALITY AMONG MEN WITH LOCALIZED PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY VERSUS RADIOTHERAPY: A MULTI-CENTER STUDY USING PROPENSITY SCORE MATCHING AND COMPETING RISK REGRESSION ANALYSES
Jae Young Jeong*, Kyo Chul Koo, Woo Jin Bang, Seung Hwan Lee, Sung Yong Cho, Sun Il Kim, Se Joong Kim, Jin Seon Cho, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung, Seoul, Korea, Republic of

10:10 PD72-05 NATURAL HISTORY OF PATIENTS TREATED WITH SALVAGE RADIATION THERAPY FOR RISING PSA AFTER RADICAL PROSTATECTOMY: A LONG-TERM SURVIVAL ANALYSIS

10:20 PD72-06 ADJUVANT VERSUS EARLY SALVAGE RADIATION THERAPY IN NODE POSITIVE PROSTATE CANCER PATIENTS: A LONG-TERM SURVIVAL ANALYSIS

10:30 PD72-07 MULTIPARAMETRIC MRI AFTER RADICAL PROSTATECTOMY PREDICTS SALVAGE RADIOTHERAPY OUTCOMES FOR PROSTATE CANCER
Vidit Sharma*, Avinash Nehra, Michele Colicchia, Mary E Westerman, Adam T Froemming, Lance A Mynderse, R. Jeffrey Karnes, Rochester, MN

10:40 PD72-08 DISTANT RECURRENCE PATTERNS IN PATIENTS WITH PROSTATE CANCER INITIALLY TREATED WITH BRACHYTHERAPY WHO EXPERIENCED BIOCHEMICAL FAILURE.
Matthew Golland-Van Ryn*, Richard Stock, David Paulucci, Nelson Stone, Ketan Badani, John Stakianos, New York, NY

10:50 PD72-09 EARLY OUTCOMES OF FOCAL BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER: COMPARISON WITH WHOLE GLAND BRACHYTHERAPY.
Victor Srougi*, Eric Barret, Mohammed Baghdadi, Igor Nunes-Silva, Silvia Garcia-Barreras, Gregory Rembeyo, François Rozet, Marc Galiano, Rafael Sanchez-Salas, Jean Cosset, Xavier Cathelineau, Paris, France

11:00 PD72-10 ASSESSING THE RISK OF EARLY AND LATE TOXICITY OF POST-PROSTATECTOMY RADIATION THERAPY: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS

*Presenting author
11:10 PD72-11 URETHRAL STRICTURES AFTER RADIOTHERAPY FOR PROSTATE CANCER - 5 YEAR DATA OF A CERTIFIED PROSTATE-CANCER-CENTRE
Jennifer Kranz*, Uwe Maurer, Gerlinde Maurer, Oliver Deserno, Joachim Steffens, Eschweiler, Germany

11:20 PD72-12 SEER ANALYSIS OF RISK OF BLADDER, RECTUM AND COLON CANCER AFTER RADIOTHERAPY FOR PROSTATE CANCER IN YOUNGER AND OLDER MEN
Diana Lopategui*, Raymond Balise, Marcelo Panizzutti, Sanoj Punnen, Miami, FL

<table>
<thead>
<tr>
<th>TIME</th>
<th>ABSTRACT</th>
<th>NUMBER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30</td>
<td>PD73-01</td>
<td></td>
<td>RENAL MASS BIOPSY IS ASSOCIATED WITH INCREASED INCIDENCE OF PATHOLOGICAL UPSTAGING TO PERINEPHRIC FAT INVASION IN PATIENTS WITH CLINICALLY LOCALIZED RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Amirali Salmasi*, Andrew Lenis, Izak Faiena, Nicholas Donin, Allan Pantuck, Karim Chamie, Los Angeles, CA</td>
</tr>
<tr>
<td>9:40</td>
<td>PD73-02</td>
<td></td>
<td>GRADING THE NON-NEOPLASTIC KIDNEY PREDICTS POST-OPERATIVE RENAL FUNCTION IN RADICAL NEPHRECTOMY SPECIMENS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Deepak Pruthi*, San Antonio, TX, Vivian Lu, Ruchi Chhibba, Evan Weins, Ian Gibson, Winnipeg, Canada, Thomas McGregor, Kingston, Canada</td>
</tr>
<tr>
<td>9:50</td>
<td>PD73-03</td>
<td></td>
<td>IMPACT OF RENAL VEIN INVASION ON THE OUTCOMES IN PATIENTS WITH RENAL CELL CARCINOMA AND CAVAL TUMOR THROMBUS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sudhir Ishwarl*, Joseph Zabell, Scott Lundy, Sarah Vilj, Venkatesh Krishnamurthi, Cleveland, OH</td>
</tr>
<tr>
<td>10:00</td>
<td>PD73-04</td>
<td></td>
<td>A COMPARISON OF OVERALL SURVIVAL BETWEEN PARTIAL AND RADICAL NEPHRECTOMY FOR T1 RENAL MASSES: A REPORT FROM THE NATIONAL CANCER DATABASE</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>David Paulucci*, Alp Tuna Bekzac, John Sfakianos, Ketan Badani, New York, NY</td>
</tr>
<tr>
<td>10:10</td>
<td>PD73-05</td>
<td></td>
<td>A MULTI-INSTITUTIONAL PROPENSITY SCORE MATCHED COMPARISON OF TRANSPERITONEAL VS. RETROPERITONEAL ROBOTIC PARTIAL NEPHRECTOMY FOR POSTERIOR CLINICAL T1 RENAL MASSES</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>David Paulucci*, New York, NY, Ronnie Abaza, Columbus, OH, Daniel Eun, Philadelphia, PA, Akshay Bhandari, Miami Beach, FL, Ashok Hemal, Winston-Salem, NC, James Porter, Seattle, WA, Ketan Badani, New York, NY</td>
</tr>
<tr>
<td>10:20</td>
<td>PD73-06</td>
<td></td>
<td>COMPARATIVE TRIFECTA OUTCOMES AFTER LAPAROSCOPIC PARTIAL NEPHRECTOMY (LPN): CLAMPING VERSUS OFF-CLAMPING FOR HIGH COMPLEXITY RENAL SCORE TUMORS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Marcos Tobias-Machado, Joãoatas Pereira*, Alexandre Hidaka, Igor Nunes-Silva, Sidney Glna, Santo André, Brazil, Hamilton Zampolli, São Paulo, Brazil, Elney Faria, Barretos, Brazil</td>
</tr>
<tr>
<td>10:30</td>
<td>PD73-07</td>
<td></td>
<td>ANALYSIS OF RISK FACTORS ASSOCIATED WITH INFECTIONS COMPLICATIONS FOLLOWING PARTIAL NEPHRECTOMY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Richmon Owusu*, San Diego, CA, Michael Liss, Dallas, TX, Sean Berquist, Abd-elrahma Hassan, Charles Field, Aaron Bloch, Unwanaobong Nseyo, Fang Wan, Zachary Hamilton, Ithaar Derweesh, San Diego, CA</td>
</tr>
<tr>
<td>10:40</td>
<td>PD73-08</td>
<td></td>
<td>THE IMPACT OF INTRA VS. POST-OPERATIVE BLOOD TRANSFUSION ON CANCER RECURRENCE AND SURVIVAL FOLLOWING NEPHRECTOMY FOR RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Yasmin Abu-Ghanem*, Zohar Dotan, Issac Kaver, Dorit Zilberman, Jacob Ramon, Ramat Gan, Israel</td>
</tr>
</tbody>
</table>

11:00 PD73-10 COMPARISON BETWEEN LAPAROENDOSCOPIC SINGLE SITE NEPHRECTOMY AND CONVENTIONAL LAPAROSCOPIC NEPHRECTOMY: A RANDOMIZED CONTROL SINGLE INSTITUTION EXPERIENCE Mohamed Eltemamy*, Cleveland, OH, Mahmoud Abdel Hakim, Ahmed El-feel, Cairo, Egypt, Ahmed Elshafei, Cleveland, OH, Omar Abdel-Razzak, Cairo, Egypt

11:10 PD73-11 MANAGEMENT OF CONTRALATERAL RECURRENCE AFTER RADICAL NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA Amir Toussi*, Vidit Sharma, Tanner Miest, George Chow, Bradley Leibovich, Matthew Tollefson, Rochester, MN

Tuesday, May 16, 2017

Video Session 12

BLADDER ONCOLOGY AND DIVERSION

The videos in this session as well as the video libraries from the 2011-2016 Annual Meetings may be viewed in the Surgical Video Library and purchased in the AUA Store during the Annual Meeting. Both are located in Hall A. AUA members receive free online access to the Surgical Video Library throughout the year through AUA University. Visit www.AUAnet.org/University to access.

Room 254 @ Boston Convention & Exhibition Center

Moderators: Gilad Amiel, Reza Ghavamian and Katie Murray

ABSTRACT NUMBER TITLE ABSTRACT NUMBER TITLE
V12-01 MULTIMODAL ENHANCED CYSTOSCOPY FOR IMPROVED BLADDER TUMOR RESECTIONS Timothy Chang*, Dhariati Trivedi, Stanford, CA, Mario Sofer, Tel-Aviv, Israel, Joseph Liao, Stanford, CA

V12-02 CONFOCAL LASER ENDOMICROSCOPY FOR BLADDER CANCER DIAGNOSIS: HOW TO DO IT & OUR PRELIMINARY RESULTS Esmée Liem*, Jan Erik Freund, Theo de Reijke, Joyce Baard, Guido Kamphuis, Pilar Laguna Pes, Martin de Bruin, Jean de la Rosette, Amsterdam, Netherlands

V12-03 ROBOTIC UTERETAL REIMPLANTATION FOR URETERO-ENTERIC ANASTOMOSTIC STRICTURES Carlos Fay*, Daniel Melecchi Freitas, Sameer Chopra, Nariman Ahmad, Andre Berger, Mihir Desai, Inderbir Gill, Los Angeles, CA, Alvin Goh, Houston, TX, Leonardo Misuraca, Salvatore Guaglianone, Mariaconsiglia Ferriero, Gabriele Tuderti, Michele Gallucci, Giuseppe Simone, Rome, Italy, Monish Aron, Los Angeles, CA

V12-04 ROBOT ASSISTED ORTHOTOPIC MODIFIED STUDER NEOBLADDER Hubert John*, Christian Padevit, Kevin Horton, Winterthur, Switzerland, Abolfazl Hosseini, Peter Wiklund, Karolinska Stockholm, Sweden


V12-06 UTILIZATION OF INDOCYANINE GREEN FLUORESCENCE ANGIOGRAPHY DURING INTRACORPOREAL URETERO-ILEAL ANASTOMOSIS FOLLOWING ROBOTIC RADICAL CYSTECTOMY Daniel Melecchi Freitas*, Carlos Fay, Nariman Ahmad, Andre Abreu, Toshihaka Shin, Inderbir Gill, Andre Berger, Mihir Desai, Monish Aron, Los Angeles, CA

*Presenting author
V12-07 ROBOTIC INTRACORPOREAL “PADUA ILEAL BLADDER”: SURGICAL TECHNIQUE, PERIOPERATIVE, ONCOLOGIC AND FUNCTIONAL OUTCOMES
Giuseppe Simone*, Rocco Papalia, Leonardo Misuraca, Gabriele Tuderti, Francesco Minisola, Mariaconsiglia Ferriero, Giulio Vallati, Salvatore Guaglianone, Michele Gallucci, Rome, Italy

V12-08 URETEROILEAL BYPASS: A NEW ROBOTIC TECHNIC TO TREAT URETEROENTERERIC STRICTURES IN URINARY DIVERSION
Guilherme Padovani*, Rubens Park, Marcos Mello, Rafael Coelho, Leonardo Borges, Adriano Nessralah, Miguel Srougi, William Nahas, São Paulo, Brazil

V12-09 ANATOMIC ROBOT ASSISTED RADICAL CYSTECTOMY IN FEMALE: STEP BY STEP TECHNIQUE
Giuseppe Simone, Salvatore Guaglianone, Leonardo Misuraca*, Francesco Minisola, Gabriele Tuderti, Mariaconsiglia Ferriero, Giuseppe Romeo, Michele Gallucci, Rome, Italy

V12-10 ROBOT-ASSISTED LAPAROSCOPIC RADICAL CYSTECTOMY AND INTRACORPOREAL NEOBLEDDER UTILIZING A VAGINAL-SPARING AND STAPLE-FREE APPROACH
Christine White*, New Brunswick, NJ, Mark Ferretti, New York, NY, Gregory Lovallo, Mutahar Ahmed, Hackensack, NJ

V12-11 LAPAROSCOPIC REPAIR OF ILEAL CONDUIT PARASTOMAL Hernia USING THE MODIFIED SUGARBAKER TECHNIQUE
Dario Garcia-Rojo*, Xavier Serra-Aracil, Angel Prera, Carlos Abad, Jesus Muñoz, Leticia De Verdences, Marta Capdevila, Eduardo Vicente, Naim Hannanoui, Younes Fadil, Jose Luis Gonzalez-Sala, Arturo Dominguez, Clara Centeno, Victor Parejo, Mario Rosado, Paula Planelles, Juan Prats, Sabadell, Spain

V12-12 ROBOTIC CYSTOPROSTATECTOMY WITH PUBECTION AND ILEAL CONDUIT FOR PATIENTS WITH OSTEOMYELITIS PUBIS
Ahmad Shabsigh*, Columbus, OH
APPROVED FOR AMA PRA CATEGORY 1 CREDIT™
<table>
<thead>
<tr>
<th>Name</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zugor, Vahudin</td>
<td>MP68-01</td>
</tr>
<tr>
<td>Zukerman, Ryan</td>
<td>MP80-09</td>
</tr>
<tr>
<td>Zumsteg, Zachary</td>
<td>MP20-02</td>
</tr>
<tr>
<td>Zuñiga, Alvaro</td>
<td>MP16-17</td>
</tr>
<tr>
<td>Zuo, Yi</td>
<td>MP99-19</td>
</tr>
<tr>
<td>Zvara, Peter</td>
<td>MP94-05</td>
</tr>
<tr>
<td>Zwaans, Bernadette</td>
<td>MP29-07, MP31-04, PD12-11</td>
</tr>
<tr>
<td>Zwarthoff, Ellen C.</td>
<td>MP34-01</td>
</tr>
<tr>
<td>Zwaschka, Theresa</td>
<td>MP19-13, MP62-07</td>
</tr>
<tr>
<td>Zylstra, Samuel</td>
<td>MP31-16, PD26-02</td>
</tr>
</tbody>
</table>
SAVE THE DATE!

AUA 2018
MAY 18–22 san francisco

SEE YOU IN SAN FRANCISCO!
Now Approved for Another New Indication

Give More Patients the **OPDIVO** Opportunity

For more information, please visit [www.OPDIVO.com/hcp](http://www.OPDIVO.com/hcp)